

# Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/US05/003312

International filing date: 31 January 2005 (31.01.2005)

Document type: Certified copy of priority document

Document details: Country/Office: US  
Number: 60/642,909  
Filing date: 10 January 2005 (10.01.2005)

Date of receipt at the International Bureau: 31 March 2005 (31.03.2005)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland  
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse

1300274

# THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

*March 23, 2005*

**THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE.**

**APPLICATION NUMBER: 60/642,909**

**FILING DATE: *January 10, 2005***

**RELATED PCT APPLICATION NUMBER: *PCT/US05/03312***



Certified by

Under Secretary of Commerce  
for Intellectual Property  
and Director of the United States  
Patent and Trademark Office

011005

20427 U.S. PTO

PTO/SB/16 (12-04)

Approved for use through 7/31/2006. OMB 0651-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

# PROVISIONAL APPLICATION FOR PATENT COVER SHEET

This is a request for filing a PROVISIONAL APPLICATION FOR PATENT under 37 CFR 1.53(c).

Express Mail Label No. EV456047543US

INVENTOR(S)		Residence (City and either State or Foreign Country)
Given Name (first and middle (if any))	Family Name or Surname	
Mark E. Jeffrey R. Hákon	Gurney Gulcher Hákonarson	Grand Rapids, Michigan Lake Barrington, Illinois Reykjavik, Iceland
Additional inventors are being named on the _____ separately numbered sheets attached hereto		
TITLE OF THE INVENTION (500 characters max)		
Combination Therapy Materials and Methods		
CORRESPONDENCE ADDRESS		
Direct all correspondence to:		
<input checked="" type="checkbox"/> The address corresponding to Customer Number: 04743		
OR		
<input type="checkbox"/> Firm or Individual Name		
Address		Zip
City		Telephone
Country		Fax
ENCLOSED APPLICATION PARTS (check all that apply)		
<input checked="" type="checkbox"/> Application Data Sheet. See 37 CFR 1.76		
<input checked="" type="checkbox"/> Specification Number of Pages 209		
<input checked="" type="checkbox"/> Drawing(s) Number of Sheets 10		
<input type="checkbox"/> CD(s), Number of CDs		
<input checked="" type="checkbox"/> Other (specify) sequence listing (169 pages); sequence listing diskette; sequence statement; postcard		
Application Size Fee: If the specification and drawings exceed 100 sheets of paper, the application size fee due is \$250 (\$125 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).		
METHOD OF PAYMENT OF FILING FEES AND APPLICATION SIZE FEE FOR THIS PROVISIONAL APPLICATION FOR PATENT		
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27.		TOTAL FEE Amount (\$)
<input type="checkbox"/> A check or money order is enclosed to cover the filing fee and application size fee (if applicable).		950.00
<input type="checkbox"/> Payment by credit card. Form PTO-2038 is attached.		
<input checked="" type="checkbox"/> The Director is hereby authorized to charge the filing fee and application size fee (if applicable) or credit any overpayment to Deposit		
Account Number: 13-2855		
A duplicative copy of this form is enclosed for fee processing.		
The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.		
<input checked="" type="checkbox"/> No. <input type="checkbox"/> Yes, the name of the U.S. Government agency and the Government contract number are:		

SIGNATURE

TYPED or PRINTED NAME

TELEPHONE

Sharon M. Sintich

(312) 474-6300

Date

January 10, 2005

REGISTRATION NO.  
(if appropriate)

48,484

Docket Number:

30847/40792

USE ONLY FOR FILING A PROVISIONAL APPLICATION FOR PATENT  
[Number 1 of 1]

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV456047543US, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: January 10, 2005

Signature: Sharon M. Sintich

011005

20427 U.S. PTO

PTO/SB/17 (12-04v2)

Approved for use through 7/31/2006. OMB 0651-0032  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person are required to respond to a collection of information unless it displays a valid OMB control number.

Effective on 12/08/2004. Fees pursuant to the Consolidated Appropriations Act, 2005 (H.R. 4818). <b>FEE TRANSMITTAL</b> <b>For FY 2005</b>		<b>Complete if Known</b>		
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27		Application Number	Not Yet Assigned	
		Filing Date		
		First Named Inventor	Mark Gurney	
		Examiner Name	Not Yet Assigned	
		Art Unit	N/A	
TOTAL AMOUNT OF PAYMENT	(\$)	950.00	Attorney Docket No.	30847/40792

**METHOD OF PAYMENT** (check all that apply)

☐ Check    ☐ Credit Card    ☐ Money Order    ☐ None    ☐ Other (please identify): \_\_\_\_\_

☒ Deposit Account    Deposit Account Number: 13-2855    Deposit Account Name: MARSHALL; GERSTEIN & BORUN LLP

For the above-identified deposit account, the Director is hereby authorized to: (check all that apply)

☒ Charge fee(s) indicated below    ☐ Charge fee(s) indicated below, except for the filing fee

☒ Charge any additional fee(s) or underpayment of fee(s) under 37 CFR 1.16 and 1.17    ☒ Credit any overpayments

**FEE CALCULATION****1. BASIC FILING, SEARCH, AND EXAMINATION FEES**

Application Type	FILING FEES		SEARCH FEES		EXAMINATION FEES		Fees Paid (\$)
	Fee (\$)	Small Entity Fee (\$)	Fee (\$)	Small Entity Fee (\$)	Fee (\$)	Small Entity Fee (\$)	
Utility	300	150	500	250	200	100	
Design	200	100	100	50	130	65	
Plant	200	100	300	150	160	80	
Reissuc	300	150	500	250	600	300	
Provisional	200	100	0	0	0	0	200.00

**2. EXCESS CLAIM FEES**

Fee Description	Fee (\$)	Small Entity Fee (\$)
Each claim over 20 (including Reissues)	50	25
Each independent claim over 3 (including Reissues)	200	100
Multiple dependent claims	360	180

Total Claims    Extra Claims    Fee (\$)    Fee Paid (\$)    Multiple Dependent Claims  
 \_\_\_\_\_ = \_\_\_\_\_ x \_\_\_\_\_ = \_\_\_\_\_    Fee (\$)    Fee Paid (\$)

Indep. Claims    Extra Claims    Fee (\$)    Fee Paid (\$)

\_\_\_\_\_ = \_\_\_\_\_ x \_\_\_\_\_ = \_\_\_\_\_

**3. APPLICATION SIZE FEE**

If the specification and drawings exceed 100 sheets of paper (excluding electronically filed sequence or computer listings under 37 CFR 1.52(e)), the application size fee due is \$250 (\$125 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).

Total Sheets	Extra Sheets	Number of each additional 50 or fraction thereof	Fee (\$)	Fee Paid (\$)
219	119	3	250.00	750.00

**4. OTHER FEE(S)**

Non-English Specification, \$130 fee (no small entity discount)

Other (e.g., late filing surcharge): \_\_\_\_\_

<b>SUBMITTED BY</b>			
Signature		Registration No. (Attorney/Agent)	48,484
Name (Print/Type)	Sharon M. Sintich	Telephone	(312) 474-6300
		Date	January 10, 2005

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV456047543US, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: January 10, 2005

Signature: \_\_\_\_\_

(Sharon M. Sintich)




## Certificate of Express Mailing Under 37 CFR 1.10

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail, Airbill No. EV456047543US in an envelope addressed to:

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

on January 10, 2005  
Date

  
\_\_\_\_\_  
Signature

Sharon M. Sintich

\_\_\_\_\_  
Typed or printed name of person signing Certificate

48,484  
Registration Number, if applicable

(312) 474-6631  
Telephone Number

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

Provisional Patent Application Transmittal (1 page)  
Application Data Sheet  
Fee Transmittal  
Charge \$950.00 to deposit account 13-2855

## COMBINATION THERAPY MATERIALS AND METHODS

5        This application incorporates by reference in their entirety U.S. Patent Application No. 10/830,477, filed April 22, 2004, and International Application No. PCT/US03/32556, filed on October 16, 2003, U.S. Patent Application No. 10/944,272 and International Application No. PCT/2004/030582.

### BACKGROUND OF THE INVENTION

10        Myocardial infarction (MI) and Acute Coronary Syndrome (ACS), *e.g.*, unstable angina, non-ST-elevation myocardial infarction (NSTEMI) or ST-elevation myocardial infarction (STEMI), are the leading causes of hospital admissions in industrialized countries. Cardiovascular disease continues to be the principle cause of  
15        death in the United States, Europe and Japan. The costs of the disease are high both in terms of morbidity and mortality, as well as in terms of the financial burden on health care systems.

      Myocardial infarction generally occurs when there is an abrupt decrease in coronary blood flow following a thrombotic occlusion of a coronary artery previously  
20        damaged by atherosclerosis. In most cases, infarction occurs when an atherosclerotic plaque fissures, ruptures or ulcerates and when conditions favor thrombogenesis. In rare cases, infarction may be due to coronary artery occlusion caused by coronary emboli, congenital abnormalities, coronary spasm, and a wide variety of systemic, particularly inflammatory diseases. Medical risk factors for MI include cigarette  
25        smoking, diabetes, hypertension and serum total cholesterol levels > 200 mg/dL, elevated serum LDL cholesterol, and low serum HDL cholesterol. Event rates in individuals without a prior history of cardiovascular disease are about 1%. In individuals who have had a first MI or ACS, the risk of a repeat MI within the next year is 10-14%, despite maximal medical management including angioplasty and  
30        stent placement.

      Atherosclerosis can affect vascular beds in many large and medium arteries. Myocardial infarction and unstable angina (acute coronary syndrome (ACS)) stem from coronary artery atherosclerosis, while ischemic stroke most frequently is a consequence of carotid or cerebral artery atherosclerosis. Limb ischemia caused by  
35        peripheral arterial occlusive disease (PAOD) may occur as a consequence of iliac,

femoral and popliteal artery atherosclerosis. The atherosclerotic diseases remain common despite the wide-spread use of medications that inhibit thrombosis (aspirin) or treat medical risk factors such as elevated cholesterol levels in blood (statins), diabetes, or hypertension (diuretics and anti-hypertensives).

5       Atherosclerotic disease is initiated by the accumulation of lipids within the artery wall, and in particular, the accumulation of low-density lipoprotein (LDL) cholesterol. The trapped LDL becomes oxidized and internalized by macrophages. This causes the formation of atherosclerotic lesions containing accumulations of cholesterol-engorged macrophages, referred to as “foam cells”. As disease  
10 progresses, smooth muscle cells proliferate and grow into the artery wall forming a “fibrous cap” of extracellular matrix enclosing a lipid-rich, necrotic core. Present in the arterial walls of most people throughout their lifetimes, fibrous atherosclerotic plaques are relatively stable. Such fibrous lesions cause extensive remodeling of the arterial wall, outwardly displacing the external, elastic membrane, without reduction  
15 in luminal diameter or serious impact on delivery of oxygen to the heart. Accordingly, patients can develop large, fibrous atherosclerotic lesions without luminal narrowing until late in the disease process. However, the coronary arterial lumen can become gradually narrowed over time and in some cases compromise blood flow to the heart, especially under high demand states such as exercise. This  
20 can result in reversible ischemia causing chest pain relieved by rest called stable angina.

In contrast to the relative stability of fibrous atherosclerotic lesions, the culprit lesions associated with myocardial infarction and unstable angina (each of which are part of the acute coronary syndrome) are characterized by a thin fibrous cap, a large  
25 lipid core, and infiltration of inflammatory cells such as T-lymphocytes and monocyte/macrophages. Non-invasive imaging techniques have shown that most MI's occur at sites with low- or intermediate- grade stenoses, indicating that coronary artery occlusion is due most frequently to rupture of culprit lesions with consequent formation of a thrombus or blood clot and not solely due to luminal narrowing by  
30 stenosis. Plaque rupture may be due to erosion or uneven thinning of the fibrous cap, usually at the margins of the lesion where macrophages enter, accumulate, and become activated by a local inflammatory process. Thinning of the fibrous cap may

result from degradation of the extracellular matrix by proteases released from activated macrophages. These changes producing plaque instability and risk of MI may be augmented by production of tissue-factor procoagulant and other factors increasing the likelihood of thrombosis.

5        In acute coronary syndrome, the culprit lesion showing rupture or erosion with local thrombosis typically is treated by angioplasty or by balloon dilation and placement of a stent to maintain luminal patency. Patients experiencing ACS are at high risk for a second coronary event due to the multi-vessel nature of coronary artery disease with event rates approaching 10-14% within 12 months after the first incident.

10        The emerging view of MI is as an inflammatory disease of the arterial vessel wall on preexisting chronic atherosclerotic lesions, sometimes triggering rupture of culprit lesions and leading to local thrombosis and subsequent myocardial infarction. The process that triggers and sustains arterial wall inflammation leading to plaque instability is unknown, however, it results in the release into the circulation of tumor  
15        necrosis factor alpha and interleukin-6. These and other cytokines or biological mediators released from the damaged vessel wall stimulate an inflammatory response in the liver causing elevation in several non-specific general inflammatory markers including C-reactive protein. Although not specific to atherosclerosis, elevated C-reactive protein (CRP) and serum amyloid A appear to predict risk for MI, perhaps as  
20        surrogates for vessel wall inflammation.

      Although classical risk factors such as smoking, hyperlipidemia, hypertension, and diabetes are associated with many cases of coronary heart disease (CHD) and MI, many patients do not have involvement of these risk factors. In fact, many patients who exhibit one or more of these risk factors do not develop MI. Family history has  
25        long been recognized as one of the major risk factors. Although some of the familial clustering of MI reflects the genetic contribution to the other conventional risk factors, a large number of studies have suggested that there are significant genetic susceptibility factors, beyond those of the known risk factors (Friedlander Y, *et al.*, *Br. Heart J.* 1985; 53:382-7, Shea S. *et al.*, *J. Am. Coll. Cardiol.* 1984; 4:793-801,  
30        and Hopkins P.N., *et al.*, *Am. J. Cardiol.* 1988; 62:703-7). Major genetic susceptibility factors have only been identified for the rare Mendelian forms of hyperlipidemia such as a familial hypercholesterolemia.

Genetic risk is conferred by subtle differences in genes among individuals in a population. Genes differ between individuals most frequently due to single nucleotide polymorphisms (SNP), although other variations are also important. SNP are located on average every 1000 base pairs in the human genome. Accordingly, a typical human gene containing 250,000 base pairs may contain 250 different SNP. Only a minor number of SNP are located in exons and alter the amino acid sequence of the protein encoded by the gene. Most SNP have no effect on gene function, while others may alter transcription, splicing, translation, or stability of the mRNA encoded by the gene. Additional genetic polymorphism in the human genome is caused by insertion, deletion, translocation, or inversion of either short or long stretches of DNA. Genetic polymorphisms conferring disease risk may therefore directly alter the amino acid sequence of proteins, may increase the amount of protein produced from the gene, or may decrease the amount of protein produced by the gene.

As genetic polymorphisms conferring risk of disease are uncovered, genetic testing for such risk factors is becoming important for clinical medicine. Examples are apolipoprotein E testing to identify genetic carriers of the apoE4 polymorphism in dementia patients for the differential diagnosis of Alzheimer's disease, and of Factor V Leiden testing for predisposition to deep venous thrombosis. More importantly, in the treatment of cancer, diagnosis of genetic variants in tumor cells is used for the selection of the most appropriate treatment regime for the individual patient. In breast cancer, genetic variation in estrogen receptor expression or heregulin type 2 (Her2) receptor tyrosine kinase expression determine if anti-estrogenic drugs (tamoxifen) or anti-Her2 antibody (Herceptin) will be incorporated into the treatment plan. In chronic myeloid leukemia (CML) diagnosis of the Philadelphia chromosome genetic translocation fusing the genes encoding the Bcr and Abl receptor tyrosine kinases indicates that Gleevec (STI571), a specific inhibitor of the Bcr-Abl kinase should be used for treatment of the cancer. For CML patients with such a genetic alteration, inhibition of the Bcr-Abl kinase leads to rapid elimination of the tumor cells and remission from leukemia.

Many general inflammatory markers predict risk of coronary heart disease, although these markers are not specific to atherosclerosis. For example, Stein (Stein, S., *Am J Cardiol*, 87 (suppl):21A-26A (2001)) discusses the use of any one of the

following serum inflammatory markers as surrogates for predicting risk of coronary heart disease including C-reactive protein (CRP), serum amyloid A, fibrinogen, interleukin-6, tissue necrosis factor-alpha, soluble vascular cell adhesion molecules (sVCAM), soluble intervascular adhesion molecules (sICAM), E-selectin, matrix metalloprotease type-1, matrix metalloprotease type-2, matrix metalloprotease type-3, and matrix metalloprotease type-9. Elevation in one more of these serum inflammatory markers is not specific to coronary heart disease but also occurs with age or in association with cerebrovascular disease, peripheral vascular disease, non-insulin dependent diabetes, osteoarthritis, bacterial infection, and sepsis.

Serum C-reactive protein (CRP) is viewed as a convenient and sensitive marker of systemic inflammation. Generally CRP is measured in serum samples using commercially available enzyme-linked immunosorbent assays (EIA). Consistent across multiple published studies is the finding of a correlation between increased risk for coronary artery disease with increased serum CRP. For example, in the Women's Health Study, CRP was measured in 27,939 apparently healthy American women. The cut-off points for quintiles of serum CRP in women were: less than or equal to 0.49, more than 0.49 to 1.08, more than 1.08 to 2.09, more than 2.09 to 4.19, and more than 4.19 mg CRP per liter, see Ridker, P.M. *et al.*, *New England. J. Med.*, 347: 1557-1565 (2001). In comparison to the lowest quintile, and even when adjusting for age, every quintile more than 0.49 mg CRP per liter was associated with increased risk for coronary heart disease with the highest relative risk of 4.5 seen for those women in the highest quintile of serum CRP (more than 4.19 mg CRP per liter). A similar correlation between increased serum CRP and increased risk for coronary heart disease in women has been reported (Ridker, P.M *et al.*, *New Engl. J. Med.*, 342:836-843 (2000) and Bermudez, E.A. *et al.*, *Arterioscler. Thromb. Vasc. Biol.*, 22: 1668-1673 (2002)). Men also show a correlation between increased serum inflammatory markers such as CR and increased risk for coronary heart disease has been reported (Doggen, C.J.M. *et al.*, *J. Internal Med.*, 248:406-414 (2000) and Ridker, P.M. *et al.*, *New England. J. Med.*, 336: 973-979 (1997)). Quintiles for serum CRP as reported by Doggen *et al.*, were less than 0.65, more than 0.65 to 1.18, more than 1.18 to 2.07, more than 2.07 to 4.23, and more than 4.23 mg CRP per liter. Unlike women, elevated serum CRP correlates with increased relative risk for

coronary heart disease only in the 4<sup>th</sup> and 5<sup>th</sup> quintiles of CRP (relative risk of 1.7x and 1.9x, respectively).

Serum CRP in women also has been measured in conjunction with lipid markers such as levels of serum low density lipoprotein-cholesterol (LDL-C). In the study by  
5 Ridker, P.M. *et al.* (2002), serum CRP and LDL-C are minimally correlated, screening for both serum markers provided better prognostic indication than either alone. Thus, women with serum CRP above median values (more than 1.52 mg CRP per liter) and also serum LDL-C above median values (more than 123.7 mg LDL-C per deciliter) were at highest risk for coronary heart disease.

10 Elevated CRP or other serum inflammatory markers is also prognostic for increased risk of a second myocardial infarct in patients with a previous myocardial infarct (Retterstol, L. *et al.*, *Atheroscler.*, 160: 433-440 (2002)).

Since CRP is produced in the liver, there is no *a priori* mechanistic explanation for why elevation in CRP and other serum inflammatory markers should be  
15 prognostic for coronary artery disease. As discussed by Doggen, C.J.M., *et al.*, one or more of the following factors were speculated to account for the correlation observed: (1) intrinsic inflammation and tissue damage within arterial lesions, (2) prior infection by *Helicobacter pylori* or by *Chlamydia pneumoniae*, (3) release of peptide cytokines including interleukin-6, or (4) activation of the complement system.

20 The end products of the leukotriene pathway are potent inflammatory lipid mediators derived from arachidonic acid. They can potentially contribute to development of atherosclerosis and destabilization of atherosclerotic plaques through lipid oxidation and/or proinflammatory effects. LTC<sub>4</sub>, LTD<sub>4</sub>, and LTE<sub>4</sub>, are known to induce vasoconstriction. Allen *et al.*, *Circulation*, 97:2406-2413 (1998) described  
25 a novel mechanism in which atherosclerosis is associated with the appearance of a leukotriene receptor(s) capable of inducing hyperactivity of human epicardial coronary arteries in response to LTC<sub>4</sub> and LTD<sub>4</sub>. LTB<sub>4</sub>, on the other hand, is a strong proinflammatory agent. Increased production of these end products, of the leukotriene pathway, could therefore serve as a risk factor for MI and atherosclerosis,  
30 whereas both inflammation and vasoconstriction/vasospasm have a well established role in the pathogenesis of MI and atherosclerosis. It has also been shown that a heterozygous deficiency of the 5-LO enzyme in a knockout mouse model decreases

atherosclerotic lesion size in LDLR<sup>-/-</sup> mice by about 95%. (Mehrabian *et al.*,  
*Circulation Research*. 91:120 (2002)). However, such genetic evidence for  
leukotriene involvement in MI or atherosclerosis in humans has not been reported.

Mehrabian et al. did report a very small genetic association study looking for  
5 correlation between promoter polymorphisms of 5-LO and carotid intimal thickening  
in normal individuals. However, their data paradoxically suggest that a lower amount  
of leukotriene production correlates with carotid atherosclerosis.

#### SUMMARY OF THE INVENTION

10 As described herein, a gene on chromosome 13q12-13 has been identified as  
playing a major role in myocardial infarction (MI). This gene, herein after referred to  
as the MI gene, comprises nucleic acid that encodes 5-lipoxygenase activating protein  
(ALOX5AP or FLAP,) herein after referred to as FLAP. The gene has also been  
shown to play a role in stroke and PAOD.

15 The invention pertains to methods of treatment (prophylactic and/or therapeutic)  
for certain diseases and conditions (*e.g.*, MI, ACS, atherosclerosis, stroke, PAOD)  
associated with FLAP or with other members of the leukotriene pathway (*e.g.*,  
biosynthetic enzymes or proteins such as FLAP, arachidonate 4-lipoxygenase (5-LO),  
leukotriene C4 synthase (LTC4S), leukotriene A4 hydrolase (LTA4H), leukotriene B4  
20 12-hydroxydehydrogenase (LTB4DH)); receptors and/or binding agents of the  
enzymes; and receptors for the leukotrienes LTA4, LTB4, LTC4, LTD4, LTE4, Cys  
LT1, Cys LT2, including leukotriene B4 receptor 1 (BLT1), leukotriene B4 receptor 2  
(BLT2), cysteinyl leukotriene receptor 1 (CysLTR1), cysteinyl leukotriene receptor 2  
(CysLTR2). The methods include the following: methods of treatment for myocardial  
25 infarction or susceptibility to myocardial infarction; methods of treatment for transient  
ischemic attack, transient monocular blindness or stroke, or susceptibility to stroke;  
methods of treatment for claudication, PAOD or susceptibility to PAOD; methods of  
treatment for acute coronary syndrome (*e.g.*, unstable angina, non-ST-elevation  
myocardial infarction (NSTEMI) or ST-elevation myocardial infarction (STEMI));  
30 methods for reducing risk of MI, stroke or PAOD in persons with asymptomatic  
ankle/brachial index less than 0.9; methods for decreasing risk of a second myocardial  
infarction or stroke; methods of treatment for atherosclerosis, such as for patients



requiring treatment (*e.g.*, angioplasty, stents, revascularization procedure) to restore blood flow in arteries (*e.g.*, coronary, carotid, and/or femoral arteries); methods of treatment for asymptomatic ankle/brachial index of less than 0.9; and/or methods for decreasing leukotriene synthesis (*e.g.*, for treatment of myocardial infarction, stroke  
5 or PAOD).

In the methods of the invention, a leukotriene synthesis inhibitor is administered to an individual in a therapeutically effective amount. The leukotriene synthesis inhibitor can be an agent that inhibits or antagonizes a member of the leukotriene synthesis pathway (*e.g.*, FLAP, 5-LO, LTC4S, LTA4H, and LTB4DH). For example,  
10 the leukotriene synthesis inhibitor can be an agent that inhibits or antagonizes FLAP polypeptide activity (*e.g.*, a FLAP inhibitor) and/or FLAP nucleic acid expression, as described herein (*e.g.*, a FLAP nucleic acid antagonist). In another embodiment, the leukotriene synthesis inhibitor is an agent that inhibits or antagonizes polypeptide activity and/or nucleic acid expression of another member of the leukotriene  
15 biosynthetic pathway (*e.g.*, LTC4S, LTA4H) or that increases breakdown of leukotrienes (*e.g.*, LTB4DH). In preferred embodiments, the agent alters activity and/or nucleic acid expression of FLAP or of 5-LO. Preferred agents include those set forth in the Agent Table I herein. In another embodiment, preferred agents can be:  
20 1-((4-chlorophenyl)methyl)-3-((1,1-dimethylethyl)thio)-alpha,alpha-dimethyl-5-(2-quinolinylmethoxy)-1H-Indole-2-propanoic acid otherwise known as MK-0591, (R)-(+)-alpha-cyclopentyl-4-(2-quinolinylmethoxy)-Benzeneacetic acid otherwise known as BAY-x-1005, 3-(3-(1,1-dimethylethylthio-5-(quinoline-2-ylmethoxy)-1-(4-chloromethylphenyl)indole-2-yl)-2,2-dimethylpropionaldehyde oxime-0-2-acetic acid otherwise known as A-81834, optically pure enantiomers, salts, chemical derivatives,  
25 and analogues; or can be zileuton, atreleuton, 6-((3-fluoro-5-(tetrahydro-4-methoxy-2H-pyran-4yl)phenoxy)methyl)-1-methyl-2(1H)-quinolinone otherwise known as ZD-2138, 1-((4-chlorophenyl)methyl)-3-((1,1-dimethylethyl)thio)-alpha,alpha-dimethyl-5-(2-quinolinylmethoxy)-1H-Indole-2-propanoic acid otherwise known as MK-886, 4-(3-(4-(2-Methyl-imidazol-1-yl)-phenylsulfanyl)-phenyl)-tetrahydro-  
30 pyran-4-carboxylic acid amide otherwise known as CJ-13610, their optically pure enantiomers, salts, chemical derivatives, and analogues. In another embodiment, the agent alters metabolism or activity of a leukotriene (*e.g.*, LTA4, LTB4, LTC4, LTD4,

LTE4, Cys LT1, Cys LT2), such as leukotriene antagonists or antibodies to leukotrienes, as well as agents which alter activity of a leukotriene receptor (*e.g.*, BLT1, BLT2, CysLTR1, and CysLTR2).

The results in Example 10 demonstrate that in patients with the at-risk FLAP and LTA<sub>4</sub> haplotypes, a FLAP inhibitor (DG-031 also known as Bay-X-1005) had a highly significant and dose-dependent effect at the cellular, whole blood and urinary metabolite level including a 26% reduction in leukotriene B<sub>4</sub> production by activated neutrophils, a 13% reduction of myeloperoxidase in whole blood, and a 27% increase in urinary leukotriene E<sub>4</sub>. Furthermore, there was evidence of a persistent effect, following discontinuation of the FLAP inhibitor, on high sensitivity C-reactive protein and serum amyloid A. This reduction in CRP and serum amyloid A was observed on top of the beneficial effects that may have been achieved by statins taken by 85% of the study subjects.

The invention provides for compositions comprising a leukotriene synthesis inhibitor and a statin. Such compositions are intended for human administration, and preferably further comprising a (at least one) pharmaceutically acceptable diluent, adjuvant, excipient, or carrier. Materials and methods for formulation and co-formulation are well known, and many are described herein in greater detail. In one variation, formulation of the composition into convenient unit dose formulations, such as pills or capsules for oral administration, including sustained release formulations, is specifically contemplated. In another variation, co-administration transdermally, *e.g.*, through a skin patch, is contemplated. In still another variation, administration of one or both agents through a drug eluting stent is specifically contemplated. In particular, the compositions may comprises a leukotriene synthesis inhibitor that inhibits the activity of a member of the leukotriene synthesis pathway such as 5-lipoxygenase, 5-lipoxygenase activating protein (FLAP), leukotriene C<sub>4</sub> synthase, leukotriene A<sub>4</sub> hydrolase, arachidonate 4-lipoxygenase, leukotriene B<sub>4</sub> 12-hydroxydehydrogenase, leukotriene A<sub>4</sub> receptor, leukotriene B<sub>4</sub> receptor, leukotriene C<sub>4</sub> receptor, leukotriene D<sub>4</sub> receptor, leukotriene E<sub>4</sub> receptor, leukotriene B<sub>4</sub> receptor 1, leukotriene B<sub>4</sub> receptor 2, cysteinyl leukotriene receptor 1 and cysteinyl leukotriene receptor 2. Any LT inhibitor is suitable for practice of the invention, and several LT inhibitors are

described herein. To help minimize side effects, an LT inhibitor that is specific for a member of the LT synthesis pathway is preferred. Exemplary inhibitors include both small molecules, biological inhibitors of proteins, (e.g., antibody substances, peptides), and biological inhibitors that operate at the nucleic acid level (e.g.,  
5 antisense nucleic acids and interfering RNA nucleic acids and zinc finger proteins).

Preferred agents that inhibit the activity of a member of the leukotriene pathway are listed in the Agent Table I herein, including the following agents: 1-((4-chlorophenyl)methyl)-3-((1,1-dimethylethyl)thio)-alpha,alpha-dimethyl-5-(2-quinolinylmethoxy)-1H-Indole-2-propanoic acid, (R)-(+)-alpha-  
10 cyclopentyl-4-(2-quinolinylmethoxy)-Benzeneacetic acid, 3-(3-(1,1-dimethylethylthio-5-(quinoline-2-ylmethoxy)-1-(4-chloromethylphenyl)indole-2-yl)-2,2-dimethylpropionaldehyde oxime-0-2-acetic acid, zileuton, atreleuton, 6-((3-fluoro-5-(tetrahydro-4-methoxy-2H-pyran-4-yl)phenoxy)methyl)-1-methyl-2(1H)-quinolinone, 1-((4-chlorophenyl)methyl)-3-((1,1-dimethylethyl)thio)-alpha,alpha-  
15 dimethyl-5-(2-quinolinylmethoxy)-1H-Indole-2-propanoic acid and 4-(3-(4-(2-Methyl-imidazol-1-yl)-phenylsulfanyl)-phenyl)-tetrahydro-pyran-4-carboxylic acid amide. In one variation, the LT inhibitor is an inhibitor of FLAP. One preferred group of compounds are described herein as BAY X1005 (also known as DG-031) as well as related compounds described in Mohrs et al., U.S. Patent No. 4,970,215,  
20 incorporated herein by reference in its entirety. In another variation, the LT inhibitor is a LTA4H inhibitor. Other preferred agents include those set forth in the Agent Table III and the LTA4H Agent list set out herein. Additional preferred agents include those described in Penning *et al.*, *Med Chem.* 2002 45(16):3482-90, Penning, *Curr Pharm Des.* 2001, 7(3):163-79 and Penning *et al.*, *J Med Chem.* 2000  
25 43(4):721-35.

AGENT TABLE III

Target	Compound ID	Chemical Name	Patent / Reference
LTA4H Inhibitor	SC-57461A	3-[methyl[3-[4-(phenylmethyl)phenoxy]-propyl]amino]propionic acid	Penning, T.D. et.al. Bioorg Med. Chem. Letters (2003), 13, 1137-1139. ibid, (2002), 12, 3383-3386
LTA4H Inhibitor	SC-56938	Ethyl-1-[2-[4-(phenylmethyl)phenoxy]ethyl]-4-piperidine-carboxylate	Penning, T.D. et.al. Bioorg Med. Chem. Letters (2003), 13, 1137-1139; ibid, (2002), 12, 3383-3386. US6506876A1
LTA4H Inhibitor	RP 64966	[4-[5-(3-Phenyl-propyl)thiophen-2-yl]butoxy]acetic acid	WO9627585
LTA4H Inhibitor	SA 6541	(R)-S-[[4-(dimethylamino)phenyl]methyl]-N-(3-mercapto-2methyl-1-oxopropyl)-L-cysteine	WO9809943
LTB4 Receptor Antagonist	Amelubant / BIIL-284	Carbamic acid,((4-((3-((4-(1-(4-hydroxyphenyl)-1-methylethyl)phenoxy)methyl)phenyl)methoxy)phenyl)iminomethyl)-ethyl ester	US 6,576,669
LTB4 Receptor Antagonist	BIRZ-227	5-Chloro-2-[3-(4-methoxyphenyl)-2-pyridin-2-yl-pyrrolidin-1-yl]-benzoxazole	Journal of Organic Chemistry 1998,63:2(326-330).
LTB4 Receptor Antagonist	CP 195543	2-[(3S,4R)-3,4-dihydro-4-hydroxy-3-(phenylmethyl)-2H-1-benzopyran-7-yl]-4-(trifluoromethyl)benzoic acid	Process: WO.98/11085 1998, priority US 60/26372 1996; J. Pharmacology and Expert. Therapy, 1998, 285: 946-54
LTB4 Receptor Antagonist	Ebselen	2-Phenyl-benzo[d]isoselenazol-3-one	Journal of Cerebral Blood Flow and Metabolism 1995, July 2-6 (S162); Drugs of the Future 1995, 20:10 (1057)
LTB4 Receptor Antagonist	LTB 019; CGS-25019C	4-[5-(4-Carbamimidoyl-phenoxy)-pentyloxy]-N,N-diisopropyl-3-methoxy-benzamide maleate	ACS Meeting 1994, 207th:San Diego (MEDI 003); International Congress of the Inflammation Research Association 1994, 7th:White Haven (Abs W23)
LTB4 Receptor Antagonist	LY 210073	5-(2-Carboxy-ethyl)-6-[6-(4-methoxy-phenyl)-hex-5-enyloxy]-9-oxo-9H-xanthene-2-carboxylic acid	J Med Chem 1993 36 (12) 1726-1734
LTB4 Receptor Antagonist	LY 213024	5-(3-carboxybenzoyl)-2-(decyloxy)benzenepropanoic acid	J Med Chem 1993 36 (12) 1726-1734

LTB4 Receptor Antagonist	LY 255283	1-[5-ethyl-2-hydroxy-4-[[6-methyl-6-(1H-tetrazol-5-yl)heptyl]oxy]phenyl]ethanone	EP 276064 B 1990, priority US 2479 1987
LTB4 Receptor Antagonist	LY 264086	7-carboxy-3-(decyloxy)-9-oxo-9H-xanthene-4-propanoic acid	US 4996230 1991, priority US 481413 1990
LTB4 Receptor Antagonist	LY 292728	7-carboxy-3-[3-[(5-ethyl-4'-fluoro-2-hydroxy[1,1'-biphenyl]-4-yl)oxy]propoxy]-9-oxo-9H-xanthene-4-propanoic acid disodium salt	EP 743064 A 1996, priority US 443179 1995
LTB4 Receptor Antagonist	LY-293111 (VML-295)	Benzoic acid, 2-(3-(3-((5-ethyl-4'-fluoro-2-hydroxy(1,1'-biphenyl)-4-yl)oxy)propoxy)-2-propylphenoxy)-	Proceedings of the American Society for Clinical Oncology 2002, 21:1 (Abs 343) [LY-293111 for Cancer] SCRI World Pharmaceutical News 1997, 2272 (13) [for VML-295]
LTB4 Receptor Antagonist	ONO 4057; LB 457	(E)-2-(4-carboxybutoxy)-6-[[6-(4-methoxyphenyl)-5-hexenyl]oxy]benzenepropanoic acid	EP 405116 A 1991
LTB4 Receptor Antagonist	PF 10042	1-[5-hydroxy-5-[8-(1-hydroxy-2-phenylethyl)-2-dibenzofuranyl]-1-oxopentyl]pyrrolidine	EP 422329 B 1995, priority US 409630 1989
LTB4 Receptor Antagonist	RG-14893	8-Benzyloxy-4-[(methylphenethyl-carbamoyl)-methyl]-naphthalene-2-carboxylic acid	SCRIP World Pharmaceutical News 1996, 2168 (20)
LTB4 Receptor Antagonist	SB-201993	3-{6-(2-Carboxy-vinyl)-5-[8-(4-methoxy-phenyl)-octyloxy]-pyridin-2-yl}methylsulfanylmethyl}-benzoic acid	WO-09500487
LTB4 Receptor Antagonist	SC-52798	7-[3-(2-Cyclopropylmethyl-3-methoxy-4-thiazol-4-yl-phenoxy)-propoxy]-8-propyl-chroman-2-carboxylic acid	Bioorganic and Medicinal Chemistry Letters 1994, 4:6 (811-816); Journal of Medicinal Chemistry 1995, 38:6 (858-868)
LTB4 Receptor Antagonist	SC-53228	3-{7-[3-(2-Cyclopropylmethyl-3-methoxy-4-methylcarbamoyl-phenoxy)-propoxy]-8-propyl-chroman-2-yl}-propionic acid	International Congress of the Inflammation Research Association 1994, 7th: White Haven (Abs W5)
LTB4 Receptor Antagonist	WAY 121006	3-fluoro-4'-(2-quinolinylmethoxy)-[1,1'-biphenyl]-4-acetic acid	Drugs under Experimental and Clinical research 1991, 17:8 (381-387)
LTB4 Receptor Antagonist	ZD-2138	3-Amino-3-(4-methoxy-tetrahydro-pyran-4-yl)-acrylic acid 1-methyl-2-oxo-1,2-dihydro-quinolin-6-ylmethyl ester	International Symposium on Medicinal Chemistry 1994, 13th: Paris (P 197)

In addition the following LTA4H inhibitors are described in USP2003/0004101A1, the teachings of which are incorporated herein by reference in their entirety:

5                    ADDITIONAL LTA4H AGENT LIST

1. 1-[2-[4-(phenylmethyl)phenoxy]ethyl]-2-methyl-4-tetrazolylpiperidine
2. 1-[2-[4-(4-oxazolyl)phenoxy]phenoxy]ethyl]pyrrolidine
3. 3-[methyl[3-[4-(2-  
10                    thienylmethyl)phenoxy]propyl]amino]propionic acid
4. methyl 3-[methyl[3-[4-(2-  
                          thienylmethyl)phenoxy]propyl]amino]propionate
5. 3-[methyl[3-[4-(3-  
                          thienylmethyl)phenoxy]propyl]amino]propionic acid
- 15                   6. methyl-3-[methyl[3-[4-(3-  
                          theinylmethyl)phenoxy]propyl]amino]propionate
7. 3-[methyl[3-[4-(4-  
                          fluorophenoxy)phenoxy]propyl]amino]propionic acid
8. 3-[methyl[3-[4-(4-  
20                    biphenyloxy)phenoxy]propyl]amino]propionic acid
9. N-[3-[[3-[4-(phenylmethyl)phenoxy]  
                          propyl]methylamino]propionyl]benzenesulfonamide
10. 1-[2-[4-(phenylmethyl)phenoxy]ethyl]-2-methyl-4-(1H-tetrazol-5-yl)piperidine
- 25                   11. 1-[2-[4-(phenylmethyl)phenoxy]ethyl]-4-(1H-tetrazol-5-yl)piperidine

In some embodiments, compositions of the invention comprise a statin, and methods of the invention comprise administration of a statin. In this context, the term "statin" should be understood to refer to any of the class of inhibitors of 3-hydroxy-3-methylglutarylcoenzyme A (HMG-CoA) reductase, the  
5 enzyme that converts HMG-CoA to the cholesterol precursor mevalonic acid. Numerous compounds with high specificity for this enzyme have been developed and approved for human therapy. Compositions of the invention may comprise a statin that is listed in Agent Table II herein, such as roxuvastatin (also known  
visastatin), fluvastatin, atorvastatin, lovastatin (also known as mevinolin), simvastatin,  
10 pravastatin, pitavastatin, mevastatin, cerivastatin, ML-236A, ML-236B, MBV-530A and MB-530B.

References to agents should be understood to include pharmaceutically acceptable salts, acids, bases, esters, pro-drugs, metabolites, and other common formulation variants of the agents.

15 An increasing body of emerging evidence identifies serum CRP as a marker for cardiovascular morbidity/mortality, and correlates reductions in serum CRP to better clinical outcomes. (See, e.g., Ridker et al., N.Engl. J. Med. 352(1): 20-28 (2005); Nissen et al., N. Engl. J. Med. 352(1): 29-38 (2005); and Pearson et al., Circulation 107: 499-511 (2003).) Serum CRP in excess of 3.0 mg/L is  
20 considered high risk; from 1.0 to 3.0 average risk; and below 1 mg/L low risk. (Pearson et al.) Compositions and methods of the invention provide tools for reducing serum CRP. Reductions in CRP can be measured on a concentration basis, where compositions and methods that achieve CRP below 3.0 mg/L are preferred; with still more preferred targets of 2.75 mg/L, 2.5 mg/L, 2.25 mg/L, 2.0 mg/L, 1.75  
25 mg/L, 1.5 mg/L, 1.25 mg/L, 1.0 mg/L, 0.75 mg/L, and 0.5 mg/L. Reductions in CRP also can be measured on a percentage basis, where clinical effectiveness is evaluated as a percentage reduction in CRP in a patient compared to no drug therapy or compared to single drug therapy. Depending on the initial CRP measurement, Compositions and methods that reduce CRP anywhere from 10%-90% or more are  
30 contemplated, e.g., reductions of 10%, 20%, 25%, 30%, 40%, 50%, 60%, 65%, 70%, 75%, 80%, or any target in between these values.

In some variations of the invention, the composition of the invention includes the leukotriene synthesis inhibitor in an amount effective to reduce serum C-reactive protein (CRP) in a human subject. In some variations, the composition of the invention includes the statin in an amount effective to reduce serum low density lipoprotein cholesterol (LDL) and reduce serum CRP in a human subject. In at least one preliminary and short term study described herein, human subjects that already enjoyed the CRP-lowering benefits of statin therapy were administered the LT inhibitor BAY-X1005, and significant further reductions in CRP were detected. Combination therapy of a longer duration may result in further CRP reduction than the 20-30% effect observed in the short term study.

In an embodiment of the invention, the compositions comprise a leukotriene synthesis inhibitor in an amount effective to reduce serum CRP in a human subject and a statin. In another embodiment, the compositions comprise a statin in an amount effective to reduce serum LDL-C in a human subject and a leukotriene synthesis inhibitor. The invention also encompasses compositions comprising a leukotriene synthesis inhibitor and a statin in amounts effective to synergistically reduce CRP in a human subject.

In one variation, the leukotriene inhibitor and the statin are included in the composition of the invention in amounts effective to synergistically reduce serum C-reactive protein in a human subject.

For practice of the invention with BAY-X1005, doses of 50-750 mg per day for adult human patients are contemplated. Doses of 100 - 500 mg, from one to five times per day, is contemplated. Doses of 250-375 mg, from one to three times per day, is preferred.

Dosing for clinically approved statins have been developed and published by the manufacturers. In a preferred embodiment, the statin is co-formulated with the LT inhibitor in a pill or capsule for administrations 1-4 times per day.

The invention provides for methods of using these compositions to reduce risk factors for cardiovascular diseases such as for MI, ACS, stroke, or PAOD. In one method, a composition comprising a leukotriene synthesis inhibitor



and a statin is administered to a human subject exhibiting one or more risk factors for MI, ACS, stroke or PAOD, wherein the composition is administered in an amount effective to reduce at least one risk factor for MI, ACS, stroke or PAOD. Preferably, the risk factor is elevated serum LDL-C or an elevated inflammatory  
5 marker such as CRP or serum amyloid A. In a highly preferred embodiment, LDL-C and CRP are both reduced clinically significant amounts, where a clinically significant amount is an amount that correlates with a statistically significant measurable reduction in risk for an adverse cardiovascular event, when analyzed in a population, e.g., in a clinical study.

10                   The invention also provides for method of using these compounds to reduce CRP in human subject. In one variation, the invention is a method of reducing C reactive protein (CRP) in a human subject, comprising administering to a human in need of treatment to reduce CRP a composition of the invention containing the LT inhibitor and the statin as described above, in an amount effective to reduce  
15 serum C reactive protein in the human subject. The identification of a human in need of treatment for CRP reduction can be based on a variety of factors described herein, including genetic factors, CRP measurements, measurements of other inflammatory markers, and measurements of non-genetic and non-inflammatory markers for risk of MI. In one variation, the method includes selecting for the  
20 administering step a human subject at risk for a disease or condition selected from the group consisting of myocardial infarction, acute coronary syndrome, stroke, or peripheral arterial occlusive disease. Thus, the invention provides a method that comprises selecting a human subject at risk for MI, ACS, stroke or PAOD and administering to the subject a composition comprising a leukotriene synthesis  
25 inhibitor and a statin wherein the composition is in an amount effective to reduce serum CRP in a human subject. The method may further comprise the step of measuring serum CRP in the human subject to monitor therapeutic efficacy of the composition, wherein a decrease in serum CRP following the administering of the composition indicates therapeutic efficacy.

30                   In still another variation, the monitoring of risk factors and/or toxicity is used to adjust dose or dosing. For example, dose or dosing of a statin or a

leukotriene synthesis inhibitor is increased if serum CRP and/or LDL and/or serum or urinary leukotriene measurements do not decrease to a target level, such as a level equivalent to the bottom 50 percentile, 40 percentile, 30 percentile, 20 percentile, 10 percentile, 1 percentile of a population, or other target percentile in between these  
5 exemplary targets. As described above, monitoring also can be used to adjust dosing to achieve a target level of serum CRP, or to achieve a target percentage reduction in CRP for a particular human subject.

The monitoring may involve parameters in addition to CRP. A benefit of the statin for many human subjects will be the reduction in serum LDL,  
10 and methods of the invention include administering the composition of the invention in an amount effective to reduce serum LDL and serum leukotrienes in the human subject. In this embodiment, serum LDL may be monitored. Other markers described herein, including serum amyloid A and myeloperoxidase, may be monitored.

15 In certain embodiments of the invention, the individual is an individual who has at least one risk factor, such as an at-risk haplotype for myocardial infarction, stroke or PAD; an at-risk haplotype in the FLAP gene; a polymorphism in a FLAP nucleic acid; an at-risk polymorphism in the 5-LO gene promoter, diabetes; hypertension; hypercholesterolemia; elevated triglycerides;  
20 elevated Lp(a); obesity; ankle-brachial index (ABI) less than 0.9; a past or current smoker; transient ischemic attack; transient monocular blindness; carotid endarterectomy; asymptomatic carotid stenosis; claudication; limb ischemia leading to gangrene, ulceration or amputation; a vascular or peripheral artery revascularization graft; an elevated inflammatory marker (e.g., a marker such as C-  
25 reactive protein (CRP), serum amyloid A, fibrinogen, a leukotriene, a leukotriene metabolite, interleukin-6, tissue necrosis factor-alpha, a soluble vascular cell adhesion molecule (sVCAM), a soluble intervascular adhesion molecule (sICAM), E-selectin, matrix metalloproteinase type-1, matrix metalloproteinase type-2, matrix metalloproteinase type-3, matrix metalloproteinase type-9, myeloperoxidase (MPO), and  
30 N-tyrosine); increased LDL cholesterol and/or decreased HDL cholesterol; increased leukotriene synthesis; and/or at least one previous myocardial infarction, ACS,

stable angina, previous transient ischemic attack, transient monocular blindness, or stroke, asymptomatic carotid stenosis or carotid endarterectomy, atherosclerosis, requires treatment for restoration of coronary artery blood flow (e.g., angioplasty, stent, revascularization procedure).

5 Human subjects that already are treated with statins can enjoy the benefit of the present invention if the subjects therapy is modified to include an LT antagonist. Thus, in still another embodiment, the invention is a method of reducing C reactive protein (CRP) in a human subject, comprising: selecting a human subject that receives statin therapy to reduce serum LDL, wherein the statin therapy  
10 optionally reduces serum CRP in the human subject; and administering to the human subject a leukotriene synthesis antagonist, in an amount effective to further reduce CRP in the human subject.

In still another embodiment, the invention is a method of reducing C reactive protein (CRP) in a human subject, comprising: identifying a human subject  
15 in need of treatment to reduce serum CRP; administering to the human subject a composition comprising a statin; and administering to the human subject a composition comprising a leukotriene synthesis inhibitor, wherein the statin and the leukotriene synthesis inhibitor are administered in amounts effective to reduce serum CRP in the human subject. The statin and the LT inhibitor can be  
20 simultaneously administered as a single composition, as described above; can be simultaneously administered as separate compositions; or can be sequentially administered. Depending on the dosing schedule, the daily administration regimen may include simultaneous administration at some times and separate administration at other times, e.g., if one agent is administered twice daily and another three times  
25 daily.

In certain embodiments of the invention, the individual is an individual who has at least one risk factor, such as an at-risk haplotype for myocardial infarction, stroke or PAOD; an at-risk haplotype in the FLAP gene; a polymorphism in a FLAP nucleic acid; an at-risk polymorphism in the 5-LO gene  
30 promoter, diabetes; hypertension; hypercholesterolemia; elevated triglycerides; elevated lp(a); obesity; ankle/brachial index (ABI) less than 0.9; a past or current

smoker; transient ischemic attack; transient monocular blindness; carotid endarterectomy; asymptomatic carotid stenosis; claudication; limb ischemia leading to gangrene, ulceration or amputation; a vascular or peripheral artery revascularization graft; an elevated inflammatory marker (e.g., a marker such as C-  
5 reactive protein (CRP), serum amyloid A, fibrinogen, a leukotriene, a leukotriene metabolite, interleukin-6, tissue necrosis factor-alpha, a soluble vascular cell adhesion molecule (sVCAM), a soluble intervascular adhesion molecule (sICAM), E-selectin, matrix metalloprotease type-1, matrix metalloprotease type-2, matrix metalloprotease type-3, matrix metalloprotease type-9, myeloperoxidase (MPO), and  
10 N-tyrosine); increased LDL cholesterol and/or decreased HDL cholesterol; increased leukotriene synthesis; and/or at least one previous myocardial infarction, ACS, stable angina, previous transient ischemic attack, transient monocular blindness, or stroke, asymptomatic carotid stenosis or carotid endarterectomy, atherosclerosis, requires treatment for restoration of coronary artery blood flow (e.g., angioplasty,  
15 stent, revascularization procedure).

The invention additionally pertains to methods of assessing an individual for an increased risk of MI, ACS, atherosclerosis, stroke, or PAOD, by assessing a level of a leukotriene metabolite (e.g., LTE4, LTD4, LTB4) in the individual (e.g., in a sample of blood, serum, plasma or urine). An increased level of leukotriene metabolite is  
20 indicative of an increased risk. The invention also encompasses methods of assessing an individual for an increased risk of MI, ACS, atherosclerosis, stroke, transient ischemic attack, transient monocular blindness, asymptomatic carotid stenosis, PAOD, claudication, or limb ischemia, by stimulating production of a leukotriene or a leukotriene metabolite in a test sample from the individual (e.g., a sample comprising  
25 neutrophils), using a calcium ionophore, and comparing the level of the leukotriene or leukotriene metabolite with a control level. A level of production of the leukotriene or leukotriene metabolite that is significantly greater than the control level, is indicative of increased risk.

The invention further pertains to methods of assessing response to treatment  
30 with a leukotriene synthesis inhibitor, by assessing a level of a leukotriene or leukotriene metabolite in the individual before treatment, and comparing the level to a level of the leukotriene or leukotriene metabolite assessed during or after treatment.

A level that is significantly lower during or after treatment, than before treatment, is indicative of efficacy of the treatment with the leukotriene synthesis inhibitor. The invention additionally pertains to methods of assessing response to treatment with a leukotriene synthesis inhibitor, by stimulating production of a leukotriene or a  
5 leukotriene metabolite in a first test sample from the individual (*e.g.*, a sample comprising neutrophils) before treatment, using a calcium ionophore, and comparing the level of the leukotriene or leukotriene metabolite with a level of production of the leukotriene or leukotriene in a second test sample from the individual, during or after treatment. A level of production of the leukotriene or leukotriene metabolite in the  
10 second test sample that is significantly lower than the level in the first test sample, is indicative of efficacy of the treatment. Similarly, the invention encompasses methods of assessing response to treatment with a leukotriene synthesis inhibitor, by assessing a level of an inflammatory marker in the individual before treatment, and during or after treatment. A level of the inflammatory marker during or after  
15 treatment, that is significantly lower than the level of inflammatory marker before treatment, is indicative of efficacy of the treatment.

To determine the effectiveness of compositions of the present invention comprising a statin, total cholesterol, LDL-C and/or triglycerides may be assessed from measurements of risk factor markers in the serum of a human subject  
20 administered the composition. A level of serum total cholesterol, LDL-C and/or triglycerides during or after treatment, that is significantly lower than the level of total cholesterol, LDL-C and/or triglycerides before treatment is indicative of the efficacy of the treatment.

The invention also pertains to use of leukotriene synthesis inhibitors for the  
25 manufacture of a medicament for the treatment of MI, ACS, stroke, PAOD, and/or atherosclerosis, as described herein, as well as for the manufacture of a medicament for the reduction of leukotriene synthesis.

#### BRIEF DESCRIPTION OF THE DRAWINGS

30 The foregoing and other objects, features and advantages of the invention will be apparent from the following more particular description of preferred embodiments of the invention.

FIG. 1 shows the results from a haplotype association case-control analysis of 437 female MI patients versus 721 controls using combinations 4 and 5 microsatellite markers to define the test haplotypes. The  $p$ -value of the association is plotted on the y-axis and position of markers on the x-axis. Only haplotypes that show association with a  $p$ -value  $< 10^{-5}$  are shown in the figure. The most significant microsatellite marker haplotype association is found using markers DG13S1103, DG13S166, DG13S1287, DG13S1061 and DG13S301, with alleles 4, 0, 2, 14 and 3, respectively ( $p$ -value of  $1.02 \times 10^{-7}$ ). Carrier frequency of the haplotype is 7.3% in female MI patients and 0.3% in controls. The segment that is common to all the haplotypes shown in the figure includes only one gene, FLAP.

FIG. 2 shows the alleles of the markers defining the most significant microsatellite marker haplotypes. The segment defined with a black square is common to all the of most significantly associated haplotypes. The FLAP nucleic acid is located between makers DG13S166 and D13S1238. Two marker haplotype involving alleles 0 and -2 for markers DG13S166 and D13S1238, respectively, is found in excess in patients. Carrier frequency of this haploype is 27% in patients and 15.4% in controls ( $p$ -value  $1 \times 10^{-3}$ ). Therefore, association analysis confirms that the most tightly MI-associated gene within the linkage peak is FLAP.

FIG. 3 shows the relative location of key SNPs and exons of the ALOX5AP/FLAP gene (exons shown in vertical rectangles). Haplotype length varies between 33 to 68 kb.

FIG. 4 shows a significant positive correlation between serum LTE4 levels and serum CRP levels.

FIG. 5 depicts LTB4 production of ionomycin stimulated neutrophils from MI patients ( $n=41$ ) and controls ( $n=35$ ). The log-transformed (mean + SD) values measured at 15 and 30 minutes of stimulated cells are shown. (7.1) LTB4 production in MI patients and controls. The difference in the mean values between patients and the controls is tested using a two-sample t-test of the log-transformed values. (7.2) LTB4 production in MI male carriers and non-carriers of haplotype A4. Mean values of controls are included for comparison. Of note, males with the haplotype A4 produce the highest amounts of LTB4 ( $p<0.005$  compared to controls). (7.3). Schematic representation of the 5-LO pathway with leukotriene bioactive products.

FIG. 6 shows a schematic view of the chromosome 13 linkage region showing the FLAP gene. (9.1) The linkage scan for female MI patients and the one LOD drop region that includes the FLAP gene; (9.2) Microsatellite association for all MI patients: single marker association and two, three, four and five marker haplotype association. The arrows indicate the location of the most significant haplotype association across the FLAP gene in males and females. (9.3) The FLAP gene structure, with exons shown as cylinders, and the location of all the SNPs typed in the region (vertical lines). The vertical lines indicate the position of the microsatellites (shown in 9.2) and SNPs (shown in 9.3) used in the analysis.

FIG. 7 shows a linkage scan using framework microsatellite markers on chromosome 13 for male patients with ischemic stroke or TIA (n=342 in 164 families at 6 meioses). The LOD score is expressed on the y axis and the distance from the pter in Kosambi cM on the x axis.

FIG. 8 shows a pairwise linkage disequilibrium (LD) between SNPs in a 60 kb region encompassing FLAP. The markers are plotted equidistantly. Two measures of LD are shown:  $D'$  in the upper left triangle and  $P$  values in the lower right triangle. Shaded lines indicate the positions of the exons of *FLAP* and the stars indicate the location of the markers of the at-risk haplotype A4. Scales for the LD strength are provided for both measures to the right.

FIG. 9 provides a schematic of the clinical trial schedule. This figure shows that at Visit 2 (on Day 1 of study) subjects were randomised into each of the three arms and to either placebo or active drug within each arm. A 2-week washout period separated the 4-week treatment periods. Cross-over was performed at week 6.

FIG. 10 shows the analysis of carry-over effect for CRP and SAA (on log-scale).

## DETAILED DESCRIPTION OF THE INVENTION

Extensive genealogical information has been combined with powerful gene sharing methods to map a gene on chromosome 13q12-13 that is associated with myocardial infarction. A genome wide search for susceptibility genes for MI, using a framework map of 1000 microsatellite markers, revealed a locus suggestive of linkage on 13q12-13. Sixty families with 159 female MI patients that clustered within and including 6 meiotic events were used in linkage analysis. At first, only female MI patients were used in the linkage analysis in an effort to enrich for patients with stronger genetic factors contributing to their risk for MI. The

epidemiological study of a population-based sample of Icelandic MI patients had previously suggested that the genetic factors for MI might be stronger for females than males, as the relative risk for siblings of female MI patients was significantly higher than the relative risk for siblings of male probands (1.59 (CI 1.47 - 1.73) vs. 1.35 (CI 1.28 - 1.42)) (unpublished data).

5 The highest LOD score (2.5) was found at marker D13S289. The LOD score results for the families remained the same after adding 14 microsatellite markers to the candidate region. The inclusion of the additional markers increased the information on sharing by descent from 0.7 to 0.8, around the markers that gave the highest LOD scores. This linkage analysis mapped a gene contributing to MI to chromosome 13q12-13.

10 The candidate MI locus on chromosome 13q12-13 was then finely mapped with microsatellite markers. Patients with myocardial infarction and controls were initially genotyped with microsatellite markers with an average spacing between markers of less than 100 kb over the 12Mb candidate region. Initial haplotype association analysis that included all genotyped microsatellite markers across the MI candidate locus, resulted in several extended  
15 haplotypes composed of 4 and 5 microsatellite markers that were significantly associated with female MI (see, *e.g.*, Tables 14 and 15 below). A region common to all these extended haplotypes, is defined by markers DG13S166 and D13S1238. This region includes only one gene, the FLAP nucleic acid sequence. The two marker haplotype involving alleles 0 and -2 for markers DG13S166 and D13S1238, respectively, was found in excess in patients. Specific  
20 variants of the gene were then sought that were associated with MI.

In order to screen for SNPs in the FLAP gene, the whole gene was sequenced, both exons and introns. Initially, 9 SNPs identified within the gene were genotyped in patients and controls. Additional microsatellite markers close to or within the FLAP gene were also genotyped in all patients and controls. Five publicly known SNPs that are located within a 200  
25 kb distance 5' to the FLAP gene were also genotyped in patients and controls. Haplotype association analysis in this case-control study including these additional markers showed several different variants of the same haplotype that were all significantly associated with female MI (see, *e.g.*, Table 8). Table 9 shows two haplotypes that are representative of these female MI risk haplotypes which are referred to herein as the female MI "at risk" haplotypes.  
30 The relative risk for male MI patients that had the female MI-"at risk" haplotype was increased (see, *e.g.*, Table 9), indicating that the female MI-"at risk" haplotype also increased the risk of



having an MI in males. These results further strengthened the hypothesis that the FLAP gene was an MI susceptibility gene.

*SNP haplotype association to MI, and subsequently to stroke and PAOD*

5 In an effort to identify haplotypes involving only SNP markers that associate with MI, additional SNPs were identified by sequencing the FLAP gene and the region flanking the gene. Currently, a total of 45 SNPs in 1343 patients and 624 unrelated controls have been genotyped. Two correlated series of SNP haplotypes have been observed in excess in patients, denoted as A and B in Table 7. The length of the haplotypes varies between 33 and 69 kb, and  
10 the haplotypes cover one or two blocks of linkage disequilibrium. Both series of haplotypes contain the common allele G of the SNP SG13S25. All haplotypes in the A series contain the SNP SG13S114, while all haplotypes in the B series contain the SNP SG13S106. In the B series, the haplotypes B4, B5, and B6 have a relative risk (RR) greater than 2 and with allelic frequencies above 10%. The haplotypes in the A series have slightly lower RR and lower p-  
15 values, but higher frequency (15-16%). The haplotypes in series B and A are strongly correlated, *i.e.*, the haplotypes in B define a subset of the haplotypes in A. Hence, haplotypes in series B are more specific than A. However, haplotypes in series A are more sensitive, *i.e.*, they capture more individuals with the putative mutation, as is observed in the population attributable risk which is less for B than for A. Furthermore, these haplotypes show similar risk  
20 ratios and allelic frequencies for early-onset patients (defined as onset of first MI before the age of 55) and for both genders. In addition, analyzing various groups of patients with known risk factors, such as hypertension, high cholesterol, smoking and diabetes, does not reveal any significant correlation with these haplotypes, suggesting that the haplotypes in the FLAP gene represent an independent genetic susceptibility factor for MI.

25 Because stroke and PAOD are diseases that are closely related to MI (all occur on the basis of atherosclerosis), the SNP haplotype in the FLAP gene that confers risk to MI was assessed to determine whether it also conferred risk of stroke and/or PAOD. Table 20 shows that haplotype A4 increases the risk of having a stroke to a similar extent as it increases the risk of having an MI. Although not as significantly, haplotype A4 also confers risk of developing  
30 PAOD.

The FLAP nucleic acid encodes a 5-lipoxygenase activating protein, which, in combination with 5-lipoxygenase (5-LO), is required for leukotriene synthesis. FLAP acts

coordinately with 5-LO to catalyze the first step in the synthesis of leukotrienes from arachidonic acid. It catalyzes the conversion of arachidonic acid to 5(S)-hydroperoxy-6-trans-8,11,14-cis-eicosatetraenoic acid (5-HPETE), and further to the allylic epoxide 5 (S)-trans7,9 trans 11,14-cis-eicosatetraenoic acid (leukotriene A<sub>4</sub>, LTA<sub>4</sub>).

5        The leukotrienes are a family of highly potent biological mediators of inflammatory processes produced primarily by bone marrow derived leukocytes such as monocytes, macrophages, and neutrophils. Both FLAP and 5-LO are detected within atherosclerosis lesions (Proc Natl Acad Sci U S A. 2003 Feb 4;100(3):1238-43.), indicating that the vessel itself can be a source of leukotrienes. It was found at first that the MI-risk FLAP haplotype was associated with  
10    higher serum leukotriene levels. Increased production of leukotriene in individuals with pre-existing atherosclerosis lesions may lead to plaque instability or friability of the fibrous cap leading to local thrombotic events. If this occurs in coronary artery arteries it leads to MI or unstable angina. If it occurs in the cerebrovasculature it leads to stroke or transient ischemic attack. If it occurs in large arteries to the limbs, it causes or exacerbates limb ischemia in  
15    persons with peripheral arterial occlusive disease (PAOD). Therefore, those with genetically influenced predisposition to produce higher leukotriene levels have higher risk for events due to pre-existing atherosclerosis such as MI.

Inhibitors of FLAP function impede translocation of 5-LO from the cytoplasm to the cell membrane and inhibit activation of 5-LO and thereby decrease leukotriene synthesis.

20        As a result of these discoveries, methods are now available for the treatment of myocardial infarction (MI) and acute coronary syndrome (ACS), as well as stroke and PAOD, through the use of leukotriene inhibitors, such as agents that inhibit leukotriene biosynthesis or antagonize signaling through leukotriene receptors. The term, "treatment" as used herein, refers not only to ameliorating symptoms associated with the disease or condition, but also preventing  
25    or delaying the onset of the disease or condition; preventing or delaying the occurrence of a second episode of the disease or condition; and/or also lessening the severity or frequency of symptoms of the disease or condition. In the case of atherosclerosis, "treatment" also refers to a minimization or reversal of the development of plaques. Methods are additionally available for assessing an individual's risk for MI, ACS, stroke or PAOD. In a preferred embodiment,  
30    the individual to be treated is an individual who is susceptible (at increased risk) for MI, ACS, stroke or PAOD, such as an individual who is in one of the representative target populations described herein.

## REPRESENTATIVE TARGET POPULATIONS

In one embodiment of the invention, an individual who is at risk for MI, ACS, stroke or PAOD is an individual who has an at-risk haplotype in FLAP, as described herein. In one  
5 embodiment, a haplotype associated with a susceptibility to myocardial infarction, ACS, stroke or PAOD comprises markers SG13S99, SG13S25, SG13S377, SG13S106, SG13S32 and SG13S35 at the 13q12-13 locus. In another embodiment, a haplotype associated with a susceptibility to myocardial infarction, ACS, stroke or PAOD comprises markers SG13S99, SG13S25, SG13S106, SG13S30 and SG13S42 at the 13q12 locus. In a third embodiment, a  
10 haplotype associated with a susceptibility to myocardial infarction, ACS, stroke or PAOD comprises markers SG13S25, SG13S106, SG13S30 and SG13S42 at the 13q12-13 locus. In a fourth embodiment, a haplotype associated with a susceptibility to myocardial infarction, ACS, stroke or PAOD comprises markers SG13S99, SG13S25, SG13S114, SG13S89 and SG13S32 at the 13q12-13 locus. In a fifth embodiment, a haplotype associated with a susceptibility to  
15 myocardial infarction, ACS, stroke or PAOD comprises markers SG13S25, SG13S114, SG13S89 and SG13S32 at the 13q12-13 locus. Additional haplotypes associated with a susceptibility to myocardial infarction, ACS, stroke or PAOD include the haplotypes shown in Tables 4, 8, 9, 14, 15, 17 and 19, as well as haplotypes comprising markers shown in Table 13.

Increased risk for MI, ACS, stroke or PAOD in individuals with a FLAP at-risk  
20 haplotype is logically conferred by increased production of leukotrienes in the arterial vessel wall or in bone-marrow derived inflammatory cells within the blood and/or arterial vessel wall. It is shown herein that FLAP at-risk haplotypes are associated with higher production of LTB4 *ex vivo*. It is further shown herein that serum leukotriene levels (specifically, leukotriene E4) correlate with serum CRP levels in myocardial infarction patients. FLAP genetic variation may  
25 drive high leukotriene levels (within the blood vessel and/or systemically), which in turn may drive higher CRP levels which has been shown as a risk factor for MI. Accordingly, individuals with a FLAP at-risk haplotype are likely to have elevated serum CRP as well as other serum inflammatory markers. The level of serum CRP or other serum inflammatory markers can be used as a surrogate for the level of arterial wall inflammation initiated by lipid  
30 deposition and atherogenesis conferred by the presence of the at-risk FLAP haplotype.

In another embodiment of the invention, an individual who is at risk for MI, ACS, stroke or PAOD is an individual who has a polymorphism in a FLAP gene, in which the

presence of the polymorphism is indicative of a susceptibility to MI, ACS, stroke or PAOD. The term “gene,” as used herein, refers to not only the sequence of nucleic acids encoding a polypeptide, but also the promoter regions, transcription enhancement elements, splice donor/acceptor sites, and other non-transcribed nucleic acid elements. Representative  
5 polymorphisms include those presented in Table 13, below.

In a further embodiment of the invention, an individual who is at risk for MI, ACS, stroke or PAOD is an individual who has an at-risk polymorphism in the 5-LO gene in the promoter region, as described herein.

In a fourth embodiment, an individual who is at risk for MI, ACS, stroke or PAOD is an  
10 individual who has an elevated inflammatory marker. An “elevated inflammatory marker,” as used herein, is the presence of an amount of an inflammatory marker that is greater, by an amount that is statistically significant, than the amount that is typically found in control individual(s) or by comparison of disease risk in a population associated with the lowest band of measurement (*e.g.*, below the mean or median, the lowest quartile or the lowest quintile)  
15 compared to higher bands of measurement (*e.g.*, above the mean or median, the second, third or fourth quartile; the second, third, fourth or fifth quintile). An “inflammatory marker” refers to a molecule that is indicative of the presence of inflammation in an individual, for example, C-reactive protein (CRP), serum amyloid A, fibrinogen, leukotriene levels (*e.g.*, leukotriene B4, leukotriene C4), leukotriene metabolites (*e.g.*, leukotriene E4), interleukin-6, tissue necrosis  
20 factor-alpha, soluble vascular cell adhesion molecules (sVCAM), soluble intervascular adhesion molecules (sICAM), E-selectin, matrix metalloprotease type-1, matrix metalloprotease type-2, matrix metalloprotease type-3, matrix metalloprotease type-9, myeloperoxidase (MPO), N-tyrosine) or other markers (see, *e.g.*, Doggen, C.J.M. *et al.*, *J. Internal Med.*, 248:406-414 (2000); Ridker, P.M. *et al.*, *New Englnd. J. Med.* 1997: 336: 973-  
25 979, Rettersol, L. *et al.*, 2002: 160:433-440; Ridker, P.M. *et. al.*, *New England. J. Med.*, 2002: 347: 1557-1565; Bermudez, E.A. *et .al.*, *Arterioscler. Thromb. Vasc. Biol.* , 2002: 22:1668-1673). In certain embodiments, the presence of such inflammatory markers can be measured in serum or urine.

In a fifth embodiment, an individual who is at risk for MI, ACS, stroke or PAOD is an  
30 individual who has increased LDL cholesterol and/or decreased HDL cholesterol levels. For example, the American Heart Association indicates that an LDL cholesterol level of less than 100 mg/dL is optimal; from 100-129 mg/dL is near/above optimal; from 130-159 mg/dL is

borderline high; from 160-189 is high; and from 190 and up is very high. Therefore, an individual who is at risk for MI, ACS, stroke or PAOD because of an increased LDL cholesterol level is, for example, an individual who has more than 100 mg/dL cholesterol, such as an individual who has a near/above optimal level, a borderline high level, a high level or a very high level. Similarly, the American Heart Association indicates that an HDL cholesterol level of less than 40 mg/dL is a major risk factor for heart disease; and an HDL cholesterol level of 60 mg/dL or more is protective against heart disease. Thus, an individual who is at risk for MI, ACS, stroke or PAOD because of a decreased HDL cholesterol level is, for example, an individual who has less than 60 mg/dL HDL cholesterol, such as an individual who has less than 40 mg/dL HDL cholesterol.

In a sixth embodiment, an individual who is at risk for MI, ACS, stroke or PAOD is an individual who has increased leukotriene synthesis. "Increased leukotriene synthesis," as used herein, indicates an amount of production of leukotrienes that is greater, by an amount that is statistically significant, than the amount of production of leukotrienes that is typically found in control individual(s) or by comparison of leukotriene production in a population associated with the lowest band of measurement (*e.g.*, below the mean or median, the lowest quartile or the lowest quintile) compared to higher bands of measurement (*e.g.*, above the mean or median, the second, third or fourth quartile; the second, third, fourth or fifth quintile). For example, the FLAP at-risk haplotypes correlate with increased serum leukotriene synthesis levels, and with increased production of leukotrienes *ex vivo*. An individual can be assessed for the presence of increased leukotriene synthesis by a variety of methods. For example, an individual can be assessed for an increased risk of MI, ACS, stroke, PAOD or atherosclerosis, by assessing the level of a leukotriene metabolite (*e.g.*, LTE<sub>4</sub>) in a sample (*e.g.*, serum, plasma or urine) from the individual. Samples containing blood, cells, or tissue can also be obtained from an individual and used to assess leukotriene or leukotriene metabolite production *ex vivo* under appropriate assay conditions. An increased level of leukotriene metabolites, and/or an increased level of leukotriene production *ex vivo*, is indicative of increased production of leukotrienes in the individual, and of an increased risk of MI, ACS, stroke, PAOD or atherosclerosis.

In a further embodiment, an individual who is at risk for MI, ACS, or stroke is an individual who has already experienced at least one MI, ACS event or stroke, or who has stable angina, and is therefore at risk for a second MI, ACS event or stroke. In another embodiment,

an individual who is at risk for MI, ACS, stroke or PAOD is an individual who has atherosclerosis or who requires treatment (*e.g.*, angioplasty, stents, revascularization procedure) to restore blood flow in arteries.

In further embodiments, an individual who is at risk for MI, stroke or PAOD is an individual having asymptomatic ankle/brachial index of less than 0.9; an individual who is at risk for stroke, is an individual who has had one or more transient ischemic attacks; who has had transient monocular blindness; has had a carotid endarterectomy; or has asymptomatic carotid stenosis; an individual who is at risk for PAOD, is an individual who has (or had) claudication, limb ischemia leading to gangrene, ulceration or amputation, or has had a revascularization procedure.

In additional embodiments, an individual who is at risk for MI, ACS, stroke or PAOD is an individual who has diabetes; hypertension; hypercholesterolemia; elevated triglycerides (*e.g.*, > 200 mg/dl); elevated lp(a); obesity; ankle/brachial index (ABI) less than 0.9; and/or is a past or current smoker.

Individuals at risk for MI, ACS, stroke or PAOD may fall into more than one of these representative target populations. For example, an individual may have experienced at least one MI, ACS event, transient ischemic attack, transient monocular blindness, or stroke, and may also have an increased level of an inflammatory marker. As used therein, the term “individual in a target population” refers to an individual who is at risk for MI, ACS, stroke or PAOD who falls into at least one of the representative target populations described above.

#### ASSESSMENT FOR AT-RISK HAPLOTYPES

A “haplotype,” as described herein, refers to a combination of genetic markers (“alleles”), such as those set forth in Table 13. In a certain embodiment, the haplotype can comprise one or more alleles (*e.g.*, a haplotype containing a single SNP), two or more alleles, three or more alleles, four or more alleles, or five or more alleles. The genetic markers are particular “alleles” at “polymorphic sites” associated with FLAP. A nucleotide position at which more than one sequence is possible in a population (either a natural population or a synthetic population, *e.g.*, a library of synthetic molecules), is referred to herein as a “polymorphic site”. Where a polymorphic site is a single nucleotide in length, the site is referred to as a single nucleotide polymorphism (“SNP”). For example, if at a particular chromosomal location, one member of a population has an adenine and another member of the population has a thymine at the same

position, then this position is a polymorphic site, and, more specifically, the polymorphic site is a SNP. Polymorphic sites can allow for differences in sequences based on substitutions, insertions or deletions. Each version of the sequence with respect to the polymorphic site is referred to herein as an “allele” of the polymorphic site. Thus, in the previous example, the  
5 SNP allows for both an adenine allele and a thymine allele.

Typically, a reference sequence is referred to for a particular sequence. Alleles that differ from the reference are referred to as “variant” alleles. For example, the reference FLAP sequence is described herein by SEQ ID NO: 1. The term, “variant FLAP”, as used herein, refers to a sequence that differs from SEQ ID NO: 1, but is otherwise substantially similar. The  
10 genetic markers that make up the haplotypes described herein are FLAP variants.

Additional variants can include changes that affect a polypeptide, *e.g.*, the FLAP polypeptide. These sequence differences, when compared to a reference nucleotide sequence, can include the insertion or deletion of a single nucleotide, or of more than one nucleotide, resulting in a frame shift; the change of at least one nucleotide, resulting in a change in the  
15 encoded amino acid; the change of at least one nucleotide, resulting in the generation of a premature stop codon; the deletion of several nucleotides, resulting in a deletion of one or more amino acids encoded by the nucleotides; the insertion of one or several nucleotides, such as by unequal recombination or gene conversion, resulting in an interruption of the coding sequence of a reading frame; duplication of all or a part of a sequence; transposition; or a rearrangement  
20 of a nucleotide sequence, as described in detail above. Such sequence changes alter the polypeptide encoded by a FLAP nucleic acid. For example, if the change in the nucleic acid sequence causes a frame shift, the frame shift can result in a change in the encoded amino acids, and/or can result in the generation of a premature stop codon, causing generation of a truncated polypeptide. Alternatively, a polymorphism associated with a susceptibility to MI,  
25 ACS, stroke or PAOD can be a synonymous change in one or more nucleotides (*i.e.*, a change that does not result in a change in the amino acid sequence). Such a polymorphism can, for example, alter splice sites, affect the stability or transport of mRNA, or otherwise affect the transcription or translation of the polypeptide. The polypeptide encoded by the reference nucleotide sequence is the “reference” polypeptide with a particular reference amino acid  
30 sequence, and polypeptides encoded by variant alleles are referred to as “variant” polypeptides with variant amino acid sequences.

Haplotypes are a combination of genetic markers, *e.g.*, particular alleles at polymorphic sites. The haplotypes described herein, *e.g.*, having markers such as those shown in Table 13, are found more frequently in individuals with MI, ACS, stroke or PAOD than in individuals without MI, ACS, stroke or PAOD. Therefore, these haplotypes have predictive value for  
5 detecting a susceptibility to MI, ACS, stroke or PAOD in an individual. The haplotypes described herein are in some cases a combination of various genetic markers, *e.g.*, SNPs and microsatellites. Therefore, detecting haplotypes can be accomplished by methods known in the art for detecting sequences at polymorphic sites, such as the methods described above.

In certain methods described herein, an individual who is at risk for MI, ACS, stroke  
10 or PAOD is an individual in whom an at-risk haplotype is identified. In one embodiment, the at-risk haplotype is one that confers a significant risk of MI, ACS, stroke or PAOD. In one embodiment, significance associated with a haplotype is measured by an odds ratio. In a further embodiment, the significance is measured by a percentage. In one embodiment, a significant risk is measured as an odds ratio of at least about 1.2, including by not limited to:  
15 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, and 1.9. In a further embodiment, an odds ratio of at least 1.2 is significant. In a further embodiment, an odds ratio of at least about 1.5 is significant. In a further embodiment, a significant increase in risk is at least about 1.7 is significant. In a further embodiment, a significant increase in risk is at least about 20%, including but not limited to about 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%,  
20 90%, 95%, and 98%. In a further embodiment, a significant increase in risk is at least about 50%. In yet another embodiment, an at-risk haplotype has a  $p$  value  $< 0.05$ . It is understood however, that identifying whether a risk is medically significant may also depend on a variety of factors, including the specific disease, the haplotype, and often, environmental factors.

An at-risk haplotype in, or comprising portions of, the FLAP gene, in one where the  
25 haplotype is more frequently present in an individual at risk for MI, ACS, stroke or PAOD (affected), compared to the frequency of its presence in a healthy individual (control), and wherein the presence of the haplotype is indicative of susceptibility to MI, ACS, stroke or PAOD. As an example of a simple test for correlation would be a Fisher-exact test on a two by two table. Given a cohort of chromosomes the two by two table is constructed out of the  
30 number of chromosomes that include both of the haplotypes, one of the haplotype but not the other and neither of the haplotypes.



In certain embodiments, an at-risk haplotype is an at-risk haplotype within or near FLAP that significantly correlates with a haplotype such as a haplotype shown in Table 14; a haplotype shown in Table 15; a haplotype shown in Table 19; haplotype B4; haplotype B5; haplotype B6; haplotype A4; haplotype A5; or haplotype HapB. In other embodiments, an at-risk haplotype comprises an at-risk haplotype within or near FLAP that significantly correlates with susceptibility to myocardial infarction or stroke. In a particular embodiment, a haplotype associated with a susceptibility to myocardial infarction, ACS, stroke or PAOD comprises markers SG13S99, SG13S25, SG13S377, SG13S106, SG13S32 and SG13S35 at the 13q12-13 locus. In another embodiment, a haplotype associated with a susceptibility to myocardial infarction, ACS, stroke or PAOD comprises markers SG13S99, SG13S25, SG13S106, SG13S30 and SG13S42 at the 13q12-13 locus. In a third embodiment, a haplotype associated with a susceptibility to myocardial infarction, ACS, stroke or PAOD comprises markers SG13S25, SG13S106, SG13S30 and SG13S42 at the 13q12-13 locus. In a fourth embodiment, a haplotype associated with a susceptibility to myocardial infarction, ACS, stroke or PAOD comprises markers SG13S99, SG13S25, SG13S114, SG13S89 and SG13S32 at the 13q12-13 locus. In other embodiments, the at-risk haplotype is selected from the group consisting of: haplotype B4, B5, B6, A4 and A5. The at-risk haplotype can also comprise a combination of the markers in the haplotypes B4, B5, B6, A4 and/or A5. In further embodiments, the at-risk haplotype can be haplotype HapB. In other embodiments, the at-risk haplotype comprises a polymorphism shown in Table 13.

Standard techniques for genotyping for the presence of SNPs and/or microsatellite markers can be used, such as fluorescent based techniques (Chen, *et al.*, *Genome Res.* 9, 492 (1999)), PCR, LCR, Nested PCR and other techniques for nucleic acid amplification. In a preferred embodiment, the method comprises assessing in an individual the presence or frequency of SNPs and/or microsatellites in, comprising portions of, the FLAP gene, wherein an excess or higher frequency of the SNPs and/or microsatellites compared to a healthy control individual is indicative that the individual is susceptible to MI, ACS, stroke or PAOD. See, for example, Table 13 (below) for SNPs and markers that can form haplotypes that can be used as screening tools. These markers and SNPs can be identified in at-risk haplotypes. For example, an at-risk haplotype can include microsatellite markers and/or SNPs such as those set forth in Table 13. The presence of the haplotype is indicative of a susceptibility to MI, ACS,

stroke or PAOD, and therefore is indicative of an individual who falls within a target population for the treatment methods described herein.

Haplotype analysis involves defining a candidate susceptibility locus using LOD scores. The defined regions are then ultra-fine mapped with microsatellite markers with an average  
5 spacing between markers of less than 100 kb. All usable microsatellite markers that are found in public databases and mapped within that region can be used. In addition, microsatellite markers identified within the deCODE genetics sequence assembly of the human genome can be used. The frequencies of haplotypes in the patient and the control groups can be estimated using an expectation-maximization algorithm (Dempster A. *et al.*, 1977. *J. R. Stat. Soc. B*, 39:1-  
10 389). An implementation of this algorithm that can handle missing genotypes and uncertainty with the phase can be used. Under the null hypothesis, the patients and the controls are assumed to have identical frequencies. Using a likelihood approach, an alternative hypothesis is tested, where a candidate at-risk-haplotype, which can include the markers described herein, is allowed to have a higher frequency in patients than controls, while the ratios of the  
15 frequencies of other haplotypes are assumed to be the same in both groups. Likelihoods are maximized separately under both hypotheses and a corresponding 1-df likelihood ratio statistic is used to evaluate the statistic significance.

To look for at-risk-haplotypes in the 1-lod drop, for example, association of all possible combinations of genotyped markers is studied, provided those markers span a  
20 practical region. The combined patient and control groups can be randomly divided into two sets, equal in size to the original group of patients and controls. The haplotype analysis is then repeated and the most significant p-value registered is determined. This randomization scheme can be repeated, for example, over 100 times to construct an empirical distribution of p-values. In a preferred embodiment, a p-value of  $<0.05$  is  
25 indicative of an at-risk haplotype.

A detailed discussion of haplotype analysis follows.

### *Haplotype analysis*

Our general approach to haplotype analysis involves using likelihood-based inference  
30 applied to NESTED MODELS. The method is implemented in our program NEMO, which allows for many polymorphic markers, SNPs and microsatellites. The method and software are

specifically designed for case-control studies where the purpose is to identify haplotype groups that confer different risks. It is also a tool for studying LD structures.

When investigating haplotypes constructed from many markers, apart from looking at each haplotype individually, meaningful summaries often require putting haplotypes into groups. A particular partition of the haplotype space is a model that assumes haplotypes within a group have the same risk, while haplotypes in different groups can have different risks. Two models/partitions are nested when one, the alternative model, is a finer partition compared to the other, the null model, *i.e.*, the alternative model allows some haplotypes assumed to have the same risk in the null model to have different risks. The models are nested in the classical sense that the null model is a special case of the alternative model. Hence traditional generalized likelihood ratio tests can be used to test the null model against the alternative model. Note that, with a multiplicative model, if haplotypes  $h_i$  and  $h_j$  are assumed to have the same risk, it corresponds to assuming that  $f_i/p_i = f_j/p_j$  where  $f$  and  $p$  denote haplotype frequencies in the affected population and the control population respectively.

One common way to handle uncertainty in phase and missing genotypes is a two-step method of first estimating haplotype counts and then treating the estimated counts as the exact counts, a method that can sometimes be problematic (*e.g.*, see the information measure section below) and may require randomization to properly evaluate statistical significance. In NEMO, maximum likelihood estimates, likelihood ratios and p-values are calculated directly, with the aid of the EM algorithm, for the observed data treating it as a missing-data problem.

NEMO allows complete flexibility for partitions. For example, the first haplotype problem described in the Methods section on Statistical analysis considers testing whether  $h_1$  has the same risk as the other haplotypes  $h_2, \dots, h_k$ . Here the alternative grouping is  $[h_1], [h_2, \dots, h_k]$  and the null grouping is  $[h_1, \dots, h_k]$ . The second haplotype problem in the same section involves three haplotypes  $h_1 = G0$ ,  $h_2 = GX$  and  $h_3 = AX$ , and the focus is on comparing  $h_1$  and  $h_2$ . The alternative grouping is  $[h_1], [h_2], [h_3]$  and the null grouping is  $[h_1, h_2], [h_3]$ . If composite alleles exist, one could collapse these alleles into one at the data processing stage, and performed the test as described. This is a perfectly valid approach, and indeed, whether we collapse or not makes no difference if there were no missing information regarding phase. But, with the actual data, if each of the alleles making up a composite correlates differently with the SNP alleles, this will provide some partial information on phase. Collapsing at the data processing stage will unnecessarily increase the amount of missing information. A

nested-models/partition framework can be used in this scenario. Let  $h_2$  be split into  $h_{2a}, h_{2b}, \dots, h_{2e}$ , and  $h_3$  be split into  $h_{3a}, h_{3b}, \dots, h_{3e}$ . Then the alternative grouping is  $[h_1], [h_{2a}, h_{2b}, \dots, h_{2e}], [h_{3a}, h_{3b}, \dots, h_{3e}]$  and the null grouping is  $[h_1, h_{2a}, h_{2b}, \dots, h_{2e}], [h_{3a}, h_{3b}, \dots, h_{3e}]$ .

The same method can be used to handle composite where collapsing at the data processing stage is not even an option since  $L_C$  represents multiple haplotypes constructed from multiple SNPs. Alternatively, a 3-way test with the alternative grouping of  $[h_1], [h_{2a}, h_{2b}, \dots, h_{2e}], [h_{3a}, h_{3b}, \dots, h_{3e}]$  versus the null grouping of  $[h_1, h_{2a}, h_{2b}, \dots, h_{2e}, h_{3a}, h_{3b}, \dots, h_{3e}]$  could also be performed. Note that the generalized likelihood ratio test-statistic would have two degrees of freedom instead of one.

### *Measuring information*

Even though likelihood ratio tests based on likelihoods computed directly for the observed data, which have captured the information loss due to uncertainty in phase and missing genotypes, can be relied on to give valid p-values, it would still be of interest to know how much information had been lost due to the information being incomplete. Interestingly, one can measure information loss by considering a two-step procedure to evaluating statistical significance that appears natural but happens to be systematically anti-conservative. Suppose we calculate the maximum likelihood estimates for the population haplotype frequencies calculated under the alternative hypothesis that there are differences between the affected population and control population, and use these frequency estimates as estimates of the observed frequencies of haplotype counts in the affected sample and in the control sample. Suppose we then perform a likelihood ratio test treating these estimated haplotype counts as though they are the actual counts. We could also perform a Fisher's exact test, but we would then need to round off these estimated counts since they are in general non-integers. This test will in general be anti-conservative because treating the estimated counts as if they were exact counts ignores the uncertainty with the counts, overestimates the effective sample size and underestimates the sampling variation. It means that the chi-square likelihood-ratio test statistic calculated this way, denoted by  $\Lambda^*$ , will in general be bigger than  $\Lambda$ , the likelihood-ratio test-statistic calculated directly from the observed data as described in methods. But  $\Lambda^*$  is useful because the ratio  $\Lambda/\Lambda^*$  happens to be a good measure of information, or  $1 - (\Lambda/\Lambda^*)$  is a measure of the fraction of information lost due to missing information. This information measure for haplotype analysis is described in Nicolae and Kong, Technical Report 537,

Department of Statistics, University of Statistics, University of Chicago, Revised for *Biometrics* (2003) as a natural extension of information measures defined for linkage analysis, and is implemented in NEMO.

## 5 *Statistical analysis.*

For single marker association to the disease, the Fisher exact test can be used to calculate two-sided p-values for each individual allele. All p-values are presented unadjusted for multiple comparisons unless specifically indicated. The presented frequencies (for microsatellites, SNPs and haplotypes) are allelic frequencies as opposed to carrier frequencies. To minimize  
10 any bias due the relatedness of the patients who were recruited as families for the linkage analysis, first and second-degree relatives can be eliminated from the patient list.

Furthermore, the test can be repeated for association correcting for any remaining relatedness among the patients, by extending a variance adjustment procedure (*e.g.*, as described in Risch, N. & Teng, J., "The relative power of family-based and case-control designs for linkage  
15 disequilibrium studies of complex human diseases I. DNA pooling," *Genome Res.* 8:1278-1288 (1998)) for sibships so that it can be applied to general familial relationships, and present both adjusted and unadjusted p-values for comparison. The differences are in general very small as expected. To assess the significance of single-marker association corrected for multiple testing we carried out a randomisation test using the same genotype data. Cohorts of  
20 patients and controls can be randomized and the association analysis redone multiple times (*e.g.*, up to 500,000 times) and the p-value is the fraction of replications that produced a p-value for some marker allele that is lower than or equal to the p-value we observed using the original patient and control cohorts.

For both single-marker and haplotype analyses, relative risk (RR) and the population  
25 attributable risk (PAR) can be calculated assuming a multiplicative model (haplotype relative risk model), (Terwilliger, J.D. & Ott, J., *Hum Hered*, 42, 337-46 (1992) and Falk, C.T. & Rubinstein, P, *Ann Hum Genet* 51 ( Pt 3), 227-33 (1987)), *i.e.*, that the risks of the two alleles/haplotypes a person carries multiply. For example, if RR is the risk of A relative to a, then the risk of a person homozygote AA will be RR times that of a heterozygote Aa and  $RR^2$   
30 times that of a homozygote aa. The multiplicative model has a nice property that simplifies analysis and computations - haplotypes are independent, *i.e.*, in Hardy-Weinberg equilibrium, within the affected population as well as within the control population. As a consequence,

haplotype counts of the affecteds and controls each have multinomial distributions, but with different haplotype frequencies under the alternative hypothesis. Specifically, for two haplotypes  $h_i$  and  $h_j$ ,  $\text{risk}(h_i)/\text{risk}(h_j) = (f_i/p_i)/(f_j/p_j)$ , where  $f$  and  $p$  denote respectively frequencies in the affected population and in the control population. While there is some power loss if the true model is not multiplicative, the loss tends to be mild except for extreme cases. Most importantly, p-values are always valid since they are computed with respect to null hypothesis.

In general, haplotype frequencies are estimated by maximum likelihood and tests of differences between cases and controls are performed using a generalized likelihood ratio test (Rice, J.A. *Mathematical Statistics and Data Analysis*, 602 (International Thomson Publishing, (1995)). deCODE's haplotype analysis program called NEMO, which stands for NEsted MOdels, can be used to calculate all the haplotype results. To handle uncertainties with phase and missing genotypes, it is emphasized that we do not use a common two-step approach to association tests, where haplotype counts are first estimated, possibly with the use of the EM algorithm, Dempster, (A.P., Laird, N.M. & Rubin, D.B., *Journal of the Royal Statistical Society B*, 39, 1-38 (1971)) and then tests are performed treating the estimated counts as though they are true counts, a method that can sometimes be problematic and may require randomisation to properly evaluate statistical significance. Instead, with NEMO, maximum likelihood estimates, likelihood ratios and p-values are computed with the aid of the EM-algorithm directly for the observed data, and hence the loss of information due to uncertainty with phase and missing genotypes is automatically captured by the likelihood ratios. Even so, it is of interest to know how much information is retained, or lost, due to incomplete information. Described herein is such a measure that is natural under the likelihood framework. For a fixed set of markers, the simplest tests performed compare one selected haplotype against all the others. Call the selected haplotype  $h_1$  and the others  $h_2, \dots, h_k$ . Let  $p_1, \dots, p_k$  denote the population frequencies of the haplotypes in the controls, and  $f_1, \dots, f_k$  denote the population frequencies of the haplotypes in the affecteds. Under the null hypothesis,  $f_i = p_i$  for all  $i$ . The alternative model we use for the test assumes  $h_2, \dots, h_k$  to have the same risk while  $h_1$  is allowed to have a different risk. This implies that while  $p_1$  can be different from  $f_1$ ,  $f_i/(f_2 + \dots + f_k) = p_i/(p_2 + \dots + p_k) = \beta_i$  for  $i = 2, \dots, k$ . Denoting  $f_1/p_1$  by  $r$ , and noting that  $\beta_2 + \dots + \beta_k = 1$ , the test statistic based on generalized likelihood ratios is

$$\Lambda = 2 \left[ \ell(\hat{r}, \hat{p}_1, \hat{\beta}_2, \dots, \hat{\beta}_{k-1}) - \ell(1, \tilde{p}_1, \tilde{\beta}_2, \dots, \tilde{\beta}_{k-1}) \right]$$

where  $\ell$  denotes log-likelihood and  $\tilde{\cdot}$  and  $\hat{\cdot}$  denote maximum likelihood estimates under the null hypothesis and alternative hypothesis respectively.  $\Lambda$  has asymptotically a chi-square distribution with 1-df, under the null hypothesis. Slightly more complicated null and alternative hypotheses can also be used. For example, let  $h_1$  be G0,  $h_2$  be GX and  $h_3$  be AX.

5 When comparing G0 against GX, *i.e.*, this is the test which gives estimated RR of 1.46 and p-value = 0.0002, the null assumes G0 and GX have the same risk but AX is allowed to have a different risk. The alternative hypothesis allows, for example, three haplotype groups to have different risks. This implies that, under the null hypothesis, there is a constraint that  $f_1/p_1 = f_2/p_2$ , or  $w = [f_1/p_1]/[f_2/p_2] = 1$ . The test statistic based on generalized likelihood ratios is

$$10 \quad \Lambda = 2 \left[ \ell(\hat{p}_1, \hat{f}_1, \hat{p}_2, \hat{w}) - \ell(\tilde{p}_1, \tilde{f}_1, \tilde{p}_2, 1) \right]$$

that again has asymptotically a chi-square distribution with 1-df under the null hypothesis. If there are composite haplotypes (for example,  $h_2$  and  $h_3$ ), that is handled in a natural manner under the nested models framework.

LD between pairs of SNPs can be calculated using the standard definition of  $D'$  and  $R^2$  (Lewontin, R., *Genetics* 49, 49-67 (1964) and Hill, W.G. & Robertson, A. *Theor. Appl. Genet.* 22, 226-231 (1968)). Using NEMO, frequencies of the two marker allele combinations are estimated by maximum likelihood and deviation from linkage equilibrium is evaluated by a likelihood ratio test. The definitions of  $D'$  and  $R^2$  are extended to include microsatellites by averaging over the values for all possible allele combination of the two markers weighted by the marginal allele probabilities. When plotting all marker combination to elucidate the LD structure in a particular region, we plot  $D'$  in the upper left corner and the p-value in the lower right corner. In the LD plots the markers can be plotted equidistant rather than according to their physical location, if desired.

### *Statistical Methods for Linkage Analysis*

25 Multipoint, affected-only allele-sharing methods can be used in the analyses to assess evidence for linkage. Results, both the LOD-score and the non-parametric linkage (NPL) score, can be obtained using the program Allegro (Gudbjartsson *et al.*, *Nat. Genet.* 25:12-3, 2000). Our baseline linkage analysis uses the Spairs scoring function (Whittemore, A.S., Halpern, J. (1994), *Biometrics* 50:118-27; Kruglyak L, *et al.* (1996), *Am J Hum Genet* 30 58:1347-63), the exponential allele-sharing model (Kong, A. and Cox, N.J. (1997), *Am J Hum Genet* 61:1179-88) and a family weighting scheme that is halfway, on the log-scale, between

weighting each affected pair equally and weighting each family equally. The information measure we use is part of the Allegro program output and the information value equals zero if the marker genotypes are completely uninformative and equals one if the genotypes determine the exact amount of allele sharing by decent among the affected relatives (Gretarsdottir *et al.*,  
5 *Am. J. Hum. Genet.*, 70:593-603, (2002)). We computed the P-values two different ways and here report the less significant result. The first P-value can be computed on the basis of large sample theory; the distribution of  $Z_{lr} = \sqrt{(2[\log_e(10)\text{LOD}])}$  approximates a standard normal variable under the null hypothesis of no linkage (Kong, A. and Cox, N.J. (1997), *Am J Hum Genet* 61:1179-88). The second P-value can be calculated by comparing the observed LOD-  
10 score with its complete data sampling distribution under the null hypothesis (e.g., Gudbjartsson *et al.*, *Nat. Genet.* 25:12-3, 2000). When the data consist of more than a few families, these two P-values tend to be very similar.

#### METHODS OF TREATMENT

15 The present invention encompasses methods of treatment (prophylactic and/or therapeutic, as described above) for MI, ACS, stroke or PAOD in individuals, such as individuals in the target populations described above, as well as for other diseases and conditions associated with FLAP or with other members of the leukotriene pathway (e.g., for atherosclerosis). Members of the "leukotriene pathway," as used herein, include  
20 polypeptides (e.g., enzymes, receptors) and other molecules that are associated with production of leukotrienes: for example, proteins or enzymes such as FLAP, 5-LO, other leukotriene biosynthetic enzymes (e.g., leukotriene C4 synthase, leukotriene A4 hydrolase); receptors or binding agents of the enzymes; leukotrienes such as LTA4, LTB4, LTC4, LTD4, LTE4; and receptors of leukotrienes (e.g., leukotriene B4 receptor 1 (BLT1),  
25 leukotriene B4 receptor 2 (BLT2), cysteinyl leukotriene receptor 1 (CysLTR1), cysteinyl leukotriene receptor 2 (CysLTR2)).

In particular, the invention relates to methods of treatment for myocardial infarction or susceptibility to myocardial infarction (for example, for individuals in an at-risk population such as those described above); as well as methods of treatment for acute coronary  
30 syndrome (e.g., unstable angina, non-ST-elevation myocardial infarction (NSTEMI) or ST-elevation myocardial infarction (STEMI)); methods for reducing risk of MI, stroke or PAOD in persons with asymptomatic ankle/brachial index less than 0.9; for decreasing risk



of a second myocardial infarction; for stroke or susceptibility to stroke; for transient ischemic attack; for transient monocular blindness; for decreasing risk of a second stroke; for PAOD or susceptibility to PAOD; for ABI less than 0.9; for claudication or limb ischemia; for atherosclerosis, such as for patients requiring treatment (*e.g.*, angioplasty, stents, revascularization procedure) to restore blood flow in arteries (*e.g.*, coronary, carotid, and/or femoral arteries); for treatment of asymptomatic ankle/brachial index of less than 0.9; and/or for decreasing leukotriene synthesis (*e.g.*, for treatment of MI, ACS, stroke or PAOD). The invention additionally pertains to use of one or more leukotriene synthesis inhibitors, as described herein, for the manufacture of a medicament for the treatment of MI, ACS, stroke, PAOD and/or atherosclerosis, *e.g.*, using the methods described herein. The invention also provides for the use of one or more leukotriene synthesis inhibitors, as described herein, for the manufacture of a medicament for reducing the risk for MI, ACS, PAOD, stroke and/or atherosclerosis using the methods described herein. These medicaments may comprise a leukotriene synthesis inhibitor alone or in combination with a statin, as described herein.

In the methods of the invention, a "leukotriene synthesis inhibitor" is used. In one embodiment, a "leukotriene synthesis inhibitor" is an agent that inhibits FLAP polypeptide activity and/or FLAP nucleic acid expression, as described herein (*e.g.*, a nucleic acid antagonist). In another embodiment, a leukotriene synthesis inhibitor is an agent that inhibits polypeptide activity and/or nucleic acid expression of another member of the leukotriene biosynthetic pathway (*e.g.*, 5-LO; LTC4S; LTA4H; LTB4DH). In still another embodiment, a leukotriene synthesis inhibitor is an agent that alters activity or metabolism of a leukotriene (*e.g.*, an antagonist of a leukotriene; an antagonist of a leukotriene receptor). In preferred embodiments, the leukotriene synthesis inhibitor alters activity and/or nucleic acid expression of FLAP or of 5-LO, or alters interaction between FLAP and 5-LO.

Leukotriene synthesis inhibitors can alter polypeptide activity or nucleic acid expression of a member of the leukotriene pathway by a variety of means, such as, for example, by catalytically degrading, downregulating or interfering with the expression, transcription or translation of a nucleic acid encoding the member of the leukotriene pathway; by altering posttranslational processing of the polypeptide; by altering transcription of splicing variants; or by interfering with polypeptide activity (*e.g.*, by

binding to the polypeptide, or by binding to another polypeptide that interacts with that member of the leukotriene pathway, such as a FLAP binding agent as described herein or some other binding agent of a member of the leukotriene pathway; by altering interaction among two or more members of the leukotriene pathway (*e.g.*, interaction between FLAP and 5-LO); or by antagonizing activity of a member of the leukotriene pathway.

Representative leukotriene synthesis inhibitors include the following:

agents that inhibit activity of a member of the leukotriene biosynthetic pathway (*e.g.*, FLAP, 5-LO), LTC<sub>4</sub>S, LTA<sub>4</sub>H, such as the agents presented in the Agent Table I below; agents that inhibit activity of receptors of members of the leukotriene pathway, such as FLAP receptors, LTA<sub>4</sub> receptors, LTB<sub>4</sub> receptors, LTC<sub>4</sub> receptors, LTD<sub>4</sub> receptors, LTE<sub>4</sub> receptors, Cys LT<sub>1</sub> receptors, Cys LT<sub>2</sub> receptors, 5-LO receptors; BLT<sub>1</sub>; BLT<sub>2</sub>; CysLTR<sub>1</sub>; CysLTR<sub>2</sub>; agents that bind to the members of the leukotriene pathway, such as FLAP binding agents (*e.g.*, 5-LO) or agents that bind to receptors of members of the leukotriene pathway (*e.g.*, leukotriene receptor antagonists); agents that bind to a leukotriene (*e.g.*, to LTA<sub>4</sub>, LTB<sub>4</sub>, LTC<sub>4</sub>, LTD<sub>4</sub>, LTE<sub>4</sub>, Cys LT<sub>1</sub>, Cys LT<sub>2</sub>); agents that increase breakdown of leukotrienes (*e.g.*, LTB<sub>4</sub>DH); or other agents that otherwise affect (*e.g.*, increase or decrease) activity of the leukotriene;

antibodies to leukotrienes;

antisense nucleic acids or small double-stranded interfering RNA, to nucleic acids encoding FLAP, 5-LO, or a leukotriene synthetase or other member of the leukotriene pathway, or fragments or derivatives thereof, including antisense nucleic acids to nucleic acids encoding the FLAP, 5-LO or leukotriene synthetase polypeptides, and vectors comprising such antisense nucleic acids (*e.g.*, nucleic acid, cDNA, and/or mRNA, double-stranded interfering RNA, or a nucleic acid encoding an active fragment or derivative thereof, or an oligonucleotide; for example, the complement of one of SEQ ID Nos. 1 or 3, or a nucleic acid complementary to the nucleic acid encoding SEQ ID NO: 2, or fragments or derivatives thereof);

peptidomimetics; fusion proteins or prodrugs thereof; ribozymes; other small molecules; and

other agents that alter (*e.g.*, inhibit or antagonize) expression of a member of the leukotriene pathway, such as FLAP or 5-LO nucleic acid expression or polypeptide activity, or that regulate transcription of FLAP splicing variants or 5-LO splicing variants (*e.g.*, agents that affect which splicing variants are expressed, or that affect the amount of each splicing variant that is expressed).






More than one leukotriene synthesis inhibitor can be used concurrently, if desired.






The therapy is designed to alter activity of a FLAP polypeptide, a 5-LO polypeptide, or another member of the leukotriene pathway in an individual, such as by inhibiting or antagonizing activity. For example, a leukotriene synthesis inhibitor can be administered in order to decrease synthesis of leukotrienes within the individual, or to downregulate or decrease the expression or availability of the FLAP nucleic acid or specific splicing variants of the FLAP nucleic acid. Downregulation or decreasing expression or availability of a native FLAP nucleic acid or of a particular splicing variant could minimize the expression or activity of a defective nucleic acid or the particular splicing variant and thereby minimize the impact of the defective nucleic acid or the particular splicing variant. Similarly, for example, a leukotriene synthesis inhibitor can be administered in order to downregulate or decrease the expression or availability of the nucleic acid encoding 5-LO or specific splicing variants of the nucleic acid encoding 5-LO.

The leukotriene synthesis inhibitor(s) are administered in a therapeutically effective amount (*i.e.*, an amount that is sufficient to treat the disease or condition, such as by ameliorating symptoms associated with the disease or condition, preventing or delaying the onset of the disease or condition, and/or also lessening the severity or frequency of symptoms of the disease or condition). The amount which will be therapeutically effective in the treatment of a particular individual's disease or condition will depend on the symptoms and severity of the disease, and can be determined by standard clinical techniques. In addition, *in vitro* or *in vivo* assays may optionally be employed to help identify optimal dosage ranges. The precise dose to be employed in the formulation will also depend on the route of administration, and the seriousness of the disease or disorder, and should be decided according to the judgment of a practitioner and each patient's circumstances. Effective doses may be extrapolated from dose-response curves derived from *in vitro* or animal model test systems.

In preferred embodiments of the invention, the leukotriene synthesis inhibitor agent is an agent that inhibits activity of FLAP and/or of 5-LO. Preferred agents include the following, as set forth in Agent Table I below:

Agent Table I

Company	Product_Name (Code)	Structure	Chemical Name	Patent Ref	Date Patent Issued/Applica tion Published	MOA
Abbott	atralleuton (ABT-761)		(R)-(+)-N-[3-[5-[(4-fluorophenyl)methyl]-2-thienyl]-1-methyl-2-propynyl]-N-hydroxurea	US 5288751, US 5288743, US 5616596	2/22/94 04/01/97	5-LPO inhibitor
Abbott	A-81834		3-(3-(1,1-dimethylethylthio-5-(quinoline-2-ylmethoxy)-1-(4-chloromethylphenyl)indole-2-yl)-2,2-dimethylpropanaldehyde oxime-0-2-acetic acid	WO9203132, US 5459150	3/5/1992, 10/17/95	FLAP inhibitor
Abbott	A-86886		3-(3-(1,1-dimethylethylthio-5-(pyridin-2-ylmethoxy)-1-(4-chloromethylphenyl)indole-2-yl)-2,2-dimethylpropanaldehyde oxime-0-2-acetic acid	WO9203132, US 5459150	3/5/1992, 10/17/95	5-LPO inhibitor
Abbott	A-93178					FLAP inhibitor
AstraZeneca	AZD-4407			EP 623614	09/11/94	5-LPO inhibitor

AstraZeneca	ZD-2138		6-((3-fluoro-5-(tetrahydro-4-methoxy-2H-pyran-4-yl)phenoxy)methyl)-1-methyl-2-(1H)-quinolinone (alternatively NH can be N-methyl)	EP 466452		5-LPO inhibitor
Bayer	BAY-X-1005		(R)-(+)-alpha-cyclopentyl-4-(2-quinolinylmethoxy)-benzoic acid	US 4970215 EP 344519, DE 19880531		FLAP inhibitor
Merck	MK-0591		1-((4-chlorophenyl)methyl)-3-((1,1-dimethylethyl)thio)-alpha, alpha-dimethyl-5-(2-quinolinylmethoxy)-1H-indole-2-propanoic acid	EP 419049, US 19890822		FLAP inhibitor
Merck	MK-866		(3-(3,4-chlorobenzyl)-3-(4-butyldimethylpropanoic acid			5-LPO inhibitor
Merck	MK-866		1-((4-chlorophenyl)methyl)-3-((1,1-dimethylethyl)thio)-alpha, alpha-dimethyl-5-(2-quinolinylmethoxy)-1H-indole-2-propanoic acid	EP 419049, US 19890822		5-LPO inhibitor
Pfizer	CJ-13610		4-(3-(4-(2-Methylimidazol-1-yl)-phenylsulfanyl)-phenyl)-tetrahydro-pyran-4-carboxylic acid amide			5-LPO inhibitor


In preferred methods of the invention, the agents set forth in the Agent Table II can be used for prophylactic and/or therapeutic treatment for diseases and conditions associated with FLAP or with other members of the leukotriene pathway, or with increased leukotriene synthesis. In particular, they can be used for treatment for myocardial infarction or susceptibility to myocardial infarction, such as for individuals in an at-risk population as described above, (*e.g.*, based on identified risk factors such as elevated cholesterol, elevated C-reactive protein, and/or genotype); for individuals suffering from acute coronary syndrome, such as unstable angina, non-ST-elevation myocardial infarction (NSTEMI) or ST-elevation myocardial infarction (STEMI); methods for reducing risk of MI, stroke or PAOD in persons with asymptomatic ankle/brachial index less than 0.9; for decreasing risk of a subsequent myocardial infarction, such as in individuals who have already had one or more myocardial infarctions; for stroke or susceptibility to stroke; for decreasing risk of a second stroke; for PAOD or susceptibility to PAOD; for treatment of atherosclerosis, such as in patients requiring treatment (*e.g.*, angioplasty, stents, revascularization procedure) to restore blood flow in arteries (*e.g.*, coronary, carotid, and/or femoral arteries); for treatment of asymptomatic ankle/brachial index of less than 0.9; and/or for decreasing leukotriene synthesis (*e.g.*, for treatment of myocardial infarction, ACS, stroke or PAOD

In one preferred embodiment of the invention, the leukotriene synthesis inhibitor is an inhibitor of FLAP such as 1-((4-chlorophenyl)methyl)-3-((1,1-dimethylethyl)thio)-alpha,alpha-dimethyl-5-(2-quinolinylmethoxy)-1H-Indole-2-propanoic acid otherwise known as MK-0591, (R)-(+)-alpha-cyclopentyl-4-(2-quinolinylmethoxy)-Benzeneacetic acid otherwise known as BAY-x-1005, 3-(3-(1,1-dimethylethylthio-5-(quinoline-2-ylmethoxy)-1-(4-chloromethylphenyl)indole-2-yl)-2,2-dimethylpropionaldehyde oxime-0-2-acetic acid otherwise known as A-81834, their optically pure enantiomers, salts, chemical derivatives, analogues, or other compounds inhibiting FLAP that effectively decrease leukotriene biosynthesis when administered to humans.

In another preferred embodiment of the invention, the leukotriene synthesis inhibitor is an inhibitor of 5LO such as zileuton, atreleuton, 6-((3-fluoro-5-(tetrahydro-4-methoxy-2H-pyran-4yl)phenoxy)methyl)-1-methyl-2(1H)-quinolinone otherwise known as ZD-2138, 1-((4-chlorophenyl)methyl)-3-((1,1-dimethylethyl)thio)-alpha,alpha-dimethyl-5-(2-quinolinylmethoxy)-1H-Indole-2-propanoic acid otherwise known as MK-886, 4-(3-(4-(2-Methyl-imidazol-1-yl)-phenylsulfanyl)-phenyl)-tetrahydro-pyran-4-carboxylic acid amide

otherwise known as CJ-13610, their optically pure enantiomers, salts, chemical derivatives, analogues or other compounds inhibiting 5-LO that effectively decrease leukotriene biosynthesis when administered to humans.

The compound can be represented by the following formula:




or a pharmaceutically acceptable salt thereof, wherein M is selected from the group consisting of hydrogen, a pharmaceutically acceptable cation, and a pharmaceutically acceptable metabolically cleavable group; B is a straight or branched divalent alkylene group of from one to twelve carbon atoms; Z is thiazolyl, optionally substituted with alkyl of from one to six carbon atoms or haloalkyl of from one to six carbon atoms; L is selected from the group consisting of (a) alkylene of from 1-6 carbon atoms, (b) alkenylene of from 2-6 carbon atoms, (c) alkynylene of from 2-6 carbon atoms, (d) hydroxyalkyl of 1-6 carbon atoms, (e)  $>C=O$ , (f)  $>C=N-OR_1$ , where  $R_1$  is hydrogen or  $C_1$ - $C_6$  alkyl, (g)  $-(CHR_1)_n(CO)(CHR_2)_m$ , where n and m are independently selected from an integer from one to six and  $R_1$  and  $R_2$  are independently selected from hydrogen and  $C_1$ - $C_6$  alkyl, (h)  $-(CHR_1)_n C=NOR_2$ , where  $R_1$ ,  $R_2$  and n are as defined above; (i)  $-(CHR_1)_n ON=CR_2$ , where  $R_1$ ,  $R_2$  and n are as defined above; (j)  $-(CHR_1)_n -O-(CHR_2)_m$ , where  $R_1$ ,  $R_2$ , n and m are as defined above, (k)  $-(CHR_1)_n -NR_2(CHR_3)_m$ , where  $R_1$ ,  $R_2$ , n and m are as defined above and  $R_3$  is selected from hydrogen and  $C_1$ - $C_6$  alkyl; (l)  $-(CHR_1)_n -S-CHR_2)_m$ , where  $R_1$ ,  $R_2$ , n and m are as defined above; and (m)  $-(CHR_1)_n -(SO_2)-(CHR_2)_m$ , where  $R_1$ ,  $R_2$ , n and m are as defined above; A is carbocyclic aryl optionally substituted with alkyl of from one to six carbon atoms, haloalkyl of from one to six carbon atoms, hydroxyalkyl of from one to six carbon atoms, alkoxy of from one to twelve carbon atoms, alkoxyalkoxyl in which the two alkoxy portions may each independently contain from one to six carbon atoms, alkylthio of from one to six carbon atoms, hydroxy,



halogen, cyano, amino, alkylamino of from one to six carbon atoms, dialkylamino in which the two alkyl groups may independently contain from one to six carbon atoms, alkanoylamino of from two to eight carbon atoms, N-alkanoyl-N-alkylamino in which the alkanoyl is of from two to eight carbon atoms and the alkyl group is of from one to six carbon atoms, alkylaminocarbonyl of from two to eight carbon atoms, dialkylaminocarbonyl in which the two alkyl groups are independently of from one to six carbon atoms, carboxyl, alkoxycarbonyl or from two to eight carbon atoms, phenyl, optionally substituted with alkyl of from one to six carbon atoms, haloalkyl of from one to six carbon atoms, alkoxy of from one to six carbon atoms, hydroxy or halogen, phenoxy, optionally substituted with alkyl of from one to six carbon atoms, haloalkyl of from one to six carbon atoms, alkoxy of from one to six carbon atoms, hydroxy or halogen, and phenylthio, optionally substituted with alkyl of from one to six carbon atoms, haloalkyl of from one to six carbon atoms, alkoxy of from one to six carbon atoms, hydroxy or halogen. Preferably, the compound is a compound or pharmaceutically acceptable salt thereof having the name (R)-N-{3-[-5-(4-fluorophenylmethyl)thiazo-2-yl]-1-methyl-2-propynyl}-N-hydroxyurea. See U.S. Patent No. 4,615,596, incorporated herein by reference.


The compound is represented by the following formula:



or a pharmaceutically acceptable salt thereof, wherein A is selected from the group consisting of straight or branched divalent alkylene of from one to twelve carbon atoms and divalent cycloalkylene of from three to eight carbon atoms; R<sub>1</sub> is selected from the group consisting of hydrogen, alkylthio of from one to six carbon atoms, phenylthio, optionally substituted with alkyl of from one to six carbon atoms, alkoxy of from one to six carbon atoms, or halogen, phenylalkylthio in which the alkyl portion contains from one to six carbon atoms, and the phenyl group is optionally substituted with alkyl of from one to six carbon atoms, alkoxy of from one to six carbon atoms, or halogen, R<sub>2</sub> is

selected from the group consisting of -COOB wherein B is selected from hydrogen, a pharmaceutically acceptable cation, or a metabolically cleavable group, -COOalkyl where the alkyl portion contains from one to six carbon atoms, -COOalkylcarbocyclicaryl where the alkyl portion contains from one to six carbon atoms and the aryl portion is optionally substituted with alkyl of from one to six carbon atoms, alkoxy of from one to six carbon atoms, or halogen, -CONR<sub>5</sub> R<sub>6</sub> wherein R<sub>5</sub> is selected from the group consisting of hydrogen, hydroxyl, alkyl of from one to six carbon atoms, and alkoxy of from one to six carbon atoms, and R<sub>6</sub> is selected from the group consisting of hydrogen and alkyl of from one to six carbon atoms, -COR<sub>6</sub>, and -OH; R<sub>3</sub> is selected from the group consisting of phenylalkyl in which the alkyl portion contains from one to six carbon atoms, and the phenyl group is optionally substituted with alkyl of from one to six carbon atoms, alkoxy of from one to six carbon atoms, or halogen, R<sub>4</sub> is selected from the group consisting of thiazolylalkyloxy in which the alkyl portion contains from one to six carbon atoms, and the heteroaryl portion is optionally substituted with alkyl of from one to six carbon atoms, alkoxy of from one to six carbon atoms, or halogen, and thiazolyloxy optionally substituted with alkyl of from one to six carbon atoms, alkoxy of from one to six carbon atoms, or halogen. See U.S. Patent No. 5,288,743, incorporated herein by reference.

The compound can be represented by the formula:




or a pharmaceutically acceptable salt thereof, wherein M is selected from the group consisting of hydrogen, and a pharmaceutically acceptable cation;

B is a straight or branched divalent alkylene group of from one to twelve carbon atoms; Z is selected from the group consisting of: (a) furyl, optionally substituted with alkyl of from one to six carbon atoms, or haloalkyl of from one to six carbon atoms, and (b) thienyl, optionally substituted with alkyl of from one to six carbon atoms, or haloalkyl of from one


to six carbon atoms; and L is alkylene of from 1-6 carbon atoms; A is phenyl optionally substituted with alkyl of from one to six carbon atoms, haloalkyl of from one to six carbon atoms, hydroxyalkyl of from one to six carbon atoms, alkoxy of from one to twelve carbon atoms, alkoxyalkoxyl in which the two alkoxy portions may each independently contain from one to six carbon atoms, alkylthio of from one to six carbon atoms, hydroxy, halogen, cyano, amino, alkylamino of from one to six carbon atoms, dialkylamino in which the two alkyl groups may independently contain from one to six carbon atoms, alkanoylamino of from two to eight carbon atoms, N-alkanoyl-N-alkylamino in which the alkanoyl is of from two to eight carbon atoms and the alkyl group is of from one to six carbon atoms, alkylaminocarbonyl of from two to eight carbon atoms, dialkylaminocarbonyl in which the two alkyl groups are independently of from one to six carbon atoms, carboxyl, alkoxycarbonyl of from two to eight carbon atoms, phenyl, optionally substituted with alkyl of from one to six carbon atoms, haloalkyl of from one to six carbon atoms, alkoxy of from one to six carbon atoms, hydroxy or halogen, phenoxy, optionally substituted with alkyl of from one to six carbon atoms, haloalkyl of from one to six carbon atoms, alkoxy of from one to six carbon atoms, hydroxy or halogen, or phenylthio, optionally substituted with alkyl of from one to six carbon atoms, haloalkyl of from one to six carbon atoms, alkoxy of from one to six carbon atoms, hydroxy or halogen. Preferably, the compound is a compound or a pharmaceutically acceptable salt thereof selected from the group consisting of: N-{3-(5-(4-fluorophenylmethyl)fur-2-yl)-3-butyn-2-yl}-N-hydroxyurea; N-{3-(5-(4-fluorophenylmethyl)-2-thienyl)-1-methyl-2-propynyl}-N-hydroxyurea; (R)-N-{3-(5-(4-fluorophenylmethyl)-2-thienyl)-1-methyl-2-propynyl}-N-hydroxyurea; and (R)-N-{3-(5-(4-chlorophenylmethyl)-2-thienyl)-1-methyl-2-propynyl}-N-hydroxyurea; (S)-N-{3-[5-(4-fluorophenylmethyl)-2-thienyl]-1-methyl-2-propynyl}-N-hydroxyurea. See U.S. Patent No. 5,288,751, incorporated by reference herein.

The compound can be represented by the formula:




or a pharmaceutically acceptable salt thereof, wherein A is selected from the group consisting of straight or branched divalent alkylene of one to twelve carbon atoms, straight or branched divalent alkenylene of two to twelve carbon atoms, and divalent cycloalkylene of three to eight carbon atoms;  $R^1$  is alkylthio of one to six carbon atoms;  $R^6$  is selected from the group consisting of hydrogen and alkyl of one to six carbon atoms;  $R^7$  is selected from the group consisting of (carboxyl)alkyl in which the alkyl portion is of one to six carbon atoms, (alkoxycarbonyl)alkyl in which the alkoxycarbonyl portion is of two to six carbon atoms and the alkyl portion is of one to six carbon atoms, (aminocarbonyl)alkyl in which the alkyl portion is of one to six carbon atoms, ((alkylamino)carbonyl)alkyl in which each alkyl portion independently is of one to six carbon atoms, and ((dialkylamino)carbonyl)alkyl in which each alkyl portion independently is of one to six carbon atoms;  $R^3$  is phenylalkyl in which the alkyl portion is of one to six carbon atoms;  $R^4$  is 2-, 3- or 6-quinolylmethoxy, optionally substituted with alkyl of one to six carbon atoms, haloalkyl of one to six carbon atoms, alkoxy of one to twelve carbon atoms, halogen, or hydroxy. Preferably, the compound is selected from the group consisting of: 3-(3-(1,1-dimethylethylthio)-5-(quinolin-2-ylmethoxy)-1-(4-chlorophenylmethyl)-indol-2-yl)-2,2-dimethylpropionaldehyde oxime-O-2 acetic acid; 3-(3-(1,1-dimethylethylthio)-5-(quinolin-2-ylmethoxy)-1-(4-chloro-phenylmethyl) indol-2-yl)-2,2-dimethylpropionaldehyde oxime-O-2-(3-methyl)butyric acid; 3-(3-(1,1-dimethylethylthio)-5-(6,7-dichloroquinolin-2-ylmethoxy)-1-(4-chlorophenylmethyl) indol-2-yl)-2,2-dimethylpropionaldehyde oxime-O-2-acetic acid; and 3-(3-(1,1-dimethylethylthio)-5-(6-fluoroquinolin-2-ylmethoxy)-1-(4chlorophenylmethyl) indol-2-yl)-2,2-dimethylpropionaldehyde oxime-O-2-propionic acid; or a pharmaceutically acceptable salt or ester thereof. See U.S. Patent No. 5,459,150, incorporated by reference herein.

The compound can be represented by the formula:




or pharmaceutically acceptable salts thereof, wherein Q is a 9-, 10- or 11-membered bicyclic heterocyclic moiety containing one or two nitrogen heteroatoms and optionally containing a further heteroatom selected from nitrogen, oxygen and sulphur, and Q may optionally bear up to four substituents selected from halogeno, hydroxy, cyano, formyl, oxo, thioxo, (1-4C)alkyl, (3-4C)alkenyl, (3-4C)alkynyl, (1-4C)alkoxy, fluoro-(1-4C)alkyl, hydroxy-(1-4C)alkyl, (2-5C)alkanoyl, phenyl, benzoyl and benzyl, and wherein said phenyl, benzoyl and benzyl substituents may optionally bear one or two substituents selected from halogeno, (1-4C)alkyl and (1-4C)alkoxy;

X is oxy, thio, sulphinyl or sulphonyl; Ar is phenylene, pyridinediyl, pyrimidinediyl, thiophenediyl, furandiyl, thiazolediyl, oxazolediyl, thiadiazolediyl or oxadiazolediyl which may optionally bear one or two substituents selected from halogeno, cyano, trifluoromethyl, hydroxy, amino, (1-4C)alkyl, (1-4C)alkoxy, (1-4C)alkylamino and di-(1-4C)alkylamino; and Q is selected from the groups of the formulae II and III:



II




III

wherein R is hydrogen, (2-5C)alkanoyl or benzoyl, and wherein said benzoyl group may optionally bear one or two substituents selected from halogeno, (1-4C)alkyl and (1-4C)alkoxy; R is (1-4C)alkyl; and R is hydrogen or (1-4C)alkyl; or R and R are linked to form a methylene, vinylene, ethylene or trimethylene group. Preferably, the compound is selected from the group consisting of: (2S,4R)-4-[5-fluoro-3-(1-methyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-ylthio)phenyl]-4-hydroxy-2-ethyltetrahydropyran, (2S,4R)-4-[5-

fluoro-3-(1-methyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-ylsulphonyl)phenyl]-4-hydroxy-2-methyltetrahydropyran, (2S,4R)-4-hydroxy-2-methyl-4-[2-(1-methyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-ylthio)thiazol-5-yl]tetrahydropyran, (2S,4R)-4-hydroxy-2-methyl-4-[2-(1-methyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-ylsulphonyl)thiazol-5-yl]tetrahydropyran, (2S,4R)-4-[2-(7-fluoro-1-methyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-ylthio)thiazol-5-yl]-4-hydroxy-2-methyltetrahydropyran, (2S,4R)-4-hydroxy-2-methyl-4-[2-(1-methyl-2-oxoindolin-5-ylthio)thiazol-5-yl]tetrahydropyran, (2S,4R)-4-hydroxy-2-methyl-4-[2-(1-methyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-ylthio)thien-4-yl]tetrahydropyran, (2S,4R)-4-hydroxy-2-methyl-4-[2-(1-methyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-ylsulphonyl)thien-4-yl]tetrahydropyran, (2S,4R)-4-hydroxy-2-methyl-4-[2-(1-methyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-ylthio)thien-5-yl]tetrahydropyran, (2S,4R)-4-hydroxy-2-methyl-4-[2-(1-methyl-2-oxo-1,2-dihydroquinolin-6-ylthio)thien-4-yl]tetrahydropyran, (2S,4R)-4-hydroxy-2-methyl-4-[2-(1,8-dimethyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-ylthio)thien-4-yl]tetrahydropyran, 4-[2-(8-fluoro-1-methyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-ylthio)thien-4-yl]-4-hydroxy-2-methyltetrahydropyran, 4-[2-(7-fluoro-1-methyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-ylthio)thien-4-yl]-4-hydroxy-2-methyltetrahydropyran, (2S,4R)-4-hydroxy-2-methyl-4-[2-(1-methyl-2-oxoindolin-5-ylthio)thien-4-yl]tetrahydropyran, (2S,4R)-4-hydroxy-2-methyl-4-[3-(1-methyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-ylthio)phenyl]tetrahydropyran, (2S,4R)-4-hydroxy-2-methyl-4-[3-(1-methyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-ylsulphonyl)phenyl]tetrahydropyran, (2S,4R)-4-[3-(1-ethyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-ylthio)phenyl]-4-hydroxy-2-methyltetrahydropyran, (2S,4R)-4-[3-(7-fluoro-1-methyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-ylthio)phenyl]-4-hydroxy-2-methyltetrahydropyran, (2S,4R)-4-hydroxy-2-methyl-4-[3-(1-methyl-2-oxo-1,2-dihydroquinolin-6-ylthio)phenyl]tetrahydropyran, (2S,4R)-4-[3-(8-chloro-1-methyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-ylthio)phenyl]-4-hydroxy-2-methyltetrahydropyran and (2S,4R)-4-hydroxy-2-methyl-4-[3-(1-methyl-2-oxoindolin-5-ylthio)phenyl]tetrahydropyran. See EP 623614 B1, incorporated herein by reference.

The compound can be represented by the formula:




wherein Q is a 10-membered bicyclic heterocyclic moiety containing one or two nitrogen heteroatoms which bears one or two thioxo substituents, and which heterocyclic moiety may optionally bear one, two or three further substituents selected from halogeno, hydroxy, cyano, amino, (1-4C)alkyl, (1-4C)alkoxy, fluoro-(1-4C)alkyl, (1-4C)alkylamino, di-[(1-4C)alkyl]amino, amino-(1-4C)alkyl, (1-4C)alkylamino-(1-4C)alkyl, di-[(1-4C)alkyl]amino-(1-4C)alkyl, phenyl and phenyl-(1-4C)alkyl, and wherein said phenyl or phenyl-(1-4C)alkyl substituent may optionally bear a substituent selected from halogeno, (1-4C)alkyl and (1-4C)alkoxy;

wherein A is a direct link to X or is (1-3C)alkylene; wherein X is oxy, thio, sulphinyl, sulphonyl or imino; wherein Ar is phenylene which may optionally bear one or two substituents selected from halogeno, hydroxy, amino, nitro, cyano, carbamoyl, ureido, (1-4C)alkyl, (1-4C)alkoxy, (1-4C)alkylamino, di-[(1-4C)alkyl]amino, fluoro-(1-4C)alkyl and (2-4C)alkanoylamino; or Ar is pyridylene; wherein R is (1-4C)alkyl, (3-4C)alkenyl or (3-4C)alkynyl; and wherein R and R together form a group of the formula -A-X-A- which, together with the carbon atom to which A and A are attached, defines a ring having 5 to 7 ring atoms, wherein A and A, which may be the same or different, each is (1-3C)alkylene and X is oxy, thio, sulphinyl or sulphonyl, and which ring may bear one, two or three substituents, which may be the same or different, selected from hydroxy, (1-4C)alkyl and (1-4C)alkoxy; or wherein R and R together form a group of the formula -A-X-A- which, together with the oxygen atom to which A is attached and with the carbon atom to which A is attached, defines a ring having 5 to 7 ring atoms, wherein A and A, which may be the same or different, each is (1-3C)alkylene and X is oxy, thio, sulphinyl or sulphonyl, and which ring may bear one, two or three (1-4C)alkyl substituents, and wherein R is (1-4C)alkyl, (2-4C)alkenyl or (2-4C)alkynyl; or a pharmaceutically-acceptable salt thereof.


Preferably, the compound is selected from the group consisting of: 4-(5-fluoro-3-(1-methyl-2-thioxo-1,2-dihydroquinolin-6-ylmethoxy)phenyl]-4-ethoxytetrahydropyran and

4-(5-fluoro-3-(1-methyl-2-thioxo-1,2,3,4-tetrahydroquinolin-6-ylmethoxy)phenyl]-4-methoxytetrahydropyran, 4-(5-fluoro-3-(1-methyl-2-thioxo-1,2,3,4-tetrahydroquinolin-6-ylthio)phenyl]-4-methoxytetrahydropyran and pharmaceutically-acceptable salt thereof. See EP 466452 B1, incorporated herein by reference.


5 The compound can be a substituted 4-(quinolin-2-ylmethoxy)phenylacetic acid derivative represented by the following formula:




10 or pharmaceutically acceptable salt thereof, wherein R<sup>1</sup> represents a group of the formula:



15 R<sup>2</sup> and R<sup>3</sup> are identical or different and represent hydrogen, lower alkyl, phenyl, benzyl or a group of the formula:









- 5         $R^4$  represents hydrogen, lower alkyl, phenyl or benzyl, which can optionally be substituted by hydroxyl, carboxyl, lower alkoxy carbonyl, lower alkylthio, heteroaryl or carbamoyl,  $R^5$  represents hydrogen, lower alkyl, phenyl or benzyl,  $R^6$  represents a group of the formula  $-COR^5$  or  $-CO^2 R^5$ ,  $R^7$  represents hydrogen, lower alkyl or phenyl, Y represents a group of the formula:

10




- 15        wherein  $R^8$  represents hydrogen, lower alkyl or phenyl and n denotes a number of 0 to 5, Z represents norbornyl, or represents a group of the formula:



- 20        wherein  $R^9$  and  $R^{10}$  are identical or different and denote hydrogen, lower alkyl or phenyl, or  $R^9$  and  $R^{10}$  can together form a saturated carbocyclic ring having up to 6 carbon atoms and m denotes a number from 1 to 6, and A and B are identical or different and

denote hydrogen, lower alkyl or halogen, or a pharmaceutically acceptable salt thereof. Preferably the compounds are selected from the group consisting of: 2-[4-(quinolin-2-yl-methoxy)phenyl]-2-cyclopentylacetic acid, 2-[4-(quinolin-2-yl-methoxy)phenyl]-2-cyclohexylacetic acid, and 2-[4-(quinolin-2-yl-methoxy)phenyl]-2-cycloheptylacetic acid, (+)-enantiomer of 2-[4-(quinolin-2-yl-methoxy)phenyl]-2-cyclopentylacetic acid, (-)-enantiomer of 2-[4-(quinolin-2-yl-methoxy)phenyl]-2-cyclopentylacetic acid and pharmaceutically acceptable salts thereof. See U.S. Patent No. 4,970,215, incorporated herein by reference.

The compound can be represented by the formula:



wherein R, R, R and R are independently hydrogen, halogen, lower alkyl, lower alkenyl, lower alkynyl,  $-CF_3$ ,  $-CN$ ,  $-NO_2$ ,  $-N_3$ ,  $-C(OH)RR$ ,  $-CO_2R$ ,  $-SR$ ,  $-S(O)R$ ,  $-S(O)_2R$ ,  $-S(O)_2NRR$ ,  $-OR$ ,  $-NRR$ ,  $-C(O)R$  or  $-(CH_2)_tR$ ; R is hydrogen,  $-CH_3$ ,  $-CF_3$ ,  $-C(O)H$ ,  $X-R$  or  $X-R$ ; R and R are independently: alkyl,  $-(CH_2)_uPh(R)_2$  or  $-(CH_2)_uTh(R)_2$ ; R is  $-CF_3$  or R; R is hydrogen or  $X-R$ ; each R is independently hydrogen or lower alkyl, or two R's on same carbon atom are joined to form a cycloalkyl ring of 3 to 6 carbon atoms; R is hydrogen, lower alkyl or  $-CH_2R$ ; R is lower alkyl or  $-(CH_2)_rR$ ; R is  $-CF_3$  or R; R is hydrogen,  $-C(O)R$ , R, or two R's on the same nitrogen may be joined to form a monocyclic heterocyclic ring of 4 to 6 atoms containing up to 2 heteroatoms chosen from O, S or N; R is hydrogen,  $-CF_3$ , lower alkyl, lower alkenyl, lower alkynyl or  $-(CH_2)_rR$ ; R is  $-(CH_2)_s-C(RR)-(CH_2)_s-R$  or  $-CH_2C(O)NRR$ ; R is hydrogen or lower alkyl; R is a) a monocyclic or bicyclic heterocyclic ring containing from 3 to 9 nuclear carbon atoms and 1 or 2 nuclear hetero-

atoms selected from N, S or O and with each ring in the heterocyclic radical being formed of 5 or 6 atoms, or b) the radical W-R; R is alkyl or C(O)R;

R is phenyl substituted with 1 or 2 R groups; R is hydrogen, halogen, lower alkyl, lower alkoxy, lower alkylthio, lower alkylsulfonyl, lower alkylcarbonyl, -CF<sub>3</sub>, -CN,

-NO<sub>2</sub> or -N<sub>3</sub>; R is alkyl, cycloalkyl, monocyclic monoheterocyclic ring;

R is the residual structure of a standard amino acid, or R and R attached to the same N can cyclize to form a proline residue; m is 0 to 1; n is 0 to 3; p is 1 to 3 when m is 1; p is 0 to 3 when m is 0; r is 0 to 2; s is 0 to 3; t is 0 to 2; u is 0 to 3; v is 0 or 1;

W is O, S or NR; X is O, or NR; X is C(O), CRR, S, S(O) or S(O)<sub>2</sub>; X is C(O), CRR,

S(O)<sub>2</sub> or a bond; Y is X or X; Q is -CO<sub>2</sub>R, -C(O)NHS(O)<sub>2</sub>R, -NHS(O)<sub>2</sub>R, -S(O)<sub>2</sub>NHR -C(O)NRR, -CO<sub>2</sub>R, -C(O)NRR, -CH<sub>2</sub>OH, or 1H- or 2H-tetrazol-5-yl;

and the pharmaceutically acceptable salts thereof. Preferred embodiments of the compounds are selected from the following and pharmaceutically acceptable salts thereof:

- 3-[N-(p-chlorobenzyl)-3-(t-butylthio)-5-(quinolin-2-ylmethoxy)indol-2-yl]-2,2-dimethylpropanoic acid;
- 3-[N-(p-chlorobenzyl)-3-methyl-5-(quinolin-2-ylmethoxy)indol-2-yl]-2,2-dimethylpropanoic acid;
- 3-[N-(p-t-butylthiobenzyl)-3-(t-butylthio)-5-(quinolin-2-ylmethoxy)indol-2-yl]-2,2-dimethylpropanoic acid;
- 3-[N-(p-chlorobenzyl)-3-(phenylthio)-5-(quinolin-2-ylmethoxy)indol-2-yl]-2,2-dimethylpropanoic acid;
- 3-[N-(p-chlorobenzyl)-3-(phenylsulfonyl)-5-(quinolin-2-ylmethoxy)indol-2-yl]-2,2-dimethyl propanoic acid, N-oxide;
- 3-[N-(p-chlorobenzyl)-3-(phenylsulfonyl)-5-(quinolin-2-ylmethoxy)indol-2-yl]-2,2-dimethylpropanoic acid;
- 3-[N-(p-chlorobenzyl)-3-(phenylsulfinyl)-5-(quinolin-2-ylmethoxy)indol-2-yl]-2,2-dimethylpropanoic acid;
- 3-[N-(p-chlorobenzyl)-5-(quinolin-2-ylmethoxy)indol-2-yl]-2,2-dimethylpropanoic acid;;
- 3-[N-(p-chlorobenzyl)-3-benzoyl-5-(quinolin-2-ylmethoxy)indol-2-yl]-2,2-dimethylpropanoic acid;

3-[N-(p-chlorobenzyl)-3-benzyl-5-(quinolin-2-ylmethoxy)indol-2-yl]-2,2-dimethylpropanoic acid;

3-[N-(p-chlorobenzyl)-3-(3,3-dimethyl-1-oxo-1-butyl)-5-(quinolin-2-ylmethoxy)indol-2-yl]-2,2-dimethylpropanoic acid;

5 2-[N-(p-chlorobenzyl)-3-(t-butylthio)-5-(quinolin-2-ylmethoxy)indol-2-yl]ethoxyethanoic acid;

3-[N-(p-chlorobenzyl)-3-(3,3-dimethyl-1-butyl)-5-(quinolin-2-ylmethoxy)indol-2-yl]-2,2-dimethylpropanoic acid;

10 3-[N-(p-chlorobenzyl)-3-(t-butylthio)-5-(quinolin-2-ylmethoxy)indol-2-yl]-2-methylpropanoic acid;

3-[N-(p-chlorobenzyl)-3-methyl-5-(6,7-dichloroquinolin-2-ylmethoxy)indol-2-yl]-2,2-dimethylpropanoic acid;

3-[N-(p-chlorobenzyl)-3-methyl-5-(7-chloroquinolin-2-ylmethoxy)indol-2-yl]-2,2-dimethylpropanoic acid;

15 3-[N-(p-chlorobenzyl)-4-allyl-5-(quinolin-2-ylmethoxy)-3-(t-butylthio)indol-2-yl]-2,2-dimethylpropanoic acid;

3-[N-(p-chlorobenzyl)-4-allyl-5-(quinolin-2-ylmethoxy)indol-2-yl]-2,2-dimethylpropanoic acid;

20 3-[N-(p-chlorobenzyl)-6-(quinolin-2-ylmethoxy)-3-(t-butylthio)indol-2-yl]-2,2-dimethylpropanoic acid;

3-[N-(p-chlorobenzyl)-4-(quinolin-2-ylmethoxy)-3-(t-butylthio)indol-2-yl]-2,2-dimethylpropanoic acid;

3-[N-(p-chlorobenzyl)-7-(quinolin-2-ylmethoxy)-3-(t-butylthio)indol-2-yl]-2,2-dimethylpropanoic acid;

25 2-[2-[N-(p-chlorobenzyl)-3-(t-butylthio)-5-(quinolin-2-ylmethoxy)indol-2-yl]ethoxy]propanoic acid;

3-[N-(p-chlorobenzyl)-4-(quinolin-2-ylmethoxy)indol-2-yl]-2,2-dimethylpropanoic acid;;

30 3-[N-methyl-3-(p-chlorobenzoyl)-6-(quinolin-2-ylmethoxy)indol-2-yl]-2,2-dimethylpropanoic acid,

3-[N-methyl-3-(p-chlorobenzyl)-6-(quinolin-2-ylmethoxy)indol-2-yl]-2,2-dimethylpropanoic acid,

3-[N-(4-chlorobenzyl)-3-i-propoxy-5-(quinolin-2-ylmethoxy)indol-2-yl]-2,2-dimethylpropanoic acid,

3-[N-(4-chlorobenzyl)-3-(t-butylthio)-5-(quinolin-2-yl-methoxy)indol-2-yl]-2-ethylpropanoic acid,

5 3-[N-(4-chlorobenzyl)-3-trifluoroacetyl-5-(quinolin-2-ylmethoxy)indol-2-yl]-2,2-dimethylpropanoic acid,

3-[N-(4-chlorobenzyl)-3-(3,3-dimethyl-1-oxo-1-butyl)-5-(quinolin-2-ylmethoxy)indol-2-yl]-2-methylpropanoic acid,

10 3-[3-(3,3-dimethyl-1-oxo-1-butyl-5-(quinolin-2-ylmethoxy)indol-2-yl)-2,2-dimethylpropanoic acid,

3-[N-(4-trifluoromethylbenzyl)-3-(3,3-dimethyl-1-oxo-1-butyl)-5-(quinolin-2-yl-methoxy)indol-2-yl]-2,2-dimethylpropanoic acid,

3-[N-benzyl-3-(3,3-dimethyl-1-oxo-1-butyl)-5-(quinolin-2-ylmethoxy)indol-2-yl]-2,2-dimethylpropanoic acid,

15 3-[N-(3-methoxybenzyl)-3-(3,3-dimethyl-1-oxo-1-butyl)-5-(quinolin-2-ylmethoxy)indol-2-yl]-2,2-dimethylpropanoic acid,

3-[N-allyl-3-(3,3-dimethyl-1-oxo-1-butyl)-5-(quinolin-2-ylmethoxy)indol-2-yl]-2,2-dimethylpropanoic acid,

20 3-[N-(4-methoxybenzyl)-3-(3,3-dimethyl-1-oxo-1-butyl)-5-(quinolin-2-ylmethoxy)indol-2-yl]-2,2-dimethylpropanoic acid,

3-[N-methyl-3-(3,3-dimethyl-1-oxo-3-butyl)-5-(quinolin-2-ylmethoxy)indol-2-yl]-2,2-dimethylpropanoic acid,

3-[3-(4-chlorobenzyl)-6-(quinolin-2-ylmethoxy)indol-2-yl]-2,2-dimethylpropanoic acid.

25 3-[N-(phenylsulfonyl)-3-(4-chlorobenzyl)-6-(quinolin-2-ylmethoxy)indol-2-yl]-2,2-dimethylpropanoic acid,

3-[N-benzyl-3-(4-chlorobenzyl)-6-(quinolin-2-ylmethoxy)indol-2-yl]-2,2-dimethylpropanoic acid,

30 3-[N-(4-chlorobenzyl)-3-(t-butylsulfonyl)-5-(quinolin-2-ylmethoxy)indol-2-yl]-2,2-dimethylpropanoic acid,

3-[N-(4-chlorobenzyl)-3-(t-butylsulfinyl)-5-(quinolin-2-ylmethoxy)indol-2-yl]-2,2-dimethylpropanoic acid,

3-[N-allyl-3-(4-chlorobenzyl)-6-(quinolin-2-ylmethoxy)indol-2-yl]-2,2-dimethylpropanoic acid,

3-[N-(n-propyl)-3-(4-chlorobenzyl)-6-(quinoline-2-ylmethoxy)indol-2-yl]-2,2-dimethylpropanoic acid,

5 3-[N-ethyl-3-(4-chlorobenzyl)-6-(quinolin-2-ylmethoxy)indol-2-yl]-2,2-dimethylpropanoic acid,

3-[N-(4-chlorobenzyl)-3-(4-t-butylbenzoyl)-5-(quinolin-2-yl-methoxy)indol-2-yl]-2,2-dimethylpropanoic acid,

10 3-[N-(4-chlorobenzyl)-3-(4-chlorobenzoyl)-5-(quinolin-2-ylmethoxy)indol-2-yl]-2,2-dimethylpropanoic acid,

3-[N-(4-chlorobenzyl)-3-(1,1-dimethylethyl)-5-(quinolin-2-ylmethoxy)indol-2-yl]-2,2-dimethylpropanoic acid,

3-[N-(4-chlorobenzyl)-3-acetyl-5-(quinolin-2-ylmethoxy)indol-2-yl]-2,2-dimethylpropanoic acid

15 3-[N-(4-chlorobenzyl)-3-cyclopropanecarbonyl-5-(quinolin-2-ylmethoxy)indol-2-yl]-2,2-dimethylpropanoic acid,

3-[N-(4-chlorobenzyl)-3-(3-cyclopentylpropanoyl)-5-(quinolin-2-ylmethoxy)indol-2-yl]-2,2-dimethylpropanoic acid,

20 3-[N-(4-chlorobenzyl)-3-(3-methylbutanoyl)-5-(quinolin-2-yl-methoxy)indol-2-yl]-2,2-dimethylpropanoic acid,

3-[N-(4-chlorobenzyl)-3-propanoyl-5-(quinolin-2-ylmethoxy)indol-2-yl]-2,2-dimethylpropanoic acid,

3-[N-(4-chlorobenzyl)-3-(2-methylpropanoyl)-5-(quinolin-2-ylmethoxy)indol-2-yl]-2,2-dimethylpropanoic acid,

25 3-[N-(4-chlorobenzyl)-3-trimethylacetyl-5-(quinolin-2-ylmethoxy)indol-2-yl]-2,2-dimethylpropanoic acid,

3-[N-(4-chlorobenzyl)-3-phenylacetyl-5-(quinolin-2-ylmethoxy)indol-2-yl]-2,2-dimethylpropanoic acid,

30 3-[N-(4-fluorobenzyl)-3-(3,3-dimethyl-1-oxo-1-butyl)-5-(quinolin-2-ylmethoxy)indol-2-yl]-2,2-dimethylpropanoic acid,

3-[N-(4-bromobenzyl)-3-(3,3-dimethyl-1-oxo-1-butyl)-5-(quinolin-2-ylmethoxy)indol-2-yl]-2,2-dimethylpropanoic acid,

3-[N-(4-iodobenzyl)-3-(3,3-dimethyl-1-oxo-1-butyl)-5-(quinolin-2-ylmethoxy)indol-2-yl]-2,2-dimethylpropanoic acid,

3-[N-(4-chlorobenzyl)-3-(1,1-dimethylbutyl)-5-(quinolin-2-ylmethoxy)indol-2-yl]-2,2-dimethylpropanoic acid,

5 3-[N-(4-chlorobenzyl)-3-(1,1-dimethylpropyl)-5-(quinolin-2-ylmethoxy)indol-2-yl]-2,2-dimethylpropanoic acid,

3-[N-(3-fluorobenzyl)-3-(1,1-dimethylethyl)-5-(quinolin-2-ylmethoxy)indol-2-yl]-2,2-dimethylpropanoic acid,

10 3-[N-(4-chlorobenzyl)-3-(3-methylethyl)-5-(quinolin-2-ylmethoxy)indol-2-yl]-2,2-dimethylpropanoic acid,

3-[N-(4-chlorobenzyl)-3-cyclopropyl-5-(quinolin-2-ylmethoxy)indol-2-yl]-2,2-dimethylpropanoic acid,

3-[N-(4-chlorobenzyl)-3-(1-methyl-1-cyclopropyl)-5-(quinolin-2-ylmethoxy)indol-2-yl]-2,2-dimethylpropanoic acid,

15 3-[N-(4-chlorobenzyl)-3-cyclopentyl-5-(quinolin-2-ylmethoxy)indol-2-yl]-2,2-dimethylpropanoic acid,

3-[N-(4-chlorobenzyl)-3-cyclohexyl-5-(quinolin-2-ylmethoxy)indol-2-yl]-2,2-dimethylpropanoic acid,

20 3-[N-(4-chlorobenzyl)-3-(alpha, alpha-dimethylbenzyl)-5-(quinolin-2-ylmethoxy)indol-2-yl]-2,2-dimethylpropanoic acid,

3-[N-(4-chlorobenzyl)-3-(2-{4-chloro-alpha, alpha-dimethylbenzyl}-5-(quinolin-2-ylmethoxy)indol-2-yl)-2,2-dimethylpropanoic acid,

3-[N-(4-chlorobenzyl)-3-(1-adamantyl)-5-(quinolin-2-ylmethoxy)indol-2-yl]-2,2-dimethylpropanoic acid,

25 3-[N-(4-chlorobenzyl)-3-((1-adamantyl)methyl)-5-(quinolin-2-ylmethoxy)indol-2-yl]-2,2-dimethylpropanoic acid,

3-[N-(1,1-dimethylethyl)-3-(4-chlorobenzyl)-6-(quinolin-2-ylmethoxy)indol-2-yl]-2,2-dimethylpropanoic acid,

30 3-[N-(1,1-dimethylpropyl)-3-(4-chlorobenzyl)-6-(quinoline-2-ylmethoxy)indol-2-yl]-2,2-dimethylpropanoic acid,

3-[N-(4-chlorobenzyl)-3-(3,3-dimethyl-1-oxo-1-butyl)-5-(quinolin-2-ylmethoxy)indol-2-yl]-2,2-diethylpropanoic acid,

methyl 3-[N-(4-chlorobenzyl)-3,6-bis(acetyl)-5-(quinolin-2-ylmethoxy)indol-2-yl]-2,2 dimethyl propanoate or  
methyl 3-[N-(4-chlorobenzyl)-3,6-bis(cyclopropanecarbonyl)-5-(quinolin-2-ylmethoxy)indol-2-yl]-2,2-dimethyl propanoate. See EP 419049 B1,  
5 incorporated herein by reference.

The term "alkyl" refers to a monovalent group derived from a straight or branched chain saturated hydrocarbon by the removal of a single hydrogen atom. Alkyl groups are exemplified by methyl, ethyl, n- and iso-propyl, n-, sec-, iso- and tert-butyl, and the like. The term "hydroxyalkyl" represents an alkyl group, as defined  
10 above, substituted by one to three hydroxyl groups with the proviso that no more than one hydroxy group may be attached to a single carbon atom of the alkyl group. The term "alkylamino" refers to a group having the structure -NHR' wherein R' is alkyl, as previously defined, examples of alkylamino include methylamino, ethylamino, iso-propylamino and the like. The term "alkylaminocarbonyl" refers to an alkylamino  
15 group, as previously defined, attached to the parent molecular moiety through a carbonyl group. Examples of alkylaminocarbonyl include methylamino-carbonyl, ethylaminocarbonyl, iso-propylaminocarbonyl and the like. The term "alkylthio" refers to an alkyl group, as defined above, attached to the parent molecular moiety through a sulfur atom and includes such examples as methylthio, ethylthio, propylthio,  
20 n-, sec- and tert-butylthio and the like. The term "alkanoyl" represents an alkyl group, as defined above, attached to the parent molecular moiety through a carbonyl group. Alkanoyl groups are exemplified by formyl, acetyl, propionyl, butanoyl and the like. The term "alkanoylamino" refers to an alkanoyl group, as previously defined, attached to the parent molecular moiety through a nitrogen atom. Examples of alkanoylamino  
25 include formamido, acetamido, and the like. The term "N-alkanoyl-N-alkylamino" refers to an alkanoyl group, as previously defined, attached to the parent molecular moiety through an aminoalkyl group. Examples of N-alkanoyl-N-alkylamino include N-methylformamido, N-methyl-acetamido, and the like. The terms "alkoxy" or "alkoxyl" denote an alkyl group, as defined above, attached to the parent molecular  
30 moiety through an oxygen atom. Representative alkoxy groups include methoxyl, ethoxyl, propoxyl, butoxyl, and the like. The term "alkoxyalkoxyl" refers to an alkyl group, as defined above, attached through an oxygen to an alkyl group, as defined



above, attached in turn through an oxygen to the parent molecular moiety. Examples of alkoxyalkoxyl include methoxymethoxyl, methoxyethoxyl, ethoxyethoxyl and the like. The term "alkoxyalkyl" refers to an alkoxy group, as defined above, attached through an alkylene group to the parent molecular moiety. The term "alkoxycarbonyl" represents an ester group; *i.e.*, an alkoxy group, attached to the parent molecular moiety through a carbonyl group such as methoxycarbonyl, ethoxycarbonyl, and the like. The term "alkenyl" denotes a monovalent group derived from a hydrocarbon containing at least one carbon-carbon double bond by the removal of a single hydrogen atom. Alkenyl groups include, for example, ethenyl, propenyl, butenyl, 1-methyl-2-buten-1-yl and the like. The term "alkylene" denotes a divalent group derived from a straight or branched chain saturated hydrocarbon by the removal of two hydrogen atoms, for example methylene, 1,2-ethylene, 1,1-ethylene, 1,3-propylene, 2,2-dimethylpropylene, and the like. The term "alkenylene" denotes a divalent group derived from a straight or branched chain hydrocarbon containing at least one carbon-carbon double bond. Examples of alkenylene include  $-\text{CH}=\text{CH}-$ ,  $-\text{CH}_2\text{CH}=\text{CH}-$ ,  $-\text{C}(\text{CH}_3)=\text{CH}-$ ,  $-\text{CH}_2\text{CH}=\text{CHCH}_2-$ , and the like. The term "cycloalkylene" refers to a divalent group derived from a saturated carbocyclic hydrocarbon by the removal of two hydrogen atoms, for example cyclopentylene, cyclohexylene, and the like. The term "cycloalkyl" denotes a monovalent group derived from a monocyclic or bicyclic saturated carbocyclic ring compound by the removal of a single hydrogen atom. Examples include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, bicyclo[2.2.1]heptanyl, and bicyclo[2.2.2]octanyl. The term "alkynylene" refers to a divalent group derived by the removal of two hydrogen atoms from a straight or branched chain acyclic hydrocarbon group containing a carbon-carbon triple bond. Examples of alkynylene include  $-\text{CH}\equiv\text{CH}-$ ,  $-\text{CH}\equiv\text{CH}-\text{CH}_2-$ ,  $-\text{CH}\equiv\text{CH}-\text{CH}(\text{CH}_3)-$ , and the like. The term "carbocyclic aryl" denotes a monovalent carbocyclic ring group derived by the removal of a single hydrogen atom from a monocyclic or bicyclic fused or non-fused ring system obeying the " $4n+2$  p electron" or Huckel aromaticity rule. Examples of carbocyclic aryl groups include phenyl, 1- and 2-naphthyl, biphenyl, fluorenyl, and the like. The term "(carbocyclic aryl)alkyl" refers to a carbocyclic aryl ring group as defined above, attached to the parent molecular moiety through an alkylene group. Representative (carbocyclic aryl)alkyl groups include phenylmethyl,

phenylethyl, phenylpropyl, 1-naphthylmethyl, and the like. The term "carbocyclicarylalkoxy" refers to a carbocyclicaryl alkyl group, as defined above, attached to the parent molecular moiety through an oxygen atom. The term "carbocyclic aryloxyalkyl" refers to a carbocyclic aryl group, as defined above, attached to the parent molecular moiety through an oxygen atom and thence through an alkylene group. Such groups are exemplified by phenoxymethyl, 1- and 2-naphthyloxymethyl, phenoxyethyl and the like. The term "(carbocyclic aryl)alkoxyalkyl" denotes a carbocyclic aryl group as defined above, attached to the parent molecular moiety through an alkoxyalkyl group. Representative (carbocyclic aryl)alkoxyalkyl groups include phenylmethoxymethyl, phenylethoxymethyl, 1- and 2-naphthylmethoxyethyl, and the like. "Carbocyclic arylthioalkyl" represents a carbocyclic aryl group as defined above, attached to the parent molecular moiety through a sulfur atom and thence through an alkylene group and are typified by phenylthiomethyl, 1- and 2-naphthylthioethyl and the like. The term "dialkylamino" refers to a group having the structure -NR'R" wherein R' and R" are independently selected from alkyl, as previously defined. Additionally, R' and R" taken together may optionally be -(CH<sub>2</sub>)<sub>kk</sub> -- where kk is an integer of from 2 to 6. Examples of dialkylamino include, dimethylamino, diethylaminocarbonyl, methylethylamino, piperidino, and the like. The term "halo or halogen" denotes fluorine, chlorine, bromine or iodine. The term "haloalkyl" denotes an alkyl group, as defined above, having one, two, or three halogen atoms attached thereto and is exemplified by such groups as chloromethyl, bromoethyl, trifluoromethyl, and the like. The term "hydroxyalkyl" represents an alkyl group, as defined above, substituted by one to three hydroxyl groups with the proviso that no more than one hydroxy group may be attached to a single carbon atom of the alkyl group. The term "phenoxy" refers to a phenyl group attached to the parent molecular moiety through an oxygen atom. The term "phenylthio" refers to a phenyl group attached to the parent molecular moiety through a sulfur atom. The term "pyridyloxy" refers to a pyridyl group attached to the parent molecular moiety through an oxygen atom. The terms "heteroaryl" or "heterocyclic aryl" as used herein refers to substituted or unsubstituted 5- or 6-membered ring aromatic groups containing one oxygen atom, one, two, three, or four nitrogen atoms, one nitrogen and one sulfur atom, or one nitrogen and one oxygen

atom. The term heteroaryl also includes bi-or tricyclic groups in which the aromatic heterocyclic ring is fused to one or two benzene rings. Representative heteroaryl groups are pyridyl, thienyl, indolyl, pyrazinyl, isoquinolyl, pyrrolyl, pyrimidyl, benzothienyl, furyl, benzo[b]furyl, imidazolyl, thiazolyl, carbazolyl, and the like. The term "heteroarylalkyl" denotes a heteroaryl group, as defined above, attached to the parent molecular moiety through an alkylene group. The term "heteroaryloxy" denotes a heteroaryl group, as defined above, attached to the parent molecular moiety through an oxygen atom. The term "heteroarylalkoxy" denotes a heteroarylalkyl group, as defined above, attached to the parent molecular moiety through an oxygen atom.








#### METHOD OF REDUCING RISK FACTORS FOR CARDIOVASCULAR DISEASE

The present invention encompasses compositions and methods for reducing risk factors for MI, ACS, stroke, and/or PAOD. The method of reducing risk factors comprise administering a composition comprising a leukotriene synthesis inhibitor, described in detail herein alone, or in combination with a statin, to an individuals at risk for any of these conditions. Individuals at risk include the target population described herein, especially individuals with elevated CRP, and those at risk for other diseases and conditions associated with FLAP and/or other members of the leukotriene pathway. In particular, the invention encompasses methods of reducing plasma CRP levels or plasma serum amyloid A levels comprising administering an effective amount of leukotriene inhibitor alone or in combination with a statin.

Statins are competitive inhibitors of 3-hydroxy-3-methylglutarylcoenzyme A (HMG-CoA) reductase, the enzyme that converts HMG-CoA to the cholesterol precursor mevalonic acid. Upon binding to the active site of HMG-CoA reductase, statins alter the conformation of the enzyme, thereby preventing it from attaining a functional structure. The conformational change of the HMG-CoA reductase active site makes statin drugs very effective and specific. Inhibition of HMG-CoA reductase reduces intracellular cholesterol synthesis in hepatocytes. The reduction of intracellular cholesterol results in an increase in hepatic LDL receptors on the cell surface, which in turn reduces the level of circulating LDL and its precursors, intermediate density lipoproteins (IDL) and very low density lipoproteins (VLDL). In addition, statins inhibit hepatic synthesis of apolipoprotein B-100, which results in a

decrease in the synthesis and secretion of triglyceride rich lipoproteins. Additional beneficial effects of statins on lipid biosynthesis include inhibition of LDL oxidation, and inhibition of the expression of scavenger receptors. Statins also reduce the accumulation of esterified cholesterol into macrophages, increase endothelial cell nitric oxide synthesis, reduce inflammatory processes, increase the stability of artherosclerotic plaques, and restore platelet activity and the coagulation process.

Because of their beneficial effects and high specificity, statins have become some of the most prescribed medicines in the Western industrialized world. In preferred embodiments of the invention, the statin is one of the following agents: roxuvastatin, fluvastatin, atorvastatin, lovastatin, simvastatin, pravastatin or pitavastatin. These agents are described in detail in the Statin Agent Table II below.

Approved Statins							(Infor from PDR)
Resigeeater to	Marketed as	Statin Name	Chemical	Structure	Patent No	Patent Expiration	Dosages (tablet sizes)
AstraZeneca	CRESTOR	ROVUASTATIN	bis[(E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-(methyl(methylsulfonyl)amino)pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid] calcium salt		6316460 6589959 RE37314	AUG 04,2020 DEC 23,2019 JUN 12,2012	5mg, 10mg, 20mg and 40mg
Novartis	LESCOL	FLUVASTATIN	[R*, S*-(E)]-(±)-7-[3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl]-3,5-dihydroxy-6-heptenoic acid, monosodium salt		5354772 5354772 5356896	OCT 11,2011 OCT 11,2011 DEC 12,2011	EQ 20mg and EQ 40mg
Pfizer	LIPITOR	ATORVASTATIN	[R-(R*, R*)]-2-(4-fluorophenyl)-(beta), [dgr]-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid, calcium salt (2:1) trihydrate		4681893 4681893*PED 5273995 5273995*PED 5686104 5686104*PED 5969156 5969156*PED 6126971 6126971*PED	SEP 24,2009 MAR 24,2010 DEC 28,2010 JUN 28,2011 NOV 11,2014 MAY 11,2015 JUL 08,2016 JAN 08,2017 JAN 19,2013 JUL 19,2013	EQ 10mg, EQ 20mg, EQ 40mg and EQ 40mg
MERCK	MEVACOR	LOVASTATIN	[1S-[1(alpha)(R*),3(alpha),7(beta),8(beta)(2S*,4S*),8a(beta)]]-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl]-1-naphthalenyl 2-methylbutanoate		There are no unexpired patents for this product in the Orange Book Database.		10mg, 20mg and 40mg
MERCK	ZOCOR	SIMVASTATIN	butanoic acid, 2,2-dimethyl-,1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)-ethyl]-1-naphthalenyl ester, [1S-[1(alpha),3(alpha),7(beta),8(beta)(2S*,4S*),8a(beta)]]-		4444784 4444784*PED	DEC 23,2005 JUN 23,2006	5mg, 10mg, 20mg, 40mg and 80mg
BMS	PRAVACOL	PRAVASTATIN	1-Naphthalene-heptanoic acid, 1,2,6,7,8,8a-hexahydro-(beta),(delta),6-trihydroxy-2-methyl-8-(2-methyl-1-oxobutoxy)-, monosodium salt, [1S-[1(alpha)(beta)S*,(delta)S*),2(alpha),6(alpha),8(beta)(R*),8a(alpha)]]-		4346227 4346227*PED 5030447 5030447*PED 5180589 5180589*PED 5622985 5622985*PED	OCT 20,2005 APR 20,2006 JUL 09,2008 JAN 09,2009 JUL 09,2008 JAN 09,2009 APR 22,2014 OCT 22,2014	10mg, 20mg, 40mg and 80 mg
Livalo	Pitavastatin		AutoNom Name: (E)-(3R,5S)-7-[2-Cyclopropyl-4-(4-fluoro-phenyl)-quinolin-3-yl]-3,5-dihydroxy-hept-6-enoic acid				

Mevastatin and related compounds are disclosed in U. S. Patent No. 3,983,140. Lovastatin (mevinolin) and related compounds are disclosed in U. S. Patent No. 4,231,938. Keto analogs of mevinolin (lovastatin) are disclosed in European Patent Application No. 0,142,146 A2, and quinoline and pyridine derivatives are disclosed in U. S. Patent No. 5,506,219 and 5,691,322.

Pravastatin and related compounds are disclosed in U. S. Patent No. 4,346,227. Simvastatin and related compounds are disclosed in U. S. Patent Nos. 4,448,784 and 4,450,171.

Fluvastatin and related compounds are disclosed in U. S. Patent No. 5,354,772. Cerivastatin and related compounds are disclosed in U. S. Patent Nos. 5,006,530 and 5,177,080. Atorvastatin and related compounds are disclosed in U. S. Patent Nos. 4,681,893; 5,273,995; 5,385,929 and 5,686,104.

Pitavastatin (nisvastatin (NK-104) or itavastatin) and related compounds are disclosed in U. S. Patent No. 5,011,930. Rosuvastatin (visastatin (ZD-4522)) and related compounds are disclosed in U. S. Patent No. 5,260,440.

Other possible HMG CoA reductase molecules are described in U. S. Patent Nos. 5,753,675; 4,613,610; 4,686,237; 4,647,576; and 4,499,289; and British patent no. GB 2205837.

The patents cited in relation to statins or other agents identified herein describe how to make and use the statins/agents, as well as biochemically active homologs thereof, salts, pro-drugs, metabolites, and the like. Such patents are incorporated herein by reference in their entirety. Dosings for the statins also have been described in patent and trade literature (e.g., Physician's Desk Reference 2004, incorporated herein by reference) and the manufacturers and clinical practitioners that prescribe them. Combination therapy using statin dosings similar to what is used when prescribing statins alone, or less, is specifically contemplated.

Compositions comprising a leukotriene synthesis inhibitor alone or in combination with a statin may comprises a leukotriene synthesis inhibitor in an amount effective to reduce a risk factor such as CRP or serum amyloid A. Effective daily doses of the leukotriene synthesis inhibitors are between .01 mg and 100g, more preferably 0.1 mg to 1 g, and all individual doses within these ranges are specifically contemplated. Exemplary single adult doses include 10 mg, 25 mg, 50 mg, 75 mg,

100 mg, 150 mg, 200 mg, 250 mg, 300 mg, 350 mg, 400 mg, 500 mg and 750 mg, from one to four times daily. The compositions may comprise a statin in an amount effective to reduce total serum cholesterol, serum LDL, and/or serum CRP. Effective daily doses are between .01 mg and 100 g, more preferably 0.1 mg to 1g, and all individual doses within these ranges are specifically contemplated. Exemplary individual doses include 5 mg, 10 mg, 15mg, 20 mg, 30 mg, 40 mg 50 mg, 60 mg, and 80 mg, 100 mg, 150 mg, 200 mg, 250 mg, and 500 mg, from one to four times daily.

Emerging evidence suggests that elevated CRP is an independent risk factor for adverse clinical outcomes. See, *e.g.*, Ridker *et al.*, N. Engl. J. Med. 352: 1 (January 6, 2005). In another variation, the invention provides compositions, unit doses, and methods of treatment where a leukotriene synthesis inhibitor and a statin are included or administered in amounts that synergistically act to reduce serum CRP levels. Synergistically effective amounts are amounts that either (a) achieve a greater percentage reduction in CRP than is achieved in an average patient using either type of agent alone, at a safe and effective amount, or (b) reduces CRP a comparable amount to single agent therapy, with fewer side effects; or (c) reduces CRP a comparable amount to single agent therapy, and also reduces at least one other cardiovascular risk factor more effectively than single agent therapy alone.

In one variation, the invention provides a composition comprising a leukotriene synthesis inhibitor and a statin for simultaneous administration, *e.g.*, in one dose. A composition in tablet, pill, or capsule form, including sustained release formulations, are specifically contemplated. In another variation, a unit dose comprising a single dose of the leukotriene synthesis inhibitor and a single dose of the statin, packaged together but not in admixture, is contemplated. In another variation, methods of the invention involve administering a composition comprising a leukotriene inhibitor and a composition comprising a statin at the same or different times, *e.g.*, administering the leukotriene synthesis inhibitor before or after administration of a composition comprising a statin. Compositions for and methods of administering the agents to an individual continuously (*e.g.*, through a patch or i.v.), one to twelve times a day, once a day, every other day, twice a week, weekly, or monthly for one or more weeks, months, or years, or for the entire life of a patient, depending on the level of risk for the individual, is specifically contemplated, to

manage serum CRP and other cardiovascular risk factor levels. It is contemplated that these compositions will be used for treatment and lifestyle management plans for primary or secondary MI, ACS, stroke, or PAOD prevention.

## NUCLEIC ACID THERAPEUTIC AGENTS

In another embodiment, a nucleic acid of the invention; a nucleic acid complementary to a nucleic acid of the invention; or a portion of such a nucleic acid (*e.g.*, an oligonucleotide as described below); or a nucleic acid encoding a member of the leukotriene pathway (*e.g.*, 5-LO), can be used in “antisense” therapy, in which a nucleic acid (*e.g.*, an oligonucleotide) which specifically hybridizes to the mRNA and/or genomic DNA of a nucleic acid is administered or generated *in situ*. The antisense nucleic acid that specifically hybridizes to the mRNA and/or DNA inhibits expression of the polypeptide encoded by that mRNA and/or DNA, *e.g.*, by inhibiting translation and/or transcription. Binding of the antisense nucleic acid can be by conventional base pair complementarity, or, for example, in the case of binding to DNA duplexes, through specific interaction in the major groove of the double helix.

An antisense construct can be delivered, for example, as an expression plasmid as described above. When the plasmid is transcribed in the cell, it produces RNA that is complementary to a portion of the mRNA and/or DNA that encodes the polypeptide for the member of the leukotriene pathway (*e.g.*, FLAP or 5-LO). Alternatively, the antisense construct can be an oligonucleotide probe that is generated *ex vivo* and introduced into cells; it then inhibits expression by hybridizing with the mRNA and/or genomic DNA of the polypeptide. In one embodiment, the oligonucleotide probes are modified oligonucleotides that are resistant to endogenous nucleases, *e.g.*, exonucleases and/or endonucleases, thereby rendering them stable *in vivo*. Exemplary nucleic acid molecules for use as antisense oligonucleotides are phosphoramidate, phosphothioate and methylphosphonate analogs of DNA (see also U.S. Pat. Nos. 5,176,996, 5,264,564 and 5,256,775). Additionally, general approaches to constructing oligomers useful in antisense therapy are also described, for example, by Van der Krol *et al.* (*Biotechniques* 6:958-976 (1988)); and Stein *et al.* (*Cancer Res.* 48:2659-2668 (1988)). With respect to antisense DNA, oligodeoxyribonucleotides derived from the translation initiation site are preferred.



To perform antisense therapy, oligonucleotides (mRNA, cDNA or DNA) are designed that are complementary to mRNA encoding the polypeptide. The antisense oligonucleotides bind to mRNA transcripts and prevent translation. Absolute complementarity, although preferred, is not required. A sequence “complementary” to a portion of an RNA, as referred to herein, indicates that a sequence has sufficient complementarity to be able to hybridize with the RNA, forming a stable duplex; in the case of double-stranded antisense nucleic acids, a single strand of the duplex DNA may thus be tested, or triplex formation may be assayed. The ability to hybridize will depend on both the degree of complementarity and the length of the antisense nucleic acid, as described in detail above. Generally, the longer the hybridizing nucleic acid, the more base mismatches with an RNA it may contain and still form a stable duplex (or triplex, as the case may be). One skilled in the art can ascertain a tolerable degree of mismatch by use of standard procedures.

The oligonucleotides used in antisense therapy can be DNA, RNA, or chimeric mixtures or derivatives or modified versions thereof, single-stranded or double-stranded. The oligonucleotides can be modified at the base moiety, sugar moiety, or phosphate backbone, for example, to improve stability of the molecule, hybridization, etc. The oligonucleotides can include other appended groups such as peptides (*e.g.* for targeting host cell receptors *in vivo*), or agents facilitating transport across the cell membrane (see, *e.g.*, Letsinger *et al.*, *Proc. Natl. Acad. Sci. USA* 86:6553-6556 (1989); Lemaitre *et al.*, *Proc. Natl. Acad. Sci. USA* 84:648-652 (1987); PCT International Publication No. WO 88/09810) or the blood-brain barrier (see, *e.g.*, PCT International Publication No. WO 89/10134), or hybridization-triggered cleavage agents (see, *e.g.*, Krol *et al.*, *BioTechniques* 6:958-976 (1988)) or intercalating agents. (See, *e.g.*, Zon, *Pharm.Res.* 5: 539-549 (1988)). To this end, the oligonucleotide may be conjugated to another molecule (*e.g.*, a peptide, hybridization triggered cross-linking agent, transport agent, hybridization-triggered cleavage agent).

The antisense molecules are delivered to cells that express the member of the leukotriene pathway *in vivo*. A number of methods can be used for delivering antisense DNA or RNA to cells; *e.g.*, antisense molecules can be injected directly into the tissue site, or modified antisense molecules, designed to target the desired cells (*e.g.*, antisense linked to peptides or antibodies that specifically bind receptors or

antigens expressed on the target cell surface) can be administered systematically. Alternatively, in a preferred embodiment, a recombinant DNA construct is utilized in which the antisense oligonucleotide is placed under the control of a strong promoter (e.g., pol III or pol II). The use of such a construct to transfect target cells in the patient results in the transcription of sufficient amounts of single stranded RNAs that will form complementary base pairs with the endogenous transcripts and thereby prevent translation of the mRNA. For example, a vector can be introduced *in vivo* such that it is taken up by a cell and directs the transcription of an antisense RNA. Such a vector can remain episomal or become chromosomally integrated, as long as it can be transcribed to produce the desired antisense RNA. Such vectors can be constructed by recombinant DNA technology methods standard in the art and described above. For example, a plasmid, cosmid, YAC or viral vector can be used to prepare the recombinant DNA construct that can be introduced directly into the tissue site. Alternatively, viral vectors can be used which selectively infect the desired tissue, in which case administration may be accomplished by another route (e.g., systemically).

In another embodiment of the invention, small double-stranded interfering RNA (RNA interference (RNAi)) can be used. RNAi is a post-transcription process, in which double-stranded RNA is introduced, and sequence-specific gene silencing results, through catalytic degradation of the targeted mRNA. See, e.g., Elbashir, S.M. *et al.*, *Nature* 411:494-498 (2001); Lee, N.S., *Nature Biotech.* 19:500-505 (2002); Lee, S-K. *et al.*, *Nature Medicine* 8(7):681-686 (2002); the entire teachings of these references are incorporated herein by reference. RNAi is used routinely to investigate gene function in a high throughput fashion or to modulate gene expression in human diseases (Chi *et al.*, *PNAS*, 100 (11):6343-6346 (2003)). Introduction of long double stranded RNA leads to sequence-specific degradation of homologous gene transcripts. The long double stranded RNA is metabolized to small 21-23 nucleotide siRNA (small interfering RNA). The siRNA then binds to protein complex RISC (RNA-induced silencing complex) with dual function helicase. The helicase has RNAase activity and is able to unwind the RNA. The unwound siRNA allows an antisense strand to bind to a target. This results in sequence dependent degradation of cognate mRNA. Aside from endogenous RNAi, exogenous RNAi, chemically synthesized or

recombinantly produced can also be used. Using non-intronic portions of the FLAP gene, such as corresponding mRNA portions of SEQ ID NO.1, or portions of SEQ ID NO: 3, target regions of the FLAP gene that are accessible for RNAi are targeted and silenced. With this technique it is possible to conduct a RNAi gene walk of the  
5 nucleic acids of the FLAP gene and determine the amount of inhibition of the protein product. Thus it is possible to design gene-specific therapeutics by directly targeting the mRNAs of the gene.

Endogenous expression of a member of the leukotriene pathway (*e.g.*, FLAP, 5-LO) can also be reduced by inactivating or “knocking out” the gene or its promoter  
10 using targeted homologous recombination (*e.g.*, see Smithies *et al.*, *Nature* 317:230-234 (1985); Thomas & Capecchi, *Cell* 51:503-512 (1987); Thompson *et al.*, *Cell* 5:313-321 (1989)). For example, an altered, non-functional gene of a member of the leukotriene pathway (or a completely unrelated DNA sequence) flanked by DNA homologous to the endogenous gene (either the coding regions or regulatory regions  
15 of the gene) can be used, with or without a selectable marker and/or a negative selectable marker, to transfect cells that express the gene *in vivo*. Insertion of the DNA construct, via targeted homologous recombination, results in inactivation of the gene. The recombinant DNA constructs can be directly administered or targeted to the required site *in vivo* using appropriate vectors, as described above. Alternatively,  
20 expression of non-altered genes can be increased using a similar method: targeted homologous recombination can be used to insert a DNA construct comprising a non-altered functional gene, or the complement thereof, or a portion thereof, in place of a gene in the cell, as described above. In another embodiment, targeted homologous recombination can be used to insert a DNA construct comprising a nucleic acid that  
25 encodes a polypeptide variant that differs from that present in the cell.

Alternatively, endogenous expression of a member of the leukotriene pathway can be reduced by targeting deoxyribonucleotide sequences complementary to the regulatory region of the member of the leukotriene pathway (*i.e.*, the promoter and/or enhancers) to form triple helical structures that prevent transcription of the gene in  
30 target cells in the body. (See generally, Helene, C., *Anticancer Drug Des.*, 6(6):569-84 (1991); Helene, C. *et al.*, *Ann. N.Y. Acad. Sci.* 660:27-36 (1992); and Maher, L. J., *Bioassays* 14(12):807-15 (1992)). Likewise, the antisense constructs described herein,

by antagonizing the normal biological activity of one of the members of the leukotriene pathway, can be used in the manipulation of tissue, *e.g.*, tissue differentiation, both *in vivo* and *for ex vivo* tissue cultures. Furthermore, the anti-sense techniques (*e.g.*, microinjection of antisense molecules, or transfection with plasmids whose transcripts are anti-sense with regard to a nucleic acid RNA or nucleic acid sequence) can be used to investigate the role of one or more members of the leukotriene pathway in the development of disease-related conditions. Such techniques can be utilized in cell culture, but can also be used in the creation of transgenic animals.

The therapeutic agents as described herein can be delivered in a composition, as described above, or by themselves. They can be administered systemically, or can be targeted to a particular tissue. The therapeutic agents can be produced by a variety of means, including chemical synthesis; recombinant production; *in vivo* production (*e.g.*, a transgenic animal, such as U.S. Pat. No. 4,873,316 to Meade *et al.*), for example, and can be isolated using standard means such as those described herein. In addition, a combination of any of the above methods of treatment (*e.g.*, administration of non-altered polypeptide in conjunction with antisense therapy targeting altered mRNA for a member of the leukotriene pathway; administration of a first splicing variant in conjunction with antisense therapy targeting a second splicing variant) can also be used.

The invention additionally pertains to use of such therapeutic agents, as described herein, for the manufacture of a medicament for the treatment of MI, ACS, stroke, PAOD and/or atherosclerosis, *e.g.*, using the methods described herein.

## MONITORING PROGRESS OF TREATMENT

The current invention also pertains to methods of monitoring the response of an individual, such as an individual in one of the target populations described above, to treatment with a leukotriene synthesis inhibitor.

Because the level of inflammatory markers can be elevated in individuals who are in the target populations described above, an assessment of the level of inflammatory markers of the individual both before, and during, treatment with the leukotriene synthesis inhibitor will indicate whether the treatment has successfully

decreased production of leukotrienes in the arterial vessel wall or in bone-marrow derived inflammatory cells. For example, in one embodiment of the invention, an individual who is a member of a target population as described above (*e.g.*, an individual at risk for MI, ACS, stroke or PAOD, such as an individual who is at-risk due to a FLAP haplotype) can be assessed for response to treatment with a leukotriene synthesis inhibitor, by examining leukotriene levels or leukotriene metabolite levels in the individual. Blood, serum, plasma or urinary leukotrienes (*e.g.*, leukotriene E4, cysteinyl leukotriene 1), or *ex vivo* production of leukotrienes (*e.g.*, in blood samples stimulated with a calcium ionophore to produce leukotrienes), or leukotriene metabolites, can be measured before, and during or after treatment with the leukotriene synthesis inhibitor. The leukotriene or leukotriene metabolite level before treatment is compared with the leukotriene or leukotriene metabolite level during or after treatment. The efficacy of treatment is indicated by a decrease in leukotriene production: a level of leukotriene or leukotriene metabolite during or after treatment that is significantly lower than the level of leukotriene or leukotriene metabolite before treatment, is indicative of efficacy. A level that is lower during or after treatment can be shown, for example, by decreased serum or urinary leukotrienes, or decreased *ex vivo* production of leukotrienes, or decreased leukotriene metabolites. A level that is “significantly lower”, as used herein, is a level that is less than the amount that is typically found in control individual(s), or is less in a comparison of disease risk in a population associated with the other bands of measurement (*e.g.*, the mean or median, the highest quartile or the highest quintile) compared to lower bands of measurement (*e.g.*, the mean or median, the other quartiles; the other quintiles).

For example, in one embodiment of the invention, the level of a leukotriene or leukotriene metabolite is assessed in an individual before treatment with a leukotriene synthesis inhibitor; and during or after treatment with the leukotriene synthesis inhibitor, and the levels are compared. A level of the leukotriene or leukotriene metabolite during or after treatment that is significantly lower than the level of the leukotriene or leukotriene metabolite before treatment, is indicative of efficacy of treatment with the leukotriene synthesis inhibitor. In another embodiment, production of a leukotriene or a leukotriene metabolite is stimulated in a first test sample from the individual, using a calcium ionophore, before treatment with a leukotriene synthesis

inhibitor, and is also stimulated in a second test sample from the individual, using a calcium ionophore, during or after treatment with the leukotriene synthesis inhibitor, and the level of production in the first test sample is compared with the level of production of the leukotriene or leukotriene metabolite in the second test sample. A level of the leukotriene or leukotriene metabolite in the second test sample that is significantly lower than the level of the leukotriene or leukotriene metabolite in the first test sample, is indicative of efficacy of treatment with the leukotriene synthesis inhibitor.

In another embodiment of the invention, an individual who is a member of a target population of individuals at risk for MI, ACS, stroke or PAOD (*e.g.*, an individual in a target population described above, such as an individual at-risk due to elevated C-reactive protein) can be assessed for response to treatment with a leukotriene synthesis inhibitor, by examining levels of inflammatory markers in the individual. For example, levels of an inflammatory marker in an appropriate test sample (*e.g.*, serum, plasma or urine) can be measured before, and during or after treatment with the leukotriene synthesis inhibitor. The level of the inflammatory marker before treatment is compared with the level of the inflammatory marker during or after treatment. The efficacy of treatment is indicated by a decrease in the level of the inflammatory marker, that is, a level of the inflammatory marker during or after treatment that is significantly lower (*e.g.*, significantly lower), than the level of inflammatory marker before treatment, is indicative of efficacy. Representative inflammatory markers include: C-reactive protein (CRP), serum amyloid A, fibrinogen, a leukotriene (*e.g.*, LTB<sub>4</sub>, LTC<sub>4</sub>, LTD<sub>4</sub>, LTE<sub>4</sub>), a leukotriene metabolite, interleukin-6, tissue necrosis factor-alpha, soluble vascular cell adhesion molecules (sVCAM), soluble intervascular adhesion molecules (sICAM), E-selectin, matrix metalloprotease type-1, matrix metalloprotease type-2, matrix metalloprotease type-3, matrix metalloprotease type-9, myeloperoxidase (MPO), and N-tyrosine. In a preferred embodiment, the marker is CRP or MPO.

The efficacy of treatment of a leukotriene synthesis inhibitor may be monitored by measuring at-risk biomarkers in plasma, serum or urine. Clinical assays are available for the following biomarkers: CRP, serum amyloid A, IL-1 $\beta$ , IL-6, IL-8, IL-10, TNF- $\alpha$ , E-selectin, P-selectin and intracellular adhesion molecule-1, vascular cell adhesion molecule-1. The relative risk of a cardiovascular event predicted by CRP

levels is low risk has less than 1 mg/L, average is 1.0-3.0 mg/L and high risk patients have greater than 3.0 mg/L. Thus, optimal therapeutic effect of a leukotriene synthesis inhibitor alone or in combination with a statin is reducing CRP level to 2.0 mg/L or lower.

5           The efficacy of treatment of a statin is monitored by measuring the level of total serum cholesterol, serum LDL and/or serum triglycerides. A level of serum total cholesterol, LDL-C and/or triglycerides during or after treatment, which is significantly lower than the level of total cholesterol, LDL-C and/or triglycerides before treatment is indicative of the efficacy of the treatment. For cholesterol management purposes, "high risk patients" have an LDL level of 130 mg/dL or higher and optimally the statin treatment will reduce the LDL level to less than 100 mg/dL. "Moderately-high risk patients" are those individuals with two or more risk factors for coronary heart disease with a 10-20% risk of heart attack within ten years. Optimally, the statin treatment will keep the LDL level under 129 mg/dL. More recent studies show an additional benefit on morbidity and mortality when statin therapy decreased serum LDL-C to less than 70 mg/dL. (Ridker *et al.*, *N. Engl. J. Med.* 352(1): 20-28, 2005; Nissen *et al.*, *N. Engl. J. Med.* 352(1): 29-38, 2005). Thus optimal therapeutic effect of a statin would be to lower LDL-C levels to under 70 mg/dL. as described by Ridker *et al.*, *N. Engl. J. Med.* 352(1): 20-28, 2005 and Nissen *et al.*, *N. Engl. J. Med.* 352(1): 29-38, 2005, statin therapy may reduce CRP. CRP is an additional parameter that may be monitored in connection with statin therapy.

#### ASSESSMENT OF INCREASED RISK

25           The present invention additionally pertains to methods for assessing an individual (*e.g.*, an individual who is in a target population as described herein, such as an individual who is at risk for MI, ACS, stroke or PAOD), for an increased risk of MI, ACS, atherosclerosis, stroke, transient ischemic attack, transient monocular blindness, asymptomatic carotid stenosis, PAOD, claudication, or limb ischemia. The methods comprise assessing the level of a leukotriene metabolite (*e.g.*, LTE<sub>4</sub>, LTD<sub>4</sub>, LTB<sub>4</sub>) in the individual, wherein an increased level of leukotriene metabolite is indicative of an increased risk. The level can be measured in any appropriate tissue or fluid sample, such as blood, serum, plasma, or urine. In one particular embodiment, the sample comprises neutrophils. The level of the leukotriene metabolite can be

measured by standard methods, such as the methods described herein. For example, in one embodiment, production of a leukotriene metabolite is stimulated in a first test sample from the individual, using a calcium ionophore. The level of production is compared with a control level. The control level is a level that is typically found in control individual(s), such as individual who are not at risk for MI, ACS, stroke or PAOD; alternatively, a control level is the level that is found by comparison of disease risk in a population associated with the lowest band of measurement (*e.g.*, below the mean or median, the lowest quartile or the lowest quintile) compared to higher bands of measurement (*e.g.*, above the mean or median, the second, third or fourth quartile; the second, third, fourth or fifth quintile). A level of production of the leukotriene metabolite that is significantly greater than the control level, is indicative of an increased risk. Individuals at increased risk are candidates for treatments described herein.

## PHARMACEUTICAL COMPOSITIONS

The present invention also pertains to pharmaceutical compositions comprising agents described herein, for example, an agent that is a leukotriene synthesis inhibitor as described herein. For instance, a leukotriene synthesis inhibitor can be formulated with a physiologically acceptable carrier or excipient to prepare a pharmaceutical composition. The carrier and composition can be sterile. The formulation should suit the mode of administration.

The invention also provides for compositions comprising a leukotriene synthesis inhibitor, as set out in Agent Table I, and a statin, as set out in the Agent Table II. The leukotriene synthesis inhibitor and the statin may be coformulated with a physiological acceptable carrier or expedient to prepare a pharmaceutical composition. This composition may be formulation to deliver the leukotriene synthesis inhibitor and statin in a single dose. The processes for the isolation and purification of statins and other HMG-CoA reductase inhibitors include different combinations of extraction, chromatography, lactonization and crystallization methods. Examples of formulations for statins, statin derivatives and statin salts are found in the following, all incorporated by reference in their entirety, U. S. Patent Nos. 6,316,460, 6,589,959,



RE37,314, 5,354,772, 5,356,896, 5,686,104, 5,969,156, 6,126,971, 5,030,447,  
5,180,589, 5,622,985, 6,825,015, 6,838,566, 5,403,860, 5,763,653, and 5,763,646,  
International Patent Publications WO 86/03488, WO 86/07054, French Patent No.  
2596393, European Patent Application No. 0221025, British Patent Nos. 2055100A  
5 and 2073199A and European Patent No. 65,835.

Suitable pharmaceutically acceptable carriers include but are not limited to  
water, salt solutions (*e.g.*, NaCl), saline, buffered saline, alcohols, glycerol, ethanol,  
gum arabic, vegetable oils, benzyl alcohols, polyethylene glycols, gelatin,  
carbohydrates such as lactose, amylose or starch, dextrose, magnesium stearate, talc,  
10 silicic acid, viscous paraffin, perfume oil, fatty acid esters, hydroxymethylcellulose,  
polyvinyl pyrrolidone, etc., as well as combinations thereof. The pharmaceutical  
preparations can, if desired, be mixed with auxiliary agents, *e.g.*, lubricants,  
preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic  
pressure, buffers, coloring, flavoring and/or aromatic substances and the like which do  
15 not deleteriously react with the active agents.

The composition, if desired, can also contain minor amounts of wetting or  
emulsifying agents, or pH buffering agents. The composition can be a liquid solution,  
suspension, emulsion, tablet, pill, capsule, sustained release formulation, or powder.  
The composition can be formulated as a suppository, with traditional binders and  
20 carriers such as triglycerides. Oral formulation can include standard carriers such as  
pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, polyvinyl  
pyrrolidone, sodium saccharine, cellulose, magnesium carbonate, etc.

Methods of introduction of these compositions include, but are not limited to,  
intradermal, intramuscular, intraperitoneal, intraocular, intravenous, subcutaneous,  
25 topical, oral and intranasal. Other suitable methods of introduction can also include  
gene therapy (as described below), rechargeable or biodegradable devices, particle  
acceleration devices ("gene guns") and slow release polymeric devices. The  
pharmaceutical compositions of this invention can also be administered as part of a  
combinatorial therapy with other agents.

30 The composition can be formulated in accordance with the routine procedures  
as a pharmaceutical composition adapted for administration to human beings. For  
example, compositions for intravenous administration typically are solutions in sterile

isotonic aqueous buffer. Where necessary, the composition may also include a solubilizing agent and a local anesthetic to ease pain at the site of the injection. Generally, the ingredients are supplied either separately or mixed together in unit dosage form, for example, as a dry lyophilized powder or water free concentrate in a hermetically sealed container such as an ampule or sachette indicating the quantity of active agent. Where the composition is to be administered by infusion, it can be dispensed with an infusion bottle containing sterile pharmaceutical grade water, saline or dextrose/water. Where the composition is administered by injection, an ampule of sterile water for injection or saline can be provided so that the ingredients may be mixed prior to administration.

For topical application, nonsprayable forms, viscous to semi-solid or solid forms comprising a carrier compatible with topical application and having a dynamic viscosity preferably greater than water, can be employed. Suitable formulations include but are not limited to solutions, suspensions, emulsions, creams, ointments, powders, enemas, lotions, sols, liniments, salves, aerosols, etc., which are, if desired, sterilized or mixed with auxiliary agents, *e.g.*, preservatives, stabilizers, wetting agents, buffers or salts for influencing osmotic pressure, etc. The agent may be incorporated into a cosmetic formulation. For topical application, also suitable are sprayable aerosol preparations wherein the active ingredient, preferably in combination with a solid or liquid inert carrier material, is packaged in a squeeze bottle or in admixture with a pressurized volatile, normally gaseous propellant, *e.g.*, pressurized air.

Agents described herein can be formulated as neutral or salt forms. Pharmaceutically acceptable salts include those formed with free amino groups such as those derived from hydrochloric, phosphoric, acetic, oxalic, tartaric acids, etc., and those formed with free carboxyl groups such as those derived from sodium, potassium, ammonium, calcium, ferric hydroxides, isopropylamine, triethylamine, 2-ethylamino ethanol, histidine, procaine, etc.

The agents are administered in a therapeutically effective amount. The amount of agents which will be therapeutically effective in the treatment of a particular disorder or condition will depend on the nature of the disorder or condition, and can be determined by standard clinical techniques. In addition, *in vitro* or *in vivo* assays may

optionally be employed to help identify optimal dosage ranges. The precise dose to be employed in the formulation will also depend on the route of administration, and the seriousness of the symptoms, and should be decided according to the judgment of a practitioner and each patient's circumstances. Effective doses may be extrapolated from dose-response curves derived from *in vitro* or animal model test systems.

The invention also provides a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the pharmaceutical compositions of the invention. Optionally associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use of sale for human administration. The pack or kit can be labeled with information regarding mode of administration, sequence of drug administration (*e.g.*, separately, sequentially or concurrently), or the like. The pack or kit may also include means for reminding the patient to take the therapy. The pack or kit can be a single unit dosage of the combination therapy or it can be a plurality of unit dosages. In particular, the agents can be separated, mixed together in any combination, present in a single vial or tablet. For example, a pack or kit of the invention may contain a single dose for delivery of both a leukotriene synthesis inhibitor and a statin concurrently, or contain two or more doses wherein one dose is to deliver a leukotriene synthesis inhibitor and one dose is to deliver a statin either in parallel or one following the other.

Agents assembled in a blister pack or other dispensing means is preferred. For the purpose of this invention, unit dosage is intended to mean a dosage that is dependent on the individual pharmacodynamics of each agent and administered in FDA approved dosages in standard time courses.

## NUCLEIC ACIDS OF THE INVENTION

### *FLAP Nucleic Acids, Portions and Variants*

In addition, the invention pertains to isolated nucleic acid molecules comprising a human FLAP nucleic acid. The term, "FLAP nucleic acid," as used herein, refers to an isolated nucleic acid molecule encoding FLAP polypeptide. The FLAP nucleic acid molecules of the present invention can be RNA, for example,

mRNA, or DNA, such as cDNA and genomic DNA. DNA molecules can be double-stranded or single-stranded; single stranded RNA or DNA can be either the coding, or sense strand or the non-coding, or antisense strand. The nucleic acid molecule can include all or a portion of the coding sequence of the gene or nucleic acid and can further comprise additional non-coding sequences such as introns and non-coding 3' and 5' sequences (including regulatory sequences, for example, as well as promoters, transcription enhancement elements, splice donor/acceptor sites, etc.).

For example, a FLAP nucleic acid can consist of SEQ ID NOs: 1 or 3 or the complement thereof, or to a portion or fragment of such an isolated nucleic acid molecule (*e.g.*, cDNA or the nucleic acid) that encodes FLAP polypeptide (*e.g.*, a polypeptide such as SEQ ID NO: 2). In a preferred embodiment, the isolated nucleic acid molecule comprises a nucleic acid molecule selected from the group consisting of SEQ ID NOs: 1 or 3, or their complement thereof.

Additionally, the nucleic acid molecules of the invention can be fused to a marker sequence, for example, a sequence that encodes a polypeptide to assist in isolation or purification of the polypeptide. Such sequences include, but are not limited to, those that encode a glutathione-S-transferase (GST) fusion protein and those that encode a hemagglutinin A (HA) polypeptide marker from influenza.

An "isolated" nucleic acid molecule, as used herein, is one that is separated from nucleic acids that normally flank the gene or nucleic acid sequence (as in genomic sequences) and/or has been completely or partially purified from other transcribed sequences (*e.g.*, as in an RNA library). For example, an isolated nucleic acid of the invention may be substantially isolated with respect to the complex cellular milieu in which it naturally occurs, or culture medium when produced by recombinant techniques, or chemical precursors or other chemicals when chemically synthesized. In some instances, the isolated material will form part of a composition (for example, a crude extract containing other substances), buffer system or reagent mix. In other circumstances, the material may be purified to essential homogeneity, for example as determined by PAGE or column chromatography such as HPLC. In certain embodiments, an isolated nucleic acid molecule comprises at least about 50, 80 or 90% (on a molar basis) of all macromolecular species present. With regard to genomic DNA, the term "isolated" also can refer to nucleic acid molecules that are

separated from the chromosome with which the genomic DNA is naturally associated. For example, the isolated nucleic acid molecule can contain less than about 5 kb, including but not limited to 4 kb, 3 kb, 2 kb, 1 kb, 0.5 kb or 0.1 kb of nucleotides which flank the nucleic acid molecule in the genomic DNA of the cell from which the nucleic acid molecule is derived.

The nucleic acid molecule can be fused to other coding or regulatory sequences and still be considered isolated. Thus, recombinant DNA contained in a vector is included in the definition of "isolated" as used herein. Also, isolated nucleic acid molecules include recombinant DNA molecules in heterologous host cells, as well as partially or substantially purified DNA molecules in solution. "Isolated" nucleic acid molecules also encompass *in vivo* and *in vitro* RNA transcripts of the DNA molecules of the present invention. An isolated nucleic acid molecule or nucleic acid sequence can include a nucleic acid molecule or nucleic acid sequence that is synthesized chemically or by recombinant means. Therefore, recombinant DNA contained in a vector is included in the definition of "isolated" as used herein. Also, isolated nucleotide sequences include recombinant DNA molecules in heterologous organisms, as well as partially or substantially purified DNA molecules in solution. *In vivo* and *in vitro* RNA transcripts of the DNA molecules of the present invention are also encompassed by "isolated" nucleotide sequences. Such isolated nucleotide sequences are useful in the manufacture of the encoded polypeptide, as probes for isolating homologous sequences (*e.g.*, from other mammalian species), for gene mapping (*e.g.*, by *in situ* hybridization with chromosomes), or for detecting expression of the nucleic acid in tissue (*e.g.*, human tissue), such as by Northern blot analysis.

The present invention also pertains to nucleic acid molecules which are not necessarily found in nature but which encode a FLAP polypeptide (*e.g.*, a polypeptide having an amino acid sequence comprising an amino acid sequence of SEQ ID NOs: 2), or another splicing variant of a FLAP polypeptide or polymorphic variant thereof. Thus, for example, DNA molecules that comprise a sequence that is different from the naturally occurring nucleic acid sequence but which, due to the degeneracy of the genetic code, encode a FLAP polypeptide of the present invention are also the subjects of this invention. The invention also encompasses nucleotide sequences encoding portions (fragments), or encoding variant polypeptides such as

analogues or derivatives of a FLAP polypeptide. Such variants can be naturally occurring, such as in the case of allelic variation or single nucleotide polymorphisms, or non-naturally-occurring, such as those induced by various mutagens and mutagenic processes. Intended variations include, but are not limited to, addition, deletion and substitution of one or more nucleotides that can result in conservative or non-conservative amino acid changes, including additions and deletions. Preferably the nucleotide (and/or resultant amino acid) changes are silent or conserved; that is, they do not alter the characteristics or activity of a FLAP polypeptide. In one preferred embodiment, the nucleotide sequences are fragments that comprise one or more polymorphic microsatellite markers. In another preferred embodiment, the nucleotide sequences are fragments that comprise one or more single nucleotide polymorphisms in a FLAP nucleic acid (*e.g.*, the single nucleotide polymorphisms set forth in Table 13, below).

Other alterations of the nucleic acid molecules of the invention can include, for example, labeling, methylation, internucleotide modifications such as uncharged linkages (*e.g.*, methyl phosphonates, phosphotriesters, phosphoamidates, carbamates), charged linkages (*e.g.*, phosphorothioates, phosphorodithioates), pendent moieties (*e.g.*, polypeptides), intercalators (*e.g.*, acridine, psoralen), chelators, alkylators, and modified linkages (*e.g.*, alpha anomeric nucleic acids). Also included are synthetic molecules that mimic nucleic acid molecules in the ability to bind to a designated sequence via hydrogen bonding and other chemical interactions. Such molecules include, for example, those in which peptide linkages substitute for phosphate linkages in the backbone of the molecule.

The invention also pertains to nucleic acid molecules that hybridize under high stringency hybridization conditions, such as for selective hybridization, to a nucleic acid sequence described herein (*e.g.*, nucleic acid molecules which specifically hybridize to a nucleic acid sequence encoding polypeptides described herein, and, optionally, have an activity of the polypeptide). In one embodiment, the invention includes variants described herein which hybridize under high stringency hybridization conditions (*e.g.*, for selective hybridization) to a nucleic acid sequence comprising a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 1 or 3 or the complement thereof. In another embodiment, the invention

includes variants described herein which hybridize under high stringency hybridization conditions (*e.g.*, for selective hybridization) to a nucleic acid sequence encoding an amino acid sequence of SEQ ID NO: 2 or a polymorphic variant thereof. In a preferred embodiment, the variant that hybridizes under high stringency hybridizations has an activity of a FLAP.

Such nucleic acid molecules can be detected and/or isolated by specific hybridization (*e.g.*, under high stringency conditions). "Specific hybridization," as used herein, refers to the ability of a first nucleic acid to hybridize to a second nucleic acid in a manner such that the first nucleic acid does not hybridize to any nucleic acid other than to the second nucleic acid (*e.g.*, when the first nucleic acid has a higher similarity to the second nucleic acid than to any other nucleic acid in a sample wherein the hybridization is to be performed). "Stringency conditions" for hybridization is a term of art which refers to the incubation and wash conditions, *e.g.*, conditions of temperature and buffer concentration, which permit hybridization of a particular nucleic acid to a second nucleic acid; the first nucleic acid may be perfectly (*i.e.*, 100%) complementary to the second, or the first and second may share some degree of complementarity that is less than perfect (*e.g.*, 70%, 75%, 85%, 95%): For example, certain high stringency conditions can be used which distinguish perfectly complementary nucleic acids from those of less complementarity. "High stringency conditions", "moderate stringency conditions" and "low stringency conditions" for nucleic acid hybridizations are explained on pages 2.10.1-2.10.16 and pages 6.3.1-6.3.6 in *Current Protocols in Molecular Biology* (Ausubel, F.M. *et al.*, "*Current Protocols in Molecular Biology*", John Wiley & Sons, (1998), the entire teachings of which are incorporated by reference herein). The exact conditions which determine the stringency of hybridization depend not only on ionic strength (*e.g.*, 0.2X SSC, 0.1X SSC), temperature (*e.g.*, room temperature, 42°C, 68°C) and the concentration of destabilizing agents such as formamide or denaturing agents such as SDS, but also on factors such as the length of the nucleic acid sequence, base composition, percent mismatch between hybridizing sequences and the frequency of occurrence of subsets of that sequence within other non-identical sequences. Thus, equivalent conditions can be determined by varying one or more of these parameters while maintaining a similar degree of identity or similarity between the two nucleic acid molecules.

Typically, conditions are used such that sequences at least about 60%, at least about 70%, at least about 80%, at least about 90% or at least about 95% or more identical to each other remain hybridized to one another. By varying hybridization conditions from a level of stringency at which no hybridization occurs to a level at which hybridization is first observed, conditions which will allow a given sequence to hybridize (*e.g.*, selectively) with the most similar sequences in the sample can be determined.

Exemplary conditions are described in Krause, M.H. and S.A. Aaronson, *Methods in Enzymology* 200: 546-556 (1991), and in, Ausubel, *et al.*, "*Current Protocols in Molecular Biology*", John Wiley & Sons, (1998), which describes the determination of washing conditions for moderate or low stringency conditions. Washing is the step in which conditions are usually set so as to determine a minimum level of complementarity of the hybrids. Generally, starting from the lowest temperature at which only homologous hybridization occurs, each °C by which the final wash temperature is reduced (holding SSC concentration constant) allows an increase by 1% in the maximum extent of mismatching among the sequences that hybridize. Generally, doubling the concentration of SSC results in an increase in  $T_m$  of -17°C. Using these guidelines, the washing temperature can be determined empirically for high, moderate or low stringency, depending on the level of mismatch sought.

For example, a low stringency wash can comprise washing in a solution containing 0.2X SSC/0.1% SDS for 10 minutes at room temperature; a moderate stringency wash can comprise washing in a prewarmed solution (42°C) solution containing 0.2X SSC/0.1% SDS for 15 minutes at 42°C; and a high stringency wash can comprise washing in prewarmed (68°C) solution containing 0.1X SSC/0.1%SDS for 15 minutes at 68°C. Furthermore, washes can be performed repeatedly or sequentially to obtain a desired result as known in the art. Equivalent conditions can be determined by varying one or more of the parameters given as an example, as known in the art, while maintaining a similar degree of identity or similarity between the target nucleic acid molecule and the primer or probe used.

The percent homology or identity of two nucleotide or amino acid sequences can be determined by aligning the sequences for optimal comparison purposes (*e.g.*,



gaps can be introduced in the sequence of a first sequence for optimal alignment). The nucleotides or amino acids at corresponding positions are then compared, and the percent identity between the two sequences is a function of the number of identical positions shared by the sequences (*i.e.*, % identity = # of identical positions/total # of positions x 100). When a position in one sequence is occupied by the same nucleotide or amino acid residue as the corresponding position in the other sequence, then the molecules are homologous at that position. As used herein, nucleic acid or amino acid “homology” is equivalent to nucleic acid or amino acid “identity”. In certain embodiments, the length of a sequence aligned for comparison purposes is at least 30%, for example, at least 40%, in certain embodiments at least 60%, and in other embodiments at least 70%, 80%, 90% or 95% of the length of the reference sequence. The actual comparison of the two sequences can be accomplished by well-known methods, for example, using a mathematical algorithm. A preferred, non-limiting example of such a mathematical algorithm is described in Karlin *et al.*, *Proc. Natl. Acad. Sci. USA* 90:5873-5877 (1993). Such an algorithm is incorporated into the NBLAST and XBLAST programs (version 2.0) as described in Altschul *et al.*, *Nucleic Acids Res.* 25:389-3402 (1997). When utilizing BLAST and Gapped BLAST programs, the default parameters of the respective programs (*e.g.*, NBLAST) can be used. In one embodiment, parameters for sequence comparison can be set at score=100, wordlength=12, or can be varied (*e.g.*, W=5 or W=20).

Another preferred, non-limiting example of a mathematical algorithm utilized for the comparison of sequences is the algorithm of Myers and Miller, *CABIOS* 4(1): 11-17 (1988). Such an algorithm is incorporated into the ALIGN program (version 2.0) which is part of the GCG sequence alignment software package (Accelrys, Cambridge, UK). When utilizing the ALIGN program for comparing amino acid sequences, a PAM120 weight residue table, a gap length penalty of 12, and a gap penalty of 4 can be used. Additional algorithms for sequence analysis are known in the art and include ADVANCE and ADAM as described in Torellis and Robotti, *Comput. Appl. Biosci.* 10:3-5 (1994); and FASTA described in Pearson and Lipman, *Proc. Natl. Acad. Sci. USA* 85:2444-8 (1988).

In another embodiment, the percent identity between two amino acid sequences can be accomplished using the GAP program in the GCG software package

using either a BLOSUM63 matrix or a PAM250 matrix, and a gap weight of 12, 10, 8, 6, or 4 and a length weight of 2, 3, or 4. In yet another embodiment, the percent identity between two nucleic acid sequences can be accomplished using the GAP program in the GCG software package using a gap weight of 50 and a length weight of 3.

The present invention also provides isolated nucleic acid molecules that contain a fragment or portion that hybridizes under highly stringent conditions to a nucleic acid sequence comprising SEQ ID NO: 1 or 3 or the complement of SEQ ID NO: 1 or 3, and also provides isolated nucleic acid molecules that contain a fragment or portion that hybridizes under highly stringent conditions to a nucleic acid sequence encoding an amino acid sequence of the invention or polymorphic variant thereof. The nucleic acid fragments of the invention are at least about 15, for example, at least about 18, 20, 23 or 25 nucleotides, and can be 30, 40, 50, 100, 200 or more nucleotides in length. Longer fragments, for example, 30 or more nucleotides in length, encoding antigenic polypeptides described herein are particularly useful, such as for the generation of antibodies as described below.

#### *Probes and Primers*

In a related aspect, the nucleic acid fragments of the invention are used as probes or primers in assays such as those described herein. "Probes" or "primers" are oligonucleotides that hybridize in a base-specific manner to a complementary strand of nucleic acid molecules. Such probes and primers include polypeptide nucleic acids, as described in Nielsen *et al.*, (*Science* 254:1497-1500 (1991)).

A probe or primer comprises a region of nucleic acid that hybridizes to at least about 15, for example about 20-25, and in certain embodiments about 40, 50 or 75, consecutive nucleotides of a nucleic acid of the invention, such as a nucleic acid comprising a contiguous nucleic acid sequence of SEQ ID NOs: 1 or 3 or the complement of SEQ ID Nos: 1 or 3, or a nucleic acid sequence encoding an amino acid sequence of SEQ ID NO: 2 or polymorphic variant thereof. In preferred embodiments, a probe or primer comprises 100 or fewer nucleotides, in certain embodiments, from 6 to 50 nucleotides, for example, from 12 to 30 nucleotides. In other embodiments, the probe or primer is at least 70% identical to the contiguous

nucleic acid sequence or to the complement of the contiguous nucleotide sequence, for example, at least 80% identical, in certain embodiments at least 90% identical, and in other embodiments at least 95% identical, or even capable of selectively hybridizing to the contiguous nucleic acid sequence or to the complement of the contiguous  
5 nucleotide sequence. Often, the probe or primer further comprises a label, e.g., radioisotope, fluorescent compound, enzyme, or enzyme co-factor.

The nucleic acid molecules of the invention such as those described above can be identified and isolated using standard molecular biology techniques and the sequence information provided herein. For example, nucleic acid molecules can be  
10 amplified and isolated using the polymerase chain reaction and synthetic oligonucleotide primers based on one or more of SEQ ID NOs: 1 or 3, or the complement thereof, or designed based on nucleotides based on sequences encoding one or more of the amino acid sequences provided herein. See generally *PCR Technology: Principles and Applications for DNA Amplification* (ed. H.A. Erlich, Freeman Press, NY, NY, 1992); *PCR Protocols: A Guide to Methods and Applications*  
15 (Eds. Innis *et al.*, Academic Press, San Diego, CA, 1990); Mattila *et al.*, *Nucl. Acids Res.* 19:4967 (1991); Eckert *et al.*, *PCR Methods and Applications* 1:17 (1991); PCR (eds. McPherson *et al.*, IRL Press, Oxford); and U.S. Patent 4,683,202. The nucleic acid molecules can be amplified using cDNA, mRNA or genomic DNA as a template,  
20 cloned into an appropriate vector and characterized by DNA sequence analysis.

Other suitable amplification methods include the ligase chain reaction (LCR) (see Wu and Wallace, *Genomics* 4:560 (1989), Landegren *et al.*, *Science* 241:1077 (1988), transcription amplification (Kwoh *et al.*, *Proc. Natl. Acad. Sci. USA* 86:1173 (1989)), and self-sustained sequence replication (Guatelli *et al.*, *Proc. Nat. Acad. Sci. USA* 87:1874 (1990)) and nucleic acid based sequence amplification (NASBA). The  
25 latter two amplification methods involve isothermal reactions based on isothermal transcription, which produce both single stranded RNA (ssRNA) and double stranded DNA (dsDNA) as the amplification products in a ratio of about 30 or 100 to 1, respectively.

30 The amplified DNA can be labeled, for example, radiolabeled, and used as a probe for screening a cDNA library derived from human cells, mRNA in zap express, ZIPLOX or other suitable vector. Corresponding clones can be isolated, DNA can

obtained following *in vivo* excision, and the cloned insert can be sequenced in either or both orientations by art recognized methods to identify the correct reading frame encoding a polypeptide of the appropriate molecular weight. For example, the direct analysis of the nucleic acid molecules of the present invention can be accomplished using well-known methods that are commercially available. See, for example, Sambrook *et al.*, *Molecular Cloning, A Laboratory Manual* (2nd Ed., CSHP, New York 1989); Zyskind *et al.*, *Recombinant DNA Laboratory Manual*, (Acad. Press, 1988)). Using these or similar methods, the polypeptide and the DNA encoding the polypeptide can be isolated, sequenced and further characterized.

Antisense nucleic acid molecules of the invention can be designed using the nucleotide sequences of SEQ ID NOs: 1 or 3 and/or the complement of one or more of SEQ ID NOs: 1 or 3 and/or a portion of one or more of SEQ ID NOs: 1 or 3 or the complement of one or more of SEQ ID NOs: 1 or 3 and/or a sequence encoding the amino acid sequences of SEQ ID NOs: 2 or encoding a portion of one or more of SEQ ID NOs: 1 or 3 or their complement. They can be constructed using chemical synthesis and enzymatic ligation reactions using procedures known in the art. For example, an antisense nucleic acid molecule (*e.g.*, an antisense oligonucleotide) can be chemically synthesized using naturally occurring nucleotides or variously modified nucleotides designed to increase the biological stability of the molecules or to increase the physical stability of the duplex formed between the antisense and sense nucleic acids, *e.g.*, phosphorothioate derivatives and acridine substituted nucleotides can be used. Alternatively, the antisense nucleic acid molecule can be produced biologically using an expression vector into which a nucleic acid molecule has been subcloned in an antisense orientation (*i.e.*, RNA transcribed from the inserted nucleic acid molecule will be of an antisense orientation to a target nucleic acid of interest).

The nucleic acid sequences can also be used to compare with endogenous DNA sequences in patients to identify one or more of the disorders related to FLAP, and as probes, such as to hybridize and discover related DNA sequences or to subtract out known sequences from a sample. The nucleic acid sequences can further be used to derive primers for genetic fingerprinting, to raise anti-polypeptide antibodies using DNA immunization techniques, and as an antigen to raise anti-DNA antibodies or elicit immune responses. Portions or fragments of the nucleotide sequences identified

herein (and the corresponding complete gene sequences) can be used in numerous ways as polynucleotide reagents. For example, these sequences can be used to: (i) map their respective genes on a chromosome; and, thus, locate gene regions or nucleic acid regions associated with genetic disease; (ii) identify an individual from a minute biological sample (tissue typing); and (iii) aid in forensic identification of a biological sample. Additionally, the nucleotide sequences of the invention can be used to identify and express recombinant polypeptides for analysis, characterization or therapeutic use, or as markers for tissues in which the corresponding polypeptide is expressed, either constitutively, during tissue differentiation, or in diseased states. The nucleic acid sequences can additionally be used as reagents in the screening and/or diagnostic assays described herein, and can also be included as components of kits (e.g., reagent kits) for use in the screening and/or diagnostic assays described herein.

#### *Vectors*

Another aspect of the invention pertains to nucleic acid constructs containing a nucleic acid molecule of SEQ ID NOs: 1 or 3 or the complement thereof (or a portion thereof). Yet another aspect of the invention pertains to nucleic acid constructs containing a nucleic acid molecule encoding an amino acid of SEQ ID NO: 2 or polymorphic variant thereof. The constructs comprise a vector (e.g., an expression vector) into which a sequence of the invention has been inserted in a sense or antisense orientation. As used herein, the term "vector" refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. One type of vector is a "plasmid", which refers to a circular double stranded DNA loop into which additional DNA segments can be ligated. Another type of vector is a viral vector, wherein additional DNA segments can be ligated into the viral genome. Certain vectors are capable of autonomous replication in a host cell into which they are introduced (e.g., bacterial vectors having a bacterial origin of replication and episomal mammalian vectors). Other vectors (e.g., non-episomal mammalian vectors) are integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome. Moreover, certain vectors, such as expression vectors, are capable of directing the expression of genes or nucleic acids to which they are operably linked. In general, expression vectors of utility in

recombinant DNA techniques are often in the form of plasmids. However, the invention is intended to include such other forms of expression vectors, such as viral vectors (*e.g.*, replication defective retroviruses, adenoviruses and adeno-associated viruses) that serve equivalent functions.

5 Preferred recombinant expression vectors of the invention comprise a nucleic acid molecule of the invention in a form suitable for expression of the nucleic acid molecule in a host cell. This means that the recombinant expression vectors include one or more regulatory sequences, selected on the basis of the host cells to be used for expression, which is operably linked to the nucleic acid sequence to be expressed. Within a recombinant expression vector, “operably linked” or “operatively linked” is intended to mean that the nucleic acid sequence of interest is linked to the regulatory sequence(s) in a manner which allows for expression of the nucleic acid sequence (*e.g.*, in an *in vitro* transcription/translation system or in a host cell when the vector is introduced into the host cell). The term “regulatory sequence” is intended to include 15 promoters, enhancers and other expression control elements (*e.g.*, polyadenylation signals). Such regulatory sequences are described, for example, in Goeddel, “Gene Expression Technology”, *Methods in Enzymology* 185, Academic Press, San Diego, CA (1990). Regulatory sequences include those which direct constitutive expression of a nucleic acid sequence in many types of host cell and those which direct 20 expression of the nucleic acid sequence only in certain host cells (*e.g.*, tissue-specific regulatory sequences). It will be appreciated by those skilled in the art that the design of the expression vector can depend on such factors as the choice of the host cell to be transformed and the level of expression of polypeptide desired. The expression vectors of the invention can be introduced into host cells to thereby produce 25 polypeptides, including fusion polypeptides, encoded by nucleic acid molecules as described herein.

The recombinant expression vectors of the invention can be designed for expression of a polypeptide of the invention in prokaryotic or eukaryotic cells, *e.g.*, bacterial cells such as *E. coli*, insect cells (using baculovirus expression vectors), yeast 30 cells or mammalian cells. Suitable host cells are discussed further in Goeddel, *supra*. Alternatively, the recombinant expression vector can be transcribed and translated *in vitro*, for example using T7 promoter regulatory sequences and T7 polymerase.

Another aspect of the invention pertains to host cells into which a recombinant expression vector of the invention has been introduced. The terms "host cell" and "recombinant host cell" are used interchangeably herein. It is understood that such terms refer not only to the particular subject cell but also to the progeny or potential progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term as used herein.

A host cell can be any prokaryotic or eukaryotic cell. For example, a nucleic acid molecule of the invention can be expressed in bacterial cells (*e.g.*, *E. coli*), insect cells, yeast or mammalian cells (such as Chinese hamster ovary cells (CHO) or COS cells). Other suitable host cells are known to those skilled in the art.

Vector DNA can be introduced into prokaryotic or eukaryotic cells via conventional transformation or transfection techniques. As used herein, the terms "transformation" and "transfection" are intended to refer to a variety of art-recognized techniques for introducing a foreign nucleic acid molecule (*e.g.*, DNA) into a host cell, including calcium phosphate or calcium chloride co-precipitation, DEAE-dextran-mediated transfection, lipofection, or electroporation. Suitable methods for transforming or transfecting host cells can be found in Sambrook, *et al.* (*supra*), and other laboratory manuals.

For stable transfection of mammalian cells, it is known that, depending upon the expression vector and transfection technique used, only a small fraction of cells may integrate the foreign DNA into their genome. In order to identify and select these integrants, a gene or nucleic acid that encodes a selectable marker (*e.g.*, for resistance to antibiotics) is generally introduced into the host cells along with the gene or nucleic acid of interest. Preferred selectable markers include those that confer resistance to drugs, such as G418, hygromycin and methotrexate. Nucleic acid molecules encoding a selectable marker can be introduced into a host cell on the same vector as the nucleic acid molecule of the invention or can be introduced on a separate vector. Cells stably transfected with the introduced nucleic acid molecule can be identified by drug selection (*e.g.*, cells that have incorporated the selectable marker gene or nucleic acid will survive, while the other cells die).

A host cell of the invention, such as a prokaryotic host cell or eukaryotic host cell in culture can be used to produce (*i.e.*, express) a polypeptide of the invention. Accordingly, the invention further provides methods for producing a polypeptide using the host cells of the invention. In one embodiment, the method comprises  
5 culturing the host cell of invention (into which a recombinant expression vector encoding a polypeptide of the invention has been introduced) in a suitable medium such that the polypeptide is produced. In another embodiment, the method further comprises isolating the polypeptide from the medium or the host cell.

The host cells of the invention can also be used to produce nonhuman  
10 transgenic animals. For example, in one embodiment, a host cell of the invention is a fertilized oocyte or an embryonic stem cell into which a nucleic acid molecule of the invention has been introduced (*e.g.*, an exogenous FLAP nucleic acid, or an exogenous nucleic acid encoding a FLAP polypeptide). Such host cells can then be used to create non-human transgenic animals in which exogenous nucleotide  
15 sequences have been introduced into the genome or homologous recombinant animals in which endogenous nucleotide sequences have been altered. Such animals are useful for studying the function and/or activity of the nucleic acid sequence and polypeptide encoded by the sequence and for identifying and/or evaluating modulators of their activity. As used herein, a “transgenic animal” is a non-human animal, preferably a  
20 mammal, more preferably a rodent such as a rat or mouse, in which one or more of the cells of the animal include a transgene. Other examples of transgenic animals include non-human primates, sheep, dogs, cows, goats, chickens and amphibians. A transgene is exogenous DNA which is integrated into the genome of a cell from which a transgenic animal develops and which remains in the genome of the mature animal,  
25 thereby directing the expression of an encoded gene product in one or more cell types or tissues of the transgenic animal. As used herein, a “homologous recombinant animal” is a non-human animal, preferably a mammal, more preferably a mouse, in which an endogenous gene has been altered by homologous recombination between the endogenous gene and an exogenous DNA molecule introduced into a cell of the  
30 animal, *e.g.*, an embryonic cell of the animal, prior to development of the animal.

Methods for generating transgenic animals via embryo manipulation and microinjection, particularly animals such as mice, have become conventional in the art



and are described, for example, in U.S. Patent Nos. 4,736,866 and 4,870,009, U.S. Pat. No. 4,873,191 and in Hogan, *Manipulating the Mouse Embryo* (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1986). Methods for constructing homologous recombination vectors and homologous recombinant animals are described further in Bradley, *Current Opinion in BioTechnology* 2:823-829 (1991) and in PCT Publication Nos. WO 90/11354, WO 91/01140, WO 92/0968, and WO 93/04169. Clones of the non-human transgenic animals described herein can also be produced according to the methods described in Wilmut *et al.*, *Nature* 385:810-813 (1997) and PCT Publication Nos. WO 97/07668 and WO 97/07669.

## POLYPEPTIDES OF THE INVENTION

The present invention also pertains to isolated polypeptides encoded by FLAP nucleic acids ("FLAP polypeptides"), and fragments and variants thereof, as well as polypeptides encoded by nucleotide sequences described herein (*e.g.*, other splicing variants). The term "polypeptide" refers to a polymer of amino acids, and not to a specific length; thus, peptides, oligopeptides and proteins are included within the definition of a polypeptide. As used herein, a polypeptide is said to be "isolated" or "purified" when it is substantially free of cellular material when it is isolated from recombinant and non-recombinant cells, or free of chemical precursors or other chemicals when it is chemically synthesized. A polypeptide, however, can be joined to another polypeptide with which it is not normally associated in a cell (*e.g.*, in a "fusion protein") and still be "isolated" or "purified."

The polypeptides of the invention can be purified to homogeneity. It is understood, however, that preparations in which the polypeptide is not purified to homogeneity are useful. The critical feature is that the preparation allows for the desired function of the polypeptide, even in the presence of considerable amounts of other components. Thus, the invention encompasses various degrees of purity. In one embodiment, the language "substantially free of cellular material" includes preparations of the polypeptide having less than about 30% (by dry weight) other proteins (*i.e.*, contaminating protein), less than about 20% other proteins, less than about 10% other proteins, or less than about 5% other proteins.

When a polypeptide is recombinantly produced, it can also be substantially free of culture medium, *i.e.*, culture medium represents less than about 20%, less than about 10%, or less than about 5% of the volume of the polypeptide preparation. The language “substantially free of chemical precursors or other chemicals” includes  
5 preparations of the polypeptide in which it is separated from chemical precursors or other chemicals that are involved in its synthesis. In one embodiment, the language “substantially free of chemical precursors or other chemicals” includes preparations of the polypeptide having less than about 30% (by dry weight) chemical precursors or other chemicals, less than about 20% chemical precursors or other chemicals, less than  
10 about 10% chemical precursors or other chemicals, or less than about 5% chemical precursors or other chemicals.

In one embodiment, a polypeptide of the invention comprises an amino acid sequence encoded by a nucleic acid molecule comprising a nucleic acid sequence selected from the group consisting of SEQ ID NO: 1 or 3, or the complement of SEQ  
15 ID NO: 1 or 3, or portions thereof, or a portion or polymorphic variant thereof. However, the polypeptides of the invention also encompass fragment and sequence variants. Variants include a substantially homologous polypeptide encoded by the same genetic locus in an organism, *i.e.*, an allelic variant, as well as other splicing variants. Variants also encompass polypeptides derived from other genetic loci in an  
20 organism, but having substantial homology to a polypeptide encoded by a nucleic acid molecule comprising a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 1 or 3 or their complement, or portions thereof, or having substantial homology to a polypeptide encoded by a nucleic acid molecule comprising a nucleic acid sequence selected from the group consisting of nucleotide sequences encoding  
25 SEQ ID NO: 2 or polymorphic variants thereof. Variants also include polypeptides substantially homologous or identical to these polypeptides but derived from another organism, *i.e.*, an ortholog. Variants also include polypeptides that are substantially homologous or identical to these polypeptides that are produced by chemical  
30 synthesis. Variants also include polypeptides that are substantially homologous or identical to these polypeptides that are produced by recombinant methods.

As used herein, two polypeptides (or a region of the polypeptides) are substantially homologous or identical when the amino acid sequences are at least

about 45-55%, in certain embodiments at least about 70-75%, and in other  
embodiments at least about 80-85%, and in others greater than about 90% or more  
homologous or identical. A substantially homologous amino acid sequence, according  
to the present invention, will be encoded by a nucleic acid molecule hybridizing to  
5 SEQ ID NO: 1 or 3 or portion thereof, under stringent conditions as more particularly  
described above, or will be encoded by a nucleic acid molecule hybridizing to a  
nucleic acid sequence encoding SEQ ID NO: 2 or a portion thereof or polymorphic  
variant thereof, under stringent conditions as more particularly described thereof.

The invention also encompasses polypeptides having a lower degree of identity  
10 but having sufficient similarity so as to perform one or more of the same functions  
performed by a polypeptide encoded by a nucleic acid molecule of the invention.  
Similarity is determined by conserved amino acid substitution. Such substitutions are  
those that substitute a given amino acid in a polypeptide by another amino acid of like  
characteristics. Conservative substitutions are likely to be phenotypically silent.  
15 Typically seen as conservative substitutions are the replacements, one for another,  
among the aliphatic amino acids Ala, Val, Leu and Ile; interchange of the hydroxyl  
residues Ser and Thr, exchange of the acidic residues Asp and Glu, substitution  
between the amide residues Asn and Gln, exchange of the basic residues Lys and Arg  
and replacements among the aromatic residues Phe and Tyr. Guidance concerning  
20 which amino acid changes are likely to be phenotypically silent are found in Bowie *et al.*, *Science* 247:1306-1310 (1990).

A variant polypeptide can differ in amino acid sequence by one or more  
substitutions, deletions, insertions, inversions, fusions, and truncations or a  
combination of any of these. Further, variant polypeptides can be fully functional or  
25 can lack function in one or more activities. Fully functional variants typically contain  
only conservative variation or variation in non-critical residues or in non-critical  
regions. Functional variants can also contain substitution of similar amino acids that  
result in no change or an insignificant change in function. Alternatively, such  
substitutions may positively or negatively affect function to some degree. Non-  
30 functional variants typically contain one or more non-conservative amino acid  
substitutions, deletions, insertions, inversions, or truncation or a substitution, insertion,  
inversion, or deletion in a critical residue or critical region.

Amino acids that are essential for function can be identified by methods known in the art, such as site-directed mutagenesis or alanine-scanning mutagenesis (Cunningham *et al.*, *Science* 244:1081-1085 (1989)). The latter procedure introduces single alanine mutations at every residue in the molecule. The resulting mutant  
5 molecules are then tested for biological activity *in vitro*, or *in vitro* proliferative activity. Sites that are critical for polypeptide activity can also be determined by structural analysis such as crystallization, nuclear magnetic resonance or photoaffinity labeling (Smith *et al.*, *J. Mol. Biol.* 224:899-904 (1992); de Vos *et al.*, *Science* 255:306-312 (1992)).

10 The invention also includes fragments of the polypeptides of the invention. Fragments can be derived from a polypeptide encoded by a nucleic acid molecule comprising SEQ ID NO: 1 or 3, or the complement of SEQ ID NO: 1 or 3 (or other variants). However, the invention also encompasses fragments of the variants of the polypeptides described herein. As used herein, a fragment comprises at least 6  
15 contiguous amino acids. Useful fragments include those that retain one or more of the biological activities of the polypeptide as well as fragments that can be used as an immunogen to generate polypeptide-specific antibodies.

Biologically active fragments (peptides which are, for example, 6, 9, 12, 15, 16, 20, 30, 35, 36, 37, 38, 39, 40, 50, 100 or more amino acids in length) can comprise  
20 a domain, segment, or motif that has been identified by analysis of the polypeptide sequence using well-known methods, *e.g.*, signal peptides, extracellular domains, one or more transmembrane segments or loops, ligand binding regions, zinc finger domains, DNA binding domains, acylation sites, glycosylation sites, or phosphorylation sites.

25 Fragments can be discrete (not fused to other amino acids or polypeptides) or can be within a larger polypeptide. Further, several fragments can be comprised within a single larger polypeptide. In one embodiment a fragment designed for expression in a host can have heterologous pre- and pro-polypeptide regions fused to the amino terminus of the polypeptide fragment and an additional region fused to the  
30 carboxyl terminus of the fragment.

The invention thus provides chimeric or fusion polypeptides. These comprise a polypeptide of the invention operatively linked to a heterologous protein or

polypeptide having an amino acid sequence not substantially homologous to the polypeptide. "Operatively linked" indicates that the polypeptide and the heterologous protein are fused in-frame. The heterologous protein can be fused to the N-terminus or C-terminus of the polypeptide. In one embodiment the fusion polypeptide does not affect function of the polypeptide *per se*. For example, the fusion polypeptide can be a GST-fusion polypeptide in which the polypeptide sequences are fused to the C-terminus of the GST sequences. Other types of fusion polypeptides include, but are not limited to, enzymatic fusion polypeptides, for example beta-galactosidase fusions, yeast two-hybrid GAL fusions, poly-His fusions and Ig fusions. Such fusion polypeptides, particularly poly-His fusions, can facilitate the purification of recombinant polypeptide. In certain host cells (*e.g.*, mammalian host cells), expression and/or secretion of a polypeptide can be increased using a heterologous signal sequence. Therefore, in another embodiment, the fusion polypeptide contains a heterologous signal sequence at its N-terminus.

EP-A-O 464 533 discloses fusion proteins comprising various portions of immunoglobulin constant regions. The Fc is useful in therapy and diagnosis and thus results, for example, in improved pharmacokinetic properties (EP-A 0232 262). In drug discovery, for example, human proteins have been fused with Fc portions for the purpose of high-throughput screening assays to identify antagonists. Bennett *et al.*, *Journal of Molecular Recognition*, 8:52-58 (1995) and Johanson *et al.*, *The Journal of Biological Chemistry*, 270, 16:9459-9471 (1995). Thus, this invention also encompasses soluble fusion polypeptides containing a polypeptide of the invention and various portions of the constant regions of heavy or light chains of immunoglobulins of various subclasses (IgG, IgM, IgA, IgE).

A chimeric or fusion polypeptide can be produced by standard recombinant DNA techniques. For example, DNA fragments coding for the different polypeptide sequences are ligated together in-frame in accordance with conventional techniques. In another embodiment, the fusion gene can be synthesized by conventional techniques including automated DNA synthesizers. Alternatively, PCR amplification of nucleic acid fragments can be carried out using anchor primers which give rise to complementary overhangs between two consecutive nucleic acid fragments which can subsequently be annealed and re-amplified to generate a chimeric nucleic acid

sequence (see Ausubel *et al.*, *Current Protocols in Molecular Biology*, 1992).

Moreover, many expression vectors are commercially available that already encode a fusion moiety (*e.g.*, a GST protein). A nucleic acid molecule encoding a polypeptide of the invention can be cloned into such an expression vector such that the fusion moiety is linked in-frame to the polypeptide.

The isolated polypeptide can be purified from cells that naturally express it, purified from cells that have been altered to express it (recombinant), or synthesized using known protein synthesis methods. In one embodiment, the polypeptide is produced by recombinant DNA techniques. For example, a nucleic acid molecule encoding the polypeptide is cloned into an expression vector, the expression vector introduced into a host cell and the polypeptide expressed in the host cell. The polypeptide can then be isolated from the cells by an appropriate purification scheme using standard protein purification techniques.

The polypeptides of the present invention can be used to raise antibodies or to elicit an immune response. The polypeptides can also be used as a reagent, *e.g.*, a labeled reagent, in assays to quantitatively determine levels of the polypeptide or a molecule to which it binds (*e.g.*, a ligand) in biological fluids. The polypeptides can also be used as markers for cells or tissues in which the corresponding polypeptide is preferentially expressed, either constitutively, during tissue differentiation, or in diseased states. The polypeptides can be used to isolate a corresponding binding agent, *e.g.*, ligand, such as, for example, in an interaction trap assay, and to screen for peptide or small molecule antagonists or agonists of the binding interaction. For example, because members of the leukotriene pathway including FLAP bind to receptors, the leukotriene pathway polypeptides can be used to isolate such receptors.

## ANTIBODIES OF THE INVENTION

Polyclonal and/or monoclonal antibodies that specifically bind one form of the polypeptide or nucleic acid product (*e.g.*, a polypeptide encoded by a nucleic acid having a SNP as set forth in Table 13), but not to another form of the polypeptide or nucleic acid product, are also provided. Antibodies are also provided which bind a portion of either polypeptide encoded by nucleic acids of the invention (*e.g.*, SEQ ID NO: 1 or SEQ ID NO: 3, or the complement of SEQ ID NO: 1 or SEQ ID NO: 3), or

to a polypeptide encoded by nucleic acids of the invention that contain a polymorphic site or sites. The invention also provides antibodies to the polypeptides and polypeptide fragments of the invention, or a portion thereof, or having an amino acid sequence encoded by a nucleic acid molecule comprising all or a portion of SEQ ID  
5 NOs: 1 or 3, or the complement thereof, or another variant or portion thereof.

The term “antibody” as used herein refers to immunoglobulin molecules and immunologically active portions of immunoglobulin molecules, *i.e.*, molecules that contain an antigen binding site that specifically binds an antigen. A molecule that specifically binds to a polypeptide of the invention is a molecule that binds to that  
10 polypeptide or a fragment thereof, but does not substantially bind other molecules in a sample, *e.g.*, a biological sample, which naturally contains the polypeptide. Examples of immunologically active portions of immunoglobulin molecules include F(ab) and F(ab')<sub>2</sub> fragments which can be generated by treating the antibody with an enzyme such as pepsin. The invention provides polyclonal and monoclonal antibodies that  
15 bind to a polypeptide of the invention. The term “monoclonal antibody” or “monoclonal antibody composition”, as used herein, refers to a population of antibody molecules that contain only one species of an antigen binding site capable of immunoreacting with a particular epitope of a polypeptide of the invention. A monoclonal antibody composition thus typically displays a single binding affinity for a  
20 particular polypeptide of the invention with which it immunoreacts.

Polyclonal antibodies can be prepared as described above by immunizing a suitable subject with a desired immunogen, *e.g.*, polypeptide of the invention or fragment thereof. The antibody titer in the immunized subject can be monitored over time by standard techniques, such as with an enzyme linked immunosorbent assay  
25 (ELISA) using immobilized polypeptide. If desired, the antibody molecules directed against the polypeptide can be isolated from the mammal (*e.g.*, from the blood) and further purified by well-known techniques, such as protein A chromatography to obtain the IgG fraction. At an appropriate time after immunization, *e.g.*, when the antibody titers are highest, antibody-producing cells can be obtained from the subject  
30 and used to prepare monoclonal antibodies by standard techniques, such as the hybridoma technique originally described by Kohler and Milstein, *Nature* 256:495-497 (1975), the human B cell hybridoma technique (Kozbor *et al.*, *Immunol. Today*

4:72 (1983)); the EBV-hybridoma technique (Cole *et al.*, *Monoclonal Antibodies and Cancer Therapy*, Alan R. Liss, 1985, Inc., pp. 77-96); or trioma techniques. The technology for producing hybridomas is well known (see generally *Current Protocols in Immunology* (1994) Coligan *et al.* (eds.) John Wiley & Sons, Inc., New York, NY).  
5 Briefly, an immortal cell line (typically a myeloma) is fused to lymphocytes (typically splenocytes) from a mammal immunized with an immunogen as described above, and the culture supernatants of the resulting hybridoma cells are screened to identify a hybridoma producing a monoclonal antibody that binds a polypeptide of the invention.

Any of the many well known protocols used for fusing lymphocytes and  
10 immortalized cell lines can be applied for the purpose of generating a monoclonal antibody to a polypeptide of the invention (see, *e.g.*, *Current Protocols in Immunology*, *supra*; Galfre *et al.*, *Nature* 266:55052 (1977); R.H. Kenneth, in *Monoclonal Antibodies: A New Dimension In Biological Analyses*, Plenum Publishing Corp., New York, New York (1980); and Lerner, *Yale J. Biol. Med.* 54:387-402  
15 (1981). Moreover, the ordinarily skilled worker will appreciate that there are many variations of such methods that also would be useful.

Alternative to preparing monoclonal antibody-secreting hybridomas, a monoclonal antibody to a polypeptide of the invention can be identified and isolated by screening a recombinant combinatorial immunoglobulin library (*e.g.*, an antibody  
20 phage display library) with the polypeptide to thereby isolate immunoglobulin library members that bind the polypeptide. Kits for generating and screening phage display libraries are commercially available (*e.g.*, the Pharmacia *Recombinant Phage Antibody System*, Catalog No. 27-9400-01; and the Stratagene *SurfZAP*<sup>TM</sup> Phage Display Kit, Catalog No. 240612). Additionally, examples of methods and reagents particularly  
25 amenable for use in generating and screening antibody display library can be found in, for example, U.S. Patent No. 5,223,409; PCT Publication No. WO 92/18619; PCT Publication No. WO 91/17271; PCT Publication No. WO 92/20791; PCT Publication No. WO 92/15679; PCT Publication No. WO 93/01288; PCT Publication No. WO 92/01047; PCT Publication No. WO 92/09690; PCT Publication No. WO 90/02809;  
30 Fuchs *et al.*, *Bio/Technology* 9: 1370-1372 (1991); Hay *et al.*, *Hum. Antibod. Hybridomas* 3:81-85 (1992); Huse *et al.*, *Science* 246:1275-1281 (1989); Griffiths *et al.*, *EMBO J.* 12:725-734 (1993).



Additionally, recombinant antibodies, such as chimeric and humanized monoclonal antibodies, comprising both human and non-human portions, which can be made using standard recombinant DNA techniques, are within the scope of the invention. Such chimeric and humanized monoclonal antibodies can be produced by recombinant DNA techniques known in the art.

In general, antibodies of the invention (*e.g.*, a monoclonal antibody) can be used to isolate a polypeptide of the invention by standard techniques, such as affinity chromatography or immunoprecipitation. A polypeptide-specific antibody can facilitate the purification of natural polypeptide from cells and of recombinantly produced polypeptide expressed in host cells. Moreover, an antibody specific for a polypeptide of the invention can be used to detect the polypeptide (*e.g.*, in a cellular lysate, cell supernatant, or tissue sample) in order to evaluate the abundance and pattern of expression of the polypeptide. Antibodies can be used diagnostically to monitor protein levels in tissue as part of a clinical testing procedure, *e.g.*, to, for example, determine the efficacy of a given treatment regimen. Detection can be facilitated by coupling the antibody to a detectable substance. Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, and radioactive materials. Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase,  $\beta$ -galactosidase, or acetylcholinesterase; examples of suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin; examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol; examples of bioluminescent materials include luciferase, luciferin and aequorin, and examples of suitable radioactive material include  $^{125}\text{I}$ ,  $^{131}\text{I}$ ,  $^{35}\text{S}$  or  $^3\text{H}$ .

As described above, antibodies to leukotrienes can be used in the methods of the invention. The methods described herein can be used to generate such antibodies for use in the methods.

## DIAGNOSTIC ASSAYS

The nucleic acids, probes, primers, polypeptides and antibodies described herein can be used in methods of diagnosis of a susceptibility to MI, ACS, stroke or PAOD, or to another disease or condition associated with an MI gene, such as FLAP, as well as in kits useful for diagnosis of a susceptibility to MI, ACS, stroke or PAOD, or to another disease or condition associated with FLAP. In one embodiment, the kit useful for diagnosis of susceptibility to MI, ACS, stroke or PAOD, or to another disease or condition associated with FLAP comprises primers as described herein, wherein the primers contain one or more of the SNPs identified in Table 13.

In one embodiment of the invention, diagnosis of susceptibility to MI, ACS, stroke or PAOD (or diagnosis of susceptibility to another disease or condition associated with FLAP), is made by detecting a polymorphism in a FLAP nucleic acid as described herein. The polymorphism can be an alteration in a FLAP nucleic acid, such as the insertion or deletion of a single nucleotide, or of more than one nucleotide, resulting in a frame shift alteration; the change of at least one nucleotide, resulting in a change in the encoded amino acid; the change of at least one nucleotide, resulting in the generation of a premature stop codon; the deletion of several nucleotides, resulting in a deletion of one or more amino acids encoded by the nucleotides; the insertion of one or several nucleotides, such as by unequal recombination or gene conversion, resulting in an interruption of the coding sequence of the gene or nucleic acid; duplication of all or a part of the gene or nucleic acid; transposition of all or a part of the gene or nucleic acid; or rearrangement of all or a part of the gene or nucleic acid. More than one such alteration may be present in a single gene or nucleic acid. Such sequence changes cause an alteration in the polypeptide encoded by a FLAP nucleic acid. For example, if the alteration is a frame shift alteration, the frame shift can result in a change in the encoded amino acids, and/or can result in the generation of a premature stop codon, causing generation of a truncated polypeptide. Alternatively, a polymorphism associated with a disease or condition associated with a FLAP nucleic acid or a susceptibility to a disease or condition associated with a FLAP nucleic acid can be a synonymous alteration in one or more nucleotides (*i.e.*, an alteration that does not result in a change in the polypeptide encoded by a FLAP nucleic acid). Such a polymorphism may alter splicing sites, affect the stability or transport of mRNA, or otherwise affect the transcription or translation of the nucleic acid. A FLAP nucleic

acid that has any of the alteration described above is referred to herein as an "altered nucleic acid."

In a first method of diagnosing a susceptibility to MI, ACS, stroke or PAOD, hybridization methods, such as Southern analysis, Northern analysis, or *in situ* hybridizations, can be used (see *Current Protocols in Molecular Biology*, Ausubel, F. *et al.*, eds., John Wiley & Sons, including all supplements through 1999). For example, a biological sample from a test subject (a "test sample") of genomic DNA, RNA, or cDNA, is obtained from an individual suspected of having, being susceptible to or predisposed for, or carrying a defect for, a susceptibility to a disease or condition associated with a FLAP nucleic acid (the "test individual"). The individual can be an adult, child, or fetus. The test sample can be from any source which contains genomic DNA, such as a blood sample, sample of amniotic fluid, sample of cerebrospinal fluid, or tissue sample from skin, muscle, buccal or conjunctival mucosa, placenta, gastrointestinal tract or other organs. A test sample of DNA from fetal cells or tissue can be obtained by appropriate methods, such as by amniocentesis or chorionic villus sampling. The DNA, RNA, or cDNA sample is then examined to determine whether a polymorphism in an MI nucleic acid is present, and/or to determine which splicing variant(s) encoded by the FLAP is present. The presence of the polymorphism or splicing variant(s) can be indicated by hybridization of the nucleic acid in the genomic DNA, RNA, or cDNA to a nucleic acid probe. A "nucleic acid probe," as used herein, can be a DNA probe or an RNA probe; the nucleic acid probe can contain at least one polymorphism in a FLAP nucleic acid or contains a nucleic acid encoding a particular splicing variant of a FLAP nucleic acid. The probe can be any of the nucleic acid molecules described above (*e.g.*, the nucleic acid, a fragment, a vector comprising the nucleic acid, a probe or primer, etc.).

To diagnose a susceptibility to MI, ACS, stroke or PAOD (or another disease or condition associated with FLAP), the test sample containing a FLAP nucleic acid is contacted with at least one nucleic acid probe to form a hybridization sample. A preferred probe for detecting mRNA or genomic DNA is a labeled nucleic acid probe capable of hybridizing to mRNA or genomic DNA sequences described herein. The nucleic acid probe can be, for example, a full-length nucleic acid molecule, or a portion thereof, such as an oligonucleotide of at least 15, 30, 50, 100, 250 or 500

nucleotides in length and sufficient to specifically hybridize under stringent conditions to appropriate mRNA or genomic DNA. For example, the nucleic acid probe can be all or a portion of one of SEQ ID NOs: 1 and 3, or the complement thereof or a portion thereof; or can be a nucleic acid encoding all or a portion of one of SEQ ID NO: 2.

5 Other suitable probes for use in the diagnostic assays of the invention are described above (see *e.g.*, probes and primers discussed under the heading, "Nucleic Acids of the Invention").

The hybridization sample is maintained under conditions that are sufficient to allow specific hybridization of the nucleic acid probe to a FLAP nucleic acid.

10 "Specific hybridization," as used herein, indicates exact hybridization (*e.g.*, with no mismatches). Specific hybridization can be performed under high stringency conditions or moderate stringency conditions, for example, as described above. In a particularly preferred embodiment, the hybridization conditions for specific hybridization are high stringency.

15 Specific hybridization, if present, is then detected using standard methods. If specific hybridization occurs between the nucleic acid probe and FLAP nucleic acid in the test sample, then the FLAP has the polymorphism, or is the splicing variant, that is present in the nucleic acid probe. More than one nucleic acid probe can also be used concurrently in this method. Specific hybridization of any one of the nucleic acid  
20 probes is indicative of a polymorphism in the FLAP nucleic acid, or of the presence of a particular splicing variant encoding the FLAP nucleic acid, and is therefore diagnostic for a susceptibility to a disease or condition associated with FLAP (*e.g.*, MI, ACS, stroke or PAOD).

In Northern analysis (see *Current Protocols in Molecular Biology*, Ausubel, F.  
25 *et al.*, eds., John Wiley & Sons, *supra*) the hybridization methods described above are used to identify the presence of a polymorphism or a particular splicing variant, associated with a susceptibility to a disease or condition associated with FLAP (*e.g.*, MI, ACS, stroke or PAOD). For Northern analysis, a test sample of RNA is obtained from the individual by appropriate means. Specific hybridization of a nucleic acid  
30 probe, as described above, to RNA from the individual is indicative of a polymorphism in a FLAP nucleic acid, or of the presence of a particular splicing

variant encoded by a FLAP nucleic acid, and is therefore diagnostic for susceptibility to a disease or condition associated with FLAP (*e.g.*, MI, ACS, stroke or PAOD).

For representative examples of use of nucleic acid probes, see, for example, U.S. Patents No. 5,288,611 and 4,851,330.

5           Alternatively, a peptide nucleic acid (PNA) probe can be used instead of a nucleic acid probe in the hybridization methods described above. PNA is a DNA mimic having a peptide-like, inorganic backbone, such as N-(2-aminoethyl)glycine units, with an organic base (A, G, C, T or U) attached to the glycine nitrogen via a methylene carbonyl linker (see, for example, Nielsen, P.E. *et al.*, *Bioconjugate*  
10       *Chemistry* 5, American Chemical Society, p. 1 (1994)). The PNA probe can be designed to specifically hybridize to a nucleic acid having a polymorphism associated with a susceptibility to a disease or condition associated with FLAP (*e.g.*, MI). Hybridization of the PNA probe to a FLAP nucleic acid as described herein is diagnostic for the susceptibility to the disease or condition.

15           In another method of the invention, mutation analysis by restriction digestion can be used to detect an altered nucleic acid, or nucleic acids containing a polymorphism(s), if the mutation or polymorphism in the nucleic acid results in the creation or elimination of a restriction site. A test sample containing genomic DNA is obtained from the individual. Polymerase chain reaction (PCR) can be used to  
20       amplify a FLAP nucleic acid (and, if necessary, the flanking sequences) in the test sample of genomic DNA from the test individual. RFLP analysis is conducted as described (see *Current Protocols in Molecular Biology*, *supra*). The digestion pattern of the relevant DNA fragment indicates the presence or absence of the alteration or polymorphism in the FLAP nucleic acid, and therefore indicates the presence or  
25       absence of the susceptibility to a disease or condition associated with FLAP (*e.g.*, MI, ACS, stroke or PAOD).

          Sequence analysis can also be used to detect specific polymorphisms in the FLAP nucleic acid. A test sample of DNA or RNA is obtained from the test individual. PCR or other appropriate methods can be used to amplify the nucleic acid,  
30       and/or its flanking sequences, if desired. The sequence of a FLAP nucleic acid, or a fragment of the nucleic acid, or cDNA, or fragment of the cDNA, or mRNA, or fragment of the mRNA, is determined, using standard methods. The sequence of the

nucleic acid, nucleic acid fragment, cDNA, cDNA fragment, mRNA, or mRNA fragment is compared with the known nucleic acid sequence of the nucleic acid, cDNA (*e.g.*, one or more of SEQ ID NOs: 1 or 3, and/or the complement of SEQ ID NO: 1 or 3), or a nucleic acid sequence encoding SEQ ID NO: 2 or a fragment thereof or mRNA, as appropriate. The presence of a polymorphism in the FLAP indicates that the individual has a susceptibility to a disease associated with FLAP (*e.g.*, MI, ACS, stroke or PAOD).

Allele-specific oligonucleotides can also be used to detect the presence of polymorphism(s) in the FLAP nucleic acid, through the use of dot-blot hybridization of amplified oligonucleotides with allele-specific oligonucleotide (ASO) probes (see, for example, Saiki, R. *et al.*, *Nature* 324:163-166 (1986)). An "allele-specific oligonucleotide" (also referred to herein as an "allele-specific oligonucleotide probe") is an oligonucleotide of approximately 10-50 base pairs, for example, approximately 15-30 base pairs, that specifically hybridizes to a FLAP nucleic acid, and that contains a polymorphism associated with a susceptibility to a disease or condition associated with FLAP (*e.g.*, MI, ACS, stroke or PAOD). An allele-specific oligonucleotide probe that is specific for particular polymorphisms in a FLAP nucleic acid can be prepared, using standard methods (see *Current Protocols in Molecular Biology*, *supra*). To identify polymorphisms in the nucleic acid associated with susceptibility to disease, a test sample of DNA is obtained from the individual. PCR can be used to amplify all or a fragment of a FLAP nucleic acid, and its flanking sequences. The DNA containing the amplified FLAP nucleic acid (or fragment of the nucleic acid) is dot-blotted, using standard methods (see *Current Protocols in Molecular Biology*, *supra*), and the blot is contacted with the oligonucleotide probe. The presence of specific hybridization of the probe to the amplified FLAP is then detected. Specific hybridization of an allele-specific oligonucleotide probe to DNA from the individual is indicative of a polymorphism in the FLAP, and is therefore indicative of a susceptibility to a disease or condition associated with FLAP (*e.g.*, MI, ACS, stroke or PAOD).

An allele-specific primer hybridizes to a site on target DNA overlapping a polymorphism and only primes amplification of an allelic form to which the primer exhibits perfect complementarity. See Gibbs, *Nucleic Acid Res.* 17, 2427-2448

(1989). This primer is used in conjunction with a second primer which hybridizes at a distal site. Amplification proceeds from the two primers, resulting in a detectable product which indicates the particular allelic form is present. A control is usually performed with a second pair of primers, one of which shows a single base mismatch at the polymorphic site and the other of which exhibits perfect complementarity to a distal site. The single-base mismatch prevents amplification and no detectable product is formed. The method works best when the mismatch is included in the 3'-most position of the oligonucleotide aligned with the polymorphism because this position is most destabilizing to elongation from the primer (see, *e.g.*, WO 93/22456).

With the addition of such analogs as locked nucleic acids (LNAs), the size of primers and probes can be reduced to as few as 8 bases. LNAs are a novel class of bicyclic DNA analogs in which the 2' and 4' positions in the furanose ring are joined via an O-methylene (oxy-LNA), S-methylene (thio-LNA), or amino methylene (amino-LNA) moiety. Common to all of these LNA variants is an affinity toward complementary nucleic acids, which is by far the highest reported for a DNA analog. For example, particular all oxy-LNA nonamers have been shown to have melting temperatures of 64EC and 74EC when in complex with complementary DNA or RNA, respectively, as opposed to 28EC for both DNA and RNA for the corresponding DNA nonamer. Substantial increases in  $T_m$  are also obtained when LNA monomers are used in combination with standard DNA or RNA monomers. For primers and probes, depending on where the LNA monomers are included (*e.g.*, the 3' end, the 5' end, or in the middle), the  $T_m$  could be increased considerably.

In another embodiment, arrays of oligonucleotide probes that are complementary to target nucleic acid sequence segments from an individual, can be used to identify polymorphisms in a FLAP nucleic acid. For example, in one embodiment, an oligonucleotide array can be used. Oligonucleotide arrays typically comprise a plurality of different oligonucleotide probes that are coupled to a surface of a substrate in different known locations. These oligonucleotide arrays, also described as "Genechips™," have been generally described in the art, for example, U.S. Pat. No. 5,143,854 and PCT patent publication Nos. WO 90/15070 and WO 92/10092. These arrays can generally be produced using mechanical synthesis methods or light directed synthesis methods that incorporate a combination of photolithographic methods and

solid phase oligonucleotide synthesis methods. See Fodor *et al.*, *Science* 251:767-777 (1991); Pirrung *et al.*, U.S. Pat. 5,143,854; (see also PCT Application WO 90/15070); Fodor *et al.*, PCT Publication WO 92/10092; and U.S. Pat. 5,424,186, the entire teachings of each of which are incorporated by reference herein. Techniques for the synthesis of these arrays using mechanical synthesis methods are described in, *e.g.*,  
5 U.S. Pat. 5,384,261, the entire teachings of which are incorporated by reference herein. In another example, linear arrays can be utilized.

Once an oligonucleotide array is prepared, a nucleic acid of interest is hybridized with the array and scanned for polymorphisms. Hybridization and  
10 scanning are generally carried out by methods described herein and also in, *e.g.*, published PCT Application Nos. WO 92/10092 and WO 95/11995, and U.S. Pat. No. 5,424,186, the entire teachings of which are incorporated by reference herein. In brief, a target nucleic acid sequence that includes one or more previously identified polymorphic markers is amplified using well-known amplification techniques, *e.g.*,  
15 PCR. Typically, this involves the use of primer sequences that are complementary to the two strands of the target sequence both upstream and downstream from the polymorphism. Asymmetric PCR techniques may also be used. Amplified target, generally incorporating a label, is then hybridized with the array under appropriate conditions. Upon completion of hybridization and washing of the array, the array is  
20 scanned to determine the position on the array to which the target sequence hybridizes. The hybridization data obtained from the scan is typically in the form of fluorescence intensities as a function of location on the array. In a reverse method, a probe, containing a polymorphism, can be coupled to a solid surface and PCR amplicons are then added to hybridize to these probes.

Although primarily described in terms of a single detection block, *e.g.*,  
25 detection of a single polymorphism arrays can include multiple detection blocks, and thus be capable of analyzing multiple, specific polymorphisms. It will generally be understood that detection blocks may be grouped within a single array or in multiple, separate arrays so that varying, optimal conditions may be used during the  
30 hybridization of the target to the array. For example, it may often be desirable to provide for the detection of those polymorphisms that fall within G-C rich stretches of



a genomic sequence, separately from those falling in A-T rich segments. This allows for the separate optimization of hybridization conditions for each situation.

Additional uses of oligonucleotide arrays for detection of polymorphisms can be found, for example, in U.S. Patents Nos. 5,858,659 and 5,837,832, the entire teachings of which are incorporated by reference herein. Other methods of nucleic acid analysis can be used to detect polymorphisms in a nucleic acid described herein, or variants encoded by a nucleic acid described herein. Representative methods include direct manual sequencing (Church and Gilbert, *Proc. Natl. Acad. Sci. USA* 81:1991-1995 (1988); Sanger, F. *et al.*, *Proc. Natl. Acad. Sci., USA* 74:5463-5467 (1977); Beavis *et al.* U.S. Pat. No. 5,288,644); automated fluorescent sequencing; single-stranded conformation polymorphism assays (SSCP); clamped denaturing gel electrophoresis (CDGE); denaturing gradient gel electrophoresis (DGGE) (Sheffield, V.C. *et al.*, *Proc. Natl. Acad. Sci. USA* 86:232-236 (1989)), mobility shift analysis (Orita, M. *et al.*, *Proc. Natl. Acad. Sci. USA* 86:2766-2770 (1989)), restriction enzyme analysis (Flavell *et al.*, *Cell* 15:25 (1978); Geever, *et al.*, *Proc. Natl. Acad. Sci. USA* 78:5081 (1981)); heteroduplex analysis; chemical mismatch cleavage (CMC) (Cotton *et al.*, *Proc. Natl. Acad. Sci. USA* 85:4397-4401 (1985)); RNase protection assays (Myers, R.M. *et al.*, *Science* 230:1242 (1985)); use of polypeptides which recognize nucleotide mismatches, such as *E. coli* mutS protein; allele-specific PCR, for example.

In one embodiment of the invention, diagnosis of a susceptibility to a disease or condition associated with FLAP (*e.g.*, MI, ACS, stroke or PAOD) can also be made by expression analysis by quantitative PCR (kinetic thermal cycling). This technique utilizing TaqMan<sup>®</sup> can be used to allow the identification of polymorphisms and whether a patient is homozygous or heterozygous. The technique can assess the presence of an alteration in the expression or composition of the polypeptide encoded by a FLAP nucleic acid or splicing variants encoded by a FLAP nucleic acid. Further, the expression of the variants can be quantified as physically or functionally different.

In another embodiment of the invention, diagnosis of a susceptibility to MI, ACS, stroke or PAOD (or of another disease or condition associated with FLAP) can also be made by examining expression and/or composition of a FLAP polypeptide, by a variety of methods, including enzyme linked immunosorbent assays (ELISAs), Western blots, immunoprecipitations and immunofluorescence. A test sample from an

individual is assessed for the presence of an alteration in the expression and/or an alteration in composition of the polypeptide encoded by a FLAP nucleic acid, or for the presence of a particular variant encoded by a FLAP nucleic acid. An alteration in expression of a polypeptide encoded by a FLAP nucleic acid can be, for example, an alteration in the quantitative polypeptide expression (*i.e.*, the amount of polypeptide produced); an alteration in the composition of a polypeptide encoded by a FLAP nucleic acid is an alteration in the qualitative polypeptide expression (*e.g.*, expression of an altered FLAP polypeptide or of a different splicing variant). In a preferred embodiment, diagnosis of a susceptibility to a disease or condition associated with FLAP is made by detecting a particular splicing variant encoded by that FLAP variant, or a particular pattern of splicing variants.

Both such alterations (quantitative and qualitative) can also be present. An “alteration” in the polypeptide expression or composition, refers to an alteration in expression or composition in a test sample, as compared with the expression or composition of polypeptide by a FLAP nucleic acid in a control sample. A control sample is a sample that corresponds to the test sample (*e.g.*, is from the same type of cells), and is from an individual who is not affected by the disease or a susceptibility to a disease or condition associated with a FLAP nucleic acid. An alteration in the expression or composition of the polypeptide in the test sample, as compared with the control sample, is indicative of a susceptibility to a disease or condition associated with FLAP (*e.g.*, MI, ACS, stroke or PAOD). Similarly, the presence of one or more different splicing variants in the test sample, or the presence of significantly different amounts of different splicing variants in the test sample, as compared with the control sample, is indicative of a susceptibility to a disease or condition associated with a FLAP nucleic acid. Various means of examining expression or composition of the polypeptide encoded by a FLAP nucleic acid can be used, including: spectroscopy, colorimetry, electrophoresis, isoelectric focusing and immunoassays (*e.g.*, David *et al.*, U.S. Pat. 4,376,110) such as immunoblotting (see also *Current Protocols in Molecular Biology*, particularly Chapter 10). For example, in one embodiment, an antibody capable of binding to the polypeptide (*e.g.*, as described above), preferably an antibody with a detectable label, can be used. Antibodies can be polyclonal, or more preferably, monoclonal. An intact antibody, or a fragment thereof (*e.g.*, Fab or

F(ab')<sub>2</sub>) can be used. The term "labeled", with regard to the probe or antibody, is intended to encompass direct labeling of the probe or antibody by coupling (*i.e.*, physically linking) a detectable substance to the probe or antibody, as well as indirect labeling of the probe or antibody by reactivity with another reagent that is directly  
5 labeled. Examples of indirect labeling include detection of a primary antibody using a fluorescently labeled secondary antibody and end-labeling of a DNA probe with biotin such that it can be detected with fluorescently labeled streptavidin.

Western blotting analysis, using an antibody as described above that specifically binds to a polypeptide encoded by an altered FLAP (*e.g.*, by a FLAP  
10 having a SNP as shown in Table 13), or an antibody that specifically binds to a polypeptide encoded by a non-altered nucleic acid, or an antibody that specifically binds to a particular splicing variant encoded by a nucleic acid, can be used to identify the presence in a test sample of a particular splicing variant or of a polypeptide encoded by a polymorphic or altered FLAP, or the absence in a test sample of a  
15 particular splicing variant or of a polypeptide encoded by a non-polymorphic or non-altered nucleic acid. The presence of a polypeptide encoded by a polymorphic or altered nucleic acid, or the absence of a polypeptide encoded by a non-polymorphic or non-altered nucleic acid, is diagnostic for a susceptibility to a disease or condition associated with FLAP, as is the presence (or absence) of particular splicing variants  
20 encoded by the FLAP nucleic acid.

In one embodiment of this method, the level or amount of polypeptide encoded by a FLAP nucleic acid in a test sample is compared with the level or amount of the polypeptide encoded by the FLAP in a control sample. A level or amount of the polypeptide in the test sample that is higher or lower than the level or amount of the  
25 polypeptide in the control sample, such that the difference is statistically significant, is indicative of an alteration in the expression of the polypeptide encoded by the FLAP, and is diagnostic for a susceptibility to a disease or condition associated with that FLAP. Alternatively, the composition of the polypeptide encoded by a FLAP nucleic acid in a test sample is compared with the composition of the polypeptide encoded by  
30 the FLAP in a control sample (*e.g.*, the presence of different splicing variants). A difference in the composition of the polypeptide in the test sample, as compared with the composition of the polypeptide in the control sample, is diagnostic for a

susceptibility to a disease or condition associated with that FLAP. In another embodiment, both the level or amount and the composition of the polypeptide can be assessed in the test sample and in the control sample. A difference in the amount or level of the polypeptide in the test sample, compared to the control sample; a  
5 difference in composition in the test sample, compared to the control sample; or both a difference in the amount or level, and a difference in the composition, is indicative of a susceptibility to a disease or condition associated with FLAP (*e.g.*, MI).

The invention further pertains to a method for the diagnosis and identification of susceptibility to myocardial infarction, ACS, stroke or PAOD in an individual, by  
10 identifying an at-risk haplotype in FLAP. In one embodiment, the at-risk haplotype is one which confers a significant risk of MI, ACS, stroke or PAOD. In one embodiment, significance associated with a haplotype is measured by an odds ratio. In a further embodiment, the significance is measured by a percentage. In one embodiment, a significant risk is measured as an odds ratio of at least about 1.2,  
15 including by not limited to: 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, and 1.9. In a further embodiment, an odds ratio of at least 1.2 is significant. In a further embodiment, an odds ratio of at least about 1.5 is significant. In a further embodiment, a significant increase in risk is at least about 1.7 is significant. In a further embodiment, a significant increase in risk is at least about 20%, including but not limited to about  
20 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95, and 98%. In a further embodiment, a significant increase in risk is at least about 50%. In yet another embodiment, an at-risk haplotype has a  $p$  value  $< 0.05$ . It is understood however, that identifying whether a risk is medically significant may also depend on a variety of factors, including the specific disease, the haplotype, and often,  
25 environmental factors.

The invention also pertains to methods of diagnosing a susceptibility to myocardial infarction, ACS, stroke or PAOD in an individual, comprising screening for an at-risk haplotype in the FLAP nucleic acid that is more frequently present in an individual susceptible to myocardial infarction (affected), compared to the frequency  
30 of its presence in a healthy individual (control), wherein the presence of the haplotype is indicative of susceptibility to myocardial infarction. Standard techniques for genotyping for the presence of SNPs and/or microsatellite markers that are associated

with myocardial infarction, ACS, stroke or PAOD can be used, such as fluorescent based techniques (Chen, *et al.*, *Genome Res.* 9, 492 (1999), PCR, LCR, Nested PCR and other techniques for nucleic acid amplification. In a preferred embodiment, the method comprises assessing in an individual the presence or frequency of SNPs and/or microsatellites in the FLAP nucleic acid that are associated with myocardial infarction, ACS, stroke or PAOD, wherein an excess or higher frequency of the SNPs and/or microsatellites compared to a healthy control individual is indicative that the individual is susceptible to myocardial infarction, ACS, stroke or PAOD. See Table 7 for SNPs that comprise haplotypes that can be used as screening tools. See also Table 13 that sets forth SNPs and markers for use as screening tools.

In one embodiment, the at-risk haplotype is characterized by the presence of polymorphism(s) represented in Table 13. For example, SG13S99, where the SNP can be a "C" or a "T"; SG13S25, where the SNP can be a "G" or an "A"; SG13S377, where the SNP can be a "G" or an "A"; SG13S106, where the SNP can be a "G" or an "A"; SG13S114, where the SNP can be a "T" or an "A"; SG13S89, where the SNP can be a "G" or an "A"; SG13S30, where the SNP can be a "G" or a "T"; SG13S32, where the SNP can be a "C" or an "A"; SG13S42, where the SNP can be a "G" or an "A"; and SG13S35, where the SNP can be a "G" or an "A".

Kits (*e.g.*, reagent kits) useful in the methods of diagnosis comprise components useful in any of the methods described herein, including for example, hybridization probes or primers as described herein (*e.g.*, labeled probes or primers), reagents for detection of labeled molecules, restriction enzymes (*e.g.*, for RFLP analysis), allele-specific oligonucleotides, antibodies which bind to altered or to non-altered (native) FLAP polypeptide, means for amplification of nucleic acids comprising a FLAP, or means for analyzing the nucleic acid sequence of a nucleic acid described herein, or for analyzing the amino acid sequence of a polypeptide as described herein, etc. In one embodiment, a kit for diagnosing susceptibility to MI, ACS, stroke or PAOD can comprise primers for nucleic acid amplification of a region in the FLAP nucleic acid comprising an at-risk haplotype that is more frequently present in an individual having MI, ACS, stroke or PAOD or susceptible to MI, ACS, stroke or PAOD. The primers can be designed using portions of the nucleic acids flanking SNPs that are indicative of MI. In a particularly preferred embodiment, the

primers are designed to amplify regions of the FLAP nucleic acid associated with an at-risk haplotype for MI, ACS, stroke or PAOD, as shown in Table 7, or more particularly the haplotype defined by the following SNP markers: In one embodiment, a haplotype associated with a susceptibility to myocardial infarction, ACS, stroke or PAOD comprises markers SG13S99, SG13S25, SG13S377, SG13S106, SG13S32 and SG13S35 at the 13q12-13 locus. In one particular embodiment, the presence of the alleles T, G, G, G, A and G at SG13S99, SG13S25, SG13S377, SG13S106, SG13S32 and SG13S35, respectively (the B6 haplotype), is diagnostic of susceptibility to myocardial infarction, ACS, stroke or PAOD. In another embodiment, a haplotype associated with a susceptibility to myocardial infarction, ACS, stroke or PAOD comprises markers SG13S99, SG13S25, SG13S106, SG13S30 and SG13S42 at the 13q12-13 locus. In one particular embodiment, the presence of the alleles T, G, G, G and A at SG13S99, SG13S25, SG13S106, SG13S30 and SG13S42, respectively (the B5 haplotype), is diagnostic of susceptibility to myocardial infarction, ACS, stroke or PAOD. In a third embodiment, a haplotype associated with a susceptibility to myocardial infarction, ACS, stroke or PAOD comprises markers SG13S25, SG13S106, SG13S30 and SG13S42 at the 13q12-13 locus. In one particular embodiment, the presence of the alleles G, G, G and A at SG13S25, SG13S106, SG13S30 and SG13S42, respectively (the B4 haplotype), is diagnostic of susceptibility to myocardial infarction, ACS, stroke or PAOD. In a fourth embodiment, a haplotype associated with a susceptibility to myocardial infarction, ACS, stroke or PAOD comprises markers SG13S99, SG13S25, SG13S114, SG13S89 and SG13S32 at the 13q12-13 locus. In one particular embodiment, the presence of the alleles T, G, T, G and A at SG13S99, SG13S25, SG13S114, SG13S89 and SG13S32, respectively (the A5 haplotype), is diagnostic of susceptibility to myocardial infarction, ACS, stroke or PAOD. In a fifth embodiment, a haplotype associated with a susceptibility to myocardial infarction, ACS, stroke or PAOD comprises markers SG13S25, SG13S114, SG13S89 and SG13S32 at the 13q12-12 locus. In one particular embodiment, the presence of the alleles G, T, G and A at SG13S25, SG13S114, SG13S89 and SG13S32, respectively (the A4 haplotype), is diagnostic of susceptibility to myocardial infarction, ACS, stroke or PAOD.

## SCREENING ASSAYS AND AGENTS IDENTIFIED THEREBY

The invention provides methods (also referred to herein as “screening assays”) for identifying the presence of a nucleotide that hybridizes to a nucleic acid of the invention, as well as for identifying the presence of a polypeptide encoded by a nucleic acid of the invention. In one embodiment, the presence (or absence) of a nucleic acid molecule of interest (*e.g.*, a nucleic acid that has significant homology with a nucleic acid of the invention) in a sample can be assessed by contacting the sample with a nucleic acid comprising a nucleic acid of the invention (*e.g.*, a nucleic acid having the sequence of one of SEQ ID NOs: 1 or 3 or the complement thereof, or a nucleic acid encoding an amino acid having the sequence of SEQ ID NO: 2, or a fragment or variant of such nucleic acids), under stringent conditions as described above, and then assessing the sample for the presence (or absence) of hybridization. In a preferred embodiment, high stringency conditions are conditions appropriate for selective hybridization. In another embodiment, a sample containing a nucleic acid molecule of interest is contacted with a nucleic acid containing a contiguous nucleic acid sequence (*e.g.*, a primer or a probe as described above) that is at least partially complementary to a part of the nucleic acid molecule of interest (*e.g.*, a FLAP nucleic acid), and the contacted sample is assessed for the presence or absence of hybridization. In a preferred embodiment, the nucleic acid containing a contiguous nucleic acid sequence is completely complementary to a part of the nucleic acid molecule of interest.

In any of these embodiments, all or a portion of the nucleic acid of interest can be subjected to amplification prior to performing the hybridization.

In another embodiment, the presence (or absence) of a polypeptide of interest, such as a polypeptide of the invention or a fragment or variant thereof, in a sample can be assessed by contacting the sample with an antibody that specifically hybridizes to the polypeptide of interest (*e.g.*, an antibody such as those described above), and then assessing the sample for the presence (or absence) of binding of the antibody to the polypeptide of interest.

In another embodiment, the invention provides methods for identifying agents (*e.g.*, fusion proteins, polypeptides, peptidomimetics, prodrugs, receptors, binding agents, antibodies, small molecules or other drugs, or ribozymes which alter (*e.g.*,

increase or decrease) the activity of the polypeptides described herein, or which otherwise interact with the polypeptides herein. For example, such agents can be agents which bind to polypeptides described herein (*e.g.*, binding agent for members of the leukotriene pathway, such as FLAP binding agents); which have a stimulatory or inhibitory effect on, for example, activity of polypeptides of the invention; or which change (*e.g.*, enhance or inhibit) the ability of the polypeptides of the invention to interact with members of the leukotriene pathway binding agents (*e.g.*, receptors or other binding agents); or which alter posttranslational processing of the leukotriene pathway member polypeptide, such as a FLAP polypeptide (*e.g.*, agents that alter proteolytic processing to direct the polypeptide from where it is normally synthesized to another location in the cell, such as the cell surface; agents that alter proteolytic processing such that more polypeptide is released from the cell, etc.)

In one embodiment, the invention provides assays for screening candidate or test agents that bind to or modulate the activity of polypeptides described herein (or biologically active portion(s) thereof), as well as agents identifiable by the assays. Test agents can be obtained using any of the numerous approaches in combinatorial library methods known in the art, including: biological libraries; spatially addressable parallel solid phase or solution phase libraries; synthetic library methods requiring deconvolution; the “one-bead one-compound” library method; and synthetic library methods using affinity chromatography selection. The biological library approach is limited to polypeptide libraries, while the other four approaches are applicable to polypeptide, non-peptide oligomer or small molecule libraries of compounds (Lam, K.S., *Anticancer Drug Des.* 12:145 (1997)).

In one embodiment, to identify agents which alter the activity of a FLAP polypeptide, a cell, cell lysate, or solution containing or expressing a FLAP polypeptide (*e.g.*, SEQ ID NO: 2 or another splicing variant encoded by a FLAP nucleic acid, such as a nucleic acid comprising a SNP as shown in Table 13), or a fragment or derivative thereof (as described above), can be contacted with an agent to be tested; alternatively, the polypeptide can be contacted directly with the agent to be tested. The level (amount) of FLAP activity is assessed (*e.g.*, the level (amount) of FLAP activity is measured, either directly or indirectly), and is compared with the level of activity in a control (*i.e.*, the level of activity of the FLAP polypeptide or



active fragment or derivative thereof in the absence of the agent to be tested). If the level of the activity in the presence of the agent differs, by an amount that is statistically significant, from the level of the activity in the absence of the agent, then the agent is an agent that alters the activity of a FLAP polypeptide. An increase in the level of FLAP activity in the presence of the agent relative to the activity in the absence of the agent, indicates that the agent is an agent that enhances FLAP activity. Similarly, a decrease in the level of FLAP activity in the presence of the agent, relative to the activity in the absence of the agent, indicates that the agent is an agent that inhibits FLAP activity. In another embodiment, the level of activity of a FLAP polypeptide or derivative or fragment thereof in the presence of the agent to be tested, is compared with a control level that has previously been established. A statistically significant difference in the level of the activity in the presence of the agent from the control level indicates that the agent alters FLAP activity.

The present invention also relates to an assay for identifying agents which alter the expression of a FLAP nucleic acid (*e.g.*, antisense nucleic acids, fusion proteins, polypeptides, peptidomimetics, prodrugs, receptors, binding agents, antibodies, small molecules or other drugs, or ribozymes; which alter (*e.g.*, increase or decrease) expression (*e.g.*, transcription or translation) of the nucleic acid or which otherwise interact with the nucleic acids described herein, as well as agents identifiable by the assays. For example, a solution containing a nucleic acid encoding a FLAP polypeptide (*e.g.*, a FLAP nucleic acid) can be contacted with an agent to be tested. The solution can comprise, for example, cells containing the nucleic acid or cell lysate containing the nucleic acid; alternatively, the solution can be another solution that comprises elements necessary for transcription/translation of the nucleic acid. Cells not suspended in solution can also be employed, if desired. The level and/or pattern of FLAP expression (*e.g.*, the level and/or pattern of mRNA or of protein expressed, such as the level and/or pattern of different splicing variants) is assessed, and is compared with the level and/or pattern of expression in a control (*i.e.*, the level and/or pattern of the FLAP expression in the absence of the agent to be tested). If the level and/or pattern in the presence of the agent differ, by an amount or in a manner that is statistically significant, from the level and/or pattern in the absence of the agent, then the agent is an agent that alters the expression of the FLAP nucleic acid.

Enhancement of FLAP expression indicates that the agent is an activator of FLAP activity. Similarly, inhibition of FLAP expression indicates that the agent is a repressor of FLAP activity.

5 In another embodiment, the level and/or pattern of FLAP polypeptide(s) (*e.g.*, different splicing variants) in the presence of the agent to be tested, is compared with a control level and/or pattern that have previously been established. A level and/or pattern in the presence of the agent that differs from the control level and/or pattern by an amount or in a manner that is statistically significant indicates that the agent alters FLAP expression.

10 In another embodiment of the invention, agents which alter the expression of a FLAP nucleic acid or which otherwise interact with the nucleic acids described herein, can be identified using a cell, cell lysate, or solution containing a nucleic acid encoding the promoter region of the FLAP nucleic acid operably linked to a reporter gene. After contact with an agent to be tested, the level of expression of the reporter  
15 gene (*e.g.*, the level of mRNA or of protein expressed) is assessed, and is compared with the level of expression in a control (*i.e.*, the level of the expression of the reporter gene in the absence of the agent to be tested). If the level in the presence of the agent differs, by an amount or in a manner that is statistically significant, from the level in the absence of the agent, then the agent is an agent that alters the expression of the  
20 FLAP nucleic acid, as indicated by its ability to alter expression of a nucleic acid that is operably linked to the FLAP nucleic acid promoter.

Enhancement of the expression of the reporter indicates that the agent is an activator of FLAP expression. Similarly, inhibition of the expression of the reporter indicates that the agent is a repressor of FLAP expression. In another embodiment, the  
25 level of expression of the reporter in the presence of the test agent, is compared with a control level that has previously been established. A level in the presence of the agent that differs from the control level by an amount or in a manner that is statistically significant indicates that the agent alters expression.

30 Agents which alter the amounts of different splicing variants encoded by a FLAP nucleic acid (*e.g.*, an agent which enhances expression of a first splicing variant, and which inhibits expression of a second splicing variant), as well as agents

which stimulate activity of a first splicing variant and inhibit activity of a second splicing variant, can easily be identified using these methods described above.

In other embodiments of the invention, assays can be used to assess the impact of a test agent on the activity of a polypeptide relative to a FLAP binding agent. For example, a cell that expresses a compound that interacts with a FLAP nucleic acid (herein referred to as a “FLAP binding agent”, which can be a polypeptide or other molecule that interacts with a FLAP nucleic acid, such as a receptor, or another molecule, such as 5-LO) is contacted with a FLAP in the presence of a test agent, and the ability of the test agent to alter the interaction between the FLAP and the FLAP binding agent is determined. Alternatively, a cell lysate or a solution containing the FLAP binding agent, can be used. An agent which binds to the FLAP or the FLAP binding agent can alter the interaction by interfering with, or enhancing the ability of the FLAP to bind to, associate with, or otherwise interact with the FLAP binding agent. Determining the ability of the test agent to bind to a FLAP nucleic acid or a FLAP nucleic acid binding agent can be accomplished, for example, by coupling the test agent with a radioisotope or enzymatic label such that binding of the test agent to the polypeptide can be determined by detecting the labeled with  $^{125}\text{I}$ ,  $^{35}\text{S}$ ,  $^{14}\text{C}$  or  $^3\text{H}$ , either directly or indirectly, and the radioisotope detected by direct counting of radioemmission or by scintillation counting. Alternatively, test agents can be enzymatically labeled with, for example, horseradish peroxidase, alkaline phosphatase, or luciferase, and the enzymatic label detected by determination of conversion of an appropriate substrate to product. It is also within the scope of this invention to determine the ability of a test agent to interact with the polypeptide without the labeling of any of the interactants. For example, a microphysiometer can be used to detect the interaction of a test agent with a FLAP or a FLAP binding agent without the labeling of either the test agent, FLAP, or the FLAP binding agent. McConnell, H.M. *et al.*, *Science* 257:1906-1912 (1992). As used herein, a “microphysiometer” (*e.g.*, Cytosensor<sup>TM</sup>) is an analytical instrument that measures the rate at which a cell acidifies its environment using a light-addressable potentiometric sensor (LAPS). Changes in this acidification rate can be used as an indicator of the interaction between ligand and polypeptide.

Thus, these receptors can be used to screen for compounds that are agonists for use in treating a disease or condition associated with FLAP or a susceptibility to a disease or condition associated with FLAP, or antagonists for studying a susceptibility to a disease or condition associated with FLAP (*e.g.*, MI, ACS, stroke or PAOD).

5 Drugs can be designed to regulate FLAP activation, that in turn can be used to regulate signaling pathways and transcription events of genes downstream or of proteins or polypeptides interacting with FLAP (*e.g.*, 5-LO).

In another embodiment of the invention, assays can be used to identify polypeptides that interact with one or more FLAP polypeptides, as described herein.

10 For example, a yeast two-hybrid system such as that described by Fields and Song (Fields, S. and Song, O., *Nature* 340:245-246 (1989)) can be used to identify polypeptides that interact with one or more FLAP polypeptides. In such a yeast two-hybrid system, vectors are constructed based on the flexibility of a transcription factor that has two functional domains (a DNA binding domain and a transcription activation

15 domain). If the two domains are separated but fused to two different proteins that interact with one another, transcriptional activation can be achieved, and transcription of specific markers (*e.g.*, nutritional markers such as His and Ade, or color markers such as lacZ) can be used to identify the presence of interaction and transcriptional activation. For example, in the methods of the invention, a first vector is used which

20 includes a nucleic acid encoding a DNA binding domain and also a FLAP polypeptide, splicing variant, or fragment or derivative thereof, and a second vector is used which includes a nucleic acid encoding a transcription activation domain and also a nucleic acid encoding a polypeptide which potentially may interact with the FLAP polypeptide, splicing variant, or fragment or derivative thereof (*e.g.*, a FLAP

25 polypeptide binding agent or receptor). Incubation of yeast containing the first vector and the second vector under appropriate conditions (*e.g.*, mating conditions such as used in the Matchmaker™ system from Clontech (Palo Alto, California, USA)) allows identification of colonies that express the markers of interest. These colonies can be examined to identify the polypeptide(s) that interact with the FLAP polypeptide or

30 fragment or derivative thereof. Such polypeptides may be useful as agents that alter the activity of expression of a FLAP polypeptide, as described above.

In more than one embodiment of the above assay methods of the present invention, it may be desirable to immobilize either the FLAP, the FLAP binding agent, or other components of the assay on a solid support, in order to facilitate separation of complexed from uncomplexed forms of one or both of the polypeptides, as well as to accommodate automation of the assay. Binding of a test agent to the polypeptide, or interaction of the polypeptide with a binding agent in the presence and absence of a test agent, can be accomplished in any vessel suitable for containing the reactants. Examples of such vessels include microtitre plates, test tubes, and micro-centrifuge tubes. In one embodiment, a fusion protein (*e.g.*, a glutathione-S-transferase fusion protein) can be provided which adds a domain that allows a FLAP nucleic acid or a FLAP binding agent to be bound to a matrix or other solid support.

In another embodiment, modulators of expression of nucleic acid molecules of the invention are identified in a method wherein a cell, cell lysate, or solution containing a nucleic acid encoding a FLAP nucleic acid is contacted with a test agent and the expression of appropriate mRNA or polypeptide (*e.g.*, splicing variant(s)) in the cell, cell lysate, or solution, is determined. The level of expression of appropriate mRNA or polypeptide(s) in the presence of the test agent is compared to the level of expression of mRNA or polypeptide(s) in the absence of the test agent. The test agent can then be identified as a modulator of expression based on this comparison. For example, when expression of mRNA or polypeptide is greater (statistically significantly greater) in the presence of the test agent than in its absence, the test agent is identified as a stimulator or enhancer of the mRNA or polypeptide expression. Alternatively, when expression of the mRNA or polypeptide is less (statistically significantly less) in the presence of the test agent than in its absence, the test agent is identified as an inhibitor of the mRNA or polypeptide expression. The level of mRNA or polypeptide expression in the cells can be determined by methods described herein for detecting mRNA or polypeptide.

In yet another embodiment, the invention provides methods for identifying agents (*e.g.*, fusion proteins, polypeptides, peptidomimetics, prodrugs, receptors, binding agents, antibodies, small molecules or other drugs, or ribozymes) which alter (*e.g.*, increase or decrease) the activity of a member of leukotriene pathway binding agent, such as a FLAP binding agent (*e.g.*, 5-LO), as described herein. For example,

such agents can be agents which have a stimulatory or inhibitory effect on, for example, the activity of a member of leukotriene pathway binding agent, such as a FLAP binding agent; which change (*e.g.*, enhance or inhibit) the ability a member of leukotriene pathway binding agents, (*e.g.*, receptors or other binding agents) to interact with the polypeptides of the invention; or which alter posttranslational processing of the member of leukotriene pathway binding agent, (*e.g.*, agents that alter proteolytic processing to direct the member of the leukotriene pathway binding agent from where it is normally synthesized to another location in the cell, such as the cell surface; agents that alter proteolytic processing such that more active binding agent is released from the cell, etc.).

For example, the invention provides assays for screening candidate or test agents that bind to or modulate the activity of a member of the leukotriene pathway (or enzymatically active portion(s) thereof), as well as agents identifiable by the assays. As described above, test agents can be obtained using any of the numerous approaches in combinatorial library methods known in the art, including: biological libraries; spatially addressable parallel solid phase or solution phase libraries; synthetic library methods requiring deconvolution; the “one-bead one-compound” library method; and synthetic library methods using affinity chromatography selection. The biological library approach is limited to polypeptide libraries, while the other four approaches are applicable to polypeptide, non-peptide oligomer or small molecule libraries of compounds (Lam, K.S. *Anticancer Drug Des.*, 12:145 (1997)).

In one embodiment, to identify agents which alter the activity of a member of the leukotriene pathway (such as a FLAP binding agent, or an agent which binds to a member of the leukotriene pathway (a “binding agent”)), a cell, cell lysate, or solution containing or expressing a binding agent (*e.g.*, 5-LO, or a leukotriene pathway member receptor, or other binding agent), or a fragment (*e.g.*, an enzymatically active fragment) or derivative thereof, can be contacted with an agent to be tested; alternatively, the binding agent (or fragment or derivative thereof) can be contacted directly with the agent to be tested. The level (amount) of binding agent activity is assessed (either directly or indirectly), and is compared with the level of activity in a control (*i.e.*, the level of activity in the absence of the agent to be tested). If the level of the activity in the presence of the agent differs, by an amount that is statistically

significant, from the level of the activity in the absence of the agent, then the agent is an agent that alters the activity of the member of the leukotriene pathway. An increase in the level of the activity relative to a control, indicates that the agent is an agent that enhances (is an agonist of) the activity. Similarly, a decrease in the level of activity relative to a control, indicates that the agent is an agent that inhibits (is an antagonist of) the activity. In another embodiment, the level of activity in the presence of the agent to be tested, is compared with a control level that has previously been established. A level of the activity in the presence of the agent that differs from the control level by an amount that is statistically significant indicates that the agent alters the activity.

This invention further pertains to novel agents identified by the above-described screening assays. Accordingly, it is within the scope of this invention to further use an agent identified as described herein in an appropriate animal model. For example, an agent identified as described herein (*e.g.*, a test agent that is a modulating agent, an antisense nucleic acid molecule, a specific antibody, or a polypeptide-binding agent) can be used in an animal model to determine the efficacy, toxicity, or side effects of treatment with such an agent. Alternatively, an agent identified as described herein can be used in an animal model to determine the mechanism of action of such an agent.

Furthermore, this invention pertains to uses of novel agents identified by the above-described screening assays for treatments as described herein. In addition, an agent identified as described herein can be used to alter activity of a polypeptide encoded by a FLAP nucleic acid, or to alter expression of a FLAP nucleic acid, by contacting the polypeptide or the nucleic acid (or contacting a cell comprising the polypeptide or the nucleic acid) with the agent identified as described herein.

The present invention is now illustrated by the following Examples, which are not intended to be limiting in any way. The teachings of all references cited are incorporated herein in their entirety.

EXAMPLE 1: IDENTIFICATION OF GENE AND HAPLOTYPES ASSOCIATED WITH MI

- 5           A genome wide scan of 296 multiplex Icelandic families with 713 MI patients was performed. Through the suggestive linkage to a locus on chromosome 13q12-13 for female MI patients and early onset MI patients, and haplotype association analysis, the gene encoding the 5-lipoxygenase activating protein (FLAP) was identified, and a 4-SNP haplotype within the gene was determined to confer a near 2-fold risk of MI.
- 10       Male patients showed strongest association to the at-risk haplotype. Independent confirmation of FLAP association to MI was obtained in a British cohort of patients with sporadic MI. These findings support FLAP as the first specific gene isolated that confers substantial risk of the complex trait of MI.



## METHODS

### *Study population*

Patients entering the study were recruited from a registry that includes all MIs that occurred before the age of 75 (over 8,000 patients) in Iceland from 1981 to 2000. This registry is a part of the World Health Organization MONICA Project (The World Health Organization MONICA Project, WHO MONICA Project Principal Investigators, *J Clin Epidemiol* 41, 105-14 (1988)). Diagnoses of all patients in the registry followed strict diagnostic rules based on signs, symptoms, electrocardiograms, cardiac enzymes, and necropsy findings.

Genotypes from 713 MI patients and 1741 of their first-degree relatives were used in the linkage analysis. For the microsatellite association study of the MI locus, 802 unrelated MI patients (n=233 females, n=624 males and n= 302 early onset) and 837 population-based controls were used. For the SNP association study in and around the FLAP gene 779 unrelated MI patients were genotyped (n=293 females, n=486 males and n=358 early onset). The control group for the SNP association study was population based and comprised of 628 unrelated males and females in the age range of 30-85 years whose medical history was unknown.

The study was approved by the Data Protection Commission of Iceland and the National Bioethics Committee of Iceland. Informed consent was obtained from all study participants. Personal identifiers associated with medical information and blood samples were encrypted with a third party encryption system as previously described (Gulcher, J.R., Kristjansson, K., Gudbjartsson, H. & Stefansson, K., *Eur J Hum Genet* 8, 739-42 (2000)).

### *Statistical analysis*

A genome-wide scan was performed as previously described (Gretarsdottir, S. *et al. Am J Hum Genet* 70, 593-603 (2002)), using a set of approximately 1000 microsatellite markers. Multipoint, affected-only allele-sharing methods (Kong, A. & Cox, N.J., *Am J Hum Genet* 61, 1179-88 (1997)) were used to assess the evidence for linkage. All results were obtained using the program Allegro (Gudbjartsson, D.F., Jonasson, K., Frigge, M.L. & Kong, A. Allegro, *Nat Genet* 25, 12-3 (2000)) and the

deCODE genetic map (Kong, A. *et al.*, *Nat Genet* 31, 241-7 (2002)). The  $S_{\text{pairs}}$  scoring function (Whittemore, A.S. & Halpern, J., *Biometrics* 50, 118-27 (1994); Kruglyak, L., Daly, M.J., Reeve-Daly, M.P. & Lander, E.S., *Am J Hum Genet* 58, 1347-63 (1996)) was used, as was the exponential allele-sharing model (Kong, A. & Cox, N.J. *Am J Hum Genet* 61, 1179-88 (1997)) to generate the relevant 1-df (degree of freedom) statistics. When combining the family scores to obtain an overall score, a weighting scheme was used that is halfway on a log scale between weighting each affected pair equally and weighting each family equally. In the analysis, all genotyped individuals who are not affected are treated as “unknown”. Because of concern with small sample behaviour, corresponding P values were usually computed in two different ways for comparison, and the less significant one was reported. The first P value is computed based on large sample theory;  $Z_{lr} = \sqrt{(2 \log_e (10) \text{ LOD})}$  and is distributed approximately as a standard normal distribution under the null hypothesis of no linkage (Kong, A. & Cox, N.J. *Am J Hum Genet* 61, 1179-88 (1997)). A second P value is computed by comparing the observed LOD score to its complete data sampling distribution under the null hypothesis (Gudbjartsson, D.F., Jonasson, K., Frigge, M.L. & Kong, A. Allegro., *Nat Genet* 25, 12-3 (2000)). When a data set consists of more than a handful of families, these two P values tend to be very similar. The information measure that was used (Nicolae, D. University of Chicago (1999)), and is implemented in Allegro, is closely related to a classical measure of information (Dempster, A., Laird, NM, Rubin, DB., *J R Stat Soc B* 39, 1-38 (1977) and has a property that is between 0, if the marker genotypes are completely uninformative, and 1, if the genotypes determine the exact amount of allele sharing by descent among the affected relatives.

For single-marker association studies, Fisher’s exact test was used to calculate two-sided P values for each allele. All P values were unadjusted for multiple comparisons unless specifically indicated. Allelic rather than carrier frequencies were presented for microsatellites, SNPs and haplotypes. To minimize any bias due to the relatedness of the patients that were recruited as families for the linkage analysis first and second-degree relatives were eliminated from the patient list. For the haplotype analysis, the program NEMO was used (Gretarsdottir, S. *et al.*, *Nat Genet* 35, 131-8 (2003)), which handles missing genotypes and uncertainty with phase through a

likelihood procedure, using the expectation-maximization algorithm as a computational tool to estimate haplotype frequencies. Under the null hypothesis, the affected individuals and controls are assumed to have identical haplotype frequencies. Under the alternative hypotheses, the candidate at-risk haplotype is allowed to have a higher frequency in the affected individuals than in controls, while the ratios of frequencies of all other haplotypes are assumed to be the same in both groups. Likelihoods are maximized separately under both hypotheses, and a corresponding 1-df likelihood ratio statistic used to evaluate statistical significance (*id*). Even though searches were only performed for haplotypes that increase the risk, all reported P values are two-sided unless otherwise stated. To assess the significance of the haplotype association corrected for multiple testing, a randomisation test was carried out using the same genotype data. The cohorts of affected individuals and controls were randomized, and the analysis was repeated. This procedure was repeated up to 1.000 times and the P value presented is the fraction of replications that produced a P value for a haplotype tested that is lower than or equal to the P value observed using the original patient and control cohorts.

For both single-marker and haplotype analysis, relative risk (RR) and population attributable risk was calculated assuming a multiplicative model (Terwilliger, J.D. & Ott, J. A., *Hum Hered* **42**, 337-46 (1992); Falk, C.T. & Rubinstein, P., *Ann Hum Genet* **51** ( Pt 3), 227-33 (1987)) in which the risk of the two alleles of haplotypes a person carries multiply. LD was calculated between pairs of SNPs using the standard definition of  $D'$  (Lewontin, R.C., *Genetics* **50**, 757-82 (1964)) and  $R^2$  (Hill, W.G. & Robertson, A., *Genetics* **60**, 615-28 (1968)). Using NEMO, frequencies of the two marker allele combinations are estimated by maximum likelihood, and deviation from linkage equilibrium is evaluated by a likelihood ratio test. When plotting all SNP combinations to elucidate the LD structure in a particular region,  $D'$  was plotted in the upper left corner and the P value in the lower right corner. In the LD plots presented, the markers are plotted equidistantly rather than according to their physical positions.

*Identification of DNA polymorphisms.*

New polymorphic repeats (e.g., dinucleotide or trinucleotide repeats) were identified with the Sputnik program. For microsatellite alleles: the CEPH sample 1347-02 (Centre d'Etudes du Polymorphisme Humain, genomics repository) is used as a reference. The lower allele of each microsatellite in this sample is set at 0 and all other alleles in other samples are numbered according in relation to this reference. Thus allele1 is 1 bp longer than the lower allele in the CEPH sample, allele 2 is 2 bp longer than the lower allele in the CEPH sample, allele 3 is 3 bp longer than the lower allele in the CEPH sample, allele 4 is 4 bp longer than the lower allele in the CEPH sample, allele -1 is 1 bp shorter than the lower allele in the CEPH sample , allele -2 is 2 bp shorter than the lower allele in the CEPH sample, and so on. Single nucleotide polymorphisms in the gene were detected by PCR sequencing exonic and intronic regions from patients and controls. Public single nucleotide polymorphisms were obtained from the NCBI SNP database. SNPs were genotyped using a method for detecting SNPs with fluorescent polarization template-directed dye-terminator incorporation (SNP-FP-TDI assay) (Chen, X., Zehnbaauer, B., Gnirke, A. & Kwok, P.Y., *Proc Natl Acad Sci U S A* 94, 10756-61. (1997)) and TaqMan assays (Applied Biosystems).

RESULTS

*Linkage analysis*

A genome wide scan was performed in search of MI susceptibility genes using a framework set of around 1000 microsatellite markers. The initial linkage analysis included 713 MI patients who fulfilled the WHO MONICA research criteria (The World Health Organization MONICA Project, WHO MONICA Project Principal Investigators, *J Clin Epidemiol* 41, 105-14 (1988)) and were clustered in 296 extended families. The linkage analysis was also repeated for early onset, male and female patients separately. Description of the number of patients and families in each analysis are provided in Table 1.

TABLE 1: Number of patients that cluster into families and the corresponding number of families used in the linkage analysis

Phenotype	Number of patients	Number of families	Number of pairs	Genotyped relatives <sup>a</sup>
All MI patients	713	296	863	1741
Males	575	248	724	1385
Females	140	56	108	366
Early onset	194	93	156	739

<sup>a</sup>Genotyped relatives were used to increase the information on IBD sharing among the patients in the linkage analysis

None of these analyses yielded a locus of genome-wide significance. However, the most promising LOD score (LOD = 2.86) was observed on chromosome 13q12-13 for female MI patients at the peak marker D13S289 (data not shown). This locus also had the most promising LOD score (LOD = 2.03) for patients with early onset MI. After increasing the information on identity-by-descent sharing to over 90% by typing 14 additional microsatellite markers in a 30 centiMorgan (cM) region around D13S289, the LOD score from the female analysis dropped to 2.48 (P value = 0.00036), while the highest LOD score remained at D13S289 (FIG. 6.1).

#### *Microsatellite association study*

The 7.6 Mb region that corresponds to a drop of one in LOD score in the female MI linkage analysis, contains 40 known genes (Table 2).

Table 2: Genes residing within the one LOD drop region of the chromosome 13q12-13 linkage peak.

LL Symbol	LL gene name
USP12L1	ubiquitin specific protease 12 like 1
RPL21	ribosomal protein L21
GTF3A	general transcription factor IIIA
MTIF3	mitochondrial translational initiation factor 3
PDZRN1	PDZ domain containing ring finger 1
MGC9850	hypothetical protein MGC9850
POLR1D	polymerase (RNA) I polypeptide D, 16kDa
GSH1	GS homeobox 1
IPF1	insulin promoter factor 1, homeodomain transcription factor

CDX2	caudal type homeo box transcription factor 2
FLT3	fms-related tyrosine kinase 3
LOC255967	hypothetical protein LOC255967
FLT1	fms-related tyrosine kinase 1 (vascular endothelial growth factor/vascular permeability factor receptor)
C13orf12	chromosome 13 open reading frame 12
LOC283537	hypothetical protein LOC283537
KIAA0774	KIAA0774 protein
SLC7A1	solute carrier family 7 (cationic amino acid transporter, y+ system), member 1
UBL3	ubiquitin-like 3
MGC2599	hypothetical protein MGC2599 similar to katanin p60 subunit A 1 2599
HMGB1	high-mobility group box 1
D13S106E	highly charged protein
<b>ALOX5AP</b>	<b>arachidonate 5-lipoxygenase-activating protein</b>
FLJ14834	hypothetical protein FLJ14834
MGC40178	hypothetical protein MGC40178
HSPH1	heat shock 105kDa/110kDa protein 1
B3GTL	beta 3-glycosyltransferase-like
GREAT	similar to G protein coupled receptor affecting testicular descent (H. sapiens)
LOC196549	similar to hypothetical protein FLJ20897
13CDNA73	hypothetical protein CG003
BRCA2	breast cancer 2, early onset
CG018	hypothetical gene CG018
PRO0297	PRO0297 protein
LOC88523	CG016
CG012	hypothetical gene CG012
CG030	hypothetical gene CG030
CG005	hypothetical protein from BCRA2 region
APRIN	androgen-induced proliferation inhibitor
KL	Klotho
STARD13	START domain containing 13
RFC3	replication factor C (activator 1) 3, 38kDa

---

To determine which gene in this region most likely contributes to MI, 120 microsatellite markers positioned within this region were typed, and a case-control association study was performed using 802 unrelated MI patients and 837 population-based controls. The association study was also repeated for each of the three phenotypes that were used in the linkage study, i.e. early onset, male and female MI patients.

The initial association analysis was performed when the average spacing between microsatellite markers was approximately 100 kb. This analysis revealed several extended haplotypes composed of 4 and 5 microsatellite markers that were significantly associated with female MI (see FIGs 1 and 2, and Tables 13 and 14). A region common to all these  
5 extended haplotypes, is defined by markers DG13S166 and D13S1238. This region included only one gene, the FLAP nucleic acid sequence. The two marker haplotype involving alleles 0 and -2 for markers DG13S166 and D13S1238, respectively, was found in excess in patients.

This was the first evidence that the FLAP gene might be involved in the pathogenesis of  
10 myocardial infarction.

Subsequent haplotype analysis that included more microsatellite markers (n=120) in the candidate region on chromosome 13q12-13, now with a marker density of 1 microsatellite marker per 60 kb, showed decreased significance of the original haplotype association.

However, the haplotype association analysis using increased density of markers again pointed

15 towards the FLAP gene. This analysis strongly suggested that a 300 kb region was involved in the susceptibility of myocardial infarction. As shown in FIG. 5.2, the haplotype that showed association to all MI with the lowest P value (0.00009) covered a region that contains 2 known genes, including the gene encoding arachidonate 5-lipoxygenase-activating protein (FLAP) and a gene with an unknown function called highly charged protein. However, the  
20 haplotype association to female MI in this region was less significant (P value = 0.005) than for all MI patients and to our surprise, the most significant haplotype association was observed for male MI patients (P value = 0.000002). This male MI haplotype was the only haplotype that remained significant after adjusting for all haplotypes tested.

In view of the association results described above, FLAP was an attractive candidate  
25 and therefore efforts were focused on this gene.

#### *Screening for polymorphisms in FLAP and linkage disequilibrium mapping*

To determine whether variations within the FLAP gene significantly associate with MI and to search for causal variations, the FLAP gene was sequenced in 93 patients and 93  
30 controls. The sequenced region covers 60 kb containing the FLAP gene, including the 5 known exons and introns and the 26 kb region 5' to the first exon and 7 kb region 3' to the fifth exon. In all, 144 SNPs were identified, of those 96 were excluded from further analysis

either because of low minor allele frequency or they were completely correlated with other SNPs and thus redundant. FIG. 6 shows the distribution of the 48 SNPs, used for genotyping, relative to exons, introns and the 5' and 3' flanking regions of the FLAP gene. Only one SNP was identified within a coding sequence (exon 2). This SNP did not lead to amino acid substitution. The locations of these SNPs in the NCBI human genome assembly, build 34, are listed in Table 3.

Table 3: Locations of all genotyped SNPs in NCBI build 34 of the human genome assembly

SNP name	Build34 start
SG13S381	29083350
SG13S366	29083518
SG13S1	29086224
SG13S2	29087473
SG13S367	29088090
SG13S10	29088473
SG13S3	29089044
SG13S368	29089886
SG13S4	29090997
SG13S5	29091307
SG13S90	29091780
SG13S6	29092536
SG13S371	29093964
SG13S372	29094259
SG13S373	29096688
SG13S375	29096874
SG13S376	29096962
SG13S25	29097553
SG13S377	29101965
SG13S100	29104271
SG13S95	29106329
SG13S191	29107830
SG13S106	29108579
SG13S114	29110096
SG13S121	29112174
SG13S122	29112264
SG13S43	29112455
SG13S192	29116308
SG13S88	29116401
SG13S137	29118118
SG13S86	29118815
SG13S87	29118873
SG13S39	29119740



SG13S26	29122253
SG13S27	29122283
SG13S29	29123643
SG13S89	29124441
SG13S96	29124906
SG13S30	29125840
SG13S97	29129139
SG13S32	29130547
SG13S41	29134045
SG13S42	29135877
SG13S34	29137100
SG13S35	29138117
SG13S181	29138633
SG13S184	29139435
SG13S188	29140805

In addition to the SNPs, a polymorphism consisting of a monopolymer A repeat that has been described in the FLAP promoter region was typed (Koshino, T. *et al.*, *Mol Cell Biol Res Commun* **2**, 32-5 (1999)).

The linkage disequilibrium (LD) block structure defined by the 48 SNPs that were selected for further genotyping is shown in FIG. 8. A strong LD was detected across the FLAP region, although it appears that at least one recombination may have occurred dividing the region into two strongly correlated LD blocks.

#### 10 Haplotype association to MI

To perform a case-control association study the 48 selected SNPs and the monopolymer A repeat marker were genotyped in a set of 779 unrelated MI patients and 628 population-based controls. Each of the 49 markers were tested individually for association to the disease. Three SNPs, one located 3 kb upstream of the first exon and the other two 1 and 3 kb downstream of the first exon, showed nominally significant association to MI (Table 4).

Table 4: SNP allelic association in the MI cohort

Phenotype	Marker	Allele	P value	RR	# Pat.	% Pat.	# Ctrl	% Ctrl
All patients	SG13S106	G	0.0044	1.29	681	72.0	530	66.6
	SG13S100	A	0.020	1.29	388	69.6	377	63.9

	SG13S114	T	0.021	1.21	764	70.0	602	65.8
Males	SG13S106	G	0.0037	1.35	422	72.9	530	66.6
	SG13S100	A	0.0099	1.36	292	70.7	377	63.9
	SG13S114	T	0.026	1.24	477	70.4	602	65.8
Early onset	SG13S100	A	0.0440	1.43	99	71.7	377	63.9

Nominally significant SNP association with corresponding number of patients (# Pat.) and controls (#Ctrl). RR refers to relative risk.

However, after adjusting for the number of markers tested, these results were not significant. A search was then conducted for haplotypes that show association to the disease using the same cohorts. For computational reasons, the search was limited to haplotype combinations constructed out of two, three or four SNPs and only haplotypes that were in excess in the patients were tested. The resulting P values were adjusted for all the haplotypes tested by randomizing the patients and controls (see Methods).

Several haplotypes were found that were significantly associated to the disease with an adjusted P value less than 0.05 (Table 5).

TABLE 5: SNP haplotypes that significantly associate with Icelandic MI patients

SG13S4	SG13S6	SG13S372	SG13S25	SG13S377	SG13S100	SG13S95	SG13S114	SG13S192	SG13S137	SG13S86	SG13S87	SG13S39	SG13S27	SG13S89	SG13S96	SG13S32	SG13S41	SG13S42	SG13S34	SG13S188	<i>P</i> value <sup>a</sup>	<i>P</i> value <sup>b</sup>	Pat. fr q	Ctrl. fr q	RR	D' <sup>c</sup>
			G				T							G		A					0,0000023	0,005	0,158	0,095	1,80	1,00
			G				T				A					A					0,0000030	0,006	0,158	0,095	1,78	1,00
			G				T									A			T		0,0000032	0,007	0,157	0,094	1,79	1,00
			G		A						A					A					0,0000046	0,012	0,158	0,083	2,07	0,89
			G			T	T									A					0,0000047	0,012	0,154	0,093	1,78	1,00
			G				T			G						A					0,0000055	0,015	0,147	0,087	1,81	1,00
			G		A											A			T		0,0000061	0,017	0,157	0,083	2,07	0,89
			G		A									G		A					0,0000063	0,017	0,157	0,084	2,04	0,89
			G				T									A					0,0000070	0,021	0,157	0,096	1,76	1,00
			G				T								A	A					0,0000075	0,022	0,149	0,089	1,78	1,00
	G					T	T									A					0,0000083	0,024	0,208	0,139	1,62	0,99
			G		A					G						A					0,0000084	0,026	0,145	0,074	2,14	0,88
			G				T	A								A					0,0000084	0,026	0,139	0,082	1,82	1,00
			G				T						G			A					0,0000091	0,028	0,156	0,096	1,75	1,00
	G						T									A			T		0,0000094	0,028	0,210	0,141	1,61	0,99
	G		G				T									A					0,0000100	0,028	0,156	0,096	1,74	1,00
	G				A											A			A		0,0000101	0,028	0,215	0,133	1,80	0,81
			G		A											A					0,0000105	0,028	0,157	0,084	2,03	0,89
	G				A						A					A					0,0000108	0,029	0,214	0,133	1,78	0,81
			G		A										A	A					0,0000110	0,030	0,146	0,075	2,10	0,88
	G						T				A					A					0,0000112	0,030	0,212	0,144	1,60	1,00
			G		A			A											T		0,0000113	0,030	0,151	0,081	2,03	0,78
			G				T					G				A					0,0000118	0,031	0,156	0,096	1,73	1,00
	G				A											A			T		0,0000126	0,034	0,212	0,131	1,79	0,79
	G						T							G		A					0,0000129	0,035	0,211	0,144	1,59	1,00
			G		A								G			A					0,0000134	0,035	0,156	0,084	2,01	0,89
	G						T									A					0,0000136	0,036	0,211	0,143	1,60	1,00
	G		G		A											A					0,0000137	0,036	0,156	0,085	2,00	0,89
			G		A			A								A					0,0000148	0,037	0,151	0,081	2,01	0,78
			G				T	A											T		0,0000150	0,037	0,160	0,099	1,73	0,87
			G		A			A								A					0,0000150	0,037	0,130	0,066	2,13	0,90
			G				T		C										T		0,0000154	0,039	0,152	0,094	1,73	0,93
			G				T									A		A			0,0000154	0,040	0,155	0,097	1,70	1,00
			G				T		C							A					0,0000157	0,040	0,141	0,085	1,76	1,00
			G	G	A											A					0,0000158	0,040	0,152	0,084	1,94	0,90
	G						T						G			A					0,0000163	0,040	0,210	0,143	1,59	0,99
	G						T			G						A					0,0000166	0,041	0,200	0,134	1,61	0,92
	G				A									G		A					0,0000168	0,042	0,213	0,133	1,76	0,81

			G		A							G				A					0,0000168	0,042	0,156	0,084	2,00	0,89
C	G				A											A					0,0000171	0,042	0,211	0,136	1,70	0,81
	G						T	A								A					0,0000183	0,043	0,192	0,128	1,62	0,85
	G				A											A					0,0000184	0,043	0,212	0,132	1,77	0,81
	G						T										A		T		0,0000193	0,046	0,328	0,251	1,46	0,99
			G				T					G							T		0,0000194	0,046	0,175	0,115	1,64	0,98
	G	G			A											A					0,0000202	0,048	0,210	0,136	1,70	0,81
	G		G		A			A													0,0000209	0,049	0,151	0,082	2,00	0,76

<sup>a</sup> Single test P values. <sup>b</sup> P values adjusted for all the SNP haplotypes tested. <sup>c</sup> Measure of correlation with Haplotype A4 .

The most significant association was observed for a four SNP haplotype spanning 33 kb, including the first four exons of the gene (Fig. 6.3), with a nominal P value of 0.0000023 and an adjusted P value of 0.005. This haplotype, labelled A4 , has haplotype frequency of 15.8% (carrier frequency 30.3%) in patients versus 9.5% (carrier frequency 17.9%) in controls (Table 6).

Table 6: Association of the A4 haplotype to MI, Stroke and PAOD

Phenotype (n)	Frq. Pat.	RR	PAR	P-value	P-value <sup>a</sup>
<i>MI (779)</i>	0.158	1.80	0.135	0.0000023	0.005
Males (486)	0.169	1.95	0.158	0.00000091	ND <sup>b</sup>
Females (293)	0.138	1.53	0.094	0.0098	ND
Early onset (358)	0.138	1.53	0.094	0.0058	ND
<i>Stroke (702)<sup>c</sup></i>	0.149	1.67	0.116	0.000095	ND
Males (373)	0.156	1.76	0.131	0.00018	ND
Females (329)	0.141	1.55	0.098	0.0074	ND
<i>PAOD (577)<sup>c</sup></i>	0.122	1.31	0.056	0.061	ND
Males (356)	0.126	1.36	0.065	0.057	ND
Females (221)	0.114	1.22	0.041	0.31	ND

<sup>a</sup> P value adjusted for the number of haplotypes tested. <sup>b</sup>Not done. <sup>c</sup>Excluding known cases of MI. Shown is the FLAP A4 haplotype and corresponding number of patients (n), haplotype frequency in patients (Frq. pat.), relative risk (RR), population attributed risk (PAR) and P values. The A4 haplotype is defined by the following SNPs: SG13S25, SG13S114, SG13S89 and SG13S32 (Table 5). The same controls (n=628) are used for the association analysis in MI, stroke and PAOD as well as for the male, female and early onset analysis. The A4 haplotype frequency in the control cohort is 0.095.

5 The relative risk conferred by The A4 haplotype compared to other haplotypes constructed out of the same SNPs, assuming a multiplicative model, was 1.8 and the corresponding population attributable risk (PAR) was 13.5%. As shown in Table 6, the A4 haplotype was observed in higher frequency in male patients (carrier frequency 30.9%) than in female patients (carrier frequency 25.7%). All the other haplotypes that were significantly  
10 associated with an adjusted P value less than 0.05, were highly correlated with the A4 haplotype and should be considered variants of that haplotype (Table 5). Table 6 shows the results of the haplotype A4 association study using 779 MI patients, 702 stroke patients, 577 PAOD patients and 628 controls. First and second degree relatives were excluded from the patient cohorts. All known cases of MI were removed from the stroke and PAOD cohorts

before testing for association. A significant association of the A4 haplotype to stroke was observed, with a relative risk of 1.67 (P value = 0.000095). In addition, it was determined whether the A4 haplotype was primarily associated with a particular sub-phenotype of stroke, and found that both ischemic and hemorrhagic stroke were significantly associated with the  
5 A4 haplotype (Table 22, below).

#### More variants of haplotype A4

Two correlated series of SNP haplotypes were observed in excess in patients, denoted as A and B in Table 7. The length of the haplotypes varies between 33 and 69 Kb, and the  
10 haplotypes cover one or two blocks of linkage disequilibrium. Both series of haplotypes contain the common allele G of the SNP SG13S25. All haplotypes in the A series contain the SNP SG13S114, while all haplotypes in the B series contain the SNP SG13S106. In the B series, the haplotypes B4, B5, and B6 have a relative risk (RR) greater than 2 and with allelic frequencies above 10%. The haplotypes in A series have slightly lower RR and lower p-  
15 values, but higher frequency (15-16%). The haplotypes in series B and A are strongly correlated, i.e. the haplotypes in B define a subset of the haplotypes in A. Hence, haplotypes B are more specific than A. Haplotypes A are however more sensitive, i.e. they capture more individuals with the putative mutation, as is observed in the population attributable risk which is less for B than for A. Furthermore, these haplotypes show similar risk ratios and allelic  
20 frequency for early-onset patients (defined as onset of first MI before the age of 55) and for both gender. In addition, analyzing various groups of patients with known risk factors, such as hypertension, high cholesterol, smoking and diabetes, did not reveal any significant correlation with these haplotypes, indicating that the haplotypes in the FLAP gene represent an independent genetic susceptibility factor for MI.

Table 7: The selected SNP haplotypes and the corresponding p-values

	p-val	RR	#aff	aff.frq.	carr.frq.	#con	con.frq.	PAR	SG13S99	SG13S25	SG13S377	SG13S106	SG13S114	SG13S89	SG13S30	SG13S32	SG13S42	SG13S35
<b>B4</b>	4.80E-05	2.08	903	0.106	0.2	619	0.054	0.11		G		G			G		A	
<b>B5</b>	2.40E-05	2.2	910	0.101	0.19	623	0.049	0.11	T	G		G			G		A	
<b>B6</b>	1.80E-06	2.22	913	0.131	0.24	623	0.063	0.14	T	G	G	G				A		G
<b>A4</b>	5.10E-06	1.81	919	0.159	0.29	623	0.095	0.14		G			T	G		A		
<b>A5</b>	2.60E-06	1.91	920	0.15	0.28	624	0.085	0.14	T	G			T	G		A		

5 Relative risk (RR), number of patients (#aff), allelic frequency in patients (aff.frq.), carrier frequency in patients (carr.frq.), number of controls (#con), allelic frequency in controls (con.frq.), population attributable risk (PAR). The patients used for this analysis were all unrelated within 4 meioses.

# 10 *Haplotype association to female MI*

Before we had typed all the SNPs that eventually lead to the identification of A4 haplotype we performed a haplotype association analysis that included 437 female MI patients, 1049 male MI patients, and 811 controls that had been genotyped with several SNPs and 3 microsatellite markers. These markers were all located within 300 kb region encompassing the FLAP gene. In a case-control study of the MI patients using these data, several haplotypes were found, that were significantly over-represented in the female MI patients compared to controls (see Table 8). All these haplotypes were highly correlated with each other.

20

25

Table 8: haplotypes in the FLAP region (FLAP and flanking nucleotide sequences) that were associated with female MI.

SG13S421	SG13S418	SG13S419	SG13S420	DG13S166	SG13S106	SG13S114	SG13S121	SG13S122	SG13S88	SG13S181	SG13S184	D13S1238	DG13S2605	p-val	N_affected	aff.frq	N_control	ctrl.frq	rel_risk	PAR	info
	C		T	0							G	-2		1.30E-05	455	0.108	811	0.048	2.4	0.122	0.615
	C		T	0		T		A	T			-2	0	7.61E-06	455	0.065	812	0.02	3.45	0.091	0.615
	C		T	0		T			T			-2	0	8.82E-06	455	0.065	812	0.02	3.47	0.092	0.602
	C		T	0		T	G		T			-2	0	9.31E-06	455	0.065	812	0.02	3.39	0.089	0.611
	C		T	0		T			T		G	-2	0	6.91E-06	455	0.063	812	0.019	3.54	0.09	0.624
	C	A	T	0		T			T			-2	0	9.76E-06	455	0.063	812	0.019	3.51	0.089	0.606
	C		T	0		T		A	T		G	-2		1.09E-05	455	0.063	811	0.019	3.41	0.086	0.618
	C		T	0		T			T	G		-2	0	1.10E-05	455	0.063	812	0.019	3.44	0.087	0.611
	C		T	0			G		T		G	-2	0	1.11E-05	455	0.063	812	0.018	3.56	0.086	0.589
	C		T	0			G		T		G	-2		1.22E-05	455	0.063	811	0.018	3.6	0.087	0.577
	C		T	0	G				T		G	-2	0	1.26E-05	455	0.063	812	0.02	3.35	0.088	0.629
	C		T	0				A	T		G	-2	0	8.59E-06	455	0.062	812	0.018	3.53	0.085	0.62
	C		T	0				A	T		G	-2		1.20E-05	455	0.062	811	0.019	3.42	0.086	0.617
	C		T	0			G	A	T		G	-2		1.21E-05	455	0.062	811	0.019	3.43	0.086	0.619
A	C		T	0			G		T		G	-2		7.93E-06	455	0.061	811	0.016	3.95	0.088	0.562
A	C		T	0					T		G	-2		1.09E-05	455	0.061	811	0.017	3.85	0.09	0.56
A	C		T	0		T			T		G	-2		5.00E-06	455	0.06	811	0.015	4.11	0.087	0.576
	C	A	T	0			G		T		G	-2		1.31E-05	455	0.06	811	0.017	3.66	0.085	0.586
A	C		T	0				A	T		G	-2		8.53E-06	455	0.059	811	0.016	3.85	0.085	0.593
A	C	A	T	0					T		G	-2		9.63E-06	455	0.058	811	0.015	4.03	0.085	0.565



Table 9 shows two haplotypes that are representative of these female MI risk haplotypes. The relative risk of these haplotypes were 2.4 and 4, and they were carried by 23% and 13% of female MI patients, respectively.

5 Table 9: Two representative variants of the female MI “at risk” haplotypes

	SG13S418	SG13S420	DG13S166	SG13S114	SG13S88	SG13S184	D13S1238	p-val	N aff	aff.frq	N ctrl	ctrl.frq	rel risk	PAR	info
Female MI															
	C	T	0	T	T	G	-2	6.38E-06	4549	0.05	8095	0.015	4.0	0.086	0.577
	C	T	0			G	-2	2.74E-05	4476	0.10	8098	0.043	2.3	0.116	0.623

**P-val:** p-value for the association. **N\_aff:** Number of patients used in the analysis. **Aff. frq:** haplotype frequency in patients. **N\_ctrl:** number of controls used in the analysis. **Ctrl.frq:** Haplotype frequency in controls. **Rel\_risk:** Relative risk of the haplotype. **PAR:** population attributable risk. **Info:** information content.

Table 10 shows that these same haplotypes were also over-represented in male MI patients compared to controls, although with lower relative risk. It should be noted that after typing and analysing more SNPs in the FLAP region these female MI “at risk” haplotypes could no longer be considered significant after adjusting for multiple testing.

Table 10: The frequencies of the female MI “at risk” haplotypes in male patients vs controls.

	SG13S418	SG13S420	DG13S166	SG13S114	SG13S88	SG13S184	D13S1238	p-val	N_aff	aff.frq	N_ctrl	ctrl.frq	rel_risk	PAR	Info
Male MI															
	C	T	0	T	T	G	-2	3.37E-01	1087	0.027	809	0.021	1.32	0.013	0.577
	C	T	0			G	-2	5.39E-01	1087	0.056	809	0.05	1.13	0.013	0.568

**P-val:** p-value for the association. **N\_aff:** Number of patients used in the analysis. **Aff. frq:** haplotype frequency in patients. **N\_ctrl:** number of controls used in the analysis. **Ctrl.frq:** Haplotype frequency in controls. **Rel\_risk:** Relative risk of the haplotype. **PAR:** population attributable risk. **Info:** information content.

10

Table 11: The marker map for chromosome 13 used in the linkage analysis.

Location (cM)	Marker	Location (cM)	Marker
6	D13S175	63.9	D13S170
9.8	D13S1243	68.7	D13S265
13.5	D13S1304	73	D13S167
17.2	D13S217	76.3	D13S1241
21.5	D13S289	79.5	D13S1298
25.1	D13S171	81.6	D13S1267
28.9	D13S219	84.7	D13S1256
32.9	D13S218	85.1	D13S158
38.3	D13S263	87	D13S274
42.8	D13S326	93.5	D13S173
45.6	D13S153	96.7	D13S778
49.4	D13S1320	102.7	D13S1315
52.6	D13S1296	110.6	D13S285
55.9	D13S156	115	D13S293
59.8	D13S1306		

Table 12 Marker Map for the second step of Linkage Analysis

Location (cM)	Marker	Location (cM)	Marker
1.758	D13S175	42.585	D13S1248
9.235	D13S787	44.288	D13S1233
11.565	D13S1243	44.377	D13S263
16.898	D13S221	45.535	D13S325
17.454	D13S1304	45.536	D13S1270
18.011	D13S1254	45.537	D13S1276
18.59	D13S625	49.149	D13S326
19.308	D13S1244	49.532	D13S1272
19.768	D13S243	52.421	D13S168
22.234	D13S1250	52.674	D13S287
22.642	D13S1242	60.536	D13S1320
22.879	D13S217	64.272	D13S1296
25.013	D13S1299	71.287	D13S156
28.136	D13S289	76.828	D13S1306
28.678	D13S290	77.86	D13S170
29.134	D13S1287	82.828	D13S265
30.073	D13S260	91.199	D13S1241
31.98	D13S171	93.863	D13S1298
32.859	D13S267	97.735	D13S779
33.069	D13S1293	100.547	D13S1256
33.07	D13S620	102.277	D13S274
34.131	D13S220	111.885	D13S173
36.427	D13S219	112.198	D13S796
39.458	D13S1808	115.619	D13S778
40.441	D13S218	119.036	D13S1315
41.113	D13S1288	126.898	D13S285
41.996	D13S1253	131.962	D13S293

Table 13 shows the exons with positions that encode the FLAP protein, markers, polymorphisms and SNPs identified within the genomic sequence by the methods described herein.

Table 13

NCBI build34; start on chr. 13 (bp)	NCBI build34; stop on chr. 13 (bp)	SNP/mark er/exon name	alias1	alias2	public SNP	Variation	minor allele	minor allele frequency (%)	start position in SEQ ID NO:1	end position in SEQ ID NO:1
28932432	28932432	SG13S421		DG00AAFQR	rs1556428	A/G	G	10.32	432	432
28960356	28960356	SG13S417		SNP13B_R10287 29	rs1028729	C/T	G	30.46	28356	28356
28965803	28965803	SG13S418		SNP13B_Y13238 98	rs1323898	A/G	T	37.38	33803	33803
28974627	28974627	SG13S44				A/G	G	0.545	42627	42627
28975101	28975101	SG13S45				C/G	G	1.111	43101	43101
28975315	28975315	SG13S46				A/G	G	0.328	43315	43315
28975353	28975353	SG13S50				C/T	C	0.495	43353	43353
28975774	28975774	SG13S52				A/G	A	6.993	43774	43774
28985244	28985244	SG13S53			rs1408167	A/C	C	30.876	53244	53244
28985303	28985303	SG13S55			rs1408169	A/G	G	6.731	53303	53303
28985423	28985423	SG13S56				G/T	T	0.353	53423	53423
28985734	28985734	SG13S57			rs6490471	C/T	C	31.356	53734	53734
28985902	28985902	SG13S58			rs6490472	A/G	A	30.935	53902	53902
29003869	29003869	SG13S59				C/G	G	5.492	71869	71869
29004696	29004696	SG13S60				A/G	A	1.812	72696	72696
29007670	29007670	SG13S419		SNP13B_K91239 2	rs912392	C/T	G	35.00	75670	75670
29015410	29015410	SG13S61				C/T	C	1.314	83410	83410
29025792	29025792	SG13S62				C/T	T	3.521	93792	93792
29026202	29026202	SG13S63			rs7997114	A/G	A	30.031	94202	94202
29026668	29026668	SG13S64				A/G	A	1.724	94668	94668
29038707	29038707	SG13S65				A/G	A	0.369	106707	106707
29042180	29042180	SG13S420		DG00AAFIV	rs2248564	A/T	A	13.66	110180	110180
29049355	29049355	SG13S66				A/G	A	20.779	117355	117355

29049446	29049446	SG13S67				C/T	T	5.965	117446	117446
29050416	29050416	SG13S69				A/C	A	16.923	118416	118416
29059348	29059348	SG13S70				A/G	A	34.364	127348	127348
29059383	29059383	SG13S71				A/G	A	8.537	127383	127383
29059402	29059402	SG13S72				G/T	T	25.536	127402	127402
29063702	29063949	D13S289							131702	131949
29064359	29064753	DG13S166							132359	132753
29066272	29066272	SG13S73				A/G	A	37.302	134272	134272
29070551	29070551	SG13S99	SNP_13_Y1 323892	DG00AAFIU	rs1323892	C/T	C	6.25	138551	138551
29081983	29081983	SG13S382	FLA267479			A/G	A	0.49	149983	149983
29082200	29082200	SG13S383	FLA267696			A/G	A	14.08	150200	150200
29082357	29082357	SG13S384	FLA267853			A/G	G	0.62	150357	150357
29083350	29083350	SG13S381	FLA268846	DG00AAJER		C/G	G	14.01	151350	151350
29083518	29083518	SG13S366	FLA269014	DG00AAJES	rs4312166	A/G	T	0.58	151518	151518
29085102	29085102	SG13S385	FLA270742			C/T	C	30.21	153102	153102
29085190	29085190	SG13S386	FLA270830			A/G	A	10.95	153190	153190
29086224	29086224	SG13S1	FLA271864			G/T	G	30.00	154224	154224
29087473	29087473	SG13S2	FLA273371			A/G	A	27.95	155473	155473
29088090	29088090	SG13S367	FLA273988	DG00AAJEU	rs4474551	A/G	G	2.41	156090	156090
29088186	29088186	SG13S388	FLA274084			A/G	A	0.39	156186	156186
29088473	29088473	SG13S10	FLA274371			A/T	T	10.23	156473	156473
29089044	29089044	SG13S3	FLA274942			C/T	T	15.17	157044	157044
29089886	29089886	SG13S368	FLA275784	DG00AAJEV		C/T	T	13.60	157886	157886
29090025	29090025	SG13S369	FLA275923	DG00AAJEW		G/T	G	12.44	158025	158025
29090054	29090054	SG13S370	FLA275952	DG00AAJEX		A/G	A	13.45	158054	158054
29090997	29090997	SG13S4	FLA276895			G/C	G	14.59	158997	158997
29091307	29091307	SG13S5	FLA277205		rs4238133	G/T	T	26.84	159307	159307
29091580	29091580	SG13S389	FLA277478			A/G	A	12.73	159580	159580
29091780	29091780	SG13S90	FLA277678			A/C	C	43.67	159780	159780
29092287	29092287	SG13S390	FLA278185		rs5004913	A/G	A	12.18	160287	160287

29092536	29092536	SG13S6	FLA278434				A/G	A	8.38	160536	160536
29092594	29092594	SG13S391	FLA278492				A/G	G	0.62	160594	160594
29092947	29092947	SG13S392	FLA278845				G/T	T	12.34	160947	160947
29093964	29093964	SG13S371	FLA279888	DG00AAJFY	rs4409939		A/G	G	25.34	161964	161964
29094259	29094259	SG13S372	FLA280183	DG00AAJFZ			A/G	C	0.24	162259	162259
29094999	29094999	SG13S393	FLA280923				A/T	T	25.66	162999	162999
29096688	29096688	SG13S373	FLA282612	DG00AAJFA			A/G	A	14.84	164688	164688
29096813	29096813	SG13S374	FLA282737	DG00AAJFB			A/G	G	12.37	164813	164813
29096874	29096874	SG13S375	FLA282798	DG00AAJFC			C/T	C	14.55	164874	164874
29096962	29096962	SG13S376	FLA282886	DG00AAJFD			A/G	G	11.99	164962	164962
29097476	29097476	SG13S394	FLA283400				C/G	C	14.66	165476	165476
29097553	29097553	SG13S25	FLA283477				A/G	A	12.21	165553	165553
29098486	29098486	SG13S395	FLA284410				A/G	A	0.79	166486	166486
29098891	29098891	SG13S396	FLA284815				A/C	C	10.15	166891	166891
29098979	29098979	SG13S397	FLA284903				C/T	C	3.53	166979	166979
29101965	29101965	SG13S377	FLA287889	DG00AAJFF			A/G	A	12.45	169965	169965
29103909	29103909	SG13S189	FLA289833				C/G	C	0.62	171909	171909
29104271	29104271	SG13S100	FLA290195	DG00AAHIK	rs4073259		A/G	G	31.55	172271	172271
29104629	29104629	SG13S398	FLA290553				C/G	G	4.94	172629	172629
29104646	29104646	SG13S94	FLA290570		rs4073261		C/T	C	15.51	172646	172646
29105099	29105099	SG13S101	FLA291023		rs4075474		C/T	T	27.91	173099	173099
29106329	29106329	SG13S95	FLA292253				G/T	G	14.74	174329	174329
29106652	29106652	SG13S102	FLA292576				A/T	T	1.17	174652	174652
29107138	29107138	SG13S103	FLA293062				C/T	T	1.28	175138	175138
29107404	29107404	SG13S104	FLA293328				A/G	A	2.17	175404	175404
29107668	29107812	EXON1								175668	175812
29107830	29107830	SG13S191	FLA293754	DG00AAFJT	rs4769055		A/C	A	30.11	175830	175830
29108398	29108398	SG13S105	FLA294322				A/G	G	0.66	176398	176398
29108579	29108579	SG13S106	FLA294503	DG00AAHII			A/G	A	28.31	176579	176579
29108919	29108919	SG13S107	FLA294843		rs4075131		A/G	G	14.85	176919	176919
29108972	29108972	SG13S108	FLA294896		rs4075132		C/T	C	1.21	176972	176972

29109112	29109112	SG13S109	FLA295036				A/G	A	1.04	177112	177112
29109182	29109182	SG13S110	FLA295106				A/G	G	0.88	177182	177182
29109344	29109344	SG13S111	FLA295268			rs4597169	C/T	C	1.14	177344	177344
29109557	29109557	SG13S112	FLA295481				C/T	T	7.10	177557	177557
29109773	29109773	SG13S113	FLA295697			rs4293222	C/G	C	22.52	177773	177773
29110096	29110096	SG13S114	FLA296020	DG00AAHID			A/T	A	20.86	178096	178096
29110178	29110178	SG13S115	FLA296102				A/T	T	13.83	178178	178178
29110508	29110508	SG13S116	FLA296432			rs4769871	C/T	T	4.05	178508	178508
29110630	29110630	SG13S117	FLA296554			rs4769872	A/G	A	4.07	178630	178630
29110689	29110689	SG13S118	FLA296613			rs4769873	C/T	T	4.07	178689	178689
29110862	29110862	SG13S119	FLA296786				A/G	A	1.06	178862	178862
29111889	29111889	SG13S120	FLA297813				C/T	C	16.00	179889	179889
29112174	29112174	SG13S121	FLA298098	DG00AAHIJ		rs4503649	A/G	G	49.36	180174	180174
29112264	29112264	SG13S122	FLA298188	DG00AAHIH			A/G	A	29.75	180264	180264
29112306	29112306	SG13S123	FLA298230				C/T	T	5.06	180306	180306
29112455	29112455	SG13S43	FLA298379			rs3885907	A/C	C	46.23	180455	180455
29112583	29112583	SG13S399	FLA298507				A/C	C	1.59	180583	180583
29112680	29112680	SG13S124	FLA298604			rs3922435	C/T	T	1.45	180680	180680
29113139	29113139	SG13S125	FLA299063				A/G	G	11.32	181139	181139
29114056	29114056	SG13S400	FLA299980				A/G	A	3.25	182056	182056
29114738	29114738	SG13S126	FLA300662				A/G	A	34.12	182738	182738
29114940	29114940	SG13S127	FLA300864				A/G	G	29.63	182940	182940
29115878	29115878	SG13S128	FLA302094			rs4254165	A/G	A	45.68	183878	183878
29116020	29116020	SG13S129	FLA302236			rs4360791	A/G	G	36.65	184020	184020
29116068	29116068	SG13S130	FLA302284				G/T	G	8.07	184068	184068
29116196	29116296	EXON2								184196	184296
29116249	29116249	SG13S190	FLA302465				C/T	T	1.02	184249	184249
29116308	29116308	SG13S192	FLA302524	B SNP 302524		rs3803277	A/C	A	49.57	184308	184308
29116344	29116344	SG13S193	FLA302560				A/G	A	0.58	184344	184344
29116401	29116401	SG13S88	FLA302617	B SNP 302617		rs3803278	C/T	C	24.71	184401	184401
29116688	29116688	SG13S131	FLA302904				C/T	T	7.19	184688	184688



29117133	29117133	SG13S132	FLA303349			A/C	A	1.10	185133	185133
29117546	29117546	SG13S133	FLA303762		rs4356336	C/T	T	37.65	185546	185546
29117553	29117553	SG13S38	FLA303769		rs4584668	A/T	A	45.50	185553	185553
29117580	29117580	SG13S134	FLA303796			C/T	T	1.22	185580	185580
29117741	29117741	SG13S135	FLA303957		rs4238137	C/T	T	0.89	185741	185741
29117954	29117954	SG13S136	FLA304170		rs4147063	C/T	T	36.69	185954	185954
29118118	29118118	SG13S137	FLA304334	DG00AAHIG	rs4147064	C/T	T	29.11	186118	186118
29118815	29118815	SG13S86	FLA305031			A/G	A	30.19	186815	186815
29118873	29118873	SG13S87	FLA305089	DG00AAHOJ		A/G	G	3.29	186873	186873
29119069	29119069	SG13S138	FLA305285			C/T	T	36.96	187069	187069
29119138	29119138	SG13S139	FLA305354			C/G	G	36.63	187138	187138
29119289	29119289	SG13S140	FLA305505			A/G/T	T	37.34	187289	187289
29119462	29119462	SG13S141	FLA305678			C/T	C	1.15	187462	187462
29119740	29119740	SG13S39	FLA305956			G/T	T	9.91	187740	187740
29120939	29120939	SG13S142	FLA307155		rs4387455	C/T	C	3.36	188939	188939
29120949	29120949	SG13S143	FLA307165		rs4254166	C/T	T	36.24	188949	188949
29121342	29121342	SG13S144	FLA307558		rs4075692	A/G	A	31.58	189342	189342
29121572	29121572	SG13S145	FLA307788			C/G	G	0.45	189572	189572
29121988	29121988	SG13S146	FLA308204			C/T	T	1.14	189988	189988
29122253	29122253	SG13S26	FLA308469			C/T	T	46.57	190253	190253
29122283	29122283	SG13S27	FLA308499			A/G	A	10.34	190283	190283
29122294	29122294	SG13S147	FLA308510			C/T	T	8.00	190294	190294
29122298	29122298	SG13S28	FLA308514			G/T	T	33.71	190298	190298
29122311	29122311	SG13S148	FLA308527			G/T	T	2.29	190311	190311
29123370	29123370	SG13S98	FLA309586			G/T	G	1.19	191370	191370
29123635	29123635	SG13S149	FLA309851			A/G	A	1.01	191635	191635
29123643	29123643	SG13S29	FLA309859			A/C	A	47.88	191643	191643
29124188	29124259	EXON3							192188	192259
29124441	29124441	SG13S89	FLA310657	B SNP 310657	rs4769874	A/G	A	4.68	192441	192441
29124906	29124906	SG13S96	FLA311122		rs4072653	A/G	G	29.72	192906	192906
29125032	29125032	SG13S150	FLA311248			C/G	C	8.22	193032	193032

29125521	29125521	SG13S401	FLA311737				C/T	C	21.10	193521	193521
29125822	29125822	SG13S151	FLA312038				C/T	T	8.57	193822	193822
29125840	29125840	SG13S30	FLA312056				G/T	T	23.23	193840	193840
29127301	29127301	SG13S31	FLA313550				C/T	T	24.20	195301	195301
29128080	29128162	EXON4								196080	196162
29128284	29128284	SG13S152	FLA314500				C/G	C	23.89	196284	196284
29128316	29128316	SG13S402	FLA314532		rs4468448		C/T	T	19.33	196316	196316
29128798	29128798	SG13S403	FLA315014		rs4399410		A/G	G	11.50	196798	196798
29129016	29129016	SG13S153	FLA315232				A/T	T	3.08	197016	197016
29129139	29129139	SG13S97	FLA315355				A/G	A	9.72	197139	197139
29129154	29129154	SG13S154	FLA315370				C/T	T	0.98	197154	197154
29129395	29129395	SG13S40	FLA315611				G/T	T	2.24	197395	197395
29129915	29129915	SG13S155	FLA316131		rs4769875		A/G	A	1.43	197915	197915
29130192	29130192	SG13S156	FLA316408				A/C	A	1.80	198192	198192
29130256	29130256	SG13S157	FLA316472				A/G	G	2.38	198256	198256
29130299	29130299	SG13S158	FLA316515				A/C	A	0.61	198299	198299
29130353	29130353	SG13S159	FLA316569				G/T	G	2.55	198353	198353
29130391	29130391	SG13S160	FLA316607				C/T	T	0.83	198391	198391
29130547	29130547	SG13S32	FLA316763				A/C	C	48.50	198547	198547
29131280	29131280	SG13S161	FLA317496				A/G	G	2.44	199280	199280
29131403	29131403	SG13S162	FLA317619				A/G	G	2.45	199403	199403
29131404	29131404	SG13S163	FLA317620				C/T	C	2.45	199404	199404
29131431	29131431	SG13S164	FLA317647		rs4769058		C/T	C	2.55	199431	199431
29131517	29131517	SG13S165	FLA317733				A/T	T	20.00	199517	199517
29131528	29131528	SG13S166	FLA317744		rs4769059		C/T	T	2.46	199528	199528
29131599	29131599	SG13S167	FLA317815		rs4769876		A/G	A	3.50	199599	199599
29132003	29132003	SG13S168	FLA318219				A/C	C	8.39	200003	200003
29133753	29133753	SG13S33	FLA319969				G/T	T	8.99	201753	201753
29134045	29134045	SG13S41	FLA320261				A/G	G	5.41	202045	202045
29134177	29134177	SG13S169	FLA320393				A/G	G	4.12	202177	202177
29134379	29134379	SG13S404	FLA320595		rs4427651		G/T	G	38.33	202379	202379

29135558	29135558	SG13S170	FLA321774		rs3935645	C/T	C	32.77	203558	203558
29135640	29135640	SG13S171	FLA321856		rs3935644	A/G	G	48.03	203640	203640
29135750	29135750	SG13S172	FLA321966			A/G	G	1.67	203750	203750
29135809	29135809	SG13S173	FLA322025			A/T	A	0.68	203809	203809
29135877	29135877	SG13S42	FLA322093		rs4769060	A/G	G	42.44	203877	203877
29136080	29136556	EXON5							204080	204556
29136290	29136290	SG13S194	FLA322506			C/T	T	0.30	204290	204290
29136462	29136462	SG13S195	FLA322678		rs1132340	A/G	G	2.46	204462	204462
29136797	29136797	SG13S174	FLA323013			A/G	G	0.56	204797	204797
29137100	29137100	SG13S34	FLA323316			G/T	G	30.23	205100	205100
29137150	29137150	SG13S175	FLA323366			A/G	A	2.40	205150	205150
29137607	29137607	SG13S176	FLA323823			A/G	A	2.24	205607	205607
29137651	29137651	SG13S177	FLA323867			C/T	T	1.64	205651	205651
29137905	29137905	SG13S178	FLA324121			C/G	C	1.40	205905	205905
29138117	29138117	SG13S35	FLA324333			A/G	A	9.52	206117	206117
29138375	29138375	SG13S179	FLA324591			A/G	A	48.14	206375	206375
29138385	29138385	SG13S180	FLA324601			C/T	T	2.50	206385	206385
29138633	29138633	SG13S181	FLA324849	DG00AAHIF	rs4420371	C/G	C	49.41	206633	206633
29139153	29139153	SG13S182	FLA325369			C/T	T	2.36	207153	207153
29139277	29139277	SG13S183	FLA325493		rs4466940	C/T	T	12.07	207277	207277
29139435	29139435	SG13S184	FLA325651	DG00AAHOI	rs4445746	A/G	A	16.67	207435	207435
29139971	29139971	SG13S185	FLA326187			A/G	G	7.66	207971	207971
29140441	29140441	SG13S405	FLA326657			A/G	A	9.66	208441	208441
29140649	29140649	SG13S91	FLA326865			A/G	A	7.78	208649	208649
29140695	29140695	SG13S186	FLA326911		rs4769877	A/T	A	25.71	208695	208695
29140703	29140703	SG13S187	FLA326919			A/G	A	1.43	208703	208703
29140805	29140805	SG13S188	FLA327021	DG00AAJFE		A/G	G	4.71	208805	208805
29141049	29141049	SG13S406	FLA327265			C/T	T	0.56	209049	209049
29142392	29142392	SG13S92	FLA328644		rs4429158	C/T	T	8.33	210392	210392
29142397	29142397	SG13S93	FLA328649			A/G	A	7.23	210397	210397
29142712	29142712	SG13S36	FLA328964			C/T	C	15.88	210712	210712

29144013	29144013	SG13S407	FLA330265				C/T	T	3.29	212013	212013
29144203	29144203	SG13S408	FLA330455				C/T	T	0.30	212203	212203
29144234	29144589	D13S1238								212234	212589
29144255	29144255	SG13S7	FLA330507				C/T	T	16.28	212255	212255
29144877	29144877	SG13S37	FLA331129				A/G	G	16.70	212877	212877
29144982	29144982	SG13S409	FLA331234				A/G	A	1.93	212982	212982
29144983	29144983	SG13S8	FLA331235			rs4491352	A/C	C	30.64	212983	212983
29145122	29145122	SG13S410	FLA331374			rs4319601	C/T	T	20.57	213122	213122
29145143	29145143	SG13S411	FLA331395				A/G	A	1.54	213143	213143
29145171	29145171	SG13S9	FLA331423				C/T	C	16.37	213171	213171
29145221	29145221	SG13S412	FLA331473			rs4769062	A/G	A	7.42	213221	213221
29145265	29145265	SG13S413	FLA331517			rs4238138	C/T	T	1.91	213265	213265

Table 14: Extended 4 microsatellite marker haplotypes

4 markers	pos.rr-frqgt1perc										
Length	p-val	RR	N af	P al	P ca	N ct	P al	P ca	Alleles		Markers
0.88	4.71E-06	6.23	428	0.065	0.125	721	0.011	0.022	0	-12 -6	DG13S80 DG13S83 DG13S1110 DG13S163
0.82	8.60E-06	INF	438	0.032	0.062	720	0	0	0	4 2 14	DG13S111 1 DG13S1103 D13S1287 DG13S1061
0.67	6.98E-06	19.91	435	0.03	0.059	721	0.002	0.003	8	6 0 8	DG13S1103 DG13S163 D13S290 DG13S1061
0.767	4.85E-06	26.72	436	0.048	0.094	721	0.002	0.004	0	0 2 12	DG13S1101 DG13S166 D13S1287 DG13S1061
0.515	1.93E-06	INF	422	0.048	0.094	721	0	0	2	0 0 6	DG13S166 DG13S163 D13S290 DG13S1061
0.864	1.68E-06	INF	424	0.024	0.048	717	0	0	0	2 0 -16	DG13S166 DG13S163 DG13S1061 DG13S293
0.927	5.38E-06	INF	435	0.034	0.067	720	0	0	4	2 14 3	DG13S1103 D13S1287 DG13S1061 DG13S301

Alleles #'s: For SNP alleles A = 0, C = 1, G = 2, T = 3; for microsatellite alleles: the CEPH sample (Centre d'Etudes du Polymorphisme Humain, genomics repository) is used as a reference, as described above. Length=length of haplotype in Mb. P-val=p-value. RR=Relative risk. N af=Number of patients. P al=allelic frequency of haplotype. P ca =carrier frequency of haplotype. N ct= number of controls. Alleles=alleles in the haplotype. Markers= markers in the haplotype.

Table 15: Extended 5 microsatellite marker haplotypes

[illegible]

																D13S1287 DG13S1061
																DG13S175 DG13S1103 DG13S163 D13S290 DG13S1061
0.705	5.28E-06	INF	435	0.027	0.053	721	0	0	0	8	6	0	8			DG13S89 DG13S166 DG13S163 D13S290 DG13S1061
0.841	4.21E-06	INF	422	0.048	0.093	721	0	0	0	2	0	0	6			DG13S1101 DG13S175 DG13S166 D13S1287 DG13S1061
0.767	4.02E-06	28.11	436	0.049	0.095	721	0.002	0.004	0	0	0	2	12			DG13S1101 DG13S172 DG13S166 D13S1287 DG13S1061
0.767	1.29E-06	31.07	436	0.047	0.092	721	0.002	0.003	0	0	0	2	12			DG13S175 DG13S166 DG13S163 D13S290 DG13S1061
0.705	4.25E-07	INF	422	0.048	0.093	721	0	0	0	2	0	0	6			DG13S172 DG13S1103 DG13S166 D13S1287 DG13S1061
0.683	6.58E-06	INF	437	0.029	0.056	721	0	0	0	4	0	2	14			DG13S1101 DG13S166 D13S290 D13S1287 DG13S1061
0.767	2.85E-06	32.43	436	0.044	0.087	721	0.001	0.003	0	0	0	2	12			D13S289 DG13S166 DG13S163 D13S1287 DG13S293
0.865	9.58E-06	18.39	451	0.023	0.045	739	0.001	0.003	0	0	2	2	16			D13S289 DG13S166 DG13S163 DG13S1061 DG13S293
0.865	5.08E-06	INF	453	0.019	0.038	739	0	0	0	0	2	0	16			DG13S1103 DG13S166 D13S1287 DG13S1061
0.927	1.02E-07	27.65	437	0.037	0.073	721	0.001	0.003	4	0	2	14	3			DG13S301

Length=length of haplotype in Mb. P-val=p-value. RR=Relative risk. N af=Number of patients. P al=allelic frequency of haplotype. P ca =carrier frequency of haplotype. N ct= number of controls. Alleles= alleles in the haplotype. Markers= markers in the haplotype

## EXAMPLE 2: RELATIONSHIP BETWEEN POLYMORPHISM IN THE 5-LIPOXYGENASE PROMOTER AND MI

5        A family of mutations in the G-C rich transcription factor binding region of the 5-LO gene has previously been identified. These mutations consist of deletion of one, deletion of two, or addition of one zinc finger (Sp1/Egr-1) binding sites in the region 176 to 147 bp upstream from the ATG translation start site where there are normally 5 Sp1 binding motifs in tandem. These naturally occurring mutations in the human 5-LO gene promoter have been  
10 shown to modify transcription factor binding and reporter gene transcription. The capacity of the mutant forms of DNA to promote transcription of CAT reporter constructs have been shown to be significantly less than that of the wild type DNA (*J. Clin. Invest.* Volume 99, Number 5, March 1997, 1130-1137). To test whether 5-LO is associated with the atherosclerotic diseases, particularly myocardial infarction (MI) in the human population, this  
15 promoter polymorphism, consisting of variable number of tandem Sp1/Egr-1 binding sites, was genotyped in 1112 MI patients, 748 patients with PAOD, and 541 stroke patients. The results, shown in Table 16, demonstrate that the wild type allele (which represents the allele with the most active promoter and thus with the highest expression of the 5-LO mRNA;  
*J. Clin. Invest.* Volume 99, Number 5, March 1997, 1130-1137) is significantly associated  
20 with MI (RR=1.2,  $p<0.05$ ). The results are consistent with a disease hypothesis that increased expression of the 5-LO plays a role in the pathogenesis of MI.



Table 16

	N_aff	Frq_aff	N_ctrl	Frq_ctrl	Risk Ratio	P-value
<b>MI patients</b>	1112	0.8701	734	0.8501	1.1803	0.048
Independent	969	0.8720	734	0.8501	1.2013	0.037
Males	646	0.8740	734	0.8501	1.2232	0.039
Females	465	0.8645	734	0.8501	1.1249	0.180
Age of onset < 60	522	0.8745	734	0.8501	1.2286	0.046
Males	353	0.8768	734	0.8501	1.2542	0.053
Females	169	0.8698	734	0.8501	1.1779	0.202
<b>PAOD patients</b>	748	0.8763	734	0.8501	1.2492	0.022
Independent	703	0.8755	734	0.8501	1.2400	0.027
Males	473	0.8774	734	0.8501	1.2613	0.033
Females	275	0.8745	734	0.8501	1.2289	0.092
<b>Stroke patients</b>	541	0.8743	734	0.8501	1.2262	0.046
Males	326	0.8758	734	0.8501	1.2427	0.067
Females	215	0.8721	734	0.8501	1.2019	0.144
Cardio / Large V	202	0.8861	734	0.8501	1.3719	0.038
Cardioembolic	114	0.8772	734	0.8501	1.2592	0.165
Large Vessel	88	0.8977	734	0.8501	1.5474	0.053
Small Vessel	77	0.8831	734	0.8501	1.2791	0.163
Hemorrhagic	27	0.9259	734	0.8501	2.2035	0.081

single sided p-values: Fisher exact test. N\_aff= number of affected individuals; Frq\_aff= frequency of the wild type allele of the promoter polymorphism in the affected group; N\_ctrl= number of controls; Frq\_ctrl= frequency of the wild type allele of the promoter polymorphism in the control group;

### EXAMPLE 3: ELEVATED LTE4 BIOSYNTHESIS IN INDIVIDUALS WITH THE FLAP MI-RISK HAPLOTYPE

Based on the known function of the end products of the leukotriene pathway and based on our 5-LO association data, the association of the FLAP haplotype with MI is best explained by increased expression and/or increased function of the FLAP gene. In other words, those individuals that have a “at risk” FLAP haplotype have either, or both, increased amount of FLAP, or more active FLAP. This would lead to increased production of leukotrienes in these individuals.

To demonstrate this theory, LTE4, a downstream leukotriene metabolite, was measured in patient serum samples. A quantitative determination of LTE4 in human serum was performed by liquid chromatography coupled with tandem mass spectrometry. The protocol was performed as follows:

5

#### ANALYTICAL METHOD

Table P1 (Protocol 1): List of Abbreviations

CAN	Acetonitrile
IS	Internal standard
LC-MS/MS	Liquid chromatography tandem mass spectrometry
LOQ	Limit of quantification
QCs	Quality controls
R <sup>2</sup>	Coefficient of determination
SS	Spiking solution

10

*Apparatus and conditions*

Table P2: Analytical apparatus and conditions

Instruments / Conditions	Details			
Analytical column	Zorbax extend C <sub>18</sub> , 3.5µm (50 x 2.1 mm)			
Column temperature	Ambient			
Pump and flow	Hewlett Packard Series 1100 Binary pump delivering 0.3 ml/min			
Mobile phase	A: Buffer: Acetonitrile:H <sub>2</sub> O (5:95 % v/v). (Containing 10 mM Ammonium Acetate and 0.1% Acetic acid at pH 4.6). B: Buffer: Acetonitrile:H <sub>2</sub> O (95:5 % v/v). (Containing 10 mM Ammonium Acetate and 0.1% Acetic acid at pH 4.6).			
Gradient	Time	%A	%B	Flow rate
	0.00	30	70	0.3 ml/min
	1.00	30	70	0.3 ml/min
	1.50	90	10	0.3 ml/min
	6.00	90	10	0.3 ml/min
	6.50	30	70	0.3 ml/min
	10.00	30	70	0.3 ml/min
Sample injection	HTC PAL autosampler 10 µl onto the HPLC column			
Mass Spectrometric system	Quattro Ultima™ Tandem MS/MS, Micromass. England.			
Recording and integration	Mass Lynx, version 3.5. All chromatograms and reports are printed out in hardcopy and stored in electronic form on the workstation hard disk drive. Recording time was 10 min.			
Retentions times	LTE <sub>4</sub> ~ 3.05 min. LTE <sub>4</sub> -d <sub>3</sub> ~ 3.05 min.			
Ionization mode	Electrospray atmospheric pressure in negative ion mode			
Scan mode	Multiple reaction monitoring (MRM)			
	Compound	Parent ion	Daughter ion	

	LTE <sub>4</sub>	438.2	333.2
	LTE <sub>4</sub> -d <sub>3</sub>	441.2	336.2

*Other instruments*

Table P3: The apparatus used for sample treatment and measurements

Apparatus	Brand	Type
Pipette	Eppendorf	Edos 5221
Pipette	Labsystems	Finnpipette 200 µl
Centrifuge	Eppendorf	5417C
Evaporation unit	Porvair	Ultravap
Vibrofix	Ika-Werk	VF-1
	Thermolyne	Maxi-mix III™, 65800
Balance	Sartorius	LA 120 S
Ultra sonic bath	Cole Parmer	8891

*Materials*

5 Table P4: Reagents for sample treatment and measurements

Reagent	Manufacturer	Quality	Art no.
Acetonitrile (ACN)	Rathburn	HPLC grade	RH 1016
Methanol	Rathburn	HPLC grade	RH 1019
Ammonium acetate	Merck	Pro analysis	1116

Table P5: Reference substances

	Details	Reference
Reference standards	Leukotrine E <sub>4</sub> from Cayman Chemical, MI, USA	20410
Internal standards	Leukotriene E <sub>4</sub> -20, 20,20-d <sub>3</sub> from Biomol, PA, USA	S10120

### *Stock solutions*

A stock solution of LTE<sub>4</sub> was prepared by the supplier at a concentration of 100µg/ml in methanol. The stock solution was diluted to a concentration of 20µg/ml in methanol and this working solution (WS-1) was kept refrigerated at 2-8°C.

- 5 An internal standard stock solution (LTE<sub>4</sub>-d<sub>3</sub>) was prepared by the supplier at concentration of 49.5µg/ml. The stock solution was diluted to a concentration of 1µg/ml in methanol and this working solution was kept refrigerated at 2-8°C.

### *Preparation of spiking solutions, calibration standards and quality control samples*

- Spiking solutions (SS) in the concentration range of 1 ng/ml to 10000 ng/ml were  
10 prepared by dilution of the working Solution.

The following spiking solutions were prepared:

Table P6: Spiking solutions for calibration standards

SS	Concentration (ng/ml)	Preparation
1	10000	500µl of WS-1 (20µg/ml) diluted to 1.0 ml with 70% MeOH/water
2	1000	100µl of SS-1 was diluted to 1.0 ml with 70% MeOH/water
3	100	100µl of SS-2 was diluted to 1.0 ml with 70% MeOH/water
4	30	300µl of SS-3 was diluted to 1.0 ml with 70% MeOH/water
5	20	200µl of SS-3 was diluted to 1.0 ml with 70% MeOH/water
6	16	160µl of SS-3 was diluted to 1.0 ml with 70% MeOH/water
7	12	120µl of SS-3 was diluted to 1.0 ml with 70% MeOH/water
8	8.0	400µl of SS-5 was diluted to 1.0 ml with 70% MeOH/water
9	4.0	200µl of SS-5 was diluted to 1.0 ml with 70% MeOH/water
10	2.0	100µl of SS-5 was diluted to 1.0 ml with 70% MeOH/water
11	1.4	175µl of SS-8 was diluted to 1.0 ml with 70% MeOH/water
12	1.0	125µl of SS-8 was diluted to 1.0 ml with 70% MeOH/water

Table P7: Spiking solutions for quality controls

SS	Concentration (ng/ml)	Preparation
13	14	140µl of SS-3 was diluted to 1.0 ml with 70% MeOH/water
14	6.0	300µl of SS-5 was diluted to 1.0 ml with 70% MeOH/water
15	2.4	120µl of SS-5 was diluted to 1.0 ml with 70% MeOH/water

After preparation, spiking solutions for calibration standards and quality controls were kept refrigerated at 2-8°C.

5

*Preparation of calibration standards and quality controls*

Fresh calibration standards and quality controls (QCs) were prepared each day by spiking blank plasma as described in Tables P8 and P9, respectively.

10 Table P8: Preparation of calibration standards

Concentration (ng/ml)	SS (µl)	Blank Plasma
1500	20 µl of the SS-4 (30ng/ml)	380 µl
1000	20 µl of the SS-5 (20ng/ml)	380 µl
800	20 µl of the SS-6 (16ng/ml)	380 µl
600	20 µl of the SS-7 (12ng/ml)	380 µl
400	20 µl of the SS-8 (8ng/ml)	380 µl
200	20 µl of the SS-9 (4.0ng/ml)	380 µl
100	20 µl of the SS-10 (2.0ng/ml)	380 µl
70	20µl of the SS-11 (1.4ng/ml)	380 µl
50	20µl of the SS-12 (1.0ng/ml)	380 µl

Table P9: Preparation of quality controls

Concentration (ng/ml)	SS (μl)	Blank Plasma
800	20 μl of the SS-13 (14ng/ml)	380 μl
40	20μl of the SS-14 (6.0ng/ml)	380 μl
8.0	20μl of the SS-15 (2.4ng/ml)	380 μl

5 *Sample preparation*

Aliquots of 400 μl of each study sample, calibration standards, QC samples and control blank are pipetted into an eppendorf vial. All samples apart from blank are then spiked with 20 μl of internal standard working solution and the samples are then vortex-mixed for few seconds. The pH of the plasma samples is adjusted to pH 4.5 using 60 μl of 10% acetic acid and centrifuged for 10 min. at 4100 rpm immediately before the extraction. The solid phase extraction 96-well plate is conditioned with 1 ml methanol and 1 ml water. Then 400μl of the plasma samples are loaded on the plate. Vacuum is applied, followed by drying the disk for 1 min. After being washed with 2ml water and 1 ml 30% methanol in 2% acetic acid. Next the plate is eluted with 0.6 ml methanol. The plate is then dried for few minutes. The methanol eluate is evaporated almost to dryness under a stream of nitrogen at 45°C. The residue is reconstituted in 30 μl mobile phase and vortex-mixed for few min. Subsequently, the solutions are centrifuged for 10 min at 10.000 rpm. and 10 μl are injected by the autosampler into the LC-MS/MS system for quantification.

20 *PERFORMANCE OF MEASUREMENTS*

The samples will be prepared and measured in batches and a typical batch will consist of:

One set of calibration standards, one extra lowest calibration standard and one blank.

Samples collected from a 16 individuals and one set of control samples (C<sub>L</sub>, C<sub>M</sub>, C<sub>H</sub>)

25 Samples collected from a 17 individuals and one set of control samples (C<sub>L</sub>, C<sub>M</sub>, C<sub>H</sub>)

### *QUANTITATIVE DETERMINATION OF ANALYTE IN PLASMA SAMPLES*

The standard curve is calculated from the peak area ratios ANALYTE/INTERNAL STANDARD of the calibration standards and their nominal ANALYTE concentrations. The  
5 unknown samples for LTE<sub>4</sub> were calculated from a quadratic regression equation where a weighted curve,  $1/X^2$ , is used. The measured peak area of the samples was converted into pictogram of ANALYTE per milliliter (pg/ml) of plasma according to the calculated equation for the standard curve.

The calculation of the regression for the standard curve and the calculations of the  
10 concentration of the unknown samples and the control samples are performed with MassLynx Software.

### *ACCEPTANCE CRITERIA*

#### 15 *Calibration standards*

The coefficient of determination ( $R^2$ ) for the calibration curve must exceed 0.98.

The calibration curve included the concentration range from 50pg/ml – 1500pg/ml.

Concentration of the calibration standards must be within  $\pm 25\%$  of their nominal value when  
recalculated from the regression equation. Calibration standards that fail these criteria (at most  
20 3 in each run) are rejected and the calibration performed again with the remaining standards.  
If the standard curve is not accepted, the samples must be reanalyzed.

#### *Control samples*

At least two thirds of the analysed quality controls must be within  $\pm 25\%$  of their  
nominal value when calculated from regression equation. If more than a third of the controls  
25 fail, the samples must be reanalyzed.



## RESULTS

Table 17 (below) shows that the female MI “at risk” haplotype was more associated with female MI patients who have high LTE4 levels (top 50th percentile), than with female MI patients who have low levels of LTE4 (bottom 50th percentile).

5 In addition, haplotype analysis, comparing female MI patients with high levels of LTE4 with female patients with low levels, showed that those with high levels had increased prevalence of the “at risk” haplotype by 1.6 fold (see Table 18). Although the association did not rise to the level of statistical significance, the results show clearly that the “at risk” haplotypes are enriched in the MI patient group that has high levels of LTE4. The carrier  
10 frequency of the “at risk” haplotypes are 12% and 20%, respectively, in the whole female MI group, but go up to 15% and 24%, respectively, in the female MI group that has high levels of LTE4. Correspondingly, the carrier frequency of the “at risk” haplotypes decrease to 8% and 18%, respectively, in the group of female MI that has low levels of LTE4 (Note carrier frequencies are twice the disease allele frequency times 1 minus the disease allele frequency  
15 plus the square of the disease allele frequency).

Note that LTE4 may simply reflect the leukotriene synthesis rate of the leukotriene synthetic pathway upstream of the key leukotriene metabolite involved in MI risk. For example, leukotriene B4 is probably more likely than leukotriene E4 to be involved in the inflammatory aspects of MI plaques but since B4 has a short half life, it is difficult to measure  
20 reliably in serum samples, while E4 has long term stability.

Table 17: Association of the at risk haplotypes for female MI, with female MI who also have high levels of LTE4 (>50pg/ml (roughly the upper 50th percentile).

	SG13S418	SG13S420	DG13S166	SG13S114	SG13S88	SG13S184	D13S1238	p-val	N <sub>aff</sub>	aff.frq	N <sub>ctrl</sub>	ctrl.frq	rel_risk	PAR	info
High LTE4															
	C	T	G	T	T	G		-23.72E-06	221	0.075	809	0.014	5.51	0.115	0.565
	C	T	G			G		-22.30E-05	220	0.122	809	0.046	2.89	0.154	0.608
Low LTE4															
	C	T	G	T	T	G		-24.65E-02	185	0.040	809	0.015	2.67	0.048	0.511
	C	T	G			G		-22.88E-02	182	0.087	809	0.048	1.89	0.08	0.622

**P-val:** p-value for the association. **N<sub>aff</sub>:** Number of patients used in the analysis. **Aff. frq:** haplotype frequency in patients. **N<sub>ctrl</sub>:** number of controls used in the analysis. **Ctrl.frq:** Haplotype frequency in controls. **Rel\_risk:** Relative risk of the haplotype. **PAR:** population attributable risk. **Info:** information content. Less association was found between the at risk haplotype for female MI, with female MI who also have low levels of LTE4 (<50pg/ml).

Table 18: Association between haplotypes that were most significantly associated with female MI, and serum LTE4 levels.

	SG13S418	SG13S420	DG13S166	SG13S114	SG13S88	SG13S184	D13S1238	p-val	N <sub>aff</sub>	aff.frq	N <sub>ctrl</sub>	ctrl.frq	rel_risk	PAR	info
High vs low LTE4															
	C	T	G	T	T	G		-21.61E-01	221	0.084	185	0.054	1.61	0.063	0.689
	C	T	G			G		-21.20E-01	220	0.13	182	0.088	1.54	0.089	0.686

**P-val:** p-value for the association. **N<sub>aff</sub>:** Number of patients used in the analysis. **Aff. frq:** haplotype frequency in patients. **N<sub>ctrl</sub>:** number of controls used in the analysis. **Ctrl.frq:** Haplotype frequency in controls. **Rel\_risk:** Relative risk of the haplotype. **PAR:** population attributable risk. **Info:** information content. Here, the group of affected individuals were defined as female MI patients with high serum LTE4 (higher than 50 pg/ml) and the control group is defined as female MI patients with low serum LTE4 (below 50 pg/ml).

#### EXAMPLE 4: ELEVATED LTE4 CORRELATED WITH ELEVATED C-REACTIVE PROTEIN (CRP)

5           The relationship between the increased production of leukotrienes and the inflammatory marker CRP, a well established risk factor for MI, was then explored. As shown in FIG. 4, a significant positive correlation was found between serum LTE4 levels and serum CRP levels.

#### EXAMPLE 5: ASSESSMENT OF LEVEL OF CRP IN PATIENTS WITH AT-RISK HAPLOTYPE

10           The level of CRP in female patients with female MI at-risk haplotypes was assessed, in order to assess whether there was a presence of a raised level of inflammatory marker in the presence of the female MI at-risk haplotype. Results are shown in Table 19. Although the association did not rise to the level of statistical significance, it was demonstrated that the average CRP was elevated in those patients with the at-risk haplotype versus those without it.

20 Table 19:

All female patients

		no	Mean CRP	SE CRP
affecteds:	With haplotype.	155	4.91	8.7
	Not with haplotype.	218	4.35	6.13

#### EXAMPLE 6: ELEVATED SERUM LTE4 LEVELS IN MI PATIENTS VERSUS CONTROLS

25           The end products of the leukotriene pathway are potent inflammatory lipid mediators that can potentially contribute to development of atherosclerosis and destabilization of atherosclerotic plaques through lipid oxidation and/or proinflammatory effects. Examples one through five show that: 1) MI correlates with genetic variation at FLAP; 2) MI correlates with high expression promoter polymorphism at 5-LO; 3) C-reactive protein levels correlate with serum leukotriene E4; and 4) Patients with MI-risk FLAP haplotypes have

30

higher levels of serum leukotriene E4 and CRP. Based on these data, it was hypothesized that serum leukotriene E4 levels correlate with MI risk.

To test this hypothesis, LTE4, a downstream leukotriene metabolite, was measured in 488 female MI patient and 164 control serum samples. The LTE4 levels for the patients were higher than that for the controls using a one-sided Wilcoxon rank-sum test. The p-value of the difference was 0.0092, thus confirming our hypothesis. Therefore, elevated leukotriene E4 represents a risk factor for MI. Serum or plasma LTE4 levels may be used to profile the MI risk for individuals to aid in deciding which treatment and lifestyle management plan is best for primary or secondary MI prevention. In the same way other leukotriene metabolites may be used to risk profile for MI.

#### EXAMPLE 7: INCREASED LTB4 PRODUCTION IN ACTIVATED NEUTROPHILS FROM MI PATIENTS

A principal bioactive product of one of the two branches of the 5-LO pathway is LTB4. To determine whether the patients with past history of MI have increased activity of the 5-LO pathway compared to controls, the LTB4 production in isolated blood neutrophils was measured before and after stimulation *in vitro* with the calcium ionophore, ionomycin. No difference was detected between the LTB4 production in resting neutrophils from MI patients or controls (results not shown). In contrast, the LTB4 generation by neutrophils from MI patients stimulated with the ionophore was significantly greater than by neutrophils from controls at 15 and 30 minutes, respectively (FIG. 5.1). Moreover, as shown in FIG. 5.2, the observed increase in the LTB4 release was largely accounted for by male carriers of haplotype A4, whose cells produced significantly more LTB4 than cells from controls (P value = 0.0042) (Table 20). As shown in Table 20, there was also a heightened LTB4 response in males who do not carry HapA but of borderline significance. This could be explained by additional variants in the FLAP gene that have not been uncovered, or alternatively in other genes belonging to the 5-LO pathway, that may account for upregulation in the LTB4 response in some of the patients without the FLAP at-risk haplotype. As shown in Table 20, differences in LTB4 response were not detected in females. However, due to a small sample size this cannot be considered conclusive. Taken together, the elevated levels of LTB4 production of stimulated neutrophils from male carriers of the at-risk haplotype suggest that the disease associated variants in the FLAP gene increase FLAP's response to factors that

stimulate inflammatory cells, resulting in increased leukotriene production and increased risk for MI.

## Methods

### *Isolation and activation of peripheral blood neutrophils*

5        50ml of blood were drawn into EDTA containing vacutainers from 43 MI patients and 35 age and sex matched controls. All blood was drawn at the same time in the early morning after 12 hours of fasting. The neutrophils were isolated using Ficoll-Paque PLUS (Amersham Biosciences).

Briefly, the red cell pellets from the Ficoll gradient were harvested and red blood cells  
10 subsequently lysed in 0.165 M NH<sub>4</sub>CL for 10 minutes on ice. After washing with PBS, neutrophils were counted and plated at  $2 \times 10^6$  cells/ml in 4ml cultures of 15% Fetal calf serum (FCS) (GIBCO BRL) in RPMI-1640 (GIBCO BRL). The cells were then stimulated with maximum effective concentration of ionomycin (1  $\mu$  M). At 0, 15, 30, 60 minutes post ionomycin addition 600  $\mu$ l of culture medium was aspirated and stored at -80C for the  
15 measurement of LTB<sub>4</sub> release as described below. The cells were maintained at 37°C in a humidified atmosphere of 5% CO<sub>2</sub>/95% air. All samples were treated with indomethasine (1  $\mu$  M ) to block the cyclooxygenase enzyme.

### *Ionomycin-induced release of LTB<sub>4</sub> in neutrophils*

20        LTB<sub>4</sub> Immunoassay (R&D systems) was used to quantitate LTB<sub>4</sub> concentration in supernatant from cultured ionomycin stimulated neutrophils. The assay used is based on the competitive binding technique in which LTB<sub>4</sub> present in the testing samples (200  $\mu$ l) competes with a fixed amount of alkaline phosphatase-labelled LTB<sub>4</sub> for sites on a rabbit polyclonal antibody. During the incubation, the polyclonal Ab becomes bound to a goat anti-  
25 rabbit Ab coated onto the microplates. Following a wash to remove excess conjugate and unbound sample, a substrate solution is added to the wells to determine the bound enzyme activity. The color development is stopped and the absorbance is read at 405 nm. The intensity of the color is inversely proportional to the concentration of LTB<sub>4</sub> in the sample. Each LTB<sub>4</sub> measurement using the LTB<sub>4</sub> Immunoassay, was done in duplicate.

30

Table 20: LTB<sub>4</sub> levels after ionomycin stimulation of isolated neutrophils<sup>a</sup>

Phenotype (n)	After 15 Minutes		After 30 Minutes	
	Mean (SD)	P value	Mean (SD)	P value
Controls (35)	4.53 (1.00)		4.67 (0.88)	
Males (18)	4.61 (1.10)		4.68 (1.07)	
Females (17)	4.51 (0.88)		4.67 (0.62)	
MI (41)	5.18 (1.09)	0.011	5.24 (1.06)	0.016
Carriers(16)	5.26 (1.09)	0.027	5.27 (1.09)	0.051
Non-carriers (24)	5.12 (1.08)	0.040	5.22 (1.03)	0.035
MI males (28)	5.37 (1.10)	0.0033	5.38 (1.09)	0.0076
Carriers(10)	5.66 (1.04)	0.0042	5.58 (1.12)	0.013
Non-carriers (18)	5.20 (1.09)	0.039	5.26 (1.05)	0.041
MI females (13)	4.78 (0.95)	0.46	4.95 (0.92)	0.36
Carriers(6)	4.59 (0.80)	0.90	4.75 (0.82)	0.85
Non-carriers (7)	4.94 (1.04)	0.34	5.12 (0.96)	0.25

<sup>a</sup>Mean  $\pm$  SD of log-transformed values of LTB4 levels of ionomycin-stimulated neutrophils from MI patients and controls. Results are shown for two time points: 15 and 30 minutes. The results for males and females and for MI male and female carriers and non-carriers of the at-risk haplotype HapA are shown separately. Two-sided p values corresponding to a standard two-sample test of the difference in the mean values between the MI patients, their various sub-cohorts and the controls are shown.

#### 10 EXAMPLE 8: HAPLOTYPES ASSOCIATED WITH MI ALSO CONFER RISK OF STROKE AND PAOD.

Because stroke and PAOD are diseases that are closely related to MI (all occur on the basis of atherosclerosis), it was examined whether the SNP haplotype in the FLAP gene that confers risk to MI also conferred risk of stroke and/or PAOD. The 'at risk' haplotype (A4 haplotype) can be defined by the following 4 SNPs: SG13S25 with allele G, SG13S114 with allele T, SG13S89 with allele G, and SG13S32 with allele A.

Table 21 shows that the haplotype A4 increases the risk of having a stroke to a similar extent as it increases the risk of having an MI. The 'at risk' haplotype is carried by 28% of stroke patients and 17% of controls, meaning that the relative risk of having stroke for the

carriers of this haplotype is 1.7 (p-value =  $5.8 \times 10^{-6}$ ). Although not as significant, the 'at risk' haplotype also confers risk of having PAOD.

Table 21:

		p-val	r	#aff	aff.frq.	#con	con.frq.	info	SG13S25	SG13S106	SG13S114	SG13S89	SG13S30	SG13S32	SG13S42
MI haplotypes															
All MI patients															
	A4	5.3E-07	1.80	1407	0.16	614	0.09	0.82	G		T	G		A	
	B4	1.0E-04	1.87	1388	0.10	612	0.06	0.67	G	G			G		A
Males MI															
	A4	2.5E-08	2.00	864	0.17	614	0.09	0.82	G		T	G		A	
	B4	1.1E-05	2.12	852	0.11	612	0.06	0.67	G	G			G		A
Females MI															
	A4	1.9E-02	1.44	543	0.13	614	0.09	0.73	G		T	G		A	
	B4	7.9E-02	1.45	536	0.08	612	0.06	0.60	G	G			G		A
Replication in stroke															
All stroke patients															
	A4	5.8E-06	1.73	1238	0.15	614	0.09	0.80	G		T	G		A	
	B4	2.3E-04	1.83	1000	0.10	612	0.06	0.71	G	G			G		A
Males stroke															
	A4	1.1E-06	1.91	710	0.17	614	0.09	0.79	G		T	G		A	
	B4	3.1E-05	2.11	574	0.11	612	0.06	0.72	G	G			G		A
Females stroke															
	A4	9.9E-03	1.49	528	0.13	614	0.10	0.74	G		T	G		A	
	B4	6.3E-02	1.47	426	0.08	612	0.06	0.70	G	G			G		A
All stroke excluding MI		8.4E-05	1.65	1054	0.15	614	0.09	0.78	G		T	G		A	
Males stroke excluding MI		6.4E-05	1.78	573	0.16	614	0.09	0.75	G		T	G		A	
Females stroke excluding MI		1.2E-02	1.49	481	0.14	614	0.10	0.72	G		T	G		A	
Cardioembolic stroke		6.6E-04	1.87	248	0.16	614	0.10	0.74	G		T	G		A	
Cardioembolic stroke excluding MI		3.8E-02	1.56	191	0.14	614	0.10	0.70	G		T	G		A	
Large vessel stroke		8.0E-02	1.47	150	0.13	614	0.09	0.83	G		T	G		A	
Large vessel stroke excluding MI		2.9E-01	1.31	114	0.12	614	0.09	0.80	G		T	G		A	

Small vessel stroke	7.2E-04	2.05	166	0.18	614	0.09	0.71	G		T	G	A
Small vessel stroke excluding MI	1.0E-04	2.31	152	0.20	614	0.10	0.71	G		T	G	A
Hemorrhagic stroke	4.4E-02	1.73	97	0.15	614	0.09	0.72	G		T	G	A
Hemorrhagic stroke excluding MI	3.9E-02	1.78	92	0.16	614	0.09	0.71	G		T	G	A
Unknown cause stroke	1.3E-04	1.88	335	0.16	614	0.09	0.75	G		T	G	A
Unknown cause stroke excluding MI	6.5E-04	1.82	297	0.16	614	0.09	0.72	G		T	G	A
<b>MI and stroke together</b>												
<b>All patients</b>												
<i>Best haplo A4</i>	4.1E-07	1.75	2659	0.15	614	0.09	0.82	G		T	G	A
<i>B4</i>	4.1E-05	1.85	2205	0.10	612	0.06	0.70	G	G		G	A
<b>Males</b>												
<i>A4</i>	1.4E-08	1.93	1437	0.17	614	0.09	0.82	G		T	G	A
<i>B4</i>	2.0E-06	2.11	1290	0.11	612	0.06	0.70	G	G		G	A
<b>Females</b>												
<i>A4</i>	3.6E-03	1.47	1024	0.13	614	0.09	0.77	G		T	G	A
<i>B4</i>	2.8E-02	1.48	915	0.08	612	0.06	0.66	G	G		G	A
<b>Patients with both MI and stroke</b>												
<i>A4</i>	6.1E-05	2.10	184	0.18	614	0.09	0.86	G		T	G	A
<b>Replication in PAOD</b>												
All PAOD patients	3.6E-02	1.31	920	0.12	614	0.10	0.84	G		T	G	A
Males PAOD	1.8E-02	1.40	580	0.13	614	0.10	0.84	G		T	G	A
Females PAOD	3.7E-01	1.17	340	0.11	614	0.10	0.83	G		T	G	A
All PAOD excluding MI	1.1E-01	1.24	750	0.12	614	0.10	0.83	G		T	G	A
Males PAOD excluding MI	8.3E-02	1.30	461	0.12	614	0.10	0.83	G		T	G	A
Males PAOD excluding MI and stroke	8.7E-02	1.32	388	0.12	614	0.10	0.83	G		T	G	A

The patient cohorts used in the association analysis shown in Table 21 may include first and second degree relatives.

5

Table 21, discussed above, shows the results of the haplotype A4 association study using 779 MI patients, 702 stroke patients, 577 PAOD patients and 628 controls. First and second degree relatives were excluded from the patient cohorts. All known cases of MI were removed from the stroke and PAOD cohorts before testing for association. A significant association of the A4 haplotype to stroke was observed, with a relative risk of 1.67 (P value = 0.000095). In addition, it was



determined whether the A4 haplotype was primarily associated with a particular sub-phenotype of stroke, and found that both ischemic and hemorrhagic stroke were significantly associated with the A4 haplotype (Table 22).

Table 22: Association of the A4 haplotype to subgroups of stroke

Phenotype (n)	Pat. Frq.	RR	PAR	P-value
Stroke <sup>a</sup> (702)	0.149	1.67	0.116	0.000095
Ischemic (484)	0.148	1.65	0.113	0.00053
TIA (148)	0.137	1.51	0.090	0.058
Hemorrhagic (68)	0.167	1.91	0.153	0.024

<sup>a</sup>Excluding known cases of MI.

5

Finally, the A4 haplotype was less significantly associated with PAOD (Table 21). It should be noted that similar to the stronger association of the A4 haplotype to male MI compared to female MI, it also shows stronger association to male stroke and PAOD (Table 21).

10

#### Study population

The stroke and PAOD cohorts used in this study have previously been described (Gretarsdottir, S. *et al. Nat Genet* **35**, 131-8 (2003); Gretarsdottir, S. *et al., Am J Hum Genet* **70**, 593-603 (2002); Gudmundsson, G. *et al., Am J Hum Genet* **70**, 586-92 (2002)). For the stroke linkage analysis, genotypes from 342 male patients with ischemic stroke or TIA that were linked to at least one other male patient within and including 6 meioses in 164 families were used. For the association studies 702 patients with all forms of stroke (n=329 females and n=373 males) and 577 PAOD patients (n=221 females and n=356 males) were analysed. Patients with stroke or PAOD that also had MI were excluded. Controls used for the stroke and PAOD association studies were the same as used in the MI SNP association study (n=628).

The study was approved by the Data Protection Commission of Iceland and the National Bioethics Committee of Iceland. Informed consent was obtained from all study participants. Personal identifiers associated with medical information and blood samples were encrypted with a third party encryption system as previously described (Gulcher, J.R., Kristjansson, K., Gudbjartsson, H. & Stefansson, K., *Eur J Hum Genet* **8**, 739-42 (2000)).

25

In addition, in an independent linkage study of male patients with ischemic stroke or transient ischemic attack, linkage to the same locus was observed with a LOD score of 1.51 at the same peak marker (FIG. 7), further suggested that a cardiovascular susceptibility factor might reside at this locus.

5

#### EXAMPLE 9: HAPLOTYPE ASSOCIATION TO FLAP IN A BRITISH COHORT

In an independent study, it was determined whether variants in the FLAP gene also have impact on risk of MI in a population outside Iceland. The four SNPs, defining the A4 haplotype, were typed in a cohort of 750 patients from the United Kingdom who had sporadic MI, and in 728 British population controls. The patients and controls come from 3 separate study cohorts recruited in Leicester and Sheffield. No significant differences were found in the frequency of the haplotype between patients and controls (16.9% versus 15.3%, respectively). However, when an additional 9 SNPs, distributed across the FLAP gene, were typed in the British cohort and searched for other haplotypes that might be associated with MI, two SNPs showed association to MI with a nominally significant P value (data not shown). Moreover, three and four SNP haplotype combinations increased the risk of MI in the British cohort further and the most significant association was observed for a four SNP haplotype with a nominal P value = 0.00037 (Table 23).

20

**Table 23 Association of the HapB haplotype to British MI patients**

Phenotype (n)	Frq. Pat.	RR	PAR	P-value	P-value <sup>a</sup>
MI (750)	0.075	1.95	0.072	0.00037	0.046
Males (546)	0.075	1.97	0.072	0.00093	ND
Females (204)	0.073	1.90	0.068	0.021	ND

<sup>a</sup>P value adjusted for the number of haplotypes tested using 1,000 randomization tests.

Shown are the results for HapB that shows the strongest association in British MI cohort. HapB is defined by the following SNPs: SG13S377, SG13S114, SG13S41 and SG13S35 ( that have the following alleles A, A, A and G, respectively. In all three phenotypes shown the same set of n=728 British controls is used and the frequency of HapB in the control cohort is 0.040. Number of patients (n), haplotype frequency in patients (Frq. pat.), relative risk (RR) and population attributed risk (PAR).

5 This was called haplotype HapB. The haplotype frequency of HapB is 7.5% in the MI patient cohort (carrier frequency 14.4%), compared to 4.0% (carrier frequency 7.8%) in controls, conferring a relative risk of 1.95 (Table 23). This haplotype remained significant after adjusting for all haplotypes tested, using 1000 randomisation steps, with an adjusted P value = 0.046. No other SNP haplotype had  
 10 an adjusted P value less than 0.05. The two at-risk haplotypes A4 and HapB appear to be mutually exclusive with no instance where the same chromosome carries both haplotypes.

#### *British study population*

15 The method of recruitment of 3 separate cohorts of British subjects has been described previously (Steeds, R., Adams, M., Smith, P., Channer, K. & Samani, N.J., *Thromb Haemost* **79**, 980-4 (1998); Brouillette, S., Singh, R.K., Thompson, J.R., Goodall, A.H. & Samani, N.J., *Arterioscler Thromb Vasc Biol* **23**, 842-6 (2003)). In brief, in the first two cohorts a total of 547 patients included those who were admitted  
 20 to the coronary care units (CCU) of the Leicester Royal Infirmary, Leicester (July 1993–April 1994) and the Royal Hallamshire Hospital, Sheffield (November 1995–March 1997) and satisfied the World Health Organisation criteria for acute MI in terms of symptoms, elevations in cardiac enzymes or electrocardiographic changes

(Nomenclature and criteria for diagnosis of ischemic heart disease. Report of the Joint International Society and Federation of Cardiology/World Health Organization task force on standardization of clinical nomenclature. *Circulation* 59, 607-9 (1979)). A total of 530 control subjects were recruited in each hospital from adult visitors to  
5 patients with non-cardiovascular disease on general medical, surgical, orthopaedic and obstetric wards to provide subjects likely to be representative of the source population from which the subjects originated. Subjects who reported a history of coronary heart disease were excluded.

In the third cohort, 203 subjects were recruited retrospectively from the  
10 registries of 3 coronary care units in Leicester. All had suffered an MI according to WHO criteria before the age of 50 years. At the time of participation, patients were at least 3 months from the acute event. The control cohort comprised 180 subjects with no personal or family history of premature coronary heart disease, matched for age, sex, and current smoking status with the cases. Control subjects were recruited from 3  
15 primary care practices located within the same geographical area. In all cohorts subjects were white of Northern European origin.

## DISCUSSION:

These results show that variants of the gene encoding FLAP associate with  
20 increased risk of MI and stroke. In the Icelandic cohort, a haplotype that spans the FLAP gene is carried by 30% of all MI patients and almost doubles the risk of MI. These findings were subsequently replicated in an independent cohort of stroke patients. In addition, another haplotype that spans the FLAP gene is associated with MI in a British cohort. Suggestive linkage to chromosome 13q12-13 was observed  
25 with several different phenotypes, including female MI, early onset MI of both sexes, and ischemic stroke or TIA in males. However, surprisingly, the strongest haplotype association was observed to males with MI or stroke. Therefore, there may be other variants or haplotypes within the FLAP gene, or in other genes within the linkage region, that also may confer risk to these cardiovascular phenotypes.

30 These data also show that the at-risk haplotype of the FLAP gene has increased frequency in all subgroups of stroke, including ischemic, TIA, and hemorrhagic stroke. Of interest is that the A4 haplotype confers significantly higher

risk of MI and stroke than it does of PAOD. This could be explained by differences in the pathogenesis of these diseases. Unlike PAOD patients who have ischemic legs because of atherosclerotic lesions that are responsible for gradually diminishing blood flow to the legs, the MI and stroke patients have suffered acute events, with disruption  
5 of the vessel wall suddenly decreasing blood flow to regions of the heart and the brain.

Association was not found between the A4 haplotype and MI in a British cohort. However, significant association to MI was found with a different variant spanning the FLAP gene. The fact that different haplotypes of the gene are found  
10 conferring risk to MI in a second population is not surprising. A common disease like MI associates with many different mutations or sequence variations, and the frequencies of these disease associated variants may differ between populations. Furthermore, the same mutations may be seen arising on different haplotypic backgrounds.

15

## SUMMARY

In summary, it has been found that: MI correlates with genetic variation at FLAP; MI correlates with high expression promoter polymorphism at 5-LO; patients  
20 with female MI at-risk FLAP haplotypes have higher levels of serum LTE4; LTE4 levels correlate with CRP levels in serum; and patients with MI at-risk FLAP haplotypes have elevated CRP. In addition, we have shown that isolated neutrophils from MI patients, produce more LTB4 when stimulated with ionomycin compared to controls. Taken together, these results show that increased leukotriene synthesis is a  
25 risk factor for MI, and that this risk is driven in part by variants in FLAP and 5-LO genes and are captured in part by measurement of levels of serum LTE4 and CRP. Furthermore, the SNP haplotype in the FLAP gene that confers risk to MI also confers risk of stroke and/or PAOD.

# MARKERS UTILIZED HEREIN

5 Table 24: Basepair position of microsatellite markers (start and stop of the amplimersin NCBI sequence assembly build 34 and primer sequences (forward and reverse).

Marker name	forward primer	reverse primer	basepair start position	basepair stop position
DG13S2393	CCTTTGCTTTGTTTCCTATTCTTT (SEQ ID NO. 4)	TCCCATTGCCCAGAGTTAAT (SEQ ID NO. 5)	22831401	22831787
DG13S2070	TCCTCATGTCTTCACCTAGAAGC (SEQ ID NO. 6)	CCACTCATGAGGGAGCTGTT (SEQ ID NO. 7)	23020439	23020651
DG13S2071	TGTCACAGGCACACACTCTCT (SEQ ID NO. 8)	GAGTATGGCTGCTGCTCCTC (SEQ ID NO. 9)	23066973	23067076
DG13S2072	ATGGCTCACACTGGCCTAAA (SEQ ID NO. 10)	TGAACAGACCAATAATAGTGCAG (SEQ ID NO. 11)	23136964	23137114
DG13S2078	AAGCCACCCTTTAAACAGCA (SEQ ID NO. 12)	GCTGAGGAAGCAACTCCACT (SEQ ID NO. 13)	23591927	23592081
DG13S2079	GCTCTGAATTCCTGGCATA (SEQ ID NO. 14)	TTAGCCCTAGTCCCACTCTCC (SEQ ID NO. 15)	23646974	23647183
DG13S2082	CAAGAGGCCTGCATAAGGAA (SEQ ID NO. 16)	AGATTGCCCGTGGCTTAAAT (SEQ ID NO. 17)	23807898	23808174
DG13S2083	TGTCTGTTCCCGTCTGTCTG (SEQ ID NO. 18)	TTCATCTCTGCCAAATTCC (SEQ ID NO. 19)	23882291	23882532
DG13S2086	GGCATGTATTCACTGCCTGA (SEQ ID NO. 20)	AAACCCATTCTTCTTCTCTTAC (SEQ ID NO. 21)	24069346	24069771
DG13S2089	TATGTGTTACGCCAGACCTC (SEQ ID NO. 22)	CCCTGCCATGTGCATTTAC (SEQ ID NO. 23)	24274920	24275129
DG13S44	CATTTGGGAAGGCAAAGAAA (SEQ ID NO. 24)	TTGCAATGAGGAATGAAGCA (SEQ ID NO. 25)	24413148	24413382
DG13S2095	TCCATTATCCATCTGTTTATCA (SEQ ID NO. 26)	GAAGAATTAATTGTAGGAGGCAA GA (SEQ ID NO. 27)	24621830	24622121
DG13S46	CTGACATCACCACATTGATCG (SEQ ID NO. 28)	CATACACAGCCATGTGGAATTA (SEQ ID NO. 29)	24652046	24652291
DG13S2101	ACGGTGATGACGCCTACATT (SEQ ID NO. 30)	TCACATGGACCAATTACCTAGAA (SEQ ID NO. 31)	24863557	24863744
D13S1254	AAATTACTTCACTTGACGATAA CA (SEQ ID NO. 32)	CTATTGGGGACTGCAGAGAG (SEQ ID NO. 33)	25316434	25316657
DG13S55	AGCCAGTGTCACAAAGGAAG (SEQ ID NO. 34)	GAGGGTGAGACACATCTCTGG (SEQ ID NO. 35)	25337471	25337753
DG13S54	AATCGTGCCCTCAGTTCCATC (SEQ ID NO. 36)	CCACCAGGAACAACACACAC (SEQ ID NO. 37)	25377308	25377463
D13S625	TTGCTCTCCAGCCTGGGC (SEQ ID NO. 38)	TTCTCTGGCTGCCTGCG (SEQ ID NO. 39)	25391207	25391395
DG13S2695	TCCTGCATGAGAAGGAACTG (SEQ ID NO. 40)	CGACATTCACCTGTGGCTCTT (SEQ ID NO. 41)	25415551	25415807
DG13S1479	TTTGATTCCGTGGTCCATTA (SEQ ID NO. 42)	TTATTTGGTCCGTGCACCTTT (SEQ ID NO. 43)	25459039	25459368
DG13S2696	GGTGACCGACCAAATAAGT (SEQ ID NO. 44)	CCAGCTTATTCTCTCTGCCTTC (SEQ ID NO. 45)	25459351	25459478
DG13S1440	GGTAGGTTGAAATGGGCTAACA (SEQ ID NO. 46)	TCATGACAAGGTGTTGGATT (SEQ ID NO. 47)	25520858	25520987
DG13S1890	CCTCTCTGCCATGAAGCTA (SEQ ID NO. 48)	CTATTGGTCTGCGGGTTGT (SEQ ID NO. 49)	25672727	25673140
DG13S1540	TACTGGGTTATCGCCTGACC (SEQ ID NO. 50)	CCAATGGACCTCTTGGACAT (SEQ ID NO. 51)	25704358	25704504
DG13S59	TTTCGGCACAGTCCCTCAATA (SEQ ID NO. 52)	CAGCTGGGTGTGGTGACAT (SEQ ID NO. 53)	25720194	25720421
DG13S1545	CAGAGAGGAACAGGCAGAGG (SEQ ID NO. 54)	AGTGGCTGGGAAGCCTTATT (SEQ ID NO. 55)	25760018	25760404
DG13S1524	AGGTGAGAGAAACAACTGTCTT (SEQ ID NO. 56)	GCCTTCTTCTAAGGCCAAC (SEQ ID NO. 57)	25843657	25843768
DG13S1529	CTGTAGACTTTATCCCTGACTTAC TG (SEQ ID NO. 58)	CAATGAATGATGAAGATTCCACT C (SEQ ID NO. 59)	26098943	26099063

DG13S1908	TGACACCATGTCTTACTGTTTGC (SEQ ID NO. 60)	GAGGATACAATGAGAACCAAATC TC (SEQ ID NO. 61)	26110282	26110493
DG13S2525	CAGGATCATCAGCCAGGTTT (SEQ ID NO. 62)	GCTGCATGTCAGTGGCATT (SEQ ID NO. 63)	26123233	26123381
DG13S1546	CCACAGAATGCTCCAAAGGT (SEQ ID NO. 64)	GAGTTCAAGTGATGGATGACGA (SEQ ID NO. 65)	26159644	26159995
DG13S1444	CAGATAGATGAATAGGTGGATGG A (SEQ ID NO. 66)	CACTGTTCCAAGTGCTTTGC (SEQ ID NO. 67)	26207544	26207727
DG13S66	TATGCGTTGTGTGTGCTGTG (SEQ ID NO. 68)	GGGCTTAGATTCTTGTAGTGG (SEQ ID NO. 69)	26279746	26279962
DG13S1907	TGTCCAGACTGCCTCCTACA (SEQ ID NO. 70)	TGCAACACCTGGTTCACAAT (SEQ ID NO. 71)	26378401	26378521
DG13S68	TTTGCGAGTCTTGTGGAGT (SEQ ID NO. 72)	ACAGTCCGCTCCCTCCTAAT (SEQ ID NO. 73)	26511587	26511825
DG13S69	ATGCTTGGCCCTCAGTTT (SEQ ID NO. 74)	TTGGCAACCCAAGCTAATATG (SEQ ID NO. 75)	26518188	26518483
D13S1250	CTCCACAGTGACAGTGAGG (SEQ ID NO. 76)	GAGAGGTTCCCAATCCC (SEQ ID NO. 77)	26721525	26721686
DG13S574	CAGCTCTGGCCATATTTCT (SEQ ID NO. 78)	GAGCCATTTCTCTGGGTCTG (SEQ ID NO. 79)	26853541	26853693
DG13S73	GGTCCGTGTCAACCCTTAGA (SEQ ID NO. 80)	CAGGTTGATGGGAGGGAAA (SEQ ID NO. 81)	26878938	26879133
DG13S1532	CGGGAAATGACAGTGAGACC (SEQ ID NO. 82)	TGCCTAGATTCTCCCGTAAG (SEQ ID NO. 83)	26899505	26899652
D13S1242	GTGCCCAGCCAGATTC (SEQ ID NO. 84)	GCCCCAGTCAGGTTT (SEQ ID NO. 85)	26943073	26943316
DG13S576	TTTCTCTCCACGGAATGAA (SEQ ID NO. 86)	AACCCATTCTACAGGGTGTA (SEQ ID NO. 87)	27121599	27121797
DG13S1917	AGGAGTGTGGCAGCTTTGAG (SEQ ID NO. 88)	TGGATTCCCGTGAGTACCAG (SEQ ID NO. 89)	27135092	27135232
D13S217	ATGCTGGGATCACAGGC (SEQ ID NO. 90)	AACCTGGTGGACTTTTGCT (SEQ ID NO. 91)	27169880	27170051
DG13S581	AGCATTTCCTAATGGTGCTTT (SEQ ID NO. 92)	CATGTTGATATGCCTGAAGGA (SEQ ID NO. 93)	27318359	27318725
DG13S1471	CACTGTCTGCTGCCACTCAT (SEQ ID NO. 94)	AGAGATTATGTATGACCTCTC TAT (SEQ ID NO. 95)	27403303	27403544
DG13S2505	TGATGAAGATCTGGGCGTTA (SEQ ID NO. 96)	TGCCTGTGCTCACTCACTCT (SEQ ID NO. 97)	27493479	27493626
D13S120	ATGACCTAGAAATGATACTGGC (SEQ ID NO. 98)	CAGACACCACAACACACATT (SEQ ID NO. 99)	27540983	27541093
D13S1486	TGGTTTAAAAACCTCATGCC (SEQ ID NO. 100)	ATCCCAAACCTCTGTACTTATGTAG G (SEQ ID NO. 101)	27623349	27623496
DG13S1495	CCTTGGCTGTTGTGACTGGT (SEQ ID NO. 102)	CAGTGGGTTGGGAGGATCAC (SEQ ID NO. 103)	27668199	27668471
DG13S1845	CACTTTGCCAGTAGCCTTGA (SEQ ID NO. 104)	TTGGGAAAGTTAACCAGAGA (SEQ ID NO. 105)	27788787	27789056
DG13S1030	TTTGGGAAGAGCCATGAGAC (SEQ ID NO. 106)	CTCTGGGCATTGGAGGATTA (SEQ ID NO. 107)	27872811	27873164
DG13S584	GGGAGACAAGTCAGGTGAGG (SEQ ID NO. 108)	CTGAGTATGGAGTCTTCATCATTA TC (SEQ ID NO. 109)	27924334	27924484
DG13S79	TGCTACTAGATTGACCAACCA (SEQ ID NO. 110)	GACTTGTAAGGATTAGTGATT CG (SEQ ID NO. 111)	28213368	28213495
DG13S80	GTGGAAGGCCTCTCTCTGTG (SEQ ID NO. 112)	TGCTTCTTGAGGGAAAGCAT (SEQ ID NO. 113)	28297121	28297353
DG13S1934	CCTTCAGAGGATTTCCCTTTC (SEQ ID NO. 114)	CTGGTTTGACTCCAGCTTCA (SEQ ID NO. 115)	28461787	28462194
DG13S1104	CCTGGCACGGAATAGACACT (SEQ ID NO. 116)	GGCCCTCTTTGCTCTGAAG (SEQ ID NO. 117)	28497694	28498071
DG13S1097	CATCCCTGTGGCTGATTAAGA (SEQ ID NO. 118)	AACAGTTCAGCCCGTTCTA (SEQ ID NO. 119)	28532382	28532543
DG13S1110	TTTCAAAGGAATATCCAAGTGC (SEQ ID NO. 120)	TGGCGTACCATAATAACAGTTCTC (SEQ ID NO. 121)	28547636	28547900
DG13S87	TTCAATGAAGGTGCCGAAGT (SEQ ID NO. 122)	TGTCTATCCCAAAGCTGCAA (SEQ ID NO. 123)	28597688	28597905
DG13S2400	GCTCAGTCCAAGTTCATGCTC (SEQ ID NO. 124)	TGGGATTGGGTCTGGATAC (SEQ ID NO. 125)	28671947	28672231
DG13S3114	CCTACTTCCATCTCCTCCTTG (SEQ ID NO. 126)	TGGAGTAAGTTGGAGAATTGTTG A (SEQ ID NO. 127)	28678081	28678248
DG13S1111	GCAAGACTCTGTTGAAGAAGAAG A (SEQ ID NO. 128)	TCCCTCTGTTTGAGTTCTCG (SEQ ID NO. 129)	28760422	28760531

DG13S3122	CCTTGGGCAGTCAGAGAAAC (SEQ ID NO. 130)	CCCGTGAAGTCTGAGAGGTG (SEQ ID NO. 131)	28778662	28778906
DG13S1101	AGGCACAGTCGCTCATGTC (SEQ ID NO. 132)	AAACTTTAGCTAATGGTGGTCAA A (SEQ ID NO. 133)	28812542	28812874
D13S1246	GAGCATGTGTGACTTTCATATTC AG (SEQ ID NO. 134)	AGTGGCTATTCATTGCTACAGG (SEQ ID NO. 135)	28903534	28903738
DG13S1103	TTGCTGGATGCTGGTTTCTA (SEQ ID NO. 136)	AAAGAGAGAGAGAAAGAGAAAG AAAGA (SEQ ID NO. 137)	28910502	28910765
DG13S3147	AAAGTGGATGCAGTTGAGGTTT (SEQ ID NO. 138)	GCTAGCCATTACAGACAACCAA (SEQ ID NO. 139)	29018341	29018591
DG13S3150	CAGGGCTCCATGTATCCATAA (SEQ ID NO. 140)	CAATCTTTGGCTTTGGGTTT (SEQ ID NO. 141)	29042766	29042948
D13S289	CTGGTTGAGCGGCATT (SEQ ID NO. 142)	TGCAGCCTGGATGACA (SEQ ID NO. 143)	29063702	29063949
DG13S166	CCTATGGAAGCATAGGGAAGAA (SEQ ID NO. 144)	CCCACCTCTGAGTCTCCTGAT (SEQ ID NO. 145)	29064359	29064753
DG13S3156	GGGAAATGGAGCTGCTGTTA (SEQ ID NO. 146)	GAGTGGGTGAGTGCAAGGAT (SEQ ID NO. 147)	29111037	29111416
D13S1238	CTCTCAGCAGGCATCCA (SEQ ID NO. 148)	GCCAACGTAATTGACACCA (SEQ ID NO. 149)	29144427	29144579
DG13S2605	TGAAAGGAAGGTCCCTGAGTT (SEQ ID NO. 150)	CCCTGCTTTGCACAAGTTATC (SEQ ID NO. 151)	29145896	29146055
DG13S163	CACATGAGGCTGTATGTGGA (SEQ ID NO. 152)	TGTGCAGGAATGAGAAGTCG (SEQ ID NO. 153)	29177152	29177313
D13S290	CCTTAGGCCCCATAATCT (SEQ ID NO. 154)	CAAATTCCTCAATTGCAAAAT (SEQ ID NO. 155)	29227323	29227512
D13S1229	GGTCATTCAGGGAGCCATTC (SEQ ID NO. 156)	CCATTATATTTACCAAGAGGCTG C (SEQ ID NO. 157)	29282262	29282396
DG13S2358	AGTCAAGGCTGACAGGGAAG (SEQ ID NO. 158)	GCTCTCAGCCCTCAATGTGT (SEQ ID NO. 159)	29342275	29342399
DG13S2658	ATTTGGGTTCTCTCCAAT (SEQ ID NO. 160)	ACAAACTCTTGCTGCTGGTG (SEQ ID NO. 161)	29348162	29348426
DG13S1460	TGCCTGGTCATCTACCCATT (SEQ ID NO. 162)	TCTACTGCAGCGCTGATCTT (SEQ ID NO. 163)	29389048	29389297
DG13S2434	TCCTTCCAGAAGGTTGCAT (SEQ ID NO. 164)	TGCAAAGTTGTTCAAGAGAGACA (SEQ ID NO. 165)	29485254	29485392
DG13S1448	CAGCAGGAAGATGGACAGGT (SEQ ID NO. 166)	CACACTGCATCACATACCC (SEQ ID NO. 167)	29499404	29499531
D13S1287	TATGCCAGTATGCCTGCT (SEQ ID NO. 168)	GTCACATCAGTCCATTGTC (SEQ ID NO. 169)	29513830	29514063
DG13S2665	GGTTTATGTCTGTGTGTGTGTC (SEQ ID NO. 170)	TGAGGGATGTCAGAGAAATATGC (SEQ ID NO. 171)	29747845	29747984
DG13S1904	TGATGAAATTGCCTAGTGATGC (SEQ ID NO. 172)	GGATCCAATCGTACGCTACC (SEQ ID NO. 173)	29767797	29767922
DG13S1490	ACCTAAACACCACGGACTGG (SEQ ID NO. 174)	CAGGTATCGACATTCTTCCAAA (SEQ ID NO. 175)	29908555	29908958
DG13S2637	GGTGA TCTAGGGAATTATTIGTC TTC (SEQ ID NO. 176)	TTGGCCACTAAGGTCCAGAT (SEQ ID NO. 177)	29941956	29942120
DG13S96	CCTTTGAGGCTGGATCTGTT (SEQ ID NO. 178)	TTTCCTTATCATTCATCCCTCA (SEQ ID NO. 179)	30166433	30166650
D13S260	AGATATTGTC TCCGTTCATGA (SEQ ID NO. 180)	CCCAGATATAAGGACCTGGCTA (SEQ ID NO. 181)	30234833	30234997
DG13S17	TTTAAGCCCTGTGGAATGTATTT (SEQ ID NO. 182)	GACATTGCAGGTCAAGTAGGG (SEQ ID NO. 183)	30288392	30288544
DG13S306	TGCATAAGGCTGGAGACAGA (SEQ ID NO. 184)	CACAGCAGATGGGAGCAAA (SEQ ID NO. 185)	30404049	30404203
DG13S2486	AGCCAGTTGTCTTCATCCTG (SEQ ID NO. 186)	TGCCTGTGCTTGTATATTCTGTG (SEQ ID NO. 187)	30411508	30411755
DG13S18	GTGCATGTGCATACCAGACC (SEQ ID NO. 188)	GGCAAGATGACCTCTGGAAA (SEQ ID NO. 189)	30456875	30457193
DG13S1062	TTTGTGTTCCAGGTGAGAATTG (SEQ ID NO. 190)	GAACCATATCCCAAGGCACT (SEQ ID NO. 191)	30551596	30551715
DG13S1093	TTGTTCCACATTCACTTCTACA (SEQ ID NO. 192)	TTAAACTCGTGGCAAAGACG (SEQ ID NO. 193)	30625918	30626190
DG13S1059	CACCATGCCTGGCTCTTT (SEQ ID NO. 194)	AACTTCTCCAGTTGTGTGGTTG (SEQ ID NO. 195)	30822917	30823246
D13S171	CCTACCATTGACACTCTCAG (SEQ ID NO. 196)	TAGGGCCATCCATTCT (SEQ ID NO. 197)	31051937	31052167
DG13S2359	TCTGTGTATTGTGTACTCCTCT G (SEQ ID NO. 198)	TCACACAATTTGAACCAATCCT (SEQ ID NO. 199)	31073673	31073849



DG13S1092	ACCAAGATATGAAGGCCAAA (SEQ ID NO. 200)	CCTCCAGCTAGAACAATGTGAA (SEQ ID NO. 201)	31113759	31113934
DG13S2629	TGATCATGTCAGCAGCAGAAAG (SEQ ID NO. 202)	AGTAACAGGTGAGGGCATGG (SEQ ID NO. 203)	31179791	31179953
DG13S1449	TGTCCATAGCTGTAGCCCTGT (SEQ ID NO. 204)	CTCAATGGGCATCTTTAGGC (SEQ ID NO. 205)	31199228	31199498
DG13S312	CAAACAAACAAACAAGCAAACC (SEQ ID NO. 206)	TGGACGTTTCTTTCAGTGAGG (SEQ ID NO. 207)	31280202	31280550
DG13S1511	TGATAACTTACCAGCATGTGAGC (SEQ ID NO. 208)	TCACCTCACCTAAGGATCTGC (SEQ ID NO. 209)	31321562	31321854
DG13S2454	GCTAGCAAATCTCTCAACTTCCA (SEQ ID NO. 210)	TCTTCTCCATGCTGCTTCCT (SEQ ID NO. 211)	31352662	31352803
DG13S314	CATGCAATTGCCCAATAGAG (SEQ ID NO. 212)	TTGGGCTTGTCTACCTAGTTCA (SEQ ID NO. 213)	31379760	31380086
DG13S1071	GCTGCACGTATTTGTTGGTG (SEQ ID NO. 214)	AAACAGCAGAAATGGGAACC (SEQ ID NO. 215)	31447431	31447669
DG13S1068	CCGTGGGCTATCAATTCTG (SEQ ID NO. 216)	AAGATGCAATCTGGTTTCCAA (SEQ ID NO. 217)	31553333	31553570
DG13S1077	CCCAAGACTGAGGAGGTCAA (SEQ ID NO. 218)	GCTGACGGAGAGGAAAGAGA (SEQ ID NO. 219)	31569360	31569733
DG13S2343	TCACAAAGCAAGCAATCACA (SEQ ID NO. 220)	TGATGGATGCACCATGTTTA (SEQ ID NO. 221)	31653489	31653608
DG13S316	TGAGAAGCCTGGGCATTAAG (SEQ ID NO. 222)	ACAAGCTCATCCAGGGAAAG (SEQ ID NO. 223)	31708002	31708244
DG13S1558	AGAGCTGATCTGGCCGAAG (SEQ ID NO. 224)	GGTGGACACAGAATCCACACT (SEQ ID NO. 225)	31986248	31986627
D13S267	GGCCTGAAAGGTATCCTC (SEQ ID NO. 226)	TCCCACCATAAGCACAAAG (SEQ ID NO. 227)	32062233	32062380
DG13S1478	TCAACCTAGGATTGGCATTACA (SEQ ID NO. 228)	TCTAGGATTTGTGCCTTTCCA (SEQ ID NO. 229)	32157761	32158137
DG13S1551	ATTCGTGCAGCTGTTTCTGC (SEQ ID NO. 230)	GCATGACATTGTAATGGAGGA (SEQ ID NO. 231)	32364898	32365153
DG13S1884	GGTGGGAATGTGTGACTGAA (SEQ ID NO. 232)	CCAGGTACAACATTCTCCTGAT (SEQ ID NO. 233)	32451203	32451315
D13S1293	TGCAGGTGGGAGTCAA (SEQ ID NO. 234)	AAATAACAAGAGTGACCTTCCT A (SEQ ID NO. 235)	32536337	32536467
DG13S1518	AAAGGATGCATTGGTTAGAG (SEQ ID NO. 236)	ACTGTCCTGTGCCTGTGCTT (SEQ ID NO. 237)	32588965	32589321
D13S620	GTCCACCTAATGGCTCATTC (SEQ ID NO. 238)	CAAGAAGCACTCATGTTTGTG (SEQ ID NO. 239)	32627749	32627947
DG13S1866	AGCCTGTGATTGGCTGAGA (SEQ ID NO. 240)	GGCTTACAGCTGCCTCCTTT (SEQ ID NO. 241)	32633306	32633709
DG13S1927	CCCACAGGCACTTTGTTAGA (SEQ ID NO. 242)	GCCTCCCTTAAGCTGTTATGC (SEQ ID NO. 243)	32691932	32692304
DG13S1503	CACTCTTACTGCCAATCACTCC (SEQ ID NO. 244)	GCCGTGTGGGTGTATGAAT (SEQ ID NO. 245)	32699827	32700058
DG13S332	TTGTACCAGGAACCAAGACAA (SEQ ID NO. 246)	CACAGACAGAGGCACATTGA (SEQ ID NO. 247)	32764576	32764751
DG13S333	GCTCTGGTCACTCCTGCTGT (SEQ ID NO. 248)	CATGCCTGGCTGATTGTTT (SEQ ID NO. 249)	32872275	32872720
D13S220	CCAACATCGGGAAGTCTG (SEQ ID NO. 250)	TGCATTCTTTAAGTCCATGTC (SEQ ID NO. 251)	32967602	32967793
DG13S1919	CAGCAACTGACAATCATCCA (SEQ ID NO. 252)	CCTCAATCCTCAGCTCCAAC (SEQ ID NO. 253)	33014255	33014477
DG13S2383	TGATTGGTTCTGTTGTTGCTG (SEQ ID NO. 254)	AGCCCAAGGCTCTTGTGAG (SEQ ID NO. 255)	33053369	33053553
DG13S1439	TCCTTCACAGCTTCAAACCTCA (SEQ ID NO. 256)	AGTGAGAAGCTTCCATACTGGT (SEQ ID NO. 257)	33070030	33070264
DG13S335	GCCAACCGTTAGACAAATGA (SEQ ID NO. 258)	CTACATGTGCACCACAACACC (SEQ ID NO. 259)	33102278	33102478
DG13S340	AGTTTATTGCCGCCGAGAG (SEQ ID NO. 260)	ACCCACCACATTCACAAGC (SEQ ID NO. 261)	33124866	33125238
DG13S1496	CGATTGCCATGTCTCTTTGA (SEQ ID NO. 262)	GAGATCTGGCCTGGATTTGT (SEQ ID NO. 263)	33215915	33216066
DG13S347	TCATTGTGTCAGCACAGAATGAACT (SEQ ID NO. 264)	GGAGGGAGGGGAAGAAAGAGA (SEQ ID NO. 265)	33280351	33280688
DG13S339	GGGAAGAGGAGATTGACTTGT (SEQ ID NO. 266)	GGAACACCATCATTCACAACC (SEQ ID NO. 267)	33352425	33352656
DG13S1926	TACAAGCTCCACCGTCCTTC (SEQ ID NO. 268)	TGAGTTGCTGCCTCTTCAAA (SEQ ID NO. 269)	33388692	33388919

DG13S1469	TGCTAATGGGCCAAGGAATA (SEQ ID NO. 270)	GCTAAATGTCCTCATGAATAGCC (SEQ ID NO. 271)	33416571	33416940
DG13S351	TGTCCTGCAGACAGATGGTC (SEQ ID NO. 272)	CCTCCGGAGTAGCTGGATTA (SEQ ID NO. 273)	33497762	33498055
DG13S26	GAGACTGGCCCTCATTCTTG (SEQ ID NO. 274)	AAGAAGCCAGAGACAAAGAAATA CA (SEQ ID NO. 275)	33584096	33584425
DG13S30	CATCTATCTTTGGATTCACTGGTG (SEQ ID NO. 276)	TGCTCCCAACATCTTACCAG (SEQ ID NO. 277)	33731684	33732071
DG13S1435	TGTCCTCTGGTCATTTCTATGGT (SEQ ID NO. 278)	CATGAATGAGAAGTGATGAATGG (SEQ ID NO. 279)	33762069	33762285
DG13S356	CAGACACTGTAACTGGCTTCG (SEQ ID NO. 280)	GCCACATTGCTATCAGCGTA (SEQ ID NO. 281)	33908746	33908957
DG13S2316	ATGTGCTGTGGTCCAGATTT (SEQ ID NO. 282)	CCTACTACTGCAATTACTCCCTAC C (SEQ ID NO. 283)	33913787	33913954
DG13S357	TGTCATAGGCTTGCGGTATTT (SEQ ID NO. 284)	TTGGTAGGGTCTTTTCCTTT (SEQ ID NO. 285)	33935177	33935378
DG13S1032	GCCTGCTCACTGTTGTTTGA (SEQ ID NO. 286)	CGGTTATCAGAGACTGGTGGT (SEQ ID NO. 287)	33967059	33967269
DG13S1557	GGCTTATTCATGTACGGCTA (SEQ ID NO. 288)	GGTTAACTCTACTTAGTCCTGAT GC (SEQ ID NO. 289)	33996100	33996249
DG13S1925	GAACCTCTGCAGGCACCTCTT (SEQ ID NO. 290)	CCTGAAGCGCTTGACTGAA (SEQ ID NO. 291)	34079148	34079570
DG13S360	TTGGCTTCTCGCTCTTTCTT (SEQ ID NO. 292)	AGCCATCAGTCACATGCAAA (SEQ ID NO. 293)	34138872	34139221
DG13S1522	AGATCTCCAGGGCAGAGGAC (SEQ ID NO. 294)	CCTTCCTCCCTCCTTCTCTC (SEQ ID NO. 295)	34195314	34195659
DG13S2324	CAGTCAAATGTCTAACCTTCC (SEQ ID NO. 296)	CTAGCAACATGGCCAAAGAA (SEQ ID NO. 297)	34224040	34224206
DG13S1517	CGTCATTGATCCCAATCATCT (SEQ ID NO. 298)	GGCTGATAGCCTCCCTTGTA (SEQ ID NO. 299)	34271358	34271587
DG13S364	ACCTTTCAAGCTTCCGGTTT (SEQ ID NO. 300)	TTCCATCCGTCCATCTATCC (SEQ ID NO. 301)	34323307	34323478
DG13S1036	TTAAAGTCACCTGTCTGTGGTCA (SEQ ID NO. 302)	TTTGTAGGAATCAAGTCAAATAAT GTA (SEQ ID NO. 303)	34525065	34525280
DG13S1037	CTTTCGGAAGCTTGAGCCTA (SEQ ID NO. 304)	CCCAAGACCACTGCCATATT (SEQ ID NO. 305)	34616658	34616926
DG13S1854	TGACAGGTTTGGGTATATTGGA (SEQ ID NO. 306)	TGCTTAATGTAGTGGCAGCA (SEQ ID NO. 307)	34622055	34622151
DG13S1038	TCCTGCCTTTGTGAATTCCT (SEQ ID NO. 308)	GTTGAATGAGGTGGGCATTA (SEQ ID NO. 309)	34702405	34702738
DG13S2366	TTGGGAATAAATCAGGTGTTGA (SEQ ID NO. 310)	GCAGCAGCTCAGCATTTCTC (SEQ ID NO. 311)	34735455	34735583
DG13S1039	CCATTTAATCCTCCAGCCATT (SEQ ID NO. 312)	GCTCCACCTTGTACCCTGA (SEQ ID NO. 313)	34743651	34743817
DG13S1840	ACAACCCTGGAATCTGGACT (SEQ ID NO. 314)	GAAGGAAAGGAAAGGAAAGAAA (SEQ ID NO. 315)	34805466	34805682
DG13S369	TGACAAGACTGAACTTCATCAG (SEQ ID NO. 316)	GATGCTTGCTTTGGGAGGTA (SEQ ID NO. 317)	34815499	34815755
DG13S2481	CAGGTTAGAGCCCATCCAAG (SEQ ID NO. 318)	AGGCTCAGCTTCATCCACAT (SEQ ID NO. 319)	34867728	34867872
D13S219	AAGCAAATATGCAAAATTGC (SEQ ID NO. 320)	TCCTTCTGTTTCTTGACTTAACA (SEQ ID NO. 321)	34956581	34956707
DG13S2351	GGGAACAGGTCACAGGTCAT (SEQ ID NO. 322)	GGAAGACTGGGTGGTCACAG (SEQ ID NO. 323)	35099146	35099320
DG13S384	TTCTTCTGCTTGTGAGCTG (SEQ ID NO. 324)	TACCCTCACCTTCTCATGC (SEQ ID NO. 325)	35499548	35499763
DG13S1507	GAAGACATTGGCAGGTCTGG (SEQ ID NO. 326)	GAGCCCTCATGTGGGATAA (SEQ ID NO. 327)	35557977	35558206
DG13S1512	TTGTTGATTCTCCATTCTGTG (SEQ ID NO. 328)	TCACCTACCTCATCTCATACTCAA A (SEQ ID NO. 329)	35668964	35669201
DG13S1556	TCTTCCGGACAAGTTTCAA (SEQ ID NO. 330)	TGGGTCAATCTGGACATTCA (SEQ ID NO. 331)	35791215	35791467
DG13S388	GCAAATGAGGCTGGTAAGGT (SEQ ID NO. 332)	TGCACTGTGGTAGAGGGAAA (SEQ ID NO. 333)	35817061	35817320
DG13S1442	CAACATACTCCTATGCCTAGAAA GAAA (SEQ ID NO. 334)	CTCACCAGGCAGAAACAGGT (SEQ ID NO. 335)	35842967	35843335
DG13S1045	CCCAATGGCATGCTTCACT (SEQ ID NO. 336)	GGTCTCCAGCATTTGGTT (SEQ ID NO. 337)	35928180	35928324
DG13S2452	AAGGCCTCTGGGTAGGTAGG (SEQ ID NO. 338)	AAGCAATCCTTATGGGCTCT (SEQ ID NO. 339)	35948528	35948826

DG13S2350	CCAGGTAATCAGAAGCCTCA (SEQ ID NO. 340)	TTCCGTTAAATCCAGCCATC (SEQ ID NO. 341)	36011840	36011961
DG13S2483	CAGGGACTGCAGTGTCTCAA (SEQ ID NO. 342)	ATGCCACATTGCGCTCTCTC (SEQ ID NO. 343)	36027396	36027703
DG13S1100	CCACCTTCCACTTAATACAAACT TC (SEQ ID NO. 344)	GAAGCAATCCATTCCAAGAAA (SEQ ID NO. 345)	36056838	36057115
DG13S1501	GTCCTGAGGGTGTCCAGGTA (SEQ ID NO. 346)	GCTGGAGAACTCCTATTCTGCT (SEQ ID NO. 347)	36215761	36215909
DG13S1868	TGGAGCTATTGCGGTTCTCT (SEQ ID NO. 348)	TCAAATCTCTCTTTCCTCCTCT (SEQ ID NO. 349)	36313203	36313417
DG13S395	CAGTTCCAGCTACGGGAGAA (SEQ ID NO. 350)	CCGCATTTAGGCAAGTCTCA (SEQ ID NO. 351)	36317151	36317507
D13S1491	AAGCACACACAGATGCTAGG (SEQ ID NO. 352)	CCTCAGCCTCCATAATCTCA (SEQ ID NO. 353)	36361442	36361571
DG13S400	GTACAGAGCCACCTTCTGG (SEQ ID NO. 354)	TCACTATGCTGCAAGGCAAG (SEQ ID NO. 355)	36369862	36370134
D13S894	GGTGCTTGCTGTAAATATAATTG (SEQ ID NO. 356)	CACTACAGCAGATTGCACCA (SEQ ID NO. 357)	36536509	36536706
D13S218	GATTGAAAATGAGCAGTCC (SEQ ID NO. 358)	GTCGGGCACTACGTTTATCT (SEQ ID NO. 359)	36830331	36830519
DG13S1553	TGGGTGAAGATGCTACCTGA (SEQ ID NO. 360)	CCCTTCTCTCTTTCCTCTCTC (SEQ ID NO. 361)	36898814	36899040
DG13S411	TGCCAGGTCTGAGTTGTAAGC (SEQ ID NO. 362)	CAGCATGAGACCCTGTCAAA (SEQ ID NO. 363)	36908058	36908265
DG13S1870	GAAAGAAAGAAAGAAAGAAAGAA AGAAA (SEQ ID NO. 364)	AATCACCAAACCTGGAAGCA (SEQ ID NO. 365)	36927423	36927632
DG13S1870	GAAAGAAAGAAAGAAAGAAAGAA AGAAA (SEQ ID NO. 366)	AATCACCAAACCTGGAAGCA (SEQ ID NO. 367)	36927485	36927632
DG13S39	TCTGAGTTAAACACTTGAGTTGC TG (SEQ ID NO. 368)	CCAGTAAATGGCAGTGTGGTT (SEQ ID NO. 369)	36957292	36957640
DG13S2415	TGTCATGGATATTTCTACATAAA CCAA (SEQ ID NO. 370)	TGAAGATGGTTATTGCTTCCTTC (SEQ ID NO. 371)	36984719	36984955
DG13S412	CGCTTTGTTTGGTTTGGTTT (SEQ ID NO. 372)	ATGCAGTTGTCCCATGCT (SEQ ID NO. 373)	37036929	37037137
DG13S414	TCCTGCACTCCAAAGGAAAC (SEQ ID NO. 374)	AACTCTGGTTTAATTCAGCTTGT C (SEQ ID NO. 375)	37047489	37047713
DG13S1872	TTCTTGAGGGCATAAAGCTGA (SEQ ID NO. 376)	CACACTCACCAGGCACTCTG (SEQ ID NO. 377)	37119505	37119608
DG13S416	CAGGTTTGATGAAGGAAATATGC (SEQ ID NO. 378)	GGGATCCTCTGCATTCTCTAA (SEQ ID NO. 379)	37125983	37126184
DG13S2607	TTTGCCAAATCAACCTTCAG (SEQ ID NO. 380)	CCTGCTTCACACCTCTGACC (SEQ ID NO. 381)	37317455	37317831
DG13S1898	ACTCACACACAACCACCACA (SEQ ID NO. 382)	GCTACTGGTGGGTCGTAAGC (SEQ ID NO. 383)	37318932	37319055
D13S1288	TTCAGAGACCATCACGGC (SEQ ID NO. 384)	CTGGAAAAATCAGTTGAATCCTA GC (SEQ ID NO. 385)	37321295	37321486
DG13S2567	AGGAAAGCCGAGAAAGCATA (SEQ ID NO. 386)	CATGTATCCACATGCCGAGA (SEQ ID NO. 387)	37416093	37416462
DG13S418	CCTTCAGCGCAGCTACATCT (SEQ ID NO. 388)	AGAACTGCGAGGTCCAAGTG (SEQ ID NO. 389)	37473016	37473380
DG13S419	GGGAGAAAGAGAGGTAGGAAGG (SEQ ID NO. 390)	TTCCCAAGTTAGCAGCATCC (SEQ ID NO. 391)	37532947	37533123
DG13S1051	TTCTAGAGGAGTCTATTTCTTTAC TGG (SEQ ID NO. 392)	GGAGCTGTCATTGAGCTTTG (SEQ ID NO. 393)	37694432	37694579
DG13S1841	CCGTGACCTACAGGGAACAT (SEQ ID NO. 394)	GGCATCGGGTGTCTCTATTC (SEQ ID NO. 395)	37715601	37715829
DG13S1052	AGACCTGCCTGTGTCTGGT (SEQ ID NO. 396)	GGAGTGAAATAAGTGGAAGTGA (SEQ ID NO. 397)	37831275	37831438
DG13S1053	CATTAAATGAGTCATAAAGGTCA TGG (SEQ ID NO. 398)	AACATTGTTGCTTTGCTGGA (SEQ ID NO. 399)	37935190	37935311
DG13S423	GGCCTTAGCTCAGTTTCTGG (SEQ ID NO. 400)	TGCAAAGACATTTGCGGATA (SEQ ID NO. 401)	37941221	37941411
D13S1253	CCTGCATTGTGTACGTGT (SEQ ID NO. 402)	CAGAGCCGTGGTAGTATATTTT (SEQ ID NO. 403)	37944396	37944533
DG13S2539	GGAACCAAGTCATTTGGGTGT (SEQ ID NO. 404)	TTATTGCTCCCTCGTCCAAG (SEQ ID NO. 405)	38050898	38051253
DG13S2509	TGCCTTAAGGTCTATTATTTCTT TC (SEQ ID NO. 406)	ACCAATGCAGGAAGACTCAA (SEQ ID NO. 407)	38067039	38067186
DG13S1863	CTGATGAAAGGACACACATGC (SEQ ID NO. 408)	TGCATTAACATGCAGCTTGAAA (SEQ ID NO. 409)	38092085	38092353

DG13S2510	GTCGTGCAATCCCGAGAG (SEQ ID NO. 410)	GGATTCCTGCTGGCTCTTCT (SEQ ID NO. 411)	38197807	38198059
DG13S1909	CTGGTGTGGTCAGGAAATGA (SEQ ID NO. 412)	GTGCTAAACACATGTGAGTGAGA G (SEQ ID NO. 413)	38309328	38309442
DG13S428	TTTGACCATGCTTTCTCTTTGA (SEQ ID NO. 414)	GCTTGATGACTCCCTGCTGT (SEQ ID NO. 415)	38346716	38347069
DG13S1858	AAGCCATTGAAAGGCAGGTA (SEQ ID NO. 416)	GGGACTTTCCGGCTTCTATT (SEQ ID NO. 417)	38371574	38371742
DG13S1911	GGTTTGGGAACCATTCCT (SEQ ID NO. 418)	GCAGAGAAGGGATTTACTCCAG (SEQ ID NO. 419)	38475656	38475877
DG13S433	ACTTGACATGGAGCAAGCTG (SEQ ID NO. 420)	AGCTCATCATGCTGTAAGGAG (SEQ ID NO. 421)	38516056	38516191
DG13S2421	CACAGGCTCTCACATTCTCG (SEQ ID NO. 422)	TGACACTCATCCCTCTGCTG (SEQ ID NO. 423)	38534972	38535357
DG13S2375	TGAGTTTCATAAGTTTACTACCTG CTG (SEQ ID NO. 424)	GGCAGGGAGAAAGGACAAAT (SEQ ID NO. 425)	38548257	38548440
D13S1248	TCCCTTATGTGGGATTAGTTGA (SEQ ID NO. 426)	CAGACATGGAAGTGAATTTTT (SEQ ID NO. 427)	38558005	38558267
DG13S1856	TGTTCATCTCTACCCATGT (SEQ ID NO. 428)	TCAATGTTCTTATTGAGTGGGAAA (SEQ ID NO. 429)	38577323	38577506
DG13S435	ATATCCACCCACCCACACAT (SEQ ID NO. 430)	TAGCTCTGAGGGCAGAGACC (SEQ ID NO. 431)	38591043	38591261
DG13S2459	CCGTCTTCCTCCACTGAT (SEQ ID NO. 432)	AGAGCACTGAGGGAGCAAAAT (SEQ ID NO. 433)	38596056	38596299
DG13S438	AGCTACAGCAGGAGGCAGTT (SEQ ID NO. 434)	TTTGAATTGAGTTGCTGTTTCG (SEQ ID NO. 435)	38676957	38677248
DG13S1865	TGTACACCACCAACCATCTG (SEQ ID NO. 436)	GGGAAGAAAGGCAAAATAGCA (SEQ ID NO. 437)	38684800	38684904
DG13S2354	GGATTGGCAATTAGCAGGTC (SEQ ID NO. 438)	GCCTGGTCAAAGATAACAGACG (SEQ ID NO. 439)	38773862	38774026
DG13S2534	CCTGATTAAGCTGGCCTTTG (SEQ ID NO. 440)	ATCCTTCTGGGACCCTCATC (SEQ ID NO. 441)	38801698	38801951
DG13S1903	GCTTTGCTTCCTTCTTGGTG (SEQ ID NO. 442)	CAACATTACGGCCAGTCTCA (SEQ ID NO. 443)	38802843	38803052
DG13S1896	GGTGCATCTGATAAGCCAAA (SEQ ID NO. 444)	GCTGTCTTGGACACAGTGGA (SEQ ID NO. 445)	38815291	38815405
DG13S443	CACCATCATCATCTGTTGG (SEQ ID NO. 446)	GAGCTCATTGAAAGGCAGGA (SEQ ID NO. 447)	38838839	38839093
DG13S445	CCATCCATCTATCCATTTATCTCT G (SEQ ID NO. 448)	GGATTTATCCTTGCCCTGCT (SEQ ID NO. 449)	38840399	38840584
DG13S447	CTATCATCCATCCATCCTATTG (SEQ ID NO. 450)	TTAGGGCAGCTACCTGGAAA (SEQ ID NO. 451)	38840751	38840928
D13S1233	AGGACTANAGATGAATGCTC (SEQ ID NO. 452)	GACATGACTCCATGTTTGGT (SEQ ID NO. 453)	38875108	38875292
DG13S2320	CCTCACCTTGCAATTCCTG (SEQ ID NO. 454)	CTGACTTGCTGTGTCGATA (SEQ ID NO. 455)	38957405	38957570
DG13S451	TTTGGGATCTTGAAGACCTTT (SEQ ID NO. 456)	TTGTGGCATGTCCTTGGTT (SEQ ID NO. 457)	39032835	39033191
DG13S180	TGTACACTGCAAACATTGCTAAA (SEQ ID NO. 458)	TTGTCCTTICATTATGACGTGTCT (SEQ ID NO. 459)	39233968	39234350
DG13S458	AAGCCTGAAAGGATACACAA A (SEQ ID NO. 460)	CAGGATCCCAGACTTTCCAG (SEQ ID NO. 461)	39475899	39476187
DG13S2547	GGTGAATCCCACCCTCATAC (SEQ ID NO. 462)	TGGTATGTTTCTATTGTTGCAT (SEQ ID NO. 463)	39612492	39612849
D13S244	GAACCACTGAGTTTTTATTAC (SEQ ID NO. 464)	AGACACAGCATATAATACATG (SEQ ID NO. 465)	39665226	39665353
DG13S2435	TGAAGCTTTGTGGCTTGTG (SEQ ID NO. 466)	GACTGAGTCCACAGCCCAT (SEQ ID NO. 467)	39863067	39863301
D13S263	CCTGGCCTGTAGTTTTTATTGTT A (SEQ ID NO. 468)	CCCAGTCTGGGTATGTTTTTA (SEQ ID NO. 469)	39878976	39879126
DG13S188	CCACCATGCAAGAAGAGATG (SEQ ID NO. 470)	GCTTTGCACTTGGCTGTCTT (SEQ ID NO. 471)	39935769	39936103
DG13S189	TTGCATGAAGTAAAGTATCCCTG T (SEQ ID NO. 472)	CACAAACCACAAGATGATTGG (SEQ ID NO. 473)	39968676	39969030
DG13S190	GGGCATCATGTCTACAACTCA (SEQ ID NO. 474)	ACCAAGGGCAGTTGCTGATA (SEQ ID NO. 475)	40027542	40027801
DG13S2370	AGGATGAAGAGGGAGGAAGG (SEQ ID NO. 476)	CCAGACTGATCTTCCTTAATTAGT TG (SEQ ID NO. 477)	40159684	40159812
DG13S196	CCTCCTCTTCTGCTGCTGT (SEQ ID NO. 478)	AGCCAAAGAACCCTAAAGAAAC (SEQ ID NO. 479)	40251445	40251793

DG13S2457	GCCCTACTTTGCCTCAGAAA (SEQ ID NO. 480)	GCAACTCATGCCAGCCTCTA (SEQ ID NO. 481)	40376042	40376447
DG13S2445	AACTGTGTTAATGATGGGCAAA (SEQ ID NO. 482)	AACGAGCGCATGAAACCTAT (SEQ ID NO. 483)	40422793	40423200
DG13S211	CCTGGTCAATTGAACCCAAA (SEQ ID NO. 484)	TGAAGGAAGATAAAGCAGGGTAA (SEQ ID NO. 485)	40434073	40434172
DG13S472	CTCTCTCTGGCCCTCTCTTG (SEQ ID NO. 486)	GGTAACCTGCCATTCTTCTACCA (SEQ ID NO. 487)	40476985	40477395
DG13S207	ACTCCACCTGAAGGGAGAAA (SEQ ID NO. 488)	TGGAAGCCACTAATTGGAGAA (SEQ ID NO. 489)	40545942	40546202
DG13S200	AATGGATGGATACCTCCTTATCA (SEQ ID NO. 490)	CTCATTGTGGCTTTCTGTGC (SEQ ID NO. 491)	40737337	40737570
DG13S198	GTACCCACACCTACCAAGC (SEQ ID NO. 492)	CGTAGCTCACATTCCCAACA (SEQ ID NO. 493)	40811813	40812059
DG13S215	GGCGAGTGAAAGAGAGGACA (SEQ ID NO. 494)	GGGTGGTAATCCCAGATGA (SEQ ID NO. 495)	40871695	40871992
DG13S221	TCTGCAACAGCCAGAATCAA (SEQ ID NO. 496)	TGTCTGTTGGCAACTTTCTGTC (SEQ ID NO. 497)	41107773	41108117
DG13S219	AGGTGAACCCAGTCCAGCTA (SEQ ID NO. 498)	TCTTAGGCAAAGGAGCCAGT (SEQ ID NO. 499)	41127591	41127734
D13S1270	ACATGAGCACTGGTGACTG (SEQ ID NO. 500)	GGCCTCAAATGTTTAAGCA (SEQ ID NO. 501)	41161654	41161831
DG13S225	TTCTGGGTGTTGCTATTCC (SEQ ID NO. 502)	TTTCCTGTCCAGTCCTGACC (SEQ ID NO. 503)	41212951	41213310
D13S1276	GTTTTGCAGGTCTAGGTCACAC (SEQ ID NO. 504)	AGGATAGCTTGAGCCCG (SEQ ID NO. 505)	41213917	41214090

All references cited herein are incorporated by reference in their entirety.

While this invention has been particularly shown and described with references to preferred embodiments thereof, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the scope of the invention encompassed by the appended claims.

#### EXAMPLE 10: RANDOMIZED, PLACEBO-CONTROLLED, CROSSOVER CLINICAL TRIAL DEMONSTRATES INHIBITION OF FLAP REDUCED BIOMARKERS OF RISK OF MYOCARDIAL INFARCTION.

The 5-lipoxygenase pathway, through FLAP, leads to the production of leukotriene B<sub>4</sub>, one of the most potent chemokine mediators of arterial inflammation. The experiments described in Example 7 showed that MI patients make more LTB<sub>4</sub> than do controls. Hence, it appears that the at-risk variant upregulates the leukotriene pathway. A clinical trial was carried out to demonstrate that patients with the genetic variation in FLAP that predisposes to MI could benefit from inhibiting FLAP, with the FLAP inhibitor DG-031. In the short term study, changes in levels of biomarkers that are associated with risk of MI were scored as evidence of changes in the risk of MI.

### Patient Population

All patients in the study had a history of MI and were carriers of specific MI-associated haplotypes in the FLAP and/or the LTA<sub>4</sub> hydrolase genes (See U.S. Patent Application No. 10/944,272 and PCT Application No. PCT/2004/030582, incorporated by reference in its entirety. The recruitment process included individuals who had previously participated in a study of the genetics of MI (Helgadóttir *et al.*, Nat. Genet. 2004;36(3):233-9. 2004). Apart from FLAP, the LTA<sub>4</sub> hydrolase gene also shows significant association to MI in Iceland and baseline mRNA expression of the LTA<sub>4</sub> hydrolase gene is greater in MI patients than in control subjects; that is subjects with at-risk variants in either the FLAP or LTA<sub>4</sub> hydrolase genes are at increased risk of sustaining MI. Thus, carriers of either the FLAP or LTA<sub>4</sub> hydrolase at-risk haplotypes were recruited and their haplotypes were confirmed by analysis of DNA from blood sample collected in the study.

Nine Single Nucleotide Polymorphism (SNP) markers were genotyped to define the at-risk haplotypes. These SP markers are set out in Table 25 below and are described in detail in Example 1. SNPs genotyping within the FLAP and LTA<sub>4</sub> hydrolase genes was performed using SNP-based Taqman platform (ABI) as described in Helgadóttir *et al.*, 2004 Mar;36(3):233-9. The haplotypes carried by each individual were estimated using the program NEMO (version 1.01) and 902 in-house population controls, as described in Gretarsdóttir *et al.*, Nat Genet 2003; 35:131-8.

**Table 25** Genotypes used to derive FLAP and LTA<sub>4</sub> hydrolase at-risk haplotypes.

	Haplotype	Allele	SNP	Allele	SNP	Allele	SNP
1	A3 (FLAP gene)	G	SG13S25	T	SG13S114	A	SG13S32
2	AF (FLAP gene)	G	SG13S25	T	SG13S114		
3	NA3 (FLAP gene)	A	SG13S122	C	SG13S32	C	SG13S8
4	HF (LTA <sub>4</sub> -OH gene)	A	SG12S25	C	SG12S223		
5	GF (LTA <sub>4</sub> -OH gene)	A	SG12S225	T	SG12S233		

The recruits were asked for permission for the use of their medical and genetic information already collected at deCODE genetics (Reykjavik, Iceland) for the clinical trial. Of over 900 patients identified as eligible by clinical and genotypic criteria, 640 returned their signed consent providing permission to use their genetic and medical data. The genotypes for the FLAP and LTA<sub>4</sub> hydrolase genes were

subsequently reconfirmed, and those who were carriers of variants in the FLAP and/or LTA<sub>4</sub> hydrolase genes were judged eligible for the study if they also met the other inclusion criteria and none of the exclusion criteria set out in Table 26. The baseline characteristics of the patients participating in the study are set out in Table 27. All patients who participated gave informed consent and the protocol was approved by the National Bioethics Committee in Iceland.

**Table 26** Study eligibility criteria.

Inclusion criteria	
	Age 40 to 75.
	Carrier of the FLAP and/or the LTA <sub>4</sub> hydrolase haplotype
	Documented CAD with previous history of MI
	Women of childbearing potential must have a negative urine pregnancy test at visit 1 and are required to use 2 adequate barrier methods of contraception throughout the study.
	Understanding of the study procedures and agreement to participate in the study by giving written informed consent.
Exclusion criteria	
	Confirmed diagnosis of congestive heart failure (CHF).
	Any experimental treatment within 2 months of screening or planned for the following 3 months.
	Acute CV event (such as ACS, MI or stroke) within 1 month prior to enrolment.
	Elevated CPK above 3 fold upper normal limit (UNL). Other liver function tests and kidney function tests above 1.5 fold upper normal limit.
	Immunocompromised subjects, including subjects known to be HIV positive or with malignant disease and/or on chronic immunosuppressive therapy.
	Subjects known to have positive serology results for HBsAg, HCV Ab.
	Treatment with immunosuppressive cytotoxic drugs or corticosteroids within 6 weeks or during conduct of study.
	Major surgery within 6 weeks prior to enrolment.
	Any other major intercurrent illness and other condition, which, in the investigator's judgement, will interfere with the subject's participation in this study.
	Subjects not willing to return for follow-up or with known history of non-compliance.
	Patients who consume more than 2 alcoholic drinks/day or ≥10 drinks/week, or history of alcohol abuse within the past 2 years. Patients must agree to comply with the restrictions on alcohol (≤2 drinks/day and <10 drinks/week and no alcohol intake within 48 hours of study visits).
	Pregnant or lactating women.
	Poor mental function or any other reason to expect patient difficulty in complying with the requirements of the study.

**Table 27.** Baseline characteristics of the study cohort.

Characteristic	250 mg/day		500 mg/day		750 mg/day	
	Active-placebo (n=32)	Placebo-active (n=32)	Active-placebo (n=32)	Placebo-active (n=32)	Active-placebo (n=32)	Placebo-active (n=31)
<b>Demography</b>						
Male/Female	24/8	24/8	24/8	24/8	24/8	24/7
Age (SD), years	66 (8)	66 (8)	65 (7)	67 (7)	64 (8)	67 (7)
Age range, years	47-75	47-75	51-75	52-75	47-75	56-75
Age > 60 years, %	78%	75%	78%	78%	69%	74%
Weight (SD), kg	86 (11)	87 (12)	86 (14)	92 (18)	91 (13)	93 (19)
Height (SD), cm	173 (8)	174 (7)	173 (8)	174 (9)	174 (7)	173 (10)
BMI (SD), kg/m <sup>2</sup>	29 (3)	29 (3)	29 (4)	30 (6)	30 (4)	31 (5)
<b>Cardiovascular history</b>						
Two or more prev. infarcts	3 (9%)	6 (19%)	3 (9%)	7 (22%)	6 (19%)	8 (26%)
Time since last MI (mo's)	146 (63)	137 (73)	143 (65)	121 (68)	129 (71)	131 (59)
Hypertension (current)	5 (16%)	10 (31%)	4 (12%)	4 (12%)	8 (25%)	7 (23%)
Diabetes	10 (31%)	8 (25%)	6 (19%)	12 (38%)	8 (25%)	10 (32%)
<b>Haplotype frequency</b>						
A3 carrier (FLAP)	8 (25%)	7 (22%)	8 (25%)	5 (16%)	11 (34%)	13 (42%)
AF carrier (FLAP)*	29 (91%)	27 (84%)	28 (88%)	28 (88%)	28 (88%)	26 (84%)
NA3 carrier (FLAP)	5 (16%)	5 (16%)	4 (12%)	3 (9%)	3 (9%)	0 (0%)
HF carrier (LTA <sub>4</sub> -OH)	13 (41%)	18 (56%)	19 (59%)	22 (69%)	13 (41%)	20 (65%)
GF carrier (LTA <sub>4</sub> -OH)	3 (9%)	9 (28%)	5 (16%)	6 (19%)	7 (22%)	3 (10%)
NA3/A3 & HF/GF carrier	11 (34%)	12 (38%)	9 (28%)	15 (47%)	9 (28%)	14 (45%)
<b>Relevant medication</b>						
Statins (%)	27 (84%)	28 (88%)	26 (81%)	28 (88%)	25 (78%)	27 (87%)
Other chol'l low'ng drug (%)	0 (0%)	0 (0%)	3 (9%)	1 (3%)	1 (3%)	1 (3%)
Aspirin (%)	28 (88%)	28 (88%)	28 (88%)	25 (78%)	27 (84%)	26 (84%)
Nitrates (%)	13 (41%)	12 (38%)	10 (31%)	8 (25%)	8 (25%)	12 (39%)
Ca-channel blockers (%)	9 (28%)	6 (19%)	9 (28%)	7 (22%)	7 (22%)	8 (26%)
ACE-inhibitors (%)	7 (22%)	10 (31%)	12 (38%)	10 (31%)	10 (31%)	13 (42%)
Beta-blockers (%)	22 (69%)	23 (72%)	23 (72%)	18 (56%)	24 (75%)	22 (71%)
Diuretics (%)	9 (28%)	13 (41%)	7 (22%)	7 (22%)	11 (34%)	9 (29%)
<b>Plasma lipids</b>						
Cholesterol (SD), mmol/L	5.0 (1.0)	5.0 (0.8)	5.2 (1.0)	4.8 (1.1)	5.2 (1.2)	5.0 (1.0)
HDL (SD), mmol/L	1.4 (0.3)	1.4 (0.3)	1.5 (0.3)	1.4 (0.5)	1.4 (0.4)	1.4 (0.3)
LDL (SD), mmol/L	3.0 (1.0)	3.0 (0.7)	3.1 (1.0)	2.9 (1.0)	3.2 (1.0)	3.0 (0.9)
Triglycerides (SD), mmol/L	1.4 (0.8)	1.5 (0.7)	1.7 (1.6)	1.3 (0.7)	1.4 (0.7)	1.4 (0.6)
<b>Blood pressure</b>						
Diastolic (SD), mmHg	79 (8)	78 (7)	81 (11)	79 (9)	78 (12)	78 (7)
Systolic (SD), mmHg	137 (13)	133 (19)	139 (22)	136 (17)	141 (22)	140 (17)
<b>Smoking habits</b>						
Never smoked	9 (28%)	4 (13%)	5 (16%)	3 (9%)	8 (25%)	7 (23%)
Prior history of smoking	18 (56%)	20 (63%)	19 (59%)	24 (75%)	19 (59%)	16 (52%)
Current smoker	5 (16%)	8 (25%)	8 (25%)	5 (16%)	5 (16%)	8 (26%)
<b>Alcohol use</b>						
Never used alcohol	4 (13%)	4 (13%)	2 (6%)	5 (16%)	5 (16%)	5 (16%)
Prior use of alcohol	1 (3%)	5 (16%)	4 (13%)	3 (9%)	4 (13%)	2 (6%)
Current use of alcohol	27 (84%)	23 (72%)	26 (81%)	24 (75%)	23 (72%)	24 (77%)

\* a common low-risk haplotype (RR 1.3) carried by 85-90% of study subjects



## Study Conduct

All study participants lived in the Reykjavik metropolitan area or its neighboring townships. All study participants were followed by the designated  
5 cardiologists at the University Hospital of Iceland, at their outpatient or private clinics, and all subjects had participated in a study on the genetics of MI. After the subject had given informed consent, a medical and medication history was completed, including co-morbidities, concomitant medications and specific details about the subject's cardiovascular history, including current status. All study participants were  
10 fasting and had not taken their medications prior to the study visit. Cardiologists examined the patients at all 8 visits and completed the case report forms. All blood was collected and processed immediately after sampling. All blood specimens used for the biomarker studies were processed within 2 hours of blood sampling.

## Study Drug

15 Patients (191 subjects) who met the study eligibility criteria were enrolled and randomized into 3 different dose-level groups: (1) 64 patients on 250 mg/day therapy with DG-031 (250 mg q.d.), vs placebo; (2) 64 patients on 500 mg/day therapy with DG-031 (250 mg b.i.d.) vs placebo; and (3) 63 patients on 750 mg/day therapy with DG-031 (250 mg t.i.d.) vs placebo. The 750 mg/day dose was well tolerated in  
20 previous phase I-III human studies (Dahlen *et al.*, Thorax 1997; 52:342-7; Hamilton *et al.*, Thorax 1997; 52:348-54), conducted on healthy volunteers and patients with asthma as a part of the drug development program for Bayer x 1005 (now DG-031). All patients received 3 tablets per day. Treatment periods, 4 weeks in duration each, were separated by a 2-week washout period. The placebo tablets were identical in  
25 shape, color, form and taste to the active tablets except that they contained no active drug ingredients. Treatment with DG-031 or placebo was in addition to the subject's standard care, including all medications and treatment plan as prescribed by the subject's cardiologist prior to enrollment. The cross-over study design is summarized in Figure 9. Due to early termination of 19 subjects (primarily related to  
30 unavailability due to travel), 11 were replaced prior to enrollment closure. Thus, a total of 191 subjects were enrolled, with 172 completing all 8 visits or 8 patients (4.4%) short of target. Three subjects did not return for early termination visit.

### **Data Analysis, Randomization and Statistical Considerations**

All data were analyzed according to a pre-established analysis plan and by intention-to-treat. Hypotheses were tested at a two-sided nominal significance level of 0.05. Each arm of the study, as well as pooled sets (combining dose levels), was considered for the primary analysis. Each such set is a standard AB/BA cross-over design and in the primary analysis of efficacy, the levels of biomarkers of MI risk at the end of the treatment periods (visits 4 and 7) were used as primary response variables. The difference between DG-031 and placebo treatment was the primary outcome, assessed separately for each of the biomarkers. Treatment effect was tested using a two-sample t-test on the period differences for suitably transformed response variables, under an assumption of normality of the transformed data. We report treatment effect as one half of the observed mean differences in the two-sample t-test, with a 95% CI. No pre-tests for carry-over effect were performed as a part of the primary analysis. Tests for carry-over were done and are reported separately from results of primary analysis. As was prespecified for the primary analysis, a simple Bonferroni-adjustment based on 10 biomarkers for the primary objective for the pooled set of the two highest doses, was used to report the outcome of the primary objective. All p-values reported are nominal.

To cancel out potential seasonal effects, carry-over effects were also studied with two-sample t-tests that compare measurements of the AB (drug/placebo) group with the measurements of the BA (placebo/drug) group. To estimate the effect of the drug at visit 3 for the AB group,  $(v_3 - v_2)$ , with  $v_3$  and  $v_2$  denoting, respectively, measurements at visit 3 and visit 2, was used. Similarly  $(v_4 - v_2)$  and  $(v_5 - v_2)$  were used to estimate effects at visits 4 and 5. For estimating the effect at visit 6,  $[(v_6 - v_2) + (v_3 - v_2)]$  was used. Note that  $v_6$  from the BA group includes the drug effect after two weeks which cancels the drug effect at visit 3 from the AB group. Similarly,  $[(v_7 - v_2) + (v_4 - v_2)]$  was used to estimate the effect at visit 7. The two higher dose AB groups were used for all visits. All 3 BA groups are used for visits 3, 4 and 5 since they had all received the same treatment until visit 5, but only the two higher dose BA groups are used for visits 6 and 7.

The sample size for this study was chosen so that each of the three arms provided, after up to 5% dropout, at least 80% power (with  $\alpha = 0.05$ , two-sided) to detect a relative lowering of 15% for a log-normal response variable, given that an assay for that variable has a coefficient of variation of 20% and the intra-person  
5 coefficient of variation is as high as 25%. Based on these assumptions, the recruitment target included 180 subjects with randomization into 3 different dose-level groups as described above.

At the enrollment visit, an independent study nurse who was blinded to the drug content, dispensed medication kits according to a computer generated  
10 randomization list. Randomization of study patients was stratified according to sex. For both strata, a permuted block design with block size 12 was used to assign patients into each of the six sequences of the study. All biomarkers were transformed using a shifted log transform (transformed value is natural log of original value plus a shifting constant for each assay). Missing data were filled in using a simple last  
15 observation carried forward (LOCF) scheme, in cases where no previous measurement existed, next observation was carried back. Statistical outliers for data sets were brought in based on IQR distance from median.

#### **Biomarker measurements:**

The ELISA and mass spectrometry assays were used to measure the levels of  
20 the MI at risk biomarkers and are summarized in Table 28. Apart from measurements in plasma, LTB<sub>4</sub> and MPO were also measured in whole blood preparations *ex vivo* following ionomycin-activation of leukocytes, using ELISA and mass spectrometry. Both dose- and time-dependent stimulations were performed to determine the maximum LTB<sub>4</sub> and MPO output of the cells. Correction was made for white blood  
25 cell count, as the amount of these mediators produced relates to the number of cells in a fixed volume. On the log scale the adjustment was based on a linear model, with coefficients determined empirically at time of blind review. Several tertiary markers were also measured including: IL-6, IL-12p40, TNF $\alpha$ , MMP-9, sICAM, sVCAM, P-selectin, E-selectin, MCP-1 and oxidised LDL.

**Table 28** Methods and assays used to quantify study biomarkers.

ELISA method				
<i>Assay</i>	<i>Supplier</i>	<i>Name of kit</i>	<i>Catalog nr.</i>	<i>Principle of the method</i>
Myeloperoxidase (MPO)	Assay Design, Inc.	Titerzyme EIA	# 900-115	A quantitative solid phase sandwich ELISA
LTB <sub>4</sub>	R&D	LTB <sub>4</sub>	# DE0275	A competitive binding immunoassay
Amyloid A	Biosource	Human SAA kit	# KHA0012	A quantitative solid phase sandwich ELISA
Cysteinyl Leukotriene	R&D	Cysteinyl Leukotriene	# DE3200	A competitive binding immunoassay
Nitrotyrosine	OxisResearch	Bioxytech Nitro tyrosine-EIA	# 21055	A quantitative solid phase sandwich ELISA
TNF- $\alpha$	R&D	Quantikine HS Human TNF- $\alpha$	# HSTA00C	A quantitative solid phase sandwich ELISA
IL6	R&D	Quantikine HS Human IL-6	# HS600B	A quantitative solid phase sandwich ELISA
IL12p40	R&D	Quantikine Human IL-12p40	# DP400	A quantitative solid phase sandwich ELISA
MCP-1	R&D	Quantikine Human MCP-1	# DCP00	A quantitative solid phase sandwich ELISA
ICAM	R&D	Parameter human sICAM-1	# BBE 1B	A quantitative solid phase sandwich ELISA
sE-Selectin	R&D	Parameter human sEselectin	# BBE 2B	A quantitative solid phase sandwich ELISA
sP-Selectin	R&D	Parameter human sPselectin	# BBE 6	A quantitative solid phase sandwich ELISA
VCAM	R&D	Parameter human sVCAM-1	# BBE 3	A quantitative solid phase sandwich ELISA
MMP 9	R&D	Quantikine Human MMP-9(total)	# DMP900	A quantitative solid phase sandwich ELISA
Oxidised LDL	Mercodia	Oxidised LDL Elisa	# 10-1143-01	A quantitative solid phase sandwich ELISA
Lp-PLA <sub>2</sub>	Diadexus San Fransisco, CA	PLAC test		A quantitative solid phase sandwich ELISA
Other methods				
Hs-CRP	Roche Hitachi 912 analyser	Hs-CRP	11972855	Immunoturbidimetric assay
LTB <sub>4</sub> (MS)	LC/MS/MS	LTB <sub>4</sub> assay		Mass spectrometer with internal standard

### **Clinical outcome**

Baseline values for the biomarker variables prior to treatment are shown in Table 29. For the primary efficacy endpoint, as specified in the statistical analysis plan, 10 variables were considered in the pooled set of subjects on 500 mg and 750 mg arms and the data is set out in Table 30. The primary efficacy endpoint of the study was confirmed by showing that DG-031 reduces levels of LTB<sub>4</sub> produced by ionomycin-activated neutrophils *ex vivo* for the pooled set of 500 mg and 750 mg arms (nominal  $p = 0.0042$ ), and this is statistically significant after correction for multiple testing. As shown in Table 30, the maximum reduction in LTB<sub>4</sub> and MPO production amounted to 26% for LTB<sub>4</sub> (nominal  $p=0.0026$ ) and 13% for MPO (nominal  $p=0.023$ ) at the 750 mg/day dose of DG-031. DG-031 also reduced significantly serum sICAM-1 (nominal  $p=0.02$ ), but no effects were observed on other tertiary markers. Lp-PLA<sub>2</sub> increased by 9% (nominal  $p=0.0056$ ) in response to the highest dose of DG-031 and there was comparable increase observed in LDL cholesterol (8%) that correlated with Lp-PLA<sub>2</sub>. In contrast, the effects of the 2 lower doses (250 mg/day and 500 mg/day) on Lp-PLA<sub>2</sub> were not significant. Urine levels of LTE<sub>4</sub> increased by 27% in response to the highest dosage of DG-031 (nominal  $p=0.00002$ ). Significant correlation was observed between the inhibition of LTB<sub>4</sub> and MPO production in response to DG-031 ( $r=0.65$ ,  $p < 0.00001$ ).

**Table 29.** Summary statistics of baseline biomarker values.

Assay	250 mg/day		500 mg/day		750 mg/day	
	Active-placebo (n=32)	Placebo-active (n=32)	Active-placebo (n=32)	Placebo-active (n=32)	Active-placebo (n=32)	Placebo-active (n=31)
<b>Primary objectives</b>						
Amyloid A	9.92 (0.94) n=32	9.84 (0.75) n=32	9.78 (0.91) n=32	9.44 (0.43) n=32	9.74 (0.43) n=32	9.63 (0.50) n=31
Hs-CRP	0.78 (0.88) n=32	0.95 (1.12) n=32	0.75 (1.19) n=32	0.46 (0.73) n=32	0.89 (0.81) n=32	0.77 (0.86) n=31
Lp-PLA <sub>2</sub>	5.47 (0.33) n=32	5.50 (0.29) n=32	5.49 (0.27) n=32	5.32 (0.39) n=32	5.51 (0.41) n=32	5.42 (0.22) n=31
LTB <sub>4</sub> in whole blood†	10.78 (0.85) n=32	11.02 (0.85) n=32	10.41 (0.65) n=32	10.54 (0.75) n=31	10.74 (0.57) n=32	10.85 (0.87) n=30
LTB <sub>4</sub> in w.b.*, corr for wbc†‡	8.14 (0.71) n=32	8.24 (0.76) n=32	7.79 (0.68) n=32	7.95 (0.69) n=31	8.11 (0.59) n=32	8.11 (0.72) n=30
LTE <sub>4</sub> in urine	6.57 (0.33) n=31	6.69 (0.32) n=31	6.53 (0.40) n=32	6.55 (0.38) n=32	6.67 (0.48) n=32	6.69 (0.40) n=31
MPO in plasma	3.72 (0.51) n=32	3.71 (0.55) n=32	3.47 (0.41) n=32	3.51 (0.37) n=32	3.71 (0.45) n=31	3.72 (0.52) n=31
MPO in whole blood	6.54 (0.49) n=31	6.67 (0.37) n=32	6.47 (0.44) n=32	6.38 (0.49) n=31	6.56 (0.34) n=32	6.64 (0.47) n=31
MPO in w. b.*, corr. for wbc†	4.69 (0.39) n=31	4.74 (0.37) n=32	4.65 (0.37) n=32	4.58 (0.44) n=31	4.73 (0.33) n=32	4.75 (0.34) n=31
N-tyrosine	3.18 (0.73) n=31	3.40 (1.02) n=31	3.25 (0.95) n=28	3.81 (1.48) n=29	3.50 (0.99) n=31	3.66 (1.42) n=30
<b>Tertiary objectives</b>						
ICAM	5.67 (0.27) n=32	5.67 (0.21) n=32	5.65 (0.29) n=32	5.66 (0.20) n=32	5.69 (0.25) n=32	5.68 (0.23) n=31
IL12p40	4.98 (0.41) n=32	4.87 (0.48) n=32	4.86 (0.36) n=32	5.04 (0.42) n=32	5.02 (0.50) n=32	4.96 (0.43) n=31
IL6	0.87 (0.40) n=32	1.15 (0.63) n=32	1.07 (0.89) n=32	0.90 (0.32) n=32	0.95 (0.71) n=32	1.11 (0.42) n=31
MCP-1	5.92 (0.39) n=32	5.90 (0.23) n=32	5.86 (0.21) n=32	5.94 (0.24) n=31	5.92 (0.23) n=32	5.91 (0.23) n=31
MMP 9	6.34 (0.39) n=32	6.40 (0.44) n=32	6.10 (0.47) n=32	6.20 (0.42) n=32	6.15 (0.43) n=32	6.15 (0.52) n=31
Oxidized - LDL	11.09 (0.33) n=32	11.06 (0.37) n=32	11.03 (0.29) n=32	11.12 (0.30) n=32	11.07 (0.33) n=32	11.08 (0.30) n=31
sE-Selectin	4.20 (0.19) n=32	4.21 (0.28) n=32	4.12 (0.25) n=32	4.19 (0.33) n=32	4.22 (0.26) n=32	4.24 (0.36) n=31
sP-Selectin	4.85 (0.30) n=32	5.00 (0.47) n=31	4.72 (0.28) n=31	4.72 (0.30) n=31	4.90 (0.48) n=32	4.77 (0.35) n=30
sVCAM	6.09 (0.18) n=32	6.06 (0.15) n=32	6.08 (0.17) n=32	6.07 (0.19) n=32	6.09 (0.24) n=30	6.10 (0.17) n=31
TNF-α	0.64 (0.48) n=26	0.56 (0.54) n=27	0.51 (0.49) n=27	0.54 (0.39) n=30	0.53 (0.46) n=29	0.47 (0.43) n=27

\*w.b. = whole blood

†baseline is not available for LTB<sub>4</sub> measured using mass spectrometry

‡corr. for wbc = corrected for white blood cell count

**Table 30.** Treatment effect based on two sample t-test for the treatment groups, the pooled sets for the two highest doses and all doses (natural log scale).

Assay	250 mg/day (n=64)	500 mg/day (n=64)	750 mg/day (n=63)	500 & 750 mg/day (n=127)	250, 500 & 750 mg/day (n=191)
<b>Primary objectives</b>					
Amyloid A	0.03 [-0.09,0.15] (p=0.61)	-0.05 [-0.17,0.06] (p=0.36)	-0.01 [-0.11,0.09] (p=0.90)	-0.03 [-0.11,0.05] (p=0.43)	-0.01 [-0.07,0.05] (p=0.77)
Hs-CRP	0.05 [-0.14,0.24] (p=0.59)	0.09 [-0.09,0.26] (p=0.34)	0.04 [-0.13,0.21] (p=0.66)	0.06 [-0.06,0.18] (p=0.32)	0.06 [-0.04,0.16] (p=0.26)
Lp-PLA <sub>2</sub>	0.05 [-0.03,0.12] (p=0.24)	0.03 [-0.04,0.10] (p=0.37)	0.09 [0.03,0.15] (p=0.0056)	0.06 [0.01,0.10] (p=0.012)	0.05 [0.01,0.09] (p=0.0073)
LTB <sub>4</sub> in w.b.*, mass spec. <sup>†</sup>	-0.11 [-0.29,0.06] (p=0.19)	-0.09 [-0.28,0.11] (p=0.38)	-0.26 [-0.46,-0.06] (p=0.010)	-0.17 [-0.31,-0.04] (p=0.013)	-0.15 [-0.26,-0.05] (p=0.0051)
LTB <sub>4</sub> in w.b.*, corr. for wbc <sup>‡</sup> , m.s. <sup>§</sup>	-0.11 [-0.28,0.05] (p=0.18)	-0.08 [-0.26,0.09] (p=0.35)	-0.30 [-0.49,-0.11] (p=0.0026)	-0.19 [-0.32,-0.06] (p=0.0042)	-0.16 [-0.27,-0.06] (p=0.0018)
LTB <sub>4</sub> in whole blood <sup>†</sup>	-0.13 [-0.35,0.09] (p=0.24)	-0.19 [-0.44,0.06] (p=0.13)	-0.30 [-0.56,-0.04] (p=0.025)	-0.24 [-0.42,-0.07] (p=0.0073)	-0.21 [-0.34,-0.07] (p=0.0036)
LTB <sub>4</sub> in w.b.*, corr. for wbc <sup>‡</sup>	-0.13 [-0.35,0.08] (p=0.22)	-0.18 [-0.42,0.05] (p=0.12)	-0.34 [-0.59,-0.09] (p=0.0089)	-0.26 [-0.43,-0.09] (p=0.0027)	-0.22 [-0.35,-0.08] (p=0.0014)
LTE <sub>4</sub> in urine	0.14 [0.03,0.24] (p=0.011)	0.15 [0.05,0.24] (p=0.0030)	0.24 [0.14,0.34] (p=0.00002)	0.19 [0.12,0.26] (p<0.00001)	0.17 [0.12,0.23] (p<0.00001)
MPO in plasma	-0.07 [-0.22,0.07] (p=0.32)	0.08 [-0.04,0.21] (p=0.20)	-0.04 [-0.17,0.09] (p=0.49)	0.02 [-0.07,0.11] (p=0.68)	-0.01 [-0.09,0.06] (p=0.76)
MPO in whole blood <sup>†</sup>	0.01 [-0.08,0.11] (p=0.78)	-0.01 [-0.13,0.11] (p=0.85)	-0.11 [-0.22,0.00] (p=0.056)	-0.06 [-0.14,0.02] (p=0.14)	-0.04 [-0.10,0.03] (p=0.27)
MPO in w. b.*, corr. for wbc <sup>‡</sup>	0.01 [-0.08,0.11] (p=0.76)	0.00 [-0.11,0.12] (p=0.94)	-0.13 [-0.24,-0.02] (p=0.023)	-0.06 [-0.14,0.02] (p=0.12)	-0.04 [-0.10,0.02] (p=0.24)
N-tyrosine	-0.03 [-0.15,0.09] (p=0.60)	-0.03 [-0.13,0.08] (p=0.60)	0.03 [-0.08,0.14] (p=0.56)	0.00 [-0.07,0.08] (p=0.96)	-0.01 [-0.07,0.05] (p=0.78)
<b>Tertiary objectives</b>					
ICAM	0.00 [-0.04,0.03] (p=0.83)	0.00 [-0.04,0.03] (p=0.81)	-0.03 [-0.06,0.00] (p=0.025)	-0.02 [-0.04,0.00] (p=0.10)	-0.01 [-0.03,0.01] (p=0.16)
IL12p40	0.01 [-0.04,0.06] (p=0.69)	0.02 [-0.04,0.08] (p=0.53)	0.01 [-0.04,0.06] (p=0.70)	0.01 [-0.02,0.05] (p=0.46)	0.01 [-0.02,0.04] (p=0.40)
IL6	-0.02 [-0.13,0.09] (p=0.68)	0.06 [-0.03,0.16] (p=0.19)	-0.01 [-0.10,0.09] (p=0.87)	0.03 [-0.04,0.09] (p=0.40)	0.01 [-0.05,0.07] (p=0.69)
MCP-1	-0.02 [-0.07,0.03] (p=0.51)	0.02 [-0.03,0.08] (p=0.35)	-0.03 [-0.08,0.03] (p=0.32)	0.00 [-0.04,0.04] (p=0.98)	-0.01 [-0.04,0.02] (p=0.69)
MMP 9	-0.03 [-0.12,0.05] (p=0.47)	0.02 [-0.06,0.11] (p=0.58)	-0.02 [-0.11,0.06] (p=0.60)	0.00 [-0.06,0.06] (p=0.97)	-0.01 [-0.06,0.04] (p=0.69)
Oxidized - LDL	0.00 [-0.08,0.07] (p=0.91)	0.02 [-0.07,0.11] (p=0.65)	0.06 [-0.03,0.16] (p=0.16)	0.04 [-0.02,0.11] (p=0.18)	0.03 [-0.02,0.08] (p=0.28)
sE-Selectin	0.03 [-0.03,0.09] (p=0.30)	-0.01 [-0.06,0.04] (p=0.82)	-0.04 [-0.09,0.01] (p=0.11)	-0.02 [-0.06,0.01] (p=0.20)	0.00 [-0.04,0.03] (p=0.75)
sP-Selectin	-0.02 [-0.11,0.06] (p=0.58)	0.00 [-0.08,0.08] (p=0.97)	0.09 [0.01,0.16] (p=0.034)	0.04 [-0.02,0.10] (p=0.15)	0.02 [-0.03,0.07] (p=0.40)
sVCAM	0.00 [-0.05,0.04] (p=0.85)	-0.01 [-0.06,0.04] (p=0.60)	-0.03 [-0.07,0.02] (p=0.24)	-0.02 [-0.05,0.01] (p=0.24)	-0.01 [-0.04,0.01] (p=0.28)
TNF- $\alpha$	0.00 [-0.08,0.09] (p=0.93)	-0.02 [-0.10,0.07] (p=0.70)	0.01 [-0.07,0.08] (p=0.85)	0.00 [-0.06,0.06] (p=0.90)	0.00 [-0.05,0.05] (p=0.95)

\*w.b. = whole blood

<sup>†</sup>measurement is not part of the primary analysis wrt adjustment for multiple testing<sup>‡</sup>corr. for wbc = corrected for white blood cell count<sup>§</sup>m.s. = mass spec. = mass spectrometry

### Tests for carry-over effects

A test for carry-over effects from the treatment phase to the placebo phase was performed as a two-sample t-test on the differences between visit 2 and 5 for patients on drug and placebo, respectively. The cohort taking drug consists of patients on 500 mg/day and 750 mg/day treatment and the placebo cohort includes patients on placebo from all 3 tracks. The resulting p-values and confidence intervals for the effect are given in Table 31 (data were not available for Lp-PLA<sub>2</sub> and N-tyrosine). No carry over effects were observed with LTB<sub>4</sub> and MPO. In contrast, marked carry over effects were observed for CRP and SAA, with reduction in CRP that was significant at the 5% level (p=0.017). SAA showed similar carry over effects that was slightly below this significance level (p=0.051).

**Table 31** Test for carry-over effect for each study period.

Assay	p-value	Effect	95% CI
CRP	0.017	-0.28	[-0.52,-0.05]
Amyloid A	0.051	-0.14	[-0.29,0.00]
LTE <sub>4</sub> in urine	0.48	-0.06	[-0.22,0.10]
MCP-1	0.084	0.07	[-0.01,0.15]
MMP 9	0.56	-0.04	[-0.16,0.09]
MPO in plasma	0.28	-0.11	[-0.31,0.09]
White blood cell count	0.57	-0.01	[-0.06,0.03]
LTB <sub>4</sub> in whole blood, corr. for wbc <sup>†</sup>	0.45	-0.10	[-0.36,0.16]
MPO in whole blood, corr. for wbc <sup>†</sup>	0.93	0.01	[-0.13,0.15]
LTB <sub>4</sub> in whole blood, mass spec. <sup>§</sup>	0.45	0.19	[-0.33,0.71]
LTB <sub>4</sub> in whole blood, corr. for wbc, m.s. <sup>§</sup>	0.64	0.12	[-0.40,0.64]

<sup>†</sup>corr. for wbc = corrected for white blood cell count

<sup>§</sup>m.s. = mass spec. = mass spectrometry

15

Figure 10 shows the estimated mean effects on CRP and SAA for the subjects receiving the two higher drug doses in the first period. Note that measurements from subjects receiving the placebo first also contribute to these estimates to cancel out potential seasonal effects. For visits 3 (after 2 weeks on therapy) and 4 (after 4 weeks on therapy), this constitutes the treatment effect, whereas the carry-over effects appear between visits 5 to 7.

20



The level of CRP dropped at visits 3 and 4, but not significantly. The reduction became more pronounced, about 25%, and significant at visit 5 ( $p=0.017$ ), and seems to persist until visit 7, during the time the subjects were on placebo. This prolonged effect is part of the reason that the drug effect was not detected in the primary analysis which did not take this scenario into account. The design of this trial does not have maximal power for studying such effects which is reflected by the large standard errors in the estimates, particularly for visits 6 and 7. Even though measurements at visits 3 and 6 are not available for SAA, the observed changes of CRP and Amyloid A between visits 2 and 5 are highly correlated ( $r=0.68$ ,  $p < 0.00001$ ). Hence it appears that the drug has similar effects on both biomarkers.

No difference was detected in the effects of DG-031 on biomarkers of MI risk between patients with FLAP or LTA4 hydrolase haplotypes when the data were analysed separately.

There was no difference in serious adverse events between the treatment groups or dose arms in the study cohort. In particular, no difference was detected in liver transaminases between the groups on active drug or placebo. The only symptom that was significantly more often reported for active drug was dizziness, experienced by 6 patients on active drug (any dose) and none on placebo ( $p=0.032$ ). This did not interfere with the daily activities of the subjects.

When taken together, the data generated through the MI gene-isolation (Example 1) and the clinical trial reported herein, show that DG031 is a safe and well tolerated drug that can, at least in part, correct a biochemical defect that confers a relative risk of acute cardiovascular events that is similar to or greater than the risk conferred by the top quintile of LDL cholesterol. Indeed, the data suggest that DG-031 reduces serum levels of CRP and SAA by approximately 25%, suggesting that this will cause reduction in the risk of acute cardiovascular events.

**EXAMPLE 11: CLINICAL TRIAL INVESTIGATING THE EFFECT OF COMPOSITIONS COMPRISING A LEUKOTRIENE SYNTHESIS INHIBITOR AND A STATIN ON BIOMARKERS OF RISK OF MYOCARDIAL INFARCTION.**

A randomized, placebo-controlled crossover-clinical trial, as described in Example 10, is carried out to investigate the effect of compositions comprising a

leukotriene synthesis inhibitor and a statin on the levels of biomarkers of risk of MI. The participants for the study optionally are carriers of variants in the FLAP and/or LTA<sub>4</sub> hydrolase genes set out in Table 25. One group of participants receives a leukotriene synthesis inhibitor alone, such as DG031. Another group of participants  
5 receives a statin alone. A third group of participants receives a composition comprising both a leukotriene synthesis inhibitor and a statin. The forth group of participants receives a placebo.


Each participant receives the treatment for at least two months and the levels of biomarkers set out in Table 28 are monitored in each participant for at least three  
10 months. It is expected that the group receiving a leukotriene synthesis inhibitor alone will have a 25% decrease in CRP levels and the group receiving a statin alone will also have a 25% decrease in CRP levels. More substantial decrease in CRP from combination therapy is evidence that the combination therapy is beneficial. In view of the data from the clinical trial described in Example 10, wherein almost all (about  
15 85%) of the participants were on statin therapy, it is expected that the group receiving the combination therapy will exhibit a 50% decrease in CRP levels.

What is claimed.

1. A composition comprising a leukotriene synthesis inhibitor and a statin.
2. A composition according to claim 1, further comprising a pharmaceutically acceptable carrier.
3. The composition according to claim 1, wherein the leukotriene synthesis inhibitor is an agent that inhibits activity of a leukotriene synthesis pathway protein selected from the group consisting of 5-lipoxygenase, 5-lipoxygenase activating protein (FLAP), leukotriene C4 synthase, leukotriene A4 hydrolase, arachidonate 4-lipoxygenase, leukotriene B4 12-hydroxydehydrogenase; leukotriene A4 receptor, leukotriene B4 receptor, leukotriene C4 receptor, leukotriene D4 receptor, leukotriene E4 receptor, leukotriene B4 receptor 1, leukotriene B4 receptor 2, cysteinyl leukotriene receptor 1, and cysteinyl leukotriene receptor 2.
4. The composition according to claim 3, wherein the leukotriene synthesis inhibitor is selected from the group consisting of 1-((4-chlorophenyl)methyl)-3-((1,1-dimethylethyl)thio)-alpha,alpha-dimethyl-5-(2-quinolinylmethoxy)-1H-Indole-2-propanoic acid, (R)-(+)-alpha-cyclopentyl-4-(2-quinolinylmethoxy)-Benzeneacetic acid, 3-(3-(1,1-dimethylethylthio-5-(quinoline-2-ylmethoxy)-1-(4-chloromethylphenyl)indole-2-yl)-2,2-dimethylpropionaldehyde oxime-0-2-acetic acid, zileuton, atreleuton, 6-((3-fluoro-5-(tetrahydro-4-methoxy-2H-pyran-4yl)phenoxy)methyl)-1-methyl-2(1H)-quinolinone, 1-((4-chlorophenyl)methyl)-3-((1,1-dimethylethyl)thio)-alpha,alpha-dimethyl-5-(2-quinolinylmethoxy)-1H-Indole-2-propanoic acid and 4-(3-(4-(2-Methyl-imidazol-1-yl)-phenylsulfanyl)-phenyl)-tetrahydro-pyran-4-carboxylic acid amide.

5. The composition according to claim 3, wherein the leukotriene synthesis inhibitor is a FLAP inhibitor.


6. The composition according to claim 5, wherein the FLAP inhibitor comprises a compound represented by the formula:



or pharmaceutically acceptable salt thereof ,


wherein R<sup>1</sup> represents a group of the formula:


10




R<sup>2</sup> and R<sup>3</sup> are identical or different and represent hydrogen, lower alkyl, phenyl, benzyl or a group of the formula:

15






$R^4$  represents hydrogen, lower alkyl, phenyl or benzyl, which can optionally be substituted by hydroxyl, carboxyl, lower alkoxy, carbonyl, lower alkylthio, heteroaryl or carbamoyl,  $R^5$  represents hydrogen, lower alkyl, phenyl or benzyl,  $R^6$  represents a group of the formula  $-COR^5$  or  $-CO^2 R^5$ ,  $R^7$  represents hydrogen, lower alkyl or phenyl, Y represents a group of the formula:



wherein  $R^8$  represents hydrogen, lower alkyl or phenyl and n denotes a number of 0 to 5, Z represents norbornyl, or represents a group of the formula:



wherein  $R^9$  and  $R^{10}$  are identical or different and denote hydrogen, lower alkyl or phenyl, or  $R^9$  and  $R^{10}$  can together form a saturated carbocyclic ring having up to 6 carbon atoms and m denotes a number from 1 to 6, and A and B are identical or different and denote hydrogen, lower alkyl or halogen, or a pharmaceutically acceptable salt thereof.

20

7. The composition according to claim 5, wherein the FLAP inhibitor comprises a compound selected from the group consisting of: 2-[4-(quinolin-

2-yl-methoxy)phenyl]-2-cyclopentylacetic acid, 2-[4-(quinolin-2-yl-methoxy)phenyl]-  
2-cyclohexylacetic acid, and 2-[4-(quinolin-2-yl-methoxy)phenyl]-2-  
cycloheptylacetic acid, (+)-enantiomer of 2-[4-(quinolin-2-yl-methoxy)phenyl]-2-  
cyclopentylacetic acid, (-)-enantiomer of 2-[4-(quinolin-2-yl-methoxy)phenyl]-2-  
5 cyclopentylacetic acid, and pharmaceutically acceptable salts thereof. [2/21/03]

8. The composition according to claim 5, wherein the FLAP  
inhibitor comprises BAY-X-1005 or a physiologically acceptable salt, formulation, or  
pro-drug thereof.

10

9. The composition according to claim 5, wherein the leukotriene  
synthesis inhibitor is (R)-(+)-alpha-cyclopentyl-4-(2-quinolinylmethoxy)-  
Benzencacetic acid.

15 10. The composition according to claim 8, wherein the statin is  
selected from the group consisting of roxuvastatin, fluvastatin, atorvastatin, lovastatin,  
simvastatin, pravastatin or pitavastatin.

11. The composition according to claim 10, wherein the  
20 leukotriene synthesis inhibitor is included in the composition in an amount effective  
to reduce serum C-reactive protein (CRP) in a human subject.

12. The composition according to claim 11, wherein the statin is  
included in the composition in an amount effective to reduce serum low density  
25 lipoprotein cholesterol (LDL) and reduce serum CRP in a human subject.

13. The composition according to claim 12, wherein the leukotriene inhibitor and the statin are included in the composition in amounts effective to synergistically reduce serum C-reactive protein in a human subject.

5 14. The composition of claim 12 or 13, that comprises a unit dose for administration to a human subject.

15. The composition of claim 14 that is a pill or capsule.

10 16. The composition according to claim 14, wherein 50 to 750 milligrams of the FLAP inhibitor is present in the unit dose.

17. The composition according to claim 14, wherein 250 to 375 milligrams of the FLAP inhibitor is present in the unit dose.

15

18. The composition according to claim 16, wherein 1 to 200 milligrams of the statin is present in the unit dose.

19. The composition according to claim 17, wherein 5 to 80  
20 milligrams of the FLAP inhibitor is present in the unit dose.

20. A method of reducing C reactive protein (CRP) in a human subject, comprising:

administering to a human in need of treatment to reduce CRP a  
25 composition according to claim 1, in an amount effective to reduce serum C reactive protein in the human subject.

21. The method of claim 20, comprising:

selecting for the administering step a human subject at risk for a disease or condition selected from the group consisting of myocardial infarction, acute coronary syndrome, stroke, or peripheral arterial occlusive disease.

5

22. The method of claim 20, wherein the composition is administered in an amount effective to reduce serum LDL and serum leukotrienes in the human subject.

10 23. A method of reducing C reactive protein (CRP) in a human subject, comprising:

selecting a human subject that receives statin therapy to reduce serum LDL, wherein the statin therapy optionally reduces serum CRP in the human subject; and

15 administering to the human subject a leukotriene synthesis antagonist, in an amount effective to further reduce CRP in the human subject.

24. A method of reducing C reactive protein (CRP) in a human subject, comprising:

20 identifying a human subject in need of treatment to reduce serum CRP; administering to the human subject a composition comprising a statin; administering to the human subject a composition comprising a leukotriene synthesis inhibitor,

wherein the statin and the leukotriene synthesis inhibitor are  
25 administered in amounts effective to reduce serum CRP in the human subject.

25. A method according to claim 24, wherein the identifying comprises identifying a human subject that exhibits one or more risk factors for



myocardial infarction, acute coronary syndrome, stroke, or peripheral arterial occlusive disease.

26. A method according to claim 24, wherein the identifying  
5 comprises measuring CRP in the human subject.

27. A method according to claim 24, wherein the statin and the leukotriene synthesis inhibitors are simultaneously administered.

10 28. A method according to claim 24, wherein the statin and the leukotriene synthesis inhibitors are sequentially administered.

29. A method according to claim 24, further comprising:  
measuring serum C reactive protein in the human subject to monitor  
15 therapeutic efficacy of the administering..

30. A method of claim 29, further comprising modifying the amount or frequency of the administration following the measuring in order to achieve a target measurement of CRP in the human subject.

# ABSTRACT OF THE DISCLOSURE

5           Linkage of myocardial infarction (MI) and a locus on chromosome  
13q12 is disclosed. In particular, the FLAP gene within this locus is shown by  
genetic association analysis to be a susceptibility gene for MI and ACS, as  
well as stroke and PAOD. Pathway targeting for treatment and diagnostic  
10 applications in identifying those who are at risk of developing MI, ACS,  
stroke or PAOD, in particular are described. The invention also provides for  
compositions comprising a leukotriene synthesis inhibitor and a statin and  
methods of using these compositions to reduce C-reactive protein in a human  
subject at risk of MI, ACS, stroke and/or PAOD.

15




FIG. 1

Haplotypes showing association  
 (p value <  $10^{-5}$ ) with the disease




FIG. 2





FIG. 3



**FIG. 4**




FIG. 5





FIG. 6








FIG. 8

FIG. 9





FIG. 10



**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☒ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**

# SEQUENCE LISTING

<110> Gurney et al.

<120> COMBINATION THERAPY MATERIALS AND METHODS

<130> 30847/40792

<140> To be assigned

<141> 2005-01-10

<160> 717

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 214000

<212> DNA

<213> Homo sapiens

<400> 1

```

gactaagatg aatatgcatt cattcaccaa aatctcatat tcccaaaaag caggaaagggt 60
agtacagtga gatggatgat gccttcacat gactcagatg tcacgtgttt ctcaccattg 120
agaccccaaa ggcacccccc cccagcattt accagaatgt gtgtgtaact atttacagtg 180
atttgtgtaa ttatttgatt gtttctcttg tatcctgtag caatgagggt agagattata 240
tcccacctac cactgcagct ccaggatcca gcttcacaaa catttggtga atgaatgaat 300
aagaaaagag gacaccccca aagaggctgc aagggaaaaa gctacaaaga cagaagcacc 360
aggaaaaagt agggctcatgt aagtcaaagc aggaaaaaag ttccatgggtg ggggtggtcag 420
cagtgtctaa tgccacgaag gcacaaagta ggataaagggt taaaaatcag cctttgggtt 480
tggaacaatat gaagcttata ggtagcctta gcgagaacaa ttccatcagg gagcagaagc 540
taactgcagt gggttgagtc atcaagcagg cataaggaag tagggatacc ccattataag 600
ctactctttc aagaagctca aatctgaagg ttaggagaat taggtcagta gctagaagga 660
aatgtggagt cgaggggctg tttttcctcc caaggagtat aaagggtgtaa cgttgcatga 720
aaccacttca gacaaaggcc gatatcaata gagaagttaa aacgcacgcc tcaagatttg 780
ggaaggcttg gggttgggct taaagaggta ggagcatatt tcctatccta ggacagagaa 840
taagaagaaa aggatagggt cccatggaga taaatttcta agtggttaaag aagaggctca 900
gaaaattcta gcatgatagg ctcacttttt tctttttcca tgaaggagat ggcaaagtca 960
actgacatga gaaagggtgac aatactgatg ggttgaagag cgatggacat ttgaaataac 1020
ttcttagacc agtagaggct ggagttcata aatcagaact ggctacaggt tatatatgtt 1080
tttttttttt tctccaacag cataagataa cagagcgaag tctgtagaaa tgaaagaaga 1140
gtcagatgag gatagctgga gctagtgcac ggagggaagc accacgggtg gagccaggtg 1200
ccccctggat ttataattca tactgaattc caacaacaga agggctctaa gcaggagagt 1260
gacagatttc agaagactga gacacatttg gtaaaaaaaa gtaggaggaa aacctgattc 1320
tggaattagg gcagccaata gacggcagta ttttcagaaa ggaggggaatg gtcaacagtg 1380
actttctagt ctggagctca ggaggaagag gcaactctac ctgatggtat taagatcatg 1440
gaggtagctg agatcaccta gcttgtgtgt gtcaaattgag aaaagaagaa agaattaggag 1500
aagttcccca ggaacacaga cattaagtgg ggctgtggtg acaacacaag aagagaggct 1560
tgcaaggagg cctgagcagc tgtcatgaga gaggtaggat ggtggactcg gagaagaggc 1620
agaagatggt cttaaaggaa ggacactgct gccaaagtagt cagccaattg gtgacaaaga 1680
aagaccctgt tgcgagaaaa aaagtcatg aagtagtagg aacgatgaca gatgacactg 1740
gggtgaagac tgaggagaga gaagtgtaa agtggaagca gagggcagac cactcttctg 1800
agacactgaa gaggcatagt tagaaataaa ggggagtcgc cagaaaggaa tttgtggcta 1860
agcaagagggt tttctttaag actgaaatac ataagcatga tttaaatgct gctgggatgg 1920
agttcacaga cctggaagac agaagacaaa gcggatcatc aagatagtgg aattttactga 1980
aatgagagag gaaaatccca tccacaggaa atgcagacat gagggagggg ccagaaggac 2040
agtgaataca tcagcaactg gtcccccaac ttctgagtga atgtggagat ataatcagg 2100
aaaggactgc atcatctccc tgggttaatga tggagtcaga gaaaagagtg tcttatacag 2160
aagttgtgat atacttggcc gggcgagctg gctcacgcct gtaattctaag cactttggga 2220
ggccaaggca ggcgacacac ctgaggctcag gaggttcatga ctggcctggg caacatggca 2280
aaatccacc tctactaaaa acaaaagcct gtaatcccag ctactaggga ggtgaggca 2340
ggagaatcgc ttgaacccag gaggcagagg ttgcagttag ccaaggctcg accactgtac 2400
tccagcctgg gcaacagagc tagactcagt ctcaaaaaaa aaaaaaaaag atgtatttat 2460

```

tctcactgta	taaatttctg	tgtaagaaat	actctctcat	atagaagtaa	atttatatat	2520
aaaattatat	agaaccacta	taaaatactc	aggtttataa	aatttatata	taaacttggt	2580
gacatataaa	attccatgta	aatgactata	aagtactctt	atatgaaaag	tatatgaatt	2640
aaattatata	tcaacttact	tttatattac	agtatttttg	ttatacagaa	gttttatatag	2700
tgacaataaa	tattttctca	gaacgatttc	acataataga	agtataaatt	atccatttcc	2760
aatagtgaag	aagaaaagca	gttccacacc	agtgcacagg	ctacgaatct	aagaggtaca	2820
aagacttcat	tcttagagac	actgaggtca	gggcatggcc	aacacatctg	aagctgatag	2880
aattggcgct	gggttggttg	gagacggtac	gggtattacta	ttacaatggc	agacgcttgg	2940
ccttgataac	tagccaatca	gggggaaaga	ttctggtttc	ctctgttatt	atctgaacta	3000
gtgtgttccc	aaaggggtta	gatggtttat	ggaaggcaca	agatcagcaa	accataaagg	3060
attagcacta	agaaggaagg	aagtagacca	agtgttaatg	gcgatgccat	gtaagagcca	3120
ggtctgcgat	gtatgttcta	catggtttgg	ggggtaaaaa	aaatgtcagc	ctccagagca	3180
cagggtttta	agcctcaagt	actgttaaca	gtagagttta	ctagtctaca	gcaggaatta	3240
caaccagtaa	ttctaaggcc	aattactcag	gcaagtttta	ctagaacaag	gaagctctgc	3300
ttcgaggtca	aatcgatttc	tgcatttata	gaagcatcta	gatgttctct	gttcaaacaa	3360
tggggtaaaa	tccccacaca	ttttatttct	gacagagtgt	tccctatatt	gcctggccag	3420
gagtgataac	attgcttggc	tattattaat	aaaacattgc	tgtggctggg	cgcagtggct	3480
cacacttgta	attctggcac	tttgggaggg	tgaggcagga	ggatcactta	actccaggag	3540
tttgacagca	gcctgggcaa	catagcaaga	tcccatctct	ctaaaaaatt	ttaaaattta	3600
ctgggtgtgg	tggcagacac	ctgtagtccc	agctcctcag	gaagctgagg	tgggaggatc	3660
acttgagccc	aagcaggttg	aggctgcagc	gtgctgtgac	tgtgccactg	cactccagcc	3720
tgcgcaacac	actgagagag	actctgtctc	aaaaaaatac	atcaaatata	aattaaaagc	3780
ccatttcttt	cttttggtag	attacagcca	tgcacttcaa	aggctagcac	aattattttt	3840
ctgcagttct	atatttagat	tctagttaga	agtaacctag	gaccttcattg	ttagaggtgt	3900
ctttggcaaa	actgttatgt	gagtgaacacg	tttaatcaat	tgaggataaa	gatgcctcat	3960
tgctaataga	gatgtggttt	aaggatttta	tgcacccagt	tcatttatta	acaacttggt	4020
taagctttat	tagctgggtc	tctactttat	aactgtgttc	tttaatttac	aagacaataa	4080
aaattaaaaat	ggtaaatggg	aaacctatct	tgtttttcaa	taaataattt	attttaataa	4140
cttcgtgggc	atggtggcca	aaacatttta	gctgtgaaaa	taatttcaat	tcataatttt	4200
ttggaatcaa	tattaaaagg	tgatatattc	tcaaatgaaa	agtggacaaa	tgatcagtta	4260
taggacatga	ttaagaaact	aacctatgagc	cacgtgcagt	ggctcatgcc	tgtaatccca	4320
gcactctggg	aggccgcggt	gagcggattg	cttgagccca	ggagttcaag	accaggctgg	4380
gcaacatggc	aaaaaccggg	ctctactaaa	aatgcaaaaa	aaaaaaaaaa	aaaaaaaatt	4440
tagctgggtt	ttggtggctt	atgcctgcag	tcccagctac	tcgggagggt	gactcgggag	4500
gctgaggcac	aagaatcatt	tgaacccagg	aggcagaggt	tgcaatgagc	tgagaataca	4560
ccactgcact	ccagctctgg	caacagagag	agagagactc	agtctcaaaa	aacaaacaaa	4620
caaacaaaca	aaccgctgcc	ctgtgcttgg	agagatctgt	ttacctttac	cactaaagac	4680
tgttggaagt	aaattttaga	aggtttataa	tacctaaaag	taatcacttc	tgtcttatga	4740
aaggttctgc	tgagattttt	ctattgtggc	cactagtggc	aatattccag	aagtcataat	4800
taaagaatat	cttttagtgg	ttcagcagtt	tttcaaatat	gtacttttat	ctctccaaca	4860
ttcatgattg	caatttttca	aattaacctc	atgatataaa	caactgtact	ctatgatgcc	4920
tcatagtaca	gaaactggag	gcagaaagag	aagttgaatg	tctaagaatc	ggtaattcta	4980
aaactcaaca	tagaccattc	agcattagtg	gttctaacaa	tcccactgca	aaatgagttg	5040
ataatgtgta	acacttttag	gaactaaagc	ataaagaacc	atgggtctct	aatgcagcaa	5100
attaaaacac	atgatagcta	caattaatga	agtacatagt	cctggctggg	cactatggta	5160
cgctcctttac	atagattatc	tcttaaatta	ttaaccccg	tttagagatg	agaacattcg	5220
ggctcaggaa	ggttatgtaa	gttatataaa	aatcacaata	taagagacag	agctaagatt	5280
tgaatccaag	tgtgaccagg	ttcatatcaa	gcttccattt	ttgaatttat	attagaggtc	5340
aataactcac	ctttgtcctt	ttaaaataat	ttttggctct	gtgacctaca	caggcaagct	5400
gttattttaca	aacaacccac	acatctagat	ggtcactgtc	tcaccgcccc	cttttaccat	5460
caggactcct	agtgagctgt	caaggggaat	gctataattt	tggaggttct	aaatctgagg	5520
gcttaagaaa	gaaagaaatt	gtaaaaagca	ggcattactc	aggggcatag	attgtcaggc	5580
agatctgtca	tgcttatagg	taacctccca	gggcaaaaaa	tatatgtgcc	caaactgcct	5640
aaatatttcc	tgtcacttca	taatactgcc	tgaatcctg	ccaaattaga	acttcatttg	5700
tgttgcttgt	caatttttaa	cgcataagca	aatcacctgg	agatcttggt	aaaatgcaaa	5760
ttctgattag	gttaggtctg	ggtctgcagt	tctgatatgc	ttccagaggg	cactgatgct	5820
gctggtccat	ggaccacact	taaagaagca	aaaaagatgt	ctgatattta	ctctctggct	5880
gcctaggagt	gcttctcatt	taagtggagt	ctctttgtgc	atcataatgg	gagggatgag	5940
ctgaaaagca	gcaaatgaag	agtggattaa	gtgtctacct	cacttcccta	ctatctgtaa	6000
caagcagggt	tgggcactgt	ggccaaccag	aaaattcttt	ccaggaccac	aacctctgag	6060
attatgttgc	aaagatgcaa	ggacaactta	gaaataattt	ccagcactgg	tggcactgga	6120
tgtctgtcag	tgggtgctgg	ggcagggtcc	tattcagact	gtgggtttacc	tgcttggccc	6180
gtttggttat	gggccatttt	ctgagtagca	tggagcatcg	cccagctgac	aagggttgtt	6240

actccaccct	tgggtgcgag	aagggaagct	tggtgctac	taagtttggg	gcaaagtaat	6300
tgtggttttg	ccattaatat	ttgatacagt	gagtcctac	tttcctcagg	tgaaactaga	6360
acttaagggg	acacgctcaa	gttctcatta	tacagtacta	agtttcaaaa	atcagcaatt	6420
ttatcaaaca	catgctctac	agcagtggtc	ggcaaacctt	ttctgtaagg	ggccagagag	6480
taaatgtttt	agagtttctg	ggccacatat	ggtttctgtt	ccagctataa	actctgccac	6540
tgtagggcaa	aagcaaccct	ccacaatata	tacatgaata	ggtgtgttcc	aaaaaaactt	6600
tatttgtgga	ccctgaaatt	tgaatttcat	aaacttttca	tgtgtcatga	aatattcttt	6660
tgattttttc	ccaacctttt	aaagatgtaa	caaccatttt	tagcctgtag	gccatataga	6720
aacaggcagt	gggctgggtt	tgctgaccct	tgctctgaag	caatgatata	tcgatccaat	6780
ttatacccac	aaatttttct	ccttgaaaacc	atgcatttaa	ttctcatctc	ttcttaccat	6840
gacaataaga	agttattcta	tataacaaa	agattgtacc	cacccaagcc	agcattttaga	6900
tcagtctatt	tgcttctcta	aaattttggg	ctttataaaa	atcaattaaa	gcaccttaaa	6960
aggtaagcag	tgatgaaata	tttgaaataa	ttggctaat	aaacatcacc	taaatagaaa	7020
ctgtgataag	aaccacaaat	gcgaaaagga	atcatgtagt	aactaatgtg	gaggatatct	7080
tggttttagag	atltgatgaa	cacgagtttt	gatttaaaaa	aatttgtgca	atactactg	7140
ctttgggtgg	gagcttgcta	tgcaagttgg	tagaaaaatt	tatcctaaag	tcacagttct	7200
ctaccactct	ggattttctc	gagctaacta	ccattccaaa	ctatttttagg	cacagttact	7260
agtttcaaga	atcaggcaaa	ttgccttggt	attagcactg	ttctttctgt	ggtcacaagt	7320
caaactactg	tggtgaataa	aattagatga	tttctttagt	ctttcctttt	tcagccctgt	7380
tagtcaattt	ccagtgtctc	attcaaagaa	aaaccaaaaa	tgtccagaat	ataaccttat	7440
tttaaaactt	gttaaccact	gatttcactt	gttaaccaa	tttttttttt	tttttttttg	7500
agaatgaatc	tcactctgtc	accaggctgg	agtgcagtg	catgatcttg	gttcactgca	7560
acctccgcct	cctgggtact	ggttcaagca	attctcctgc	ctcagtcctc	cgagtagctg	7620
ggattacagg	tgtgcacccc	cacaccagc	taattttttt	gtacttttag	tagagtaggg	7680
gtttccacct	gttgcccggt	ctagtcttaa	actcctgacc	tcgtgatccg	cccgccctgg	7740
cctcccaaag	tgtgtggatt	gcaggcatga	accactgcgc	ccagcctggt	aaccaaattt	7800
ctaatacac	acacttgagg	cccagtaaat	gctgtctgaa	aagaggggtg	tggtgggtgag	7860
gcaactgagg	ggctaacata	ctgatagctg	ctgaaatctt	ctacagctct	ttcttggttag	7920
aacactccat	cacgggtccc	aggcccacac	cacatgaagg	aacttctagc	tctcttgctt	7980
gtcttttacc	caaagttagt	tagcaagtcc	tgggaactaa	acagcattga	cacacttgaa	8040
gaagacaatt	aggcaaatcc	caactgctgt	gctcctgcag	ctaaagatga	agactcgtcc	8100
attgggcagt	tgattaattg	tacctagaaa	attaatttca	atgggtccat	gacaacatac	8160
gggcagtgaa	gctctagtgt	tccccctggg	tggaaatctc	caggatgtat	agtctcccat	8220
accagctcat	cctcccattt	ttccagattc	tggttcttct	ctcttaccta	gtgtgtagt	8280
ggccaaatgg	tggtccccca	aaaagatatg	tccatgtgtt	aaccctggaa	actgtggatg	8340
taaccttatt	tggaaaaatg	gggcccagg	cagtgggtgt	catgtgtagt	cccagaactt	8400
tgagaagcca	aggtgggaga	atcgttgagg	cccaggagt	caagaacagc	ccaggcaaca	8460
tattgagacc	cccgctctct	taagcaataa	aaaattagct	aggtgtgggt	gcatgcacct	8520
gaagtccag	ctacttgaga	ggctgaggca	gaaggactgc	tcaagcccaa	ggagttcaag	8580
gctgcagtga	gctatgatca	tgtcacccca	ctccagcctg	ggtgacagag	tcagactccc	8640
tgtctcagga	gaaaagaaaa	aaaggtcttt	gtaaatgtaa	taaagaatct	tgagataaga	8700
tcactctgat	ttaggtgga	ccctaaatcc	atgacattt	gtccttacia	aagaaaggtg	8760
gagggaaact	tgagacagac	acagagggga	gggccttgtg	aagcaggaag	catagatgca	8820
gttacaagtc	aagggaatgcc	aaggactgtc	tacaaccaga	agccaggaga	gatgcattgg	8880
atgattttct	cctcacagcc	tccagaactt	ctggcctcca	ggactgtgaa	gaatcaattt	8940
ctgttggttt	aagccacca	gtttgtgtgt	catttggtat	ggcaatggca	gtattaggac	9000
tctaatacac	agtataaaaa	aataaaaaa	gggccaggcg	tggtggctca	gacctataac	9060
cccagcactt	tgggaggcta	aggcggggag	atcacttgag	gtcaggagtt	tgagaccaac	9120
caggccaaca	tggtgaaacc	ccatctctat	taaaaataaa	aattagttgg	gcatgggtgg	9180
gtgcatctgt	aatcccagtt	actcaggagg	ctgaggcaga	agaatcgctt	gaacccagga	9240
agtggagggt	gtagtgaatg	ccactgcact	ccagcctggg	tgacagagct	agactccttc	9300
atcctaggac	acagccaagt	cttacgtagc	aaaaagaagt	tgtaaagggt	ctgtagttct	9360
gcattaagca	acacaggcat	gtacctatga	attatatgat	tataaaagt	ctcggacagg	9420
cccatttcaa	acttggcctc	tttccaccaa	ctgtgtactg	tttctcattc	cataactaga	9480
gattatgtct	ttatatcctg	tcaaaaaagt	gaatttttgt	gggctaagac	attatccctg	9540
tgttaaatgc	accagtctta	gtgtaaacaa	gcctagtctc	tttttcattt	tggtgtgcta	9600
gtatgcattt	gtatatgcta	ggcagtgtag	taggcacctt	aaatacatta	ccttggttaa	9660
cctctacagg	attctgggag	gtaggcatta	tccccatttt	atagatgaga	acactgagaa	9720
gacaatgttc	ataagtgcgt	cacttgtctg	agatgacata	tttactaagt	agcagaacca	9780
ggcctcgagc	tactcagctc	gatttccaaa	gcccctgctc	ttaatcacat	caacttcttt	9840
cctatatcac	ctttcccaga	gtgcgctctc	atggataaag	agcagaagta	taagttacta	9900
ggcagcagaa	aactgtagag	gtgggaagat	tagataaaaa	atgtaaataa	gaaggcttta	9960
agacacaaaa	atcaaatgta	aatactttat	aacctgaatc	agtgttgtg	ttcatgaggg	10020



tagagggtcgt	gcattttatc	tctaggtctg	gtgatgccaa	tcctgatcta	cagccagcag	10080
caacagttcc	ctagcctgcc	tagaagtttg	taaatgcatg	ggctttggta	ggaggaagac	10140
gagagaaagc	agaacagatt	attacaaacc	cagtgcattc	ccccttgatg	ggtcaacagc	10200
gattttctttg	taagtgaagg	acagcacact	ggttttgatg	actcacgaga	gagtaggagg	10260
gaaaaagaag	tctgaggcat	tgccctggaag	cctcgctctg	cttaaacaag	tacactaatg	10320
gctcatgcct	gttactccca	gcacttttga	aggccaagat	gggtggatca	cttgaggcca	10380
ggagtttaag	cccagcctgg	tcaacatagc	gagacctttt	ctctattaaa	aataaagaag	10440
aaagaaagta	ataatgattc	aagttctcat	tctctacaaa	attcacttat	gactttccaa	10500
atgctagtga	aaacttttag	gtattgcaaa	actgccttaa	tgcataacgg	gattctcatt	10560
ttacttagtc	taagatgact	ttttcacttt	gaacttctgc	atctttatga	tcgcttagct	10620
ttctgacaag	caatttcagt	aagtgtttat	caatttgcac	ccacacgctg	acacataggg	10680
gtctacttac	atatccttca	tgttaattgag	cttttgtaaa	tcacttttct	acatggtaca	10740
cttctgattt	tgtgtgcagc	tttcttgttt	agcactgtga	ttaaatgctc	tgcttccctac	10800
acccttagga	acaatgagaa	taaaagcgta	atgttgggta	cttcttcata	tcaaaggaag	10860
ttcatctcct	ggttattaaa	agctattatt	aaatggccat	ctttttgtgc	ccctgtgtta	10920
agcactctac	caagatacca	ttaaatagat	aagggccaca	ctccatagag	atgatgggtc	10980
tatattctgt	attttctggg	ggagttctaa	tttcatgcaa	ttccttcttc	ttaaataaag	11040
gcaattctct	aaatatatta	cctaattgtgc	tttcactttc	atattcttgt	aagatttttc	11100
acataaatca	attctcaaaa	aatagtatca	taggcctttt	aaaaatagtc	atgttcaaaa	11160
gtcaggctca	tgaataaatg	tgtgcattca	ttacatatat	tttcataaat	tcaaatttaa	11220
aagaataaga	gtagctagaa	ggtggaagaa	aaatcttatt	ctgattagga	atgcacaatc	11280
acaagaaaat	ttgtgatata	tatagtcatt	ttattctgta	ttgttttatt	ttgattttgg	11340
taagacaaga	aacaatgtag	aaagtttgac	aacttaaaaa	agtaatatga	gtgtgagaaa	11400
gtcctctctc	aggattagca	aaaaaatggg	tttttttttc	tttttttccg	agatggagtc	11460
tcgctctctc	gccaggctg	gagtgcagtg	gcgcaatctt	ggctcactgc	aacctccgct	11520
tcccgggttc	aggtgattct	cttgccctag	cctcccaagt	agctgggact	acaggcatgt	11580
gccaccatgc	ccggctaatt	tttttttatt	ttagtagaga	cgggggttca	ccatgctggc	11640
caggctggtc	ttgaactcct	gaccttgtga	tctgcccgcc	ttagcctccc	aaagtgtctg	11700
gattacaggc	gtgagccacc	gtacccagcc	taaatggcca	agttttatta	tggacaatta	11760
agctgtagaa	taaaaatcta	cttttaatat	ctggcatagt	gcctagtggg	tttgaagcca	11820
caagcaggtt	tacaaaaaac	atttaaatcc	atctgaatct	acagaaaact	aagattacct	11880
aagcagaaaa	tgaaaatagt	tcaggattaa	ggaagattaa	caaatgaaga	gtatatgtat	11940
tttagaagta	ttactttata	tttttatagt	ataataataa	tatttacggt	cctacactta	12000
taatgagttt	cgtatatata	ttaaaataat	ttaatggatt	agtatgttta	tatttgcttt	12060
tagtaaaatt	ggtgtatgat	aaactcagtt	gtctacattg	tgagactaca	cctgaggcaa	12120
tttctgtggt	gatatatacc	tgaatagcac	atattacttg	ggagcaaata	aaatagcttc	12180
aggcctaatt	ttgcaagtcc	atgatgggag	agtaagcatg	acttcaaaga	actgactttc	12240
agttaaaact	tgaagaatga	atgtgacaac	agcaagtata	aaacaatgcc	aggcagaggt	12300
gggactgttc	atgggtatca	gggtaagtgt	gttgataaat	gctcaaagta	ggaaatacct	12360
ttcttcccc	acacatgtca	gaaaataact	gcaatagaat	gcaacgacat	ctcagagata	12420
aagtgttcaa	cttagctctc	agagaccggt	cagttacatt	ttgtaatgac	attggaattg	12480
attgcatttt	gaaggcaatt	ctaaatgcaa	agctctcatt	ttgttgatag	aagctggggt	12540
atttattatg	aaatttcaaa	aatttaagtaa	aatatctaatt	taggattata	ccagcaaagg	12600
caaattttaga	attcaagact	tcattgatcca	tggttaagatt	attttaatgc	aactctgcta	12660
attaactgaa	atttccttta	actctcacat	ctgcctttta	cttcttaaga	catttttcta	12720
gtatttcacc	agagcaagat	atcagaaggg	taaatctctt	accaatgaac	tttgctaatt	12780
cttagtgact	ccgttgaccc	tggtgtaagg	atcaggaaca	aagtgaatga	aatacatatt	12840
aatacatttc	gctttctctc	aattccaaag	accactctaa	agaataagtt	atttgtgggt	12900
atttatctgaa	acttgggatt	aaaagagacc	gtgattaccc	ttcagggatt	ttggcaaaac	12960
ttaagccatt	tcactctgaag	agcaaaagcaa	gcctcccaca	ctcttggctt	attctcacia	13020
ttatctagat	atctagcaac	aaaactcttg	agtagtttgt	taactacaga	tgccaagggc	13080
tgacagtttc	actttcagtt	ttcagaatat	cttttgtttc	agtgggtgtaa	gcacaccatc	13140
agaatctcta	ctatttataa	taattaaagt	ataattgttaa	cttccattag	atgtagtact	13200
taaaggaatc	tagaagacac	aactcattaa	ttataggaat	ttgactgcaa	attcttcttg	13260
ggggctctgaa	ttgcaaagga	ggcatctttg	taagtccagac	tcaactcatt	actctgtgat	13320
gcaggctcct	ccaaatggca	gcagaaacgt	attactctct	agaaacacta	cagtagtgtc	13380
acaatttcag	ggttctgtag	agataaggac	aaattgacag	aaacacattc	ttagaaggac	13440
agtatcattt	aaaataaaaa	tactgtcata	attgtacacc	aggatagctt	ctccataata	13500
aattctttat	gattttctga	tttttagaaa	tcagaattga	actttttaat	gtgaaaaaaa	13560
tgagagaatt	gtttcaaaat	aggaccacat	ttctgtgtat	aatttttaaa	gttttaaaaa	13620
atttgattag	tagactgata	aactgaaaca	tttttgataa	gcttttcatt	acatacaaac	13680
catataattt	gtaaaaaatt	ggaaattatt	caaaacttca	cataactaaa	gtgaccaaat	13740
aaatactgga	gaggaaagaa	aaggagtcaa	atgaatctag	cattttcttt	tttttttttt	13800

ttttggagaa	aggggtctcac	tgtgccacccc	aggtggggagt	gcaatggcac	gatcatggct	13860
cactgcagcc	tcaactttat	gggcttaggt	gatectccca	cctcggcctc	ccaagtagca	13920
gggactacag	gcatgcgcca	acacgtccag	ctaatttttt	tggtattttt	tgcagagacg	13980
aggtttcacc	aggttgccgt	ggctgatctg	gaactcctgg	tctcaagtga	tctacccaac	14040
tcagcctccc	aaagtgtctg	gattacaggg	gtgagccacc	gcacccggcc	taatctagca	14100
ttttctaaaa	ggaaggaccc	agcagtgaac	ggcaatatca	ataatcatgt	tcaagactat	14160
cagacatgca	agctggggat	gaatgggtgg	aaggggaaaa	tgatgaataa	atgatgaaca	14220
caagtataga	cccagtggtg	ttgagatgcc	caagatgcca	gtgagatatt	caaagtttaa	14280
ctcaaaaagcc	acttcccata	tgaatccttg	acaaacactc	ctacgtccaa	ctggaattaa	14340
tttctcttct	gggctcccac	agcactctgt	atttttctaa	tagcataaca	ctattttggt	14400
tgtagatatt	tctctgatag	cattactatc	tttctctttt	atcacaactg	tttgaagttc	14460
ttttgcctct	tgcattccact	gttgcccaat	cccactgctg	gaaggctcat	cttattaagt	14520
tctgtattcc	tagtgctaac	acactgtcta	ccatagatga	tggtcaataa	atgggtgcta	14580
aatgaattct	cttgtgataa	tagcactatg	gcaacataat	cgacggtaaa	aattttcttct	14640
caatgtttac	tttttagcaga	atgcattcat	ttatcaactt	tcattgagaa	tatgctaatt	14700
tccatgaccc	tagtaggaaa	taggaaaaat	aagatgaatg	taataagggtg	ctcattctac	14760
tgaaagtctt	gactagtggg	gaattatgga	tccaactttt	catgaaatgc	cttcagtggt	14820
aagaattctc	atatttggaa	taaaaaatgt	tatgggttgt	gccaaagatac	ctacataact	14880
cataattttg	tagagggctg	tccttactgc	agaaatgtat	actactatag	tcatatgtgg	14940
aaattctttt	tatgatgcta	actgcatgct	aaccagactt	tttaatttaa	tacttgcatt	15000
aaataaaacca	tgctaggaat	ccaggaatct	agcttggttt	attttccata	caatgtactc	15060
tttgtaatat	gcataatac	cataaaaaat	ctattaatgg	cctcgtacta	aagatgtgtc	15120
tggtggggaa	tcagttatct	tgtataattt	tactttaatt	gatataattaa	aatctagcaa	15180
aaatataaac	tccagagtaa	agtatctgca	tggtgtgcat	atgtttatta	ttttaagttg	15240
cagcgtatac	attttcatgc	cataaagtta	taaaatgaaa	aaatagtagc	cttttataatt	15300
aagttcatgc	ttatgtagtt	agtaaaaaaca	agaaagcaat	taacatacaa	accatgatgg	15360
tggttaaact	tgcttcagtt	tgtgtttttt	aaaatttgaa	agtgagaaat	acagctcgaa	15420
gtcagctcat	attttcagta	agtactgatg	aggatgtact	ggccctattg	actacgtgta	15480
ccccattaaa	atatttgtga	gtctaaaagg	tcatatgacg	ctgttccttc	actctagcaa	15540
caggccatac	atgtcttaca	tagggactct	gttcaattca	ttaatacctc	ctgaagtgtc	15600
caacatcggt	gttcatttat	agtagatact	caatacatac	tccattaact	gaattctaag	15660
ataaactgtc	tgttactgac	agaaaattttc	acttaaggga	gtctccgtgg	ctgaaggcaa	15720
ttttgaaatc	ctgtaaaaaga	acccactcct	ctccccaagt	aatgaagttt	gtcagtttca	15780
agcctgtaat	aaggtactga	cttaaaaatta	atttttcta	aatacagtac	tgctatgtat	15840
cctaatgtggg	gttagtcaat	gataggaaaa	aaacataaga	cagagtcaca	tttaaaaatg	15900
tgtgcttagg	tgcatgggtga	cacctgctg	tagtccagct	attccagggg	ctgaggcgagg	15960
aagatccctt	gagctcacga	gtttgagggt	gcagtaagcc	actgcactca	gcctgggcaa	16020
cagagtggaga	ccctgtctct	aaaaaaaatt	cgttttaagt	gtgctcagga	cataacagga	16080
gccgctggta	acatgccatt	tccactgtga	atatggtaag	gacagaatcc	ctgtctctag	16140
gccctcttcc	actagtcaat	ctcatcatca	ccatcaaggc	caacattggt	attctctcct	16200
ctgagacaaa	gtctttgaca	ttttctatac	tatactatgt	cttcctctcc	ccaaatgcat	16260
atacaaaata	aatttgaatg	cttctttctc	catttagtgt	aatttttttt	ataacataga	16320
cccaattttc	aaaccccaca	atgggtggatt	ttatttgatg	tattgtaaaa	agcgctggat	16380
tgaagtcaaa	tggttgggga	gacctaaatt	ctactcctgc	ctgtaccatg	aaagagacaa	16440
atcccaaggc	tttgcagggc	ttcagcttcc	ttgtttgtag	aataaagaat	tataaaatca	16500
tctcttttgg	tctactggg	caataaaaag	ctatgattct	aagcctgttc	cctttttctca	16560
cctaagaata	caaatttgat	acaaagaggc	cgcagaatgt	gtcaaacact	ccctgttgcc	16620
tggaattctc	tcttcttttg	ggttcagggg	taaaggatag	ttatttctta	agtctccctt	16680
tgctttcttc	tgcttgcttc	gtaaatat	ttccatcttg	gcagtcctac	atgtcttctc	16740
actctacatg	ttttccctag	gtgatgtgac	ccagcctgtg	gcttccactg	ccatccacac	16800
acgtcgtctg	ctctctccac	atcagcatcg	caactatctc	ctggaagctt	tccaagtgtc	16860
gaactacagt	aacctcaacc	gaactgctgt	tcattcaccc	cacaggcttg	cccctcctct	16920
gcattcttgg	gagaacctga	gagtcactct	aaactcctcc	ttccacctca	ctccccacat	16980
caaactcgatt	accaacttgt	gctgatttta	tcttcaata	ctctccagaa	ttgtcgtctg	17040
catggactga	atatttgtgt	tccccaaat	tcatatgtcc	taatccctga	tgtgactgta	17100
tttagagacg	tgacctctaa	ggagtaatta	aggttcagtg	aggtcaaagg	tgtagccctg	17160
atctgatagg	atcagtgtcc	ttataagaag	agactagagc	tgggcacagg	ggctcacacc	17220
tgtaatccca	gtattttggg	aggctgaggt	gggaagatca	ctcaaggaga	ggagtctgag	17280
accagcttgg	gcaacagagt	gagactccat	ctctacaaga	aaataaaaata	gtcagacaca	17340
gtggtacaca	cctgtgggtc	cagctcctca	ggaggctgag	gcaggaggat	ggcttgagcc	17400
caggaatttg	aggctgcagc	aagctatgat	cacacctctg	cactccagcc	tgggtgacag	17460
catgagaccc	agtctcttta	aaaaaaaaaa	aaaaaaaggc	catatatagc	ccagaagagc	17520
gtcctcacca	aaacccaatc	ctgatagcac	ctggaggact	tccagcctcc	agagctgtga	17580

gaaaattttct	gttgcttgca	cogcccagtc	tgtggtattt	tgctgtggca	gccccagctg	17640
actcatcagt	gaccttctct	ctgttacccg	agagtagctc	atcatcctct	cttccctaga	17700
gtccagccac	tctctcacat	ctacctacct	agcagtatca	ctgtgggtta	gagtcagatc	17760
actgcggtat	aagtcctcat	tctgccactg	cctgtgtaaa	tctgagcaag	ttactttaatc	17820
tctctgtgtg	tcagtaacct	ccctgtgaaa	tgaggctaata	aatagcaggg	ttgtttcaac	17880
aaggcgatac	atgcataatg	cttacaacac	agcttggcac	attataagca	ttcaacgaaa	17940
agtgagctac	tattatctca	tccgttatca	gaataaacca	cctaagccac	aaggctgccc	18000
acatcatcct	catgttttaa	aacacttcag	tgggctcccc	accatcaaca	ggataaagtc	18060
caagcttctt	tagcattttt	tagaggctcc	atatgaatcc	ccaagttcca	ctacaggaac	18120
acaggtgaac	tttccactcc	aacctcaggc	tcttctgtgt	cactcctcat	ccacatggag	18180
gtaagcagca	agagactccg	tgcagttcct	ggtggttccc	tgacctctag	gcagactctc	18240
cccagccctc	tgectgcaac	gtccttgccc	tttgcttccc	ttggccagct	cccattcatt	18300
ctccttgatt	ctgcttggaa	gtttccctct	caggaaaggct	ttatgaacct	tagttaggtt	18360
tatgaacca	tctttgtctc	tttcatacct	tttgcaaggcc	tttattttatt	atgacattta	18420
accattatca	tactgaagtg	acctgttggg	gtgtctttgt	tccccactag	acagaaaact	18480
caagatcaga	gaccagttct	tgctcttttt	tttttttttt	tttttttttt	ttgtatcaca	18540
gtgttttagca	gcctgtctata	tggtaaatgt	cagtaaatagt	tccacaaaact	gaatggaatt	18600
gagctcttga	atctagacca	tcttttccat	acccatcact	cctgtcttag	ttgaagtctt	18660
tatttcccat	ttgaagcaat	gcaaaggatt	tccataactct	aatctctctt	ttcttcacac	18720
catcctttta	acagccgaca	gaatgggtcat	cctaaagcac	atatactcta	tcttacatat	18780
cctagattcg	gaacctctct	gggcttctca	ccatataaga	agaaagtcta	acctccttag	18840
caaggtgcat	aggtcttcaa	tgggctccac	ctcacttctc	tatatatacc	tatactcttg	18900
ctacactaaa	cttctttctt	actgttgctg	gaacaagttc	aacgctttca	aacctccctg	18960
actttgcata	tgcagttcat	tctgtcagga	atgcccttct	ctcttatgcc	tgggatattc	19020
tcattcatte	catattgacct	atttcataag	tcactcctta	atgaagcctt	tcttagatat	19080
ccactggggc	aatcagctgc	ttgtctctgt	ttccacagca	cattgttcac	acagatagca	19140
caggacttac	cacaagttat	tataattttg	tctgtcttgc	ccatttgaat	ccaagggcaa	19200
ggacggaatc	attctcatct	ttgtatgtcc	tgggaactag	aactgtacct	gagacataat	19260
aaacacttga	tatgttttga	atttttaaat	aagttaatatga	acggaatggc	tagaaaaagt	19320
gagaagaaac	tctggcttac	tgtatatcat	actgtcatac	taaaaatata	tactgaagac	19380
agaatcacat	tatatcatca	cttttcacgc	tataggccat	gatccattat	gaaaaagagg	19440
atagtaaaaa	aatcacaggg	cacaattttt	gtttctgtca	cacacatgtg	tacctgtata	19500
ttggactgga	atgtaaaacg	catgttccat	tgtagaacgt	ggttttaaaa	gaggcttgga	19560
aaacactgca	tatggtcatt	tcttagttta	gtacaattta	ttattttcgt	aataacctca	19620
gctataatat	aagtctacca	tgaagcattt	tggggagatt	aaatgagatg	tgaaaagtaa	19680
actgtttaga	tagactgaat	tcatatcata	gcttgctctg	atactttaca	aaacatttaa	19740
ccttaccac	aagttttagt	ttctcacta	aagtcacctc	gaggacagta	atgggatctt	19800
cctcacagag	tattgtgagg	aatacataag	agaacgtacg	taaatgcttg	gcacttagta	19860
tttattcaat	aaatcttagc	aatgatgatg	ataacaacat	ggtacctggc	acataagaga	19920
gttaaaaaat	agttttcttca	gtcaaatgtg	cttacattga	tagttgatac	taactggggt	19980
taaaagggtca	ttgctggcat	ctcagaaaga	tagattacag	tgaaataaaa	aatgactact	20040
gcttaaaatg	aattgaagact	tatttacaaa	gtcatgttca	tctggtacaa	taatgaagtc	20100
gctcaatttg	gagaaaatga	caaataatac	aagtgaatat	acaatcttac	ttaagacgaa	20160
agaaatagga	caccaggcta	actatcagtc	tcctaaacca	caactttatt	tctgatacaa	20220
agagacagtg	agacaatcag	ggcttccctc	aaataaatta	cttaatctct	cttcaattca	20280
gttttgcatc	tgtaaatata	aataactaca	atttcacagt	atttccattt	aaaaagttct	20340
agtgaacat	cagaaacaag	aacttagtag	gtgttcaaaa	agaaatataa	gttctgcttt	20400
gttagccagc	aaatagttgc	ctgtttctag	ccctcacttc	ttttctccta	aatccctata	20460
ttgcatttat	ttaaactaaa	gtgctggatg	tggcactacg	agaaagaaaa	agatatttgg	20520
taatcttggt	aaaatcatta	gacatcccag	gctatctgga	atcaccttgg	gctcacagtt	20580
agacatcagc	tatggcttgt	tttattttaa	aattcatcca	ctgatgcatg	ataatggaat	20640
tcacaggaga	gcaattttacc	aaaaaaaaaga	aattttattga	tttataatgt	gagatattaa	20700
tttagccaca	aatattttatt	gagcatctcc	tacatgccag	ggaatggact	atatatggca	20760
ggaaaacaga	taccaatcat	ttatatcagg	catttttttc	taatagaagg	atattcgca	20820
gagacaatgc	atagcaccat	gccttgcaag	taacagacat	ttaataacta	ttagttgaat	20880
aaaattggag	actagaatga	tacataaaga	ggcaagaaag	agcaaagata	agcctttctg	20940
agaattttcta	tcatgttttg	ctcaatagct	tgtctttatc	cactgcttgt	atttttccat	21000
gtagctaata	ctcattgggtc	gttagaattg	agacaccctt	tccttgaaat	caggagctat	21060
aggaggccat	tcttctctact	gggcatttttc	tttctgggac	agggctctac	tctgtcacct	21120
aggctggagt	tcactatagc	cttgaaagtc	accatgccag	tgggctcaag	gaatcctctt	21180
gccaaagagg	tgggattaca	ggcatgagtc	acctgcctaa	cctatttggc	atttctactg	21240
tagacaaagc	agacttacag	cagtagggtct	acctgcctaa	tacaaaaaga	aaaaaaagaa	21300
ttttaacaaa	caaatgaggg	aatcagatcc	agaaagtgtat	tcttataact	tagattactt	21360

agagtagatc	tataatctgc	tctagatcca	ctgcatacag	tgggcccttc	ttatcatatt	21420
ccataaatag	cactttttctc	agcccagctt	ttgatgatag	ctgaacagac	taacagtttg	21480
tctaacaaag	gctagagaag	gggatagcaa	ataatggccc	acaggctgaa	tcctgcctgc	21540
tgctcatttt	tgcaaagttt	tattagaata	cggtcatttc	cactcatttt	cacactgtca	21600
atggctgctt	ttgcgctaca	gcagcagagc	tgggtggttg	gggcaggggt	cacatggcta	21660
acaaagacta	aaatacttat	catctgacct	tttacagaaa	gtttgctgat	ccttggagtg	21720
tacaagtatt	ctatatgttt	gattaagaac	agaaccacaa	gtattagaag	ttagaccagc	21780
aggtggtaaa	gctgatcatc	tactaatata	atggaaattg	gggttcccaa	tcaggactct	21840
tgctttgata	gaaggccatc	ttaacgagga	gggagacacc	tgcaggcaaa	gtcagaattt	21900
tctgcaggaa	aagttttgag	tccattttccc	cttgtgaaca	agtgtcagc	tatgcatttc	21960
atcttttagta	accatgcttc	tatacctggg	tctccttggc	aaagattttct	ttcttcagta	22020
agtctcaaga	ctttctggga	aggtagggag	atatgggggt	aaaagtgtcc	caggacttac	22080
tgaaggaagt	gttttatgat	tatctgatag	aatcactgta	tcatggtaga	gaaggcaaac	22140
agaataaat	ctgaaaatag	aggtgagggt	gaacaaatgg	gcactaaaag	tgaactcagc	22200
atcaggaagg	tagcaaaaca	agacatcagt	caaagatatg	gggtgattca	gacctaaagga	22260
agatttaaatg	tgggatgttt	ccgtgtgcca	ggagctggac	acttaagcaa	gaggagatcc	22320
aggaatgttg	ctaaaaccat	ggcctccata	ctttatttga	attagcacia	cttatccttg	22380
tttctttcat	tttgcaatca	aaatctttta	aaacacatta	tttaaaaata	cattatttta	22440
aaagctagaa	tgaaaattat	galatcattt	aggtggttta	aaaaacatcc	accagccggg	22500
cgtgggtggct	catgcctgta	atcccagcac	tttgggagtc	cgaggcgggc	agatcacgag	22560
gtcaggagat	tgagaccatc	ctggctgaca	cggtgaaacc	ccgtctccac	taaaaataca	22620
aaaaatlaac	cgggcgtggg	ggcgggtgcc	tgtggtccca	gctactcggg	aggctgaggc	22680
cggagaatgg	catgaaccog	ggaggtggag	gttgcagtga	gctgagatcg	tgccactgca	22740
ctccagcctg	ggtgacagag	caagactcca	tctaaaaaaa	aaaaacaaaa	accatccacc	22800
aaaatgggaa	gaagtgatga	aaaattacag	tccaagaaga	agggccatag	ctgtttaaat	22860
caattgggat	atltgttata	taatataaac	ccacgtaacg	acaggtattt	aacaaatgtt	22920
tctgctgaat	ttgacgattc	catttccctt	acatcccata	tgcaatccat	cagcacccca	22980
catccaaccc	atcagtagat	cctgtcagca	ttggctccca	aatataacct	aatctaaca	23040
catatcctac	tatctctgct	gctacaactt	tagtctgaaa	tctcataatc	tcccacttgt	23100
actactgtag	atgactctga	atgagtcttc	ttgcttccat	tccacacagc	atccatactg	23160
actatatttt	tttttcaatt	ttttgtagag	acggggtctt	gccatgttgc	ccaggtctgt	23220
cttgaactcc	tggtttcaag	ggatcctccc	acctaacctt	cccaaagtga	taggatttca	23280
agtatgagcc	actgtgccta	acctgacttg	atcttttctaa	gcataaatct	aataatgccc	23340
cttccttgat	taaaccttcc	aatgaattca	catttaagcaa	acaacctggc	caggtgtgat	23400
ggttcatgcc	tgtaatctca	gcactttggg	agaccaagat	gggaggatca	cttgaggcca	23460
ggagctcaac	atcagcttag	acaacatggg	gaaactacat	ctctacaaaa	aatacaagaa	23520
ttagctgggc	atggtgggtg	acctatagtc	ccagctactc	gggcggctga	gctgggagga	23580
tcacttgagc	cctggagggtc	aaggcagcag	tgagctgtga	ttatgccact	acacttcagc	23640
ctggatgaag	tgagacctgg	tctccaaaaa	aaaaaaaaaa	aaaaaaaaaga	agcagggcaa	23700
gggtggctcac	acctgtaatc	ccatcacttt	gggaggccaa	ggcaggcctc	ctggatcatg	23760
aggtcaagag	atcgagacca	tcctggccaa	catggtgaaa	ccccatctct	actaaaaata	23820
caaaaattag	ctgggcattg	tggcatgcac	ctgtagcttc	aggtacttgg	gaggctgagc	23880
caggagaatt	gcttgaaccc	gggaggcgaa	ggtgtcagtg	agccaagatt	gcctggtgac	23940
agagcgagcg	agactctgtc	tcaaaaaaaa	aaaaaaaaag	aaagaaagaa	agaaagaaag	24000
aaagaagaaa	tccttagtcc	tgtcttaact	acttgagagg	ctgagggagg	aggatcactt	24060
gaacctagga	atlttagggt	ccagttagct	atgacagcac	cacggtgctc	tggtctggag	24120
agagttagac	cttgtctcta	aagaagagaa	aagaaaagaa	tgaatgaatg	aacaaaaaga	24180
aagaaggaaa	ggaaaagaag	agagagagag	agagaggaag	aaaggaagga	aggaaacaaa	24240
ataaaataaa	ataataaata	aataaaccca	aatccaactt	ctttacccta	atcaacaagg	24300
ctcaataaat	ctcatgccaa	ctaagtctct	gaacagctcc	ttccattcta	ttgccagatt	24360
actccatctt	tcagccacaa	gaccttttta	tcttcttttt	accagccaaa	cacaatccta	24420
cctcagaaca	tgtgcacttt	ttctttttctc	tgacttgaat	ctcctccacc	cattatataa	24480
tcttagctca	aagaggcttt	tcttgacaac	ttagcgaaag	tatttatccc	agtcattctc	24540
tgctacatta	ttccaattta	ttttctccat	agtacatttc	agcacataaa	gatttctcta	24600
gtatgtgctt	gttgcccttc	cccaacctcc	taaaatgtca	gcattccttg	agggcagaga	24660
ctgtttcatt	cctgtatcat	cagcacctaa	gacagttcct	ggaacatacc	aagtacttaa	24720
taaaaatttg	tttattgact	agctatgaca	cattttactt	atataatttc	attttctcag	24780
caaaatgaac	actttgaaat	gtaattaat	actgattttt	gcagtatttt	ctaattattt	24840
aaataaaata	tttactattt	tggccaacca	gaattcttac	attgttttag	caccagata	24900
gcttctaata	atgcttacaa	ttaacacaat	tttatctagc	aatatgtatt	tatcactaga	24960
cagaatgcac	tgaactcttc	ttcatttaata	aaaagcaatc	caggctgggt	gcagtggttc	25020
acgcctgtaa	tcctagcata	gtggaaggcc	gaggaggagg	gatcacttga	taccaggaat	25080
tcgagaccag	cctggccaac	atggcaaaac	cccatctcta	taaaaaacac	aaaaatttagc	25140

tgggtataat	agcagacatc	tatagtccca	gctactcagg	aggctgagag	gtgggaggac	25200
tgcttgaccc	caggagattg	agggttgag	gagccgtgat	tgtgtcactg	cactccagcc	25260
tgggctacag	aatgatacct	catctaaaaa	aaaaaaaaaa	ttagccaggc	atggtggcat	25320
gcacctgtag	tcccagctac	tcaggaggct	aagggtgggag	ggtcacctga	gcctggaagg	25380
tagagactgc	agtggagccct	gggtagcccg	cgccactgca	ctccagccct	gagtgacaga	25440
gaccagttt	caaaaaaaca	caaaaaacag	aaaacaaaac	aaacaaaaca	aaaaacccaa	25500
tgcattgctg	aaatgttaaa	tccattataa	agaaaagtac	aggggtgggc	atggtggttc	25560
atgcttgtaa	tcccagcact	ttgggaggcc	aagggtgggca	gatcacttaa	ggtcaggaat	25620
tcaagaacag	cctggctaac	acagtgaaaa	atgcaaaata	caaaataagc	cgggagtggg	25680
ggcgcatgcc	tghtaatccca	gctactcggg	aggctgaggg	gggagaatcg	cttgaacctg	25740
ggaggtggag	gttgacagtc	gccaaagatcg	aactccagcc	tgggtaacag	agactccatc	25800
tcaaaaaaaa	aaagtaaaaa	gtatatagtt	gattctgcag	ggacttaaaa	aagtataaat	25860
atctttttta	aaatcacaaa	gctctgatat	ctgcaggttt	atgactaact	actagctcac	25920
tcccatgaat	acacgtatgt	aaacaggctc	tatacaatct	acaatcccag	actaagggga	25980
aaaaactgtc	ctgtcactgt	gggtctccaac	ccttggccca	tttctttcct	cttgaccaca	26040
aaactttctc	ggagttgctt	gtttcctctt	gatccactta	tcttttagccc	actccaatct	26100
ggcatcggtt	ctcagtagtc	tccactaaaa	ctgcttttat	gaaggccatc	aatgacgttc	26160
atgctgccaa	atccagcaga	cacctcctgt	tttctaattt	tttttattgt	tattttttta	26220
gagactgggt	cttgctctgt	caccaggtcg	ggaatgcact	gatgccatca	tagctcactg	26280
cagccttaac	ctccctgagt	tcaagagatc	ctctacctc	agctgggact	acaggcatgc	26340
acagctatgc	ctggctaatt	actcaatctt	taacatagct	gataattccc	tccttgaaac	26400
actctcaact	tttaagaaac	cctgttatct	tcctcctaca	tttttagcca	gttcttctat	26460
cagcttctcc	ttatctgacc	tctaaatgtt	aagaacatta	acaaagactg	aacctagttt	26520
ttttctcccc	ttactgtact	gctcctgggc	gatgtcaatc	agtcccattg	ctttagatac	26580
tatctgttga	aacactgaaa	tcactgggtt	tttttgtttt	tttttttttt	tttttttttt	26640
ttgagatgga	gtttcgctct	gttgcccagg	ctggagtgc	gtgggtgcaat	ctcggtcac	26700
tgcaagttcc	acctcctggg	ctcaagcaat	tttctgctt	cagtctccc	agtactggga	26760
ttacaggtgt	gtgccaccat	acccagctaa	ttttctatt	ttagtagaga	tgggggttca	26820
ccatgtgtcc	aggctgggtc	taaactcctg	acctcaggtg	atctgcccac	cttggcctcc	26880
caaaggttgg	gaaaagatat	cccaatcttt	ttcctatgat	ttcttaattg	atctacttga	26940
catatccact	tggactttta	ataggcatct	caaacttaat	gtgttcaaaa	taaacctcgt	27000
gactttccct	cccaaacctg	tccctacctc	cctcaataac	taatattatc	attcttatat	27060
tcatatattg	aataaatgtt	tgttccccca	agtatttggt	gctataaatt	tatgaagaat	27120
tcttttctca	ctagttatta	taattaaaat	gtaatattta	ttttctttta	aaactttact	27180
ttgtaggatt	attatttttt	aaacagggac	caacaataaa	taacttctct	acttgattaa	27240
aactagggtc	tctcttgtgt	ctccctcagg	actatttctt	tgtaaaaaca	ataggctaaa	27300
tcagtactgg	tgtcaagaaa	atcataatct	cacaacttta	taaatacagc	atgtggcaga	27360
ggattttccc	atcttatata	gtaataaaat	tttcagctgt	gccatggcta	aaagtttacc	27420
atcaaagttg	gaatttttaa	ttagaggtag	tcacttttct	ttctttttta	agaaatggag	27480
tctcactatg	ttgcccaggc	tggagtgcag	tggctatttg	caggcatgac	cacagcacgc	27540
tacagcatcc	tggcctcaag	caattctcct	gcctcagctt	gccaaagtag	tgggactaca	27600
ggctccctgc	accacaccca	gcagaaatat	ttagctttct	gaatttctca	agtgtgtgta	27660
tgaatgagac	tagtgggggt	cttaaccaag	cttagcagga	tttttagtga	tttatataat	27720
aacttggatt	tgtatctacc	agcatgttct	ttgaggtaca	ggtatgtctt	ttatatctcc	27780
taatatagtt	cattacaatg	ctaaatacta	agatgtgatg	ctcacacact	acagaatagc	27840
caagcaaagt	aactacttat	tctcataggg	ctattataat	taacaaattc	ttgtatcacc	27900
ccatcattat	caacaacaac	atgataggat	ttccttttat	cttgaagagt	ctggaaaaag	27960
ggtaacagag	agatatttct	gaggaacaaa	ctggtaattg	gggagctact	gtgtccatta	28020
caatactcct	tctagaagct	caatacataa	tgactaatct	ctggaaaaaa	gcaagtgtga	28080
gaatggaagg	ctcttcttca	aactatgcaa	aatgaatcaa	tcagcagtga	acaaatttat	28140
gagccaaaca	aattcctaca	aaaattacca	tcatatgctg	tcatgcatgt	ctgccagtct	28200
atttatcata	ttattttaaga	aacaaacatt	tattgaagat	ttatcatgtg	ctcagcactg	28260
ccaaagagga	aataaagagc	ataatatcta	ttcttagaaa	ataacattaa	cacaaataga	28320
aaacaagaaa	ccataatggt	aaaaatatata	catagtaaca	cagaaagaca	atgtataatt	28380
atacatacgc	actaaagcaa	agataacata	atttataaat	tatgaggtac	agaatagtta	28440
gattctgaaa	attaaaataa	tcaggaaaaa	cttcatgaag	atgagatctg	ggctggatcc	28500
caaaggatag	gcagggtggat	catgtagaac	aggggaaagg	agttcctgat	cggggatata	28560
atatatgtaa	aaactcggag	acaggactga	gcgtgaaatg	ttaatgggac	agtaaagaaa	28620
tcttctctct	cagcggggga	aaaaacagaa	taatgggaaa	ctgcatgggt	aaaagggttt	28680
atgttaagat	agtgtcttga	cacaaaagat	cttaaagttg	agtcaaaaga	gtacaatgaa	28740
agcattagaa	atagaagata	aaacacaaat	aggccgggtg	cagcggctca	tgccctgtaat	28800
cccagcactt	tgggaggcca	aggtgggtag	atcacttgag	gtcaagagtt	tgagaccagc	28860
ctggccaaca	tgggtgaaacc	ccgtctctac	taaaaatata	gaaattagcc	gtgaatgatg	28920

gctcgtgcct	gtagtccag	ctatttggga	ggctgaggca	ggagactcgc	ttgaatctgg	28980
gaggcgagg	ttgcagttag	ccgacatcgc	gccactgcac	tccagcctgg	gtgacagagc	29040
aagcctctgt	ttaaaaaaa	acggtaaaaa	taaataacat	ttactattgt	tttctgatga	29100
tatatatggc	ctctaattgt	aaagctgaat	gcctagttta	ccactttttt	tttttttttg	29160
agacggagtc	ttgctcttgt	tgcccaggct	ggagggcaat	ggcacgatct	tggctcacca	29220
caacctctgt	ctcccagggt	taagcgattc	tccagcctca	gcctcccag	tagctgggat	29280
tacaggcatg	tgccatcatg	ctcagctaatt	tttgtatttt	tagtagagat	ggggttttct	29340
catgttggtc	aggctgggtc	caaactccca	acctcagggtg	atccaccgc	ctcagcctcc	29400
caaagggctg	ggattacagg	cgtgaaccac	cgcgcccggc	ctatcattct	tattttatgc	29460
attaggaaac	taaggctcaa	caagattaaa	gctgtctagg	gtcacaaga	ttgtaagtgg	29520
aggggctaga	attcaaaatg	agacctgctt	gactcctaag	cctgtaccat	ttctactata	29580
tttagagtga	agtagatggg	ttgaagaaat	atttaggagg	tgaaatttca	aaagtgtaca	29640
gtcagaagag	aagacatata	tggaaaccta	aattttcaca	cagtaaagtg	tcaataataa	29700
aggcataatg	ccaaaaatg	agaggctgtg	catgttggct	catgcctgta	atcccagcac	29760
tctgggaggg	tgaggcagga	agatcacttg	agcccaggag	tttgacacca	acctggccaa	29820
cacagcgaaa	ccccatctct	actaaaaata	caaaaaatta	gctggtaatg	gtggtacaca	29880
cctgtaatcc	cagctactca	ggaggctgag	gcatttagagt	cacttgaacc	tgggaggcag	29940
aggttgccat	gagccaagat	tgtgccactg	cactctagcc	tgggcaacag	agtgagactc	30000
tgtctcaaaa	aaaaaaaatg	gaagactcga	gggctagaac	cctgaaattg	ggaatgaaca	30060
ggactggctg	aaaatgtttc	ttgcacctga	taaaaatcct	gaagaagaat	gctttaaata	30120
gataagaaag	gagagagaga	ggtagggcagt	gagaggagac	caccttaagt	aatcagagat	30180
tacttacgtt	ggttactcag	gctgggtctct	gaatctgatt	ataaatgaaa	tagagattac	30240
ttaaaacaaa	gggctgtaag	gtagcactgt	ccagcagcac	tttctatgat	ggaaatcttc	30300
tatatctgca	ctgtccaata	aggtgtagct	gtagcacat	gtggccactg	agtacttaga	30360
atatagctac	gacaaccgag	aggctgaatt	ttaaatttaa	tttaagtgaat	tcaaacaaat	30420
ttatttttaa	tacagcactt	taaattttat	ttttaaattt	taatctatta	tttatttaga	30480
gactgggtta	tgagactggc	taatttttgt	atttttggtg	gagacggcgt	ttcaccatgt	30540
tgcccaagtt	agtctcaaac	tcccgggctc	aagtgatcca	cctgccttgg	cctccccgca	30600
aagtgtgag	aatacagggtg	tgagtcaacca	cgcccggcct	aaacttaaat	ttaaatagcc	30660
acgtgcggtg	agtggctacc	atactgcaca	tgcaactgta	agatgtagaa	gtcagatgtg	30720
agcaagaaaa	tgacaagccg	ttcaatgctg	ttagagaatg	aaattcaagg	ttccaatgat	30780
ctgaacttgt	gtcccccaa	attcgtatgt	tgaaatctta	atcctcaatg	caacagtatt	30840
aagaatttgg	ggcttttagga	ggtaatttgg	ttttgagggg	ggagccctca	tgaataggat	30900
gagcacctga	ggtagcctct	ttgacccttc	caccatgtga	ggacacacca	cgaaggcacc	30960
atgttgggaag	cagagagtga	gcactcccaa	gacactgaat	ctgccacatc	ttgatttttg	31020
gcttctcagc	ctacagaact	gtgagcaata	aatatctgct	gtttataaat	tatccagtgt	31080
aaagtatttt	gttatagcag	cctgaataga	ctaagacaaa	ggtaggactaa	ggcaggataa	31140
cagggttagaa	aaggaggcag	ggcctttttt	tttttttttt	tttttttgag	acaaagcctc	31200
actctcacc	aggctggagt	gcaatggcat	gatcttggct	cactgcaacc	tccacctcca	31260
gggttcaagc	aattctcctg	tctcagcctc	ccaagtagct	gggattacag	gtgtgcacca	31320
tcacaccag	ctaattcttt	gtatttttag	tagagacggg	gtttcactat	gttggccagg	31380
ctagtcttga	actcttgacc	ttaaatgatc	caccgcctc	ggcctcccaa	agtgtctggga	31440
ttacaggtgt	gaaccatcgc	gcctggccga	ggcacagtgt	ttttacagag	aagcctgttt	31500
aagggtttaat	catataaaat	gtatgatata	cagtaagttt	tgatataaaa	aagaaacacc	31560
tggcgatttt	atataatata	ttgtgctaag	gaattttaag	cactctacat	tctgtctctc	31620
aagctctgta	aagagcacca	gggatttttt	tttttttttt	ctttttgaac	agggctctgc	31680
tctgtcagcc	aggctggagt	gcagtggcac	aatcttggct	cactgcaacc	tctgcctctc	31740
gggctcagcg	attctccac	ctcagcctcc	tgagtgggtg	ggaccacagg	cgcagtccac	31800
tacatctggc	taattttttg	tagagatggg	gtttgcccac	gttgcccagg	ctggctttta	31860
actcctgggc	tcaagcagtc	ctccacactt	ggcctaccac	gcattgctgg	ccacaacagg	31920
gattttttaa	tgtaagacta	cctagtcaac	tcttattcta	tattaacaat	atagacaaga	31980
aataacctct	aagtaatctc	tatttcattt	ataatcagat	tcagaggttc	tcttatgctt	32040
tacaatattg	tctactgtg	ggtagcgcaa	taactaagg	aatctgaaag	accagttata	32100
ttatatacta	tagttaaatg	catttcaact	gcattgggaga	aagcaactgt	gttctttcct	32160
ctcaatttta	acagaaggaa	aattgtcaaa	attagcttat	ttagaatgtc	ctatcagaga	32220
attattttga	ttaaaatata	tttttaatca	ataaaatatt	tctctttggg	caataactgt	32280
caatatagaa	taatatctag	ccacaaaatt	aaaaaaaaaa	cattttcccc	tattattacat	32340
tcattggatct	tcttgaattt	ctgttatcta	gggtgcttta	aaagtcatat	ttctgataat	32400
atgaaatcac	agctcctttt	ctttggcata	tttagttact	gtattaagaa	aatgtacaac	32460
acataattta	gaatgggtaa	ttattatatt	ctctttattc	ttatattgaa	aatgacatga	32520
aaattaccag	tcttcccagg	taatataatt	taagttaag	aacatctaca	tactacaacc	32580
aatacccat	cccctatgtt	atgtttggaa	aaacatagaa	gtatcttttag	tagtactctt	32640
agaaattatc	ccagggttcag	catattggta	ttttatttcc	aggtttaagt	tacagtattt	32700

tgggcacccc	aagtttaata	aactattccc	tgcagaaacc	tgacaagtga	agttgtggct	32760
gggaatatgt	tagtcttcag	ataaaatgaa	ttgtttaaga	atttgctaaa	gatctcaaag	32820
catctttctt	aaatctaaag	aaagtcagga	acaaagccac	aaccaggacc	atagcatcag	32880
aagatggaaa	gttgctttgt	cttcaaactt	aaaaaacatt	ttccatttta	aaataatttt	32940
actattttacc	tgtgatactg	ttgaaaatta	tgaaaaaaca	gataatttaa	aatttagtgc	33000
tttttttttaa	aaaaaaaaaa	aaagcgaatc	cctgggacac	ttcatatagt	gcaaaacaac	33060
aattcaagaa	ttcaagcatt	gaaagaaata	atctcttata	ccccagtcct	tgaaagggat	33120
tgcctttact	actgttccca	tctttatgtc	catatgtacc	taaggcttat	ctcccactta	33180
caagtgagaa	actattcagt	atggcttagt	catttttaat	gcaagagaat	aggtaaaaaat	33240
gccaagcacc	agccagagtt	ttttctttgc	agatagatgt	gactcttaca	ggagcagcag	33300
ggatttccca	ctttggggcg	aaagcagcat	ttaggtattc	ccccccagt	gcagttacag	33360
accacccccc	cgtagaagct	gctcctgtcc	tctgtggcat	gtcagcctct	gattatcttt	33420
taataaacia	tatggcatat	taagtctctt	ttatgcccct	ctttgtattc	ccaggtaacca	33480
cctccatgtc	aggataaaca	gaatttggtg	atgtttgttg	aataaattta	gcagaagtgt	33540
aaagaaaaat	cctgtttcta	cagaaagata	ccactggctt	ttggggagcc	cgagttcatg	33600
atgaaactaa	agaaagccac	aaaagttcac	ctcaatgcca	agacatttct	tgatttttga	33660
aaacccagtt	gtcgaaccac	ccatctatag	aaacttgaaa	gactaaaaac	tatcttactc	33720
taaacatttt	ctaggaagtt	gattctacaa	cacatttttg	ttttccaatt	tggcttctaa	33780
taattatttc	aaagtttctg	tggcctaaat	tttgttttac	attgatccct	tgaatggact	33840
actgtttcca	catttttagaa	catttaaaaa	gatactctaca	acccagagtct	aatcataaaa	33900
aaaatcagac	agatccaaaa	tgtggaacat	tccactaaaa	aaggagtggg	gagaggtctt	33960
tattcttcca	aaaatatcaa	tgccataaaa	gacaaagacg	gctatggaaa	tgttacagat	34020
tgaaggagac	taaagttaaa	tgcaagaaaag	gaaaaaatgg	catataggac	agtattgaat	34080
tgaactgaaa	aactggatta	caatagtaga	gtatcaatgt	taaacttgct	gaagtgtcta	34140
actgtatttc	ttaggaatta	ttcacctaag	aattttaggca	cacagatatg	atgtatgtaa	34200
gttaccctta	aatggcttag	aaaaaaatgt	gtgtatattc	atttacatac	gtatctacac	34260
acacgtgtat	tagcgggaaga	gagcaaggca	cacatgtgca	taagtataaa	agcaaataag	34320
atgaaatctt	tattttttaa	tttaattttg	taagtttcag	ctttttaaaa	tttttagattc	34380
cggggataca	cgtgcagtta	ttacttgggt	atattgtgtg	aagctgaggt	ttggacctct	34440
aatgttctctg	tgtccacaac	agtgaacaca	gtaccagca	cgcagttttt	cagcccttgc	34500
ccccccctc	ccgtctctcc	tctgtctctt	tggagttccc	agtgtctact	gttcccctct	34560
ttatgtccat	gtgtacccaa	gacttatctc	ccacttacaa	gtgagagcat	gcagtattta	34620
gttttcttgt	tctgcgttag	ttccggttag	ataattgcct	ccagttacat	tcatgtcact	34680
gcaaaggatt	tgatttcatt	cttttttaatg	gctgtgtagt	attccatggt	gtataggtaa	34740
cacattttct	ttatccactc	atcaattaat	gggcacttac	attgatttca	tgtgttttgt	34800
attgtgaacg	gtgtgcaat	gaacatctga	gcgcagggtg	ctttctggca	gaatgattta	34860
ttttctctgtg	ggatatatac	cagtaaatgg	attgtcagct	cagataagta	tttctatttt	34920
tagttgctct	ccacaggggt	agaactaatt	tgcattccca	ccaacggcgt	gtaagtgttc	34980
ccttttctcc	acggcctcgc	caacatacgt	tcttttctga	tttttaatat	tagccatttt	35040
gaactggtaa	gagatggtgt	ctcattgttag	tttggctttg	catccaaatg	agacaaaatc	35100
ttaatgacag	gtgaatctag	gtaaaaggca	tacagacgtt	ctttgtgttg	tttttttaac	35160
ttacatttga	agttattttc	aaatgaaaaa	taaaagcaag	caaaaaaagg	tcattcttca	35220
tctagtaaac	tcttcaaaga	ttaccacccc	cttcaacagt	ttttctgtgt	tctagtgtgt	35280
cttctcccat	ttgttttagat	ctttgttgaa	atgtagtctc	agataaaaaa	ttgtattttt	35340
atttctttta	catatttcaa	acaatctaaa	ttctttttta	atgaaactca	ttaaaaatac	35400
tgcattttgt	tctaaataaa	atggtagagg	taatttgcac	ctttccaaac	agaagcaata	35460
ggagcaaccc	agatgtttcta	gccacgatcc	aagtcaacca	cattcaatct	aagaagtaat	35520
tgaaggctgt	aacgacttct	gtaaggccta	caaaaatgag	ttcagacaca	agctctgtct	35580
agtaaaaaatc	tagtggcaga	tgatatatac	aatgatctga	gaaaaaggca	gaatcaacaa	35640
aggttgtatt	tttatctatt	gctgcgttag	atatttccct	aacttttagta	gcttgaaaca	35700
ataaacattt	attatttcat	aaagtttctg	tggtcagaaa	tccaggagca	gcttaactgg	35760
gtggatctgg	ctcagctgta	gacaagatgt	cggctgggac	ggccatccct	tgagggctct	35820
gagggctttg	agggctgcac	gatccaattg	caaggtggct	cactcacata	ctaggcaagt	35880
tactgctggg	tgtctggagg	agaccttagt	ttcttatcac	atggacctct	ccacagggct	35940
gctggaatgt	cctcatgacc	ttccccatag	tgagtattcc	aagacaggaa	agtgggaagg	36000
acaatgtctt	tcatgacctt	gcctcaaaaag	tgacatactg	tcattttacac	aatattctac	36060
tggctgtaca	agttaatcct	atttagtctg	ggaggggact	gcataagggc	atgagtaaca	36120
agaggcaaga	atccttgggg	gccatcttgg	aagctggcta	cacagaagag	aaaacaccag	36180
gggagtgcga	agaagggtgca	attaaactca	attccttggt	atgccaatgg	taagaaatat	36240
taggtgatct	ctggggtgta	acctttttaa	tttagttctt	cactgaataa	tctggccagt	36300
aattgtaata	caaaatacgg	cactctgaca	atattctctc	cctttataat	caattacaca	36360
ccagaatata	tataaagaaa	gacttacaaa	gtcacaaagta	attgttttgt	attattttta	36420
taatcacata	ctagggccct	acaattagca	ttcacaaaca	tcactccatg	ttggccagat	36480



aagtctgtct	ttatagtgg	ttaccatacg	cgcccttagca	tgaagttaca	tgtgggttcc	36540
ttagccatca	gatgctccaa	atgcaaaaaa	tgtctcacca	cagtcacaga	atcatggaat	36600
cctaaagtta	cctgggggtt	ctgaaaatct	catgggaaca	actcacgaga	attaaggctt	36660
aagaaagtga	tttatcaaag	aacaaaacca	gcaagacttg	agtttagaac	tcgcagcaga	36720
gttgtgacta	gaacctgttg	aaataggcaa	tgtagaaaacc	cagactaagg	cacattctct	36780
acaactttac	tatgcaagta	tgcttagata	ctccttagca	aacagcaggc	cttgagtaaa	36840
ttctttcaga	actgaataca	caaaggatac	agaacggaat	acactaacia	tagtgcata	36900
tgtgctcatt	tctgtaatat	aaatgaatta	attctgatcc	atctataatt	tattattgct	36960
ccatgattaa	cggaaggcat	aggaaagatg	actggaatag	tgtaactagt	acaaacaagt	37020
attacacttg	actgaacctc	attacactgc	aattgcatat	tatatagtat	gtagggtgac	37080
aaatactggg	ttagtcagtg	gacctacatt	tgaatactgg	ttctgctcct	agacagctgt	37140
atgatttgaa	tgacttcttt	atactttcat	agtttctctg	ttcttctctg	taaaacaaag	37200
gcttagaaga	tattatgggt	tagattatgc	cccttaca	agatgctgaa	gtcctaaact	37260
acaatacctg	tgaatgtgac	tttatattgga	aatagggtct	ttgcaagtga	taaagaagag	37320
gtcatggagt	gacctaatcc	aatacgacca	gtgtccttat	aaaaaaaaagg	aaatttggt	37380
acagatacac	acaaacaagg	agaatatcaa	atgaacatga	aggcagagac	cggggcggt	37440
catctacaag	ccaagggaca	ccaaagattt	tcagcaaatc	accagaagtt	aggaagagtc	37500
atgggacagg	ttctcacagt	cctcagaaga	aacccaccat	gtcaatacat	cattttggac	37560
ttctagtctt	cagaaccgta	agaaaataaa	tttttggtgt	tcaagctacc	caatttggtg	37620
tactttgtta	cagcagtcct	agcaaaactaa	tacaaatgag	ctcttaacac	tgggtctaaa	37680
taggataatc	ctatgaaatg	ctacaaatgt	ttgggaagat	ttctcatact	caactgttta	37740
cagtatacca	caagcctgtc	agttgaagat	acaaacagac	cctctataat	cctctatact	37800
tatatgcaag	gaacagcaca	ctttttctgc	aaaaggctcag	atagtaaaca	ttttaggctt	37860
tgtgggccaa	acaaggtttc	tgttacattt	tttttttata	actccttaaa	aatgtaaaaa	37920
tcacctcat	cccaacggac	tacaggaaca	gacctcaggt	cacatttgac	tcatagcctg	37980
acctctgggtg	tgtagggtta	acaagcctcc	ttccctggg	ctccttttct	tttcagcatt	38040
ccaagccaaa	ggaaactatc	tttttcaa	cattttctct	cctagggtggg	acatcttaca	38100
ccagcccagg	catgcttccg	atagccttag	agtagctgtc	ccttcctcag	aattactgtc	38160
taattggcta	gaagttagca	actttttaca	tttttccctc	aattcctttc	cattaagaag	38220
aaggcatgca	cgggcaaat	acttgtgact	atcaatgaca	tactctcaga	agcaccagta	38280
cccctgtgtt	gtttctaaac	ccattctaat	agacacatac	cccaagggtta	tgctgtttgt	38340
catctcacia	aatgacttac	atctagagat	ttaaataatt	aatgtacttt	tcataactac	38400
caggtacagt	agatctgata	atggcagagc	taagcacata	tacagaaagt	agggcaagg	38460
ccagagactc	attttaaagc	aatgttacaa	gatcgtcact	gttgcttttc	atttttctaa	38520
atgtggccac	tgctgttttc	tcactaaagg	aaatgtttta	tgtaaagtga	ataacagtac	38580
ctggcataaa	ataagtgtc	aataaatggt	aaggccttct	ctccctcttc	aactggcctc	38640
ctcatttttc	acaaagtga	atagaaaaac	aacatcctgt	ataatcctgt	tgcttaggaa	38700
aaataactaa	agcttgctag	acaaaataca	cctgaaaata	taggaagtga	gctatagctg	38760
gcctatatgc	atgtatgttg	gaacaggaca	agatagtgt	gggtgggggtg	aagaggacag	38820
agaaatggaa	ggaaaggggc	tacagccttg	gtggcaaaat	aaaggataag	acgactcttt	38880
taaaatggct	tatttcaaat	gctgggttgt	gaaacttaat	ttgattactt	catgagaaac	38940
agcatctata	atccatccct	gatttttcta	caacaaaaat	ttattattta	ttttatgttt	39000
gtgtgtagat	cttttatata	tatacatgta	cacacgtata	tgtatatatt	atatatgcat	39060
atgcataat	atgtgtatat	acatatataa	tatatgtgt	gtgtatgtgt	gtgtatatat	39120
aattttttta	aaggaatggg	gtctcactat	gttgcccagg	ctggacttga	actcctgggc	39180
tcaagcaatc	ctccacctca	gctcccaag	tagcaacca	cagttttagt	tttgaaaaaa	39240
taacaaatat	taaacaccca	tgtgtaagg	ttggtactgg	gcctgtgttt	agtttgcagt	39300
ggctgtcgta	acgtaacact	acaggccggg	cacaacggct	cacgcctgta	atcccagta	39360
tttatgaggc	caagggtggg	ggatcacctg	aggctcaggag	tttgagacca	gtctgaccaa	39420
catggagaaa	ccccgtctct	actaaaaata	caaaatagc	catgtgtggt	ggctcatgcc	39480
tgtaatccca	gctacttggg	agactgaggc	aggagaatcg	cttgaacctg	ggaggcggag	39540
gttgtgatga	gctgagatca	ggccattgta	ctccagcctg	ggcaacaaga	gcaaaactct	39600
gtctcaaaaa	caaaaaaaca	aaaacaaaaa	aaccctgata	acactacaga	ctgggtagct	39660
ggaccaacag	aaatttattt	tctcacagtt	ctggaggctg	gaaatctaag	ataaagttgt	39720
tggctgggtt	ggtttctgag	gcctctctcc	ttacttgca	gatggctgct	ttcttgaaat	39780
gtcctcacat	agctgtccct	ctgtctgttt	ctgggtgtct	cccacgtatc	caaatttccct	39840
cttcttataa	agatactagt	catattggat	tagggtccac	cataaagacc	tcatttaaac	39900
ttaatcacct	ttttacggcc	ctgtgtccaa	atacagtcac	attccgagtt	ccaggggatt	39960
agggcttcaa	cctatgaatt	gggggtgggg	cacaattcag	cccgtaacag	gcctagacct	40020
taatttgc	acatacagt	tagatttata	gtatagtaac	tgcatctgtg	ctcatctaaa	40080
tgtcataccc	aaatgaaata	atatagcatg	atgatctgaa	tttattaaag	gcaatttttc	40140
ctatagaaac	ccaaatctat	aaattatata	caaactgtgg	taagttactc	gataccttgc	40200
caggactcat	ctatgggtgt	agatagacca	caaagagtag	cactgaaaga	tccttttctt	40260



aatcacagtt	tcctcactgg	cttgccacaa	aacctaataa	tcttctattc	tttcattggc	40320
aattttattc	ccctgaaaat	gtaaataatc	tctggcagag	caatctatta	agtgatcatc	40380
agccactaac	accttagggg	agaacagctc	agatcacagt	cttaaaataa	attccatcag	40440
tatgaaat	tctttattac	tgctccgcta	ctggaatgtt	agatcactgt	ctgctttaat	40500
aataattctg	gtgtaggtca	ttcaaatttt	gtttaagata	ataagacaaa	tagcaggtat	40560
aaaaacattc	cgtcatctaa	taaagcaacc	cgagaacagt	aagaagaacg	tgatgaaatt	40620
aacatttttg	agtacctgct	aggaatcaag	tattctgcta	gatattttag	aatcatctc	40680
aattcaatcc	taaaaattat	tctgtataat	agtatagggt	gagtattcct	aatccaaaaa	40740
tctgaagctt	tttttttctt	gagacggagt	tttgctcttg	ttgaccaggc	tggagtgcaa	40800
tggcgcaatc	ctgactcact	gcaacctccg	cctcctgggt	tcaagtgatt	agggatactc	40860
aactggctaa	atataatgca	aatattttcaa	aatctgaaaa	aaccctaaatc	tgaacactt	40920
ctggtcccaa	acatttcagg	caagggacac	tcaagttgta	ttaatcccat	tttacagaag	40980
aagaacacag	ctcagataaa	tgaacatctc	agagcttgtt	gatagcaaag	gagagattga	41040
aactgtcagg	cctctgatcc	caagccaagc	catcacttcc	cctgtgactt	gcatgtatac	41100
atccagatgg	cctgaagtaa	ctgaagatcc	acaaaagaag	taaaaataac	cttaactaat	41160
gacattctac	cactgtgatt	tgtttctgcc	ccaccctcac	tgatcaatgt	actttgtaat	41220
ctccgccacc	cttaagaagg	ttctttataa	tttccccac	ccttaagaag	gttctttgta	41280
attctcccca	cccttgagaa	tgtaatttgt	gagatccacc	gctgcccgca	aaacattgct	41340
cttaacttca	ccacctatcc	caaaacctat	aagaagtaat	gataatccac	caccctttgc	41400
tgactctctt	ttctgactca	gcccgcctgc	accagggtga	aataaatagc	catgttgctc	41460
acacaaagcc	tgtttggtgt	ctcttcacat	ggacacgcat	gaaagaaacc	ctacctggtt	41520
ctgtgtctta	cctgttgggg	gcctgtggtc	aaactactag	tacggagttt	tagtgtctct	41580
actttaaaaa	tgagggttgt	ggccggggcg	ggtggctcac	gcctgtaatc	ccagcacttt	41640
gggagggcga	ggcgggcgga	tcacgaggtc	aagagatcga	gaccatcccg	gctaaaaacg	41700
tgaaaccccg	tctctactaa	aaatacaaaa	aaatttagcg	ggcgtagtgg	cgggcgctcg	41760
tagtccagc	tacttgggag	gctgaggcag	gagaatggcg	tgaaccgggg	aggcgagctg	41820
tgcaagtgag	cgagatcccg	ccactgcact	ccagcctggg	cgacagagcg	agactccgtc	41880
tcaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaatgagg	gttgtaagg	41940
aactacctac	tttttatagc	attgtagtga	agttgaaatg	aattaatcca	catatattat	42000
agtggtgtag	aatgcagcag	aactgatgat	gtatgacttc	taagactagt	ccttaagaga	42060
cctgcagttt	ttgcttttgc	cctcttgga	cactcctgtt	gccatgttaa	gaaaaactct	42120
ggggagacta	tgaagggaaga	gagcatactc	ggggcagggg	ggtgaacagg	acgtgcacat	42180
gtacgagcgt	acaagccagg	tgacaccagt	accacagcct	cagacatgtc	accggggata	42240
ccagcaccac	agcctcagac	atgtcaccgg	ggacaccagc	accacagcct	cagacatgtc	42300
accggggaca	ccagcaccac	ggcctcagac	atgtcaccca	gggacaccag	cancagcacc	42360
acagcctcag	acatgtcatc	ggggacacca	gccccatggt	ctcagacatg	tccttgaggc	42420
ccacttagac	ccttcaacct	cagcccagct	gctaactgac	taacagccaca	tgaacagata	42480
cagggtgagac	cagaggaaac	ttccagtcac	ctaccagatc	atgacaaaata	ataaacgatg	42540
ttttttaaac	cacaaagatt	tggagcagca	tttgttacac	aaaattagac	aactattaca	42600
gttcgactaa	aaacatgttc	attttacaata	ctaaattaga	agtgtaaaga	tgggagaaaa	42660
acttcatact	ttaaaagtca	ttttttcctc	caaaaacttc	caactttgaa	aaactgattt	42720
ttataatgca	taaaatttaa	aataacctta	gaatttatat	gagtagcata	gccagctggc	42780
tttattatct	gttgtagtca	acacttcaat	aatcactgat	gttttagaac	tcttcagatt	42840
tagaactctt	gcccttgctt	tagtctggtt	taagctaaat	aattgttctt	cctcaagaac	42900
aaatgacctt	acctcgtttt	gttttctctg	tctgagagaa	acacattagc	agtctcccat	42960
cttggttttt	cttttctctg	caccagggac	agagggcagt	ggtgtgatca	cagctctgca	43020
gcacgacttc	cccaggttca	ggtgatcctc	ccacctcagc	ctcccaagga	gctgggacca	43080
caggcacatg	ccaccagctc	cagcttaatt	ttgtattttt	ttggtagaga	tcaggtttct	43140
ccttattggc	ccagactgat	cttgaattcc	tgggtgaag	caatctgcct	gcccctggct	43200
ctccaagtgt	taggattaca	ggtataagcc	accgtgcagc	cttatatttt	gttttaaat	43260
ttcctctgta	ttttctctct	tggcaaattg	tttagggagt	ttcttttagt	tatcagacta	43320
aattttcaagg	ctttccttcc	aattttgaca	tgtaaacagt	ccctcatttc	tgcttatcta	43380
gtgattatct	ccaaatctgt	gtttacagtc	tagctgtctc	tcctgagatt	aagacttggt	43440
tctctaacta	cctgtagtca	gaatctcctc	ttggaagtat	caaggaggca	gttcaaaact	43500
gaactgggca	ttggctccac	tccttctcct	tctctttact	attaataccc	tttctctcct	43560
tctatatgac	cacactaagt	cttatttagg	catcgtttct	tctgggagac	ctttgtagaa	43620
tctctgaggt	tatgttaaca	tgctaagggt	ttcttgacat	tctcagattg	ggttaggtga	43680
acttttagca	acttatcttt	ttactaaaaa	gtcatccctc	agtatctgtg	gggaattggg	43740
tctaggactc	cctaaggata	tcaaaatctg	catgagcagc	ccaggtgaga	ccagcagaag	43800
cactttacag	tcacatcaga	gatcatgaca	aataataaat	catgtttaag	ccacaaagtc	43860
ctttacataa	aatgggtatg	tatttgcata	taacctacac	atcttctctg	atcctttaa	43920
tcactctctag	tttataatac	ctcatacgat	gaaaatacta	cgtaaatagt	tggtatactg	43980
tattgttttag	ggaataatga	caaggaaaaa	agtccacgcg	tgttcagaat	agatgctttt	44040

ttttctcgtc	taatattatg	gatccacagt	tggttgaatc	cacagatgtg	gaatccatgg	44100
ataccaagga	acgactgtat	gcattttgac	aattatactt	ctcatcttac	catgcattca	44160
acaaacagaa	catgtaaagc	ggtgataatg	ctgtgatgaa	aaataaagca	ggggaagagg	44220
ctgcatccat	ctagtggaaa	cgatgccctt	ttcaatctgc	acaaagagaa	aaagctgctc	44280
tccaagttgg	ggggtgggtg	ggtcaggtat	gtaaattggg	caggaaggga	tctgtaggca	44340
cttacagatt	tgacgctaatt	gagatgggaa	gccacaggaa	ggttgtgaag	aaaagacaag	44400
acatgatctg	attcatgttt	tgatctgata	cactggttgc	tagatggaga	ataagctgca	44460
tgggcgtgag	aggaagcaga	aacaatagga	gggtaatgct	ataatccagt	ggtccataat	44520
ccaatatccc	cccaaggaac	agttcggcaa	tgtctggtga	catttctggc	tgtcacaact	44580
gttggggcgg	agtgctactt	gcattctagca	ggtagaagct	agggatgcta	ctaaacatcc	44640
tacaatgcac	aagacagccc	ttcccccaac	attgctggcc	caaaacgctg	atagtaccaa	44700
ggctgagaaa	ctctgttata	atctgtccta	gaattgtagt	tggattgaga	tggcagtggt	44760
aagagctgga	gaagtgcctta	gcttcccaat	ttgtttgttt	ttgagacgga	ttgagacgga	44820
gtctcgctct	gtcgcccggtg	ctggagtgc	gtggcgtgat	ctcggtctac	tgcaagctct	44880
gctcctggg	ttcacgccat	tctcccacct	cagcctcccg	agtagctggg	actacgggcg	44940
cgtgccacca	caccagcta	atTTTTTgt	atTTTTtagta	cagacagggt	ttcaccatgt	45000
tagccaggat	ggtctccatc	tctgatccc	gtgatccacc	cacctcggcc	tcccaaagt	45060
ctgggattgc	aggcgtgagc	caccgcgccc	ggcctgaatg	TTTTTaaagt	actggtgacc	45120
atattcgctg	agggattaaa	tgtaaggat	gaggggaaaa	taggaatcag	acaccagggt	45180
ttactgcctg	agcaatgaga	agaacgacgt	tcctcatacg	gagatgagga	agaatgtgga	45240
atagcaggta	aatagcatgt	gcttgctttg	tttggggctg	tgagaagag	actgatggga	45300
ccaacgtgct	cagttctgga	tatattaaac	ttggaatgcc	tatttggcac	caagtgaatg	45360
tatcaggtag	gcagatggat	aaatgagctt	gaagttcagg	ggagaggctg	gggtggcaat	45420
atgaacttgg	gagttctccac	atctgaatga	tatttaaagg	tatacaacag	gataaggatga	45480
tttaggaact	aaacacaaat	tgagacgaga	tcctgagcca	gaggcactcc	gatgtttaaa	45540
aaagaggagg	aaccatcaaa	agataactaag	gagaagccaa	gaagtaggag	aactgagagt	45600
ctgagagaat	cattatactc	atTTgatcga	ctgcaacaaa	tgctgcttag	aggtcaagca	45660
aatgaggac	taagcaagga	ccaccagggt	tggcaacatg	gaggccaatg	ccgacgtgga	45720
aatgagagtt	ttggtgggaa	gacaggaata	aaagtctcac	aggtctgaat	tcaagagaga	45780
gaacagcaga	agaagggtag	aggtggtagc	cataaacaat	gatacattct	cttgaggcct	45840
tttcttgcaa	agctcagtg	agaaacatgg	ttccagagag	ggattttttt	ttctctcatt	45900
ttacatatgc	aaacatatata	aaaagctgaa	agaattgttt	gacaaccacc	cttattctta	45960
ccacagattc	aacatttaatt	gccatatgtt	ttccctgtat	gtactgtgta	ttgtttgagg	46020
ataacttccc	ctctaaatat	acctcggatg	tatctcctaa	aataagtcca	ttctcctaca	46080
tagccatagt	aaccatgaac	acacctagga	aaattaaaaa	tatatctctc	aatatattat	46140
atagctgggt	atattacata	ttcccccaata	tgtgatttgc	aaaccaggat	caagtcaaat	46200
tccatgcaca	atctttgggt	gtcatgtgtc	tttggctctc	attaataatg	atgactgtgt	46260
gaaaagacct	gtcctataga	ataaatttga	ctgattatgt	catgccattg	aacttgtttt	46320
tctattctag	aaggatagtt	ttttagggtg	gtgaatacat	ttattactct	tggcacaata	46380
gtctaacatt	tcccaatttc	cttataatct	tgccctttca	ttttcagaaa	atcaattatt	46440
ccaagatttg	tttttcattt	atcatcactt	attagctctg	aagactcaac	tgagcaactt	46500
tcagggttta	attaccctat	attcagaaaa	aaactactac	catctctcat	ttaccctaa	46560
aattctatagg	agagcatgtc	ttaaagctga	tcaataacca	aaccacacat	tttattgtat	46620
atattacatt	tggaaagcaa	aatgaatttc	ctaaaatttc	ttccctgatt	agcaaaatag	46680
tgccctcgaa	cacttgaggg	tgaaagttgt	tgtcaaatat	gcctacatga	ctggaaatta	46740
tgacatccaa	atgagttcac	tgggtctgat	aataatatgc	tctacatgct	tatgtctatg	46800
taataaacag	cttacatctg	gatgagaaaa	ttgattatag	aaatatttgg	gcttctacaa	46860
ctggtcactc	acttgaagt	acttaaaagc	acttaaaatg	caaactgacc	taacaatgct	46920
tatgggttag	attccaaaga	atgttttaggc	tatgttataa	tatgttataa	catcttctgc	46980
cacaatcttc	aagtgattta	tcttttctgt	tgtgttgaat	agctatagaa	gacaaatgaa	47040
ttctgcactc	ctgaattcaa	tgaacatttc	aagtttccct	acttacactg	taagattacg	47100
tagcatattt	taagaaataa	attataatca	ttttatttca	cttattgaac	ttcttttaag	47160
ctttggcatt	agaattttta	tcaaagcact	gccacttgct	tacagtgatg	gttttttagg	47220
tctttgggccc	tatggactat	ttcaatgacc	ttcactagcc	atctagtcca	ccttatecta	47280
attattacca	ctgcaaaaaga	aacctcact	tgaataaatc	agtagatggg	catgaggcac	47340
ctcccaggag	actataatta	ttaactcata	ctaaaatcaa	aattgtagct	attatcactc	47400
atatgggttg	gctctgtgtc	tccacccaaa	tctcatcttg	aattgtaatc	cccacgtgtc	47460
aaaggagaag	cctgggtgcga	aaggactgga	tcatgggggg	ggccttcccc	cttgctgttc	47520
ttgtgaaaga	gttctccgat	ggtttaaacg	catgggactt	cctcctactt	gctcgtcttc	47580
ttctgccacc	atgtaagatg	tgcccttgct	cccccttgcc	ttctgcatg	attttaagtt	47640
tcttgaggcc	tccccagcca	tgcagaaatt	tgagtcaatt	aaacctcttt	tctttgtaaa	47700
ttaccacgtc	tcaggtagtt	ctttacagca	gtgtgaaaat	agactaatat	aatcacctta	47760
tggttaagtct	gtctataaat	cacctgaact	ttcacagact	atctagaaga	acatgtaacc	47820

agagtagttc	ttgatcatgc	tatataaatt	actgatacag	aaatagagct	agacaggaag	47880
gggctggtag	tagagaatca	tcctctggac	atattctcac	agcctaactc	ctagctagca	47940
aattttataa	tatatataaa	aatacaatta	tttcacaaaa	ttaccatgaa	acgattttat	48000
tgggatatta	gacattactg	aattacttgt	tctgtgaggt	atacagtcaa	attaacatgt	48060
tataaaattg	tggtagccgg	cccccaagat	ggcctccaat	gaatccttca	cctcttggtg	48120
ttcatacctt	tgtgtaggtg	ggtctgtgta	acccatagaa	tacagcacag	tgacagttag	48180
tcacttccga	ggtttaggtg	tgaaagacac	tgtgggttct	gcctctctct	cagatcacgt	48240
gctctggggg	aaaagccagg	tgtcattttg	tgaagacact	caagcagcct	ttagatgact	48300
gcaaccacat	aagaggctcc	gaactggagc	cactcagcta	aaccactccc	agatttctga	48360
ccatgtatca	tttcatacac	aatgtatgaa	atgacaaatg	tctgttggtt	taagctgttt	48420
ggggaataat	ttgttacata	acaaaatata	actaatacaa	taatacatac	tgatttaact	48480
gaagtgttaa	cttcataact	tatttaggtg	ctaaaaatca	cagcaaccgg	atgcaaagta	48540
ctaaaaaaaa	aatccattaa	tacctattga	gtactgttga	gggcatgagg	aaagctcttt	48600
catactccac	ataaaaactt	cttaccgtta	tattcattgg	tgacctctac	tcttaactcc	48660
tttctaggat	aggaggggct	aactgatctg	acagcaagtt	tgggagaaaa	aattctgagg	48720
ctcggccaac	ttcctctctt	ctttccattt	gggatttggc	tgactgaaga	gggtcatttg	48780
ttttggcctg	ctctctttaca	cagtaaatgt	agtgggacaa	gctctattct	tggtgataga	48840
aaaactcgaa	ttttaaatct	gcctagtctc	ttgcagctcg	ttgttgctcc	aaatctcagc	48900
taccttttga	aacaactttt	ttcagtaaac	ttaatttcaa	tcttcattgt	atttaactgg	48960
atccaaacac	aggcagataa	aaaagggtgg	gcattactta	tcaacctcta	aactaagttt	49020
aattttgtgc	cctcatggag	tttatagtat	atttgaggtt	taaactaaaa	cacctgggtt	49080
taaacagaaa	ctataaaaaa	cacgattaat	aggtagggcc	gggcgcggcg	gctcacgcct	49140
gtaatcccag	cacttggggg	ggccaaggcg	ggtggatcac	gaggtcagga	gatcaagacc	49200
atcctgggta	acacgggtgt	aaaccccgct	tctactaaaa	atacaaaaaa	ttagcccggc	49260
gtagtgggtg	gagcctgtag	tccagctcac	tcaggacgct	gaggcaggag	aatggcgtga	49320
accggaagg	cggagcttgc	agtgagccat	tgcgccactg	cactccagcc	tgggtgacag	49380
agccagactc	cgtctcaaaa	aaacaaacaa	acaaaaaaca	aataggtgaa	aggccgtgat	49440
cattggtaag	cgtaagaaaa	tctgagggag	aaaaaaatat	agatgccccg	gccccatgcc	49500
aaactcatgg	aatcatgcat	gaaacccaag	cagctgcagt	tttaacaagt	tcccaatata	49560
tagttgacct	ctgaacaatg	caggtttgaa	ctgcctgggt	ccacttataa	aatggatttg	49620
atttttttca	ataaaagtta	caccgagtgt	gctgcctctc	cctccctccc	tccctacatg	49680
ctcctgctct	taagcctctg	ccatgaggct	taagacagca	agaacaaccc	gtcctgttta	49740
tttcaatagt	tttggggggg	gcagggtggt	tttggttaca	tggataagtt	ctttagtggg	49800
gattttctgag	atttttagtgc	aactgtcacc	tgagcagtgt	acactgtatc	caacatgtag	49860
tcttttaacc	cccatccaac	cttcttcccc	aaccgcgaatc	cccaaagtcc	actgtatgat	49920
tctttgacct	ctgtgttttt	atagcttagc	tcccactttt	aagtgagaac	ataccatttt	49980
tgggtttcca	ttcctgagct	acttcactta	gaattactgg	ctccagctcc	atccaaattg	50040
ctgcaaaaaga	tattattttcg	ttccttttga	tggatgaata	gtattccacg	atgtacataa	50100
acattttctt	tatccactca	gctcctcttc	agtctactca	atgtgaaggt	gacaaggacg	50160
aagatcttta	tgatgatcca	tttccactta	atgattagta	aatatactta	cttttccctta	50220
tgattttctt	agtaactttt	tttctctaac	ttactttatt	gtaagaatac	agtatataac	50280
acatatgaca	tacaaaaatac	gttagtcaac	aatatatgct	atcagtaaac	ttccagtgat	50340
cagtgggcta	tcctgagcta	cgttttttgg	gcagtcaaaa	gcatggggaa	ggagaggggtg	50400
gtccctaacc	cctgtgttgc	tcaagggtca	attgtaataa	taccatttta	agaatccatg	50460
gtatatatgg	taagtgaac	aactctagaa	gagagtgcct	ggagttggaa	aaggaaagag	50520
aaaacagaat	ttaaagcaat	ctgtaaagga	catgcagggt	ttagatgagg	tggaggggtg	50580
agggaaaacc	aacatctgct	gtgagggcct	attaactgcc	agacattgtt	ctatgtctta	50640
cctcatttaa	gagaaattta	tttcacacat	ggaaaaactg	aagcccagag	aggttaaata	50700
atttgacctga	ggccaaaatt	agttaaataa	cagaagtggg	attagtagat	gttttcattt	50760
tatcagtcaa	actgagcctc	agggaggtta	aatattttgt	atgaagtaac	aaaactgaga	50820
ttaatatatg	gccaggttta	aatgagatct	gtaaatctaa	tgcttactac	aaaacaaaaa	50880
aaaaaaagtg	ggaagaaaag	gtctatatgt	cttagcaaaa	cagaggtagg	gaagcaaaaa	50940
taaacttaca	aaatcagatt	agaccaccaat	aaaacagtcc	ccatttttaac	ttatgtgggtg	51000
agaaccatat	attaaagacc	accagtggct	taaaaatctt	tttaaaaaat	gaatctgttt	51060
tcattattca	ttagtttttt	tctaataaat	aatgtatctt	aactgatata	tttactaaac	51120
aattaccagc	tccaatttagc	actcagttac	aattcaatca	ttaaactgac	cctcaattta	51180
gctgtcaacc	tagtcaaaac	agttaagtga	ttttacgggtc	atcctcagtt	gcagaagtat	51240
aatgtttatg	gctggagtca	ttttattttt	aactaacatt	ttttaaaaag	attgctttgt	51300
aacaatgtgt	tatgagtctt	ttgtggtaaa	tactgctttt	tttttgagac	gcagtctcgc	51360
ttttttcccc	aggctggagt	gcagtggtgc	gatctttggg	ctgaggtctc	tgccctcagc	51420
tcctgagtga	ctgggactac	aggcatgcgc	caacgtgccc	agctaatttt	ttgttttttt	51480
agtagagatg	gggtttccac	atgctggcca	ggctgggtctc	gaactcctga	cctcgtgatc	51540
tgcccacctc	ggccttccaa	agtgtctggga	ttacagctat	tttaaggact	ttttaaaaag	51600

tgaagctaaa	catttattca	tccctattcc	tcactctatag	ggacttgtgc	tctatttttc	51660
tttgaagact	gaagtaaaaa	ttcacctttg	tgagggtcct	cctataatta	aaattaatca	51720
ttttttcctc	catagcttct	acaaaacatt	gcctgtacaa	ctctattttg	cacttatttc	51780
atccccgcctt	gtatgaaaac	tatttggtta	caaacgtttc	tacttctctt	taggaataag	51840
gactatgcat	tattcactgt	tgtattctcc	ctgcaatttat	ggcagtcctt	tgcacattaa	51900
atacaagctt	tttggctctg	tgcactctct	catctggctg	ttcatctgta	ccctttaaaa	51960
catcctttat	taaaaaaa	gtaaatgtaa	aaaaaaa	aagccattga	tgaaaaagtt	52020
aatagctttc	tcaataagaa	aagagtatca	attatgcata	cgtctgaact	aacaaacatg	52080
aatgaaatag	gctatttta	acattctgtt	ttaaaagtag	gtttggtcag	ccatgtaa	52140
tgaaaattgg	gagccacca	gataactcat	caacaaatat	gcactatgta	ctaggcacta	52200
tatagatgat	ggtgaaccaa	acagatgtaa	tccttgctct	tacagatctc	acaacctact	52260
atggggccaa	aaatatatgt	gtatgtgtgt	gtgttatata	tatatacaca	cacatacatg	52320
tatatatata	tatacacata	cacatatata	catacgcaca	catacacata	tatacacaca	52380
catacatatg	ctatgaggaa	aacaaacagg	tggtgagaaa	gaattagagt	aggggtagag	52440
gacagagggc	tcctcaaata	gggtggacag	cttgacacaa	gacactcgag	ctaagactcc	52500
aaggatgaga	agacagttat	gtaaagaaaa	ggggactagc	attgtcagca	ggtagctaag	52560
gccttaaagc	agacagtc	gtgctgcaat	gccagcttca	agcgaatata	gttactaaag	52620
catatctaac	cttctatgtg	aatgtagtta	ctaaagcata	tcctccaact	ttccattttt	52680
cttttgctat	tgtttctacc	acttctcctt	ttctgttgac	aattatttta	aatttccctgg	52740
ctaaattaaa	tgatggcatg	aactctgggg	aaagtaagac	tacctatgtc	caaataatcc	52800
taaattcctt	ctagtcctta	tgactgatca	attcacctcg	aagtgacaac	tatgtcccaa	52860
ttaggaaaga	gtgtttcttt	atctgcactt	aattttttga	tttggaggct	tcctgatgtc	52920
taatcaacat	gttgtgtgat	tacttcaaca	agtacttata	gaacgttatt	ttgtcactgg	52980
aaaaacgttc	tgctgttttc	tgaactttag	gttgctctag	agtctaggaa	gagtgaactt	53040
acctaagca	gttcttaatt	actggacatt	ctcagactctg	ctagagctac	atgtccaatt	53100
acgagaatat	actggaaaaa	gccctggatt	agaaatgaga	ggatgtaggt	tttagtacca	53160
ggtcagccac	cttggttaatg	caaatttgag	taaattgtta	cttcttttag	gccttgtttt	53220
tgctgttttg	tttttctgac	agtatggctt	ctgtgggtcca	ggctggagtg	cagaggcaca	53280
atatcaggtc	cctgcagctt	ctacctccca	ggatcaagcc	attttcatgc	ctcatcctcc	53340
tgagttagct	ggattacagg	catgtgccac	cacacccctg	aactcctgac	ctcaagtgat	53400
ctgcttgctt	cagcctccca	aagtgtctgg	attagagggtg	tgagccactg	tgcttagcct	53460
tacacattgt	tttcttactg	gtaaagtggg	aatatctaga	agttgcatgc	tacataaatt	53520
caaccatata	ttattggcaa	aaaattttta	agaaaaacat	cagcttaaga	gtactaattg	53580
agtacatgcc	ttggaatgag	catgagctgg	aaagaacaaa	cctgttggtta	catcactcat	53640
tgctgttttc	atatgtctgt	cattgtaaat	cttgctcagt	ggcatgattt	tagtgtttaa	53700
agatttattt	gtttgtttgt	ttaggacaaa	gtctctacac	ataatctact	tgcttcatat	53760
atacatactt	atgcataatta	tgtatgtaca	tacatgtctt	cagggctcac	atgaaaaaac	53820
agccattcag	gtgatgtgat	ttatctcata	tgcttacttt	agagtcaaca	gggtgttgac	53880
tcactatac	aatactggca	tggagaacac	ataagtcaaa	gtagacagga	cccagccgta	53940
ccattggcta	gggcacaaat	atattcacat	atgtggagaa	tgatgtacgt	agaaaggctt	54000
tcattgcaca	atgctcttta	ataaagatct	ggaaaaaaa	aacacctaaa	tgttcaaaaag	54060
gatagggtag	atgaaataat	ggtacattat	aaaatggag	attatgcagc	cataaaaaata	54120
aggaaatacc	ttaaataata	acagaacaac	ttttaaggta	agtgaacaaa	taaggtagcat	54180
aatcactatg	catagtatgt	accatttaca	tagaaaaagg	gaagaaaaat	aaaatatata	54240
tagtaattta	tttgttctta	catgtgtaaa	atttttctga	aaaatatacc	agaaactggg	54300
agcactgggt	gcttcttagg	cagaaaatga	ctgagtatcc	ttttgtacct	tttgaatttt	54360
gaaccacgtg	aatgaatgtg	ttacctatga	acaaaatgac	aagtttagat	cagcaagaca	54420
gcagtttgag	atgaaatggg	attacaccct	tagtaggaaa	aactttttta	agcaggtggg	54480
acttctaaga	gcaaatacct	gcacatggaa	tgttgaaact	ataagggaact	ctccttaaga	54540
gatccatcta	ttccaaactt	ctcattttat	agatctgtaa	actgagacct	taaaaattca	54600
gtgacttgca	taaggtcaca	cagcagaaga	gatgggatta	gatgctagat	attccaatat	54660
caagttttaga	ctattaaaaa	ttcagtgact	tgtgtaaagg	cacacagcag	aagagatggg	54720
attagatgtc	agatattcca	gtatcaactt	tagactatta	tcacaccatc	ttctcatatt	54780
ctgggggcaa	aacagaacca	agtaagtttg	ggctacatta	cgagttgtca	tgtttttgg	54840
tttgtttttt	tgagatggag	tcttgctctg	tcgctcaggc	tggagtgcag	tggtgtaatc	54900
tcagctcatt	gcaatctctg	acccccgggg	ttcaagcaat	tctccctgcc	ttagcctccc	54960
gagtagctgg	gtttacaggc	gcctcccacc	gcgcccgggt	aatttttgta	tttttttttt	55020
tttttttttag	tagagacggg	gtttcaccat	cttggccagg	ctggtcctga	actcctgacc	55080
tcgtgatcca	cccacctcag	cctcccacaa	tgctgggatt	acaggtgtga	gccaccacgc	55140
ccggccgag	tgctaatgtt	tatctaattg	ttagagtcta	atgtataaat	taaccttag	55200
ccttgaact	actaatttct	tgtttggatc	actatacggc	tacacttaaa	aatatgctgt	55260
gcataacctt	atcattgcat	gtatacaata	tgatagatgc	atgatatgac	agacacacaa	55320
tatgatacac	gtattttttt	ctatcctaac	acatctgaat	ttactgaaat	aactaaaatg	55380

tcttaagtta	cttttttaaa	tatacacatg	catagcacaa	gcgtgttgcc	aaaaatatga	55440
atacagggtt	acaattcctt	aactaaaacc	caagggttgg	atgtgtttta	gaaataagaa	55500
tttcatacaa	tttttaagtg	ttacagggtg	tataaaccat	tatataacac	ataccagggg	55560
ccaagggcag	caccccataa	tcaaacatat	taatatagtt	tcagcaaaac	acatgggata	55620
aagactatat	acagcttctc	aatagttcag	gtcatatttt	gtaccaaact	gaattttgtt	55680
gccaaagctta	agaagttttt	ggtttttcacc	gctttctgaa	tgtagatttg	agatgtggga	55740
ttacagactg	tactcataga	gtgcttctag	aaagcagtc	gtcacttcaa	ctctcatttt	55800
ttttttatga	gactaaaaaa	gaaatcatag	caagtagctt	ttatatccca	ggtttggggc	55860
aaagacttgt	attgtgggtt	aggaatctaa	cttagtagaa	gggtgcacgag	ctgacatcgt	55920
gagtggtctaa	aatgagagaa	aaaaagagaa	aatcctaata	atacagaagc	actgaactac	55980
tgcagctgtt	cgtaggttat	taattttaata	aaagcttctc	ccctttaaat	catgtgagtt	56040
tataactgga	aataggtcaa	taaaatttct	gtcccacact	gctgacaagc	gatggacgca	56100
attagcttta	atcccactgg	aaggtactgc	actctctctg	ggaccaggat	atgtagaaaa	56160
aagcatttca	aatatatagg	aataaccaga	aatgtataca	gtatttctcaa	cttggggaccg	56220
ttactctata	atataaacga	aaggggtttt	ctagtcaatc	tctgtctgat	tctgtacca	56280
aagttcttcc	ctttataagt	cttgtagctac	cttttacaag	aggaaaaagc	tctagagcga	56340
aaacacagaa	cacactaaaa	tcccttccct	tctctttaca	actcaagccc	cgctccatt	56400
ttgtttctga	tactaatttt	tcttctgaaa	aaataccaaa	tttacactga	aagactaaaa	56460
ttcaactttg	cagacaacgt	tttaaaaaat	acaattcagt	ttggtgatgt	tgttttgcag	56520
tcttacaatt	ttagctacat	tttaactgaa	ccaattgttt	tggtcaattt	atgagttaat	56580
actcagcaag	tttgtttttt	acaaatagtg	tattccattc	taaaaaatgga	agtagcagtg	56640
gtgaacaaga	aaacaaccct	ctgagttttg	tctatttcag	gaggaagtac	tactttctcc	56700
aattttaatc	acaattcata	aaaaagaaaa	acctaactag	ctagatctta	aatatacaaa	56760
tacatttaaca	atctagtata	gcaacagaaa	aaggttaaca	aactaaccag	cctatttttg	56820
tctggagaaa	ccccaacaaa	ctgctggatt	ctctggccat	ttgcattcag	aagtacaaaa	56880
aactaaaatc	ctttttacta	aataatttct	tctacacgag	acttggttcc	tccacaccac	56940
cctatccaaa	ttgtcagcat	tattccagaa	tataatcatt	tagtttgaga	ccactaaaaa	57000
accccgagct	ccaaaatacc	aattgtgggt	tttctgtaaa	gaaatggtca	gaaactacaa	57060
attgttatcc	taggacacag	aaccaatcga	ccaaaaggac	ttctggaata	tgctgcccc	57120
aagattttaga	atgcacaggg	agaaatagca	tacgcggtca	cgatgtccct	taagccatag	57180
gaccttctca	cgaaagcaaa	ggcttaaaact	tatcaaatga	gaactcccc	tttctctgaa	57240
gttaaaacaa	ggcagggcag	ctggaattag	agcagcaggg	acagatcggc	tggtgactag	57300
tcagaacggg	tcgtggaatg	caaagtcctc	gcgctttcgc	tgctccccct	accgtgagaa	57360
gatctgggag	ggaggaaagg	aggagaaaca	ccccagaatc	ctggtagaaa	agccccggc	57420
ctcgaagatg	ggctctaggg	agacagggag	gggcagctcc	gtgtgtgatg	accctttgtg	57480
aactgcact	ctgtggcagc	ttcagctcca	ccgaggtctt	gggagagcgg	actacggatg	57540
cccgccggcg	cccagctgtg	aaggccgcgc	cgcgaggagag	ggtccatggc	acccccggc	57600
gcttcggaag	cccttccctc	tcccacctcc	gcgggtcacc	ccaggaacca	gcggctcccc	57660
accacgctcg	cgcggaaccac	ggaacagcga	cgcgcaagca	ggtctctttc	gtcagcgtaa	57720
tcctccgca	gaaagccgcg	cactagtttt	aatcacgccc	cacccccctg	ccgctggcgc	57780
cacctccgcc	actcgggcgc	tttccagcag	cttccagaaa	cgctgcctcc	ccaaaccag	57840
ccactcacac	atggcgggct	cagcagccac	cgcccccgcc	cctcctcgct	gccgcagctg	57900
caactgcgtc	tgcgccacaca	gggcggacag	ccagcctctc	gcggaaggcg	accggaagtg	57960
ctcacgtctt	caccttcccc	gccacgccac	cgctctttca	ggcccagcgt	gcagcaggaa	58020
ggaggactct	tttgccgcgg	actcaagccg	gaagccgcct	tcctagtggg	gacgcgagtg	58080
ggggaggagc	agtcagaggg	gaacgtgggt	tgaacgttgc	aactagggtg	gagatcaagc	58140
tggaacagga	gttccgatcg	acccggtacc	aagaagggga	gtgcccgcgg	caggtaaggg	58200
agaagaggga	ggggtttctt	tccgctctcg	aaattgggaa	aagagacaga	gctgggatga	58260
cctatggggt	agtccgcgcg	ctgaaaggat	gggctgggct	gggacggggt	tcaagtggga	58320
aaggttgatg	attaaggtat	agagttggac	ttacagatcc	gtttgggcgc	agagaggtga	58380
acgctgaaga	gaaaccagag	tttgttttcg	ttttccaagg	agcgtggaga	tgggcagggt	58440
taacggaccc	tgcgcctcct	tccgcttctt	agtttggggtg	ttgaaactca	cctcctttgg	58500
tctgttctgt	ctctgattca	agacagttgg	gttttggtacc	tgacagggtc	gggtgcagaa	58560
agctgacctc	gttctctcgc	ttccaggctg	gttggtggcct	cgcttttgac	agttcacgtg	58620
ccgagcctac	tcgctctcgg	agggcgagct	caaatgggtg	ggtttaaggc	ccccctctcg	58680
aacagctgtt	tccctggggt	tctccatttt	gcacacagga	gtgtgaatta	agtttaattg	58740
aatacttttt	gcgattccca	gggccacctt	gacacgttca	ttgtgctatc	taactgggtt	58800
catgctgggc	taataattca	cattaaggct	tctggagtat	aagtggttca	cagaagtatg	58860
aaaaggggat	gttagaagaa	agatgctggg	ggtgaagtag	agttgaggaa	gacagaactg	58920
gaaagctagg	ttggtttcac	agtacaatga	gcttttaggtc	ataatactac	ctttaggtta	58980
tattgggctg	tttggacgga	gtttgctgta	atcagggtag	agtaaataga	gaattttaaa	59040
ctaagcattg	acaggctcag	acttgtagag	gcacatcttt	gacagtgata	tggaagggaa	59100
agaggttagag	atttgagacc	tttccaaaga	actgtccaca	gaatttggtg	acttactgtg	59160

cgaagagggga	aataaagaat	aggggaacaac	tcaagactttt	ctagtctgtg	tgtttggaag	59220
gatggagacg	cccacattta	agtgagatat	gggaaggagg	agcagattgt	ttttgaagg	59280
aggaagagca	gttacttagg	gtcaaattaa	gttgtaaaat	cccccccg	attttgtatg	59340
taagtcaaag	tgaattgtat	ttggaagaag	aactggggag	cccacctctg	gtatTTTTTT	59400
tatgtccctc	atatggacaa	ataaacctct	ggtattaaat	gaatttttctt	ttgggggatt	59460
ctatatattc	gggatttcaa	ccaccaacct	atctggtttt	tcccgcgtgaa	atggtgggtg	59520
atggaatcag	gagagcagat	ttgggagactc	tttataTTTT	ataattgaga	gagacaaaaga	59580
gaaaaccggt	tgatttgaaa	aagttttcta	ggttccctca	ggtagatgga	aattttcatc	59640
aaaaacagtt	tattcaagg	acatagccta	ctagtttccc	atltgagagt	accgcagaat	59700
gatacgacgt	gtactgcttc	tctacgcaga	atgaagtata	aaattagcac	caaatagtaa	59760
ctttaatttg	tcaggtgcta	aactttttac	atgctttatc	tcatttaatt	cttagaagaa	59820
actaatttta	caagtaagt	tctggacca	catctgcagg	tacaaagcct	gaaaagcgta	59880
agtttgactc	ctacatagtt	ctcttttgta	agtagattat	aaatagaacc	agccaaagg	59940
aataagttgt	ctgtgcctaa	aaagaaagaa	aaaagttagc	atcagtagtt	ctcaccagaa	60000
ggggtgattt	tgtctaccag	gggacatttg	gcaagtcagg	aaacttttgg	ctggtggatc	60060
tagagggtaa	aggtcagtg	cgctgctaaa	catcgtcagt	gcatagaaca	gccttcacaa	60120
acaattattt	ggtcaaagat	atltgtagt	ctgcagttga	gaaatttctg	tcttatgggt	60180
atltcttcag	gaataggaaa	ttagattctg	ccgatacttt	ctttaaaaag	cagttttatt	60240
tttgaaatta	ttccttggct	tgaagggttt	gtgaagttta	tatagccgaa	ccagaatagc	60300
gtaattagat	tttaaagtga	attgtgagcc	atcgattccc	aggagatggg	tgtcatagaa	60360
tcattggattc	ttggatttgg	gaaagactta	tgcctagaat	tattttacaa	catttctgct	60420
aagtggtaat	tctcctctgc	cctaaagggtc	tctgtatttt	gattttccta	tcattgtgaa	60480
cccacaatta	aaatgctctt	aattattttt	tgtttacact	gagctccggt	ctcttgtaat	60540
ttttactctg	ttaaatgtgg	tctgcacca	taggactgca	ctcaaaaaca	gcttggcaca	60600
tatgtaattt	gtactaggac	agtgtttata	ttttgtttca	gataacaaaa	taagttaaat	60660
gtgggtgtaa	ttagatcatt	tacaaataat	aatttgttag	cagcttttaa	taagtagtat	60720
ttttcccaac	tgggtgaagta	ttaatgttgg	tagttgaaaa	caataggaat	gtatggaata	60780
tatggttcac	tgggtctttt	gttccctgtca	aatagtggca	caatggatct	gggggtttttc	60840
tcagtataat	gctggcatat	ttgtttcaaa	ttgtacatag	actctaaaaa	gttaggcttt	60900
caaattctgg	tcaatatagt	ttgctttaaa	tagtagctgc	ctctactaca	agtttttatt	60960
aatttgttga	caaatgagtc	tgtatgaaa	accgggtctg	ttgccagtca	ctacctctg	61020
ttcacaaatt	tgtctgggttt	ataaatatag	gtatcatttt	cacttcaaga	ttataatttt	61080
agaatatgtt	tattctagga	catatagccc	tcaaaatctg	cttactatat	acgtcttata	61140
aaatagcatg	gttctttttt	atagtaaata	gaatttttat	ttaatgtct	attgactttt	61200
tttttccagg	gttcattgaa	aaaatcctta	gtgatattga	catgtctcaa	gtgacataaa	61260
ttagccaatg	atcggaatg	atggattctc	cgaagatttg	aaatgggttg	ccagtgtattg	61320
gaccagggac	tgatataagg	atatcttcac	tccacatggt	gggggtatttg	ggaaaagtta	61380
gtgaacttat	tttttgctctg	agtgc aaagt	tttttttttt	tctctatttt	tgagacttaa	61440
attcaatttt	gatgtttacca	gttaacttct	aaaaaattgt	gtcttccacg	gaaatcttac	61500
agtaatggcg	aaagattggt	ttaatgtgtt	tacctttctg	tgttttattg	atacatgaaa	61560
gtggaaataa	aacatagacc	ttatgattta	ctgttctttg	aaaatatggt	acataaaattc	61620
tcccgggtaa	ttgatgtttac	ttttttcctt	gcaaaataaa	ttgatactat	tcttaacaca	61680
taaaatttaa	tattttaaaac	tataacataa	tcttttttgg	aataatagct	gtattttaaag	61740
gcttatatgc	atltcttttg	tttgccatgt	ttaaaatacc	ttgtcaggat	acttgttaatt	61800
gaaaattata	atltttttctg	gttacctttc	catttaactt	ttaatatttt	gatataattct	61860
aggaatgtct	atattttta	ttgctttatt	tctcttttag	aatttttgatt	cagctaaagt	61920
tccatcagat	gagtattgcc	ctgcttgtag	agagaaggga	aagttaaaag	ccttaaagac	61980
ttaccgaatt	agttttcaag	aatctatctt	tttgtgtgag	gatctgcagg	taaagattta	62040
atcttatata	gtatatataa	gatttttctt	ttttcttttg	cttttttatt	aattgtttta	62100
aaagtttact	cattttttgt	tttttagact	agatttttaa	tatgtaatct	cagtttgtaa	62160
gtctgtctgg	tatacaatgt	tatttttcca	cctaccctta	cttggttgcg	taaagatgtt	62220
cgtttttatt	gccatttgat	ttgcgagagg	agaaaataca	tttcaagggt	tttttctttt	62280
tttttaacct	tttgagggtc	cttggttagct	attagcatat	agtagttact	ctctcatctc	62340
tttggtttat	ctttgcaact	gatgggaaaa	gttatgaatt	tctaattgtac	ctggaagagt	62400
atlttgaaaa	ttggttagtc	caaaaccagt	atatatactc	tgaactaaag	agagtataga	62460
atcttgtaaa	ttctaaaaga	tccpttttaga	agctctaaat	cgctttttaga	attatagtaa	62520
tttgtagcga	ctggtacggc	ttttatatag	cagctcatta	aattctgtaa	tactccacat	62580
tttattgtat	ttgacagttt	atgagactgt	ctcatacact	tttaattctc	agaactttgc	62640
aagatttgta	ttcctatttc	atgaataaga	aaataaattg	atlttcagagg	gtttgggaac	62700
ataagatcct	gtacacagtg	cagagctgtg	gttggaatac	agacttctaa	tttcagatct	62760
gtttattcca	gcaaaaaatt	agcagttcat	cagaattacc	tggagtgtct	tttaataaatt	62820
tctgagtatc	acccccagat	gctgattcaa	tagagttggc	ccagaattct	gtgggtttgt	62880
aacatttgag	gatgagctg	atcatcatca	gccagggttg	gaaaatacta	gactaaatca	62940

catggttgtt	aatagatact	tatgctgggt	ataatttgaa	gtaaagtaat	cccaggcgtg	63000
tctacaaata	taaatttctt	tatgtttata	ttcagtaatt	ttttttatga	gtgtcactgt	63060
ttggcactgt	tgcagataca	atgttaggat	acaataataa	aacaaaaatt	tcttgccctt	63120
aaggaagtta	tgtcatagag	tgggaaagac	agtgaacaag	tatgtgtttt	tctgtcaggt	63180
gataaaaagt	gctgtggaga	aaaataaggc	agtagggact	ggaatgccaa	agtaggggga	63240
gtttgcaatt	ttaaataagga	tggtaggggg	aacgcttcaa	tgaaaagtgc	aattcgagca	63300
aaagcctgaa	agaggtgaag	agcagtgagc	ttcttaggca	ggggaagcaa	gttccaggaa	63360
ggccctgaga	gaatggaggc	tgcctgtcat	gtttgtgcta	ctgcaatgaa	agcagcagag	63420
cgatagaagg	tggatcagaa	aaataatggg	ggagctggac	caagtagggg	cttataagcc	63480
attgtaagct	ttctggcttt	tactatgggt	gaaaccagga	accatggcag	agatgttggc	63540
agaggagtga	cataagttga	cttcagtgtt	aaaagcatta	ctgtggctgc	actgttgaaa	63600
atatatgtaa	tgggcaagac	ctgaagcagg	gagattagtt	atagtataat	atgaattata	63660
tttggctcct	gtctatgggt	tccgttacag	agctaaaagt	cttgggaattt	cctgaatgat	63720
aagagtgtcc	tgttattcag	aatgagcctg	tttgctaaca	ccgggggttca	tactattgtg	63780
gtgacttagg	atggagccgt	agatagcctc	agatggggca	agtagctgga	aagaccacat	63840
gattagagaa	ttaacgggtt	agaactttta	gccccacgta	caggcctcca	ggaaaggagt	63900
ggaggggctg	gagatcaagc	tgtataaaaa	tatcaagatt	tggatttaat	gagtgggttg	63960
ctgggggctg	gtgccgtgta	ggaggtggta	tgcttagagg	aagtgggaagc	ttcatacctc	64020
ttctgtccca	taccttgccc	tactcatttc	ttcatctata	ccctttataa	tatcccttag	64080
gataaaccaa	taaacataag	taagtgtttg	tttgagttct	gcgagctgtc	cttgcaact	64140
agttatgccc	aagaaggggg	agtgggaacc	tttgtagcca	gtcagtcaga	tgtactgggtg	64200
gcctggatgt	gggattggca	tctgaagtgg	agggagtcac	gggactgagc	cctcaacctg	64260
taggatctga	catggtctct	aggtagataa	catccaaatg	gaattggatt	ataggatacc	64320
catttgggtg	cctctggaga	attgcttggg	gtgggggaaa	agccccaca	catctggtca	64380
caaaagtgtg	ctgggaggat	agaatatgtg	aaaattgtca	taatcaaaat	ggagtccact	64440
gtgttaaaaa	agaaaaaaa	atcctgactg	gccaggcaca	gtggctgaca	actgtaatcc	64500
caacactttg	ggaggctgag	gcaggaggat	tgcttgatcc	caggaattgg	agaccagccc	64560
atgcaacata	gtgtggcctt	gtctctacaa	aaaaaaaaat	ttaaattagc	tgggcatggg	64620
ggtgtgagtc	tgtagcccca	gctacccggg	agggggacta	cgggtgcacg	gcaccatgc	64680
caggaggctc	aggtcgcagt	gagctgtgat	tgtgccactg	cattccagtc	aggatgacag	64740
agtgtgagac	cctgtctcta	ttaaaagaaa	aaaaaaaagac	aaatagatcc	aggaaaggct	64800
atgaagagag	agctttcatg	cataaatacc	aaaatatctc	aaaagactct	gcaaaaacca	64860
cacccttgca	caaaggccat	catgaaatac	ttctgaaata	cacagaaaat	acatcatgaa	64920
ataaatacac	agaaaatact	tctgcaagga	catctgccca	gcaactgcct	ggtccatctg	64980
tggacgggtg	tcatccttgt	tattgatcct	tgtaggccaag	ggttaattatc	tcaaaacaag	65040
tatgctatcc	cctttaaatt	ccttttgtct	ccttttgtct	ttcttacct	cctgaacac	65100
acacagttta	ctatggcatg	tgtattccca	ttggaatact	ttattcctga	ataaatgtca	65160
ctttcttttt	agaagcttct	ctttctttt	tatttagatt	gataagtaga	aaggaaaaaa	65220
agcttttttc	cctttggact	agttgaaggc	agttgcagta	ttctggggga	gagggtgggtg	65280
gcagagggtg	tgaggcatgg	ttggagttta	tttatacttt	gaaggtaaag	ccaacaggat	65340
ttgctgaaag	attgggatat	gggggttgaa	agaggaatca	aggatagttc	caagattttt	65400
ggcttgaaaa	attgaagaa	tggaaatcgt	aattactgag	ctgggaagac	ttggaagagc	65460
aaggtttttg	ggagaagatc	aggactgtaa	gaatagagaa	gtccttgtcc	ccaggagtta	65520
ggttttttgg	tattaaagtt	agatgtacta	catagatttt	tagttgggtt	tttgtttttt	65580
gttttttttt	tttttttttt	tgagacggag	tctcgtctct	tcacgaggct	ggagtgcagt	65640
ggtgcgatct	cggctcaccg	caacctccga	ctccctgggt	caagggattc	tcctgcctca	65700
gcctcctcag	taggtgagat	tacaggcatg	tgccacccag	cccagctaatt	ttttgtattt	65760
ttagtagaga	cggggtttca	ctatggccag	gatgggcttg	atttccctgac	ctcaggtgat	65820
ccaccacact	cggcctccca	aaatgctggg	gttacagggtg	tgagccacca	cgcccagccc	65880
ggagttttgg	tttttgaagc	attctttttc	aagtgataaa	gcaaaaaata	tataatcaag	65940
aatttttaagt	atatactttg	gaaatgttaa	aaaggaacat	gagtaattta	ttattatttt	66000
tttaatttct	agtcagcaat	gagagcccag	tgtactttat	gaagttagatt	ggtttacacc	66060
aggagtgagc	agacattttg	tatgatgcac	aaacaaggaa	tgattttttt	gtttttttaa	66120
tggttagaaa	aatatcaaaa	taaaaaatgc	cagaaaaaat	caaaaagaagg	gccagggtgca	66180
gtgtttcaca	cctgtaatcc	cagcactttg	ggaggccaag	gtgggtggat	tctcttgagg	66240
tcaggagttc	gagaccagcc	tggccaacat	ggtgaaaacc	tgtctctact	aaaaatacaa	66300
aatagccggg	tgtggtggca	tatgcctgta	atcccagcta	cttgggaggc	tgaggcagga	66360
gagtcgcttg	aagccagtgg	cagaagttgc	agtgagccaa	gatttgagcc	actgcactcc	66420
agcctgggcg	acagaggaga	ctctatctca	aaataaataa	ataaataaat	aaataaataa	66480
ataaatcaaa	agaagaatac	cctttcataa	tatgtgaaaa	ttaaatgaaa	ttcaaatttc	66540
agtgttcata	aataaagttt	taccggaaca	tagccatgct	caatcattta	tgtattgttc	66600
atggcttctt	ttgcatacaa	caacagagtt	gggtagttgt	gacagactat	gtagctcata	66660
aaatctaaat	atttattatc	tagcccttta	tcagtaaact	ttgctgatcc	ctgtataagt	66720



cctctgaatc	aaattatttc	caaagagttc	cgttataaaa	tttggagttt	actctgctgt	66780
aaattgcaaa	gaaccatttg	gaaaacctct	tttagtcagg	tatttacatt	aaaatgttcc	66840
ttgatttgta	aacactaata	ttcaagactg	gtccaaaatt	ataccaaatt	gaaactctca	66900
agtgttttta	aacagtagga	agttttaact	tttttttttt	cgtggagtag	tctatcattc	66960
agcgtttact	ttggaacatt	taattagctc	tttttaaaaa	cccatgaaat	ttataataaa	67020
aatttttaaa	cattaatggt	gagtaatcaa	agaaaaacttt	ttttgttttc	tccatttgta	67080
aaatgagtac	attattatta	taatttgctc	ttggccatcac	cttggtgata	attacttata	67140
caagtataag	aagacatggt	atgttttcct	ttttcctatt	tcacaagaat	aagtacagga	67200
atttacttaa	gctgctccaa	aactcagtga	aagagacagg	attaggtttt	tttcagcatt	67260
ggatttttaa	tgatactaga	tggttgctgt	gggctaaaaat	actaatgctt	tgtgtatatt	67320
tttatgactt	ttttgaagac	agcttaaaaag	ctttatttcta	gttataaaaa	tgatacatgt	67380
tcactgtaaa	tagaaacaaag	tcaggtatac	agagatacaa	atatttagaa	catgtggaaa	67440
gaggcaacaa	aatttttata	aaagaaaaaa	gataaaaaatc	tgaaatcatt	aattttataag	67500
ggaaaaatca	gggcaaggac	aaatttatatt	acagattggc	ctatgggtggg	agcacagatt	67560
atatagagaa	aagtcagtga	agacacttgc	gaagagtgtg	ggtggaaatc	actaagtttt	67620
gcagtcccgg	ggcctcttat	ggtttattac	tgttttgctc	tttttttttt	tttaatatgc	67680
attcctttgg	aaccaagggg	ttattatggt	ttgaataaaag	tagaggtgta	agtaggatgc	67740
atataccatg	atcttgacta	cttgagattc	acaaagggtt	ttcgtctcag	gatttttttt	67800
tctcttaaaa	aaatttggtat	taatttttaa	attgtaaaaa	aattcatcaa	cttaaccatt	67860
tttatgtata	gagttcagga	gtattaggtta	tattcacttg	tgcagcagat	ctctagaact	67920
tttttcatct	tgcaaaactg	aaactctgta	cccattaaac	aaccacttcc	cattttctctc	67980
tccccagct	tctggcaacc	attctagttt	ctgtttcttt	tct'ttttttt	tcttttgaga	68040
tggagtctct	gtcgcccagg	ctggagtgtta	gtggcatgat	ctcggctcgc	tgcaacttct	68100
gctctcgggt	tcaagcagtt	ctcctccctc	agcctcctga	gtagctggga	ctacaggggt	68160
gcaccacat	gcttggttaa	tttttttttt	tttttttttt	tttgtatttt	tagtagagac	68220
gggggtttca	ccatgttggc	caggctggtc	tcgaactcct	gacctcaggt	gttctgcctg	68280
cctcagctc	ccaaagtgtc	gggattacag	gcttgagcca	ctgtaccggg	cctctagttt	68340
atgtttctat	gaatcagact	cagtacctca	tataaacgga	atcatacagt	atttgccttt	68400
tttgtgactg	gcttatttca	cttggcataa	tggcctcaag	attcatccat	gttgtagcat	68460
ggatgaatat	acagtttagga	gttccctttt	tttttttaagt	cttaatctcc	agttttattc	68520
tgtttattta	tttattttat	tatactttta	gttctgggat	acatgtgcag	aacgtgcagg	68580
cttggtacat	aggtatacac	gtgccatggt	ggtttgttgc	acctgtcagc	ctgtcatcta	68640
cgttaggtat	ttctccta	gctatccctc	ccctagcccc	ctaccgccg	acaggccccg	68700
gtgtgtgatg	ttccccctct	tgtgtccgtg	tgttctcatt	gttcagctcc	cacttacgag	68760
tgagaacatg	cgggtgtttg	ttttctgttc	ctgtgttagt	ttgctgagaa	tgatgggttc	68820
cagctccatc	catgtctctg	caaaggacat	gaggagtttc	ttacttttaa	ggttgagtaa	68880
tattccacat	tatgtgtatg	ccacattttc	tttatccatt	cacctatctg	cagatgcttg	68940
agttgctttc	actttttggg	aattgtgaat	aatgctgcag	tgaatgtggg	tgtgcaggta	69000
ccttttcaag	attctgcttt	tgagtttttt	ttggatacgt	acctttttat	gatgctttta	69060
atacatatat	gctattttta	aaggattctc	agttttctga	catatgatag	gacttaggaa	69120
gtaatctcaa	agcatcatgt	tgacagggtg	ttagttgatg	gtgactgcag	ctagttggaa	69180
agtcagaaga	atctagaaga	tgtccattta	tactaaagaa	tttcatagta	agtgcagtat	69240
tatgagtgtta	atgttcaatt	ggtagaagag	gctatctgag	gggatttagt	gcatttccagt	69300
tatctgttgg	tgtgaaacga	atcaccttga	aacttagtcg	ctcaaaaatt	ttaatgggtg	69360
ctgggcatgg	tggctccat	ctggaaactcc	agcactttgg	gaggccgagg	caggcagatt	69420
gcttgaaccc	aggagtttga	gagcagcctg	ggcaacgtgg	tgaaaccttg	tctctacaga	69480
aaataccgtg	gcaggcgctt	ttagcaccag	ctacttggga	ggctaagggt	gtaggatctc	69540
ttgatcccat	gaggcagagg	ttgcagtgag	ctgggactcg	gccactatac	tccagccttg	69600
ataacagagc	cagaccctgt	ctcaaaaaaa	aatttttaatt	gctccattta	ttatttcaca	69660
tgattatgtg	agttgactag	ggaattctta	cacatcacac	catgtcagct	gggacagctg	69720
aatgtccac	atggctggca	gttgggtacta	gctgctagct	ggaagttag	ttcaaatagt	69780
cagccagggg	tctcagttat	tttccatgag	gttctctcca	tgaggccagc	tgggctcttc	69840
acagtgtgat	agctgggact	aagaaggagt	gttccagaag	aagggttgt	cctcttgagc	69900
cagtgccttat	caggcctcta	tgtatatcat	gtgtgcta	gttccatcaa	agctagtcac	69960
agggccaaag	caactctgta	cagtgtaggg	actggctgca	ggaggccatg	aattaccagg	70020
agggtgtagt	ctctagttca	tagggagggg	catcaagata	gtagtctacc	atacttgtgt	70080
aaaagaaggc	attaattaac	tattattatt	attattatta	ttattttaga	gacagggtct	70140
tgtctgtttg	cccaggctgg	agcagtagag	tggggcaatc	atagctcatt	gcagcctcca	70200
actcctgggc	ttaagcaatc	ctcccatctc	agcctcccaa	gtagctggga	atacgggagt	70260
gtactgctat	gcccactcga	aaaagaaggg	atatttttaa	agcagacctt	tagtgtagag	70320
ggttcctgaa	tttgttattt	aaaatattct	ggtagttttt	aaacttagga	aagaccactg	70380
gattccttta	gtgatatgtt	tacattgttg	ttatttggca	taaatttgtgt	taatgcacag	70440
taagatttca	tgaagtcatt	aaaattcagc	cacttggact	ctaaacccaa	taaagatgta	70500



aaacagcagt	gctatgagat	gcataattcag	tttcaaaata	taggaaacac	agaaattact	70560
ctgtgcactt	ttaatttgaa	aatactttta	aaatgtgtag	tataatgtag	tgtctgtccc	70620
aaaagagtaa	cattcattat	agtgtttctt	tacgttgttg	aaaattttta	attcacttaa	70680
cattagattt	ttattaaagc	aaaaatatgt	tttccttatt	agcttaccct	tttgtaactc	70740
agattaaacc	cttgattgtt	caaattaacc	tgaaaaaaat	tattcttttg	gaggccaaac	70800
ttttgattaa	gtagttgttt	gtctctaat	ttttcaaatt	tatgtgtata	aatataacct	70860
gtcatcaaat	caatgctaac	attctataca	tgtttttcat	gatatgaaaa	ctataaaaca	70920
tgaagttatt	tgaatttggt	tagtttttat	catttttatt	ttactttcca	gtgcatctat	70980
cctttgggct	ctaaatcact	taataaccta	atttctcctg	atttgggaaga	atgtcacact	71040
ccacataagc	ctcagaaaag	gaagagctta	gaaagcagct	ataaggattc	acttctttta	71100
gcaaattcca	aaaagactag	aaattatatt	gctattgacg	gtggaaaagt	tttgaacagc	71160
aaacataatg	gagaagtata	tgacgaaacc	tcgtcaaact	tacctgatag	tagtgggtcaa	71220
cagaatccaa	ttaggacagc	tgattccttg	gagcggaatg	agattttgga	agctgatact	71280
gttgacatgg	ctactacaaa	agatcctgct	acagttgatg	tctctggaac	tggcagacct	71340
tcccccaaaa	atgaaggatg	tacatctaaa	ctggaaatgc	cactggagag	caaagtaca	71400
tcatttcccc	aggctttatg	tgtccagtgg	aaaaatgctt	atgctctctg	ttggtttagac	71460
tgtatcctgt	cagctttggg	gcactcggaa	gagttaaaga	acaccgtgac	tggactgtgc	71520
tcgaaggagg	aatctatatt	ctggcggttg	cttacaaaaa	ataatcaagc	aaatacactt	71580
ctatatacca	gtcaattgag	tgggtgttaa	ggttggtact	aatattttat	ttttatttac	71640
ttattttatc	atctggagtc	agggctctcat	tctgtcacc	aggctggagt	gcagtggcat	71700
gatcatgtct	ccttgcagcc	ttgacttccc	tggctcaggt	gggcctccca	cctcagtcct	71760
ccaagtagct	ggaactacag	tcgtgcacca	ccatagccag	ctaagatagt	gagatgggtg	71820
ccccactgtc	ttgcccaggc	tggactcgat	ttcctgggtg	caagcacctt	tcccgccctca	71880
gcttcccaaa	gtgtcgggat	tacaggcatg	agtcaccatt	ccagcctact	tgtctttaat	71940
tcttaaaaaa	attaatgttg	agttttgtct	cccagcatgt	gggaaagatg	tcatacattg	72000
cttctgtttc	ctggaggcct	gggagcaagg	agcccaggaa	cagtatcacg	aagcttgaga	72060
taataccagt	tacattatcc	tgactgcccc	aaaggcagtt	tttttgtttt	ttttttttat	72120
actttaagtt	ctgggggtaca	tgtgcagaac	gtgcagtttt	gttacatagg	tatacgtgtg	72180
ccatgggtgg	ttgttgcacc	catcaaccog	tcacctatat	taggtatttc	tcctaattgt	72240
gtccttcccc	aaccctcca	ttccccatca	ggccccagtg	tgtgatgttc	ccctccctgt	72300
gtccatgtgt	tctcattggt	caactgtcac	ttatgagtga	gaatataatg	tgtttgggtt	72360
tttgttcttg	tgttagtttg	ctgagaatga	tggtttccag	ctttatccat	gtccctgcaa	72420
aggacatgaa	ctcatccttt	tttatggctg	catagtattc	tatgggtgat	atgtgccaca	72480
ttttctttat	ccagtctatc	attgatgggc	atttgggttg	gttccaagtc	tttgctattg	72540
tgattttttt	tttttttttt	ttttttttta	gacagagcct	cactctgttg	cccaggctgg	72600
agtgcgatgg	catgatctca	gctcactgca	acctccgcct	ctcaggttca	agcaattctt	72660
ctgcctcagc	ctcccaagta	gctgggacta	caggcgccca	ccaccaggcc	cagctaattt	72720
ttgtattttt	agtagagaca	gggtttcacc	atgttggtca	ggctggctct	gaactccaga	72780
cctcatgate	tgccctgcct	ggcctcccaa	agtgtgaaa	ttacaggtgt	gagccaccat	72840
acctggccta	ggcagtcctt	ttcaaaaact	taagactgtg	cttgtgtctc	agggtgtcag	72900
gataatagtg	gttagtttta	agtgttttaa	ctactgaaaa	gcagaatgaa	gaagttagta	72960
aaaatcacc	ataatcacac	aacctcctaa	gatctcttgg	cacaataagg	gatatgtttt	73020
tcattttatt	ctctgtaaaa	taggatactt	atgaacctac	ctcccaacac	aggaagaatt	73080
aaaacattcc	caataactta	catttaacct	tgcgtttcct	cccatcccat	tctctacctc	73140
ccccccataa	gtaatcatta	tctgaaatgt	gtttcatcat	tccatctttt	cttagttttt	73200
cttacatgtg	tttatctaaa	cagtatacag	tagtctcccc	ttattgtagt	tgtacttttc	73260
ttgggttcat	ttaaccgag	gtctgaaagt	agatgagtat	agtacagtaa	tatattttga	73320
gagagagggg	gaccacattc	acataacttt	cattacagca	tattgtttata	attgttgatt	73380
tttattatta	gttttaaatc	tactatgcct	aattataaaa	cttgatcata	ggtatgtagt	73440
tataggaaaa	agcataatat	ataaaatggt	tagttactat	ccaaggtttt	aggcatccac	73500
tggggctctg	gaagggtatc	ctctcagata	atgggggatg	gatgggtact	aacctgtgat	73560
atacaatggt	tttccctata	catacataat	tatgatcaag	tttaatttaag	agtaaatata	73620
atgtggggca	ggtgcagtg	ctcacatctg	taatcccagc	actttaggaa	gctgaagcgg	73680
gcagatctca	tgaggtcaag	agttcgagac	cagcctggcc	aacatgggtga	aaccccatct	73740
ctactaaaaa	atacaaaaat	tggctggcta	tgggtggcaca	cgctgtagt	cacagctact	73800
ctggggaggt	gaggcaggag	aattgcttga	accaggagg	tgggaagtga	acaatcactt	73860
gaacctggga	tcacgccact	gcactccaac	ctgcctgggt	gatagaatga	gactctgtct	73920
caaaaaaaaa	aaaaaaaaaa	aaaaagtaaa	gtaaatgtgg	ctcaacatgt	tgctgtcagt	73980
tggaaacatt	gtttctgatc	gtgtcttcca	cccacaaatt	gaatgctttt	tccatcttaa	74040
cacttatctag	gcactgtggc	cataacttga	gcagttgaga	tgcaacagca	aaatttagca	74100
aaatttcttt	ttctttcttc	gcagtttcat	ggataagaga	tttgttctta	gatctcagca	74160
acctcagcat	atgatttttt	tctttaagtt	gagaactttg	acctttttac	ttagagaagc	74220
attttacagc	ttctcttttg	catatctgaa	ttgccagcat	tactatgctc	gtgctttggg	74280

gccattatta	agtcacaataa	gggttgcttg	aacacaagca	ctgcaatacc	atggcaatag	74340
atcgcatcac	caagatggct	gctaagtga	ccacaggcag	gagtgtagac	agcatggaca	74400
cattagacga	aggggaagatt	cacgttgcca	gtggaacaca	gcaggacagc	aagagagttc	74460
atgatgctac	tcagaatggc	atgaaattta	aagcttataa	attgtttctg	gaattttccg	74520
cttaatat	tcagaccacg	gttgagttca	ggtaactgaa	accataggaa	gcaaaacacg	74580
gatgaagagg	gaccacttcg	tattgcctaa	tttagtttgt	tttgatcttc	tgggaccttt	74640
ttttcttggt	gtaaaaattt	atggggctgt	ttatagttgt	ggctcattga	tttttcattg	74700
ctacataata	cttccatttt	gtaaatataa	cagaatattc	atctacctgt	cagtggacag	74760
tgggggtttt	ttgccattat	aaatgctgct	gctgtgacca	tttggggggc	aagtctcctg	74820
gggcacagta	tgagtttccc	ttctgtataa	caaagggaatg	gaaaattata	gactttcgtg	74880
tccaaattta	caagataatg	acaattgttt	tccaaagtgg	ttgtaccaag	caatttctccc	74940
attaatagtg	tatataagag	gtcttcctga	tccatatatt	cttcttggtt	tattttcaca	75000
cttttgagat	ttttgctatt	tgagtggat	aaaatggctc	gtgatcttga	tttgccgttt	75060
ccacattttg	aagaggttgt	cggctctatg	tgtatatatt	gctcatattt	gttccctctt	75120
ctgtgaaatg	ctttttgtat	cttatcccta	tttgttctgt	tctgttgatt	gtcacgtttt	75180
aattgatttg	tatgagtttg	ttccttgat	cattgttgct	agagttacat	cagatgtgtt	75240
gctgaatctg	ctcccagttt	gcagcttgty	tttttacttt	ttaaaaactg	tcttgattta	75300
tagggaagtc	tttatctttt	catttgagc	tagtaatggt	tgtggctttt	taaagaaatt	75360
attactattc	ccaaggtcag	aaaatcattc	acctatattt	taactgaaaa	gttataaagt	75420
tttgcttttg	acattgaaat	ttctcattca	gttggaattc	atattgatgt	gtggtatgag	75480
gtaaggatcc	atttttttcc	catttgcata	gccagttttt	gtagctccac	tttattttct	75540
cacttgatct	gccatgccac	ctctagcatg	tatcaacata	tcatgtatgt	gtgcagctgt	75600
tccttaactc	tcaattttat	tctcttggtt	actttgtcta	accagcact	catacttttt	75660
aaattattat	ggctaccttg	tagggcaaga	atcctcactt	ttattcaact	tcttttgaag	75720
tgtcttgatg	ctatcttttt	ctgatctttac	ttggccatat	atattttggg	gacagatgtg	75780
acatcatacc	aagctttctt	tgcttgacat	tgtagatatt	ttcttattca	ttaatgtgct	75840
aaaaattttg	agtttggtca	tacagtcttt	tatatggatc	ttatacatcg	tttccctctt	75900
gtaaacatt	caggctgtta	ctagtttttg	ctgttggtgaa	ttaacaccag	gacaaatatc	75960
catatatctt	ttgaattaat	tactgactag	tttcttagga	aagatattag	aatatgaata	76020
ttaaaggctt	tgtctgaatac	agttttcaga	atggttgtac	caatatataa	ttccattttc	76080
attatgtaga	aaaaatacct	cagtggtttt	taaccacctt	tggttagaac	attcaagaag	76140
ttatgggttt	gttaggtaag	aaatattttg	tttcagtgt	ggttttcttt	gagactgaac	76200
ttttttgtgt	gtgtcagtc	tttacagttt	tttgcaattt	ttaaaattca	gtttctcaca	76260
agcattttgc	ctttgacttt	tcttctattt	ctgctttctc	taattacaga	aaccccagtg	76320
ttaagtaggt	gacagttcag	ttgtttgctg	cagaagagca	gcagttcaat	attggaatta	76380
actttaattt	tatgttttta	atctgttact	aattttttac	agaataattg	tagtttttat	76440
aatctgggta	attatatgtt	tgagctgcat	tactttgcaa	tgtaaagtgtt	tttttttggc	76500
atggtcaaat	aacaaaaatt	ctgggttaatg	cttatttcat	attacaggag	aatccagata	76560
tttcatttag	gaaacatata	agcagagtgt	gatcaggctg	tatgaattat	ttataagaga	76620
tgtgagtga	aagatctatt	tgtagcttaa	gagtgaagtag	agtcagatgc	atgtagagtc	76680
ttttattcaa	aataattttc	ttattaatct	tggatagttt	cttgtcacag	taattccatt	76740
ttgaagataa	taaatattac	cataaagaag	tgatcaaaaa	catagatatg	tgtgcccaca	76800
ggatattatc	acaatagtat	ttataatagt	gaaaaaagaa	acaactaaaa	tgtctggcaa	76860
taggagaatg	attaataaag	cgatgtttca	gctgaatata	gtggcatgcg	cctgtaagcc	76920
cagctactca	ggaggttgag	gctgcaagat	ggcttgagcc	caggagttaa	tgaccagccc	76980
aggcaacata	gcaagaccct	gtctccaaac	acacaaacac	acacacaagt	gctatgtttc	77040
agtcactgta	taataactag	ccagattttt	tgttgttgtt	gttttgtttt	tgttttttgt	77100
ttttgagaga	gcatctcact	tgcccaggct	ggagtgcagt	agtacaatca	cagctcactg	77160
cagcttgtag	aaccttaacc	ctcctgggct	caaattgatcc	tcccacctca	gcctcctgag	77220
tagctgggac	tacgggtggg	taccaccata	cccagctttt	tttctaagag	ataggggttt	77280
cactatgttg	cccaggctgg	tcagttttta	atgaagcaca	tttggtgtaga	caaagcagga	77340
tgtggaaccg	gataaacact	atggtgccac	tgaagacccc	ttcaaacccc	tcaaaaatga	77400
catagaaggg	aaatatgaga	tattagtttg	ggaataaatt	gtaactttat	taagactcct	77460
tataaattta	tctgttcccta	tgacctggct	aagttcaata	aaagttacac	agagtggaaat	77520
aaatgggttag	acatcatttg	tagtataagt	aattgcacat	aaggaggtaa	ctttagctgt	77580
tttagagata	gacatagtat	ctgaaagggt	agttatttta	ctagacctgt	gattatttgg	77640
gtgagaaagg	ctttcactga	gattttaccc	attcagtaag	tactaatgat	atttgtgtga	77700
tagcatatat	taagggaata	tatggtatac	cacagagaaa	gaattaaagga	aattttgtgt	77760
tttgcttttt	gtctgtttgc	aaaacttact	gactcagctt	tcattcttgg	gaatgtgtca	77820
gtttctctgtg	ggaagataa	cattgatgag	gaattgataa	tgttctctgt	atttttctag	77880
atggagattg	taaaaaactt	acctcagaaa	tatttgcaga	gatagagacc	tgtctgaatg	77940
aagttagaga	tgaatttttt	attagccttc	agccccagct	tagatgcaca	ttaggttaagt	78000
aattggtaaa	acttacttgt	attatactca	tctaccatat	agaaatatgt	acctcataag	78060

gaaatataat	actgtttgat	taccttggat	gatcatattc	ttgggagaga	gaatctgagt	78120
agtttgactt	aggaatctac	cactgggtaa	gttattgtag	ggcagagctg	ttccatataa	78180
atatgtaggc	tgggtgtcca	cctcttgaga	gtgggtgcag	ttctcagaac	caggagaatt	78240
ttagggggca	tatcattagt	tgcttctcta	gtacgtttcc	tagtagacag	atctagcatt	78300
tttaacctca	attgtgcatt	aaaaagcacc	gaggggaattt	aaaagtaa	gccaatgctg	78360
gggcatttga	attaggatct	cagggatggg	gctcaggaaa	tcagtaattt	ttagaaaccc	78420
cacatgattg	ttatatgtac	ccagggttta	gaatctcatc	taaaccaacc	atagtaattc	78480
tacttcccta	ccagtgattg	gttttaggaat	gtccttgtgg	tagagttttg	gccagtggat	78540
attaagagaa	atatgctgat	ggccttttgg	gaaagcttcc	tcgccttttag	aaagggcaca	78600
aggatgggac	ctctttgttc	tctgtgactt	ggtttttggc	ctgtgggagt	ggcgtgcagc	78660
aagtgagcta	gagagtctgt	ccaaaccttt	ctaaattttt	ttagtattgc	gaaaaggagc	78720
tgcgggggtt	ttttgtttgt	ttttgttttg	aaagggcctt	ttgttttatt	tttcttgtat	78780
ccttgattta	actcttctat	taatgttata	gtagcagaat	atgatactcc	ctattagtaa	78840
taaccatata	tatgtaaaat	atcagtgcc	tctagttttt	ctctcaatga	gtgacattta	78900
acttatatta	aaaaatgata	tttatatttt	ataataaaat	cagttgttgc	tactgatttg	78960
tctagcatgt	acaaaagaca	ccatgcttcc	agatcattat	aaaatatgat	attttataat	79020
atatattaca	tatatattata	acatatattat	atacttagaa	tatatattat	aaggctgggc	79080
ttggtggctc	atgcttgtaa	tcccagcact	ttgggaggcc	aaggcaggcg	tatcacaagg	79140
tcaagagatt	gagaccatcc	tggccaacat	ggtgaaaccc	tgtctctact	aaaaatacaa	79200
aaattagccg	ggcgtggtag	tgtgtgcctg	tagttccagc	tactcgggag	gctgaggcag	79260
gagaatcgct	tgaacttggg	agacagaggt	tgcaagtgcg	tgagatcacg	ccattgcatt	79320
ccagcctggg	gacagagcga	gactccgtct	caaaaaatgt	atatatatat	atatatatat	79380
atgtgtgtat	gtgtgtgtat	gtgcgtgtgt	atatatatat	atcgggaagc	atggcatctt	79440
ttgtacactc	tggacagctc	ttgacgtact	tctttgactc	atgcttctgc	cccctaattt	79500
tcactttttt	tcctacattt	tattaaaatt	aatatataat	agttgtatat	ctgctttatt	79560
tttcatggac	ttatacatat	atatttatct	tgttcttata	aaagtctgat	ttttcgtatg	79620
ccaaatttct	gacatttctc	cctctaggcc	tgaagaactg	ttgtaattta	tgcatacagat	79680
aggccctcag	atggaatgaa	tattcttttt	tcttttatatc	aagggtgta	ttacatatag	79740
taagaccgtt	tttaagtgtg	tacagctctg	taaccctcac	tacaatcaag	atataggact	79800
ctgtcactct	aaaacttctc	accagggtca	tcacccccag	ccactgatct	gttgagcgaa	79860
tactcatttc	aaaggagctt	tttccgtta	atccctagag	tttagatgga	agggcttttcg	79920
tgggtgcattt	agcagatacc	atttcccttc	tagactccct	acttcagttc	ccagttgaat	79980
taaagaatgg	tttctcccc	agcctgagtc	actacccttc	ttatccctga	taattatttt	80040
tggaaacaa	ttacatcttt	tgctccacct	ccgccatggg	cctgggttttc	tatgtaacag	80100
aagggaattt	taaattattg	ttttgtgtaa	tcataataat	tgggcaagca	tacagctctt	80160
ttcagtgact	gaggatttct	ctcttgtttt	actgcccat	caaggatagg	tgctatattt	80220
tagctgaaga	ttctactaat	gaaatgctct	gtaactatat	aacttattta	aagatgtgtt	80280
ttgagctctt	tcataatatt	ttaatctcatg	gagaacttta	tgtatttttag	acctgaagat	80340
tttatattgt	cattatgaaa	tgtaaattgt	ttgctttttc	agttaatata	tagttacaat	80400
agaatacggg	tttaaaggct	gataatgaat	tacaaaattg	tgctatatga	catactgttt	80460
atgcatacag	tgttgcatat	tttcatttct	aggatattga	tttgtatttc	tacttacaaa	80520
aaaacttttt	aaaacttatt	ttatggctgg	gcccgggtggc	tcacacctgt	aatcccagca	80580
ccttgggagg	ccgaggcggg	tggatcacct	gaggtcagga	gttcaagatc	agcctggcca	80640
acatggtgaa	accctgtctc	tactaaaaat	acaaaaaatt	agccggacgt	gggtgtaggtg	80700
cctgtaatcc	cagctactcg	ggaggctgag	gcaggaaaat	tgcttgaaac	caggaggcag	80760
tgggtgcagc	gagcagagat	tgcgccattg	cactccaacc	tgagcaacaa	gtgcgaaact	80820
ccttctcaaa	aagaaacaaa	aaaacttttt	ttaatgtttt	tgttcaaaag	tagcagtgcg	80880
actatcccg	aaaggtgact	actaaaatag	cctttgtaac	tactgatatt	tatagaatat	80940
gcttaggggt	aggggtataac	tcgcttgtat	tatactcatc	taccatgtag	aaatatgtac	81000
atcataagga	aatataatac	tgtttgatta	ccttggatga	tcataattct	gggagagaga	81060
atctgagtag	tttgacttag	gaatctacca	ctgggttaagt	tattgtaggg	cagagctgtt	81120
ccatataaat	atgtaggctg	gtgttccacc	tcttgagagt	gggtgcagtt	ctcagaaccg	81180
ggagaatatt	taggggacat	attgttagtt	gcttctctag	tacttttccc	agtagacaga	81240
tctagcattt	ttaacctcaa	ttgtgcatta	aaaagcaccc	agggaattta	aaagtaaaata	81300
ccaatcatag	ggacatttga	attaggatct	caggggaagg	gctcaggaaa	tcagtaattt	81360
ttagaaaccc	cacatgattg	ttattgctta	ggtaataaca	cctactgtct	accttgtggt	81420
cctgccaaag	tgactgttcc	tggccatgtt	ccaggcaact	gtagttccag	gctaggggga	81480
gaactggacc	atggaagtga	ggctctgtcc	agggtagggg	aagggatgga	aggtgactgt	81540
tcttggccat	gttccaggca	actgtagttc	caggctaggg	ggagaactgg	accatggaag	81600
tgaggctctg	tgcagggtag	gggaagggtg	ggaaggactc	agtctcttgg	gccaaatcgg	81660
taaggcagca	tctaagctcc	tctgagaata	ggaaggagag	caaccaattg	gaaaaagaat	81720
gggaaacatg	tagattctcc	tgtttacctt	actttccagt	ctcaaagctg	gaagccagca	81780
ttcactgttc	agttattttt	aatgacaaca	agattcaaat	cttcagttgt	aaagttgtta	81840

aaggaaagga	ttagactgaa	aagttaagaa	gaacggtaga	tgaagagtcc	aaagagttga	81900
ggctggcat	ttaaccattg	tgtggccacg	ccctctccac	aggtggaaca	agatgatcag	81960
aatagaaatg	gccaatctctg	atgtgtttct	acagtgtttc	actgattaca	ttttttaaca	82020
tctgtagcaa	accatttcca	taattttttt	tttttttttt	agagacgagg	tctcgcctctg	82080
tcacccaggc	tggatgacg	cggcatgatc	atagctcact	gcagcctcaa	attcctgggc	82140
tcaaagtgc	ctcctgcctt	agcctcctaa	gtagcttgga	ctacaggtgt	gtagcaccac	82200
tctcagctaa	tttatttcat	tttatttttt	gtagagataa	tgccctcgcta	tattggccag	82260
gatggctctca	aacgttcata	gaaactgggt	ttaggttcct	agaggctggc	agcaattctc	82320
agaggtaacg	caagcagtct	tctgccttg	gcctcccagt	gtgctgggat	tacaaggtgt	82380
gagccaccac	acctcatcaa	tttttgttt	aatatactct	aaggcttatc	atagttccga	82440
gatctttttt	tttttctga	gaaatctaga	aagatggaag	acagtatggg	tcttttgtgg	82500
attttttgc	ctaagaaatt	ttcataaatg	ctcgccaagg	aaaaggaaag	agatcaaagt	82560
ggtaattaaa	tcttttaggat	ggacattttt	agaaaaatgc	tttataaact	tcccctctcc	82620
caactctgag	tgacttattg	tgtcatactg	tattaacaca	tattcatgct	gtaaatatag	82680
taagaaaaga	caatagtcca	caattttggg	ttagtttttg	ccattattga	ttatgagcag	82740
taattcttcc	ttttcttttt	gaagggtgata	tggaaagccc	tgtgtttgca	tttcccctgc	82800
tcttaaaact	agaaacccac	attgaaaagc	tcttctctata	ttctttttct	tgggactttg	82860
aagtgtcgca	gtgtggacac	caatatcaaa	acaggttagt	ttcttttgtt	ttttaaaatg	82920
ggttcttcta	gtttctccac	cactaagggt	aagagaacaa	tttgagcacc	agacactaca	82980
gtttgcttgc	ttctttaaac	tgggaagggc	aaaacctcat	cgtttgatag	actgctagta	83040
ggatatttcc	taaggagtcc	ttcagtggga	aatagggacg	atgagaggaa	taatacacct	83100
cccttctcca	gagtccttgc	tgagtagaat	acctctcaga	atgccatgaa	actgtaggca	83160
tttttgttta	ttcctctatt	agaaatgagg	ggttttgctt	gtttacttta	ggtttctaac	83220
attatagaca	ctagttttag	gctcttggag	gctagcagca	attctcagag	gtaatgcaag	83280
cttccccatt	tcttcccgta	gtcctgtgaa	agaccagcca	cctccagaag	cctacacatg	83340
agtcttctca	gccatacttt	ctgcttttcc	taatgcctct	cagcagcgta	ttagaaaggc	83400
catgatcgat	gtacctgtta	ccttcaggct	ttgcataagg	tgtatatgaa	acataatgaa	83460
tttcgtgttt	aggctcagggt	cccatcccca	ggttacctct	ttatcttgga	gacacttctg	83520
gtcccataca	tttcagataa	gagatattca	acctgtaccc	accacgtaag	gagaggaata	83580
ggtttttagaa	gaggagtccag	ggaggcaagg	tattcccaga	gggatattct	cacttgggtcc	83640
atacctgaga	aagttgctgg	ctggcagtta	ggaagatgac	cagactggct	caattgttctg	83700
tgtattcaaaa	ttattacaat	agaaataact	ctttccaccc	ccccccgccc	tttttttttt	83760
tttgagttgg	agtctcgtct	cvgtcacaca	ggctggagtg	cagcagcgctg	atcccggctc	83820
actgcagcct	ccacctcctg	ggtaaagcg	attctccttc	ctcagcttcc	tgagtagctg	83880
ggattacagg	tgtgtgccac	cacgcccggc	tgatttttgt	atttttagta	gagacaggggt	83940
tttgccactg	tggccagggt	ggcttgaac	tcttgacctc	aggtgatcca	gccacctgag	84000
cctcccacag	tgtctgggatt	acaggtgtga	gccaccatgc	ctagccacac	ttttctttag	84060
cttaagtgtc	taagttagaa	aacttgaagt	ctctctaagt	tactcaagta	aaatgtgaga	84120
taaaaaatatt	acttttgaag	gccgggcaca	gtggctcaca	tctgtaatcc	cagcactttg	84180
gtaggccgag	gcgggtggat	cacgaggtca	ggagtttgag	accagcctgg	ccaacatggg	84240
gaaacgctgt	ctctactgaa	aatacaaaaa	ttagccgggc	atgatggcgg	acacctgtag	84300
tccagctcat	tcgggaggct	gaggcaggag	aataaactga	aaccggaagg	tggaggttgc	84360
agtgaagctga	gattggacca	ctgcactcca	gcctgggtcaa	caagaatgac	actccgtctc	84420
aaaaaaaaatt	aaaaaaaaatt	acttagatat	tcattatcta	aatatgaaat	ccttttttagg	84480
tatttaagga	gtagtcaagg	agagttcagt	ctgggaggat	gctccaggga	atgcaggcaa	84540
caaaggtttt	gttttttttt	taactgggtta	actcagatct	actagaacag	ggtaagggag	84600
gccacagagt	agacaccatg	agcaaagcta	acctcctga	gttgaaaaaa	ttatggacga	84660
gaagttatca	ttgaaattaa	ctgttggcag	acatatccaa	agaatatcgc	aaggattttg	84720
tccctttatg	catcctgaga	cagatgaatg	tgtggaatgg	cagctgggtg	gcaacagagc	84780
gatattggca	tgggtggtgat	acagggaaat	agtttcatcg	tgtaaaaagc	catggaacaa	84840
agatacataa	tggctgctct	gcagaaaaat	ccacgtcccc	tctccaaagg	gcctgtttta	84900
ctctgatgta	aaaattgggt	cagataaatt	ttcatattaa	gctttttgtt	gagtaaaact	84960
ttgtaatagt	ccccaaaact	cccactagaa	cagggtgaga	attaacgttt	tattcatacc	85020
taggacttaa	ataatttagt	gtaagcaagt	gagtatgaga	acacatctgt	ttccagctct	85080
ctatcattgc	tttatataaa	ttctctgggt	ttctcctcac	agtaactcag	tgagggaagat	85140
cctagtgtcc	tcatttggca	cgtatggata	tgacagcttg	aaaggggtta	gattgatctc	85200
caagatgaca	cactgtaaat	ggcagagtca	ggagacacac	ttaggctctt	ctggcctcta	85260
agactttctt	gctcactgtg	gtatactcct	taatcactac	ctgggtttta	aataatataa	85320
ataaccttgc	tgattaaaa	cagcttaatt	gtagctttctc	tggaatccat	atcttagttg	85380
tttgacagtt	tctcgttgag	tgtcttctgt	gtgttaggaa	ctcaggcact	ggaaatagtg	85440
tatctttgcc	aaatttacta	attaggtaga	gagataatac	acgaacacat	aatagaggtc	85500
cagtgaactc	gtaattaatc	tgatctttgg	gctgcttaac	gttagctttg	aatgcaagat	85560
gttaaatgcg	tttttagagat	atatagcaca	aactgtgaga	gctcaaggga	gggaagccac	85620

tagccgcttt	tgtttgcttt	tttgtttttt	aaaaataatc	ttacttttgt	ctaaaaataa	85680
aagtagttat	agaggggaaag	ctaaaatgaa	gtgacgtttt	cttaaataatg	ttttaatatg	85740
tcataactta	aaactttatt	ccacttaatc	tgaaggagaa	ctgtccagca	aattcctttg	85800
tttttgtgaa	gctgttttta	gtgccagcat	aagggctttt	tactcaactt	ggaaagtgtg	85860
accagagtc	agttaaaaac	atagtcctca	gaggcagatc	tcaggtctgt	tatttatcac	85920
tgtactctat	gtgtcacttt	ccccatctgt	aaaatgggga	taagaatagc	acctgcctct	85980
gagagtgtgt	tggaaagtga	gtgtccagtg	ccatgccctt	tgacatagt	ttaagtgttc	86040
agaaatgtca	gatgtcatgt	ggagaattaa	cacttacttg	ctgagacagt	ctccttttta	86100
taaactaaac	agtaggagcc	tttacataac	aattatcttt	gaaaatttaa	gaatttagca	86160
gaaatcagtg	catttggtga	tatctttatg	ttgcttttgt	tttaaaatgt	taacctccct	86220
gactactgat	gtttttaaca	gacagtgctt	cctcacaaga	tttataagta	tttgctattg	86280
tttagaaagg	aagcttgtat	ctcttaagta	gctgctcttt	aaattacaaa	tatttttatt	86340
aaagtggatg	cagttgaggt	ttagtgtaca	tctttaaagg	tcactctttt	agatggcggt	86400
gctctcaagt	attcagacta	aagtgc aaat	ttagaacttg	tgtaacctgt	gaaaacaaaa	86460
tttggttcaca	attaatgctg	tgtgtgtgtg	tggttttttt	ttaaggatta	aaaaaagtta	86520
agttgtatgt	attcctgatt	ttatgtttgg	aaacatcccc	ttttcatttt	tggttgtctg	86580
taatggctag	ccagtttgag	ttatttgagt	aaggggtgag	ctcttaataa	atttgacaac	86640
cttagaagac	tggttcttca	ctaagggcta	ttttttcccc	cttgggacat	ttggcaacat	86700
ctacagacaa	ctggatgccg	ttactggcat	ctggtgagg	gaggccagg	atgatgctta	86760
acatctctaca	gtgcacagga	cagtgcctca	cagcaaagac	tctctggtga	aaaatgcagt	86820
gataccattg	aggaacctg	tctttttttc	ttgcttcac	tcatagtga	aagatatggg	86880
aaattaacat	ggagcatctt	cacagagctt	ctttactaga	ggtaggagg	aacattgcca	86940
tattaacatg	atttggggaa	ataagaaagt	atgaatcacg	aaaaagggga	ggaatacttt	87000
tagacattgg	tttaaattaa	tgtaaatgca	tttaacgtta	atgaatttgt	tatgtcattt	87060
ttttataggc	tctgtgaag	tctggtcacc	tttacaaatg	tcactccctga	gtggcaccca	87120
cttaatgctg	cccatttttg	tccatgtaac	aattgcaaca	gtaaatcaca	aataagaaaa	87180
atggtattag	aaaagtgagt	taaaattgtc	ttataatttt	tagtacaaaa	tgaagggtga	87240
tttacatttt	tcttaatgtg	taggattgaa	aatggtgaca	acaacttacc	tttctgaaat	87300
ttgagttaac	atataatttt	gggttgccag	ctgcctcgct	ctatctggcc	agtgaagcca	87360
ctgtcacggg	gaagccactg	aaaagccaac	ttaggtgac	tctctggccc	cactctccta	87420
gtgtctttcc	ttctttttgc	cttttttctc	cctttaagga	tatcaagctt	cagtttttct	87480
ctcctctgcc	aagtgtatgg	agtttctaga	attctgggat	ttccttaatc	agatttcaag	87540
aactaagatg	attcaaagat	aagccacagg	ctcatctctc	tgaatttcca	tcttctccta	87600
gatctcagca	tgctaattcc	tcactcatct	gaaagctatc	tagtggcctt	gagcagatat	87660
attttcattg	tattttgcc	gcttttctgt	ttgtcctcag	ttggggaggt	tggtcagcat	87720
tactttttcc	agtattacca	gagaaccact	tgtttaaact	cacaggtcag	ttccatctca	87780
ggcgttttcc	ctctgtctca	ttaatgcact	cacacatgta	cacaacctct	ctactcttca	87840
ttttcagctc	aatcgtacat	taaggaaatg	ttttgaggtc	taattttgat	taataaagaa	87900
ccgggaacat	taacctttat	gcccttgaat	gtgccagaaa	cccttcagaa	tctttcctaa	87960
aggtttatcc	tcattgaagt	aataaatcct	cagttttatc	gtgcttacag	gctcaaaagg	88020
gaaaaagggc	agtagtcccc	tgttccctcc	tccaggtatc	tactttaaac	cttcaaatta	88080
aggtagtatt	tacttttact	tttcaaattg	atgtgcctat	tctaccgtaa	tgagtcctgt	88140
tctcctttta	tagtaattga	gactagggtt	cactcaccaa	cacctgggccc	ccatctctgt	88200
ttagcctttc	cctgtccttt	caatgcaatt	gcgtatttgg	ctaactcagt	actcgggtgt	88260
tgcattgtta	ttaatataca	tgtgttatcc	cctcttcagc	caagcagtat	atatagttag	88320
gtttcacttt	tacaattctt	atttttccgg	gaattgttat	ttgccttggt	ttcatttggt	88380
ttattatgta	ctgtgagttt	ttgccaaata	ctttaagac	ttattaataa	attttcaata	88440
ctcagatgct	tcacagtttt	ttactctgtt	cctctccctt	ttttttcttg	gaactctttc	88500
ctgccacctt	tactcttttg	ctgcagtcgt	cgctgggtcc	tctctgggccc	tgccagcatag	88560
ggtgctcttt	attatgtaca	cacttccagt	cactatcgta	gttttttagcc	caaggcctca	88620
tccccacatt	ctatcacatc	tggtgcccac	aaatatccag	tccttttaggg	gttctctggg	88680
aaaaataagc	tcttcttttg	catcaacata	tgcactccgt	agtactcatg	tcttcacttt	88740
gccggttctg	ctgggtaagg	tgccacttct	ctggttgctt	tctgtcctct	aaatatattg	88800
cttcttattt	gcttattttc	ctttctttgt	cctttttggc	tcatactctt	tttgcccttc	88860
actattattt	gatagcattt	gtgtaggagg	gcgaagtggg	aagggaagg	aggtgtctgt	88920
atctgtctga	agattacaga	agtctgtaat	ctgtcttggc	tgccaggtgt	cagttttgag	88980
atgtaaatgt	tgatgatgag	gtgaggagaa	gagcagcaga	gcatggggtc	tgccatcctg	89040
ccttggaacca	tggcctgctt	taggctgctt	ggtgtatatg	atttcactca	gctgttcata	89100
cctgtctttt	cctgtgcccc	agcactgaac	atagactcgt	accattgttt	tgtgtaattc	89160
gttaattggg	tgcattgcag	catatatatt	ttttaactat	acaaataagt	tgcttccctt	89220
aaagattcat	gctctgatct	ggaaatggat	tcattaggta	aaagtctttt	aatggaaaaa	89280
gtgttttgag	ttccagtggg	ccaatttatg	agcagaattt	ataatgtggg	catttctctg	89340
tttcttcaaa	agtaaatgga	actagtgtat	gaagtttcac	ttaaatttta	aatgcccaagg	89400

tctttatata	agtcctttgt	gttttttttaa	ttttgaaatt	tgtataaactt	gatttggtttg	89460
tgtctaattg	aatttagaaa	taaatttaaat	atagtttttta	gggctaacct	aaaagtaatt	89520
gggttcacat	tggtgtcata	tgtaattaaa	acatatagaa	tcctaaaaac	taattaaagt	89580
ccttggacac	cttatctcac	ataaccacac	tctctaattgt	ctccccattg	ggaaaagagt	89640
ccattgataa	atcaggtgaa	ttatgcctag	cgggccccaaa	tctgctactt	ttctttaagt	89700
tgtttaggag	ttacattcag	accatggtga	catggagcac	caagaactta	gaatcagatt	89760
tcattttact	tgacaaactc	ttgaaaggtc	actgccacag	tctctcttga	gtgcaaggct	89820
atggctatgc	tttgtagcac	agggacgcga	tattttctctg	ctatcttttg	gtagcagagg	89880
ttaacacagc	tccttgtgc	tttctttctc	tcttttctat	tttcttttct	tttcctaagg	89940
atagatcttt	aaataggagg	agtttaaccc	catgttaggt	gaattcaaat	ggatcttagc	90000
ctgatgtctc	ttgttctctt	ttggttccag	tttggttaat	tcctttcatc	caattttcca	90060
gtggttgagg	gagaacctaa	cttgctctcc	tcgactctga	gcacatcct	tcactgacag	90120
ttcaggcatt	gtgggttaga	agaagtctga	gaacaaaacc	tagggataaa	gtttagtaga	90180
gatgggggtt	caccatgttg	gccagggttg	tctcgaactc	ccgacctcag	gtaatccacc	90240
tgccttggcc	tcccaaagtg	aggctggaaa	taagacatgc	tgggaattgta	agtaggacac	90300
tagagtctag	gggaatcaaa	gaggaaaatg	aacagaaaag	ggaaggggaa	ggatattatt	90360
tgattgactc	caagatgcta	ctgtttgtaa	gttttaccat	tttaaaaaata	tgccattaag	90420
aaagaaatgc	tgggcgggga	tgggtggctta	tgctgtagt	cccagcactt	tgggaggctg	90480
aagcggacag	atcacctgag	actaggaatt	tgagaccatc	ctggccaacg	tgggtgaaacc	90540
gcactctctac	taaaaatata	aaaatcagct	ggatatggtg	gcacatgcct	attgtcccag	90600
ctactcagga	ggctgagaca	ttagtactgc	ttgaactggg	gaggcaaagg	tttcagttag	90660
cagagattgt	gccactgcac	tccagcctgg	gcaacagagt	gagactgtct	caaaaaaaaaa	90720
aaaaaaaaaga	aagaaatgct	gcttattttaa	ctgtgttctg	tcaatgttaa	ggtgtatccc	90780
gactctcagag	atggttaacaa	atgggaaaaa	atttggaatt	cattaggcat	ttggaacctta	90840
caaagttttc	gcggggcata	gtggctcatg	cctgtaatca	ctttgggagg	ccaaggcggg	90900
tggattacct	aaggctcagga	gttcgagacc	aatctggcca	acatggtgaa	accccatctc	90960
tactaaaaat	acaaaaatta	gctgggtgtg	gtggcatgcg	cctgtagtcc	cagctactca	91020
ggaggctaag	gcaggagaat	cgcttgaacc	cagggggcgg	aggttgcaga	gagctgagat	91080
cgtgccttgc	actccaactt	ggacaacaga	gtgagacgcc	atctcaaaaa	caaacaaacc	91140
aaaaaaaaaaa	aaaaaatttc	atagttacag	aaagttagat	ggaggccata	ccgagatttt	91200
cgacatggta	gtaaaactct	gcattatggc	tctgttctgc	atcatctctg	ttctgcactg	91260
tttcaactcca	catcagaccc	tggatagctt	tgggtgtactg	gtcgatcttg	tggcagtaag	91320
gctagtgtaa	ttaagaggat	attttaaaac	ttaacatata	attgctctag	ttgttgtctc	91380
ttttttgctg	gttaagaaaa	tcaaatttct	atcctatctg	aatctcatag	cagacttttg	91440
agatttctga	caagtcattt	cttactacct	aggggaatgt	acttgtaact	agctagagtc	91500
tgagtattct	ctacatccag	ggaattgggc	tgagtgtgga	ttttggctct	ggcagttttt	91560
acttttatta	atttgcaaaa	cttggaatgt	acaagaagca	cttaagatat	taaaaatgtg	91620
tcagggtggt	ttacatgcgt	tatttatcac	gttaatatgt	tctagggatc	tttccacgtg	91680
taaacttatg	taaaggcagg	aaactagtga	gatttcatat	ataaggtcaa	aagagattgt	91740
tttagtaact	agcctcagaa	agtatcttga	aagggtattat	taatcccagc	ggaactaaat	91800
attagtaaa	agtcaggcca	ggcgtgggtg	cttatgcctg	cagcctggcc	actttggggag	91860
gccaaggcag	gcagatcact	tgaagtgcag	agttcgagac	gagcctggcc	aacatccgtga	91920
aacctgtctc	ttactaaaaa	tagtagtggt	tggtagtggt	gcgcctgcct	gtaatccagc	91980
tctcaggag	gctgtgggtg	gagaatcact	tgagcccagg	aggcggagat	tgcagtgaag	92040
tgagattgca	ccactgcact	ccaacctggg	tgacagagct	agtgctctgc	tcaaaaaaag	92100
aaaaaaaaaaa	aggtcagata	ggtgcctaaa	gcctgtgtgt	ctcgctatga	gaatacatct	92160
caagttttac	tgtggttcat	tgattcagac	atgtagttca	cattttaacc	tgtctgaaat	92220
ggtaatatgt	gaaattgatg	tcatgatata	gtttaattgg	cagcatgttt	tcatagtgtg	92280
acattttata	attagtgaat	tcttagattt	gatgaaatag	atatgatttt	ttaaagtggg	92340
aaagtttagt	gttatagaca	gtttgcagga	ctttttattt	tgtaggtact	taaattttga	92400
ggacttaatt	attctctaat	aaagtgattg	acaaggatta	atgtataaat	tataccttgt	92460
cagtctgaac	aatctgcagt	ttggacattg	attcaaattc	atttaggctg	aataaatttt	92520
gataaactaa	gtaagttttg	acagctattt	aaatattggg	aaaggggata	ttcaacattt	92580
ttcttacatc	ctgagagctt	tgttaaattt	agttatttga	gacccattgg	gttctatttt	92640
ctgggttcagc	atgttgctgt	aatggtaaaa	tacaattttg	aaattatagt	tgtcttgaag	92700
ttaataataa	attgaccaat	atgttgattt	tttttctcta	cttagttaca	aattgaactt	92760
ttcctaagta	gaacttttaa	tttgacaggc	cccctttgct	tcctgaggta	actgaaatag	92820
gccaaattaa	tgtttttttg	aatatcttag	gtttgttgct	ttctttcaca	tgttacctac	92880
cccacttaac	aaaagcaatt	aatctcagca	cttgatgcca	aagaaaattc	taaaaggtct	92940
ggattttttc	cttggatttg	acaaagttag	tacaattggg	cttttaagac	aaagctgcac	93000
tgtctgttac	agagcaattt	ttgttttaag	gtctgtgtta	gagtcatact	gcatgtgac	93060
ttccaactgt	ctgggatacc	attctgaaaa	gggttttagt	ttacataact	cttagagaga	93120
gttctccatt	tctaattaag	gcacacatct	ggaggtgctc	aagaaaaatt	agtgcagtta	93180

gccttggaag	tgttatgtgt	gactagttca	cttcagacat	cttttgtata	atcagacaca	93240
tggcattaaa	tttatttaac	ttctcttgct	tttctctccc	acagagtatc	tcccatattc	93300
atgttgcaact	ttgtagaagg	cttaccacag	aatgacttgc	agcactatgc	atttcatttt	93360
gaaggctgtc	tttatcagat	aacttctgta	attcagatc	gagcaaataa	tcattttata	93420
acatggattt	tagatgctga	tggtaagtgt	ttagaggttt	tcttttaaga	taattggcat	93480
agaaactaaa	ttctagcatg	tggggacttt	ttgggttttg	ttttataaaa	aaagacaaac	93540
tttgtcctga	ctctttctct	ctccattctc	gcctttgcct	tctgcccctc	ctcgcatcta	93600
ttaaaagtga	tgggttttagt	atcctgtctc	attttttcct	ttccttacat	catgtattat	93660
aggtaaacac	atgcgcagtg	gtgtatttct	cttttagaca	aaggatgaga	ttactactgt	93720
tagctcagtt	tttttttccc	tacttaacat	ctttgctttt	attttttaga	catatttcta	93780
agactattaa	acattagact	tacgtagccc	ttctgtcatt	gtgaaatata	tagtttacta	93840
acagctacca	tcaagataaa	gcctttattt	aaataattaa	acttcttagt	ggaaaagctaa	93900
gtaagcacag	tttatggatt	ttgggaattt	ttgccttgca	tttgtctgat	atggtaaaat	93960
attgagtttg	tttttctcat	aatgttcaact	ttgtcttaga	caagataact	caatcccctt	94020
aaagggttgt	atcaagccat	tgataagggc	tcactttgat	ataaccattt	tctgttattt	94080
agacactctt	tcacacttcc	tattttctct	ctggggatgg	tttgaatgga	tgacacaata	94140
ccatattata	aaagcacttt	acaaactgta	acttatgtta	taaatgtaat	tattacctta	94200
aggttttacc	ctggtttcaga	tttgagtggg	agtagttctt	tacaatacaa	aacaacttat	94260
tttaactttt	tttgcatttc	aaagaatgat	caatccactt	caggtgcagc	atggtttcca	94320
accctgacag	catggaagaa	tcatttattt	agcttctaaa	aatgtgcagg	ctgtacccta	94380
gaccagcctt	ggggatttagg	cccaaataat	aatgttgggt	gtttttggta	ttgggttttg	94440
gcccgcctac	ccgcccttcc	ttcttctggt	ctctctctct	attctctctc	tctctctctt	94500
tctctctctc	cttcttttgt	ccttcatctc	ttctctctct	ctcttttttt	tttgagacag	94560
catctcacta	tattgcccag	gctgttctca	aactcctggg	ctcaagtgat	cctctgcctt	94620
cagcttctcg	agtagctagg	actacaggca	catgctatgg	caatactgtt	ttaaacattg	94680
ttttcaaggc	tcccagggtg	attccagtg	gggtcatgtg	gtagagaacc	actgacacag	94740
gcaaacaaag	gatacataaa	gttgtctatt	taatgggtag	gtgcaggtag	tagataagag	94800
tgtagccaca	taaaccacat	gcttagtgaa	cgggttttgt	ttgtgtgtat	gtgagggatt	94860
agcatctctg	agtatatatt	gttttccctt	ttgaaactta	tcagagaatt	catatgtctg	94920
ttatgtgact	aatgctcaca	ttaaaaaaag	ttatgtgact	ttttttaatt	catatgtctt	94980
tttaattcat	ttattcattc	atatgtctgt	tatgtgacta	atgctctcat	aaaaaaagta	95040
atgctcagtt	tacttttttt	atatcagatc	atatatatat	gttttttttt	ttgagatgga	95100
gttttgctct	tgttgcccag	gctggagtg	attggcgcag	tcttgtctca	ccaccacgtc	95160
tgcctcccgg	gttcaagtga	ttctcctgcc	tcatecctct	gagtagccgg	aatacacgca	95220
ggcgctacca	tgcctggcta	attttgtatt	tttagtagag	acaggggttc	tccatgttgg	95280
tcaggtttgt	cttgaactcc	caacctcagg	tgacccaccc	gcctcggcct	cccgaagtgc	95340
tgggatttga	ggcatgagcc	accgcaccgg	gccatatctt	atattttta	aaatatttta	95400
atttgggtctg	taaatttttt	tttttgggga	atgtgtttta	agtctgtgtt	gagtcctaga	95460
catttggtgt	tctcagatag	tcactagtga	taccttaaca	ttaaccagcc	tgttggaac	95520
taaattggcc	tgaagtgaca	actaaggaaa	gggtctcttc	tcctttctta	atctttgcat	95580
tccttaagat	tagttctttg	taggaaggct	ttgaagtctg	gtggcaagta	ccctttatcc	95640
ctcacaattct	taagataaag	tctttctgag	cattaaaaag	tgactgtggg	agatagtcta	95700
aatgagtttt	ctgtgtgtgc	tctgagaaat	ctttttttca	aaaaaggata	gatgtacttg	95760
tataaggaaa	agagaaactg	agcgcacttt	caatatattaa	gtaagtgtct	ctaacatgtt	95820
ttgcaacata	aaatgatgac	cactgtgttg	gtcattactt	ctctactgct	aaaacaatgt	95880
tttctaaaa	aatatactcc	ttagaaaaaa	atatagtgtc	ttgggtgtgc	actgttgtaa	95940
tccaagggaat	aggaaatggt	ttgtagtaag	tgcgatgggtg	tttgacatcg	tgatttatta	96000
atlttatcaca	tttggtttca	tagaaataga	gtaagctacg	tatttgctgt	gccgcaatta	96060
ccatgacatt	acacttgtat	ctatttctgt	ttcatagatg	tgtagatatt	gatataata	96120
gtggaagtat	ggattgtttt	gataagtttc	taatgaaagt	acagatattt	gttgattatt	96180
tattaagaaa	ggttggttact	catccaagcc	cgtgggttagc	ttttcccaa	ttatcatgtg	96240
gtagtaagta	aaatgtaaag	aaatatatcc	tcccttaacc	ccacaccacc	tgttagcacc	96300
tagccacctt	cctttacttc	tcagccgtac	tttttgtatt	tttttgttgt	agtggtaaaa	96360
tataaataac	ataaaattta	ccattttaac	atttgtaagt	gtacaattca	ttggcattga	96420
atacattgtg	tgcaaccacc	atcaccatca	ggactttttc	atcaacccaa	acagaaacta	96480
ctcattaaac	aataactccg	catccttcca	ccccaaagcc	ctggtaacca	ctatttctact	96540
ttctgtctct	gtgaatctgt	ctattctaga	tacctcatag	aagtggaaac	gtacattatt	96600
tgtccttttg	tgtctggctt	attttactca	gcataatttc	aagattcatt	tgtgttgtgg	96660
gatgtagcag	aatgtcattc	ctttctaaag	ctgagtagca	ttgtatgtat	tatccattta	96720
tctgttacgg	acatttgact	attgtgaata	atgctgttgt	gaacattggg	ggacaaggaa	96780
ctgaaagtcc	ctgcttttca	ttctttttgg	cataaacctta	caagagggaat	tgctgggtct	96840
taacggtaat	tctgtgttta	atttttggac	gaactgccag	actgtttcca	cagcagttgt	96900
actattttac	atccccacca	gcgttacaca	aggattccaa	tttctctaca	tccttgccaa	96960



catttgctat	tttctatfff	tttttaataa	tatccatcct	aatgggtgtc	tttttttttt	97020
tttaaggaa	tggtttaaac	aggttacctt	cttactcctc	attcatgctt	tagttgacta	97080
cataaggacc	cctctcccta	ttggcaccat	tgaattgttt	caggcaaaaa	taactgccag	97140
cgacacactg	ctttaagtaa	tggacttttc	ccaagttttg	tattaatatt	tcagtatttg	97200
gtagtgcate	ctactgctag	tttttaaaact	cttcccttgt	catctatcat	ctcattctct	97260
cttgacaaat	gtgaaaatgg	aagctcagaa	ataaaacaag	aattaaaacg	aatagtgatc	97320
cttcaggtaa	caagcttcat	ttatcatgaa	aacatatatg	tatgaaacat	tctgttttct	97380
gatgttattg	gataaattag	gtgataacca	aattctaagt	tccaaaaaatt	aaatatactc	97440
tatctaagga	ctttaacatg	gcagacaatg	gtgacaaggt	caagaacatg	tttttagagtc	97500
ttctcctttg	gtcgggtattc	aatgatataa	cagttgaaaa	ggccagaaga	aagttaacct	97560
aggatgggtg	tttttgaata	tctaactttc	acttctttcc	catcttccag	gaagttggct	97620
ggaatgtgat	gacttaaaag	gcccattgttc	tgaaggcac	aagaaatttg	aagttcctgc	97680
ttcagagata	catattgtta	tttgggaaag	aaaaatatcc	caagtgcacg	ataaagaagc	97740
tgctgcctt	ccacttaaaa	agactaatga	ccaacacgct	ctcagtaatg	agaaaccagt	97800
atctttaaca	tcgtgttctg	tgggtgatgc	tgctcagct	gaaacagcct	cagtaactca	97860
ccctaagat	atatcagttg	ccccctgtac	tctttcacag	gacacagctg	taactcatgg	97920
agatcattta	ctttcaggtc	caaaagggtt	ggttgacaat	attttacctc	tgacacttga	97980
agaaactatc	cagaaaaacag	cctcagtttc	acagttaaat	tctgaagctt	tctgtttaga	98040
aaataaacct	gtagcagaaa	atacaggaat	tctcaaaacc	aatactttgc	tatcacaaga	98100
atcactaatg	gcttcttcag	tatcagctcc	atgtaatgaa	aagcttattc	aagaccaatt	98160
tgtggacata	agttttccat	cccaagttgt	aaatacaaac	atgcagtcag	tacagctgaa	98220
tacagaagat	actgtaataa	ctaaatctgt	gaataatact	gatgctactg	gtcttataca	98280
gggagtgaag	tcagtagaaa	ttgagaagga	cgctcagtta	aaacaatttc	ttacaccaa	98340
aactgaacaa	ttaaaaaccag	aacgtgtcac	atctcaggta	tctaatttga	agaaaaaaga	98400
aactacagca	gattctcaaa	ccacaacatc	taagtcat	cagaatcagt	ctctgaaaga	98460
aaatcagaag	aagccatttg	tgggaagttg	ggttaaaggc	ttaataagca	ggggtgcttc	98520
ttttatgcca	ctctgtgttt	cagctcataa	tagaaacact	ataactgatt	tacaaccttc	98580
agttaaaggg	gtaataaatt	ttggtggctt	taaaactaaa	ggtataaacc	agaaggccag	98640
ccacgtatcc	aagaaaagctc	gtaagagtg	aagtaagcct	cctcccatca	gtaagccacc	98700
agcaggccct	ccatcgtcta	atggcacagc	tggccacca	catgctcatg	ctgcttcaga	98760
agttttggaa	aagcttgga	gcacctcatg	tggagctcaa	ctcaaccaca	gttcttatgg	98820
gaatggtatt	tcttcagcaa	accatgaaga	cttgggtggaa	ggtcagattc	ataaaacttcg	98880
tctaaaactt	cgtaaaaagc	taaaggcaga	aaagaagaaa	ttagctgtct	ttatgtcttc	98940
cccgaagac	agaacagttc	gaagtgaaaa	tctagaacag	gtgccccagg	atgggtctcc	99000
aaatgattgt	gaatcaatag	aggacttgtt	aaatgagcta	ccatatccaa	ttgatattgc	99060
cagtgagtc	gcattgcacca	ctgttccctg	tgtttccctg	tacagtagtc	aaactcatga	99120
agaaatttta	gcggaattat	tgtctctac	acctgtttca	acagagctgt	cagaaaaatcg	99180
ggaagggtgac	tttaggtatt	tgggaatggg	agatagtc	atccccacc	cagtaccaag	99240
tgaattcaat	gatgtttccc	agaacacaca	tctgagacag	gaccataatt	attgtagccc	99300
caccaagaaa	aatccatgtg	aagttcagcc	agactctctg	acaaataatg	cctgcgttag	99360
aacattaaac	ttggagagtc	cgatgaagac	tgatattttc	gatgagtttt	tttccctctc	99420
agcattaaat	gcttttagcaa	atgacacatt	agacctacct	catttcgatg	aatatctgtt	99480
tgagaattat	tgaattaatg	cttgttaact	tttttcatat	aatatttatt	attattagaa	99540
gaacttacia	tgtgttcagg	tagtgtttat	acactggact	tgtgtaatta	cttgtgtaat	99600
aacctgaac	aaaatgcaag	gtttaacctt	tggttctgcc	catgaagcat	gtaatctttc	99660
ttacacatta	aaatcactga	atgtgtttct	ctttttgggt	tcattttgtt	cttgtgagag	99720
tatgaggatt	tcaaaatgtt	aaagatgaaa	agtggcgtct	agttttctgac	agtttgtaca	99780
gttgtagtca	ttacattttt	agatttgaag	ttttgggtat	gttagtggtta	tgagtgatct	99840
ttgtgggtg	tttcttcccc	tggaaaacctg	ttgctcgtgg	cgctttgccc	acggtgccc	99900
agttcttgtc	ctgtgtccag	atatgcagac	aaatgaagg	tgaagaagaa	gaagaggagc	99960
tttattttagt	gttagaacag	ctcagaagga	gaccacacag	gagcagctcc	cctgtgtcgg	100020
cgggcaggtc	gtccctcaag	tgttcagctc	tcagcagaga	aaaggccctg	gagaggggtga	100080
ctcctctcag	ctctcagcag	agaagcagcc	ctggagaagg	tagcttctgt	tcgcaggcag	100140
attgtccaga	ggtcctgctg	ctctcagacg	gggcccctga	gaggatagct	tctatccata	100200
ggcaggttgt	tctgcgtctc	ctacaggtct	ctgaagctct	tagcagagag	ggtagctcct	100260
ccctgttgtc	ggtcgtccca	ccctctgctc	agttctggct	gagcctgggg	cattttacgg	100320
gcctcggggg	aggaagtgca	tacttactgg	cctggaaaag	gcaccagttc	ccactcctac	100380
aggtgggact	ggcagcctgg	ccctcagcct	tcaggccctc	cctgttcag	gcttccaggc	100440
ttacccccct	gctttgatct	gagagctgg	gccaatagca	gggagaagcc	aagctgcaga	100500
ggcaagcact	tccgagcctg	caaaagcctg	cccccaaaag	tcgagggatg	cctgagctg	100560
caccgcacc	caggagggtg	gagatcttgc	ctgctccaag	gctgcagccg	gaatgtagc	100620
aggctgactg	gagcacctgc	caccatcatt	agttcaagag	tttatgcaga	tttaagttgt	100680
atacggtata	tgaatgtgtg	acagttttcc	ttatgggtgt	gtggccttct	gtaagagcct	100740



acgcctggtt	gttacaccgg	tagagtgcgt	tggaatgtaa	actttcccta	tgtcacttat	100800
ctcctttatc	tctccataca	gaggagggca	agaaaccttg	ttacttgaac	tttagtaatg	100860
ttaagtgate	aataaatcta	tataataatg	atagcagaaa	aaagttacct	gtttttgtga	100920
tgatgtacaa	actttacatg	ttatcacaaa	taccatcttt	cttcccaaga	cattttacttc	100980
tgtaacccaa	gtgggacacc	atctaacagt	tctgttttgg	gagagagtaa	taaccagtgc	101040
ttgtgaggtc	tgtttagatgt	tggttgtgat	atatgagata	gatgttattt	catttagacc	101100
tcaacattcc	tgtgcgtgag	atacttttat	cacatcttac	agataaggag	actgtactca	101160
ttcagttgtg	gagctgagat	tgagtagagt	ggctattaca	gcagttgagt	gctgagctta	101220
tcaatatatg	ttccactcct	caggcttcat	ttaaagtagg	atgccccaac	agcaccactg	101280
ccgtagagat	ttgagttaac	agcagtactt	actgaggttt	aaggctggca	gccagtgtcc	101340
ttgcagtaaa	attattttgct	agggactcag	tacttcataa	tctatttgtc	agattttactc	101400
ctaagcttct	gtgttgtttt	attttttttc	tgacaaaagt	agtgcataat	gtcaaggaaa	101460
aactagggaaa	ataccaaaaa	aaaagatttt	tgaccatgca	ttttaatact	tagtgactac	101520
aaacattttc	ctatttttatg	catatagatt	ttaaataaac	gtgagatcct	attgtatctg	101580
ttttaatgga	taaacattgt	ttcactgttt	taagattctg	aggtgattta	tactgtcttg	101640
ccattgttaa	ttgcagcagt	tagccttggt	gataaatttt	tgcattggatc	caagttttgt	101700
tttccaggag	tggagttgct	tgggtcaaagg	aaatgcacat	ttaaggtttt	ttggtgattg	101760
catgactgac	ttccctgggc	cctcgccaac	actaggtagt	agtattggga	ggaagggggg	101820
aaccaatcct	gggtgctcca	agattactag	tgagcctgaa	cattttctat	aactattgtc	101880
cacttgagtt	gttgttttgt	tttttttttg	gtggaggcgg	gggtgggttt	aagaattgct	101940
tatcctttgc	ttgtactaat	tatcctttca	acaaatattt	ctagattact	gctaaggacc	102000
aagcactggt	atcagcctga	gataaggcag	cacactagaa	ggaaatcctt	gctccttttg	102060
agtttgctt	ccaaacatgg	agatcaatat	ataatgttag	gtagtaatag	gagatacatg	102120
cagttgatcc	atgtcatttg	tagtagttat	ggtcaataaa	gttgccctga	acactgaatt	102180
agtataaact	gaaataactgt	tcctagggga	aataggttcc	tgctagcctg	tggtcatgag	102240
atttttgtca	aacaatcact	atataacctt	ttctgtttct	gtttaagac	atgttatttg	102300
atctatatgg	ttgattcttt	acattaacat	ggccaacagc	actgtaactc	agcctgaacg	102360
aagcttatct	gacacatggt	gttctccata	aggcacatca	tagctttctg	tgcttaggaa	102420
cactagacgg	cacttcagca	ctgcacttga	ggacgtttta	aacagtgaaa	tcaacaaaaa	102480
gcacaaaaaa	atgcaacaat	aggctgggca	agggtgctca	cgctgtaat	cccatcactt	102540
agggaggccg	aggcggggcg	atcacgaggt	caggagatca	agaccatcct	ggctaaccacg	102600
gtgaaacccc	gtctctacta	aaaatacaaa	gaattagccg	ggcgagggtg	caggcgccctg	102660
tagtccagc	tactcgggag	gctgaggcaa	gagaatggtg	tgaacctggg	aggcggagct	102720
tgaagtgagc	cgagattgcg	ccactgcact	ccagcctggg	cgacagagcg	agactgcgtc	102780
tcaaaaaaaa	aaaaaaagga	acaataacaa	agacactagt	cccccaaaaa	tacacttgtt	102840
tacagtgtga	gtgaaagag	gaagggtggg	tattgacttg	tttgacctca	gctggaaatg	102900
tgcacgtcct	gtgactcaaa	tttttctctg	ttctgtgcac	gcatgtccac	gaataaccac	102960
aagaagcact	gaaagcattg	attttttaggg	ttacaaatta	attttagcaa	gtaaatgaat	103020
tcacaaatac	ggaatctgtg	agtaatgagg	actgattctt	tttttttttg	gagatggagt	103080
ttcactcttg	tagcctaggc	tggagtgcaa	tggcatgac	tcggctcact	gcaacctccg	103140
cctcccggtt	tcagcctcca	cctcccggtt	tcaagcgatt	ctcctgcctc	agcctcccga	103200
atagctggga	ttacaggctt	gcaccaccat	gcccggctaa	tttttgtatt	tttagtcag	103260
acggggtttc	accatgttgg	ccaggctagc	ctcgaactcc	tgacctcagg	caatccaccc	103320
acctcagcct	ctcaaagtgc	tgggattaca	ggcgtgagcc	accgcgcccg	gccgaggact	103380
gattcttatg	tcagatggca	ctaaatgcta	tggagaagag	gagtggatga	gagggagaag	103440
tatttttagac	caggtagact	tgggaaggtt	cttggagggtg	ggtgatgttt	gagaagaggc	103500
ttcaataaag	ttagggagct	cgccatgtga	ttgcaggaag	agcgttccag	gagaacaaaa	103560
gtcatgaaga	gtgagtgcct	ggcatgtgtc	tggctgtttt	gggctgctat	aacaaaaatac	103620
cttagactgg	gtaaaatgta	taaaataatag	aagtgtattg	cttatagtcc	tagaagctgg	103680
gaagtccaag	atcaagggtat	cagcacatcc	tgggtgaaagc	tgctctgctt	catggctggt	103740
tctctcactg	tcttcacatg	gcataagagg	ggcacagagc	cctcaaccgt	ctctccagtg	103800
gccccatctc	ttagtactgt	tggattgggg	atttagactt	cactaatttt	ggggggacac	103860
aaacattgag	accacagcag	catgactgag	gataagcaag	aggccagtgt	gggtgagcag	103920
agtgatcagt	gaaggagagt	taggacatga	gtaaaagaggc	tagcagacac	cagatctcat	103980
atggctttgt	aggccatagt	gaggactttg	tttaagctga	gaataataga	taacctcagg	104040
aaagtttcag	gcaagagggg	aacatgatct	gatctgggtt	ttaaaaggat	cactgaagtg	104100
gggagactgt	ctacagatgg	tctgaatagg	agtcctagtc	tattacaatc	tccttggagt	104160
ttaggggtgg	aactggagggt	gttcaagagt	agttggatta	ctgttggatt	tcaaaagtag	104220
agccaacact	atatgtgcat	tggctgtgag	gtagaagagg	agtcaaaatg	aactccaggt	104280
tttattgagc	gagcaattgt	gccatttctc	gagatgggtc	agatttggga	aggaaagaat	104340
ttaaagggga	taagataatc	ccattaggag	tgtgttaagt	gtgagattcc	tattagactt	104400
tcgagtggag	atgatttaat	aggaagatag	atctgcaaca	ctggagctca	gcgagagagg	104460
acaccctgga	gatagccgtt	tgggaattag	gaatgtgtgg	atcatgttat	aggatggggg	104520

catttaggga	cttaaaacag	ctctgaagaa	caaaaatggt	gccttgatct	tggacttct	104580
ggtttataga	actgtgagca	atataatat	atTTTTTca	agacagagtc	ttgtccgtc	104640
atccaggctg	gagtgagtc	gcaccatctc	ggctcactgc	aacctccact	tcctgggttc	104700
agcaattctg	gtgctaagc	ctcccaagtg	gttgggacta	taggtgtatg	acaccatgcc	104760
cgactaattt	ttgtattttt	ttgtagagac	agggttttgc	catgttggcc	aggctgggtc	104820
caaactcctg	acctcaagtg	atctgcctgc	cttggcctcc	caaagtgcct	ggattatagg	104880
cgtgagccac	catgcccaag	ctaaatttct	aacatttata	aattatccag	tctaagatat	104940
tttTgtatag	cagcccaagc	agaccaaggc	aaaggccaag	cacacttgct	cctcctgact	105000
tttgcctctc	ctggaatggt	cttcccttag	tcacatgggt	gcctgcctag	cttcattcaa	105060
taggagtggt	gtgccttgaa	aatacaagga	agaatgcttt	tttttttttt	aaaaggaagg	105120
gatgattatc	tgtcagatgc	tgctgaaaaa	gagtaataga	gtaattggcc	actggctctg	105180
gcaataggga	agtttagctc	gctaactcca	catgaacagt	ttcacatgaa	caagtgtgag	105240
tgggctcaag	agaagggaatg	gtgagaaagt	ggagctatgg	actcactctt	gaaacatttt	105300
ctgggtgcctc	gtagggtcaa	gtgttttgg	ggtttttgg	actgttctga	agatgggaga	105360
ggctgacaca	tggatgttgt	agggtgagaga	agggggcgctt	gcgggggcaa	acttctccag	105420
ggatgggatt	ccagtgtcta	agaggaggcg	gtgtgacct	aagagctaga	aaaattattt	105480
tattaatagg	aaagacaaag	tacttaggct	cagatgctaa	gagatttgct	gataaaagaa	105540
tgagaacggg	ctcttctgat	tattttcttg	gggaaataaa	tagatcatca	gctgaggggtg	105600
tgaggggaga	aggagttgaa	catggaggaa	gacaggtgtg	aaatattggt	ctcagaattg	105660
agagcgaatt	gaatagggac	atgcagtggt	cttgctaagc	tgtgcggaga	gcccgtagga	105720
agtttatggg	catcaattta	atggcgacca	gccaagatgg	tggtttattt	ttctccagtt	105780
gtatttaact	gctcaggtgc	aggacagaga	gactaagtgt	gaagttaatt	tcagccaacg	105840
tagaggaatt	gtcaggcaga	tgggacaagg	agatagagga	gaaaaggaat	aaggcttctc	105900
gcaagggtaa	tgattgttagg	gatggataag	taaggaaacac	aggaagtggc	tgtctgctga	105960
gtgggtggcag	agctcagtg	gtcagagcaa	ggttcaaaga	atggcagaga	ggcacttgtg	106020
gaggaaagtaa	gctggctaga	aagtagtgtg	cttgaaatta	agcttctgga	gatagcaagg	106080
ttacaggtga	tgacaaagtc	tgagtatgac	aaggaaactg	cagggccaga	gttggaaga	106140
attcatgaaa	aatgaggaga	aagaggcacc	aagaggctgg	gatagcacat	ggattgtctc	106200
tgtgtgaggg	aaagtcattc	aaatggcagc	agtggcccta	gcagaaagaa	atatacagtg	106260
agccggagca	aaaactcctc	aggacaggca	gaacgccatg	aaaacggcag	atgacagcca	106320
aaggagcagg	ggcaggggct	cagtccaaag	gttttcagag	tcactggagg	gttgagtggg	106380
aaggggaggg	agtggttgaa	atggcaacaa	ggaagaacct	ctctcatctc	caggcccaaa	106440
agtatgtgga	atgcgggaga	taagacagcc	accactggcc	agggctgtaa	agggacattc	106500
agcgaatatt	caggttccat	ttagcacgac	agcagggaag	ggactgttgg	cagaaaaaaa	106560
ctggggcag	gggattaaag	acagaccaca	cattccaaaa	ggcaccgtgg	gagggctcag	106620
gggcgaggtt	aggctcaggg	ttcagtgctc	tgggagactc	agtcttcaca	gggtgacagc	106680
gatcaagagt	ctcaggtagg	ctgggtgcag	tggctcatgc	ctgtagtccc	agcactttgg	106740
gaggccgaga	cgggaggatt	gcttgaagcc	aggagtttga	gaccagtctg	accaacatgg	106800
caaaacccca	tctctactaa	aaatacaaaa	atcaactggg	catggtggcg	tgtgctgtga	106860
gtcccagcta	cttgagaggc	tgaggcaaga	gaatcacttg	aacctgggaa	gcagagggtt	106920
cagttagctg	agatcgtgcc	actgcactcc	aacctgggca	acagagttag	acctgtctc	106980
aaaaacaaca	acaacaaaaa	agaaaagagt	acaacttatg	aaggggtctc	ctggggagag	107040
ggtttttggg	attctcctgc	ctctcaaaagt	cttgggatta	tgggcgtgag	ccaccacacc	107100
cagccgaggg	aggctgagtt	ctaattgttg	tatctctctt	gggattggcc	tcctgggcag	107160
tttaaaagac	aaggcaagga	atcttttgga	gaaagagact	gggggcaagg	tgtgtctgaa	107220
caagaagtgt	gagaagctct	gtgggctccc	ttcagacttc	cagtcgttga	attgggatct	107280
catttatatc	agctctaggt	gtaacgatat	taaatcttct	ctgtcatttg	gcaatttttg	107340
tttatgcttg	atcatcattt	ttaatgtttc	gacatgtaga	agtttaacat	tattttacat	107400
tcttttctct	ctggcatcat	gttttagcaa	gattgtttcc	acaaaaagaa	tatatatatc	107460
ttctaatagaa	actacgtttc	tttttttttt	ttcctttgct	ttctcttttg	gtatatgaat	107520
ctttgattat	ttgtaatgta	ttttgatgtg	taacactgaa	gtttctattt	tgtactattt	107580
ttttccccaa	acagtaaact	tattgttcaa	atacttattg	aacaaccttc	actattcttt	107640
aaccatttag	aatacgccat	tcacatatct	ttcatactac	atttaataac	attttttaat	107700
taaaaaatat	tctattgatt	tgtttatttt	gagacacagg	tatgaaactg	gctaattttt	107760
gtatttttgt	ttaaataccga	aattcaactgt	gttgccaagg	ctggtctcga	actcctgggc	107820
tcaagcaatc	tgcccacctt	ggcgtctcaa	agtgtctggg	ttacaggtgt	gagccgctac	107880
acccggccac	acccggccaa	cacatattat	ttgttattac	atttaattcc	cacagtacat	107940
tgaaattatc	agggaaaagt	tttcagtgaa	acattattga	acgccacatt	aaaagtgtaa	108000
attacaaaga	tttaatgcca	atttttcaga	agaaaaaaga	ccaggaggaa	ggcttatgaa	108060
gttttagcca	ctctctcatc	cacctaccat	ttcacgatca	tgactgtgtg	aagtcaggaa	108120
aagagtaaga	aaagtgaag	atacaattga	ttagagagtt	ttgctggata	ctatagatga	108180
aaagaacaca	aaatggaaca	gcctcttcaa	gcttagagtc	aacggctgta	gtcccaagaa	108240
ctgtagtcag	aggcggtagg	gccccaaagac	atgacttatg	gcattggagg	aagaggatgc	108300

tttgggagtt	catggtagaa	gaggcgga	aaatctggtg	gattaaagaa	agcatcccaa	108360
agtgcatta	aactaatgac	taaattctga	gctgttttca	ggggcaaagc	ctgtttgggc	108420
accctgcca	cacttaaaga	gtcacctagg	tatggttcgt	gggctctgaa	caggcctgct	108480
cagtgaacat	atttgtgact	gtttctccgg	cccttttagc	tgtattgagt	aaaatttaaa	108540
gagaccattg	ttttggccta	agctcctgcc	ctaggcccaa	agaacagacc	aaacctgaat	108600
ggcttcactt	gtcctagggtg	ctgtgtactc	aaactgaact	ttgaaacagg	tcgggtttttc	108660
aaaaaaagca	aaagattcac	agcaaccaat	tagaagaggc	ccggtcaacc	tgagccagca	108720
tgatgaggct	cttctgcttt	aatcctacaa	ggaaagaaac	tttgaaatga	ccaatctgct	108780
ttcattcttg	gtttctgctt	tctttgggtc	atttctgcct	gtaaaacct	tctcctctgc	108840
tcagctcatt	gaagtacctt	tctatttata	gatgggatgc	tgcccgaact	atgtatcgct	108900
agtaaaagcc	aattaaatta	ttacactcga	tttggtggaa	ttttgctatt	ttgacagctt	108960
ttcaaaaaca	ccagtagggt	cacatcccta	attccccagc	cagtgttccc	tcaaggaacc	109020
atggaagaag	caaagggtgc	tgaaaggcgc	ctcaggatgc	ttctaagcac	ggcacatcca	109080
tgaaaaggca	cttactaata	tttgaggata	agcaaaagcac	tgcaagtgcg	ataaatctag	109140
tattggagaa	gttcaaaata	atcagtagat	taacacagaa	gccagagctt	atagggagaa	109200
aaggaaccct	atgaaatact	tcaaataccg	aaacgaacat	gcatttctctg	tttagttagt	109260
gcaggtacgt	aaaagcttgg	taaagtacct	ttcttgccag	ctttctcttt	cttacaagcc	109320
ttttcactgg	gctgggaggc	tgatattatc	taaatatgct	gaggagggtc	aagtatctcc	109380
acaactcacc	tcagagtga	tgctcccttc	ggccttaagg	caatataaac	cagccctggt	109440
tagcaggata	gcaaaatgtt	tgcggttgta	aactggtgtc	ccattggctg	tggcgcttgt	109500
ggtgtaaaga	atccctgtgc	ttggtaatta	atagagaaat	tctatatttt	aaacttcagt	109560
tgtatattgg	ctcttatcca	tggcagattt	tcacgtatgt	gttatttttt	tatttattca	109620
gagccggagt	ctcgctttgt	cgcccaggct	ggagtgcagt	ggcgcgatct	tggctcattg	109680
cagcctctgc	ctcttgggct	caagcaattc	ttctgcctca	gcctccctag	tagctgggac	109740
tacaggtgac	tgcaccacg	cccggtcaat	tttttgtatt	ttagtagaga	tggggtttca	109800
ccgtgttgct	caggctgggtc	ttgaatttct	gagctcaggc	aatccgccc	cctcggcctc	109860
ccaaagtgtc	gggattatag	gtgtgagcca	tcattgctcg	ccctatgtga	tatttattac	109920
aatgaattcc	aatgatcaga	cctatactca	agtataagtg	aatatatcat	tcaatgaagt	109980
ataaatgata	attatgttca	tattcacaca	tacaataatg	tactcaagtt	tattgtctaag	110040
gtaattcaga	atctccttat	tttgaagtgt	gcatttgata	tacctgtttg	ggaataacta	110100
gtttcttate	tttgacagaa	aataattttg	ttgttttgtt	tttactaaaa	aagcatgggtg	110160
aaaaatggct	ccattttctaa	gagaggtaac	taaaatatcg	caatttgctg	ggtgtcatta	110220
aagtaactca	caagggaaaa	aatgcaaat	ggtatctgct	gatggagtaa	atctccgcag	110280
aagtgatgac	cctgaaagga	tcaatataat	aaagcccctc	ccagctgggtc	attccagatt	110340
gcaacaataa	agcattaagt	gttaaaacct	caaggcagct	tttttttttt	tttttttgtct	110400
caagtccctt	attattaatt	ttatagacct	acttaattac	taagccaaaa	aaaatcaaac	110460
ttgtttctct	ttgtgacttg	tcaatagtat	taaactattc	tggtttttta	tttttgtgtt	110520
accttaaggt	ctccagttta	gtaatttttc	tgtacctaaa	cacttcggat	ttgacatgct	110580
ttgtggcctt	tatcagtagt	tagaatgtaa	atccaataaa	taaagtaaaa	gccagggtctt	110640
caaaacctgg	gggccaagaa	ctctgtttta	gagggcctgt	gactctcttg	gacactggac	110700
aaaatctcat	ctctaaatat	ggataatttt	gggagagggg	ctttaggctg	tcatttggat	110760
tttcacagg	ctccatgtat	ccataaggta	gtctcttggg	aagtttgact	tcaataaagt	110820
aagtttaact	taaaactaaa	atgaaattta	actgaaaaac	aaaatccaat	gaaagatgct	110880
ttcttatgca	aaaacaaaca	aacaaaaaaa	aaacaaaaaa	accccaaaaa	acccaaagcc	110940
aaagattggt	tctgaaatta	ggttctaggt	tccagagcaa	ctccatgggtg	gggaatcagc	111000
cacatgtaaa	gtaagctaag	agtttggaca	atttgttaata	tttatctcta	ggtttcttta	111060
agaccctttc	agattttgaa	ttcctattag	tagcatcagc	caggttctaa	atgtaggcat	111120
caccatagac	acttcccac	tgctgcagtc	cccaacactt	gcccattttt	cccttgaatt	111180
gcacccatgc	tgccctctcc	aggcctattt	gaacccagaa	cctcgtttgtg	cctcgtttga	111240
aatataattt	cctcctaact	agtctctgat	ctactatttc	ccctacattg	ctgccacact	111300
aatcacctaa	aatagatttc	attctaccct	gaaacagaaa	tctctaataa	gttactccct	111360
tcccttacgg	ggtaaagtta	gccacatcct	aggtaattcaa	ggaccttcca	ggagctaaga	111420
acatttcccc	tgacacctct	tgaagtacac	ttgtcctatg	tactggttat	gttcattttct	111480
taccctcgct	ctcgttttgt	ctggaatttt	ccttggcctt	aaatgcctct	cacctgcctg	111540
cccacatctc	tcagggttgt	ttcaaatcct	caatgaaaggc	tcacagcccc	agtctatgtt	111600
ggccacttac	ttcgtggcct	gggaacattt	ttctttggct	gacttgctga	cactccatca	111660
gatgcatttt	tatctgggtg	tccatctgtg	aaccataccc	tgagaaggca	gagagtgcct	111720
ctgcactgaa	catgtgctag	gggacaggtc	tgtgctagag	gggcaagcac	tgggaatgaa	111780
gaactggctc	ctactcccaa	ggagttcata	tctcagtggg	ggtgacaagc	aactcactgt	111840
ttccgggggt	tgtgggtgact	gctgggagaa	ggggtgtcta	tattagatcg	aagcagcatc	111900
agggggaggt	ccctgagaag	gtgatgcctc	agcggatgtc	tcccagctaa	gtgggggtga	111960
ggtggagaag	ggcagagcag	ggagaggatc	taggtggggc	gtgtaagtct	gcatgggtaa	112020
ctcagggaac	ccttggtaac	tgcattgtaac	tgtgtgaagc	tttcatgaag	gaacatggta	112080

ggagactagg	gatatggacta	tagaagccct	tttgctaagc	tcaagaat	gaggccggga	112140
gcggtggctc	acgcctgaaa	tcccagcact	ttgggaggcc	aaggcggg	gatcacgagg	112200
tcaggagatc	gagaccatcc	tggctaacat	ggtgaaaccc	cgtctctact	aaaaaaaaag	112260
tacaaaaaat	tagcggggcg	tgggtggcggg	cgcccgtagt	cccagctact	caggagctg	112320
aggcaggaga	atggcatgaa	cccgggaggc	ggagcttgca	gtgggcggag	actgtgccac	112380
tgcactccag	cctgggcaac	agtgaagac	tccatctgaa	aacaacaaca	acaacaaaaa	112440
atttgaagt	tatcttgaag	gaaatccctt	ggagcctaaa	aatgatcatt	gataacagaa	112500
aatgatctct	gctctcgct	agggtaatat	attcagcttc	aaagtggag	ggcatgtttt	112560
ccaagggcat	gttttctaag	tccctgtaat	tgtagtata	gcaaataat	gccctgcac	112620
ttgaaatgta	agactaggtt	tgaacagtat	ataaattatc	ttatgatcta	atttccctc	112680
attttgtggt	ttctactata	agctacccag	aagtgtagac	aggacgtttg	gaatttgatg	112740
ggcatcgga	agattcctac	ctaagaacat	tttttttttt	tttttttttt	ctgagaagga	112800
gccttgctct	gtcaccagg	ctggagtga	gtggcagcat	ctcagcttac	tgcaacctcc	112860
acctctcagg	ttcaagtgat	tctcctgct	cagcctcctg	agtagctggg	actacagggtg	112920
tgcaccatca	tgcctagtta	atttttatat	ttttaataaaa	ggcaggattt	cactatgtta	112980
gccaggctgg	tcttgaactc	ctgaccccat	gatctgccc	ccttggcctc	ccaaagtgt	113040
gggattacag	gtgtgagcca	ctgcgcccgg	cctctaagaa	aatttttgag	agctacttgt	113100
tctgttgct	ggaattccac	cgtaagtacg	acgttggtgc	tccttctcca	gggctactaa	113160
ctaacaaca	gagggatttg	tgttatcgac	aattatttga	ttgataacta	tcagcaacaa	113220
tttgccaagg	cattccctta	aagatagcct	agtgaactta	ttactactc	cttcttccag	113280
gcttctaagt	tctgttggag	gtaagttagat	cccagagata	aagcacctac	cataggacct	113340
gaatcttgg	agaaataaat	tatatcatca	tgttatcata	ttatcatgtg	tttttctatc	113400
tttaaagtct	tatgtgaata	ttctgcttga	aaaatatgtg	tcctctgtta	gaccagagtt	113460
gaaaaattgt	tattcaagaa	cttgaacag	gaaccgcac	aatttctgct	ggagttta	113520
ttcagggtta	attctgtcag	caatctaagg	taaacattaa	catttttccc	tagattcaag	113580
tccgttgctc	aaaagctgta	acagaactta	actgaataaa	tagtttctta	agatggtaag	113640
cttccatattg	cttataatga	ctcctctaca	cgttttcatc	tggaaggctg	ctcatgcttt	113700
tgggaagcaa	gaagacaatc	ttaaataact	acatttgctt	tttggtggtg	ccagattttt	113760
ctgagaaaca	ccaatggaat	ttataaatc	accagtcaat	gggcaattga	gttgctgttt	113820
tgtattacc	actgcggtt	gtgagcattg	ttgggaagg	gtcttgaagc	acacgtgcaa	113880
gtttcccttg	gataagtagt	aggaatagaa	ttggcaaac	atggcttcca	gtgcagacac	113940
agtctctccc	ttgggcccag	ccactaggca	ccacacatta	agaggataat	gtctgtccat	114000
gtcctagaaa	cgttgttagca	tcatgctcct	attcgattaa	aaatctcatt	attaaaatga	114060
accatcgggt	aaatgttgct	tccggaaaag	aagcactgac	cgtccctggg	tgggctcgaa	114120
ccaccaacct	ttcggttaac	agccgaacgc	gctaaccgat	tgcgccacag	agaccagtt	114180
actcagccg	cgtgcgggtg	tgtacagatt	tccgcggcgc	cggcagccgc	tctagccacc	114240
ctgggctg	ccaccaccag	cgttgccacc	ccagcagcgg	gctgagaagt	cgcggggcgc	114300
gccgaggagg	cagcgggaagc	ggccgagggtg	cccagcggcc	gccgcggggg	gagaggctgt	114360
gccccgggcg	gcgggagggg	gcgggcgagg	ccgcgtgact	ccgggcttct	ctggggacga	114420
agcgcgcccc	tccgtggcggc	agcggccagt	ggtccgcagt	cggcccggac	tccgggtagg	114480
aaagatcctc	tcagcaatgg	ctgcgcgcca	tgcgtgctct	gcggcgggga	ccgtgcgggc	114540
cgggcgcgcc	accagtaacc	agggaccag	gggagaacct	gccaagggga	ataggtcgca	114600
cggagagaat	accagacgct	tggagggaag	aaccacgtgc	tgtacaggtt	taaaggatgg	114660
agagtcacgt	gcgcttaggt	cccaaactta	agggaacctaa	ccctttttct	gggttgccgc	114720
tattgcccct	tctccttaga	cagtttttca	tctcatcacc	tctcaccctg	taaaatgcaa	114780
cgaacataga	taggctgtgt	atcaatgtag	actgtatgta	tatctgtgct	tccgtacataa	114840
aaagaatatg	atttttgcca	ccttctaaga	accaatttgc	accccathtt	gaggcatatg	114900
gcctctgttg	agattgcata	gtttaggggg	catcaaaaaa	gccttataga	gggactggca	114960
attaagatag	cctttcagtt	tgaatggcc	attgaaggct	tctcccttct	cctgacttct	115020
gaattttttt	tttttttttt	tttttttttt	tttgagatgg	agtcttgccc	tgttgctgga	115080
gtgcaatggc	gcgatctcgg	ctcactgcaa	cctccgcctc	ccgggttcaa	gcgattcctg	115140
cctcagcctc	ccgagtagct	gggaatacag	gcgcctgcca	ccacgccag	ctaacttttg	115200
tatttttagt	agaggcgggg	tttcgccatg	ctggccaggc	tggcttggtg	ctcctgacct	115260
cgtgatccgc	ccgcctccgc	ctcccaaagt	ctgggtagta	cattacaggc	gtgagccacc	115320
gtgcccggcc	aattttttta	ggcgcaactgt	tcagtgccac	taagtacatt	cacattgtta	115380
tgaactatc	accgccatcc	atttccagaa	ccttttcatc	ttccgaaaca	gaagctccct	115440
accattaca	cggttaactca	cgattcccct	cctctagtcg	gaacaatcac	cattctactt	115500
tctgtccctt	tgaatttgac	tactcttaga	gacctcatgt	aaatggagtc	atccggtgtt	115560
tgcctgtggc	tggcttattt	cacttaccat	atgtcttcaa	ggtccatcca	cgttgtagcc	115620
tgtgtcagga	tttccctcct	ggataaggct	gaataagctg	cactgtatgc	aggtatcgca	115680
ttttgctttt	ccattcatct	ctccgtgaac	attagggttg	cttccacctg	cagctatgaa	115740
catgggtcta	caaataactg	attccctgct	ttcaattctt	ttgggaatat	acccagagat	115800
ggagtagctg	gatcacatgg	tttgctattg	gctgtaccat	tttacattcg	caccaacagt	115860

gtacaagagt	ccctattttct	cctcatctat	ttttttttta	aataatgggc	atcctaattgg	115920
gtatgaagta	tcatctcatt	gtgggttttc	tctgcatttc	tctaacgatt	agtgggtgtg	115980
ggcatctttt	ccagacacca	ccaatctgaa	ttctatggcc	cttcgtttac	tcacttcctc	116040
ccagcaagag	ccattttctgc	ttcagcaagg	aggaagctgc	gactgataga	gggaaagggc	116100
ccagggggct	tgcagagtgg	ggcctgtgcc	atgcaaggag	aggagaagaa	ggtggatctt	116160
tgagtaggac	tatctggaga	tccctgcttc	acaaggctct	tgcttgtgtg	ctgggcagct	116220
tttggagcta	gttatcttta	tttttagccct	tgagggatat	ttaggcattg	ggtgcttgtg	116280
agcagccaat	ccatgaagaa	ggaactgatg	gtctccacct	tggaaatatt	ggaagagata	116340
atgccgtcca	aattgcagtt	ttagaagtta	acttaaaatt	atgctatttt	aatggaattt	116400
tgggtgcatt	tccattttct	tcttaagaat	tgctggaatt	tcttaagtgt	ttaggtgatg	116460
atctcttttt	gtgattcctt	ttttaaaaaa	caacaacaaa	atctttcaaa	tacataagaa	116520
ataggccggg	cacggtggcg	taatcccacc	actttgggag	gccgaggagg	gcggatcatg	116580
aggtcaggag	atcaagacca	tcccggctaa	cacggtgaaa	ccccgtctct	actaaaaaat	116640
acaaaaaatt	agccggggcg	ggtggcgggc	gcctgtagtc	ccagctactc	gggaggctga	116700
ggcaggagaa	tggcatgaac	ccgggaggcg	aagcttgacg	tgagcctaga	tcgcaccact	116760
gtacttttagc	ctgggcgatg	gagcaagact	gtctcaaaaa	aaaaaaaaag	aaaaaaaaaag	116820
aaagaaatag	accttttatt	ttctgtaact	ccacaaaatt	tctattttga	ttccctatta	116880
tttctgtatt	gtcaacacag	tctcagtcac	ttcaagatcc	tgtttgtgcc	tttccttgga	116940
gtcattttcca	agtgtcaagg	ctttgggtcca	tgagtcgcat	gtgcacactc	atggctgtag	117000
agggagtttt	gctcccgggtg	aagggtcttgg	tggtctcttct	ataccttgat	tgagggaag	117060
gaatcttatg	tgaagttagc	tttgttgtat	cagatattcc	ataaagccat	ttctgggaca	117120
gtccccctctg	tttatcggac	cacaagcttc	tctgtcctca	tcaagcccac	ctttataactt	117180
cattttctcca	gacttcatgt	ccagactgtg	ggatgaacaa	gtggttataa	ggttttagag	117240
gctcctgtag	cactagatgg	aaggcaaaaa	aaggaaataa	cctttaagca	tgctctcgat	117300
tccttaaatc	ccatctgaaa	gtcttaagga	tgcttctcca	gtcatactta	tttgacaata	117360
ttacctaatt	ttctccatta	gccccagctc	aggggtcttt	cttcttccat	attcacatgg	117420
gtgcaatggg	tttctgaaag	gaaaacagca	ttactagggc	agtaacattt	aattaatcac	117480
aggtacttat	caaactacaa	aacaggcatt	ccaggaactg	ggtgtttctg	tttgtaaaat	117540
tacactctcg	tgtacatgct	cccactaaaa	tgtaagtctg	ctgaggatgg	aggttttggt	117600
ctctttgtct	tgtctgttaa	ccccaacact	gcagcagggc	ctggcacata	gcaggcatg	117660
agggactatg	cactgaaatca	atgaggaaat	gaaaaccagg	accatgaagt	aaactggaca	117720
aaataaaaatg	tgatagaaaa	tctaaattcc	taatacataa	ggagcactta	tcaattgata	117780
tttacaaaaat	cttttttaca	ttcaattaaa	gacaacataa	aacaaataag	aatggggaca	117840
ggaacagaaa	attcccccaa	agaaaaaaat	atatatacat	ggtacagcca	ttgtggaaag	117900
cagtattggag	ttctcaaaaa	tattaaaata	gaactatcat	ataatccagc	aatcccattc	117960
ctgggtatat	aatgaaatga	aacgaaatca	gtacccccaa	gaggtgtctg	cactcccattg	118020
tttattgcag	cattagttac	aacagccaag	atattggaatc	aaccatcag	cagatgaaag	118080
gataaaggac	atgtgataca	tatacacaat	ggagtagtat	tcagccttaa	aaaagaagaa	118140
aatcctgtca	tttgcaacaa	catggatgag	cctagagaac	atactaaatg	aaataagcca	118200
ggcatagaaa	gacaaatgct	gcatagtctc	acttaggtgt	ggaatctaaa	aaagtcaaat	118260
taaaaaaaaa	tgtcaagcag	agaatagaat	ggtagttgcc	agggactctg	ggaagtagca	118320
gggggtgggg	tggaggggag	gggatgggca	gaagtgtgtc	aaaaggtaga	aagtttccag	118380
tagacagggtg	taagttctgg	ggatctattg	tacagctggg	tgactgtagt	taatactgga	118440
ttgtgtactt	aaaaattgct	cacccaaaaat	gttctcacca	aaaaaatgat	gtttggatat	118500
gttaaacagt	ttgatttaat	cattttgacg	tgtgtgtgtg	tgtgtgtgtg	tgtgtgtgtg	118560
tgtatacatc	aaaacatcac	attatatacc	atatacaatt	aatatataca	atttttgtca	118620
aagaaaaaat	gcacatgacc	aatatgataa	aagtttagtc	tcactagtaa	taaaaatcaa	118680
aattaaatga	aataaaaaat	tctttcccca	aatcgcaaaa	gagaaagaaa	ggtaatacta	118740
aaacacagtc	acgggtgtagt	gagagggctg	ctctcacaca	ggactgatga	gaataaaaat	118800
ggagagcagt	gtggtaatat	acataattaaa	caatgtatat	accctctcat	tttagaaatt	118860
ctatattaga	aatccatcct	aagaaaaata	ccagggatgt	gatcaaaatt	ttgaatgcag	118920
cagcacagta	ttattttataa	tagttataaaa	taagaaacaa	cctgaatgtc	cagcaacagg	118980
caaaaaatgat	aaataaattg	tggcatattt	aagctggtgg	ctcatgctg	taatcccagc	119040
acttttggag	gctgaggcag	gaggatctct	tgaggccagg	agtttgaaac	ctgtctgggc	119100
aacataacga	gacccagctc	ctacaacata	ttttttaaaa	ttaggtgggg	catggtaact	119160
catgcctgta	atcccagcac	tttgggaggc	tgaggtgagc	agatcacctg	aggtgaggag	119220
tttgaaacta	gcctggccaa	catggtgtaa	caccatctct	acaaaaaata	caaaaattag	119280
ccaggggtggg	gtgcgttccct	gtagtcccag	ctactcggca	gactgaggta	ggagaatcac	119340
ttgaaccggg	gattcggagg	ttgcatttag	ctgataatcat	gccactgcac	tccagcctgg	119400
gtgagaccct	gtctcaaaaa	aaaaaaaata	agataaagaa	aaaattagct	ggcgctgggt	119460
ctgtacgctc	gtagtcccag	ctattccgga	agctgaagcg	gggggattgc	ttgagcccag	119520
gaatttaagg	ctgcagtgag	ctatgattgt	gccactccgc	tccagcctga	gtgagaaagc	119580
aagactctgt	ctcttaaaaa	aaaaaaagtg	atatattttt	aaaatagagt	atattactta	119640

tatagacatc	aaaaacaata	ttttcaaggg	atatttataaa	acataggatc	atgacaaaat	119700
gtaaagtcca	aaggtaagat	ggagaatgga	gaactgtggg	gaactgtata	atctgacaat	119760
tcgtagtgtc	atacatcttt	ctgtgtgctg	gtgctgttag	aacactttgt	acgcatacc	119820
tcattttaagt	tcagcatccc	taggtggcag	atactattat	tatattccag	ttttgtttca	119880
cgttgtatat	gcggtgtgag	ccccaatatg	ggatgtgtgt	gtgcacatgt	gcagtatttg	119940
gaaagttcta	tgaaatatta	ttagtggta	tctctgggag	gtgattttta	ttccttttcc	120000
agtatgttct	caagcatttg	ctgcaagcag	tcttttgcgg	ggccagggtt	gagaggcagc	120060
agcagtttcc	ctaaattaca	gatagaggga	ggtaggtggt	tatgcttggc	cagatctctg	120120
tctaggggta	gaggagtgcc	tgtgtgtggg	tagggacacc	ggcggggggc	tttgccaaac	120180
acagtggaac	tgtcacgctg	gtctctcttc	tcaactcttt	cactcacctg	agaaaagggt	120240
gtctatggac	catgcacact	tctgtgggga	attttacaag	atgtgaatca	tcagtgatga	120300
agatgctttc	atttaaaaag	aattggagta	cctgagatta	gagataactt	ctaccctttt	120360
aaaaattttt	taaaaatttc	tttgcaactga	tttttttctt	tcgtttttat	gagttgtttt	120420
catttggttg	ggataactca	atctacagga	gaatattaag	acttttttaa	ttttaaaaaa	120480
tatactttca	aatacttaat	acattttgtg	ttaaatgaca	gccagcagat	attgactgaa	120540
ttgggctaga	tgcttcaggg	atctcccttc	cattttaagac	tctccgagag	gccattcctg	120600
actgcaggtc	actgtattat	ttttaatttt	aaaattttta	cttacttatt	ttattttaatt	120660
ttattttttg	agacagagtc	tcactctgtc	gcccagggtg	gagtgcagtg	gcacaatctc	120720
agctcactgc	aacctccacc	tcccgggctc	aagcgattct	cctgcctcag	cctcctgact	120780
agctgggggt	acagggtgcag	gccaccacac	cccgttaatt	tttgtatatt	tagtggagtc	120840
agggattcgc	catgtttggc	aggctagtct	caaactcctg	acctcaagcg	atccttccac	120900
ctcagcctcc	caaaatgctg	ggattacagg	cctgagccac	cccactcggc	ctactttatt	120960
aatccacttg	cagaaacagg	atatacacaa	aaacgtttca	aggctgtaag	tgccactgca	121020
tggcaccat	ggtaaacggt	ttacaaattt	gagtcaggaa	caatcattag	tgtcactagc	121080
aacaaaaatc	aaaatttaaat	gaaataaaaa	atttctttcc	ccaaatggca	aaggagaaaag	121140
aaaggtaata	ctaacacgca	gtcagggtgt	agtgaagagg	ccgctctcac	acaggactgg	121200
taagtacaga	gccatggagt	aagcaggctc	tgagctgaca	ctggagagga	tccttttttt	121260
tttttatatt	tattttttta	gagtcagggt	cttgcttttt	taccagggct	ggagtacagt	121320
ggtgccatca	tagctcactg	cagcttcaaa	ctcctgggct	caagagatcc	tcctgcctca	121380
gcataccccc	tagcagggac	cacaagttag	aggatccttt	agtgttgta	aggagaagga	121440
acagagggtg	ggatgggtgg	gcacagacac	aggagcacag	ctgaagcaga	ggattacaaa	121500
gggtggagcc	tgatgtaaa	aaaccttaata	ggtgacagag	catggaggct	cttgaatacc	121560
aggctggaaa	ctgcattagg	aacgggtgctc	ataattgcag	aaaattttac	atggcctaga	121620
tagtcatcaa	aggatgatgt	acaaacaact	atggcatatt	tatacaatgt	gccgacagga	121680
tgcactgaac	attttgaaca	acaaagagac	ttgataatgg	cgagggtttg	aggagggtgaa	121740
tcaggatgca	aaaaagcaca	acaactaata	aagttgattg	atgacaaaac	ctatcaaaag	121800
gcagccagga	gaaaagctac	tggttacctc	cagggagctg	gtgaggggagg	ctgggtggga	121860
ggatctaccc	ttctgaattc	tgagggcacc	tccagtgtgg	ccctcagaaa	gcaggagctt	121920
ccaggctaga	atcagatccc	gacatccctg	ttaattccac	ggattccaca	ccgagtcaga	121980
tttatgattt	actatagggt	tttaaaaacc	aaattgcagg	gatgctagcc	tatcacagct	122040
tatctcagac	attgtccact	aaggatataca	gagtgctgcc	tgttcctttg	gtaccctaatt	122100
caggaacccc	catcagatct	gctccttcc	gtgggttagt	gagtaacacg	aaggcttacc	122160
atctcacaca	gataactggt	catagggtcca	gcagaagttt	aaaacagaaa	atgaggaaaag	122220
ccatgtgatt	aactgctgcc	agactgtttg	tggtacaaac	agcagttcct	taggcattgc	122280
ctgggacatg	caataatttc	tggtacacaa	tctgtggtag	ttaaaatgct	gcacgatgaa	122340
agctatctga	tttggtattca	ttattagggtg	agccatctcg	tctgcaattt	ggttccacca	122400
ttttcattta	acaaatgtaa	aaaagtttat	taagctctta	cazagttatg	ctgggcaaat	122460
atgcaaaaagt	ccagatcacc	taccgcagga	actaactctag	cctcctctct	gggcaccctg	122520
ttgtttgggg	ctgggcagtt	ctttcctgtg	tagaaccatc	tagggctgaa	taggtcattc	122580
tgacacctgg	gcacctctgc	ctgctcgtaa	atgggacaat	cagaaagggc	ccttatgttt	122640
ccaaactttc	tttaaagtag	ctgttctgaa	aacatggtcc	agggaccctt	gattgtccct	122700
gagacctttg	aggggatctt	caagggttaa	attaatgtca	taataatact	aatatgttat	122760
ctgtcttttt	tcactctcac	tttctcacac	gtgaacagtg	gcattttcca	ggtgacagag	122820
tgtgtgataa	tgaacctaac	tgaatgcaga	gcaaaacatg	agaacctagt	tttttcaatc	122880
aaaccagacg	tgaagagat	ttgcaaaaaat	gaaaaaacaa	tgctatcctc	ctcacaaat	122940
ttttgtttta	gaaaataaag	ttattttttcc	tagaaatgtt	tttgagttaa	tcagtcatag	123000
gtttattatt	ataattaaaa	aatgaaatat	acatacacag	acatattttt	taaagttctc	123060
agttttaatc	tctttttttt	tttttttttt	tttgagacgg	agtctcgctc	tgctgcccag	123120
gttgagtgcc	agtggtgcga	tctcagctca	ctgcaagctc	cgctccctg	gttcgcgcga	123180
ttctcctgcc	tcagctccc	gagtagctgg	gactacaggc	accgcggacc	gcgcccggct	123240
aattttttgt	attttttagta	gagacgggtg	ttcaccatgt	tagccaggat	ggtctcgatc	123300
tcctgacctc	gtgatctgcc	cacctcgccc	tcccaaagtg	ctgggattac	aggcgtgaac	123360
caccacgccc	ggtctcagtt	ttaattttcta	atacagtaag	tattgatcag	tgtgccccac	123420



attagtaaaa	gctcttgggg	tcctcagtac	ttcttttttaa	gagttgtcaa	ggagtcctgt	123480
gacccaaaat	aggagagcca	ctgccctaga	aggacagccc	cagcccgggt	caggaacaac	123540
tgggacagaa	cctactgctc	ctagtggatt	gtaatatgat	aggatttaac	cttcaagggt	123600
tcaactcttg	gcaagagtc	atgagggggc	atggtttgtc	ctgagcattg	cttactgtta	123660
acaggagcaa	gttccttagg	ctggtgagcc	aagccagcct	gacgctggcc	atggacatct	123720
tagtgggctg	cttgttctag	tgtgggtttt	cattttatgg	gaaatgtcat	ctgctctaag	123780
gctcttctca	tttggggaaa	tcacaagttc	tcagaatggt	tgtctctctt	ggttggggcc	123840
tctataatta	aattataaaa	cagaggtaat	ggttaagtaa	tgcaagattt	gacagaaacc	123900
acagaggatt	taggggttaa	tttgagttag	gcaaaggggg	gatgaagatg	agcggctcctg	123960
gagacaagaa	aaagattgga	tgaagctggg	cacggtggct	cacgcctgta	atcccagtac	124020
tttggggagg	caaggtgggc	agatcacttg	aggccaggag	tttgagacca	gcctggctaa	124080
cataatgcaa	ccccgtctct	actaaaaata	caaaaattag	ccaggcgtgt	tgggtgtgtgc	124140
ctgtagtcac	agctacttgg	gaggctgagg	catgagaatc	gcttgaatcc	gggaggcaga	124200
ggttgacagt	agcagagatc	atgccactgc	actccagcct	aggcaacagg	gtgagactct	124260
gtcttctttt	tttttgagac	ggagtctgtc	gccagggctg	gagtgcagtg	gcatgatctc	124320
tgctcactgc	aaagctccgc	tcccagcttc	aagcgagtct	cctgcctcag	cctcccaggt	124380
agctgggatt	acaggcatgt	gccaccacac	ccagctaatt	tttatatttt	tagtagagac	124440
gggggtttcac	catgttggtc	aggctgggtc	caaactcctg	acctcgtgat	ctgcccgcgc	124500
cggcctccca	aagtgcctgg	attacaggtg	tgagccacca	tacctggctg	agactctgtc	124560
tttaaaaaaa	aaagagagag	agggagagaa	agattggatg	aaacaacaga	gtggggagga	124620
cctgtgagct	tggtagcttg	gtgaaggcag	ggctttattg	ggggccttag	aggggatcca	124680
ataaagggtt	ccagtcattg	tagtgacctt	aagaaaatag	cattttaaca	tctttcattt	124740
cataatagac	agtcacagtt	tacaagacct	tttccataca	ttccttatga	catccatctt	124800
acagcccaga	ggcaagtgtg	gcactctctc	ctctcacaaa	tacaaaaact	cagcctctag	124860
agggccgcga	cctgctcagg	gtgatgtgca	attcagggat	gacagagtgc	aggtctccag	124920
cccagtggtt	atccctcaca	ggcacgttgc	ctgtcaggtg	gcagtataaa	actttgtaca	124980
agaaatcaag	ttgcattagt	cagtcggatt	ccccaaatga	tcacattgta	gatgggtgat	125040
gctgtgggca	gagcaagggc	tgctgtttct	tgggcaaaac	aatcagtcct	cctccccccc	125100
aaaataaatg	aatgccaatg	gtgtgacttt	attttatttt	ttttattttt	attattattt	125160
gtgagacaga	gtctcactct	ttcacccagg	ctggagtgca	atggcatggt	ctgggtcac	125220
tgcaacctct	gcctcctggg	ttcaagcgat	tctcccgcct	cacctctccg	agtagctggg	125280
actacaagtg	catgccactg	cacccggcta	atttttgtat	tttttttaag	tagagacagg	125340
gtttcactat	gttggtcagg	ctggctctga	actcctgacc	tcattgatcca	cctgcctcag	125400
cctcccaaag	tgctgggatt	acaggcatga	gccaccgcgc	ccagcaatgt	gactttataa	125460
ttacagaatg	taggactcag	ctcccactat	tgttatgact	caatattctc	ttagataatg	125520
tttggggcac	tagctttacg	gcagcattgc	ccggtgggta	atggtgtagc	tttgacggca	125580
gactgaccat	attaaaattc	gatcacacca	tttgctaagc	ctgtggactc	gggcacgctt	125640
ctttctctgc	gttagtttcc	tcctctgtaa	aacacgggat	atgctataaa	cacacccaag	125700
tcctagaatt	gttatatgag	ttagaaaaga	taggcaaata	caactctcac	aagacagcct	125760
ggcctccagt	aagtgccact	gagtgtttgc	tcttattgta	cagtggctcc	aagtgcctct	125820
gtcttggaat	attttctgacc	aggtggctat	gtctcctagt	aacttaccaa	tcctgttgag	125880
tcttaataag	cacgtctttg	atgectacag	tgcagctgaa	tttccaggcc	tcattactgg	125940
agacacaate	atcctatatg	cttttttcca	ttgtgtttta	ataaagtggg	acatgtgtat	126000
ggcaccagat	caaacagtac	agaacaagtt	acaatggaag	agaatggcct	cccagctttc	126060
ctgaaatcct	caactcagag	acaacttttt	tttttctgac	ggtttcttta	tacagccctt	126120
tttgtgggta	ccttcctaac	tctagaaaaa	ctattcttac	ctctgtttat	ttacttagaa	126180
acattagacg	ttacctttca	actcctcagt	atgaagcttt	agttttcagc	accccaggcc	126240
accacctctc	ttccaggact	tactacttat	actggtggta	ggtggaattt	taaaattcat	126300
cagcattctt	ttgtgattct	ctgtgtgttc	cagttttaca	gcaacccgta	cttgttgcat	126360
gagtacagta	gaactgggag	gctcataact	tagcctgcag	gacttttcac	ttaaagcctg	126420
gccctcaggg	tgatgtcacc	cacctcattg	tgcttggttc	aggagttag	tcctcagtt	126480
gcctgggtgt	atagtttgga	tgttcagcac	ctccaaatct	cacattgaaa	tgtgatctcc	126540
aatgttggat	gtggggcctg	gtgggaggtg	tctgggtcat	caggtgggtc	cctcttgat	126600
ggcttggtgc	cttccccatc	gtaacgagtg	agttcttgct	ctggcagttc	acacaagagc	126660
tggtttttta	aaggagcctg	gcaccttccg	ctctttctct	tgctcttctt	cttcccttcc	126720
tttgtcacta	aaagcttcc	gagccctcac	cagaagcggg	gcagatgctg	gtgccatgct	126780
tggacctcct	gtagaactgt	gagccaaata	aactctttcc	tataaattac	ccagtttcag	126840
gtattccttt	atacaatgca	aaacagactc	acacatctgg	taaacccag	ttgtttgctt	126900
ctaggaaga	cgggaggagt	ggggagctgg	tgagggtttc	cactgcattg	tctattttca	126960
ggcaaggtgt	ctccactgag	taggcttcac	attcagagct	ctgggtaagg	tgggcaggaa	127020
gaggggttga	ggctgcccac	aggagggaga	gaagaaggct	gaatccttca	gtgacaacct	127080
gtgaaccaga	gtcttagctc	tctttgaata	ttttgttcag	tatctttggg	ttttgtttta	127140
ttttgcctag	gggtaaatgc	tgactgcctg	ttctctggac	aggaatggag	aagatgggtg	127200

tagcaggggtt	gctgtttcata	tgtagacatt	catgcagtc	ctctcttttc	agcacacttc	127260
ttactttctgc	cctgggttca	ggtgctgact	ctgagccag	aaaccttcta	gggttctgtt	127320
aggtagattg	gcttccaccg	tctttgcgac	aaccacagaa	aattcttagac	tgttttctct	127380
tggggcttca	ttagtcaact	tgcttcagtc	tgtcttgcat	cttctaaata	tttatagatc	127440
tctctctttt	ggtggagtg	cagaaaatgc	tagttgacca	cccaatatc	aaattatcct	127500
gcctccttaa	taacagaata	tcattggatg	tggtgggtaa	ataatatacc	ctaactttcc	127560
ttgcagagag	gggtggccaa	tgagatggaa	atgaaagtca	ttgggaaaga	ctcccaagac	127620
atctctttaa	acaagacaga	ctgaagcaag	ttgactaatg	aagcccaaag	ctagcagttg	127680
tttttgttta	tctttgcctc	ttcttcttct	ttcctgtggg	gacaaagggc	agtgatatct	127740
ggagctgcag	cagccatttt	ggcataatgt	tggaaaagcc	aagagactct	cagagaccgc	127800
agctccagca	gttttttatt	ttttccaaat	atttgctcca	ctgcaggagg	atgagatatt	127860
cgtgttttgt	gccttgtgac	tgtaggagga	ctgcacttcc	ctgccttgtt	gtcaagtttc	127920
cccatgtggg	ctgctttggc	cagtaaaaca	tgagtgggag	aagcttggtg	aaccattgca	127980
tgtctaccag	cttttttgct	ctcttccctt	tggcattaga	aaggcatgtc	caggatggag	128040
ttgttccctc	agcctagatt	gggttatgag	aagctagctg	ggggagtcca	gtaacatata	128100
aagcgagtta	gaaataaaac	tttggtgttg	taagctatat	atataatata	atataatata	128160
atataatata	atataatata	aatatgtatg	taatatataa	atacatatta	tacttttaag	128220
tctagggtag	atttgcacaa	tgtgcaggtt	tattacatag	gtatacatgt	gccatgttgg	128280
tttgctgcac	ccatcaactg	ctcatttaca	ttaggtattt	ctcctaagtc	tatccctccc	128340
cagcccccca	ccctcaaca	agccctagtg	tgtgatgttc	cccttctctg	gtccaagtgt	128400
tctcattgtt	caattccac	ctatgagtga	gaacatgtgg	tgtttggttt	tctgtccttg	128460
tgatagtttg	ctgagaataa	tgggttccag	cttcattcgt	gtccctgcaa	aggacatgaa	128520
ctcatccttt	tttatggctg	catggtattc	catgggtgat	atgtgccaca	ttttcttaat	128580
ctagtctatc	atttggtgac	atttgggttg	gttccaagta	tttgctattg	tgaatagtc	128640
cgcaataaac	atatgtgtgc	atgtgtcttt	atagtagcat	gatttataat	tctttggata	128700
tatacccgat	aatgggatca	ctgggttaag	tggattttca	agttctagat	ccttgaggag	128760
tgcgccact	gtcttccaca	gtgggtgaac	taatttacac	tcccaccatc	agtgtaaaag	128820
cattcctatt	cctatgtctc	cacatcctct	ccagaatctg	ttgtttcctg	actttttaat	128880
gattgccatt	ctaattggcc	tgagatggta	cctcattatg	gttttgattt	gcatttctct	128940
gatgaccagt	gattgatgag	attttttcat	gtgtctgttg	gctgcataaa	tgtcttcttt	129000
tgagttagtgt	ctgttcatat	tgtttgcccc	ttttttgatg	gggttggttg	tttttttctt	129060
tgtaaatttg	tttcagttct	ttgtagattc	tggatattag	ccctttgtca	gatgggtagg	129120
ttgcaaaaat	tatctcccat	tctgtagggt	gcctgttcac	tctgatgata	gtttcttttg	129180
ctgtgcagaa	gctctttagt	ttaattagat	cccatttatc	tattttggct	tttggtgcca	129240
ttgcttttgg	tglttttagac	atgaagtcct	tgcccatacc	tatgtcctga	atgggtatcg	129300
ctaggttttc	tcttagggtt	tttatgggtt	ttaggttcaa	catttaagtc	tttaaccat	129360
cctgaattaa	tttttggtata	aggtgtaagg	atgglttcca	gtttcagctt	tctacatatg	129420
gctggccagt	tttccagca	ccatttatta	aatagggaat	cgtttcccca	tttcttgagc	129480
tacagatatt	ttgagtttgg	ttaccacagt	attatctagt	ggaagttgac	ttatacagta	129540
tgtaatagga	taaatatagg	tgtgtaacag	aatat taagt	gttcgtgttt	caaagctgag	129600
gggaaaatgt	taaaagtgtt	cacacactct	aaaaagagat	tagctaaaac	tgcttcatta	129660
accacacttt	ggggaaacca	gttctgagat	tcttctccat	tactctgaca	ggttggacc	129720
tctggggagc	agatctcaag	atcaagttat	gagtgcgaaga	ggtgtgttgg	gaagcgatgg	129780
ttgtaaaaga	atcctgcagt	agcaccaggc	acaagtctgt	ccagggagag	gaggacttct	129840
actctctacc	agcatctctc	ctaagtcccc	ttaggggacg	ggggcaagga	agtgtctggg	129900
agggcagggc	atgggttctg	gctaggactc	cacccccctg	gggcctgtac	ccacggacct	129960
aggtgaagac	aggcactcct	gccttctcgc	ccaacgggtg	cgtttcccaa	gatcatcctg	130020
gcctgccacg	ccccatcta	cctattaaac	tccccacact	tcccaaacc	ctagcaggca	130080
gacacacatc	ggtggaagaa	gacaggagcg	gctggacatt	gaaaggacgt	cgagaggagc	130140
acacctgcac	accatcgacc	agcggaaacg	ggcagagtgt	ggctggagca	gtcggagggg	130200
agcctggggc	gctgactcca	ggggaaaacc	atctcctttc	tggctcccc	ctctgctggg	130260
agatactttc	actgaataaa	accttgcaat	cattctccaa	gccacactgt	gatccgattc	130320
ttcctgtaca	ccaaggcaag	aacctgggat	acagaaagcc	ctctgtcctt	gtgataaggt	130380
agagggctcta	actgagctgg	ttaacacaag	ctgcctatag	acagcgaaac	tgaaagagca	130440
cacaatagca	cacactcatt	ggggcttcag	gagctgtaaa	tatccacccc	tagacgctgc	130500
catggggcgg	gagccccaca	gcctgcccgt	ctagaggttt	gagcagcggg	acactgaaga	130560
agagagccac	acctcatcg	cacgtcctgc	gagggagaca	agggaacttt	tccggtttca	130620
cttctgcttg	gcttgagctg	gcactgaagc	acctttttcc	ctcctcactg	agggagcaga	130680
ggggaaaagc	ggtagaacta	acaggctaac	aatgtcctc	cgaaaatata	tcgatatttt	130740
ggatccctag	agataggtag	tcacggcagc	cgcgaggtgc	atgtgggtct	cctttcaaga	130800
aagaacttgc	tgtcagcgt	tgaagaatgc	agttggccaa	cagcctccag	ctgctctgtc	130860
ttcagcatct	gccatggcat	ctgagctgag	gtcatgttct	tcttgggagg	tccccagcag	130920
aaggatcacg	tgggaagctcc	acaagctcca	cagatgttcc	aggagaggaa	taggcagcat	130980



ttggaagaca	tatcctgcca	taacagaggg	catttgctag	tagagacaac	aaacagcaac	131040
agccaagtaa	acaaacacac	aagcacaaag	cactttctcc	catttcccct	cattgatcct	131100
gtccgggtag	aagctgggga	ggaagtagaa	taggggtgagg	cggggtgggg	ctggggggcc	131160
tacaccttct	tccttccccc	gcaggctcctg	tccttggggcc	aggcttgaac	taggggaatg	131220
ggaaaagctg	tgaagtgaat	gagaattagg	agtttttatt	tagactggac	ttgaattttt	131280
tttttttttt	tttttttttt	gagacagagc	ctcgctctgt	caccagggct	ggagtcccgt	131340
ggcgccatct	tggtcacta	cagcctctgc	ctcccggggt	caagcgatcc	tcccaccaca	131400
gtctcctgag	tagccgggat	tacagggtgcc	tgccaccatg	cccagctatt	tttttttttt	131460
tttgtatttt	tagtagagac	agggcggtcac	cgtgttgggc	aggctgggtct	cgaactcctg	131520
gcctcaagtg	atctgtccgc	ctcggcctcc	ccaagtgcta	ggattatagg	agtgaagccac	131580
cacgcctggc	ctggacttga	atttttaatt	cctaaaaaat	aactaccagt	taaaatttaa	131640
aaatgaccaa	aaaagctatg	ggatatgctg	atgttttgct	ttggggataa	ggaaaagata	131700
tctgggttag	cggcattgaa	aacagtgtag	ggagagaaaa	actcattcct	ggctcaccct	131760
tttgagtccc	actatctcaa	taatctgatg	ttatatgaca	cacacacaca	cacacggagg	131820
aatcctggaa	gactccatat	caagggtggg	atgaagggtga	ccagtgggtg	ataggattat	131880
aggtgtgtgt	ttattttatt	attttaatta	ccttttttta	gagacaggg	ctctgtcatc	131940
caggctgcag	tgcaagtggg	tgatcatggc	tcactgcagt	cttgcactcc	agggctcaat	132000
cctcctgcct	cagtctcctg	agtagctgga	gctgcagtca	tgaccaacg	tgcccaacta	132060
atttacttta	ttttattttt	tattttttgt	taagatggaa	tctcatttta	ttgcctaggc	132120
tggtcttaaa	ctcctgggtt	caagcattcc	tcctacctca	gcctctcaaa	gtgctggaat	132180
tactgcactt	ggccctatta	tatttttaaa	aaatttcaat	agtttttagg	gtaaaagtgg	132240
ctttgggttac	atagatgaat	tgtatagtga	tgaagtctgg	attttttagt	tacccatcac	132300
ccaaatagtg	tacattgtac	ccaatgagta	gtttttcatt	cctcaccccc	acactgtccc	132360
cactctctag	tcctctgatg	tccattatag	caccctgctt	ttgcgcactt	agagcttacc	132420
tcccacttag	aagtgaagac	atgtggtagt	tggttttccc	ttcctgagtt	acttcactta	132480
ggtcagtggc	ctccaatttc	atctgagttg	ctgcacataa	catgatttca	ttcttttttt	132540
gactgagtag	tagtccatct	ctctctctca	cacacacaca	taacacacaca	cacacacaca	132600
cacacacaca	cacattttatc	cactcatcca	ttgatgggca	cttaggttgc	ttctatatct	132660
ttgcaattgt	gaattgtgct	ccaataaaca	tacatgtgca	agtgcgtgtt	tttctccctt	132720
ttatccttct	tttcttccct	atgcttccat	aggtactgag	aaagagtctt	ttttatataa	132780
ttattttctt	tcctttggga	agatacccag	tagtgggtag	gcttgatcca	atggtagatc	132840
tggttttagt	tcctttgagaa	atctccatat	tatctccata	ttgttttcca	tagagattgt	132900
actaattttac	attcccacca	acaatgtatg	tgttccattt	tcactgcatc	ggcaccaca	132960
acggttggtt	tttgactttt	taataatggc	cattctgggt	ggggttaagg	ggtatctcac	133020
tgtggtttta	acttgtattt	ccctgataat	tagtgatggt	gagcatttaa	gaaatatatt	133080
tgttggtccat	ttgttatatt	tcttttaaga	aatatctctt	gaagtgtgtt	gcccactttt	133140
taatgtgatt	atttgttttt	tttcttgcct	gatttttttg	agttccttgt	agcttctgaa	133200
tattagtcct	ttgtcagagg	tatagtttgc	aaatactttc	tcccattctg	taggttgtct	133260
ctttactctg	ttgggtattt	cttttgctat	gcagaagctt	tttagaataa	ttaggtccca	133320
tttacttatt	tctgttattt	tgttgcattt	gtttttgggg	tgtttagtcac	aaattctttg	133380
cctagaccaa	tgtccagaag	agtttttcct	aggttttctt	ctagaatttt	tatggtttca	133440
ggctcttagt	ttatgtcttt	aatccatctt	gaattaattt	ttgtatatgg	tgagagatag	133500
gaacccgggt	tcattctttt	acactacatg	tggtctatcca	attttcccag	cactgtttat	133560
tgaataggat	ttcctttccc	cagtgtatgt	ttttgtttgt	ttggctgaag	atcagttggg	133620
tgtagggtatt	tggtttttatt	tctgggttct	ctatgctatt	ctacttttat	accggttcca	133680
tgctgttttg	attacaatag	cctcgtagta	taatttgaag	ttgggtaatg	tgatgcctcc	133740
agatttgctc	tttttttgct	taggattgct	ttggctattt	ggacccctct	ttggtctcat	133800
ataaatttta	ggattgggtt	ttctaattct	gtgaaaaatg	acattgggtat	tttgataagg	133860
gttgcactga	atctgtggat	tgctttgggt	agtatagtca	tttttacaat	attgattctt	133920
ctaataccata	agcatgggat	gtttctccat	ttgcttgtgt	catctattat	ttctttcaat	133980
agtgttttgt	aattctcctt	gtaggggtct	ttcacctcct	tggttaagta	tattcctatg	134040
tattttattt	ttattttttg	cagctattgt	aaatgggatt	gagttcctga	tttgattttg	134100
agcttgggca	tcattgggtg	atagcagtgc	tagtgatttg	tgtacattga	ttttgtaacc	134160
taacactact	aaattcactt	atcaaatctg	ggagattttt	gaggattcct	taggattttc	134220
taggtatgag	atcatatcat	tggttagagg	agtttgagtt	tctcttttcc	agtttggatg	134280
ccctttattt	ctttctcttg	cctgattgct	ctgactaggg	cttctagtag	tatgttgaat	134340
agaaatgggt	aaaagtgggc	atccttgtct	cattctaatt	tttaggggga	aatgctttca	134400
acttttcccc	attcattttg	atgttggctg	tgagtttgct	atagatgatt	cttactattt	134460
tgagatatat	tcatttgatg	cctagtttgt	tgagggattt	tatcataaaa	ggaggctgga	134520
ttttattgaa	tgctttttct	gcatttatta	aaatgattac	gtttttcatt	tttaattctg	134580
tttatgtcat	gaatcacatt	tattgactta	tgtttatttg	ttgcttacat	ctactttcta	134640
attttactat	aataaacatg	tataattttg	ttatcagaaa	agtaaatgta	aaagtgagtt	134700
ttaattttta	aacttggggc	taagtcttcc	tgccctccaa	gcccatcccc	ttcctgatat	134760

ctggggcttc	cctcctcaag	cctgctctgc	aggataagg	gatacagtc	acatgcctgc	134820
tgctgggttg	gcccattgata	acctccatgg	gcaatgtctg	agcctctgct	gttgagtttt	134880
gctttacaca	ctcctggcaa	ggaaaggatg	gccaacatgg	cttgacatg	ggttgctgat	134940
aattgggtgat	gtctcatgac	tgggtctgcc	tggagggtct	gctgtaagtc	cctgatagga	135000
ggaacatgga	cctgcacaag	agcagaactt	atctgacact	gaagaggaca	cttcaagaac	135060
agattatcaa	agtctagctc	agggagaaat	atactttaga	gcagaatgag	gaatggcgag	135120
gcagctgagc	ttagacacaa	gcagaaggaa	atccatgggt	agggcacagg	caaggaaagg	135180
ggctgagaga	gcattagtgg	gggcagtcag	gggcagtggt	caggatgctc	ggatgccagc	135240
gtgaacaatc	gcataagat	taaacaccat	gaggatcggt	agacttctctg	tcatatgtct	135300
ccagggtggtg	ctccaaatat	cctaaaccag	atgacagcac	ccctccacc	tctgctgtat	135360
aagcacatct	gctctcctat	aatcattccc	acatagcaat	ttatcatttt	tattgatatt	135420
tcttcatctt	atacacgtat	aagtgtgtct	tttattttta	aaaatttgca	ttcctttaat	135480
tgctttggag	attgtgcatt	tttctctctg	ttgatttact	ctgccaataa	acatgtaatc	135540
ctaccataag	catgttttac	ttgtgtaatc	aacccaaata	aaaaatttaa	aaaggaaatca	135600
ctgactatga	attagacatg	tggataggca	ccagggttgc	agacatggcc	cacgttcttg	135660
catataacttg	cactgtggct	ggggcattgg	atgggtacat	taaaaggatt	aaagtaatat	135720
aaggcagtat	ttattaagtg	ttgagtgagc	actacagaac	ccaagtgcctg	agggagtttc	135780
atgcaggaag	agatcaagag	taacacagag	aagaagaata	gatcaattta	gcgcattcat	135840
ttaaaaattc	accttttgca	taaggggatg	tgtcttttgt	ggggaggagg	ggagtccga	135900
ttggcagttt	gttctcaggg	agcttgaaga	agagatcttg	gagaggagac	gcagagaaaa	135960
caaataaga	aaatgtcaaa	atggaagggg	ttggcccggc	tatgcatacc	ttagttagct	136020
taggtagagt	ctaaactttt	acaagtgggt	tcaatagggtg	tgtttggtct	gggttctttg	136080
ggaggtatca	taggagaatg	aaggcagggg	ggacgcttcc	agcaccaaaa	ttcaaaggga	136140
aatgtattta	acatgcatag	cattgtttta	ctctctttcc	atttgaggca	tatcttaaaa	136200
attccatttg	gagcatatct	taaaaaaccc	attctcttga	caatgggtct	aaaaggggga	136260
aacatccttt	gcaacagaat	cattcattct	ctcattcatc	aaccactgat	tgtgtactaa	136320
gtgtcagacc	tgatctccat	cctgcctggg	atggcactag	cttctgtctt	gagacaagca	136380
ttgtgataaa	ccatgaccac	aaaaagggca	gttttataaa	cacaagtctg	ccaggctttc	136440
agcaattcta	aatttccctt	tgcaagtcag	gctggagtta	atggctcttt	cctgcagcgg	136500
cggagatgac	agggctctcc	cacagtgcct	agcaggcagt	ttgaaagccc	cacttctgt	136560
ctctgcatgg	gcgagtgtcc	actggaagcc	actgagagga	aggaggga	cctcagaaac	136620
cggcccttgc	ctggctgctt	cacctagaa	agcccaggca	gaggaggga	aggtgaagtg	136680
ctgaaaaaga	ataaaaaagg	gggaacatga	aaaagagcaa	gagcaggga	gaggcaggga	136740
cgggaagga	ggggaagcac	ggaaacagcc	aatgtcaagg	agaagaaaag	atggctggtg	136800
gaaaggagct	tcagggaatt	gggacacagc	cctgtcttat	tgcaaaagat	ggaaaccttg	136860
aaggagaaca	ggaaggaaaa	agaaaacaag	tcogtctgag	ctggcagggt	ccactttctc	136920
attctacaga	gaggcacaga	gaggcaatga	cttgcccaag	cttgcccaag	ggggcaggtt	136980
cttgaaagga	tcattctgcac	tctctctccc	ttaatgcatt	cttacctctt	ctttactcgt	137040
gagtcagtc	tgaaggacaa	gctgcctgaa	gtcccacaca	gatgggcctg	gggcaagcat	137100
caaacatcct	gggggcccctg	ggtgaggttt	gctttttaa	tccaggtcag	ggaaaggga	137160
gtctttaagt	tgtctgctct	aagcttagta	atccccctca	gagttatggg	tgcggtgtct	137220
ggggtagccg	ttgcgtctct	gggcaaatat	cctggagaat	gcagtgttgg	ttgtctgagc	137280
tggggacaga	gtgacagcat	agttgcattg	agagctggag	gctcctgcag	ctgtacaggt	137340
aagggtgctga	aattctccac	caacccttcc	tctttgccc	cagcaccacg	aagataacct	137400
tctttgaata	tgtggaagtc	tggtctccaa	actttctaac	attctcatgt	cagtcttaat	137460
agattcagct	cagttactgc	ctcctccagg	aagtcctcct	tgtctgcaaa	tcggctgccc	137520
accatgccgg	ctcactcata	gttttaactc	tgtatctttc	taatattgct	tagccactc	137580
tgtcaggatt	tcagtcagct	tccttctcct	agactaggag	ttgcctcagg	ccaggaggac	137640
cagccttggt	catatctgta	ccctgcaaac	ctgtcaatgc	ccaaacctgc	tcagtgcctt	137700
ggagtatgga	accagccgtc	aatgcaggaa	tgttacactc	taagagtcc	caaaggtaga	137760
gagatgaggg	attgggtgctg	gaagtgggag	gttattctaa	ggatgggtat	ggcaggaaac	137820
acaattatag	ttcaggaggt	ggagtgtcca	ggagtgggag	gagagggaact	gggagaaaga	137880
gcagagagtg	aaagtgagag	cgggcacaaa	gaaagggaaa	aagagtcagg	gatcaacca	137940
agtgcatgct	tccttttcag	ccctgccagg	atgtgcaggg	cggctgctgt	ggacgcgtca	138000
aggctcagcc	tcaaacatgt	cttcttccct	gacttttgct	tatcatttcta	aagctagggtc	138060
atttaaaaag	ttcttttggt	ttctttccac	cgatactctg	atttctgaca	ttcgccaaaa	138120
agaggtcaag	accctggcat	accgccctac	taagattaaa	ataaatatta	tccattgaaa	138180
ctgttatatt	ttccttaact	gttatattgta	gagttaaaga	ttcccatgat	cgcgctgggt	138240
ctaacaatcat	ttttggctct	tttgagatca	aatttgcaat	ttgatgcaaa	aatagctgtg	138300
acgcataatgt	gtgtggtatg	gtgtggtatg	gagatttttt	atcattacat	cttctttgtc	138360
cctgcctttc	tgctttctctg	tccttttaat	ttgcgggctt	ttggcaacca	cagcacgggt	138420
ctgggtttct	aggagtttct	tttgtaggat	caaaccgcta	gttggctctt	ggccctgtga	138480
tagggccctg	ggctaactta	ttgggaaaat	gttgcgtgtaa	ccctgccc	gaggtgcctg	138540

tgacatgggc	cgccatcttc	tccctcttccc	ttggcttcag	ccccacctag	aaacctgaac	138600
aaacattttc	cttgacattt	cataaagtgt	cagtggtctc	tcatttagca	aaatacatcc	138660
caggggaagt	caaaagtga	aaaaggccgt	aacttcttct	tcttctcagg	gacctacaga	138720
aaatatgtgg	cacctcggca	gcctggcctg	cagcaactccc	ctccccatcg	gtgagtcctg	138780
ctacagtggg	tccaggtgtc	tggacgcccg	gcacgcacgg	ctctctgcag	acctctggac	138840
agtaccatgg	gagccgcaca	gtccctgcct	gttctgtccg	gcagttcttg	tttcccagca	138900
ccctgtctca	ggtgagaggt	tccctcttct	gtcgggcttc	tccctccctgc	tgtgaacccc	138960
aaatatctga	ggcaggtcaa	tttaggaacc	ttattttgcc	aaagttgagg	atgtacccat	139020
gacacggcct	caggaggtcc	tgaagacaag	tgcccagaggt	gatcgcgcca	cagcttggtt	139080
ttatacattt	atacagacat	cagtcaatat	atgtaagata	aacattgggt	cggtcccgaa	139140
aggccggaca	actccaagt	gagagggggc	ttccagttca	caggtagata	agagacaaaa	139200
tgttgcatct	ttttgagttt	ctgattagct	tttccaaagg	aggcaatcag	atatgcattt	139260
atctcagtg	gcagaggggt	gacttggaat	ggaatggaag	gcagttctca	gtttaaattt	139320
tcccttttag	ttagtgattt	tgggggtccca	agattttatt	tccattcact	ctgcagacag	139380
gggcttctgt	gcattccagg	agccctcct	cacagaagga	agcaggccat	taatgagacc	139440
caatccagct	tcaaccacct	ggtaacaatt	aggacatcac	ttctctgagc	aagagctcct	139500
gcctgtccat	gagttatcaa	gacattccaa	ttgttccctc	acatctttga	catgaagact	139560
tgaggggggt	agattttcca	gggggcttga	tggcatgttc	tcttcaactgt	tccctgcccc	139620
ggctatccaa	gtgaccttg	gcaggggaaga	ggcccagagt	tgcagaatct	ctgttctcac	139680
aagccattgc	caaccocggag	agtggctttg	ccactattcc	tagcatgttg	ttggctattt	139740
caggaatggg	agtatttgac	ttttcccttt	gcagtgattg	ctgcaaggag	aggaattgag	139800
agactcaagt	ccctgagata	aatattttat	aactattact	gaaagggagt	atgtcaaaga	139860
aaaaatgtgg	agaaacttca	gcttgaacac	atagtttaaa	tccagcttgg	gtgtactcca	139920
gtgggcatgg	atgtattact	gttttgaggt	gcattcttct	atgatcaata	cacagaagca	139980
aacaggccac	gtgggtaaac	agtaattttc	atttaccagg	gtgaatatgg	aagtcctctt	140040
gtttccatgt	catgatgaag	gaaagcaagg	accatctttt	gccaaaggaac	agtggctgtg	140100
ggggaactga	ggagatggaa	ggacaaggca	gtcaaaagct	ttggaacaac	tctttttttg	140160
agatggagtt	ttgctcttgt	tgtccaggct	ggagtgcatt	ggcacgacct	cggtcaccca	140220
caaccgctgc	ctcccagggt	caagtgaatc	tccctgcctca	gcctcccagag	tagctgggat	140280
tgcaggtatg	ctccaccatg	cctgggcta	tttgtatttt	taatagagac	gggatttctc	140340
cacgttgggt	agctgggtct	gaactcccga	cctcagggtg	tccacctgcc	tccgctccc	140400
aaagtgtctg	gattacaggc	atgagccacc	ataccgggcc	cttttttggg	ataattttat	140460
aggttttcaa	actattacac	ttaccttttt	atataagaga	caggacatag	tcactgaaca	140520
atcactccag	attttaagta	agtccaggat	gggatgacaa	tggaaacaac	atgaaatgaa	140580
aggaagaatg	tgtcactggg	atgtccacac	gtctccaaat	ctctcacctc	tgtcagctgc	140640
aaacagagcc	tgaataaagt	gtttcctctg	tgcacagcct	ccacaacttc	ctccctccac	140700
gtttctcact	cactcctctc	cagcacttct	ctccgggttc	tgcttataaa	cttgaaccgg	140760
gctatgcaaa	aattataact	gtggaaatta	tgacagtga	agagatcaga	cctaaccgac	140820
tccatcttgc	ttctaacctt	taagctgtcc	ttgttcattt	ttgggctgaa	ctaactttgg	140880
gaaggaattc	agttcatggg	agaactctga	aacaaaattg	ataatagccc	tttcctgaaa	140940
agaccccttt	cttgccctggg	gacaagtctg	ccattgtagg	actaacaagt	taactacaag	141000
attagaaatt	aaggttttagg	gttcatgacg	ctccagcttc	caagagtcta	aacctcccca	141060
aattgtcctt	ggggataaca	tcaactgtgt	aaaagcttaag	accagtgcct	gagatatatt	141120
gtagaccctg	ctctggatgg	atcagctgac	accatccaga	ctggtaattt	ggctcaacca	141180
gctctgccat	cccaccagg	aacagaaaaa	tactcacttc	atcaccccat	gagtcacatc	141240
ctaacctgac	caatcagcac	tccctacttc	ccaggccctt	actcgccaaa	tctgcctttg	141300
gaggcagata	acaacttatc	tttaaaaaat	ctgatccctg	aatgctcagg	agactgattt	141360
gagtaataat	aaaactccgg	ctctgcatga	attactcctt	ttccattgca	attctcttgt	141420
cttgataaat	tgggtctgtc	taggcagcca	gcaaggcgaa	ccctttgggc	ggttacaaa	141480
tcatcctctg	tggagagta	ggagtccatg	gagaaattgg	ttgcaaatta	caaaatttta	141540
ttgtaagggt	aacttgctcc	agtgtccgtc	tgtgcagcga	agggcccttg	catgggttag	141600
tgattgcaag	ttgagcctct	agggtcaggt	tgtctaggtt	tccatcccag	ctcattcact	141660
tattatctgt	gtgttcttga	gcaagctcct	taatcaattg	aggctttgtc	cttctgtttg	141720
tataatgatg	agaataataa	cctccacaat	aacctcatca	taagggttgt	gtgaagatgg	141780
atcagataat	atataatgtg	agtgtctata	acagtgcctg	gcacataaaa	aatgctcaaa	141840
aatcttaagt	gttattaata	ataaactgac	atataattct	tgagcagggt	ggtggtaaat	141900
gggtgttctt	tttattaagc	tttaagtggt	gcatagatca	tattaattct	ttttatgcat	141960
atgatataat	gcacatgcat	gaaaatacat	gcattaaaaa	taaatgagca	tttatgagat	142020
ttagtttagc	agtcacatgt	cccaggatta	caagccagca	ataatgggtt	ggaaaacatt	142080
ccaacccatt	gaaaacattg	caaacatttc	ctggaccatc	atgattatta	gtgcaaaaca	142140
atggaaccgc	ccacaggttc	tattcttggg	ttaaaaaaat	atgattatta	cggaataaat	142200
actgattccc	taagaattaa	tatctgagca	agtttctttt	tttctctgtc	ttcttgggaag	142260
atcagcaggt	tctagattca	atggagtcac	taggattgag	ccaccagtat	acgccagtc	142320

tctccagaac	ggccacctgg	tgggtgggcac	taaggcagtc	tcagatgagg	actgattgac	142380
ttttgtgtga	actcaaaactg	ccaaagtccc	tcctcaccct	tgcaaaacttc	aaagcacaac	142440
tttcaaagca	ctactttctt	tcttggctct	caattctctg	cctagaaaaa	gggaggtgtt	142500
ggcaaggatg	tttgttttagt	tctgggcac	agtcaatggt	acccagatct	tgctgaacag	142560
aaaagacaca	gatttgtttc	tctgaggcag	ttggtagtgc	ttattgctta	ttgctctcag	142620
gggcttctgc	agcagtagaa	gggcccctctt	cccctgccat	gccacactga	gaggagcatc	142680
cttggagtc	tggttggaat	ctgtttttgt	tatgctagtc	ctcttccgca	tgctagctgt	142740
tgcatgagc	ggatatgtgt	acctgtttat	cttctccact	aggctctaag	aagccaggtt	142800
tcttaaagga	aggaagctga	tcttgtttat	cttgaagtcc	tcacagtga	attgctcagt	142860
caatgttgag	tgtatgaatg	aataaacggg	aaccatcacg	aaaaagccga	aaatacagt	142920
gaaagactgg	atcataaaat	cttctaagca	aatttttttt	cctcttacac	tccattttcca	142980
aatagataaa	gtatttttta	aaatccctac	agaatattct	aacacactga	gttgacagaa	143040
tagagatttt	taaatgcagt	gtcatttggc	cagccatttg	tgagaattta	taaatgtttc	143100
agtaggttga	aaacactata	aaagcaagga	ctatgttcat	acccaacagc	tggcacttag	143160
tatgaatgct	aaatgaaaca	ttctcttctc	tttcaagagt	cagtccaacc	agtgacctg	143220
acaagaagga	aggcacattt	aactcaattt	aatgaactct	tatagagcat	ctccttctcc	143280
aagtgtcttg	ctaaggatgg	ggtaaaaaa	tgaataagtc	ttggattctg	tccttcagga	143340
atttctcagt	tttggaggca	gatacatttg	cacccaacta	ttatcctagg	cagagtgtga	143400
taagtacgat	aatagcagta	aaagctctaa	gttaggcagg	agaggaggag	ctcgttaaa	143460
cttatggggc	ctgggaggct	ttcgggcggg	taaactccag	ggggacagct	aggcatctgg	143520
ctgctggaat	tgggaggagg	atcattttta	gtggctacaa	ctctgggtgc	acaggactag	143580
aggggtgagg	ccaagatggg	aaattgtggc	agccatcttc	cacactgggc	gcccgcggac	143640
ccttgcttcc	tggatattcat	attattgtgt	agtgtccccc	aacattgtat	cagggttggc	143700
ctgtgtgacc	aattgcatac	ggtgggaatg	atgggtgtgt	acttctaaga	ccagttcata	143760
gaagatgtgg	ccaattccct	tactgtcttt	ttttttggca	ggggagtgcc	gagtttcacc	143820
cttgtcgccc	aggctggagt	gcaatggtgc	gatctctgct	cactgcaacc	tctgcctccc	143880
aggttcaagt	gatttctctg	cctcagcctc	ccaactagct	gtgattacag	gtatgcgcca	143940
ccatgcctgg	ctaattttgt	attttttagta	gagacgggg	gagatcaatg	aggcagtc	144000
ttggccagcc	tggttttgaa	ctcctgacct	caggtgatcc	acccgcctcg	gcctcccaa	144060
gtgctgggat	tacaggcatg	cgccaaccgc	gcttggccct	tactgtcctt	tggatcagct	144120
gctctggggc	taggtcaatc	cttcatgtga	ctgcagcccc	agccaacatc	tggactgaaa	144180
cccatgagac	accctgagcc	aaaaaagccc	agctaagact	tccctgcattt	ctgaccacca	144240
gaaactgaga	aaagaaatgt	tttgttgttg	ctttaagcca	ctgacttctg	gggtcatttg	144300
ttttgcagaa	atagatagca	gatacagaaa	agcaggctgg	tggaaacagt	tgggaaacac	144360
cttgattttc	agggagttgc	actttgttta	tgtgcaatgg	tgcaactgtt	ttagaaagac	144420
acaaagattg	taatactggt	gatgggcata	atacgggttg	tcaagaggag	tgactgagc	144480
ggggataaatt	taagaggcca	cagcagtagt	gtggcaagag	gtaatgagg	aattgaactt	144540
ggtgggaatg	ggtgagatca	acgaggcagt	caatatgggc	agtgagtgtg	aaggagctgc	144600
gaaggatgat	tctttgggtt	tgagcttagg	aacatgagag	aaccaagatc	tcatttatcc	144660
aaagaggaaa	caagagaagt	agcccctgtt	tgggggcagg	gctgggtagg	aggaaaagag	144720
tggagacgtc	tatctcccca	ggaagagagc	cccctgcttc	cagatcccag	tggatggcag	144780
ggcactcggc	actgggctcg	cttgagaaac	tttccctgga	gggcagggct	144840	
gctctgtttc	acagcccata	tccctcatgg	ccaagtgttc	ctcagtgac	agtcctcgcc	144900
atcaatattt	ttagcatgtg	gtctttcaga	gactaaagag	tggcatccat	ctcctgaaac	144960
tccttcccca	gctgacagct	ggtgaccctg	ggaggaggga	gcttcaggga	gcctgatggg	145020
cgagagtctg	ttccaatgcc	aatccattgg	aagagatgaa	gtcagaccgg	agtttgatag	145080
aaagcctact	tcttcccttg	tatccagctg	tggagacct	ccaacatcaa	tgcaaaccag	145140
aagctaacac	ccagttcata	tatcccaagt	ggaaggaaag	ttctcgtgga	attgtcttac	145200
atgacagtaa	cataaatcct	gaaggtaata	cttgggcagg	taatgttaga	aaagaacccg	145260
aacataggca	ttgctattat	agatccctagg	ataggcctga	gcaaaaaact	tctgggattc	145320
ataacatgct	tctgttgaat	ctgatagagg	gagttagatc	cactccaaat	ggagtctgat	145380
ttggggcaaa	gcaaagagta	tggaaaggaaa	cttgagaaaag	ggggacagct	tctcaaatgg	145440
agtctggcca	cagctggggc	tggaaaagag	acatgactgc	gcttgacagag	tggtgagaat	145500
ttgctgctag	aatttttaag	ttgtgtgttt	tcatttttat	gataatgtaa	actgagataa	145560
gcatattctc	tgtatcccca	atgagcccc	cctctaggag	gactaccttg	ccaccttate	145620
cataaatgtg	tttataaatt	attttgatgc	cagctggtat	tttttaaaaa	gtggtttttg	145680
actcacaana	aaaaccatga	tggatttaat	acataacaaa	gcatttgtgt	caagtgaagg	145740
ccaagtaaca	tcttagcgct	ctgtgtgagc	gaagggtgtc	tggcagttca	aacaagaatg	145800
ccgatgaagc	tggccaggat	ggccaaggct	accttgggtg	gtttgagggg	aatttagagt	145860
tagaaaaaaa	aaaaaaggca	cctgacagcc	tgaactaatg	tggttacctg	gaattttggg	145920
gttttgaagc	tttgcattta	atttgcagct	tatggcctga	aggaaaagac	aggtgaaatg	145980
catatcctgg	gatgagtcac	ctggaggaga	gggctgggaa	ggggctgagc	tgacatgct	146040
cagatcttct	cccaggctta	tgcacccagt	gagtcagtc	ttcttccaac	gggatagagt	146100

gtgagagaga	gcagggaaca	gaagccagag	tctctgttaa	atttctcggt	acatttctgt	146160
tagagaatgg	aagtttctct	atcgtaggag	accttgagag	cctgggtag	aaattacccc	146220
tttgtcatgt	attttctctc	cagaaatagc	atggccactg	tcactgctaa	gctggagtat	146280
catgagcaca	atttctctca	ctttctatac	ccatgccttt	ctaggagatt	ggtggctcca	146340
tcaaaaagga	gttaaaaaga	agcagcacta	ttttgtggaa	tacaatcatc	accattatca	146400
ccatcagcac	caccaaccag	caccaccatt	atcaaaagca	ttcacctggt	gtctgcctta	146460
caaaactgcaa	actgcagtag	gtatttgtaa	tagaatgttt	cctttccccc	ttgggtagctg	146520
cagaaaagct	ggagaatggt	ttggtatcaa	cacactaggt	tgcattgcta	atcatgtgat	146580
ggccccatga	cagtctctgt	tggctgggtg	agttcagggtg	gacgactgca	ggattttgtt	146640
cttgggagcct	cagttctgac	tgggcttggg	gtgtaaaagg	tttgggagcc	agatgacaag	146700
agtatttgat	gggtagaata	atgggttcat	ccaaaagatc	accagaatgg	ttattaaata	146760
gtacaaagga	ggaatttact	ggtaatacca	gtttgcaaac	agagaagaga	gtctccaatg	146820
tggactgaaa	gtgctctctc	tttgaagagg	ggaaggacag	attgggtttt	atgcctcaca	146880
ggactggtag	catacatatt	cagcagggtt	ttggggaaaa	tctatacata	tttataaggt	146940
gagctgatgc	ctgcataata	gataaacata	tatgtaacat	acttttcata	ttcatttttg	147000
gactgggttt	tggcactaaa	atttgtggaa	tttggctcct	tatgttaaaa	ggtgaactag	147060
aggacacaaa	gacgggttgt	gtgcaccctc	tataaactgg	ctgaaactgg	cttaaggtct	147120
gcaactgcct	atccaaaag	aatgtttgta	agggcaggcc	tctgtccagt	cagagttgta	147180
gtggtccagg	ttgtaaatca	actttttatg	ctctttttgt	tagagagttc	agctgtagga	147240
atttagaaat	ttgccatgcc	tgccaggccc	tgaacctttg	acccataggt	aactttatct	147300
ccttaacctt	agggctcagtc	ttagttgata	tggggcatct	attctgggtat	ctcagatcct	147360
atgggtcaaga	gaaaagatcc	tccacaagag	ggctcctatgt	ggctgcaaaa	actgctctga	147420
gctaaatcca	ctcaaaatca	ctgcaggatg	tcactactag	aaaatagggc	agggataggg	147480
atccccctcc	catgctgcca	gaaaatgcct	gatagcttac	ctccccggc	ccttgaggct	147540
cccttggaa	aggcacatgc	aatccccatc	ccaccaata	gagcttgtcc	tagagctcag	147600
ttttttccca	tagttttccc	acccacttgc	accagaaaat	ctaataaagt	catgtgatta	147660
atacaattca	ttttatcacg	cttctgaaga	tttaagagag	agcggtcaca	ttggattcca	147720
cagtaccgac	cttctgacga	ttcttcattt	cacctttatc	tatttttatt	tttattttat	147780
ttttttttcg	agacggggtc	tcactctgtc	acccaggctg	gagtgcagtg	gggcaattac	147840
ggctcactgc	aacctctgcc	ttctgtgtc	aagcaatcct	cccacctcag	cctcccaagt	147900
agctgggagc	ataggtgcac	atcaccaagc	ctggctaat	ttttgtattt	ttggtagaga	147960
tgggggttca	ccatgttgcc	caggctggtc	ttgaacttct	gagctcaagt	gatctgcca	148020
ccatagcctc	ccaaagtgt	gggattactc	acgtgagcca	cctcgccctg	tccctttcac	148080
ctttattate	tttgccctta	actctagtgc	ttcctccctg	aatcagttaa	ggattgcatt	148140
tggctgcatt	aacagaaacc	tgactgcaga	agcttaacca	aatagggtag	tttttaaaga	148200
gagattcact	acatcacgca	aattgcacaa	attttaagt	catagttcaa	tgagttttga	148260
caaattgtaga	ataacatagc	tatataaaac	cattccatca	aaaaaatttt	atcaccatag	148320
gaaatttgtgt	cctgtccctt	tcttgtcaat	cccaactcct	ccccacaagg	caaccttcat	148380
tctcatttct	ctcaccatag	cttagtttta	catgtttcta	taatacagca	tcatataaat	148440
ggaataatac	agaatgcaat	cttttgtatg	aagcttcctt	tggctcaatg	taatgtttat	148500
gagattcact	catgtttatt	aatgtatcag	tagtgttttc	atttatattt	cctagtgttc	148560
tattgaataa	atataactaca	atttgtttat	ccacttattt	gttgatgaac	atttgaccg	148620
ttggcaattt	ttgacctatta	tgcataaagc	tgttaaaaaa	cattcttgta	caagtcttc	148680
atttcatatg	tttttctttt	tctgaggtaa	ataactacaa	gtagaattgt	tgggtaataa	148740
ataggcatcc	atctaataat	ataagcaact	gcacaacagt	ttttcaacgt	ggctgtacta	148800
tttcaactct	ccaatagcaa	cgtatgtgtt	ttccagctac	tccacatgct	cactggcatt	148860
tctgtttgcc	agtttaaaca	tttcagccat	tccagtggat	atgaaatctc	tctggctata	148920
ataattgtat	ttctctgatg	actaattatg	tcaagccctc	tttcaaatgc	ttatcagcca	148980
cttctatact	gtcctctgtg	acatgtccgt	tcaacttttt	tgtctattct	ttaaaaacat	149040
tgggttgttt	gtctttttct	tagtttgtct	tttgcttttc	atttatagga	gtacatatct	149100
tcggaataca	agtcctttgt	cagataaatg	tatttgtaat	aattttctcc	tagtttgtgg	149160
tttgcccttt	cacattctta	atatcttttg	atgagtggaa	actaactttc	aaattatgtt	149220
cagtagatta	acttgttttt	gttttgtttt	gttttgtttt	ttgtttttaa	cactgggtct	149280
cacttgttgc	ccaggctgga	gtgtagtgg	gccatcatgg	ctcactgcaa	cctctgcctc	149340
ctggactcaa	gggactctcc	tgcctcagcc	tcccaagtag	ctgggaccac	aagcacgcac	149400
cactacactt	ggctactttt	ttatattttt	ggtagacaca	ggatttcgcc	atgttgctca	149460
ggctgggtctg	gagctcctga	gctcaagcga	ttcaccacc	tcagcctacc	aaagtgtctg	149520
gattacaggg	gtgagccacc	acgcccagtc	gagtagatca	agtttttaatt	ttatggccag	149580
tagagatcta	tttcaaggct	ctctattttg	ttctgttgct	ctatttatct	acctttatgc	149640
caattttctt	ctcttttgat	tcagatagg	ttataataat	aattattttt	tccagggatt	149700
agatggacca	gggtgtgtga	agttgttcaa	gggagtgatc	aagagcctgg	ctcctttcat	149760
ccttctgttc	catctccttt	ggctcatgga	ttttgttttc	caagtggcaa	gatggcgctt	149820
ccacctttgg	tatcctatct	tagttcctgg	cagaaagaaa	ggaacaggct	aatggccctg	149880

atgagtctac	ccccttttaa	caggagaaaa	tttaaaaaac	aaaaaccatg	aaaccctttc	149940
ccagaggcaa	caaccagaat	tccattttatc	tttcattgac	cagaacagac	cacatggtca	150000
ctgggtggg	caatggagac	tggggagatg	aataattttta	aggtggcata	ttccagaaga	150060
acactgtgca	ctgattgcat	taatgaaccc	attaatgtgc	caaggggagg	tttacctatg	150120
agcatgggca	aattagaacc	cactcttgga	gctgcagggtg	agccaatccc	acctaaacag	150180
tgtggatgct	acaagatggg	gaagtaaatt	gattctattc	cataccctaa	cctctctcca	150240
agatgtattc	ttaaaataga	agaggggaaga	cagaagaaaa	catccagaat	atatttttat	150300
tgtcttttac	ttcttcagtg	catttttagat	cagtgtcttct	caatctggca	aggggcatgc	150360
aggaggatgt	gagttttatc	aggaaaacta	cacaaccccc	caaccacaat	gctaccccca	150420
ctcctgtgga	ccttcttttaa	gagagactca	ctattataga	tggagtgtgat	acgatttttaa	150480
gagaggccat	atattatttg	ctttctgtct	tgaaaaaactt	gtgatttttc	tgtattgtgc	150540
tactgccaaa	gagaatagaa	acctgactga	gggtgtcaatg	tttatgtaac	tgatttcatg	150600
tactttctgt	agttctacca	tttctgatgg	ttaaaaattt	cttgtgtgtg	tgcagttggg	150660
gagtgtgtcc	tcctccttct	gctcttatac	cacacattag	cacatcaaaa	tgctctaattc	150720
tttgtatgat	tatgtggcat	gtggtgatgc	agcctcacag	tggaaaaact	tctcttgggc	150780
cattgcaaat	gtaacatttc	tttcaatcag	atagtgccat	taaggatttc	attatggccg	150840
tcacatcctg	tgacatctct	aaacatgcag	cattagggcc	taagtgcagc	cctgcaggta	150900
gagtggccag	gtttaacaaa	taaaaattac	acgctggcca	ggcggggtgg	ctcatgctcg	150960
taatcccagc	actttgggag	gctgaggcag	gtggatcatt	tgaggtcagg	agttcgaaac	151020
cagcctggcc	aacatggtga	aaccccatct	ctactaaaaa	tacaaaaatt	agctgggcat	151080
gggtggcaaat	gcctgtaatc	ctagctactt	gcgaggctga	ggcaggagaa	tcacttgagc	151140
cctggaggcg	gggggtgcag	tgagcagaga	tcacaccatt	gcactccagc	ctgggtggca	151200
gagcgagatt	ctgtctaaaa	aacaacaccg	tatttggggc	atgctgatac	taaaaaatta	151260
tttctgtttt	gtctgaaatt	aaaatttaaa	ttggggggccc	tgtattttac	tgggcaaccc	151320
atlttgcaata	tcagcaacaa	tctcttattc	agaccactga	ttaagtgtgc	aaaatttgaa	151380
tctctgaaca	gtacctatgt	ccttgatatc	ttaaattaat	gagtgtctta	gacactcaaa	151440
gcaggaggaa	gcattatggc	agatgtttga	gccccagaga	tgtccatgag	cacagcatag	151500
agctcagagc	cttctttatt	atlttgcttca	cgacagagca	aaggactgca	gcaggttgac	151560
tgatataaaa	gttttaccat	gtctcacagc	aggcctttgc	tcaagtttcc	agtaaggata	151620
ttgtatcatt	tcttgectgc	agtacttgta	aatccactta	cactgcctgc	tgttgagtca	151680
ttgttttctg	cttgagtagc	atgtcatcct	tgttccataga	agatagttag	tttagagaca	151740
gtagccaagc	aacagcagag	cagcctcaac	caaaaacgatt	ttccattttg	gtgggatgaa	151800
ttgaaacaca	agcatcttct	atccagggga	gatttgggga	tcataaagaa	tcaatctgag	151860
ctggtaccac	catattggct	gctgcatttt	ctagagttgc	cgtaactagt	ctcacaaagt	151920
gggagggttt	acacaacaga	catgtattgt	ctcatagttc	tggatgctag	aaatctggaa	151980
tcaaggctcc	aggggagaag	ctgctccatg	gttttctctt	agcttctggt	gttgccagca	152040
atccctgggtg	ttccttggcc	cgcaggcgga	tactcccat	ctctgcctcc	attgtcacac	152100
ggcatttttcc	cagtgtgcct	gactctgtgt	ttcttctcat	aagaacatcg	gtcatattgg	152160
attacaggcc	cgtgtactc	cattatgacc	tcactttaac	ttaaacaatt	acatctgcag	152220
tgatcctgtt	tgcaaataag	gtcacattct	gagggtccag	gaattagaac	atagacatat	152280
ctttttgggaa	caaaaattcca	gtgataaacg	tttcggagac	agactagtcc	tggagtttltg	152340
aaggtgagca	aggaccaagg	tgccaggatt	ctcattttgt	aagggtccagg	aacaaagtga	152400
tgttaataga	aagaacatgt	ttttgtttgt	ttattttgtt	ttgagacagt	ctcactccat	152460
caccacaggct	ggaatgcagt	ggtacaatct	cggctcactg	ccgctgccat	ctcccagggt	152520
caagcgattc	tectgcctca	gcctcctaag	tagctggaat	tacagggtgtg	tcccaccatg	152580
cccagctaat	ttttgtatat	ttgtgtgtgt	gtgtgtgtgt	atatatatac	acacacacat	152640
acatacatat	atatacatat	atataatata	acacacacac	acataatata	atatataaaa	152700
tatatatttc	ttttagttaga	gactgggttt	cacctgttg	cccaggctgg	tctcgaactc	152760
ctgcgctcaa	gtgatccacc	tgtcttgga	tccttaagt	gtgggactac	aggcacaac	152820
caccacgccc	agacagaagg	aatatgtttc	cttccagtct	cacttgactg	gctgcttccc	152880
tagataacaa	cagaggatgt	ctggtgcagt	tctcattgct	ggggagtcta	aactggaata	152940
aaacacccac	tatctccatc	aggcttgca	tagagcccag	ctctagctgg	agagaaagaa	153000
gctaaccgcg	acagacacag	gactgtaggc	agggagcatc	cgggggtatt	tgggtcctgg	153060
ctctgatgtg	cctaaggcca	acttctctct	ggccatgctg	gcgtgcatga	gctcactaat	153120
cttctctttt	gccttccatt	ttctccaatc	ctgacttagc	aaagggtggg	caaaagagac	153180
tctgtgtgag	ttcgagcaaa	gcctgagatg	ctggattttc	caagatacga	gaaggggctg	153240
ggggctgggt	gaactggtgg	tggaggagg	aaggattaat	ttccaaggga	ggggaagggg	153300
cgaggacatc	aggccccggg	gactttgaag	agagggtcgt	gggtaggagg	tagatcaagt	153360
ggagtgcac	aaaggtcagg	aaagaggaag	gtgccacact	gtccttcgac	agacttgagt	153420
ctctgggact	tcctcctgc	acgggtacaag	gaaatgagta	agtgcagata	tgttgtaact	153480
tctggccctc	tgacattgca	ctgccccgat	gtcacagttg	gaaactgtac	ctgcccccat	153540
ccttgtctgg	gggtgtgttg	gtctggggag	ggctgggtgaa	gcaagaggtg	ctcagaaaaa	153600
ggacagaaat	tgcttctcat	tatctgggca	tttggagggtg	aaggggtcac	agctctggca	153660



aagatgggggt	tgaaaggggcc	cggactccag	ggagggggcag	ctctgcatgg	cctgattcct	153720
gcacccacc	tttccccct	cacacctcct	ctcatctccc	gtttttgaag	aggaggaccc	153780
tgacacatct	ggacaattct	gcaagaactc	tgtagaactg	acttcactgt	gaaccaggct	153840
ccagaagtca	acagaaacaa	aatgctcac	atttaatcac	gatgctccct	ggcatacaca	153900
gaagactctg	aaaactttctg	aatttgggaa	atcctttggc	accttggggc	acattgggaa	153960
cataagccat	cagtgtggt	gtgtgtgtgt	gtgcgcgcac	acgcgcgtgt	gtgtgcatct	154020
tctaccatgc	ctcctacaaa	tttgacctgg	gcccaggggc	atgttcggtg	gtttttaaga	154080
accgaggctc	ccagaagcag	tattggggcag	ctagagtggc	cccaggatct	atatcaaact	154140
ctacctgttt	ctgaacccaaa	tttcttctag	aattttattc	cataaatctg	aattatggtg	154200
tcagactcct	agcatacact	aaaggaactc	tctgccttgc	attaaataac	aggagttacc	154260
cctggaggta	actcctagcc	ctggctcttt	agagaacaga	tgccgaatag	gcattagggg	154320
atgtgatgga	tgtgctaact	ttcaaaaaaa	aaaaaaaaaa	aaggcctgag	ctgagtgtct	154380
agagattcac	aaaaagctga	cagcatctct	ctgttccatt	ggaagctggg	tgatcctttc	154440
tactctttcc	tgagaaaggc	agttgggcag	gaaaaagctg	tatctctgtc	ctcactgaga	154500
gggtttccca	gtctgagggt	gaaggatcag	gagagggaga	cctgacgggt	cgatgtgggg	154560
catcatccac	ttgagtgaga	accagagggg	tcccgtcatt	gcccagggca	gatgtctccat	154620
tttggggggc	atcattcatt	ctttcctgtt	ctccctgcac	tcctctggct	cctgcccagg	154680
agaggtggcc	gctggcaaga	gagcttgggt	gaggtgggag	gtgggagggtg	gggggtgggg	154740
gggtggggagt	tcttgagcca	ggacctagcg	catagctctc	agcctgctga	tggctgtctt	154800
ggatgcttca	aaggggagaa	gatacctagat	gtgggaaaca	ttggtgggcg	ttctgtctgg	154860
gcactctgtag	cctctgagaa	ggctaccagt	ctctcctaag	cttacgccgt	cacacctgtg	154920
gcacttggtg	aatgacttta	cttagcttac	agcctctggt	tcctgttggg	aaacttaggg	154980
cttgccacag	tgttcatttt	cctttgctgg	caactccgtt	cctggcactt	atcatattac	155040
ccactgtact	ccccgcttag	agctgtgtca	aggttctgag	aatctatccc	ttggcttgga	155100
aggggtcatc	tctctggcca	gatcatcttc	tgataggctc	tgaggcacca	caacacatag	155160
gaggcttgct	ctctctctgg	ggttcactgc	cttgctcctt	ctccagggtca	atatgtgacc	155220
ttggaccggt	tgttgagtc	ccctggctcat	tcagaaacaa	ttgggtttcc	ctggctttgg	155280
agcctggcag	cctggctttg	agaaccgggc	tttaacttgt	cacatgacta	tggccaagt	155340
cctggggctc	tccaagcttc	acttccctctg	taaaaagggc	aataatataa	tacctgtctt	155400
attgggtttt	gtccatgtta	gatgagacat	tgggtacaaa	gcacttggtc	ccgtgcctgg	155460
cacatttact	gcacttaatg	tatgatagtt	ttcttattat	tctaataaac	aatatggctt	155520
tgggagtata	gttctgccac	attgcagtgg	ccagagtga	ggtggtgagt	gccttctggg	155580
gccctgggag	tcaaggttat	ccgcatgccc	tttcttgctt	gctcctcagt	gtggctgcct	155640
ctatgtccac	accatgcaga	tgaacacagg	agtttgaaac	tctgaggccc	acagtgggat	155700
ggggaggcag	ggacatcact	tatgggggtg	gaagtcaacc	attccccagg	aatggcccc	155760
agctgctttt	tccatgaact	ctcttgaac	cctgtggagg	ccacalctgt	gttggggcgg	155820
tctttcccat	gaggatatgt	tcagatggcg	agggattttg	aaaagccctc	catagagttt	155880
cctttcataa	cacatgatca	tccccctggg	cttctgggtt	tttttctttc	aggaccttat	155940
tttcaggcaa	gtggcctttg	acctctaagg	ctgtcctttc	ctagctaccg	aatccagcat	156000
tcaaagtgat	ggaaatatgt	atatatagta	atagtaaaat	atcagcactt	aatggcctga	156060
taagaatgtc	actgcaatgc	tgagtttgga	ccaacatttg	cctgctcctg	ccattgagcc	156120
cgggctcccc	tccagactcg	agctgtgtga	agggatctga	gtaactaggg	ctgtgtcaga	156180
gtggcgatga	cagccaccac	atgctaagga	agagacccc	aaggacaagg	agaatccac	156240
gtggagctac	ttgcttcttt	gtcagtcttg	tttttcttat	ttcacaacct	tctaaaacac	156300
aatctctcaa	cctctattgt	tagcttgcat	ttttcaatca	tgagcacagc	tttacctgge	156360
tccatgcttt	gattgactct	acctgccaac	actgcaacaa	cagggaagg	gacaccggcc	156420
tcataccatt	agatggtgtg	tagcctgggc	atgaggataa	ttaaaaactc	ccaaggggat	156480
tttaacatgt	aacacagttt	ggaaaccatt	gatgtaagat	cttcttactc	aacatgtgtt	156540
ccaaggagct	gttgtatcag	cttatcagaa	atgtagatca	ggccgcactt	ggacctgtag	156600
aatcagaatc	tgcattttat	cagattccga	cattatttgt	atgaacatta	gcttttgaga	156660
agtgttgctt	taagagacta	aggggggtcaa	tctacctcac	tttgagctc	tgtgttccct	156720
agtcattggc	taaaatatca	gccccccctgc	aatgagccat	cctcccttgt	atagtcatgt	156780
atggcctgtg	aaccttttagc	caactggaag	tgggagggga	cacagtccac	aaaacactat	156840
cctgactttt	gacaccaact	acaagtcaag	gggttcccca	aaccaccctg	agttgtgata	156900
attcgctggg	agatctgaca	gaactcactg	aagggtgtta	tactcatggt	tgtgatctct	156960
tataggggagg	gaatacagat	taaaatcagc	caaaggaaga	agcacacagc	acagagtcca	157020
ggacagtgcc	tgacatggag	ccccacgggt	cctctcccg	ggagtacagg	acagcgccac	157080
tctcctggca	ttgatgtgtg	acaacacaca	gggagtgttc	cccaccaggg	aagccttggt	157140
gtccagggtc	tttactgtgg	ctctgtcaca	tgactcacagc	tgactgcccc	tgcggccgat	157200
cgtttccag	actctccacc	gctacacatc	actcacagtc	cctgctctaa	atcacacacc	157260
atgacccaat	gtccccgggc	aaatgaaaac	acctctagca	ggcaggacgt	tccaaagcct	157320
tagagatcac	ctctcagaag	ctgagggcag	aagccagacc	tctttttggg	caggggtaaa	157380
ttctttatta	ctgtttttga	aaaaactccc	aaattgagtt	tttctcttct	acttacagca	157440

gcataacaac	aatcatcaat	gcagaagact	tctgcgagca	aaggtgtggg	ggaaaacccc	157500
aagcagtggg	cactagctgg	tgtcctccaa	tttgattctg	atgctgtcta	ctgggagata	157560
gtgtcagatc	ctcaagccta	aaccctcctt	ctcccagtc	gagggctggc	ctttggaact	157620
tctgaccaat	ccacttcaag	ttgaggttcc	aaccactccg	ctctttgggt	ttgggttgatt	157680
tgctagagtg	gctcacagaa	ctcagggaaa	cacagctacc	agttttattgc	gaaggacatt	157740
ttaaaggata	aaagtaggca	gataaagaga	tgcatagggc	gaggtgtgga	aaggtcccta	157800
gtgcaggagc	ttctgtccat	gtggagcggg	ggtgcaccac	cctctcagta	catgaatgag	157860
ttctccttca	cctgcctatc	agcctctaca	tgttcagctc	cccaacccag	tcctcttggg	157920
tttttatgga	agcttcaaga	caccacacatt	ctttccccag	agtatagggc	aagaccttct	157980
ctggggaggg	ttttaagacc	cacagtcaga	aaggtggggg	ggggtcaaga	ttagagtect	158040
gccttgacgg	gcaggtgaaa	ggggtagggg	gagtaggtga	gaaaaattct	gtttatTTTT	158100
tctttttttt	tttgagacgg	agtttctctc	ttgttgccca	gggtggagtg	caatggcaca	158160
atctcagctc	actgcaacct	ccgcctccca	ggtttaagcg	attctcctgc	ctcagcctcc	158220
cgagtagctg	ggattacagg	cgtgtgccac	catgcctggc	taattttgta	tttttaatat	158280
agacaggggt	tctccatggt	ggtcaggctg	gtctcaaaact	cctgacctca	ggtgatccac	158340
ttgcctcagc	ctcccaaagt	gctgggatca	caggtgtgag	ccactgcatc	tggccaaaag	158400
attctgtttt	tgaggcctgc	ctctgaggtc	taacacactc	aacattataa	caagactgta	158460
gtaagggcta	tgggagttat	gagccaggaa	ctgtggatga	aaacctatca	cagatatgca	158520
tatatatata	tatatatata	tatgcataat	tataataact	ccacaactac	acactgcctt	158580
attgctcagt	tcttctctcc	atgtctctga	cccaccttgc	cccccttctc	ccatcctttt	158640
ctccattgca	tacctatcca	ctgtgccctt	tggaaatgctc	acaccatgaa	ctgcaaactc	158700
tcgtgtggct	tcagcctctt	ctctgaaagt	tcctctcacc	tattactttc	tctggaacct	158760
gccatccctg	ccacctttct	aaaaaaggcc	ttttattctc	ttcattccac	aaagctcagt	158820
gtcaaaaact	ggggtttaca	ctggaagctg	aggtcacatc	agtagccggg	atcagggctg	158880
ccctagctgc	ccaatgcagc	tccaggcctc	cctgtaaaac	cttgaccttt	gaggtcatga	158940
cagccctctc	ctgctatgct	catagctgac	cactgaactc	ctggacactc	cctcccccaa	159000
gttcacagag	aatgtgggca	catgccttac	agtcttccct	tgatccaaac	tactgccttc	159060
atcttgagtg	acagcagcat	cttttggaatg	tcttggcctg	tctagcttta	tttttttgtg	159120
ttctgccatc	aagttgctac	ttctgttgcc	atcgtgcctg	tcagcgcagt	gcaggtctgt	159180
gtgaaatccc	acgaactcag	gcatacacat	gaccgggtct	gagtcctgtc	tcagttgtca	159240
gctagttgtg	caatgaaggg	aaagggacct	acactttcca	agcctcaatt	cactcatcta	159300
tggcatgggtg	acaataatgg	aggttgattt	aaagtccctt	gtaagaatta	agagttataa	159360
tagacataaa	gtgctgtatc	tggatatacct	agaaaacatt	ccataaaaagt	tagtaattgt	159420
tggatcatgta	atgatgactc	tctaggctag	gatttcagct	tcattgcatg	cacatgggtc	159480
actcacaggg	cgtgaacctc	ctctgtctca	gtaacctcat	ctgaggaccg	ggataaatcat	159540
accgcttcaa	agggatgtca	taaagattaa	ataatatgtg	taaggctgct	tgcatttagc	159600
tgcattcaac	aaatctttct	gtatctttct	cctcatcttc	ccttactttc	ttgcttatta	159660
tctgctctag	gtatagattt	cagagaacta	agcttggttac	aatccttcat	aaaataacca	159720
ggttgggttag	ggcatttcca	agagtcaata	ctgttttagtg	actattctct	gtttaatcta	159780
ttttgattgt	ccaggggtcat	cttttgctat	gtcataggtt	gttggcttct	tctagagaag	159840
tgagacgatg	gacaagtctc	aagtgaagtga	ggcgactggg	caggatattc	cgctgaaaaa	159900
tcatgttcag	ttctaattcg	tgattgtaat	tcaatcacag	cctgagaaca	gtaggactgt	159960
agttcaaatg	ctctgttccc	tttttttttt	cccagaggat	aatttttttt	tttcttttag	160020
atggagtctt	gctctgtcac	taggctggag	tgcagtggcg	tgatctcggc	tcactgcaac	160080
ctccgcctcc	tgggttcaag	caattctcct	gcctcagcct	ccaagtagc	tgggactaca	160140
ggcacatgcc	accacgcccc	gataattttc	gtatttttag	tagagacggg	gtttccctt	160200
gttggccagg	gtggtcttga	tctcttgacc	tcatgatccg	cccacctcgg	cctcccaaag	160260
tgtgtggatt	acagggctga	gccaccgcgc	cgggcctcta	gaggataatt	tttaaatgtg	160320
cttttgcaat	tggaaaaatg	gattggcatt	tttttcta	tttctaata	gatacgctgt	160380
cggatgctat	ggattactta	aacctctggg	ctacctagaa	agatcttta	gtggttctca	160440
acaagcttca	tacgcaatgt	aaattgtatt	atctctcagg	atgtgtgaga	acatctgttt	160500
ttcttcta	gcagtaaa	tataaggggc	tcttgggata	tcttttaaat	agacttaata	160560
caacattcag	gaatgataac	aaaatataat	cacagttgta	agggaaatgtg	agcatttcat	160620
attaataaca	ttggaacctt	atgtttaata	cagtgttaaa	agttgacaaa	catgtaggag	160680
tcagaaaatt	caattaaaat	tatcacagta	atatgaattt	agccacatcc	tgtgttagtt	160740
atgaaatcca	tttaacacca	caaacagtaa	tatttttagc	cagtttatct	aaaaggaaaa	160800
caggaactaa	accactttca	tgcaatatat	actctgttaa	tgtggtcagg	ctaattttgc	160860
tgggggaagg	aacttaactt	ttgaatat	gaatgccag	tcatttaatc	tgaatatcct	160920
atttctctgc	atgttgcaaa	atttttgtca	ataaaaggca	gaaaaagaaa	tctcttctcc	160980
atgctcatcc	ctaagaaatc	gggtgtgtcg	taccctgaga	gcatttttatg	gaggggacaa	161040
ccacttttct	aattttctct	cccacttctc	tgtgggcaca	aatgctcttt	ggttgaaaga	161100
gttgtaattc	agtcccaaga	tgaggtgtgg	ttactgcac	cctaacctat	atctggggac	161160
cccacagcca	cacacatggg	ggaaatggag	cttgtcattc	agttctccag	ccattgcaca	161220



gggttcatgg	actcttcggt	gatccacccc	cacgcttctt	ctctctgcta	gccgaacaca	161280
cttctctctt	ctttatcagg	aggccatagg	agaaggggcat	tcatttttaa	tacacataca	161340
tctgcatcaa	gtctaatttt	gccatgtctc	aatccaactg	tcaaattgggt	tgtttggggg	161400
ctatgggtgct	tatcaaacat	ttactcaaga	atagccaaaa	ttagccaagc	aaggagaact	161460
tcagcaacgt	ccccaaatgg	ccccaaccaa	gtactgttaag	actgaggata	gctaaagggg	161520
cttgagaggg	acttctcagg	cagtggcccc	gacatttatc	tgttttttta	agtgagaaat	161580
ctgagtacca	ttcttgactc	ctcttcctta	cccccaacc	ctcactaagc	cttgtgctac	161640
tatttagtaa	acagaccctc	aatgcacaaa	cttctgtcta	aggccatggc	caccacccta	161700
gtctaatacca	ccatctcttc	tctggaacag	accccagctg	ctctccctgt	ctctgtgctg	161760
gtctctcaat	ccatgctcca	cactgcagcc	agagtgtctc	acaatgcaaa	tccatttgtg	161820
agactcctcc	tcttaaaaatc	ctcaagtggc	ttctctttgc	ccccaggatc	attttgaaac	161880
tccttaaatgg	aagaggcatg	gccctttggg	atgtgggtcc	ccaacccctc	ccacatcatc	161940
tttccaatca	gatttcccac	taaatggaaa	ttttttcagg	tcctcaactt	tatggtagact	162000
ttctcttgct	caggatcttt	gaacataactg	tttctctttt	ccttttgtat	ttgccaaagc	162060
aacacttctc	ctggtaagat	tttcttgaca	tcctctataa	aaaaagattg	agatagttga	162120
ctacccaaaa	tgtttcccat	tcattccaag	ctctattcaa	ggcagtaaag	tgcccggctg	162180
acagattgca	ttcctcatct	tttctgaagc	tagcaatggc	catgcaacag	cattctggcc	162240
aataagatag	aagtccaagt	tgaagggtgg	gatttccaag	aaagctcgtt	gaagacataa	162300
ttcctcattt	cacttcttac	tccttctctt	tctgtcttcc	taaaatgcgg	tgcagatggc	162360
agacacttca	aagctgtctc	aggcaatcag	gtgatgttaa	ggcagaaacc	agctttatga	162420
tgggtagaac	aggaagaaag	aaggcaccta	tggtcttggt	caccttgaac	cacaccagca	162480
ctgccttgcc	tacccctgga	attcctttta	tgagaggcaa	atgagagctt	acgtgtttta	162540
gccattgcta	ttttattttt	ttttgtttat	atgcaaaaga	acttaatcct	aactgatatt	162600
aacactaact	gggtctattg	cttggtacca	agccaatgca	tgacacatgg	tatatatgct	162660
cagtaagtat	ttggtgaatg	agtgaggcaa	tgaagaaca	tagaggatat	atataacagt	162720
cctcctgccc	agatgtcatc	tgatcctctt	taggatctgg	gcccataaaa	ctgtatctga	162780
tatagtttga	atatttggtc	cctacaaatc	tcatgttgac	attttatccc	taatattgga	162840
ggcagggcct	agtagggagt	gttttggtca	tagtgataaa	tggcttggtg	cgttctcac	162900
agtaacgagt	gagtttttat	tctagtgttt	cctgcaagaa	ctgattgtta	aaagagcttg	162960
gactcctcca	ccccctctc	actcttgctt	cctctctctc	accttgtaat	ctctacaagc	163020
tttccactc	cccttctctt	tttgccataa	gtggaagatt	tctgaggcct	caccagaagc	163080
agatgttggt	tccatgcttc	ttgtacagcc	tgcaagaacca	tgagccaaat	caacttcttt	163140
tctttataat	tatccagtct	caggatattcc	tttatagcaa	cacaaatgga	ctaagacagt	163200
ttctaattgct	atgggttcctt	tagtaggtca	gtgtaaaacc	ctggatcact	cctgtaacaa	163260
attacttgga	actcttctca	ccatacatat	ttaaaaatag	ttgccatggt	gaaaatccta	163320
taagatcata	ttttatttca	aatccaacaa	ctcattgcta	aggagatata	agaagcagaa	163380
aatacacaga	gactaatgtg	ttgatgattt	ttgtgaggga	cataaggctc	gtgtctaagat	163440
tcattttttt	gcattgtggat	gtccagtgtg	tccagcacca	tttgttgaaa	agactatctt	163500
tgctccactg	tattgctttt	tctcctttgt	catagatata	tggtcacctt	accttagagt	163560
cacagatgaa	tggtcctatt	acttaactac	tgaaaatata	ggccaaagca	aacagaggaa	163620
taagggatata	ataataaagt	atltgtgtac	ttgacttgcc	tctaaaggaa	gcattgctg	163680
tctgtgtaaa	agaaatgggt	gagagttttc	caccattcaa	tatttctaata	ctttctgaaa	163740
tacaaagcca	gggacatctc	taatccatac	attccatagt	ttgggttaata	taaattcctt	163800
tattaaatcc	ttattaaata	aagttattta	tgtttctatg	aaactcattt	taactcctaa	163860
gtgaaaaata	ctactgagct	aactaaacat	caaacatttt	taatttttta	aattttttta	163920
gagacagggg	cttgctatgt	tgcccaggct	ggctttgaac	tcctgtgctc	aagcgatcct	163980
ccaaactcag	cctcccaggt	agctgggact	acaggtgcat	gccactgtgc	tcagctaaac	164040
atttttttga	aatgctcttt	taaaatcaat	tttattgaag	tataagttac	ataccataaa	164100
agtactcatt	ttgagtgtac	agattgacaa	gttttgacaa	atgtgaacaa	ccatgtaacc	164160
atcaccaaaa	ataaagatat	gagacatttc	cattacccca	aaaagtcccc	gtgtccctct	164220
ccagtcaata	tccagcccta	gccccagctc	caggcaacca	ccaatctgct	ttctgttgct	164280
ataaattgta	cttatctttt	ctagtgtttc	atacaaatgg	aatcatacag	catttactct	164340
tttgtgtctg	tcttcttctg	ctcagtgtaa	tgtttttgag	attcatctat	gttctgtgct	164400
tcagtagtgt	gttcttttta	ttactggata	attccattat	aagaatatac	cacaatttgt	164460
ttatccattt	actgcctgat	gggcattttg	ttgtttccag	ctttgaacta	ttttgaatcc	164520
taaaagactg	ccagttttga	atgagacccc	agaacaatga	atgtaggctc	tgtatacaag	164580
ttcaggctgc	tgggcaactt	aggccttaag	acacaactct	gccacttagg	ccttaagaca	164640
caactgacat	gatgggtgct	aaagtggctg	tgatggaaaa	ggaggctggt	tggagccttt	164700
ggagtgcctt	tataggtgaa	ccccagcata	gcacctaatg	atltggagca	aagctgtgtc	164760
attccccaaa	gataactatt	cgccctttga	gaaactcctt	ctagctacta	tcaataataa	164820
acacagaatg	catcaccatg	ggccaccgtg	ttgtcttttg	acctgagttt	ccattgtgaa	164880
caagagtcac	ttgatccaag	gcagaaagtt	gggtgcacac	agcagtgttc	catcatcaaa	164940
tggaatatga	gattggggcc	aagtaggtcc	tgacagacaca	aataagttgc	aagagcaagt	165000

agtacaggcg	cttggcctgg	ccagtactgt	tgccaagttg	actgcttccc	ctcagttctgc	165060
atctgtggct	tcatggggag	tttcctatga	ccacttgatg	gaggaaaaaa	caaattggag	165120
catagtttat	agtgttggt	ctacccaaag	tggttagctg	aggcactaca	tctccactct	165180
ggggtgccc	tgaaggacag	tgccaaagga	aaacccccctc	agtgagcaga	acttggagca	165240
atacaagtgg	gtgttcattt	tacctagaag	agaagatgtc	cgtgagttac	agatctacac	165300
aaaatcacag	agagtgggta	atcgtttagt	ctgatgggtca	gggacttcca	agagacatga	165360
ttagaaaact	ggtgacaagg	agtcctgggg	aagaggcata	tggatacctc	tgaacacaca	165420
caaaacatga	gaatatgtat	cccatatgaa	tggttaaccaa	agagcagcca	caacagaaga	165480
ggatttttaa	atcagctgaa	taagatgatt	cattctgaca	gcatcagcta	gtctctttcc	165540
ccagccactg	ttgcccagtg	ggcttacata	tatcatggcc	atgggggcag	ggctatgtat	165600
ggacacagca	acatgaattt	ccactcatca	aggccaattt	ggctccagcc	attgctgagt	165660
gctcagcctg	ccaagataga	aatctacgcc	aatatggcac	cattccctgg	gctagaaaac	165720
caactgggtg	aagggttgatt	acattggacc	atttccatca	tgggaagggg	agtgccttgt	165780
cttccctggg	atagacattt	actctggata	tggatgtgcc	ttccctgact	actacaatgc	165840
tctgccaaac	ctaccatcca	tgggcttaat	tttatttgtt	ataaaaatttc	aaccaccatt	165900
gcttctgacc	aaggaagtaa	tcttacagca	aaggaagtac	agatatgagc	ttctgatcat	165960
gggcttcact	ggcctcacag	tgaagcaggt	ggccagatta	gaacagtggg	atggatttta	166020
aaggctcagt	tacagcacca	gctgggtagc	aacaccctgc	tggcctgggg	ttatgtcctg	166080
caggatgctt	taagtcagtg	accaatatat	gatgtatttt	ctcccattgt	caggattcat	166140
gggtccaaga	atcatggggg	caaaatggga	gtggcttttc	tcactatcac	cctgggtgtt	166200
gggtagtaat	ttttccttcc	cattcctgta	actttgggct	ctgctattgc	agaaatctta	166260
gctcctgtgg	ggggaatgct	tccatcaggg	aatacaatgg	tggttccact	aaactgacag	166320
ctgagtttgc	catctcctcg	tgccagtgaa	tacacaagca	aggaaggggg	ttcctttctc	166380
acctagggtg	actgatccta	attaccaagg	agaaattgga	ctgccacttc	acaatgaggg	166440
tgaggagtat	gtactctatg	tgtctgtgat	taatgtcaat	agaaagtgc	accaacctag	166500
tacacagagg	actgatcatg	gtccaggccc	ttcaggaatg	aagatttgag	tcaccaggca	166560
aggaacttgg	actcactgag	gagggcatat	tccaaggaga	atattttatc	tatgtccatc	166620
tatgtccatc	tatattccat	ctgtgttccc	cttggaaattc	ctattcatga	acatggggaa	166680
ttccaagggg	aatatagaat	gagtagtgga	aggtagttat	aatgtaaagt	caaaaaccac	166740
acaaccaatt	tgagaaatga	ggaaggtaat	agtggtgaat	atgtcttctt	tatcttgata	166800
taaatgtatt	tgtgcatata	ttaaccagtt	tatttattta	ttattatttt	ttgagatgag	166860
ctctcgccat	gttggcccagg	ctggtcttga	actcctgggc	tcaactgatt	ctaccattta	166920
gtcctccgag	tagctgggac	tacaggcatg	caccaccata	cccagctgac	cagttttttc	166980
ctattcctct	acttaatttc	tctactatac	aacataatat	gtgttaatgg	tagttaactt	167040
tatatctcag	tattaagtca	caagatatca	aaaagggaat	gcgacttagt	tacaagcaga	167100
atgaatatca	ctcaaagatg	aataaagaga	agagggttag	tgcattttct	gttggatgag	167160
agaaagtttc	attgttaggc	agaagcatga	tttttcttct	tttttttttt	tccaagggtct	167220
cactctgtgg	cccaggctgc	agtgcagtg	tgcatctctg	gctcactaca	acctctgcct	167280
cccgggttca	agtgattctc	cagcctcagc	ctccagagta	gctgggatta	taggtgcgcc	167340
aggttaat	ttgtattttt	agtagagaag	gtgtttctcc	atgttggcca	ggctgggtct	167400
gaactcctgg	cctcaagtga	cccacctgct	ttgacctccc	aaagtgcag	gattacaggt	167460
gtgagccact	gtgcacagtc	accacggctc	ttttgggagg	caactttagc	atggttaaga	167520
gggtgcgaatg	gattgttaagc	taacaccagg	taagccctgg	tagatgtgta	ttgtgtcagt	167580
gggcctacgc	tggagccatg	tttccccaaa	ttcacttttc	ctatgtacct	ctggattagt	167640
gtgggcccact	ggagacattt	cacatgagat	gaggaaggtg	ggagtgaagg	agcagcatct	167700
ttttacacta	agcaggtcgg	ggagggcatg	tggctctgtc	tcacattggt	gggaatctgt	167760
ccatcatctg	gttggcttag	gtcagtggtg	gagttcacag	ctgttccagc	ttctgtctgga	167820
aactccttgc	gttctctagc	ctgctccgtg	atgagggcat	cagattctcc	tgcagaaagc	167880
cccagtggtg	aagttggggc	ttcatgttgg	tgagtgatag	ttacgggttc	tagcccaacc	167940
tgtgggttct	tgcaaatttc	agtgtcagct	cagtcttgcg	ggttttgggt	tgtccttgct	168000
tcccacactt	catgccttcc	tttccctcct	gacagtctgc	ccttttagatt	ttaggattca	168060
gcaccagcca	cagaaacagc	aacctcactg	ttaagggttg	aattgtatct	ccccaaaagg	168120
taggttgagg	ccctacctgc	caggacttca	gaatgtaacc	tcatctggga	atagcatcat	168180
tgcaaatata	attaattaa	atgagggcat	actggctcag	gatgggctcc	taattcaata	168240
caactaatgt	ccttctatga	cagccacagg	aagacagaaa	cgccaaggga	gaacaccata	168300
tgctgatgga	ggcagtgcca	gctgccagcc	aaggattata	accagaagtc	aggaaaaagc	168360
aagaaggaat	cctcccttag	tgattttaca	gggagcatag	ccctgctgac	accttgattt	168420
tggactttta	ttccccaaaa	ctgtaaaaca	atacacttct	gttgttttaa	gccactcagt	168480
ttgtgctact	ttgttatggc	aactccagaa	aacaaaaata	cactcagact	gtttaatcaa	168540
cctccataat	tgataaagg	ctaataccct	taataaatcc	cttaaaaatg	tctgtgtata	168600
tatatttaaa	aatataaaat	atcttctagt	ggttctgcat	ctctggtcaa	tccctgactg	168660
atacagaata	tgtattttca	tttctaata	tgaaatacct	gaatgaaatt	tctaggacat	168720
atggtaagtg	tatgttttag	ttttaagaaa	ctgccaactt	gggggaattg	cttgaggcca	168780

ggagttcaaa	cagcctgggt	aacagtgata	ccctgtctgt	acaaaataaa	aaatattagc	168840
agcgtgtggt	ggtgtgtgtc	tgtagtccca	gctactcagg	aggctgaggt	gggagattca	168900
cctgagccca	gatctttgaa	gttatagtga	gctatgatca	cgccactgca	ctctagcctg	168960
ggtgacagag	tgagaaagct	ggtctctaaa	aaacaaacaa	acaaaaaaga	aactgtcaaa	169020
ctcttcccaa	catggttgcca	tttttacatt	taccattttta	cattcttacc	agcaatgatt	169080
gatagttcca	gttgctccat	acccttgctg	accattccaa	tagatgtatt	gtgttatctc	169140
attgtagttc	taatttgtat	ttccctagtg	attaatgatg	tttaacatct	tttcatgcac	169200
ctattggcta	tatgtatata	ttcttttagca	aaatatatgt	tgttatttga	agagcgggaag	169260
ttttacattt	tgatgaagtc	taatttattg	attttttttt	tcttagatgg	ctcatgcttt	169320
ttgtgttatc	taaaaaaaat	ttgccttctt	catggtcaca	aagactttct	cctatgtttt	169380
cttttggaag	cttttatatt	ttagttttta	tgtttatgtt	taagacccat	ttctagttac	169440
aatttgtgtg	atttttttga	agggtcaagg	ttcattttct	tttcataaag	aatgtacagt	169500
tgttctagca	cccttgttaa	aaagactttc	ctttcccat	tgaactactt	tgtcaaaaat	169560
caactgagca	tatatgggca	tcatagaatt	taatcctgtt	agaactgaat	gttcccaagg	169620
caggccatgc	ccatgactga	cctcctttcc	ttggattgcc	tacaaaacag	ataaagctaa	169680
gtctggagca	aagaaatcca	tgtctaacct	gtattttttt	tttttttttt	ttagatgggg	169740
tctcgtctcg	tcacccaggc	tggagtgcag	tggcgtgatc	ccagctcact	gcaatctctg	169800
cctcctgggt	ctcagtgatt	ctcctgcctc	agcctccga	ggggctggga	ttgtaggcgt	169860
gcaccactat	gcccacttaa	tttttgtatt	tttagtagag	atagggtttt	gccatttttg	169920
ccagactgtc	ttgaactcct	gacctcaggt	gatctgcctg	cctcggcctc	ccacagtttt	169980
gtgattatag	gcatgagcca	ccgtgcccg	ccttaacctt	tgttttctta	cacaacacac	170040
tacgtgatgt	tttccacatg	catgggtcat	ttgcttcatt	tacgtacaaa	tgcataagca	170100
atatactgtg	tggtgtgagt	ttgtgatggg	aaaaggaaga	agttttgccg	atactacact	170160
ggcttctctg	tatctgtctg	tgtgaatggc	tatggacttt	gtcttctatt	tgttcgctta	170220
gcgcagatag	gatcagctta	caacttaaga	ttctagagaa	agagggtcat	atctgtaaag	170280
cactctgagc	atgtgtgaag	tttaatcaat	agcatatgag	gttacagcaa	attcactatc	170340
tttgtttctt	cagctataga	atggcatgag	gattcatctc	aatttagttc	aattctgttc	170400
agaaccatga	gctagctgtt	catgggaagg	aagcccacct	gattgtggcc	aggggaaggag	170460
aaacaacact	ttaaccagg	tgatttgggt	ctcacagaca	ccattggcat	gtgacatctg	170520
gaacagacca	tgcctggctc	ctgttcgtat	cacttactat	tcagctcaat	attggtctga	170580
atattcttta	gactgactga	aatgaaaagg	aactgttgtg	taaccatcca	taattccagg	170640
ctgtagacct	gggtgtgata	tctatgcctt	gcctggcaca	gacccacact	cctgctcctt	170700
ctccctcacc	accagtcaat	ccttgtctca	atgaacagg	agggcaaccc	tgaatgggga	170760
gtggagggaa	gagatgtcat	gagatggcaa	cgtgcacctt	gaagtggagg	tgaaggctat	170820
gtgaatgttg	taggctgaca	gccgggcata	gtggccccgt	tgccatggcg	atggaggcat	170880
ggttgctgga	agtgtctgca	cagctcctag	gatttttaac	agcagctggg	cagagcctcg	170940
gcgtccctga	attgttgccc	ccctgagtca	ctgcttgycc	ccagctgtcc	tgatctgtgc	171000
tgacaaatgg	ttgtccttca	cagtcaaaact	actaacagta	ctctaattaa	tgaatgtgct	171060
aattattctt	gcctactccc	agcatatttg	tctaactaac	ctgtcacaca	cagatcagtg	171120
cagcatatgc	ataattacgg	agagcgctgg	gagcagggga	tgggtgggag	aggggtgggc	171180
tgcgagccct	gtcgtgtgtg	gatatttctt	gtaaagttac	ctttgtctaac	ggtcagatgt	171240
cgtggggata	tgttatttcc	cgtgaagtgt	atatgtcttc	ctttctttcc	tttctaagaa	171300
tctctcttca	gggtgagggg	gccattgtct	agtgctttag	cctgtgaggg	gattgccagg	171360
tacaaatgca	gaaggaccag	ggagcccagg	ttctgaagac	gattccggta	gcagcacgta	171420
gggtgattaa	aactccagac	tttaaagcca	gaccggcctg	ggcttgaacc	cttgttctgc	171480
tccttgctat	gtgggtcttt	gccttgacca	catttttttt	ttttttttta	gacaggatct	171540
ccctctcttg	cccaggctgt	aatgcagtgt	tgcgatcaca	gctcactgaa	gcctccatct	171600
ctacagcctc	aagcgatcct	cctgcctcag	cccagagt ag	ctgggactac	aggtctgtgc	171660
caccacgtcc	agctaattta	cttttgtaga	gttgggggtc	ttgctatgtt	gccaggctg	171720
ttctccaact	cctggactca	agccatcttc	tagcctcggc	cttccaaagt	gctgggacta	171780
taggcgtgag	ccacgggtgcc	aggcccttga	ccacattttt	aacccctctg	aacctcagtt	171840
tcactttctg	ggcaatggga	gggggggtaat	ttgtccctca	gagggttgca	ctgaggggca	171900
aatgtgaggg	tctgggtaca	atgcccagta	cagactagg	ccccacgaca	cagccgctca	171960
gcggctccgg	attctgggct	gctctggact	gcggccaggc	ggtcttctgc	gggaatccgg	172020
gcaggcaggg	cgggtctgcg	tccctccccc	ggctctcccg	gtgccccttg	tctttttgtt	172080
ctgtctcagc	agctctctat	taagatgaat	ggcatttcca	aaggcttcac	ctctgataag	172140
tgttcctctg	cagctgcagc	cagaatctta	atgtgcgcgc	tgtaatttaa	tggccgtctc	172200
ggctattaac	acgtctctct	cgggtgaagt	ggactccctc	catccccggg	cctctgcacg	172260
tgctctgcgc	gctgggtggg	ggtgactcca	aggagctcag	agcgggggtg	ccggcacctc	172320
tcggcaggag	cctttcgacc	ttctaagcgt	cgaatggctg	gacttttctc	ccatgtgtgg	172380
ggccccagaa	ggtgtggggc	cccagaaggt	gtggggtccc	tgctttccac	ggagcccggg	172440
aggtttccag	tgatgggtggg	ggctgaccac	gttgggtccc	gtgggtgctg	ttttcatgtg	172500
ccggcagatt	gggatgagtt	taaaagacag	aagcgtgtag	gatagagaaa	cttcttttaa	172560

aactggaaat	tttaattctgg	ggattataac	tattggacag	tcaagtgcaa	gagtgaatac	172620
actttctcact	ccctcctccc	aattttttatt	tgccgggatta	gtcagtcctcc	ctctgccaca	172680
tgataattgt	gagaactacc	agggctcttca	ttctcctgcc	atctgggttga	cctctccaag	172740
aatggacacc	cgggcagcct	gggccaatga	ggctgtccta	agagttttaga	tgagagaagt	172800
cagtctttga	caggtgatgg	aagctgtaaa	atgtaaaact	ccacagttgg	tgaagatgtc	172860
tccaggaaac	aggtctgcag	agagaatacg	tttgacatgc	taagagaagc	tgagagagag	172920
cgagaggaga	gattggaaga	aagacagaga	cagaggtaga	gagaaggga	agagagagag	172980
aaagggacag	aagagagaga	aaaaagaggg	ggccgggcgc	ggtggctcac	gcctgtaatc	173040
tcagcacttt	gggaggccga	ggcgggcaga	tcacgaggtc	aggagatcga	gaccatcccg	173100
gctaacacgg	tgaaccccc	gtctctacta	aaaaatataa	aaaaaattag	ccaggcgtgg	173160
tggtgggtgc	ctgtagtccc	agctactgag	gaggtcgaga	caggagaatg	gcgtgaaccc	173220
gggaggcaga	gcttgcagtg	agctgagatc	gcgccactgc	actccagcct	gggcaacaga	173280
gcaagactcc	gtctcaaaaa	aaaaaaataa	aaagagagga	agggcgaggag	agagagagag	173340
agaaagctct	ctagctccaa	ggcctaacca	catctctgtt	cttttcaact	tcagctgtca	173400
gattttttaga	ctcttttgagt	gaataaatte	tccttttttgc	ttaaactagt	ttgagctaag	173460
tttctattgc	ttgcaactgg	aatactttgt	aagaggactg	gccttcattt	ctgatgcatt	173520
gtcactaaga	tgtaatgtgt	agaagagcta	acgctttatg	gggttcaaac	tccttggcta	173580
ccaaaacctt	aacatcccc	gaaacttacc	aaactgcagg	tatgaattgg	atctcactaa	173640
ggatgaatata	caaatcttgc	aagtgtgag	ccctaaccga	ctttgttaata	actctgtggt	173700
agttaatttt	atgtcaaat	gattgagcta	aaaaatgccc	aggtagctgg	taaaatgttt	173760
ttttctgggt	gtgttaggga	gggtgtttct	gaaagagatc	agcactggaa	tcagcggact	173820
aagtaagaa	ttcccacct	caccaatatg	gtgggtgtca	tcaatccact	gagggcctga	173880
atagaacaaa	aagcgggcag	aagggcaaat	tcctcttct	ctttgagctg	ggccatccat	173940
cttctcctgc	ccttggacac	tggagcccc	tggttctccag	cttttgatt	cagactgggt	174000
ccttgaccat	tgcctccat	cttctcctgc	ccttggacac	tggagccct	tggtctccag	174060
cttttgatt	cagactgggt	ccttgaccat	tgcctcctt	gatgctcagg	cctttgaatg	174120
cagactgggt	tcaccagca	gcttttctga	gtctccagct	tgagatggc	aaaccatgaa	174180
acttcatgg	gtccatgagc	atgtgaacca	atttctatta	taaatctgca	atatatatat	174240
atgaggagac	ttatttatat	attggttcag	tttctctgga	gagccttggc	taataataaag	174300
tctatactct	acaaagtgc	ctaggtactc	agggagtacc	caagtgtgtc	atgaccagcc	174360
cgacagcct	ggctgctggc	ttcccgcac	acaactctgc	acgctgcctt	catcagcctt	174420
tctctctcag	ctgaaccgag	ggcatggaag	cgggcctctg	gcactgtacc	tatgaggag	174480
caatatcttc	cctacactg	acctcttccg	tgccgagatg	cagcctctcc	tgctgccact	174540
agttacagt	gtccatgttc	cctttcaaa	tgaagttttg	ataaaagcac	ctcttaacca	174600
atgccaaata	gctaagtctg	ggacaaaagat	tgacaggtatt	ttgcattttc	catgtaacct	174660
cagagggatt	gccattcaca	ctgatctgag	ctgcagaata	caggcagcc	acctcaccca	174720
cccagagggt	ccaactcttat	actttctcag	aaagcacagc	cactctactc	ttattcagtt	174780
gaaaagaatt	tcaggaagg	tgtttctgcg	attgcctcag	aaaagtcagt	tccttttggg	174840
aatttccctt	agggatcatc	tgtaactcca	tttctgcctt	ttacctgaat	tcctttgggtt	174900
ggtttgaatt	cttttggttta	atttatgaat	tccttttatt	acttttctct	gaagaaatgg	174960
agatatcagc	tgctccctccc	cactgccatt	tattccttcc	ttcattcaaa	ccttatgtgg	175020
ctgctactca	cgtgtgttta	agtggtcact	ttttttcttg	gaattcaaaa	aaagaaggac	175080
agtatattggg	gcacagatct	tttggtgttc	tatacatttt	tttaaagtgtt	cattttacat	175140
ttgtgtgtgc	gtgtgtgtgt	gtgtgtgaga	cagtcttgct	ctgttgccca	ggctggagtg	175200
cagtggcata	atcattggct	cactgtagcc	tcaaagtcct	gggccaagc	aatcttccca	175260
cctcagccac	ccaaaatgct	ggggttacag	gttttatgcca	ctctgtctga	cctgaaagtt	175320
ttgggtttac	tttcccttct	ttctctttgc	tgaagtcaga	gatgatggca	gcttccagat	175380
tctctgggtgc	ctgtgctggc	ctcgtgctgg	tcagtgtctt	gggtccagga	ttcattcttg	175440
agactctcag	ggaagtttcc	catgacaagg	aaatgtagga	gagtgtgctg	gctttgcgtg	175500
ctcctctgcc	aagccctgct	tctcctgggtg	ggacacactg	aaccacagcc	agggcatttt	175560
gggtggttagt	taaaaaaaaa	aaaaaaaaaa	aaaaaaggaa	gaagaaggca	ctgtgtaatt	175620
gtgccgggga	tcttcagaaa	ttgtaatgat	gaaagagtgc	aagctctcac	ttcccttccc	175680
tgtacagggc	aggttgtgca	gctggaggca	gagcagtcct	ctctggggag	cctgaagcaa	175740
acatggatca	agaaactgta	ggcaatgttg	tcctgttggc	catcgtcacc	ctcatcagcg	175800
tggtccagaa	tggttaaggaa	agcccttcac	tcaggggaaga	acagaagggg	agattttctt	175860
tgatgggtgt	ttggaagtca	ggcttaaaaa	attgtgtctg	tgtgtgcgca	tgacaaaaca	175920
cttttacctt	atcttttattt	tcttcttttt	atttgaatgt	atagggttgt	gtgtatttct	175980
gtgtaaat	ggggttttcc	tcctcttagt	ctttcacttt	tgtggtgatt	accagtccca	176040
tttttagagc	cagggttgca	acttgaaggt	tttgctaaaa	ccctcaccga	agtgtctatg	176100
atcagcat	taactgttaa	ttaatgtggc	caggcaaggg	gtggaagggtg	agaagactag	176160
aaaggaaca	tgatatacac	atttactcag	atactgggct	tttctaaccat	ctgcagtga	176220
attgaagtta	ccagtcattct	gcagtctaaa	aagaaagtga	ttttgggagg	tgcgtagaaa	176280
aatcatctt	attatttttc	ctctatatta	cttttttctt	tttttctcct	gaagaaactt	176340

tttttttgg	tgataccttc	tttttctcta	gcacgtataa	ttttggaagc	atttttcata	176400
tgcagtgtat	acttcagaaa	gagagagaga	gagaggaaaa	ttgtcctgtt	cagcgtttgc	176460
atttccatta	ttcctgctat	tagttaaaaa	caacaacaac	aacaaaaaac	aagcaggata	176520
cctagatctg	gaaaagggag	aattgtgtag	agctgtcttc	ctaaagtctt	gagttagggc	176580
tgcctcagac	cactttcata	actatctcca	gtggctttgt	gttttatatt	tattaagata	176640
gagaaaaaaa	gagtaattac	taagggcagc	tgctgtagct	ttatgggtgat	tactgaacat	176700
tgacatgctg	tcacgttttt	ggaactttga	gtatttaatc	actttgggat	attctatttt	176760
cccccatctt	gagtggtggac	agatgctggt	gatgtagcct	tctgggcaca	gagcaagcct	176820
ccccctcagc	ctctgcacca	gaaaggctca	gcttcacaca	ctccaagtat	gttttctaca	176880
agaactacac	tttgtggctt	tctgacccaa	acatttttat	actaaattac	acacaacaaa	176940
gttgtagctc	agagagggaa	caaattggctt	atttaggcca	ccattttctt	gagccattat	177000
gatttcacac	agggctccct	tggccctgta	aattggcaag	gattccatta	ttcaaccgcg	177060
atacatgtac	agagaccctg	ctctggccca	gatagtattc	tgggtacagg	cggatagagc	177120
aggaaacaaa	acagctacag	tgatggacag	gtcagcctgc	agcaatgcct	gcagtctctg	177180
caaaggtagc	tgatgggtg	ggcaggtggc	tagcacttat	tcagctctgg	aaggatctcc	177240
cctctggcct	ctccccctgac	acccatcaat	aaaactgagg	agcatcggtg	gacaggggac	177300
cttgtgcccc	ctccccctgct	gtgcagttgg	ggctgaaccc	agctacgaag	tttgagctca	177360
ctctctccag	ctccccctca	attcagagct	gaactgtggg	aagcttcaga	gctctctggt	177420
tcaaggacag	gttctcctca	cctctcctaa	tggaggtgca	ccagggaaact	ggccctgctc	177480
tgcccagggc	tttctcctgg	actttgccat	catggtctag	caaaccctgt	tcagattgag	177540
gtgagtgggtg	agatttcogaa	ttctttttga	cagataggat	taagtcttct	tctgtgggac	177600
aagtgggagg	tagaggtaag	attaaagatg	gccaaatgtc	tgagtccctga	cagccacaat	177660
atggagatct	agacttttta	cagaccacag	ggcacagggg	cctcactaac	agagttcccg	177720
gaagtgatga	gtgtgctggg	ggcttcctgg	ttgaagagac	actagaatgg	accagctggg	177780
agctaatttt	ttgggctgga	gtgtgatggc	ctgcacatca	ctgcctctgt	ccctccattg	177840
tcacagctgc	cccttaggag	ccagctgagg	caatttgtgg	tcagagtgc	tttgcacagt	177900
tgtcctgctc	gtgttcagga	agggagtttc	tgtggtccct	ttgaaaccac	agaagagccc	177960
ctcgtatagc	tctcaatgga	gggggcaaaa	cattcaaata	actcaggaga	taacacaact	178020
atttgttttt	aactgtgagt	tttttaggcaa	tcacaaagat	ccagatgtat	gtccaagcct	178080
ctctttgcaa	ttctaattaa	cctcaatggt	gcaaccatag	acctacctta	cagagttcaa	178140
aaaaatatgc	aaaaaccctg	cctttcttct	tcctcatacc	ccaaaatgcc	attctgaaca	178200
tttctgttta	gttaaaaaaa	gatttccatg	gtgttaccag	gcactgtaca	cagtctgtgt	178260
cccaagacaa	ggaggtacag	ttccacatgc	gcccattgact	gggttgggct	ctgcactctc	178320
tctatacttt	gagagcctga	ttttctgtga	ttgggcagag	ctggcccacc	tggtgcaatg	178380
tcctcctctg	cctttcaaac	atgttttagt	catcaagatc	ttcaaatttg	taaccctttc	178440
cagcttgatc	cagcagaatg	cagatttgga	aaaacagaa	gagtttaaaa	tacatgattc	178500
taagaaacct	ggaccagaa	tatcaaaact	tggtttccca	gagaatatag	caaattgggt	178560
cattggccaa	tactatgaca	ttggcttttg	agaaaagaaa	ggctttattg	caaggctggc	178620
cagcaaggag	acaggagtgt	ggctcaaatc	tgtctcccca	gtttggggct	tagggcaagt	178680
tttaattaca	cagacgcatt	tcttatgagt	agcaggcaga	gagcctccaa	cttcttctgc	178740
ctaggtacca	gcagcttaga	catgatgcaa	acctgggaag	cacatactgt	atttggagaa	178800
agtgattggg	aagaaatgtg	agctgagggg	aggggctcag	tgccctgag	ctacacttag	178860
tgatggcaga	ggaaggatgt	cctcccgcag	gagcgtgttc	cacatctgct	ctggttgtag	178920
ggggagctgg	caggcattag	cagcggcctc	tttcccccaa	gagaggcagc	ctcctccaag	178980
ttttggcgac	attatggccc	tgcaatcata	agggttttgt	agcatagtgc	taaggaggga	179040
aatggagctg	ctgttactag	ttccacccca	acacacacac	acacactcac	aagaaacctc	179100
acaagcaccg	tattggaaga	ctttgccatc	caacctggga	tttgacaggc	tctagaagca	179160
gaatcataga	ctcatgaagt	tcccccaa	caggaatctt	ccttacagta	accccaacc	179220
acccccctcc	accgcctcca	ccggctgctt	cttcttgaac	actgcagtgt	ttggaaaact	179280
cacaaacttc	caagcttgcc	tttctatttg	ttgcatggat	tgaaagcttg	cgttgtgtga	179340
agaatggcgc	ttcctgctgt	gcttagtttt	atctcatata	atctttgcac	catttaatcc	179400
ttgcactcac	ccactcatgc	aactgccttt	gcagagactg	gaggggcccgc	tgtaggctga	179460
cctttccttc	actgtacctc	ttttgttccc	tgtttatttc	ccctgcaccc	aggacactgc	179520
ctggcacaaa	gacaggtcct	tataagtgtc	tgcaagtga	taaagatata	tatatatta	179580
ttgttatttt	tgagacagtt	tcactctgtc	acccaggctg	gagtgcagta	gcgcaatctc	179640
agctgactgc	aacctctgcc	tcccaggctc	aagtgattct	catgtctcag	cctcctgagt	179700
agctaggact	acaagcatgt	gccaccacgc	ccagctaatt	tttgtatttt	tagtaaggac	179760
agggtttcac	catggtggcc	aggttggcct	ccaactcctg	acctcaagtc	atcctcctgc	179820
ctcgacctcc	caaagtgcctg	ggattacagg	catgaaacca	gcctagaaat	acatactatt	179880
atttattctt	gttttacaga	taagcaaaagt	gagtcatgga	gaatttgggt	gaaagctcca	179940
aggtcaggag	tcgtgaagct	gggattaaaa	cctaatactc	tgactttaga	gagtagacac	180000
ttgctccatg	catattgcct	ccaattcatt	cattcaagca	ctcctgctc	aagaagttct	180060
ttcttatgtt	gagctgaaat	ctgcagccct	atgcgtttta	cccagcagtc	ctggtgctgt	180120

tccctaaaat	cacttagact	gtgcctgctc	tttctgtgtt	tacagtgtca	gctgtaatat	180180
ccccctcttc	ggcctaacgt	ttctgaagtc	ccttgccact	gggtctcctc	tcctcttcct	180240
gtgttctttc	taagaacacc	tatgcagata	ggtgtcttct	gtacagggaa	gctgttcctg	180300
agatccgggc	atcgactctg	ttagaataat	ctacgtatga	gttatttttt	tgagaactat	180360
gtgtcattgc	tgactcatat	taactctgtg	gttaactaaa	atctcaagat	ctctttatgt	180420
ttgttgagaa	acttatttaa	cttctctggc	cctccgtttc	cttcaactgag	cagtggagtg	180480
attgataacc	tcacacctgtg	gttgctgaag	gtcttgcaca	agatgatata	gttaaagtag	180540
ctagcagtg	ccacgtacgg	cggatgcctc	acaacgggtt	gcagccatct	ctctatctgt	180600
gtctttgtct	ctctctcaca	ctggtttttg	cttactgtta	gcagctagcc	gagataagtg	180660
tgtttatggt	ctttgcatgt	attgtttctg	tagcatactg	gaggattaca	agaggttggg	180720
gagtggaggg	gcggtgagga	gtagacaaag	gcagccaact	cttccaagtt	tagcttagaa	180780
ggaaggagcg	gtaaacccta	gttgaatggt	ggactgaagc	aggtttgttt	ttgttttgtt	180840
taaaggatag	ggaagatctg	tgcggttttc	caggataaag	aaaaggagag	aatatgatat	180900
taaagattct	ggaagtggga	gaaggagcaa	tgaataacag	acttgaagtc	agtggcatgg	180960
acagggtcaa	gatcacagtt	agaggatgca	gccttagaga	aaaggaaggg	gctcggttct	181020
ctgagcaagg	agggaaagaa	gagaggcaga	tgcagagaag	tacggcacat	cgtgctgctg	181080
gtttagagaa	taacctctga	cttttaataa	agtcacccct	cggatccct	gggggattag	181140
ttctatgacc	tcctctggat	gccaaaattc	gtggatgctc	aagtcctga	tataaaatgg	181200
catagtattt	gcatttaacc	tacacacatc	ctccatatcc	tttttttttt	tttttttttt	181260
tttttttttt	tttttgtgag	atggagtctt	gctctgtcgc	cctggctgga	gtacagtggc	181320
tcgatcttgg	ctcactgcaa	gctccgctc	cgggttcat	gccattctcc	tgccctagcc	181380
tacaggtgcc	tgccaccacg	cccagcta	tttttttttg	tatttttttag	tagagacagg	181440
gtttcaccat	gttagccagg	atggtctcga	cacatccctc	atatacttta	agtaacctct	181500
agataatctc	tagattactc	gttttgtctt	tttttttttt	ttttcttttt	gagatggagt	181560
ttcactcttg	tcacccaggc	tggagtgc	tggtgcaatc	tcagttcact	gcaacctccg	181620
cctcctgggt	tcaagcaatt	ctcctgtctc	agcctcctgt	gtagctagga	ttacaggccc	181680
ctccccaccc	ccacccccca	acaactggct	aatttttgta	tttttagtag	agatgggggtg	181740
tcaccacggt	ggcctggctg	gtcttgaact	cctgacctca	ggtgatctac	ccgcttcagc	181800
ctcccaaagt	gatgggatta	taggcatgag	ccactgtgtg	tggcctagat	tacttataat	181860
acctgataga	atgtaaatgc	tatgtaaa	gttgttatac	tgtattgtta	aaagacagta	181920
acaagaaaaa	aaatctgtac	atgttcagtc	cagacaaatg	gttttctgtt	tttttttttt	181980
ttttttaata	tttttggtea	gtggttgggt	gactccagga	atgcagaacc	cgcagatata	182040
gaagggtgat	tatgcgttca	gaggcaggga	ataccatctt	gggttccaga	aagaaaatga	182100
tcagcatttt	ctgtcatact	ctggtaaaaa	cagatctttt	gaatggacag	gtgtattaaa	182160
ccctgtggag	ctggctgggc	ctggcggtc	acgcctgtaa	tcccagcact	ttgggaggct	182220
gagycaggtg	tcagcagagg	tcaggagttc	gagaccagcc	tggccaatat	ggtgaaaccc	182280
caactctact	aaaaatacaa	aaattagccg	ggcgtgatga	cgcagcctcg	tagtcccagc	182340
tactcgggag	gctgaggcag	aagaatcgct	tgaaccctgg	aggtggaggt	tgcaagtggc	182400
cgagatcacg	ccactgcact	ccagcctggg	caacagagtg	agactccgta	tctaaaaaaa	182460
aaaaacaaaa	acctgtggag	ctgatgaaat	cctgcaggga	gcttcacggt	gacagcaaga	182520
ggagaaacac	atccccatat	gccccgcaga	gtttgaagtc	ccggctgcac	ctctccccag	182580
cagcaggttg	actctggaaa	gttgccagct	tcttaactac	agagtgggaa	cagtaactac	182640
cattgcacag	agtgggtgca	aagctctgtg	acggaaatca	tggcaagtgc	ccaccacatt	182700
gcctgggatg	aggtgggccc	ttcctttacg	taagagagcc	ctacagatac	actcaaagtg	182760
ggcacattcc	tacagaagga	gtgttatttg	tgtagaaaag	aaaaacatga	aaggctttta	182820
ttcctataca	caataaagca	cccccttaat	gtctttttga	ggaggataat	atgaaattga	182880
tgaagaggaa	ccctgtgggt	ggatccctga	caatcacatg	tatccctttt	ttcactcttg	182940
aaaaaggagt	aaaggaataa	aatagaaggg	gagagggggc	agagagacct	tcaccgccc	183000
ccccccaccc	cccatcatcc	aatctatagt	caaacctctc	agactgtgtc	tccttggcat	183060
ctctgacacc	cccaccgcca	ccaccccgat	caattcctat	cttatccccc	tatcctggat	183120
ctgattctgc	taagttcctg	ccacactaaa	gacaggggtg	ctttctgatg	acaacattcc	183180
tctgcttaaa	cctgtcagta	attccttggt	gctctcagac	ggaactaagt	tctgaatttc	183240
ttcacacggc	ttctcagcaag	gtcacagtca	ccctgctagg	cccagggggc	aaatctcaat	183300
ggtcatcttc	ttgaagacct	ggctcagtta	ttctcttctc	attgaggctc	acgacccccc	183360
cttcttgcac	gcctcaaacg	gcccccttacc	atgctcttct	ttcgcccata	gctcagcaca	183420
ccatatcatt	ttaatattatg	tattttgctt	aatgtggatg	atctgtctcc	tcctctgctg	183480
tcctcaccag	agcatcagtt	cctcaaacca	aggctctttg	ttttgttctt	ggatgcaagc	183540
taaagtctctg	gcattgtggca	aatggctcata	gatacatgtc	attgaaagaa	tgattcatca	183600
cctccctctt	tggtcttctc	tgtggttcta	ccaaatccca	ttccctcccc	agtgcctctc	183660
attccccctc	cttgggtgaa	cattctgaa	cacagacagt	tccttaccct	gaacctttgc	183720
atattttgtt	ctcttagctt	agagcggccc	ctctccctcc	gtctgcttgg	ctaatttcta	183780
cttgttcttc	agattttatc	ttagatgtca	ttccctcaag	gaatccttct	gtgactcaac	183840
atggaattaa	gttgccctcc	ttgaccctga	aagcaccatg	tactcaatct	catcttggca	183900



tgactcactt	tgctgtgtgg	aatgtctgct	ttccttgttt	gtctattcct	ttagactgta	183960
agatcctaga	aagtgggggc	cgtgccttgc	tcatgactgt	gttttctaaca	ccaaacacag	184020
tgttcàgtag	agagcagctg	ctgagtagct	ttctgctaaa	tgacagttga	tggaggacat	184080
ttaggggtgc	ttggagggtca	agtcaaggag	gcattttaaca	ttctagtaaa	acaaggaagt	184140
aacaggctcc	tgaacatgcc	cacaatgaac	cagatgcaaa	ccttttccct	tggcaggatt	184200
ctttgcccc	aaagtggagc	acgaaagcag	gaccacagaat	gggaggagct	tccagaggac	184260
cggaacactt	gcctttgagc	gggtctacac	tgccaagtga	gtcctaacc	tgatgttgct	184320
aataagtggg	ggcatgggca	ggggggcctc	cttctaggag	tgatgaccac	ccttaatacc	184380
acatgtctgt	ctgagccaag	tttctgagcg	ccaggagggt	gaggaagggt	ggacttcacc	184440
agagaggctt	tgtggacacc	ctttatcatc	ttagtgagtg	ctagtgtcaa	aacaaaggga	184500
gtggggatat	ggggcacatt	ggtggaggga	ggtgtgatct	ctgcagcttc	agaaagatct	184560
gaaagagtca	tttggttaga	gaagttgacc	tatttctctg	ggggttagac	cagggttgct	184620
actgtgaaca	ccagccatga	ctcaccagtc	accttcagaa	gccacaggca	ggacatgctg	184680
acgacagcct	tcaactcacc	caccccttgc	tcccttgcgg	gtggaagtct	ggagggtgaca	184740
ccactgcatt	ttctaacacg	ggggctcctt	gagcaactag	aacaagaaca	gaaagaatgg	184800
ggacatttagc	aggtgctttc	ccccctctctc	attcttttct	ttgaataaaa	aggttggttg	184860
aaaacacctg	agcggctcct	aaagatgggt	gcaatctatt	cgggatgcaa	atccgaatga	184920
atgttattca	aatgtctctc	tcttctttat	gcagagtgtg	tttcaaggct	cagccagtgg	184980
caggcatgct	ggggactatg	gactacggac	taggggcctg	tcacagagga	aggcctcatg	185040
ctagagagct	aaggaggagg	ctggccttca	gttccatccc	aggagcaact	ttgatgttcc	185100
cagagatcct	tccaaagggg	gagtcattgg	cacccaagaa	aaatgtattc	agaatgccaa	185160
gaatggtgca	aactcaggac	aaagattcac	actgcagggt	tggagtccct	gggcttgctg	185220
ctggccacct	gggaggagg	gtcccccttca	ggggtagcgt	tggtttccctg	tgaattaaac	185280
tggcttcaag	ggatctcgac	tgaacaggcc	tatatcacac	tcactgatat	actctctctt	185340
cagtccttct	cctcatctag	gtatttttaa	ttgtttcagt	gagggtgtagg	catgaggggt	185400
ttggaggggg	catctcctcc	attgcagttt	ttcattggct	gctttgctcc	ctcagctccg	185460
aaatcgctgg	gccactctcg	aacgcattag	tacggtagtc	acaggttgat	tgcctggccc	185520
cttgccctct	gtgggcattt	tccctttcag	acagcccctg	agtactcaca	gtgctgctac	185580
agtggggccc	ctagatctcc	ctctttctcc	atgctcccac	gtgctctggg	ctccactccc	185640
ttctcccaag	cacttctgtc	cagggtctatt	ccagcagctt	gacctcaagg	aaatcctttg	185700
ctaaactgat	tatagagagg	tttctatttt	aacatttagg	tcttccatgt	attaattctc	185760
agaatcaatt	taagatgttt	aaagggtgtg	tttaagacat	tttaaaacca	tttggaggag	185820
agtacagaaa	ttatgtcact	tgtgtgcagc	ctctttgcac	cat.ctgcaga	gaaagatact	185880
agagtccgcg	cttggacaca	tccacatgca	agagggtgcaa	agaagggtgtc	tttgatgagg	185940
caaggtcaaa	acttctcccc	agacgaaatc	caaagaaagc	atttctacta	tgtatatca	186000
gtttggaaaag	aaaaacttct	gccaggtgac	tgcattctca	ctggtcacat	tgtgttccca	186060
tggactcctc	agctcaacca	atltggagaa	gttatgggtgc	aatttcacca	tatctgggta	186120
gaagttaagt	ttccaatttg	ctggcaatga	agaagaaatg	gagcaggcca	ggctgtgtag	186180
tttctgccac	gtgcccccg	gagtgaacag	ctctgtttgt	aagaagccat	ggtgcttaga	186240
cctgggctcg	ctagttgcca	gcctccaaat	tgcagaagtg	ccctttgggt	ggtggctatg	186300
ctgtgtcact	tgggaagggtc	gtttggaagt	tccacagtcg	ttgtgggggtg	ccagagatta	186360
aaaagcgtaa	gaaagtgtat	gttgcgtcct	gttgcgtcct	gggcatcccc	accgtgtggg	186420
tgtgtcagcc	cagctctcaa	aacccatggg	tctgtacact	caacctccat	gagaggggag	186480
gagaaggatg	agggagggga	gagatagcca	tggaaaggta	ggaactaagc	aggcagggtg	186540
gagagttttc	tgtaaagaca	aaactgtctg	gacactgctg	cggttctggt	acaaagacca	186600
cttctcctcc	gggccagcaa	catatctgtg	tgcctgtctg	ggttgtaaaa	aggggtcaaag	186660
atcaatgcag	caggcagcta	catgctggca	aaaggccagag	gcagctggtc	tgtttgctctg	186720
tgccaggaaa	ccactgggaa	tgggggtgtg	tgttatctta	ggagaaagtc	gtcccagcag	186780
cagcttctcc	aggggcatcc	aagagcactg	aaaagggttg	caagatgacc	catgaggctg	186840
caggaagaaa	agaacatgca	tttaatcttg	ctatctgaaa	agtaagacat	gaagctttcc	186900
tcatttttta	tatacacatg	gacagtagta	tgtgtatata	gtttatatgc	aaatataactt	186960
gttataaggt	tgcattgctca	aaatttttgg	ttcatgggggt	gtgggatcat	aatggtttag	187020
ggaccatggc	tatcaaggaa	aaacagcatg	aaggataaat	gatactgggt	gattaaaaag	187080
acagatgcat	gtatttttag	cataaaacac	aactgctgac	tgatacacat	agctcaagat	187140
tctggggcag	ctgctgaaca	gatacactag	ccagtggtggc	tcatcggctc	agacttggcc	187200
tttaattaatg	ggctgtccct	ccacccatct	cccatgagggt	cagagctgag	ccagggtttg	187260
agagctaaaa	ggaattggac	ctggactctg	ttcacgtgta	tattttaatt	ctaattaatt	187320
cattcttttg	aaagacagag	tcacactctg	ttgcctaggc	tggagtgcag	tggcacgatc	187380
ttggctcact	gcaacctcgg	ctcccccagt	ctaagttatt	ctcctgcttc	agcctcctag	187440
gtagctggga	ttataggcac	atgcccccat	gcaagtactaa	ttttgtgatt	tttagtagag	187500
acgggggtttc	accatgtcag	gctgggtcttg	aactcctgac	ctcaggttat	ccacccgcct	187560
tggccccctca	aagtgttgga	attacagggtg	tgagccaccg	tgcctggcct	gttcacatgt	187620
ataaaacaca	gtttaatgtc	ctattcccag	ccaatgagca	tggctagagc	agccttggtc	187680

aaagtttggg	ttttggagaa	aaatccttgt	tagctgacct	aagattcctc	tttgtgagt	187740
taagtaagca	caggttgcag	agaggagaag	ggtctctgga	gaggtgtaat	tttctaaatg	187800
gattacaagt	tcatggactt	ttaacagggtg	ttacagggga	taacaagttc	tttatagaca	187860
gacttttgag	gacgtttaag	ggtattctga	ttcttggttt	tctaagaggg	gaatgtatta	187920
tttaactaca	gacaccccta	ccgcccactt	tttgcagagt	gtatcaaaac	atgttttttg	187980
aataccacc	tcatgtcgct	tctccctgca	tctcttatct	cttggtgtcc	attctagact	188040
cactttcttt	ctgtttttta	tttttatttt	tttttgagat	ggagcttcac	tctgtcacca	188100
ggctggagt	cagtgggtgca	atcttggtctg	actgcaacct	ctgccttccg	ggcttaagca	188160
atttttgtgc	ctcagcctcc	tgagtagctg	ggattacagc	atgcaccacc	atgtccggct	188220
aatttttgta	tcttttagtag	agacaggggt	tcactatgct	ggccagcctg	gtctcaaact	188280
ccttacctca	ggtgatctgc	ccgcctcggc	ctcccagagt	gctcagatta	cagacgtgag	188340
ccactgggtg	ctggcctaga	ctcactttca	agtggtcatag	acttgtaaaa	ttattttaag	188400
gtgataggtc	tacaatgata	ctgtcaatta	gtattgacac	tattattaat	aaactgttat	188460
taattatatt	tacttacttt	aaattaatcc	aaactaatta	acggaacact	aaagagtttc	188520
tatgttttat	tcccagaggt	ggagaaaaat	gaaagggaat	atagcaacga	attcttttct	188580
ccataaaaac	atgaatagt	cagcacatca	agttgaacat	accacagcaa	attgttgcaa	188640
gatctgctga	gtagctccta	tttagacctc	aaggaatgag	actcaaaatg	ggttcatcag	188700
ttctgttttg	cagaaaaaat	agcgcaaaat	ttctcaaaag	aaaatccaga	ataataataa	188760
tttgtcaata	ggaaagacat	ttccactggg	ggttaagaag	gaagacattg	gaacaatgat	188820
agccaccact	tattgaatgc	ttactgtgag	ccaggtggca	cttcaccttg	tttcattctc	188880
acaacagtct	aggggaagtaa	ttactaatgt	ctccatccac	ctcttgtaga	tgagcaaact	188940
gaggctcatt	gaggctagga	aatgcaccca	cactcacata	gcccataaga	ggcagccatg	189000
gcattgggcc	cagacctagt	gaacttcaaa	gactacacga	gcagccactg	ggcagctgtc	189060
atggctaaag	ccacttgaat	tcagcccagg	agcaaccccc	tctccaggag	gggcacataa	189120
gcttgcagct	ttgggtgaaa	gtgacatttg	aagtccctga	tggcgagagg	gactgtcttg	189180
agccagagcc	aggaacaagg	ctctgagaat	attctggaaa	tccacaggag	gaacccattt	189240
tcttacagct	gggagaat	cattcaactc	caggctgacc	atgtttttat	aggaacgaag	189300
gtgacttgaa	ctaatagtca	ggaatgggtg	aatacggacc	caatgtcaaa	tacttaggca	189360
gttcacattt	ctaatagtca	aatcccttag	acaattaaga	attttttttc	ttttgcataa	189420
cccagacaaa	atcgctactt	aaaaacaaac	caaagaccgg	aaacatgaga	aagagaagga	189480
agcaggggaa	atcttttggt	ctaataagtt	tttaaacaat	aagagcacca	gatattttac	189540
cccatcagac	acagaatggt	attogaataa	ccaaaaaagg	aattttttct	ctaagtttct	189600
tgaactggaa	aatgaatcat	attttctcag	tcttgaggct	gcaattttgt	gcctctagta	189660
acataataga	atagatgtga	tgccagtgcc	cagtagctgc	tgcaattgtt	acttggggac	189720
ctgttttatt	actaagcact	tcaccccgat	gataaatttg	taggggcctc	ctgccctttg	189780
gagctcctac	cgtgtccatt	agatcagttg	aaattctggg	attcagagca	ctttgcaagg	189840
tcagcagggg	tctgtctttt	ctgtcctgtt	cctgggtttt	ggttgtgcct	ggattccagg	189900
gtaggtttct	catctgttac	cttcatagac	ttctccagaa	aaggatcttt	tgaccatcag	189960
aggaccacga	agattccatt	ggtgaggcgc	agataacctg	atctctctgg	gttctctgca	190020
gggcacagat	gaagggtctg	ccattcccaa	gttctcagtg	gtaccactga	ggcatgagac	190080
cctaattggt	tgcatgagca	gtttgaaaaa	tgcatctttg	tttttaccta	tataatcaca	190140
tgaacccggt	ggttctcaaa	cgtcagcagg	catcagcatc	acatggaggg	cttggttaaaa	190200
cagattttctg	ggccccaaca	cagagtttta	aatctggaag	gcctgagggtg	ggtgtgaaca	190260
tttgcatttc	taacatgttc	tcgatgctgc	tgccgcctct	ggtcccgaga	gcatgcctgg	190320
agaactgcca	ccttcgacca	tggaactgtga	gaattcacat	ggacctcaga	attataatca	190380
gtctctcagt	tttacagata	aggaaactaa	atccagagag	attgttttgc	caatggtgaa	190440
cagctgggtt	aagtcaggat	ggagacttta	atcctagtca	agtgaccttt	cctctgtatt	190500
tatttccctc	cctttttatg	cctctcaagt	ctagttacac	tgtttttcat	ggatgggcat	190560
atttattgtc	ctgatctgga	ctgcagactt	ctcaggagga	cacctatgat	ttaattttag	190620
atagttgaag	agttaacaga	catggctttg	gagacagact	gattatgggtg	tgaatcccg	190680
ctttgccact	ccctagctgg	atgacctga	gcaagtattt	cagcttctcc	aagcctgagt	190740
tccttatttg	aaacatgaga	gcaattgtga	taggcagaat	aatggccccc	tcaccaatca	190800
tgccacacat	ctaactctag	gaacctgtga	atatgttatg	ttacatggca	aggggaaatt	190860
caggcagcta	gccagttggc	cttaaaataa	agagattatc	ctggatgatc	tgggtaggac	190920
ctgatgtaac	cacaagggtc	tttttaatgt	ggaagaagga	ggcataagag	tagatgtcag	190980
agtcattcaa	aataagaaag	atttgatggg	ccatccctga	ctttcagggt	ggaaggaggt	191040
tctgagtcaa	ggaatacagg	tgacctctag	aagctggaga	aggcaaggaa	atggtttctc	191100
ccctagaagt	tccagaagga	ttgcagccct	gctaatatct	tgactttata	gccctttgag	191160
atttattttg	gattttctgac	atcctgaacc	atagtaaaag	ggtgtttttt	gtttttttga	191220
gacagagtct	tgtctgtgtg	cctgggctgg	agtgcagttg	tgtgatcttg	gctcgctgca	191280
acctccgct	cccaggttca	agtgattctc	ctgcctcagc	ctcctgagta	gctgggatta	191340
caggtgcttg	ccaccacacc	tggctatttt	ttgtgttttt	agtagagaca	gggtttccacc	191400
atgttggcca	ggctgggtctt	gaactcctga	ccttgtgatc	tgccctgcctc	agcctcccaa	191460



attgctggga	ttacaaggcg	tggtgtttta	agccactcag	tttgtggcca	cttgttacag	191520
cagcaagagg	aaactcatac	agttatcatg	tgaactcaca	ggaatatggg	gagttaaaaa	191580
gagaggaagg	gtgcaaaaaca	tccacggtag	agtgagaact	ctccagggag	tgaggactgt	191640
gcccagcata	cagtgatcac	cctcttagta	agctaagttt	ctgagcacca	gcttttttga	191700
gttgactttg	ttgtcttttaa	catttgaaga	tcacccttct	ttgtcagacc	tggcttgacg	191760
acctgggctg	atttgtggat	ctgatagaaa	agtttcctta	gttgggctct	tctccccgac	191820
cacccccatg	ccagtgtggc	cacatcctct	gtctgcattg	ctcactcttc	aattccaaga	191880
agcgcagggg	caccgccagg	aacaggaacc	ctgccagagg	aatacatcaa	gaaaccaagt	191940
ctcccttacg	catcacccgt	ggaacagagt	taatggatta	tgaacatgtg	tttgctttat	192000
accattgttt	gtttcccagg	tggcagctgg	ctgccccatc	ttattgggta	gatgtaagtg	192060
gaattacgaa	tgggatttat	gtttcatgca	cgatgggtgat	tattaacttc	aactttcagg	192120
taattttcag	accacattgc	actaacttgg	tctctgattg	tttttctcct	tgtttgttta	192180
ttctgcagcc	agaactgtgt	agatgcgtac	ccacttttcc	tcgctgtgct	ctggctcgcg	192240
gggctacttt	gcagccaagg	taactcagac	ttccctttgt	tcattctcct	tctataaagt	192300
gcatctcaag	gaggttcaaa	gggcaggctt	tttgttgaaa	ggactttgcc	tgacctctgg	192360
ctcccatctg	tgaagccctg	gagaggtgag	agccctcggg	aggccgtgtt	tcaggcatgc	192420
tctgcacccg	tgcagagcgc	gtgtgataat	gcattgctaa	tgcttgctcc	ctgggtggctg	192480
gctgagagct	gctgtgctga	caagggtggg	ttaaggctaa	atgtgactca	gaatccttaa	192540
gcagtgttag	ttcagatata	agggcatat	aaatgagagt	gcctgagggg	tctatttttg	192600
gaccgctgtc	acttggctct	tctgctaata	agcttccagt	gtgggtggccc	tccttcaggc	192660
atgtttccac	tgagccacgg	gctggatgcc	acatccccgg	ccttcccaca	gttatcagca	192720
gcccacaggg	ttgacttgag	caagttggaa	agacaaatca	acttccagag	ttgatttaac	192780
attgagtggg	aatcagtcac	acttttggtc	ccctttcggg	gccacgcctg	gcactgtgcc	192840
tgggtggcga	ctggcatgaa	ctggccagct	tctgtggccc	tggagggcac	aggcagaaag	192900
gccacactca	gtcccatgat	gaactgttta	agacttattg	ttgtctcccc	gctctgtaaa	192960
gtagatagag	tggattttat	gtcccttatt	acctttcagg	atactttgac	tcaggggagat	193020
aaagtaactt	gggtacagct	actcagctgg	tgaagaacac	aggcagaatg	agtgcctggg	193080
tcttttgact	taaaattctg	gatttttcac	aaagatcctc	ttactttatt	catttacata	193140
ataaatatat	attgaagagc	tactctgtgc	caagccctgt	gcctagatat	acagtgataa	193200
ataaagagta	gcttctagag	gtcacctggc	ggtagggcac	aggccagctg	gcaagatgga	193260
ccacagaagt	cagtgaatga	agacaatgac	aaaggtggga	agcgccatat	gggaagagaa	193320
ccaagttcag	tgatagagag	cagaggtgag	gcggcagcag	aaaccactta	agggacacca	193380
cgtggcactc	cttctgtgct	gagaaggctg	tcagtaagct	caccatttat	ttcctatttt	193440
ctctcctgag	ttaaatagga	aacatgtctc	gcattacttg	aaaaatcaag	tcaaactatg	193500
ctcttactag	gagttatggg	tctttttatg	tcttagatga	tgcttgatct	agatgaatgc	193560
ggacttgctg	tagctatagata	aatacaatgg	gagtttgaag	gtgtttcgta	gccctggaaa	193620
taggtatttc	ctgtcaaaac	aagctttgtc	attgccagca	gacaaaagca	tcagtaacct	193680
tgggtgataa	tcgtcatttc	ttaggaataa	agtagactgt	agaatttttt	ttagcagaaa	193740
ggaaacccaa	agataattct	agtgc aaatc	cctcacttta	tagagcagaa	gctcaagtcc	193800
cagaggaaca	agtggcttga	acgaacatca	gaattttagg	ggctggattt	gtaccctcct	193860
ggtgccagca	gcccacttcc	ctgcaggagg	cactcacctt	ccttgccacag	gggtatgagt	193920
gtggccattt	tccaccata	atctctgtta	gctcatgttc	aattgggttc	ccattgaaag	193980
aaaaatggac	cagtaagttg	gagcagaatc	attcagatgg	tataacataa	ggaaaaactt	194040
tgcccaaggc	aaatcgtgat	tgtgacagct	ttgtgatttt	tagagaatag	catgggccag	194100
gcacagtggc	tcatgcctgt	aatcccagca	ctttggggagg	ccgaggcagg	cagggtcactt	194160
gaggttggga	gttcgacaac	agcctgacca	acatggagaa	accctgtctc	tactaaaaat	194220
acaaaattag	ctgggcgtgg	tgggtgcatgc	ctgtaatgcc	agctactcgg	gaggetgagg	194280
caggagaatc	acttaaacct	gggaggcgga	ggttgcgggtg	aaccaagata	gcaccattgc	194340
actccagcct	gggcaacaag	agtgaactc	cgtctcaaaa	agagttcaca	gtttctcttt	194400
tgctttgatt	ttcttatctg	ccggataaca	atagtatttt	ggaaggcagg	aggaattgtg	194460
gaaagaaatg	ggttttgggg	agtggctgat	tggaggcaaa	tccaaggaca	ctcattgctg	194520
gtgtgtgact	ccaggcagtt	actcagcttt	tccaagcctc	agtttcctta	ttgtaaaaca	194580
ggaccatggg	ctagctagta	gcattcctat	gggtgagtga	ataatatgta	taaagctcct	194640
gacacagtgc	ttggcatata	tcagattgag	ccatgtaaaa	ctgccaatat	ctggctattt	194700
atgacctaca	aaaatagcat	ttcatatgat	tccacctaac	atctgaagcg	caataaatgt	194760
tattattgat	aatgcagggtg	gtgggtgataa	agttttgaaa	tcagaaagac	ctggcttcaa	194820
attccacgcc	ttcactggcc	tgacttattt	tcattcattt	gacaaatatt	attttgaaca	194880
cccctatgtg	ccaggcacta	tgccaggctc	agagatgatc	taggaaaaag	acagatgtcc	194940
tcatctgtct	taggctcttg	tggcctaage	ctaaatttcc	tcgtctgtca	aatggtgaca	195000
gtaacacact	ccttaccaga	gagctgggag	gatttggagc	tcaagttccc	aaaacgccag	195060
gagcactgcg	gcagggtgaaa	agtattccct	caatggcgga	agtgtttaaa	ttgcttttat	195120
atctgtagct	ctagataaca	ctagtccag	cttagttaac	tcccagctcc	aagccttcag	195180
gacttcatag	agttattggg	gtgctgctct	tggcagtttc	ccaaaaagct	agaatgcaga	195240

gggaatctcc	ttcccaaaaa	gctagaatgc	agagggaatc	tccttcccaa	aaggctagaa	195300
cgcagagggg	atctccttcc	caaaaggcta	gaacgcagag	ggaatctcct	tcccaaaagg	195360
ctagaatgca	gagggaaatgt	ccttctcttc	taaattggtag	ctgttagttc	aagaaaggtt	195420
aaacattgtg	ctgtggggag	gctcaggggt	gaagggtgta	cttttaagag	aaccagtttc	195480
agagctgggt	ttgggggtta	agccctaccc	tctgccccct	tttacgagct	gacagcctta	195540
tgaagcctg	gttgaccacc	tgaacccaag	tttccacatc	tggaaataga	aatgtgggta	195600
ctagttatgt	tgaagagact	caggttagat	gatagatatg	caaatacctt	ggaaaccagg	195660
agtgtccagt	cttttgggtt	ccctgagcca	cactggaaga	agagttgtct	tggggccacac	195720
atagaataca	ctaaccctat	caatagctga	tgagctaaag	aaaaaacggt	gcaaaaaaaa	195780
tctcatattt	ttaagaaagt	ttatgaattt	gtgttgggct	gtattcaaag	ccatcctggg	195840
ccacgtgcca	cccgagggct	ccgggttggg	caagtttgtt	gtaaacaatg	ccatgatgcc	195900
ggcataaagg	cgttaccagt	attaggaagg	ttctcaggtt	tcctctagcc	cttgggctct	195960
tttccctgaag	tgcgtgtgtc	ttctgctaga	ttttgtgacc	aatggttgatt	gcctaattgg	196020
gctaacagca	tgttttgggtg	gctacgaaac	tgacacaggt	gttttcattt	ctccacttag	196080
ttcctgctgc	gtttgctgga	ctgatgtact	tgtttgtgag	gcaaaagtac	tttgtcggtt	196140
acctaggaga	gagaacgcag	aggtaggtaa	ctgggactac	taaagaactg	tggagcgatt	196200
cctgattttt	gagcaggaag	agtgaacaat	caaaacagta	tttgactaga	ttcacggctc	196260
cgtagcatcc	ccttgggtgg	gaggggggag	gctgactagg	acctctgatt	cttctttccc	196320
tgagctttga	aggctctgaa	aatacagctg	gggggacttg	cccagttttc	ttattaagca	196380
attcctccgc	atgggtgctgg	ctttcaagg	gtgcttcagt	gctgtttgct	gcacgtgctc	196440
tgcagcccca	cacctgcac	tcccgccctg	cagagctctg	cgctggaatg	acatttttag	196500
tctgggttcc	caggcctcct	gagagtgaag	tgtttcattg	tttgtctaga	gaaatgagaa	196560
ctaaagcttg	caacctgtga	taagttgtcc	tgaggaacat	atctttcagg	gaccagaaga	196620
aagaattgtt	ggaaataaag	atgcagtaag	atgcagacat	gacagcaggg	tgcagcggct	196680
cacgcctata	atcccagcac	tttgggaggc	tgagggtggg	ggatcacctg	aggtcaggag	196740
tttgagacca	gcctggccaa	catggtgaaa	ccccgtctct	actaaaaaat	atacaaaaca	196800
ttagccaggc	atgggtggtgg	gcgcctgtaa	tcccagctac	tccataggct	gaggctggag	196860
aatcgcttga	accagggagg	cagaggttgc	agtgcgcca	gattgcgcca	ctgcactcca	196920
gcctgggcaa	caaaagcaaa	actccatctc	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaag	196980
gcagacacga	gactgtgaaa	ctgactagca	tcaccattgc	attgtttata	gatgttgcca	197040
gacagaaaag	cccaagcag	cacagtacct	tcctgacatc	tggactagga	aattctagatt	197100
ttagtaaaa	acatgcta	acttacagaa	gaaatgtcgg	cgttagagta	tgcgctcagt	197160
tccttagaga	ttgcaattcc	taatgcacta	gtatgggttc	aggtgccagg	aacacgttct	197220
gtgaggttgc	tgcgccagg	gctgacccca	gccttccaca	ccattttcct	tccttgtgtt	197280
cacagccgct	ctgtctttta	caatagcacc	cctctctagt	ggctaattgg	ctctatgatt	197340
agatagcatc	cttcagtagt	gataaaggca	gtgacatcct	agggaggtca	gcgggtgaaa	197400
gcgctatata	tggaaaacct	gagagcctgt	gaagctcaag	gacttgacgg	ggttgaccg	197460
tgagccgggc	tgcagctgga	aaaagaatga	ctgttctttc	agcagatcct	tccttgtgcc	197520
atctctttct	tcattcctct	ctagtggcat	tcttatttat	cctctaaaac	cacaattcca	197580
ttatctctcc	tattcttate	aacactgccc	taaattgat	tctttattct	cttttgccct	197640
ggaaaacctc	tatcatgcct	tttcccattg	gattacctcg	ttaagagtgg	gggtggaatg	197700
tctagcaatg	aaataagagg	gtcttctctt	ttgcctggct	ccctatgcag	ccctattcta	197760
ccccctgcaa	agtcaccagg	atgtggctca	gtcactgtct	ctctcttcat	ctgtcaccac	197820
ttgcttgaga	tcctacagct	gctttaatte	cgagaccatc	tgcagaacat	gacaaaaatt	197880
gtccacctac	ccacatgtcc	ttttaacttt	aaaggcttta	ctaactgatt	cctattaggg	197940
aatgaacaga	ggtggcaaaa	ataaacaata	ggagattgat	ttacaagaaa	tctttaaaa	198000
agtagatttc	ttcggacctc	attgaaatat	aaatggcctg	ccttcttgtg	tccttccctg	198060
gtctccctct	ttaggtgata	agaagaagat	cctgcagccg	ccataaccgc	ccatctgcgc	198120
gggttctaga	cccccttctc	ctccccctct	gccgtggtag	gcattactga	tgaatcatgg	198180
tgtcttttct	tcagagagcc	aaacctggcc	tcggaatcct	ttttaacaca	gatactgctt	198240
aacacaacca	ctctgagcag	ctgtcataag	tagaagtaat	agatactaga	agaaatgtct	198300
aagcctaata	tagacaaaaa	tacggcctga	tatagatgca	agccagaggg	gctttatggg	198360
taaatgcaag	gagattttca	accctgccgt	ctagaagcta	cttgctgaga	tcttcttcag	198420
ttgggcccac	ctcctcccca	ggcctctctt	ctgttctctg	gctatgtcac	acttggactc	198480
tgcagacacc	taatgtctct	gggacctgct	ttagtctctg	acctcaccaa	ccgaggagga	198540
attgctagat	gagatccttc	ccccgggaatt	tctctcttga	acccagatg	gtccgttgcc	198600
cctttccaga	agttgctcca	gccctgtccg	ccttaggaagt	tcagtgtcat	ccttgatcca	198660
gtgggttaggg	aagacattcc	ataatgaatg	ccccagtctg	agcttcttcc	ttcaggettcc	198720
aggtgcccct	gcgaggattt	tgcagctccc	tttttaatgc	cctctagaag	tttctggctc	198780
ttattttcag	ccttctcatc	tactctctct	gacccttccc	tctatcctgt	ttagtctacc	198840
tgtagcagtt	actaccacgc	agtgaaggat	gaatcttggg	ttcgtttctt	ttctcttctt	198900
ttcttttttc	tcttctcttt	tccccctccc	ttcccttccc	tccttccaca	tcacctcacc	198960
tcacctcacc	ttacatagtc	ttgctctgtc	acccaaactg	gagtgcagtg	gcctgatctt	199020

ggctcactgc	aacctccacc	tcttcccagg	ttcaagtgat	tcttatacct	cagcctcttg	199080
agtagctgag	actacaggtg	tgcactacca	cacccagcta	atTTTTtTga	TTTTtagtag	199140
agataggggt	tagctatggt	ggccaggctg	gtctcgaact	gctgaactca	agcaatctgc	199200
catccccggc	ctcccaaagt	actgggagta	taggcataag	ccacccatga	tgcccagcct	199260
gaatcttggg	ttcttcccca	ttcattttaag	ctattacctg	ggcctgaact	caatggcacc	199320
tggcaccaac	tggcaactga	ctcttgggtc	tttattacct	accttcccta	gcaggcactg	199380
ggttgctccc	tcttccctatc	ccatggagtc	ctgtccctctg	ttgggggtcc	tactgatcct	199440
cttggaata	tgaagttctc	agctcaatgg	tgggtgggca	atgactgcc	actcttgagg	199500
ccaatgaact	caggttacc	cactcctcct	cctcctgagt	tgctcactca	ctcctcattc	199560
actcaacatt	gattcagtag	atatttgcta	cctgctctgt	gccaggtacc	aggtcagttg	199620
ctgaaggagt	aacagtgaac	atgacggagt	ctttgtcccc	aaggagaccc	aagggtgtctc	199680
ctagagccag	gggcacattg	caagaccaa	tatatccaac	ttacccaaat	aatcatagac	199740
ctagttctca	aaaagcaaga	agactgattc	ctcgttgtca	ttctcctcct	tcagcatcaa	199800
tgttttagag	tctgtgggccc	cctccaagtg	tggagtattg	tgttacttca	ccagagtttg	199860
aggagaaaca	ttcttctttt	ggaaggccgg	ggagcataga	tggatatcaa	ggctgctgtt	199920
tctaaaagcg	aaaccaccca	aacaacagta	ttagaatcat	ctgtgggtgct	tattaaagat	199980
acagattcct	gggccccatc	ccagacttat	gaatcagaat	ctctgccaga	ggaagcctga	200040
gaatttgcat	tctcagatga	ttctgcattc	tcagataaca	cattcttttag	gtgattctta	200100
cacacactgg	agtttgggaa	tcgctgaagg	ctgttcactt	ctcttttctg	agaaatgatt	200160
cattcatttc	agaaatatatt	gcagaggtcc	ttatttattg	gagatttgtg	gggtgggcaga	200220
ggagaaatat	cttgtcctca	cagagcttac	aatttttatt	ttcttttagag	gtcaccaggc	200280
ttaaaatgac	acttccctaa	attctgaaaa	gaacagattt	ttaaaacaag	aagggtactgt	200340
aatgtt.ttct	gttccctacct	cgtattttgt	tcacattaag	aacctggggg	gggaagtggg	200400
ggaggggggg	tgactggcgg	ggggccacag	agagctgagc	tgggggtggc	tcgaactcct	200460
gaactcaagc	aatctgccag	cctcagtcctc	ccaaagtgtc	gggattatag	gcatagcaca	200520
cccacgatgc	ctgggtggaa	ctcagggtcc	tggatgcctg	ggcgccccc	tctcccacac	200580
tacggcgctc	catcctagaa	gtgggttagca	cctttgagat	gggaattatt	tagcaggatg	200640
cttttgtgtt	ttcatgtaag	ttttatgctg	cctgtggagg	gcacagctgt	ttcaaaacta	200700
ataaccaaat	cctgggtctcc	gaagtctgaa	ggcatccttt	gccctgcagt	gcaaagcacg	200760
ggattctggc	ctcacacagg	caggtctgaa	cctcctgtgt	gcctcttgct	ggctgtggga	200820
cctgaggcaa	atcatgcaac	ctctcttttc	tgtttgccta	gatggaaaat	aggtttacaa	200880
tacgc'ccca	taggatggct	gtgagaatta	aagggaagtca	tgggtgtaca	atacctggcc	200940
ccgaaagatg	cttaataatt	taattctgac	cttccctcact	catttaggat	tatgtaccaa	201000
cttttagaaa	caatgaaaga	ttagttagtc	ttctgtgggt	ggtataaaaa	aaaaatagaa	201060
acatgaaaga	gatgtcctcc	ttgttcaagg	gctaatagacc	ctgggtgtgcg	ctgtctaggc	201120
cccaaggttc	ttccttccct	gtccacagca	tttcaggttc	tcgcagctt	tgctgagcct	201180
gggtcagggt	cggtatctgc	ccaccatgct	cacttgccac	agctgtggcc	ccatttccaa	201240
acttcagaga	cttaaagggtg	cagctaataga	tgtgcccggc	ctgggggtcac	attccctgag	201300
ccctgcagac	aagggtgagc	gaggctgagc	tcttatcttc	cacaccctgt	gcacagcctg	201360
ggaagagtta	aagcacccta	gtcctatgct	gcgaggggcca	catgccctga	gaccttgga	201420
aaaatcctac	ctgaattgaa	gagcatcact	atttcatcag	gaggcgctgc	catttcattt	201480
ttcacttcgg	ttttatcttg	agtgtaaaac	agcttcgcaa	atcacttttt	cttgtttctg	201540
taatgagcat	atgggtggct	cattcggtgtg	ataaatctga	gccaccacga	tatttgactt	201600
ttcacaattt	aatttatctg	aacctcttat	tctctggcta	aaaaatatcc	cttacttgga	201660
cttcttttatt	ttattttcaa	ttcccttacc	agcactagca	ggggactctg	tactcatctg	201720
ctggcgctgc	cataacaaag	cactgcagcc	tggggggctc	aaaccacaga	atttattctc	201780
tcacagtctc	agaggctaga	agtccaagat	caaagtgtgg	gcagggtcgg	tttctcctgc	201840
agcctctctc	cttggtttat	agagtgccac	cttctacctg	tgtcttcaca	tcattcctcc	201900
actgagcatg	tctgtgtcca	aatctcccc	tcttataaga	ccccagtcac	actggatgag	201960
gatccaccca	tatgagttca	ttttacctta	attatctctt	taaacaccct	gtctccaaat	202020
acagtcccat	tctgaggaac	tgagagtaaa	gattcaacat	atgaattttg	gaagggtacc	202080
aattcagccc	acaacaccct	cttttgggat	gtttattttt	ccccttaagg	agctagttag	202140
gatgtcttat	ctcatgaaca	tgactgtgaa	caggaaaaca	gggagagaat	gaagctggcc	202200
aaggaaacagg	gctgggtgtca	gctagcagtg	cttttctgat	gtgagtgggt	cccacaggga	202260
gcttggttaa	atgcagattc	tgattcattt	ggttccagag	ggacctgaga	tttcccattt	202320
ctgacaagtt	tccagtgtgg	gggctgatgc	tgctgggtcca	cggaccatac	tttgagttag	202380
aaggagcttg	atacataatg	gctgagtgtg	tttcagactc	ctgctgtaga	aaaattatga	202440
gttggtgggg	cgtgggtggct	cacgcctgta	atcccagcac	tttgggaggc	cgagggtggc	202500
agatcacctg	aggtcaggag	ttcgagacca	gcctggccaa	catggtgaaa	caccatctct	202560
acaaaaata	caaaaattag	ccaggtgtgg	tggcagggtg	ctgtaatccc	agctactcag	202620
gaggctgagg	caggagaatc	gcttgaaccc	gggaggcaga	ggttgcagtg	atctgagatc	202680
gtgccactgc	actccagctg	ggcaatagag	cttgactcag	tctcaaaaaa	aaaaaaagaa	202740
aagaaaaaga	aaaattatga	gttatattat	cagcatatgg	ggtgcctttc	aaattgataa	202800

aattttcta	attaaacctg	tggatgccaa	atgctgctct	ctgattatgg	caggaaacgg	202860
cacttggcag	tacgaagtta	gctgttgggc	tgagctggct	catcttgttg	tgcggtectg	202920
attgcctaaa	gatgccttcc	caggatcttt	actaacaatc	ctcctgagtc	atttggactt	202980
tcccaacctg	ttatcacctc	tcagatgggc	cagccatgga	ggcagtcaga	ggagggctct	203040
gcagagggag	ggcagaaaca	gggtggcctc	tgcatgccat	taggaggtca	catctcactg	203100
ggggatgcag	tttaggattt	agtgccttgg	agagaaggat	agagtatatt	aaaacatgtc	203160
tccgctaggc	atggttggtt	acgcctataa	tcccagcact	ttgggaggcc	gaggtgagtg	203220
gattgcctga	gctcaggagt	tcaagaccag	cctggctaac	atgacgaaac	ctcatctcta	203280
ctaaaataca	aaaagttagc	tgggagtggg	ggcgtgcgcc	tgtagttgca	gctacttggg	203340
aggctgaggg	atgagaatca	cttaagccca	gaagactgag	gttgacagtga	gccgagattg	203400
caccactgca	ctccagcttg	ggctacagag	tgagactcta	tctcaaaaac	aaagaaacaa	203460
acaacaacaa	taacaacaaa	aaccaagtct	ctccctccac	tcaaaaatgc	aagggcctgt	203520
ctcccattgc	tgggtgcccc	ggtctcatga	atgtagatat	gaattattcc	agtcagcctc	203580
aggagaatag	aatgagccct	cagatgccga	agcacctttc	agattccacc	ggttttatcg	203640
gctcatttaa	acttcaactc	taacacagtc	ctgcattaca	cacgtgtctg	tcgttatggg	203700
cagctgcaga	gagggcttta	atggtcctaa	tgctcagtga	ggatgcccaa	tggtcaacag	203760
aacctgccat	cttcaggcca	tcaaggagct	ctggagttaa	ggaaatcatg	agagcacaga	203820
ggggcgggta	cagcagagcc	ctcgtggtaa	tgggttttga	ggtctaggct	ctcttcactt	203880
gggtttgaaa	taagttcaat	gactagtaat	agctgagaca	cttctaccct	tcaaatgaag	203940
taaatgggaa	aatggagcat	tgttgagtcc	agggagctat	aatttaaacc	ccatatactt	204000
aaaaggggta	acatttttgt	gtgtgtgaaa	ttggtgtcat	tcgcactgca	tctacagttt	204060
tctttttcct	tctcttccag	cacccctggc	tacatatttg	ggaaacgcat	catactcttc	204120
ctgttctca	tgtccgttgc	tggcatattc	aactattacc	tcatcttctt	tttcggaagt	204180
gactttgaaa	actacataaa	gacgatctcc	accaccatct	cccctctact	tctcattccc	204240
taactctctg	ctgaatatgg	ggttggtgtt	ctcatctaata	caataacctac	aagtcagctc	204300
aattcagctc	ttgagagcat	tctgctcttc	tttagatggc	tgtaaactca	ttggccatct	204360
gggcttcaca	gcttgagtta	accttgcttt	tccgggaaca	aaatgatgtc	atgtcagctc	204420
cgcccttga	acatgaccgt	ggcccccatt	ttgctattcc	catgcatttt	gtttgtttct	204480
tcacttatcc	tgttctctga	agatgttttg	tgaccaggtt	tgtgttttct	taaaaataaaa	204540
tcgacagaca	tgattttaagc	tgatagttga	ggggttttgt	taatggcttt	tgggggattt	204600
atctctatac	ccacaaacga	ctagtttggt	ttcctcaaac	taaatgataa	tattaaaaat	204660
acacatcctg	gccagggtgtg	gtggctcata	cctgtaatcc	cagcactttg	ggaggccgag	204720
gcagggtgat	cacttgagggt	caggaattaa	gaccagcctg	gccaatatgg	tgaaagcctg	204780
tctgtactaa	aaatacaaaa	attagccagg	tatgctgggtg	gatgcttata	atcccagcta	204840
cttggggagg	tgaggcagga	gaattgcttg	aacccgggag	gtagaggttg	cagtgcagcca	204900
agatcagccc	acttgacctc	agcttgggca	acagagtgag	actccatctc	aaatataaaa	204960
aaatacacat	ctggcttctg	gaaaaattac	ttgaagatct	tttatgacat	ccatccctct	205020
tcacacagcc	atgtgaatta	ggttggtatc	ttcatatact	agcatcgtgc	ccagcacttc	205080
catgttatac	agtttataat	gttctgtaat	tccctgtggg	aacctaaagt	aatgagagga	205140
ccgtcatacg	tgcccccaaa	tattggcaaa	ccaatgaata	aatgaatgaa	tgagtttatg	205200
aatcgctaac	tggtctgtatt	taatgaagta	tgtgtgttga	gccatttccc	acagtgtgga	205260
cagattttgc	ccacaattgc	ggcctcttcc	caaaggccct	accacctaat	gccatcacac	205320
tggggatttg	atttcaacat	gtgaatttgg	ggagagtgca	aacactcaga	ccatagcacc	205380
atctcagtaa	atgtcccact	ggtcactcag	ttcatagtga	cagtgatcca	gccactgtca	205440
tgacaggtgc	cacttggcag	aaacagcaca	gcttgggaaga	tggcgggggtg	tagtcaagat	205500
tccaggatcc	ccaacagaga	agccagctct	tataggggag	ccattcatca	ggattgaact	205560
ctcaatcgag	ctggacagta	ataggtgggt	ctgtgttatt	ccccagatga	gtatcatgac	205620
agtcacaatc	ctaggaaggc	tgtgaagcct	ccccagctct	tcttccagtt	gctgtcttgg	205680
gcagcagaga	tgatggaatg	tggagtctgg	cgtgggtctga	ggcctgaatc	catgtgcctc	205740
atgtatgatg	ctcaggcaag	aggatctctc	aattcaaggg	agagggcctg	aatgagcctt	205800
gctttccagg	cctgtctgat	ggtccaggct	gaagcccctc	ctggcttgca	ctgccagacc	205860
tcatccagca	ggagctcctt	ggcattgact	gcttcaggat	agttgcttct	gctctgagtg	205920
ctctctaaa	agcagtgtct	taccatccaa	gctgggcttt	tcttttcttc	ttgctgatag	205980
ggaaggcatg	ggacattgca	ggatgggaagt	ggcccccagg	ccttctcatg	cctgggcttg	206040
gtttggaagg	tggtcagggtg	atcaataatc	ctgattggcc	tggcattgag	gagttttcct	206100
gggatgtggg	cctttcgggtt	ttttaaaaat	tatttttatt	gatacacata	ttttaggtta	206160
tttgtggggg	gcatgtgata	ctttattatg	tgtgtggatt	gtgtaatgat	gaagtcaggg	206220
catttagggt	cttcatcacc	ttgattatca	tttctatgtg	ttgagaacat	ttcaagttct	206280
cagttccagc	tattttgaaa	tagacagtcc	attttgttag	ctacagtcac	ccaacccggc	206340
tgtcagacat	tggaaacttac	tectattgaa	ctgtgtattt	gtacccattc	accaaatgct	206400
ctttgggctt	tcagttttac	aactgggatg	atcctgggaa	aactaaagta	aatcagacac	206460
ccgacgtgtg	agctaggtta	taatatgccc	agtggaccct	ggggacatct	tagctttcag	206520
aggctcatgct	gtccaagctg	actgtggggc	tccagaagg	tggggagagg	aaatgatgca	206580

atggcccatc	agaggcacta	cttggggcct	ggggccagag	tgcattgtcta	aggcattaag	206640
gggaggggag	agcagccttc	ataattatga	agaggagtct	cagggtgcaca	gcttctgatg	206700
agggacagct	tctaattgaa	gacagcattg	tgtaatgctc	aaactccctg	tcttcagagt	206760
gcctgtgtga	tcccaccatc	agttctgtga	cttctcccta	agcctcaatt	ttgcatgtgt	206820
tacattggga	taataatagt	gccaaactca	tggggttgtg	aggaataatg	aggtaaagca	206880
attgaaaagg	tttagcacia	tataagtgtc	caataaaaagc	cattattatt	attttattac	206940
actagttttc	aattcctgca	tagcaaattc	ttgcaaattg	agggactcaa	aacaatataa	207000
atttattatc	tgacagtttt	tctgggtcag	aggctctact	aggctgtaat	cagaggggcaa	207060
ccaaagctgt	gatctcagct	gaagctcagg	attctcttcc	aagctcactg	gttgttggca	207120
gaattcagtt	ctttccagtt	ggaagactaa	agcctacagt	cttcagtctc	tagaagcctt	207180
ttctctggca	caggtttctc	tacaacatgg	ccatttatgt	ctttaaggcc	aataggagaa	207240
catgattagc	atattttttt	taagtgaact	ttagaccctt	ttttaagggc	ctatctgatt	207300
aggccaggcc	caagtgaact	ttaagtcaac	tgattagaga	tcttaattac	atctgcaaag	207360
tcccttcatt	tttaccgtat	aacataactt	agtgaaggga	gtgaaattgc	aaccagggtc	207420
tgctgcact	ccacggaagg	ggattctgca	gaagtgtggg	tcacggggggg	gttatttttg	207480
gattctgcct	acgtcactga	gtcaaaagaa	gctgaatggt	tgtgatgctg	aggttttttg	207540
gcagcagcag	tgtgtgtgtg	tgagtgaatt	catacgtatg	accacctggg	aagaaaggag	207600
gctgtgggtt	cctccacctt	ctggcagaca	gagaaatttc	tttttttttt	tgagacaggg	207660
tctggctctg	ttaccccagg	tggagtgcag	tggtctgatc	tctgctcact	ggctcactgc	207720
agcctctgcc	tcccagggtt	aagtaattct	tgtgcctcaa	ctccaagtag	ctgggattac	207780
agacacacac	tgccacgcct	ggctaatttt	tgtattttta	gtagagacga	ggtttttgcca	207840
tgttggccag	gctgggtctg	aactcctgac	ctcaagtgat	ccgcccacct	cagcctccca	207900
aagtgtctgg	attacagacg	tgagccacca	ttaaccattt	ttctatctcc	tgtgggaaag	207960
ggcacagtga	aagaacagat	gaagctgaga	catacaagtg	aactcctccc	tcctctccat	208020
ttagactaaa	ataggattat	tcatactgag	attctccctg	gttgcaaaga	gataatctgt	208080
gcaactgggt	ttttacaatt	atccctaccc	tatgctttcc	tcactctgtc	tcctcgtagt	208140
cagctcaggc	tgctataaca	aaacaccata	actgggggct	tttgaacaac	aaaactttac	208200
ttctcacagt	tctagaggct	ggaaatccaa	gatcaagttt	ctggcagatt	cggtgtctaa	208260
tgaggtcctg	ctttccagtt	tatagacagt	gccttatcgc	taccgcctta	cacagtggaa	208320
ggagaggacg	agaagctcct	tgggcttttt	tttgtttctt	tctttctctc	tctctctctt	208380
tttttttttt	tttaataagg	cactaatctta	gtccattttg	tgttgctaaa	aggaacactc	208440
gaggttgagt	aattttatttt	attttaaaaa	gtggccaggc	atggagggtt	atcctgtaac	208500
cctaatectt	taggaggcca	aaacagcagg	attgtttgag	gccaggagtt	caagaccagc	208560
ctaggcaaga	tagtgagacc	ccatctaccc	catctctact	aaaattttta	aaaattagct	208620
gtgtgttgta	aagtgtgctt	gtagtcccgg	ccacttgaga	ggctgagggt	ggtggagttc	208680
aaggctgcag	tgagttatga	ttgagccact	gcactccaac	ccgggtaacg	gggcaagacc	208740
ttgtctctat	tttaaaaaaa	aaaatcttta	tgtgggtcac	tattctgggt	ggctggaaag	208800
ttcaagattg	ggcatctgca	tctggtgaca	gcctcatgtc	gcttccagtc	atgggggaag	208860
acgaaggaga	gctggcacgt	gcagatatca	cgtgttgagg	gcagaagcga	gagagagagg	208920
ggagagatgc	caggctcttt	ttacaacca	gcactgggga	aactaataga	gtgagagctc	208980
actgactcct	gaggggaggc	attaatctat	tgatgagcga	cctgcctcca	tgacccaaac	209040
acctccaacg	tcaacccacc	tccaacactg	ccacactagg	gattaacttt	caacttgaga	209100
tttagagggg	ggaaacttac	aaactatcgc	aggcactaat	accactcatg	agggctccac	209160
cttcatgacc	taatcacttc	ctaaaggcct	tacctcttaa	tctcatcaca	ttgaggattc	209220
gattttcaact	tgaatttttg	ggggacacca	acattcaggc	catagcatca	tctcaataac	209280
tgtcccattg	gtgggtcactc	aggccccaaa	caaagggaacc	ttcctccatt	cctttccgcc	209340
ctcccaccca	cagtcaatca	tccccaaagt	ccatcagctc	cacctttaac	ggccaaccca	209400
cctctgccac	atctcaccat	ctccactgct	atccctgtca	cctggggcca	ccattctctc	209460
tcctggacag	tctccatagc	cacctctgtc	agatttattt	tattttttta	tttttttttt	209520
tgagacaggt	tcctgctctg	ttgcccagac	tggagtgtcca	tggcatgatc	acatctcact	209580
gcggcctcca	tcacctgggc	tcaagcaatc	ctcccatctc	agcctcccaa	gtagctggga	209640
ctactggcac	caccatacct	ggctaatttt	ttgttgttgt	tgtttaattt	ttaatacaga	209700
tgaagcctca	ctatgttgcc	caggctgtct	ttgaactcct	gggtcaagt	gacctccgg	209760
ccttggcctc	ccaaagtgtc	gggattacag	gcctgagcca	ccgtgccag	ccatcagat	209820
gttaatgcta	cacgcacttg	cttaaaatcc	ccagataaat	tctcgctgct	ccttggaataa	209880
ttcccacaca	ccttggcggtg	gccatgcagg	ctctgtgtcca	tcggatatgt	ccctgcccc	209940
tctcccaact	cctcctttcg	cttgctcggt	cactcagttc	cagccacatt	gccctgggag	210000
ctgctcccac	catggggctt	cctaattgcac	tgggtctctc	catgcagtgg	ggcctctccc	210060
tccttttact	cagtgtctcc	cagcaccacc	ctcctccaga	gccttccctg	accaccacac	210120
ctacacactag	gcccttctc	ctccacgctc	cctcctccac	cccggcctcc	taccacagtg	210180
tactttcttt	atactcgtcg	ccacctgaaa	ttagatcatt	tatttaccce	tttatttgtt	210240
cagtttgctt	tgtccgttag	aatataagct	tccaaagggc	aggagctttg	cctatatattg	210300
taggccgggc	atacaatgag	cactcaaaaa	aatatttgat	gagtgtatga	aagaacagac	210360

tgggttatgt	aattgtgcct	acttacctat	atgaccgtgt	ggtgggggtt	atgggtgggtg	210420
tgggtggtgat	ggctataggg	ctataagcaa	at ttggggaca	gggagtctaa	gaaatgttct	210480
taaatttttag	taagcaaagc	atcctctaca	gaacctgtct	taaaacatga	aagttcctta	210540
gtgctacccc	cagaggtatg	at ttggtagg	tcaaggatag	ggcctggaaa	ttcacattct	210600
tggttaagatg	ttcttcatcc	gggggtttgtt	gaccaccttt	tcagaagatt	tttgctctgt	210660
agctgtacta	cccaatgcag	tagttcgtag	tcagtgtggc	tcctgagccc	ttgaagtgtg	210720
gctcctctga	actgagacgt	gctgtaaagt	taaattgcac	accggagttt	gaagagttaa	210780
tacaaagaaa	aaggaatgca	aaacatctca	tttaataatgc	tttactactga	ttacatattg	210840
aaatggtaat	cttgtagata	tagtgcgtta	aataaaaatat	actgttaggc	traatttcac	210900
gtcttttatac	ttttaatgtg	gctactagaa	aaat ttaaat	aacatattca	gctcacatta	210960
tactcctatt	gaacagagct	gatctataag	ttccatggaa	gatggcaagt	cttcgcagct	211020
gaaataaagg	ctggatccca	ttctacgggc	tcactcttag	caatgatttc	ttgcagacga	211080
tattgaaaaa	tgtggcaatg	aaagt tacca	caagcatcaa	accagtcctg	cctaaatctg	211140
gaaaatagtt	atctgaggct	gttagcatat	gatcatgaga	gcgtttcacc	atggatttct	211200
gatcacagat	gtggcacatt	attaaaatat	cactttttaca	gtcaccctag	aggctagggt	211260
tatctgaata	tggagaaaga	aacagcttgt	ggagctgttg	tataaatgaa	attactagaa	211320
agtaatgcac	tcaattgcat	attggctcgg	gggggttattc	ttattaaaat	gtttagagag	211380
gactttctgt	tcattttctgc	agaattgtct	ttcaaattaa	gaatttgctt	gacacgctaa	211440
tagaccacag	tcccaagaga	agtttatcct	tttttcttct	tatccttgct	aagcacttag	211500
atgctctgct	gataggtagc	atatattgtc	tatatgaagc	ttttgtgtta	acattgacta	211560
gtcctgcaag	ttggcacact	cttacttggc	ctaaaagaaa	tcagcaccag	gctttaagaa	211620
aatcagatga	tctacctaaa	ggaacacaac	tctgtctctc	ttttgacaat	tggtgtaaac	211680
aaattttaat	ggaaatttgc	cttaatttgtg	aagaagttgc	tgctaaaatg	gacttgccat	211740
taatggactg	gaacccattg	cataagcaga	atgaaatata	agccttctca	ggattcacac	211800
ttataaaaaa	ccatttcagcc	aatcaacaag	agggcaaaaag	aacaaacatt	tgatgtgtta	211860
ttacttaatt	tagtgcataat	gcatttgggt	cctcaatgtc	agcactatgg	caaccagaac	211920
atggccacaa	taactgtctg	gaaatgtcta	ttcttacctg	gaccagcag	gccatgcccc	211980
actgattata	taatctccct	ctctccttgt	tacggctga	atgcttgcat	ccctcaaaaa	212040
ttcatgtgtt	gaaatcctaa	cccccaaggt	gatgatatta	ggaggtcggc	cttttgagag	212100
gttattagggt	catgaagaca	gcactcctcat	gaatgggatt	agtgtcctta	taaaataggc	212160
ccaagggagc	tcattcactt	tgtccaccat	gtgagaacac	agcgagagg	caccatttat	212220
gcaccaggaa	atgggccttt	tccagacaat	ctgtcgggtgc	ctggatcttg	gacttcacag	212280
cctctagaac	tgtgagaaat	taatttgttt	tttataagcc	accaaactta	tggttttttt	212340
tatagaaacc	gtaatggact	aaaacactcc	ctaattatat	ttaaacttat	cagtgcactg	212400
ggcagtgaac	tattaaaaga	atgctggcca	acgtaattga	caccataagg	ctggatgatt	212460
cttgtaatttt	tcagcctcag	aaaaaggctg	gggagaggag	tcaggggaaa	ggaggtgggtg	212520
tgtgtgtgtg	tgtgtgtgtg	tgtgtgtgtg	tgtgtgtgtg	gggtggatgcc	tgctgagag	212580
gaaagagcta	taataacatt	ctgtgggttca	gctgacacat	cctttctgca	tccccctcaa	212640
tcacctgggt	taatggggac	ctcgctaattg	tctgaacctc	atctcatttt	aaccttttgt	212700
ttcaaagcct	ctcttttcat	gacttccccg	ccttcatttt	tcccatatgg	tgggtttatt	212760
attaagacat	taaatgagag	tggacaggta	ggcaaaggag	gtgggttgca	ggggagt tga	212820
gggttgccctg	tgtacttttc	tagactgttc	cacttcacat	cagtgaata	ttcccaattg	212880
atactatcat	gaaacaaagc	aaatgaaatg	ctgagcacgg	agcttcgtct	tgatgaaatg	212940
ctgaaagaaa	agaaaggaaa	aataaagtag	ccattat ttt	tgcccttctc	cccaccccca	213000
tgtttactac	tcttatttct	cttttgattt	gttgtgttg	aagcacagca	tcagaaaaac	213060
tcccagtttt	gagagataac	tcagtgttta	gttcaacttaa	acctgagaaa	ggagaagagg	213120
atgccaccgt	gaggtccagg	acgtaaagag	gaaaaaaaaca	gacaaaaaaa	tcccatatgaa	213180
atgaaaatgt	gaaagaggcg	ctttcgagca	gatgagtgtt	gtagattaca	gtgttgagag	213240
ctgtttgtgt	ccagagctgc	ttgctgcacc	tggcgggata	aacactggtc	taacagagga	213300
tccttgtttc	aaggaggctg	ccttttattt	gggggggacaa	aattgttctt	gaaagctgct	213360
cagtgggttca	agctacagca	tgggtggacta	gcagaatgga	ctccagggcc	tccgaggaga	213420
cagtgactgc	tgccagaaat	agtcaaggat	agaaagggaag	gacttcactg	aggcctggga	213480
gaagattatg	gaatgggact	gacagcagtg	acggggagta	aaaggggggtg	tctgggggaa	213540
ttgtgcccc	tggtagagc	tagaggggtc	acaaagactt	aacccgacgc	atctctctca	213600
ccctggagat	tgggcccgtt	caatctaact	ggatggctat	aatttaaaaag	gtttaggtat	213660
tatgacaaac	atggatatat	taggtgatag	caatgcaaaa	tgcatatggc	ttcttgatat	213720
aaaacacaag	acttgaaagc	agcatctttg	gctgggtact	acagccaccc	tcctctgtca	213780
ctaagggagg	ctttgggtgga	aagggctgag	agcctctaga	ctgtgaacaa	aagtaggcac	213840
agaagaacag	ttggagataa	taagtaaacc	atcttgacag	gaatgaagaa	tttctgaaa	213900
ggaaggtccc	tgagttaggt	tttcagtagt	atgtgtgtgt	gagttattga	aagtgtttgg	213960
gggggtgtgtg	tgtgtgtgtg	tatgtgcagt				214000

<210> 2  
 <211> 161  
 <212> PRT  
 <213> Homo sapiens

<400> 2

```

Met Asp Gln Glu Thr Val Gly Asn Val Val Leu Leu Ala Ile Val Thr
 1          5          10          15

Leu Ile Ser Val Val Gln Asn Gly Phe Phe Ala His Lys Val Glu His
          20          25          30

Glu Ser Arg Thr Gln Asn Gly Arg Ser Phe Gln Arg Thr Gly Thr Leu
          35          40          45

Ala Phe Glu Arg Val Tyr Thr Ala Asn Gln Asn Cys Val Asp Ala Tyr
          50          55          60

Pro Thr Phe Leu Ala Val Leu Trp Ser Ala Gly Leu Leu Cys Ser Gln
          65          70          75          80

Val Pro Ala Ala Phe Ala Gly Leu Met Tyr Leu Phe Val Arg Gln Lys
          85          90          95

Tyr Phe Val Gly Tyr Leu Gly Glu Arg Thr Gln Ser Thr Pro Gly Tyr
          100          105          110

Ile Phe Gly Lys Arg Ile Ile Leu Phe Leu Phe Leu Met Ser Val Ala
          115          120          125

Gly Ile Phe Asn Tyr Tyr Leu Ile Phe Phe Phe Gly Ser Asp Phe Glu
          130          135          140

Asn Tyr Ile Lys Thr Ile Ser Thr Thr Ile Ser Pro Leu Leu Leu Ile
          145          150          155          160

Pro
```

<210> 3  
 <211> 873  
 <212> DNA/RNA  
 <213> Homo sapiens

<400> 3

```

acttcccctt cctgtacagg gcaggttgtg cagctggagg cagagcagtc ctctctgggg 60
agcctgaagc aaacatggat caagaaactg taggcaatgt tgcctgttg gccatcgta 120
ccctcatcag cgtgggtccag aatggattct ttgcccataa agtggagcac gaaagcagga 180
cccagaatgg gaggagcttc cagaggaccg gaacacttgc ctttgagcgg gtctacactg 240
ccaaccagaa ctgtgtagat gcgtacccca ctttcctcgc tgtgctctgg tctgcggggc 300
tactttgcag ccaagttcct gctgcgtttg ctggactgat gtacttggtt gtgaggcaaa 360
agtactttgt cggttaccta ggagagagaa cgcagagcac ccctggctac atatttggga 420
aacgcatcat actcttctg ttctcatgt cgttgctgg catattcaac tattacctca 480
tcttcttttt cggaggtgac tttgaaaact acataaagac gatctccacc accatctccc 540
ctctacttct cattccctaa ctctctgctg aatatggggg tgggtgtctc atctaataca 600
tacctacaag tcatcataat tcagctcttg agagcattct gctcttcttt agatggctgt 660
aaatctattg gccatctggg cttcacagct tgagttaacc ttgcttttcc gggaaacaaa 720
tgatgtcatg tcagctccgc cccttgaaca tgaccgtggc cccaaatttg ctattcccat 780
gcattttgtt tgtttcttca cttatcctgt tctctgaaga tgttttgtga ccaggtttgt 840
gttttcttaa aataaaatgc agagacatgt ttt                                     873
```

<210> 4

<211> 24	
<212> DNA	
<213> Homo sapiens	
<400> 4	
ccttttgcttt gttcctatctt cttt	24
<210> 5	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 5	
tcccattgcc cagagttaat	20
<210> 6	
<211> 23	
<212> DNA	
<213> Homo sapiens	
<400> 6	
tcctcatgtc ttcacctaga agc	23
<210> 7	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 7	
ccactcatga gggagctggt	20
<210> 8	
<211> 21	
<212> DNA	
<213> Homo sapiens	
<400> 8	
tgtcacaggc acacactctc t	21
<210> 9	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 9	
gagtatggct gctgctctc	20
<210> 10	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 10	
atggctcaca ctggcctaaa	20
<210> 11	
<211> 23	
<212> DNA	
<213> Homo sapiens	
<400> 11	
tgaacagacc aataatagtg cag	23



<210> 12	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 12	
aagccaccct ttaaacagca	20
<210> 13	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 13	
gctgaggaag caactccact	20
<210> 14	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 14	
gctctgaatt ccctggcata	20
<210> 15	
<211> 21	
<212> DNA	
<213> Homo sapiens	
<400> 15	
ttagccctag tcccactctc c	21
<210> 16	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 16	
caagaggcct gcataaggaa	20
<210> 17	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 17	
agattgccgg tggcttaaatt	20
<210> 18	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 18	
tgtctgttcc .cgtctgtctg	20
<210> 19	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 19	
ttcatcctct gccaaattcc	20

<210> 20	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 20	
ggcatgtatt cactgcctga	20
<210> 21	
<211> 23	
<212> DNA	
<213> Homo sapiens	
<400> 21	
aaacccattc ttcttcctct tac	23
<210> 22	
<211> 21	
<212> DNA	
<213> Homo sapiens	
<400> 22	
tatgtgttca gcccagacct c	21
<210> 23	
<211> 19	
<212> DNA	
<213> Homo sapiens	
<400> 23	
ccctgccatg tgcatttac	19
<210> 24	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 24	
catttcggaa ggcaaagaaa	20
<210> 25	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 25	
ttgcaatgag gaatgaagca	20
<210> 26	
<211> 23	
<212> DNA	
<213> Homo sapiens	
<400> 26	
tccattatcc atctgttcat tca	23
<210> 27	
<211> 25	
<212> DNA	
<213> Homo sapiens	
<400> 27	
gaagaattaa ttgtaggagg caaga	25

<210> 28	
<211> 21	
<212> DNA	
<213> Homo sapiens	
<400> 28	
ctgacatcac cacattgatc g	21
<210> 29	
<211> 22	
<212> DNA	
<213> Homo sapiens	
<400> 29	
catacacagc catgtggaat ta	22
<210> 30	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 30	
acggtgatga cgctacatt	20
<210> 31	
<211> 23	
<212> DNA	
<213> Homo sapiens	
<400> 31	
tcacatggac caattaccta gaa	23
<210> 32	
<211> 25	
<212> DNA	
<213> Homo sapiens	
<400> 32	
aaattacttc atcttgacga taaca	25
<210> 33	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 33	
ctattgggga ctgcagagag	20
<210> 34	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 34	
agccagtgtc cacaagggaag	20
<210> 35	
<211> 21	
<212> DNA	
<213> Homo sapiens	
<400> 35	
gagggtgaga cacatctctg g	21

<210> 36	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 36	
aatcgtgcct cagttccatc	20
<210> 37	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 37	
ccaccaggaa caacacacac	20
<210> 38	
<211> 18	
<212> DNA	
<213> Homo sapiens	
<400> 38	
ttgctctcca gcctgggc	18
<210> 39	
<211> 18	
<212> DNA	
<213> Homo sapiens	
<400> 39	
ttcctctggc tgctgcg	18
<210> 40	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 40	
tcctgcatga gaaggaactg	20
<210> 41	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 41	
cgacattcac tgtggtctt	20
<210> 42	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 42	
tttgattccg tggccatta	20
<210> 43	
<211> 21	
<212> DNA	
<213> Homo sapiens	
<400> 43	
ttatttggtc ggtgcacctt t	21

<210> 44	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 44	
ggtgcaccga ccaaataagt	20
<210> 45	
<211> 22	
<212> DNA	
<213> Homo sapiens	
<400> 45	
ccagcttatt ctctctgcct tc	22
<210> 46	
<211> 22	
<212> DNA	
<213> Homo sapiens	
<400> 46	
ggtaggttga aatgggctaa ca	22
<210> 47	
<211> 21	
<212> DNA	
<213> Homo sapiens	
<400> 47	
tcatgacaag gtgttggatt t	21
<210> 48	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 48	
cctcctctgc catgaagcta	20
<210> 49	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 49	
ctatttggtc tgcgggttgt	20
<210> 50	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 50	
tactgggtta tcgctgacc	20
<210> 51	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 51	
ccaatggacc tcttggacat	20

<210> 52	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 52	
tttcggcaca gtcctcaata	20
<210> 53	
<211> 19	
<212> DNA	
<213> Homo sapiens	
<400> 53	
cagctgggtg tggtagacat	19
<210> 54	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 54	
cagagaggaa caggcagagg	20
<210> 55	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 55	
agtggctggg aagccttatt	20
<210> 56	
<211> 23	
<212> DNA	
<213> Homo sapiens	
<400> 56	
aggtgagaga acaaacctgt ctt	23
<210> 57	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 57	
gccttccttc taaggccaac	20
<210> 58	
<211> 26	
<212> DNA	
<213> Homo sapiens	
<400> 58	
ctgtagactt tatccctgac ttactg	26
<210> 59	
<211> 24	
<212> DNA	
<213> Homo sapiens	
<400> 59	
caatgaatga tgaagattcc actc	24

<210> 60	
<211> 23	
<212> DNA	
<213> Homo sapiens	
<400> 60	
tgacaccatg tcttactggt tgc	23
<210> 61	
<211> 25	
<212> DNA	
<213> Homo sapiens	
<400> 61	
gaggatacaa tgagaaccaa atctc	25
<210> 62	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 62	
caggatcatc agccaggttt	20
<210> 63	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 63	
gctgcatgtc actaggcatt	20
<210> 64	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 64	
ccacagaatg ctccaaaggt	20
<210> 65	
<211> 22	
<212> DNA	
<213> Homo sapiens	
<400> 65	
gagttcaagt gatggatgac ga	22
<210> 66	
<211> 24	
<212> DNA	
<213> Homo sapiens	
<400> 66	
cagatagatg aataggtgga tgga	24
<210> 67	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 67	
cactgttcca agtgctttgc	20

<210> 68	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 68	
tatgcgttgt gtgtgctgtg	20
<210> 69	
<211> 22	
<212> DNA	
<213> Homo sapiens	
<400> 69	
gggccttaga ttctttagt gg	22
<210> 70	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 70	
tgtccagact gcctcctaca	20
<210> 71	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 71	
tgcaacacct gggttcacaat	20
<210> 72	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 72	
tttgcgagtc cttgtggagt	20
<210> 73	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 73	
acagtcgct ccctcctaata	20
<210> 74	
<211> 18	
<212> DNA	
<213> Homo sapiens	
<400> 74	
atgcttgccc ctcagttt	18
<210> 75	
<211> 21	
<212> DNA	
<213> Homo sapiens	
<400> 75	
ttggcaaccc aagctaatat g	21



<210> 76	
<211> 19	
<212> DNA	
<213> Homo sapiens	
<400> 76	
ctccacagtg acagtgagg	19
<210> 77	
<211> 17	
<212> DNA	
<213> Homo sapiens	
<400> 77	
gagaggttcc caatccc	17
<210> 78	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 78	
cagctcctgg ccatatttct	20
<210> 79	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 79	
gagccatttc tctgggtctg	20
<210> 80	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 80	
ggtccgtgtc aacccttaga	20
<210> 81	
<211> 19	
<212> DNA	
<213> Homo sapiens	
<400> 81	
caggttgatg ggagggaaa	19
<210> 82	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 82	
cgggaaatga cagtgagacc	20
<210> 83	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 83	
tgcctagatt ctcccgtaag	20

<210> 84	
<211> 16	
<212> DNA	
<213> Homo sapiens	
<400> 84	
gtgcccagcc agattc	16
<210> 85	
<211> 16	
<212> DNA	
<213> Homo sapiens	
<400> 85	
gccccagtc aggttt	16
<210> 86	
<211> 21	
<212> DNA	
<213> Homo sapiens	
<400> 86	
tttctctctc cacggaatga a	21
<210> 87	
<211> 21	
<212> DNA	
<213> Homo sapiens	
<400> 87	
aaccattct cacagggtgt a	21
<210> 88	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 88	
aggagtgtgg cagctttgag	20
<210> 89	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 89	
tggattcccg tgagtaccag	20
<210> 90	
<211> 17	
<212> DNA	
<213> Homo sapiens	
<400> 90	
atgctgggat cacaggc	17
<210> 91	
<211> 19	
<212> DNA	
<213> Homo sapiens	
<400> 91	
aacctggtgg acttttgct	19

<210> 92	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 92	
agcatttcca atggtgcttt	20
<210> 93	
<211> 21	
<212> DNA	
<213> Homo sapiens	
<400> 93	
catgttgata tgcctgaagg a	21
<210> 94	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 94	
cactgtctgc tgccactcat	20
<210> 95	
<211> 27	
<212> DNA	
<213> Homo sapiens	
<400> 95	
agagattatg tgatgtaocc tctctat	27
<210> 96	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 96	
tgatgaagat ctgggcgtta	20
<210> 97	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 97	
tgctgtgct cactcactct	20
<210> 98	
<211> 22	
<212> DNA	
<213> Homo sapiens	
<400> 98	
atgacctaga aatgatactg gc	22
<210> 99	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 99	
cagacaccac aacacacatt	20

<210> 100	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 100	
tggtttaaaa acctcatgcc	20
<210> 101	
<211> 25	
<212> DNA	
<213> Homo sapiens	
<400> 101	
atcccaaact ctgtacttat gtagg	25
<210> 102	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 102	
ccttggtgtgt tgtgactggt	20
<210> 103	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 103	
cactcaggtg ggaggatcac	20
<210> 104	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 104	
cactttgcca gtagccttga	20
<210> 105	
<211> 21	
<212> DNA	
<213> Homo sapiens	
<400> 105	
ttgggaaagt taacccagag a	21
<210> 106	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 106	
tttgggaaga gccatgagac	20
<210> 107	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 107	
ctctgggcat tggaggatta	20

<210> 108	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 108	
gggagacaag tcaggtgagg	20
<210> 109	
<211> 26	
<212> DNA	
<213> Homo sapiens	
<400> 109	
ctgagtatgg agtcttcatc attatc	26
<210> 110	
<211> 22	
<212> DNA	
<213> Homo sapiens	
<400> 110	
tgctactaga ttgaccaac ca	22
<210> 111	
<211> 26	
<212> DNA	
<213> Homo sapiens	
<400> 111	
gacttgtaaa ggatttagtg atttcg	26
<210> 112	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 112	
gtggaaggcc tctctctgtg	20
<210> 113	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 113	
tgcttcttga gggaaagcat	20
<210> 114	
<211> 21	
<212> DNA	
<213> Homo sapiens	
<400> 114	
ccttcagagg atttccttt c	21
<210> 115	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 115	
ctggtttgac tccagcttca	20

<210> 116	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 116	
cctggcacgg aatagacact	20
<210> 117	
<211> 19	
<212> DNA	
<213> Homo sapiens	
<400> 117	
ggcctccttt gctctgaag	19
<210> 118	
<211> 21	
<212> DNA	
<213> Homo sapiens	
<400> 118	
catccctgtg gctgattaag a	21
<210> 119	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 119	
aacagttcca gcccgttcta	20
<210> 120	
<211> 22	
<212> DNA	
<213> Homo sapiens	
<400> 120	
tttcaaagga atatccaagt gc	22
<210> 121	
<211> 24	
<212> DNA	
<213> Homo sapiens	
<400> 121	
tggcgtagca tataaacagt tctc	24
<210> 122	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 122	
ttcaatgaag gtgccgaagt	20
<210> 123	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 123	
tgtctatccc aaagctgcaa	20

<210> 124	
<211> 21	
<212> DNA	
<213> Homo sapiens	
<400> 124	
gctcagtcca agttcatgct c	21
<210> 125	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 125	
tgggattggg ttctggatac	20
<210> 126	
<211> 22	
<212> DNA	
<213> Homo sapiens	
<400> 126	
cctactttcc atctactcct tg	22
<210> 127	
<211> 24	
<212> DNA	
<213> Homo sapiens	
<400> 127	
tggagtaagt tggagaattg ttga	24
<210> 128	
<211> 24	
<212> DNA	
<213> Homo sapiens	
<400> 128	
gcaagactct gttgaagaag aaga	24
<210> 129	
<211> 21	
<212> DNA	
<213> Homo sapiens	
<400> 129	
tccctctgtt tgagtttctc g	21
<210> 130	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 130	
ccttgggcag tcagagaaac	20
<210> 131	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 131	
cccgtgaagt ctgagaggtg	20

<210> 132	
<211> 19	
<212> DNA	
<213> Homo sapiens	
<400> 132	
aggcacagtc gctcatgtc	19
<210> 133	
<211> 24	
<212> DNA	
<213> Homo sapiens	
<400> 133	
aaacttttagc taatggtggt caaa	24
<210> 134	
<211> 25	
<212> DNA	
<213> Homo sapiens	
<400> 134	
gagcatgtgt gactttcata ttcag	25
<210> 135	
<211> 22	
<212> DNA	
<213> Homo sapiens	
<400> 135	
agtggctatt cattgctaca gg	22
<210> 136	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 136	
ttgctggatg ctggtttcta	20
<210> 137	
<211> 27	
<212> DNA	
<213> Homo sapiens	
<400> 137	
aaagagagag agaaagagaa agaaaga	27
<210> 138	
<211> 22	
<212> DNA	
<213> Homo sapiens	
<400> 138	
aaagtggatg cagttgaggt tt	22
<210> 139	
<211> 22	
<212> DNA	
<213> Homo sapiens	
<400> 139	
gctagccatt acagacaacc aa	22



<210> 140	
<211> 21	
<212> DNA	
<213> Homo sapiens	
<400> 140	
cagggctcca tgtatccata a	21
<210> 141	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 141	
caatctttgg ctttgggttt	20
<210> 142	
<211> 16	
<212> DNA	
<213> Homo sapiens	
<400> 142	
ctggttgagc ggcatt	16
<210> 143	
<211> 16	
<212> DNA	
<213> Homo sapiens	
<400> 143	
tgcagcctgg atgaca	16
<210> 144	
<211> 22	
<212> DNA	
<213> Homo sapiens	
<400> 144	
cctatggaag catagggaag aa	22
<210> 145	
<211> 21	
<212> DNA	
<213> Homo sapiens	
<400> 145	
cccacttctg agtctcctga t	21
<210> 146	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 146	
gggaaatgga gctgctgtta	20
<210> 147	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 147	
gagtgggtga gtgcaaggat	20

<210> 148	
<211> 17	
<212> DNA	
<213> Homo sapiens	
<400> 148	
ctctcagcag gcatcca	17
<210> 149	
<211> 19	
<212> DNA	
<213> Homo sapiens	
<400> 149	
gccaacgtaa ttgacacca	19
<210> 150	
<211> 21	
<212> DNA	
<213> Homo sapiens	
<400> 150	
tgaaaggaag gtcctgagt t	21
<210> 151	
<211> 21	
<212> DNA	
<213> Homo sapiens	
<400> 151	
ccctgctttg cacaagttat c	21
<210> 152	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 152	
cacatgaggc tgtatgtgga	20
<210> 153	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 153	
tgtgcaggaa tgagaagtcg	20
<210> 154	
<211> 18	
<212> DNA	
<213> Homo sapiens	
<400> 154	
ccttaggccc cataatct	18
<210> 155	
<211> 21	
<212> DNA	
<213> Homo sapiens	
<400> 155	
caaattcctc aattgcaaaa t	21

<210> 156	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 156	
ggtcattcag ggagccattc	20
<210> 157	
<211> 25	
<212> DNA	
<213> Homo sapiens	
<400> 157	
ccattatatt tcaccaagag gctgc	25
<210> 158	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 158	
agtcaaggct gacagggaag	20
<210> 159	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 159	
gctctcagcc ctcaatgtgt	20
<210> 160	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 160	
atttgggttc ctctcccaat	20
<210> 161	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 161	
acaaactctt gctgctggtg	20
<210> 162	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 162	
tgcttggtca tctaccatt	20
<210> 163	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 163	
tctactgcag cgctgatctt	20

<210> 164	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 164	
tccttccaga aggtttgcat	20
<210> 165	
<211> 23	
<212> DNA	
<213> Homo sapiens	
<400> 165	
tgcaaagttg ttcaagagag aca	23
<210> 166	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 166	
cagcaggaag atggacaggt	20
<210> 167	
<211> 21	
<212> DNA	
<213> Homo sapiens	
<400> 167	
cacactgcat cacacatacc c	21
<210> 168	
<211> 18	
<212> DNA	
<213> Homo sapiens	
<400> 168	
tatgccagta tgcttgct	18
<210> 169	
<211> 19	
<212> DNA	
<213> Homo sapiens	
<400> 169	
gtcacatcag tccatttgc	19
<210> 170	
<211> 23	
<212> DNA	
<213> Homo sapiens	
<400> 170	
ggtttatgtc tgtgtgtgtg tgc	23
<210> 171	
<211> 23	
<212> DNA	
<213> Homo sapiens	
<400> 171	
tgagggatgt cagagaaata tgc	23

<210> 172	
<211> 22	
<212> DNA	
<213> Homo sapiens	
<400> 172	
tgatgaaatt gcctagtgat gc	22
<210> 173	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 173	
ggatccaatc gtacgctacc	20
<210> 174	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 174	
acctaaacac cacggactgg	20
<210> 175	
<211> 22	
<212> DNA	
<213> Homo sapiens	
<400> 175	
caggtatcga cattcttcca aa	22
<210> 176	
<211> 26	
<212> DNA	
<213> Homo sapiens	
<400> 176	
ggtgatctag ggaattatct gtcttc	26
<210> 177	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 177	
ttggccacta aggtccagat	20
<210> 178	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 178	
cctttgaggc tggatctggt	20
<210> 179	
<211> 23	
<212> DNA	
<213> Homo sapiens	
<400> 179	
tttccttatc attcattccc tca	23

<210> 180	
<211> 22	
<212> DNA	
<213> Homo sapiens	
<400> 180	
agatattgtc tccgttccat ga	22
<210> 181	
<211> 22	
<212> DNA	
<213> Homo sapiens	
<400> 181	
cccagatata aggacctggc ta	22
<210> 182	
<211> 23	
<212> DNA	
<213> Homo sapiens	
<400> 182	
tttaagccct gtggaatgta ttt	23
<210> 183	
<211> 21	
<212> DNA	
<213> Homo sapiens	
<400> 183	
gacattgcag gtcaagtagg g	21
<210> 184	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 184	
tgcataaggc tggagacaga	20
<210> 185	
<211> 19	
<212> DNA	
<213> Homo sapiens	
<400> 185	
cacagcagat gggagcaaa	19
<210> 186	
<211> 21	
<212> DNA	
<213> Homo sapiens	
<400> 186	
agccagttgt ctttcattct g	21
<210> 187	
<211> 23	
<212> DNA	
<213> Homo sapiens	
<400> 187	
tgctgtgct.tgtatattct gtg	23

<210> 188	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 188	
gtgcatgtgc ataccagacc	20
<210> 189	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 189	
ggcaagatga cctctggaaa	20
<210> 190	
<211> 22	
<212> DNA	
<213> Homo sapiens	
<400> 190	
tttgtgttcc aggtgagaat tg	22
<210> 191	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 191	
gaaccatata ccaaggcact	20
<210> 192	
<211> 22	
<212> DNA	
<213> Homo sapiens	
<400> 192	
ttgttccac attcattcta ca	22
<210> 193	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 193	
ttaaactcgt ggcaaagacg	20
<210> 194	
<211> 18	
<212> DNA	
<213> Homo sapiens	
<400> 194	
caccatgcct ggctcttt	18
<210> 195	
<211> 22	
<212> DNA	
<213> Homo sapiens	
<400> 195	
aacttctcca gttgtgtggt tg	22

<210> 196	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 196	
cctaccattg acactctcag	20
<210> 197	
<211> 16	
<212> DNA	
<213> Homo sapiens	
<400> 197	
tagggccatc cattct	16
<210> 198	
<211> 25	
<212> DNA	
<213> Homo sapiens	
<400> 198	
tctgtgtgta ttgtgtactc ctctg	25
<210> 199	
<211> 22	
<212> DNA	
<213> Homo sapiens	
<400> 199	
tcacacaatt tgaaccaatc ct	22
<210> 200	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 200	
accaagatat gaaggccaaa	20
<210> 201	
<211> 22	
<212> DNA	
<213> Homo sapiens	
<400> 201	
cctccagcta gaacaatgtg aa	22
<210> 202	
<211> 21	
<212> DNA	
<213> Homo sapiens	
<400> 202	
tgatcatgtc agcagcagaa g	21
<210> 203	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 203	
agtaacaggt gagggcatgg	20



<210> 204  
 <211> 21  
 <212> DNA  
 <213> Homo sapiens  
  
 <400> 204  
 tgtccatagc ttagccctg t 21  
  
 <210> 205  
 <211> 20  
 <212> DNA  
 <213> Homo sapiens  
  
 <400> 205  
 ctcaatgggc atctttaggc 20  
  
 <210> 206  
 <211> 22  
 <212> DNA  
 <213> Homo sapiens  
  
 <400> 206  
 caaacaaca aacaagcaa cc 22  
  
 <210> 207  
 <211> 21  
 <212> DNA  
 <213> Homo sapiens  
  
 <400> 207  
 tggacgtttc tttcagtgag g 21  
  
 <210> 208  
 <211> 23  
 <212> DNA  
 <213> Homo sapiens  
  
 <400> 208  
 tgataactta ccagcatgtg agc 23  
  
 <210> 209  
 <211> 21  
 <212> DNA  
 <213> Homo sapiens  
  
 <400> 209  
 tcacctcacc taaggatctg c 21  
  
 <210> 210  
 <211> 23  
 <212> DNA  
 <213> Homo sapiens  
  
 <400> 210  
 gctagcaaat ctctcaactt cca 23  
  
 <210> 211  
 <211> 20  
 <212> DNA  
 <213> Homo sapiens  
  
 <400> 211  
 tcttctccat gctgcttcct 20

<210> 212	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 212	
catgcaattg cccaatagag	20
<210> 213	
<211> 22	
<212> DNA	
<213> Homo sapiens	
<400> 213	
ttgggcttgt ctacctagtt ca	22
<210> 214	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 214	
gctgcacgta tttgttggtg	20
<210> 215	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 215	
aaacagcaga aatgggaacc	20
<210> 216	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 216	
ccgtgggcta tcaatttctg	20
<210> 217	
<211> 21	
<212> DNA	
<213> Homo sapiens	
<400> 217	
aagatgcaat ctggtttcca a	21
<210> 218	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 218	
cccaagactg aggaggtcaa	20
<210> 219	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 219	
gctgacggag aggaaagaga	20

<210> 220	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 220	
tcacaaagca agcaatcaca	20
<210> 221	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 221	
tgatggatgc accatgttta	20
<210> 222	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 222	
tgagaagcct gggcattaag	20
<210> 223	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 223	
acaagctcat ccagggaaag	20
<210> 224	
<211> 19	
<212> DNA	
<213> Homo sapiens	
<400> 224	
agagctgatac tggccgaag	19
<210> 225	
<211> 21	
<212> DNA	
<213> Homo sapiens	
<400> 225	
ggtggacaca gaatccacac t	21
<210> 226	
<211> 18	
<212> DNA	
<213> Homo sapiens	
<400> 226	
ggcctgaaag gtatcctc	18
<210> 227	
<211> 18	
<212> DNA	
<213> Homo sapiens	
<400> 227	
tcccaccata agcacaag	18

<210> 228	
<211> 22	
<212> DNA	
<213> Homo sapiens	
<400> 228	
tcaacctagg attggcatta ca	22
<210> 229	
<211> 21	
<212> DNA	
<213> Homo sapiens	
<400> 229	
tctaggattt gtgcctttcc a	21
<210> 230	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 230	
attcgtgcag ctgtttctgc	20
<210> 231	
<211> 22	
<212> DNA	
<213> Homo sapiens	
<400> 231	
gcatgacatt gtaaattggag ga	22
<210> 232	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 232	
ggtgggaatg tgtgactgaa	20
<210> 233	
<211> 22	
<212> DNA	
<213> Homo sapiens	
<400> 233	
ccaggtacaa cattctcctg at	22
<210> 234	
<211> 16	
<212> DNA	
<213> Homo sapiens	
<400> 234	
tgcaggtggg agtcaa	16
<210> 235	
<211> 24	
<212> DNA	
<213> Homo sapiens	
<400> 235	
aaataacaag aagtgcctt ccta	24

<210> 236  
 <211> 21  
 <212> DNA  
 <213> Homo sapiens  
  
 <400> 236  
 aaaggatgca ttcggttaga g 21  
  
 <210> 237  
 <211> 20  
 <212> DNA  
 <213> Homo sapiens  
  
 <400> 237  
 actgtcctgt gcctgtgctt 20  
  
 <210> 238  
 <211> 20  
 <212> DNA  
 <213> Homo sapiens  
  
 <400> 238  
 gtccacctaa tggctcatte 20  
  
 <210> 239  
 <211> 21  
 <212> DNA  
 <213> Homo sapiens  
  
 <400> 239  
 caagaagcac tcatgtttgt g 21  
  
 <210> 240  
 <211> 19  
 <212> DNA  
 <213> Homo sapiens  
  
 <400> 240  
 agcctgtgat tggctgaga 19  
  
 <210> 241  
 <211> 20  
 <212> DNA  
 <213> Homo sapiens  
  
 <400> 241  
 ggcttacagc tgccctcttt 20  
  
 <210> 242  
 <211> 21  
 <212> DNA  
 <213> Homo sapiens  
  
 <400> 242  
 cccacagagc actttgtag a 21  
  
 <210> 243  
 <211> 21  
 <212> DNA  
 <213> Homo sapiens  
  
 <400> 243  
 gcctccctta agctgttatg c 21

<210> 244	
<211> 23	
<212> DNA	
<213> Homo sapiens	
<400> 244	
cactctttac tgccaatcac tcc	23
<210> 245	
<211> 19	
<212> DNA	
<213> Homo sapiens	
<400> 245	
gccgtgtggg tgtatgaat	19
<210> 246	
<211> 22	
<212> DNA	
<213> Homo sapiens	
<400> 246	
ttgtaccagg aaccaaagac aa	22
<210> 247	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 247	
cacagacaga ggcacattga	20
<210> 248	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 248	
gctctgggtca ctctgctgt	20
<210> 249	
<211> 19	
<212> DNA	
<213> Homo sapiens	
<400> 249	
catgcctggc tgattgttt	19
<210> 250	
<211> 16	
<212> DNA	
<213> Homo sapiens	
<400> 250	
ccaacatcgg gaactg	16
<210> 251	
<211> 21	
<212> DNA	
<213> Homo sapiens	
<400> 251	
tgcatctttt aagtccatgt c	21

<210> 252	
<211> 21	
<212> DNA	
<213> Homo sapiens	
<400> 252	
cagcaactga caactcatcc a	21
<210> 253	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 253	
cctcaatcct cagctccaac	20
<210> 254	
<211> 21	
<212> DNA	
<213> Homo sapiens	
<400> 254	
tgattggttc tggtgttgc g	21
<210> 255	
<211> 19	
<212> DNA	
<213> Homo sapiens	
<400> 255	
agcccaaggc tcttgtgag	19
<210> 256	
<211> 21	
<212> DNA	
<213> Homo sapiens	
<400> 256	
tccttcacag cttcaaactc a	21
<210> 257	
<211> 22	
<212> DNA	
<213> Homo sapiens	
<400> 257	
agtgagaagc ttccatactg gt	22
<210> 258	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 258	
gccaaccggt agacaaatga	20
<210> 259	
<211> 21	
<212> DNA	
<213> Homo sapiens	
<400> 259	
ctacatgtgc accacaacac c	21

<210> 260	
<211> 19	
<212> DNA	
<213> Homo sapiens	
<400> 260	
agttttattgc cgccgagag	19
<210> 261	
<211> 19	
<212> DNA	
<213> Homo sapiens	
<400> 261	
acccaccaca ttcacaagc	19
<210> 262	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 262	
cgattgccat gtctctttga	20
<210> 263	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 263	
gagatctggc ctggatttgt	20
<210> 264	
<211> 23	
<212> DNA	
<213> Homo sapiens	
<400> 264	
tcattgtcag cacagaatga act	23
<210> 265	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 265	
ggagggaggg aagaaagaga	20
<210> 266	
<211> 22	
<212> DNA	
<213> Homo sapiens	
<400> 266	
gggaagagga gattgacttg tt	22
<210> 267	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 267	
ggaacaccat cattccaacc	20



<210> 268	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 268	
tacaagctcc accgtccttc	20
<210> 269	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 269	
tgagttgctg cctcttcaaa	20
<210> 270	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 270	
tgctaattggg ccaaggaata	20
<210> 271	
<211> 23	
<212> DNA	
<213> Homo sapiens	
<400> 271	
gctaaatgtc ctcatgaata gcc	23
<210> 272	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 272	
tgtcctgcag acagatggtc	20
<210> 273	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 273	
cctccggagt agctggatta	20
<210> 274	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 274	
gagactggcc ctcatctcttg	20
<210> 275	
<211> 25	
<212> DNA	
<213> Homo sapiens	
<400> 275	
aagaagccag agacaaagaa ataca	25

<210> 276	
<211> 24	
<212> DNA	
<213> Homo sapiens	
<400> 276	
catctatcctt tggattcagt ggtg	24
<210> 277	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 277	
tgctcccaac atcttaccag	20
<210> 278	
<211> 23	
<212> DNA	
<213> Homo sapiens	
<400> 278	
tgtcctctgg tcattttctat ggt	23
<210> 279	
<211> 23	
<212> DNA	
<213> Homo sapiens	
<400> 279	
catgaatgag aagtgatgaa tgg	23
<210> 280	
<211> 22	
<212> DNA	
<213> Homo sapiens	
<400> 280	
cagacactgt aaactggctt cg	22
<210> 281	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 281	
gccacattgc tatcagcgta	20
<210> 282	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 282	
atgtgctgtg gtccagattt	20
<210> 283	
<211> 25	
<212> DNA	
<213> Homo sapiens	
<400> 283	
cctactactg caattactcc ctacc	25

<210> 284	
<211> 21	
<212> DNA	
<213> Homo sapiens	
<400> 284	
tgtcataggc ttgcggtatt t	21
<210> 285	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 285	
ttggtagggt cctttccttt	20
<210> 286	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 286	
gcctgctcac tgttgtttga	20
<210> 287	
<211> 21	
<212> DNA	
<213> Homo sapiens	
<400> 287	
cggttatcag agactgggtgg t	21
<210> 288	
<211> 21	
<212> DNA	
<213> Homo sapiens	
<400> 288	
ggcttatttc atgtacggct a	21
<210> 289	
<211> 26	
<212> DNA	
<213> Homo sapiens	
<400> 289	
ggttaaactc tacttagtcc tgatgc	26
<210> 290	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 290	
gaactctgca ggcacctctt	20
<210> 291	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 291	
cctgaagcgc ttgtactgaa	20

<210> 292	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 292	
ttggcttctc gctctttctt	20
<210> 293	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 293	
agccatcagt cacatgcaaa	20
<210> 294	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 294	
agatctccag ggcagaggac	20
<210> 295	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 295	
ccttcctccc tcctttctctc	20
<210> 296	
<211> 22	
<212> DNA	
<213> Homo sapiens	
<400> 296	
cagtcaaatag tctcaacctt cc	22
<210> 297	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 297	
ctagcaacat ggccaagaaa	20
<210> 298	
<211> 21	
<212> DNA	
<213> Homo sapiens	
<400> 298	
cgtcattgat cccaatcatc t	21
<210> 299	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 299	
ggctgatagc ctcccttgta	20

<210> 300	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 300	
acctttcaag cttccggttt	20
<210> 301	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 301	
ttccatccgt ccatctatcc	20
<210> 302	
<211> 23	
<212> DNA	
<213> Homo sapiens	
<400> 302	
ttaaagtcac ttgtctgtgg tca	23
<210> 303	
<211> 27	
<212> DNA	
<213> Homo sapiens	
<400> 303	
tttgtaggaa tcaagtcaaa taatgta	27
<210> 304	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 304	
ctttcggaag cttgagccta	20
<210> 305	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 305	
cccaagacca ctgccatatt	20
<210> 306	
<211> 22	
<212> DNA	
<213> Homo sapiens	
<400> 306	
tgacaggttt gggatatattg ga	22
<210> 307	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 307	
tgcttaatgt agtggcagca	20

<210> 308	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 308	
tcctgccttt gtgaattcct	20
<210> 309	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 309	
gttgaatgag gtgggcatta	20
<210> 310	
<211> 22	
<212> DNA	
<213> Homo sapiens	
<400> 310	
ttgggaataa atcaggtggt ga	22
<210> 311	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 311	
gcagcagctc agcatttctc	20
<210> 312	
<211> 21	
<212> DNA	
<213> Homo sapiens	
<400> 312	
ccatttaatc ctccagccat t.	21
<210> 313	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 313	
gctccacctt gttaccctga	20
<210> 314	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 314	
acaaccctgg aatctggact	20
<210> 315	
<211> 22	
<212> DNA	
<213> Homo sapiens	
<400> 315	
gaaggaaagg aaaggaaaga aa	22

<210> 316  
 <211> 23  
 <212> DNA  
 <213> Homo sapiens  
  
 <400> 316  
 tgacaagact gaaacttcat cag 23  
  
 <210> 317  
 <211> 20  
 <212> DNA  
 <213> Homo sapiens  
  
 <400> 317  
 gatgcttgct ttgggaggta 20  
  
 <210> 318  
 <211> 20  
 <212> DNA  
 <213> Homo sapiens  
  
 <400> 318  
 caggtagag cccatccaag 20  
  
 <210> 319  
 <211> 20  
 <212> DNA  
 <213> Homo sapiens  
  
 <400> 319  
 aggctcagct tcattccacat 20  
  
 <210> 320  
 <211> 20  
 <212> DNA  
 <213> Homo sapiens  
  
 <400> 320  
 aagcaaatat gcaaaattgc 20  
  
 <210> 321  
 <211> 23  
 <212> DNA  
 <213> Homo sapiens  
  
 <400> 321  
 tccttctgtt tcttgactta aca 23  
  
 <210> 322  
 <211> 20  
 <212> DNA  
 <213> Homo sapiens  
  
 <400> 322  
 gggaacaggt cacaggtcat 20  
  
 <210> 323  
 <211> 20  
 <212> DNA  
 <213> Homo sapiens  
  
 <400> 323  
 ggaagactgg gtggtcacag 20

<210> 324	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 324	
ttcctttctgc ttgtgagctg	20
<210> 325	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 325	
taccctcacc ttctcatgc	20
<210> 326	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 326	
gaagacattg gcaggtctgg	20
<210> 327	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 327	
gagccctcat gttgggataa	20
<210> 328	
<211> 22	
<212> DNA	
<213> Homo sapiens	
<400> 328	
ttgttgattc tccattctg tg	22
<210> 329	
<211> 25	
<212> DNA	
<213> Homo sapiens	
<400> 329	
tcacctacct catctcatac tcaaa	25
<210> 330	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 330	
tcttcgggac aagtttccaa	20
<210> 331	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 331	
tgggtcattc tggacattca	20



<210> 332	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 332	
gcaaatgagg ctggtaaggt	20
<210> 333	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 333	
tgactgtgg tagagggaaa	20
<210> 334	
<211> 27	
<212> DNA	
<213> Homo sapiens	
<400> 334	
caacatactc ctatgcctag aaagaaa	27
<210> 335	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 335	
ctcaccaggc agaaacaggt	20
<210> 336	
<211> 19	
<212> DNA	
<213> Homo sapiens	
<400> 336	
cccaatggca tgcttcact	19
<210> 337	
<211> 19	
<212> DNA	
<213> Homo sapiens	
<400> 337	
ggttctccca gcattggtt	19
<210> 338	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 338	
aaggcctctg ggtaggtagg	20
<210> 339	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 339	
aagcaatcct tatgggctct	20

<210> 340	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 340	
ccaggtaatc agaagcctca	20
<210> 341	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 341	
ttccggttaa tccagccatc	20
<210> 342	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 342	
cagggactgc agtgtctcaa	20
<210> 343	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 343	
atgccacatt tgctctctc	20
<210> 344	
<211> 25	
<212> DNA	
<213> Homo sapiens	
<400> 344	
ccaccttcca cttaatacaa acttc	25
<210> 345	
<211> 21	
<212> DNA	
<213> Homo sapiens	
<400> 345	
gaagcaatcc attccaagaa a	21
<210> 346	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 346	
gtcctgaggg tgtccaggta	20
<210> 347	
<211> 22	
<212> DNA	
<213> Homo sapiens	
<400> 347	
gctggagaac tcctattctg ct	22

<210> 348  
 <211> 20  
 <212> DNA  
 <213> Homo sapiens  
  
 <400> 348  
 tggagctatt gcggttctct 20  
  
 <210> 349  
 <211> 23  
 <212> DNA  
 <213> Homo sapiens  
  
 <400> 349  
 tcaaattctt ctttctctct cct 23  
  
 <210> 350  
 <211> 20  
 <212> DNA  
 <213> Homo sapiens  
  
 <400> 350  
 cagttccagc tacgggagaa 20  
  
 <210> 351  
 <211> 20  
 <212> DNA  
 <213> Homo sapiens  
  
 <400> 351  
 ccgcatttag gcaagtctca 20  
  
 <210> 352  
 <211> 20  
 <212> DNA  
 <213> Homo sapiens  
  
 <400> 352  
 aagcacacac agatgctagg 20  
  
 <210> 353  
 <211> 20  
 <212> DNA  
 <213> Homo sapiens  
  
 <400> 353  
 cctcagcttc cataattctca 20  
  
 <210> 354  
 <211> 20  
 <212> DNA  
 <213> Homo sapiens  
  
 <400> 354  
 gtacagagcc caccttcttg 20  
  
 <210> 355  
 <211> 20  
 <212> DNA  
 <213> Homo sapiens  
  
 <400> 355  
 tcactatgct gcaaggcaag 20

<210> 356	
<211> 23	
<212> DNA	
<213> Homo sapiens	
<400> 356	
ggtgcttgct gtaaataataa ttg	23
<210> 357	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 357	
cactacagca gattgcacca	20
<210> 358	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 358	
gatttgaaaa tgagcagtcc	20
<210> 359	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 359	
gtcgggcact acgttttatct	20
<210> 360	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 360	
tgggtgaaga tgctacctga	20
<210> 361	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 361	
cccttcttcc tttccctctc	20
<210> 362	
<211> 21	
<212> DNA	
<213> Homo sapiens	
<400> 362	
tgccaggtct gagttgtaag c	21
<210> 363	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 363	
cagcatgaga ccctgtcaaa	20

<210> 364	
<211> 27	
<212> DNA	
<213> Homo sapiens	
<400> 364	
gaaagaaaga aagaaagaag aaagaaa	27
<210> 365	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 365	
aatcaccaaa cctggaagca	20
<210> 366	
<211> 27	
<212> DNA	
<213> Homo sapiens	
<400> 366	
gaaagaaaga aagaaagaag aaagaaa	27
<210> 367	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 367	
aatcaccaaa cctggaagca	20
<210> 368	
<211> 25	
<212> DNA	
<213> Homo sapiens	
<400> 368	
tctgagttaa acacttgagt tgctg	25
<210> 369	
<211> 21	
<212> DNA	
<213> Homo sapiens	
<400> 369	
ccagtaaagtg gcagtgtggt t	21
<210> 370	
<211> 27	
<212> DNA	
<213> Homo sapiens	
<400> 370	
tgatcatggat atttctacat aaaccaa	27
<210> 371	
<211> 23	
<212> DNA	
<213> Homo sapiens	
<400> 371	
tgaagatgggt tattgcttcc ttc	23

<210> 372	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 372	
cgctttgttt ggtttggttt	20
<210> 373	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 373	
atgcagttgt cccacatgct	20
<210> 374	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 374	
tcctgcactc caaaggaaac	20
<210> 375	
<211> 25	
<212> DNA	
<213> Homo sapiens	
<400> 375	
aactctgggt taattcagct ttgtc	25
<210> 376	
<211> 21	
<212> DNA	
<213> Homo sapiens	
<400> 376	
ttcttgaggg cataaagctg a	21
<210> 377	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 377	
cacactcacc aggcactctg	20
<210> 378	
<211> 23	
<212> DNA	
<213> Homo sapiens	
<400> 378	
caggtttgat gaaggaaata tgc	23
<210> 379	
<211> 22	
<212> DNA	
<213> Homo sapiens	
<400> 379	
gggatacctct gcattttctct aa	22

<210> 380	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 380	
tttgccaaat caaccttcag	20
<210> 381	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 381	
cctgcttcac acctctgacc	20
<210> 382	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 382	
actcacacac aaccaccaca	20
<210> 383	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 383	
gctactgggtg ggtagtaagc	20
<210> 384	
<211> 18	
<212> DNA	
<213> Homo sapiens	
<400> 384	
ttcagagacc atcacggc	18
<210> 385	
<211> 25	
<212> DNA	
<213> Homo sapiens	
<400> 385	
ctggaaaaat cagttgaatc ctagc	25
<210> 386	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 386	
aggaaagccg agaaagcata	20
<210> 387	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 387	
catgtatcca catgcccaga	20

<210> 388	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 388	
ccttcagcgc agctacatct	20
<210> 389	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 389	
agaactgcga ggtccaagtg	20
<210> 390	
<211> 22	
<212> DNA	
<213> Homo sapiens	
<400> 390	
gggagaaaga gaggtaggaa gg	22
<210> 391	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 391	
ttcccaagtt agcagcatcc	20
<210> 392	
<211> 27	
<212> DNA	
<213> Homo sapiens	
<400> 392	
ttctagagga gtctatttct ttactgg	27
<210> 393	
<211> 21	
<212> DNA	
<213> Homo sapiens	
<400> 393	
ggagctgtca cttgagcttt g	21
<210> 394	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 394	
ccgtgacctc cagggaacat	20
<210> 395	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 395	
ggcatcgggt gtttctattc	20



<210> 396	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 396	
agacctgcct gtgttctggt	20
<210> 397	
<211> 23	
<212> DNA	
<213> Homo sapiens	
<400> 397	
ggagtgaat aagtggaact gga	23
<210> 398	
<211> 26	
<212> DNA	
<213> Homo sapiens	
<400> 398	
cattaaatga gtcataaagg tcatgg	26
<210> 399	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 399	
aacattgttg ctttgctgga	20
<210> 400	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 400	
ggccttagct cagtttctgg	20
<210> 401	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 401	
tgcaaagaca tttgcggata	20
<210> 402	
<211> 19	
<212> DNA	
<213> Homo sapiens	
<400> 402	
cctgcatttg tgtacgtgt	19
<210> 403	
<211> 23	
<212> DNA	
<213> Homo sapiens	
<400> 403	
cagagccgtg gtagtatatt ttt	23

<210> 404	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 404	
ggaaccagtc atttgggtgt	20
<210> 405	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 405	
ttattgctcc ctctccaag	20
<210> 406	
<211> 26	
<212> DNA	
<213> Homo sapiens	
<400> 406	
tgccttaagg tctattattt cctttc	26
<210> 407	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 407	
accaatgcag gaagactcaa	20
<210> 408	
<211> 21	
<212> DNA	
<213> Homo sapiens	
<400> 408	
ctgatgaaag gacacacatg c	21
<210> 409	
<211> 23	
<212> DNA	
<213> Homo sapiens	
<400> 409	
tgcattaact atgcagcttg aaa	23
<210> 410	
<211> 18	
<212> DNA	
<213> Homo sapiens	
<400> 410	
gtcgtgcaat cccgagag	18
<210> 411	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 411	
ggattcctgc tggctcttct	20

<210> 412	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 412	
ctggtgtggt caggaaatga	20
<210> 413	
<211> 24	
<212> DNA	
<213> Homo sapiens	
<400> 413	
gtgctaaaca catgtgagtg agag	24
<210> 414	
<211> 22	
<212> DNA	
<213> Homo sapiens	
<400> 414	
tttgaccatg ctttctcttt ga	22
<210> 415	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 415	
gcttgatgac tccctgctgt	20
<210> 416	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 416	
aagccattga aaggcaggta	20
<210> 417	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 417	
gggactttcc ggcttctatt	20
<210> 418	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 418	
ggtttgggaa ccattctcct	20
<210> 419	
<211> 22	
<212> DNA	
<213> Homo sapiens	
<400> 419	
gcagagaagg gatttactcc ag	22

<210> 420	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 420	
acttgacatg gagcaagctg	20
<210> 421	
<211> 21	
<212> DNA	
<213> Homo sapiens	
<400> 421	
agctcatcat gctgtaagga g	21
<210> 422	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 422	
cacaggctct cacattctcg	20
<210> 423	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 423	
tgacactcat ccctctgctg	20
<210> 424	
<211> 27	
<212> DNA	
<213> Homo sapiens	
<400> 424	
tgagtttcat aagtttacta cctgctg	27
<210> 425	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 425	
ggcagggaga aaggacaaat	20
<210> 426	
<211> 22	
<212> DNA	
<213> Homo sapiens	
<400> 426	
tcccttatgt gggattagtt ga	22
<210> 427	
<211> 23	
<212> DNA	
<213> Homo sapiens	
<400> 427	
cagacatgga actgagattt ttt	23

<210> 428	
<211> 22	
<212> DNA	
<213> Homo sapiens	
<400> 428	
tggtccatct ctctacccat gt	22
<210> 429	
<211> 24	
<212> DNA	
<213> Homo sapiens	
<400> 429	
tcaatgttct tattgagtgg gaaa	24
<210> 430	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 430	
atatccaccc acccacacat	20
<210> 431	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 431	
tagctctgag ggcagagacc	20
<210> 432	
<211> 19	
<212> DNA	
<213> Homo sapiens	
<400> 432	
ccgtccttcc tccactgat	19
<210> 433	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 433	
agagcactga gggagcaaat	20
<210> 434	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 434	
agctacagca cgaggcagtt	20
<210> 435	
<211> 21	
<212> DNA	
<213> Homo sapiens	
<400> 435	
tttgaattga gttgctgttc g	21

<210> 436	
<211> 21	
<212> DNA	
<213> Homo sapiens	
<400> 436	
tgtacaccac caaccattct g	21
<210> 437	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 437	
gggaagaaag gcaaatagca	20
<210> 438	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 438	
ggattggcaa ttagcaggtc	20
<210> 439	
<211> 22	
<212> DNA	
<213> Homo sapiens	
<400> 439	
gcctgggtcaa agataacaga cg	22
<210> 440	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 440	
cctgattaag ctggcctttg	20
<210> 441	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 441	
atccttctgg gaccctcatc	20
<210> 442	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 442	
gctttgcttc cttcttggtg	20
<210> 443	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 443	
caacattacg gccagtctca	20

<210> 444	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 444	
ggtgcatctg ataagccaaa	20
<210> 445	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 445	
gctgtcttgg acacagtgga	20
<210> 446	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 446	
caccatcatc atctggttgg	20
<210> 447	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 447	
gagctcattg aaaggcagga	20
<210> 448	
<211> 25	
<212> DNA	
<213> Homo sapiens	
<400> 448	
ccatccatct atccatttat ctctg	25
<210> 449	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 449	
ggatttatcc ttgccctgct	20
<210> 450	
<211> 23	
<212> DNA	
<213> Homo sapiens	
<400> 450	
ctatcatcca tccatcctat ttg	23
<210> 451	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 451	
ttagggcagc tacctggaaa	20

<210> 452  
 <211> 20  
 <212> DNA  
 <213> Homo sapiens  
  
 <220>  
 <221> misc\_feature  
 <222> 8  
 <223> n = A,T,C or G  
  
 <400> 452  
 aggactanag atgaatgctc 20  
  
 <210> 453  
 <211> 20  
 <212> DNA  
 <213> Homo sapiens  
  
 <400> 453  
 gacatgactc catgtttggt 20  
  
 <210> 454  
 <211> 20  
 <212> DNA  
 <213> Homo sapiens  
  
 <400> 454  
 cctcaccttg caatttcctg 20  
  
 <210> 455  
 <211> 20  
 <212> DNA  
 <213> Homo sapiens  
  
 <400> 455  
 ctgacttgcc tgttggcata 20  
  
 <210> 456  
 <211> 21  
 <212> DNA  
 <213> Homo sapiens  
  
 <400> 456  
 tttgggatct tgaagacctt t 21  
  
 <210> 457  
 <211> 19  
 <212> DNA  
 <213> Homo sapiens  
  
 <400> 457  
 ttgtggcatg tccttggt 19  
  
 <210> 458  
 <211> 23  
 <212> DNA  
 <213> Homo sapiens  
  
 <400> 458  
 tgtacactgc aaacattgct aaa 23  
  
 <210> 459  
 <211> 24



<212> DNA  
 <213> Homo sapiens  
  
 <400> 459  
 ttgtcctttc attatgacgt gtct 24  
  
 <210> 460  
 <211> 23  
 <212> DNA  
 <213> Homo sapiens  
  
 <400> 460  
 aagcctgaaa ggatacacac aaa 23  
  
 <210> 461  
 <211> 20  
 <212> DNA  
 <213> Homo sapiens  
  
 <400> 461  
 caggatccca gactttccag 20  
  
 <210> 462  
 <211> 20  
 <212> DNA  
 <213> Homo sapiens  
  
 <400> 462  
 ggtgaatccc accctcatatc 20  
  
 <210> 463  
 <211> 24  
 <212> DNA  
 <213> Homo sapiens  
  
 <400> 463  
 ttggtatggt tcctattggt gcat 24  
  
 <210> 464  
 <211> 21  
 <212> DNA  
 <213> Homo sapiens  
  
 <400> 464  
 gaaccagtga gtttttatta c 21  
  
 <210> 465  
 <211> 21  
 <212> DNA  
 <213> Homo sapiens  
  
 <400> 465  
 agacacagca tataatacat g 21  
  
 <210> 466  
 <211> 20  
 <212> DNA  
 <213> Homo sapiens  
  
 <400> 466  
 tgaagctttg tggcttggtg 20  
  
 <210> 467

<211> 20  
 <212> DNA  
 <213> Homo sapiens  
  
 <400> 467  
 gactgagtcc acagcccatt 20  
  
 <210> 468  
 <211> 25  
 <212> DNA  
 <213> Homo sapiens  
  
 <400> 468  
 cctggcctgt tagtttttat tgtta 25  
  
 <210> 469  
 <211> 22  
 <212> DNA  
 <213> Homo sapiens  
  
 <400> 469  
 cccagtcttg ggtatgtttt ta 22  
  
 <210> 470  
 <211> 20  
 <212> DNA  
 <213> Homo sapiens  
  
 <400> 470  
 ccaccatgca agaacagatg 20  
  
 <210> 471  
 <211> 20  
 <212> DNA  
 <213> Homo sapiens  
  
 <400> 471  
 gctttgcact tggctgtctt 20  
  
 <210> 472  
 <211> 24  
 <212> DNA  
 <213> Homo sapiens  
  
 <400> 472  
 ttgcatgaag taaagtatcc ctgt 24  
  
 <210> 473  
 <211> 21  
 <212> DNA  
 <213> Homo sapiens  
  
 <400> 473  
 cacaaaccac aagatgattg g 21  
  
 <210> 474  
 <211> 21  
 <212> DNA  
 <213> Homo sapiens  
  
 <400> 474  
 gggcatcatg tctacaactc a 21

<210> 475	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 475	
accaagggca cttgctgata	20
<210> 476	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 476	
aggatgaaga gggaggaagg	20
<210> 477	
<211> 26	
<212> DNA	
<213> Homo sapiens	
<400> 477	
ccagactgat cttccttaat tagttg	26
<210> 478	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 478	
cctcctcttt ctgctgctgt	20
<210> 479	
<211> 21	
<212> DNA	
<213> Homo sapiens	
<400> 479	
agccaaagaa cccaaagaaa c	21
<210> 480	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 480	
gccctacttt gcctcagaaa	20
<210> 481	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 481	
gcaactcatg ccagcctcta	20
<210> 482	
<211> 22	
<212> DNA	
<213> Homo sapiens	
<400> 482	
aactgtgtta atgatgggca aa	22

<210> 483	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 483	
aacgagcgca tgaaacctat	20
<210> 484	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 484	
cctggtcaat tgaacccaaa	20
<210> 485	
<211> 23	
<212> DNA	
<213> Homo sapiens	
<400> 485	
tgaaggaaga taaagcaggg taa	23
<210> 486	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 486	
ctctctctgg ccctctcttg	20
<210> 487	
<211> 23	
<212> DNA	
<213> Homo sapiens	
<400> 487	
ggtaacttgc cattcttcta cca	23
<210> 488	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 488	
actccacctg aaggagaaa	20
<210> 489	
<211> 21	
<212> DNA	
<213> Homo sapiens	
<400> 489	
tggaagccac taattggaga a	21
<210> 490	
<211> 23	
<212> DNA	
<213> Homo sapiens	
<400> 490	
aatggatgga tacctcotta tca	23

<210> 491  
 <211> 20  
 <212> DNA  
 <213> Homo sapiens  
  
 <400> 491  
 ctcattgtgg ctttctgtgc 20  
  
 <210> 492  
 <211> 20  
 <212> DNA  
 <213> Homo sapiens  
  
 <400> 492  
 gtacccacac ctcaccaagc 20  
  
 <210> 493  
 <211> 20  
 <212> DNA  
 <213> Homo sapiens  
  
 <400> 493  
 cgtagctcac attcccaaca 20  
  
 <210> 494  
 <211> 20  
 <212> DNA  
 <213> Homo sapiens  
  
 <400> 494  
 ggcgagtgaa agagaggaca 20  
  
 <210> 495  
 <211> 20  
 <212> DNA  
 <213> Homo sapiens  
  
 <400> 495  
 ggggtggtaat tcccagatga 20  
  
 <210> 496  
 <211> 20  
 <212> DNA  
 <213> Homo sapiens  
  
 <400> 496  
 tctgcaacag ccagaatcaa 20  
  
 <210> 497  
 <211> 22  
 <212> DNA  
 <213> Homo sapiens  
  
 <400> 497  
 tgtctgttgg caactttctg tc 22  
  
 <210> 498  
 <211> 20  
 <212> DNA  
 <213> Homo sapiens  
  
 <400> 498  
 aggtgaaccc agtccagcta 20

<210> 499  
 <211> 20  
 <212> DNA  
 <213> Homo sapiens  
  
 <400> 499  
 tcttaggcaa aggagccagt 20  
  
 <210> 500  
 <211> 19  
 <212> DNA  
 <213> Homo sapiens  
  
 <400> 500  
 acatgagcac tggtgactg 19  
  
 <210> 501  
 <211> 20  
 <212> DNA  
 <213> Homo sapiens  
  
 <400> 501  
 ggcctcaaat gttttaagca 20  
  
 <210> 502  
 <211> 20  
 <212> DNA  
 <213> Homo sapiens  
  
 <400> 502  
 ttctgggtgt tcgctattcc 20  
  
 <210> 503  
 <211> 20  
 <212> DNA  
 <213> Homo sapiens  
  
 <400> 503  
 tttcctgtcc agtcctgacc 20  
  
 <210> 504  
 <211> 22  
 <212> DNA  
 <213> Homo sapiens  
  
 <400> 504  
 gttttgcagg tctaggtcac ac 22  
  
 <210> 505  
 <211> 17  
 <212> DNA  
 <213> Homo sapiens  
  
 <400> 505  
 aggatagctt gagcccg 17  
  
 <210> 506  
 <211> 396  
 <212> DNA  
 <213> Homo sapiens  
  
 <400> 506  
 gattatatcc cacctaccac tgcagctcca ggatccagct tcacaaacat ttgttgaatg 60

aatgaataag	aaaagaggac	acccccaaaag	aggctgcaag	ggaaaaagct	acaaagacag	120
aagcaccagg	aaaaagtagg	gtcatgtaag	tcaaagcagg	aaaaaagttc	catgggtggg	180
tggtcagcag	tgtctaatr	cacgaaggca	caaagtagga	taaagggtta	aaatcagcct	240
ttggtttttg	caaatatgaa	gcttatcggt	agccttagcg	agaacaattc	catcagggag	300
cagaagctaa	ctgcagtggg	ttgagtcac	aagcaggcat	aaggaagtag	ggatacccca	360
ttataagcta	ctctttcaag	aagctcaa	ctgaag			396

<210> 507

<211> 396

<212> DNA

<213> Homo sapiens

<400> 507

acaaaaatta	ccatcatatg	ctgtcatgca	tgtctgccag	tctattttatc	atattatttta	60
agaaacaaac	atattattgaa	gatttatcat	gtgctcagca	ctgccaaaga	ggaaataaag	120
agcataatat	ctattcttag	aaaataacat	taacacaaat	agaaaacaag	aaaccataat	180
gttaaaaaata	ttacatagya	acacagaaaag	acaatgtata	attatacata	cgcactaaag	240
caaagataac	ataatttata	aattatgagg	tacagaatag	ttagattctg	aaaattaaaa	300
taatcaggaa	aaacttcatg	aagatgagat	ctgggctgga	tcccaaagga	taggcaggtg	360
gatcatgtag	aacaggggaa	aggagtctct	gatcgg			396

<210> 508

<211> 396

<212> DNA

<213> Homo sapiens

<400> 508

aactaaagaa	agccacaaaa	gttcacctca	atgccaaagac	atctcttgat	ttttgaaaaac	60
ccagttgtcg	aaccacccat	ctatagaaac	ttgaaagact	aaaaactatc	ttactctaaa	120
cattttctag	gaagttgatt	ctacaacaca	ttttggtttt	ccaatttggc	ttctaataat	180
tatttcaaag	tttctgtgrc	ctaaattttg	ttttacattg	atcctttgaa	tggactactg	240
tttccacatt	ttagaacatt	taaaaagata	tctacaaccc	gagtctaate	ataaaaaaaaa	300
tcagacagat	ccaaaatgtg	gaacattcca	ctaaaaaagg	agtggggaga	ggtctttatt	360
cttccaaaaa	tatcaatgcc	ataaaagaca	aagacg			396

<210> 509

<211> 396

<212> DNA

<213> Homo sapiens

<400> 509

acccttcaac	cccagcccag	ctgctaactg	actacagcca	catgaacaga	accaggtgag	60
accagaggaa	acttccagtc	acctaccaga	tcatgacaaa	taataaacga	tgtttttttaa	120
accacaaaga	tttggagcag	catttggtac	acaaaattag	acaactatta	cagttcgact	180
aaaaacatgt	tcattttacra	tactaaatta	gaagtgttaag	aatgggagaa	aaacttcata	240
ctttaaaagt	catttttttcc	tccaaaaaact	tccaactttg	aaaaactgat	ttttataatg	300
cataaaaaatt	aaaataacct	tagaatttat	atgagtagca	tagccagctg	gctttattat	360
ctgttgtact	caacacttca	ataatcactg	atgttt			396

<210> 510

<211> 396

<212> DNA

<213> Homo sapiens

<400> 510

atgaccttac	ctcgttttgt	tttccctgtc	tgagagaaac	acattagcag	tctcccatct	60
tgtttttcc	tttctgtca	cccaggacag	agggcagtg	tgtgatcaca	gctctgcagc	120
acgacttccc	caggttcagg	tgatcctccc	acctcagcct	cccaaggagc	tgggaccaca	180
ggcacatgcc	accacgtc	gcttaatttt	gtattttttt	ggtagagatc	aggttttgcc	240
ttattgcccc	aagctgact	tgaattcctg	ggctgaagca	atctgcctgc	cctggcctct	300
ccaagtgtta	ggattacagg	tataagccac	cgtgcagcct	tatattttgt	tttaaatatt	360
cctctgtatt	tttctctctg	gcaaattgtt	taggga			396

<210> 511  
 <211> 396  
 <212> DNA  
 <213> Homo sapiens

<400> 511  
 ttttttggta gagatcagggt tttgccttat tgccccaagc tgatcttgaa ttcctgggct 60  
 gaagcaatct gcctgccctg gcctctccaa gtgttaggat tacagggtata agccaccgtg 120  
 cagccttata ttttgtttta aattttcttc tgtatttttc tctctggcaa attgtttagg 180  
 gagtttcttt agtttatcrg actaaatttc aaggctttcc ttccaatttt gacatgtaaa 240  
 cagtcacctca tttctgctta tctagtgtt attcccaaact ctgtgtttac agtctagctg 300  
 tctctcctga gattaagact tgtttctcta actacctgac ggcagaatct cctcttgga 360  
 gtatcaagga ggcagttcaa aactgaactg ggcatt 396

<210> 512  
 <211> 396  
 <212> DNA  
 <213> Homo sapiens

<400> 512  
 gctgatcttg aattcctggg ctgaagcaat ctgcctgccc tggcctctcc aagtgttagg 60  
 attacaggta taagccaccg tgcagcctta tattttgttt taaattttcc tctgtatttt 120  
 tctctctggc aaattgttta gggagtttct ttagtttata agactaaatt tcaaggcttt 180  
 ccttccaatt ttgacatgya aacagtcctc catttctgct tatctagtga ttatteccaa 240  
 atctgtgttt acagtctagc tgtctctcct gagattaaga cttgtttctc taactacctg 300  
 acggcagaat ctctctcttg aagtatcaag gaggcagttc aaaactgaac tgggcattgg 360  
 ctccactcct tctcttctc tttactatta atacc 396

<210> 513  
 <211> 396  
 <212> DNA  
 <213> Homo sapiens

<400> 513  
 taagtcttat ttaggcacgt tttcttctgg gagacctttg tagaatctct gaggttatgt 60  
 taacatgcta aggttttctt gacatttctc gattgggtta ggtgaacttt tagcaactta 120  
 tctttttact aaaaagtcac ccctcagtat ctgtggggaa ttgggttctag gactccctaa 180  
 ggatatcaaa atctgcatra gcagcccagg tgagaccagc agaagcactt tacagtcacc 240  
 tacaggatca tgacaaataa taaatcatgt ttaagccaca aagtccttta cataaaatgg 300  
 tatagtattt gcatataacc tacacatctt cctgtatcct ttaaatcact tctagtttat 360  
 aatacctcat acgatgaaaa tactacgtaa atagtt 396

<210> 514  
 <211> 396  
 <212> DNA  
 <213> Homo sapiens

<400> 514  
 aagcagttcc taattactgg acatttctcag atctgctaga gctacatgtc caattacgag 60  
 aatatactgg aaaaagccct ggattagaaa tgagaggatg taggttttag taccagggtca 120  
 gccaccttgt taatgcaaat ttgagtaaat tgttacttct tttaggcctt gtttttctgt 180  
 ttttgttttt ctgacagtm tggctctgtg gtccaggctg gagtgcagag gcacaatatc 240  
 aggtccctgc agtctctacc tcccaggatc aagccatttt catgcctcat cctcctgagt 300  
 agctgggatt acaggcatgt gccaccacac cctcgaactc ctgacctcaa gtgatctgct 360  
 tgctcagcc tcccaaagtg ctgggattag aggtgt 396

<210> 515  
 <211> 396  
 <212> DNA  
 <213> Homo sapiens

<400> 515  
 gaatatactg gaaaaagccc tggattagaa atgagaggat gtaggtttta gtaccagggtc 60



agccaccttg	ttaatgcaaa	tttgagtaaa	ttgttacttc	ttttaggcct	tgtttttgct	120
gttttgtttt	tctgacagta	tggtctctgt	ggtccaggct	ggagtgcaga	ggcacaatat	180
caggtccctg	cagtctctrc	ctcccaggat	caagccattt	tcatgcctca	tcctcctgag	240
tagctgggat	tacaggcatg	tgccaccaca	ccctcgaact	cctgacctca	agtgatctgc	300
ttgcctcagc	ctcccaaagt	gctgggatta	gaggtgtgag	ccactgtgcc	tagccttaca	360
cattgttttc	ttactggtaa	agtgggaata	tctaga			396

<210> 516

<211> 396

<212> DNA

<213> Homo sapiens

<400> 516

gttttgtttt	tctgacagta	tggtctctgt	ggtccaggct	ggagtgcaga	ggcacaatat	60
caggtccctg	cagtctctac	ctcccaggat	caagccattt	tcatgcctca	tcctcctgag	120
tagctgggat	tacaggcatg	tgccaccaca	ccctcgaact	cctgacctca	agtgatctgc	180
ttgcctcagc	ctcccaaakt	gctgggatta	gaggtgtgag	ccactgtgcc	tagccttaca	240
cattgttttc	ttactggtaa	agtgggaata	tctagaagtt	gcatgctaca	taaattcaac	300
catatattat	tggcaaaaaa	ttttaaagaa	aaacatcagc	ttaagagtac	taattgagta	360
catgccttgg	aatgagcatg	agctggaaag	aacaaa			396

<210> 517

<211> 396

<212> DNA

<213> Homo sapiens

<400> 517

ggcaaaaaat	tttaaagaaa	aacatcagct	taagagtact	aattgagtac	atgccttggg	60
atgagcatga	gctggaaaga	acaaacctgt	tggtacatca	ctcattgctg	ttttcatatg	120
ctgctcattg	taaatcttgc	tcagtggcat	gatttttagt	tttaaagatt	tatttgtttg	180
tttgtttagg	acaaagtcyc	tacacataat	ctacttgctt	catatataca	tacttatgca	240
tattatgtat	gtacatacat	gctctcaggg	ctcacatgaa	aaaacagcca	ttcaggtgat	300
gtgatttato	tcatatgctt	acttttagagt	caacagggtg	ttgactccac	tatacaatac	360
tggcatggag	aacacataag	tcaaagtaga	caggac			396

<210> 518

<211> 396

<212> DNA

<213> Homo sapiens

<400> 518

tttatttgtt	tgtttgttta	ggacaaagtc	tctacacata	atctacttgc	ttcatatata	60
catacttatg	catattatgt	atgtacatac	atgctctcag	ggctcacatg	aaaaaacagc	120
cattcagggtg	atgtgattta	tctcatatgc	ttacttttaga	gtcaacaggg	tggtgactcc	180
actatacaat	actggcatrg	agaacacata	agtcaaagta	gacaggaccc	agccgtacca	240
ttggctaggg	cacaaatata	ttcacatatg	tggagaatga	tgtacgtaga	aagggtcttca	300
ttgcacaatg	ctctttaata	aagatctgga	aaaaaaaaac	acctaaatgt	tcaaaaggat	360
agggtagatg	aaataatggt	acattataaa	atggaa			396

<210> 519

<211> 396

<212> DNA

<213> Homo sapiens

<400> 519

tctgtcaccc	aggctggagt	gcagtggcat	gatcatgtct	ccttgcagcc	ttgacttccc	60
tggctcaggt	gggcctccca	cctcagtcct	ccaagttagct	ggaactacag	tcgtgcacca	120
ccatagccag	ctaagatagt	gagatgggtg	ccccactgtc	ttgcccaggc	tggactcgat	180
ttcctgggtg	caagcacctt	tcccgcctca	gcctcccaaa	gtgctgggat	tacaggcatg	240
agtcaccatt	ccagcctact	tgtctttaat	tcttaaaaat	attaatgttg	agttttgtct	300
cccagcatgt	gggaaagatg	tcatccattg	cttctgtttc	ctggaggcct	gggagcaagg	360
agcccaggaa	cagtatcacg	aagcttgaga	taatac			396

<210> 520  
 <211> 396  
 <212> DNA  
 <213> Homo sapiens

<400> 520  
 atcattgatg ggcatttggg ttggttccaa gtctttgcta ttgtgatttt tttttttttt 60  
 tttttttttt taagacagag cctcactctg ttgcccaggc tggagtgcga tggcatgata 120  
 tcagctcact gcaacctccg cctctcaggc tcaagcaatt cttctgcctc agcctcccaa 180  
 gtagctggga ctacaggcgc ccaccaccag gccagctaa tttttgtatt ttttagtagag 240  
 acagggtttc accatgttgg tcaggctggc cttgaactcc agacctcatg atctgcctgc 300  
 cttggcctcc caaagtgtg aaattacagg tgtgagccac catacctggc ctaggcagtc 360  
 tttttcaaaa ctctaagact gtgcttgtgt ctcagg 396

<210> 521  
 <211> 395  
 <212> DNA  
 <213> Homo sapiens

<400> 521  
 ggtatgaggt aaggatccat ttttttccca tttgcatagc cagtttttgt agctccactt 60  
 ttttttctca cttgatctgc catgccacct ctagcatgta tcaacataat atgtatgtgt 120  
 gcagctgttc cttactctc aattttattc tcttggttac tttgtctaac ccagcactca 180  
 tactttttta attattaygg ctaccttgta gggcaagaat cctcactttt attcaacttc 240  
 ttttgaagtg tcttgatgca tttttttct gatcttactt ggccatataat attttgggga 300  
 cagatgtgac atcataccaa gctttctttg cttgacattg tagatatttt cttattcatt 360  
 aatgtgctaa aaattttgag tttggtcata cagtc 395

<210> 522  
 <211> 396  
 <212> DNA  
 <213> Homo sapiens

<400> 522  
 gtttctaaca ttatagacac tagtttttagg ctcttggagg ctagcagcaa ttctcagagg 60  
 taatgcaagc ttcccattt ctcccgtag tctgtgaaa gaccagccac ctccagaagc 120  
 ctacacatga gtcttctcag ccatactttc tgcttttctt aatgcctctc agcagcgtat 180  
 tagaaaggcc atgacgagtg tacctgttac cttcaggctt tgcataaggc gtatatgaaa 240  
 cataatgaat ttctgtgtta ggctcaggc ccatccccag gttacctctt tatcttggag 300  
 acacttctgg tcccatatat ttcagataag agatattcaa cctgtacca ccacgtaagg 360  
 agaggaatag gttttagaag aggagtcagg gaggca 396

<210> 523  
 <211> 396  
 <212> DNA  
 <213> Homo sapiens

<400> 523  
 gcattctatta aaagtgatgg ttttagtata ctgtctcatt ttttccttc cttacatcat 60  
 gtattatagg taaacacatg cgcattgtgt tattttctct ttagacaaag gatgagatta 120  
 ctactgttag ctacgttttt ttttccctac ttaacatctt tgcttttatt ttttagacat 180  
 atttctaaga ctattaaaya ttagacttac gtagcccttc tgcattgtg aaatacatag 240  
 tttactaaca gctaccatca agataaagcc tttattttaa taattaaact tcttagtgga 300  
 aagctaagta agcacagttt atggattttg ggaatttttg ccttgcattt gtctgatag 360  
 gtaaaatatt gagtttgttt ttctcataat gttcac 396

<210> 524  
 <211> 396  
 <212> DNA  
 <213> Homo sapiens

<400> 524  
 gataactcaa tccccttaaa gggttgtatc aagccattga taagggtca ctttgatata 60

accat	ttttct	gttatt	taga	cactct	tttca	cacttc	cctat	tttctc	cctg	gggatg	ggttt	120
gaatg	gatga	cacaat	acca	tattata	aaaa	gcactt	taca	aactgt	aact	tatgtt	tataa	180
atgta	attat	tacctt	aarg	ttttacc	cctg	tttcag	attt	gagtgg	aagt	agttct	tttac	240
aatac	aaaac	aactt	at	ttt	ttt	gcattt	caaa	gaatga	tcaa	tccact	tcag	300
gtgcag	catg	gtttcc	aacc	ctgac	agcat	ggaaga	atca	tttatt	tagc	ttctaaa	aat	360
gtgcag	gctg	taccct	tagac	cagcct	tggg	gattag						396

<210> 525

<211> 396

<212> DNA

<213> Homo sapiens

<400> 525

tcctct	ctct	ctct	ctct	ctct	ctct	ctct	ctct	ctct	ctct	ctct	ctct	60
ctctct	ctct	ctct	ctct	ctct	ctct	ctct	ctct	ctct	ctct	ctct	ctct	120
aaactc	cctgg	gctca	agtga	tcctc	cctgcc	tcagct	tcct	gagt	agctag	gactac	aggc	180
acatg	ctatg	gcaata	actrt	tttaa	acatt	gtttt	caagg	ctccc	cagg	gattcc	cagt	240
tgggt	catgt	ggtaga	gaac	cactga	acaca	ggcaa	acaaa	ggata	acataa	agttgt	ctat	300
ttaat	gggta	ggtgc	aggta	gtagata	aaga	gtgtag	ccac	ataaa	accaca	tgcttag	tga	360
acggt	tttgt	gtgtg	tga	tgtgag	gggat	tagcat						396

<210> 526

<211> 396

<212> DNA

<213> Homo sapiens

<400> 526

ttcagg	ttcc	at	tttag	cacg	acagc	aggga	agggact	gtt	ggcag	aaaaa	aactg	ggggca	60
gtggg	attaa	aga	cagac	acca	cacatt	ccaa	aaggc	accgt	gggag	gggtca	ggggg	cgagg	120
ttagg	tctag	gctt	cagt	gt	cctgg	agac	tcagt	cttca	cagggt	gaca	gcgat	caaga	180
gtgcag	ctta	ggct	gggt	trc	agtgg	ctcat	gcctg	tagtc	ccagc	acttt	gggag	gccga	240
gacggg	agga	ttgct	tgaag	ccagg	agttt	gagacc	cagtc		tgacca	acat	ggcaa	aaccc	300
catct	tact	aaaa	at	acaa	aaat	caact	g	ggcat	ggtgg	cgtgt	gcctg	tagtccc	360
tacttg	agag	gctg	agg	caa	gaga	aatc	act	tgaacc					396

<210> 527

<211> 396

<212> DNA

<213> Homo sapiens

<400> 527

taaat	gatca	ttatg	ttcat	attcac	acat	acaata	aatgt	actca	agttt	attgct	aagg	60	
taatt	cagaa	tctc	cttatt	ttgaag	tgtg	cattt	gat	at	acctg	tttgg	gaata	actag	120
tttct	tattct	ttgac	agaaa	ataat	ttt	gt	ttt	gtt	ttact	aaaaa	agcat	ggtga	180
aaaat	ggctc	cattt	ctawg	agagg	taact	aaaat	atcgc	aattt	gctgg	gtgtc	attaa	240	
agtaac	tcac	aagg	gaaaaa	atgca	aat	tg	gtat	ctgctg	atgg	agtaaa	tctcc	gcaga	300
agtga	tgacc	ctgaa	aggat	caata	tatta	aagccc	ctcc	cagct	ggtca	ttcc	agatt	360	
caaca	ataaa	gcatta	agtg	ttaaa	acctc	aagg	ca					396	

<210> 528

<211> 396

<212> DNA

<213> Homo sapiens

<400> 528

ctcat	caagc	ccacct	ttat	actt	cat	ttc	tccag	acttc	atgtc	cagac	tgtggg	atga	60
acaag	tgggt	ataagg	ttt	agagg	ctc	cct	gtagg	actag	atgga	aggca	aaaaa	aggaa	120
ataac	cttta	agcat	gctct	cgatt	cctt	a	aatccc	atct	gaaag	tctta	aggat	gtctt	180
ctcag	tata	cttatt	tgrc	aatatt	ac	ct	aattt	tctcc	attag	cccaa	gctc	aggggt	240
ctttc	ttctt	ccatatt	ccac	atggg	tgc	aa	tggtt	ttctg	aaagg	aaaac	agcatt	acta	300
gggcag	taac	attta	aattaa	tcac	aggt	ac	ttat	caaact	acaaa	acagg	cattcc	agga	360
actggg	tgtt	tctgt	ttt	gta	aaatt	ac	ctcgt						396

<210> 529  
 <211> 396  
 <212> DNA  
 <213> Homo sapiens

<400> 529  
 taggactaga tggaggcaaa aaaaaggaaa taacctttaa gcatgctctc gattccttaa 60  
 atcccatctg aaagtcttaa ggatgtcttc tcagtcatac ttatttgaca atattaccta 120  
 attttctcca ttagcccaag ctgagggttc tttcttcttc catattcaca tgggtgcaat 180  
 gggtttctga aaggaaaaya gcattactag ggcagtaaca tttaattaat cacagggtact 240  
 tatcaaacta caaacagggc attccaggaa ctgggtgttt ctgtttgtaa aattacactc 300  
 tcgtgtacat gctcccacta aaatgtaagt tcgctgagga tggagggttt ggtctctttg 360  
 ctctgtgctg taaccccaac actgcagcag ggcctg 396

<210> 530  
 <211> 396  
 <212> DNA  
 <213> Homo sapiens

<400> 530  
 gctgcatagt ctacttagg tgtggaatct aaaaaagtca aattaaaaaa aaatgtcaag 60  
 cagagaatag aatggtagtt gccagggact ctgggaagtgc gcaggggtgg ggggtggagg 120  
 gaggggtagg gcagaagttg gtcaaaaagg acaaaagtct aggttagacag gtgtaagttc 180  
 tggggatcta ttgtacagmg tgggtgactgt agttaatact gtattgtgta cttaaaaaatt 240  
 gctcaccaaa aatggtctca ccaaaaaaat gatgtttgga tatgttaaac agtttgattt 300  
 aatcattttg acgtgtgtgt gtgtgtgtgt gtgtgtgtgt gtgtgtatata atcaaaacat 360  
 cacattatat accatataca attaatatat acaatt 396

<210> 531  
 <211> 396  
 <212> DNA  
 <213> Homo sapiens

<400> 531  
 ggggtaaatg ctgactgctt gttctctgga caggaatgga gaagatgggtg cttagcagggt 60  
 tgctgttcat atgtagacat tcatgcagtc actctctttt cagcacactt cttacttctg 120  
 ccctgggttc agttgctgac tctgagccca gaaaccttct aggggttctgt taggttagatt 180  
 ggcttcacc gtctttgcra caaccacaga aaattctaga ctgttttctc ttcgggcttc 240  
 attagtcaac ttgcttcagt ctgtcttgca tcttctaaat atttatagat ctctctcttt 300  
 tggtggagtgc gcagaaaatg ctagttagacc acccaatatt caaattatcc tgcctcctta 360  
 ataacagaat atcattggat gtgggtgggt aataat 396

<210> 532  
 <211> 396  
 <212> DNA  
 <213> Homo sapiens

<400> 532  
 atggagaaga tgggtgctagc aggggttgctg ttcatatgta gacattcatg cagtcactct 60  
 cttttcagca cacttcttac ttctgccctg gggttcagttg ctgactctga gccagaaaac 120  
 cttctagggt tctgttaggt agattggctt ccaccgtctt tgcgacaacc acagaaaatt 180  
 ctgactggtt ttctctctcrg gcttcattag tcaacttgct tcagtctgtc ttgcatcttc 240  
 taaatattta tagatctctc tcttttggtg gagtggcaga aaatgctagt tgaccacca 300  
 atattcaaat tatcctgcct ccttaataac agaatatcat tggatgtggg gggtaataaa 360  
 tataccctaa ctttccttgc agagaggggt ggccaa 396

<210> 533  
 <211> 396  
 <212> DNA  
 <213> Homo sapiens

<400> 533  
 cagggttgct gttcatatgt agacattcat gcagtcactc tcttttcagc acacttctta 60

cttctgccct	gggttcagtt	gctgactctg	agcccagaaa	ccttctaggg	ttctgttagg	120
tagattggct	tccaccgtct	ttgcgacaac	cacagaaaat	tctagactgt	tttctcttcg	180
ggcttcatta	gtcaacttkc	ttcagtctgt	cttgcatctt	ctaaatattt	atagatctct	240
ctcttttggt	ggagtggcag	aaaatgctag	ttgaccaccc	aatattcaaa	ttatcctgcc	300
tccttaataa	cagaatatca	ttggatgtgg	tggttaaata	atatacccta	actttccttg	360
cagagagggg	tggccaatga	gatggaaatg	aaagtc			396

<210> 534  
 <211> 396  
 <212> DNA  
 <213> Homo sapiens

<400> 534						
tgggattgag	ttcttgattt	gattttgagc	ttggccatca	ttggtgtata	gcagtgctag	60
tgattttgtg	acattgattt	tgtaacctaa	cactactaaa	ttcacttate	aaatctggga	120
gatttttgag	gatttccttag	gattttctag	gtatgagatc	atatcattgg	tagaggtagt	180
ttgagtttct	cttttccart	ttggatgccc	tttattttct	tctcttgcc	gattgctctg	240
actagggctt	ctagtactat	gttgaataga	aatggtgaaa	agtgggcac	cttgtctcat	300
tctaattttt	agggggaaat	gctttcaact	tttccccatt	cattttgatg	ttggctgtga	360
gtttgtcata	gatgattctt	actattttga	gatata			396

<210> 535  
 <211> 396  
 <212> DNA  
 <213> Homo sapiens

<400> 535						
tcttttgecc	tgcctttctg	cctttctgtc	cttttaattt	gcgggctttt	ggcaaccaca	60
gcacgggtct	ggtttcctag	gagtttcttt	tgtaggatca	aaccgctagt	tggctcttgg	120
ccctgtgata	gggccctggg	ctaacttatt	gggaaaatgt	tgctgtaacc	cctgcccaga	180
ggtgcctgtg	acatgggcyg	ccatcttctc	ctcttccctt	ggcttcagcc	ccacctagaa	240
acctgaacaa	acattttcct	tgacatttca	taaagtgtca	gtggctcctc	atttagcaaa	300
atacatccca	gggaagtcca	aaagtgaaaa	aaggccgtaa	cttcttcttc	ttctcaggga	360
cctacagaaa	atatgtggca	cctcggcagc	ctggcc			396

<210> 536  
 <211> 396  
 <212> DNA  
 <213> Homo sapiens

<400> 536						
catggatttt	gttttccaag	tggcaagatg	gcgcctccac	ctttggtatc	ctatttttagt	60
tcctggcaga	aagaaaggaa	caggctaattg	gccctgatga	gtctaccccc	ttttaacagg	120
agaaaattta	aaaaacaaaa	accatgaaac	cctttcccag	aggcaacaac	cagaattcca	180
tttatctttc	attgaccara	acagaccaca	tggtcactgg	tggtggcaat	ggagactggg	240
gagatgaata	tttttaagggt	ggcatattcc	agaagaacac	tgtgactga	ttgcattaat	300
gaaccatta	atgtgccaa	gggaggttta	cctatgagca	tgggcaaatt	agaaccact	360
cttggagctg	caggtgagcc	aatcccacct	aaacag			396

<210> 537  
 <211> 396  
 <212> DNA  
 <213> Homo sapiens

<400> 537						
tgggtggtggc	aatggagact	ggggagatga	atatttttaa	ggtggcatat	tccagaagaa	60
cactgtgcac	tgattgcatt	aatgaaccca	ttaatgtgcc	aaggggaggt	ttacctatga	120
gcatgggcaa	attagaaccc	actcttgagg	ctgcaggtga	gccaatccca	cctaaacagt	180
gtggatgcta	caagatgggr	aagtaaattg	attctattcc	ataccctaac	ctctctccaa	240
gatgtattct	taaaatagaa	gaggggaagac	agaagaaaac	atccagaata	tatttttatt	300
gtcttttact	tcttcagtgc	attttagatc	agtgtctctc	aatctggcaa	ggggcatgca	360
ggaggatgtg	agttttatca	ggaaaactac	acaacc			396

<210> 538  
 <211> 396  
 <212> DNA  
 <213> Homo sapiens

<400> 538  
 tgagccaatc ccacctaacc agtgtggatg ctacaagatg gggaagtaaa ttgattctat 60  
 tccataccct aacctctctc caagatgtat tcttaaaata gaagagggaa gacagaagaa 120  
 aacatccaga atatattttt attgtctttt acttcttcag tgcatttttag atcagtgtct 180  
 ctcaatctgg caaggggert gcaggaggat gtgagtttta tcaggaaaac tacacaaccc 240  
 cccaaccaca atgctacccc cactcctgtg gaccttcttt aagagagact cactattata 300  
 gatggagttg atacgatttt aagagaggcc atatattatt tgctttctgt cttgaaaaac 360  
 ttgtgatttt tctgtattgt gctactgcc aagaga 396

<210> 539  
 <211> 396  
 <212> DNA  
 <213> Homo sapiens

<400> 539  
 ggggttcagt gaggagagat cacaccattg cactccagcc tgggtggcag agcgagattc 60  
 tgtctaaaaa acaacaccgt atttggggca tgctgatact aaaaaattat tcattgtttg 120  
 tctgaaatta aaattttaat tggggggcct gtattttact gggcaaccca ttgcaatat 180  
 cagcaacaat ctcttattsa gaccactgat taagtgtgca aaatttgaat ctctgaacag 240  
 tacctatgtc cttgatattc taaattaatg agtgtcttag acactcaaag caggaggaag 300  
 cattatggca gatgtttgag ccccagagat gtccatgagc acagcataga gctcagagcc 360  
 ttctttatta ttgtcttcac gacagagcaa aggact 396

<210> 540  
 <211> 396  
 <212> DNA  
 <213> Homo sapiens

<400> 540  
 catttgcaat atcagcaaca atctcttatt cagaccactg attaagtgtg caaatttga 60  
 atctctgaac agtacctatg tccttgatat cttaaattaa tgagtgtctt agacactcaa 120  
 agcaggagga agcattatgg cagatgtttg agccccagag atgtccatga gcacagcata 180  
 gagctcagag ccttctttrt tatttgcttc acgacagagc aaaggactgc agcagggttga 240  
 ctgatataaa agttttacca tgtctcacag caggcctttg ctcaagtttc cagtaaggat 300  
 attgtatcat ttcttgctg cagtacttgt aaatccactt acactgcctg ctgttgagtc 360  
 atttgtttcg tcttgagtag catgtcatcc ttgttc 396

<210> 541  
 <211> 396  
 <212> DNA  
 <213> Homo sapiens

<400> 541  
 ttgcagttct cattgctggg gagtctaaac tggaaataaaa caccactat ctccatcagg 60  
 cttgcactag agcccagctc tagctggaga gaaagaagct aaccgcaca gacacaggac 120  
 tgtaggcagg gagcatccgg gggatatttg gtccctggctc tgatgtgcct aaggccaact 180  
 tctctctggc catgctggyg tgcattgagc cactaatctt cctttttgcc ttccattttc 240  
 tccaatcctg acttagcaaa ggttgggcaa aagagactct gtgtgagttc gagcaaagcc 300  
 tgagatgctg gattttccaa gatacgagaa ggggctgggg gctgggtgaa ctgggtgggtg 360  
 aggaggggaag gattaatttc ccaaggaggg gaaggg 396

<210> 542  
 <211> 396  
 <212> DNA  
 <213> Homo sapiens

<400> 542  
 gagaaagaag ctaaccgcga cagacacagg actgtaggca ggagcatcc gggggatttt 60

```

gggtcctggc tctgatgtgc ctaaggccaa cttctctctg gccatgctgg cgtgcatgag 120
ctcactaatc ttcctttttg ccttccattt tctccaatcc tgacttagca aagggtgggc 180
aaaagagact ctgtgtgart tcgagcaaag cctgagatgc tggattttcc aagatacgag 240
aaggggctgg gggctgggtg aactgggtgg ggaggaggga aggattaatt tcccaaggag 300
gggaaggggc caggacatca ggccccgggg actttgaaga gagggtcgtg ggtaggaggt 360
agatcaagtg gagtgcacaa aaggtcagga aagagg

```

<210> 543  
 <211> 396  
 <212> DNA  
 <213> Homo sapiens

```

<400> 543
catgcctcct acaaatttga cctgggcccc gggccatggt cgggtggtttt taagaaccga 60
ggctcccaga agcagtattg ggcagctaga gtggccccag gatctatata aaactctacc 120
tgtttctgaa ccaaatttct tctagaattt tattccataa atctgaatta tgggtgtcaga 180
ctcctagcat acactaaakg aactctctgc cttgcattaa ataacaggag ttaccctctg 240
aggtaactcc tagccctggc tctttagaga acagatgccg aataggcatt aggggatgtg 300
atggatgtgc taactttcaa aaaaaaaaaa aaaaaaaggc ctgagctgag tgctcagaga 360
ttcacaaaaa gctgcacaga tctctctgtt ccattg

```

<210> 544  
 <211> 396  
 <212> DNA  
 <213> Homo sapiens

```

<400> 544
ctttggagcc tggcagcctg gctttgagaa cggggcttta acttgtcaca tgactatggc 60
caagttcctg gggctctcca agcttcactt cctctgtaaa aagggaata atataatacc 120
tgtcttattg ggttttggcc atgttagatg agacattggg tacaaagcac ttggtcccg 180
gcctggcaca tttactgcr c ttaatgtatg atagttttct tattattcta ataaacaata 240
tggctttggg agtatagtgc tggcacattg cagtggccag agtgaagggt gtgagtgcct 300
tctggggccc tgggagtc aa gggtatccgc atgccctttc ttgcttgctc ctcagtgtgg 360
ctgcctctat gtcacacca tgcagatgca acaggt

```

<210> 545  
 <211> 396  
 <212> DNA  
 <213> Homo sapiens

```

<400> 545
acatgatcat ccccttgggc ttctgggttt ttttctttca ggaccttatt ttcaggcaag 60
tggcctttga cctctaaggc tgctctttcc tagctaccga atccagcatt caaagtgatg 120
gaaatatgta tatatagtaa tagtaaaata tcagcactta atggcctgat aagaatgtca 180
ctgcaatgct gagtttgggc caacatttgc ctgctcctgc cattgagccc gggctcccct 240
ccagagctga gctgctgcaa gggatctgag taactagggc tgtgtcagag tggcgatgac 300
agccaccaca tgctaaggaa gagatcccca aggacaagga gaatcccacg tggagctact 360
tgcttctttg tcagtcttgt ttttcttatt tcacaa

```

<210> 546  
 <211> 396  
 <212> DNA  
 <213> Homo sapiens

```

<400> 546
ccgaatccag cattcaaagt gatggaaata tgtatatata gtaatagtaa aatatcagca 60
cttaatggcc tgataagaat gtcactgcaa tgctgagttt ggaccaacat ttgcctgctc 120
ctgccattga gcccgggctc cctccagag ctgagctgct gcaagggtatc tgagtaacta 180
gggctgtgtc agagtggcra tgacagccac cacatgctaa ggaagagatc cccaaggaca 240
aggagaatcc cacgtggagc tacttgcttc tttgtcagtc ttgtttttct tatttcaaa 300
ccttctaaaa cacaatctct caacctctat tgttagcttg catttttcaa tcatgagcac 360
agctttacct ggctccatgc tttgattgac tctacc

```

<210> 547  
 <211> 396  
 <212> DNA  
 <213> Homo sapiens

<400> 547  
 tcttattttca caacctttcta aaacacaatc tctcaacctc tattgttagc ttgcattttt 60  
 caatcatgag cacagcttta cctggctcca tgctttgatt gactctacct gccaacactg 120  
 caacaacagg gaaagggaca ccggcctcat accattagat ggtgtgtagc ctgggcatga 180  
 ggataattaa aaactcccwa ggggatttta acatgtaaca cagtttgga accattgatg 240  
 taagatcttc ttactcaaca tgtgctccaa ggagctgttg tatcagctta tcagaaatgt 300  
 agatcaggcc gcacttggac ctgtagaatc agaactctga ttttatcaga ttccgacatt 360  
 atttgtatga acattagctt ttgagaagtg ttgctt 396

<210> 548  
 <211> 396  
 <212> DNA  
 <213> Homo sapiens

<400> 548  
 cttttgacac caactacaag tcaaggggtt ccccaaacca ccctgagttg tgataattcg 60  
 ctgggagatc tgacagaact cactgaaggt tgttatactc atgggttgta tctcttatag 120  
 ggagggaata cagattaaaa tcagccaaag gaagaagcac acagcacaga gtccaggaca 180  
 gtgcctgaca tggagcccyt acggtcctct ccggtggagt cacggacagc gccactctcc 240  
 tggcattgat gtgtgacaac acacagggag tgttccccac caggggaagcc ttggtgtcca 300  
 gggctctttac tgtggctctg tcacatgagc acagctgact gcccatgcgg ccgatctgtt 360  
 cccagactct ccacgcgtac acatcactca cagtcc 396

<210> 549  
 <211> 396  
 <212> DNA  
 <213> Homo sapiens

<400> 549  
 gtgggtcaca gaactcaggg aaacacagct accagtttat tgcaaggac attttaaagg 60  
 ataaaagtag gcagataaag agatgcatag ggcaggtgtt ggaaagggtc ctagtgcagg 120  
 agcttctgtc catgtggagc ggggggtgcac caccctctca gtacatgaat gagttctcct 180  
 tcacctgect atcagcctyt acatgttcag ctcccccaacc cagtcctctt gggtttttat 240  
 ggaagcttca agacacccac attctttccc cagagtatag ggcaagacct tctctgggga 300  
 gggttttaag acccacagtc agaaagggtg ggtgggggtca agattagagt cctgccttga 360  
 cgggcaggtg aaaggggtag ggggagtagg tgagaa 396

<210> 550  
 <211> 396  
 <212> DNA  
 <213> Homo sapiens

<400> 550  
 cgggggtgca ccacctctc agtacatgaa tgagttctcc ttcacctgcc tatcagcctc 60  
 tacatgttca gctccccaac ccagtcctct tgggttttta tggaagcttc aagacacca 120  
 cattctttcc ccagagtata gggcaagacc ttctctgggg agggtttta gaccacagt 180  
 cagaaagggt ggggtgggkc aagattagag tctgccttg acgggcaggt gaaaggggta 240  
 gggggagtag gtgagaaaaa ttctgtttat tttttctttt tttttttgag acggagtctc 300  
 actcttggtt ccaggggtg agtgcaatgg cacaatctca gctcactgca acctccgct 360  
 cccaggttta agcgattctc ctgcctcagc ctcccc 396

<210> 551  
 <211> 396  
 <212> DNA  
 <213> Homo sapiens

<400> 551  
 atgagttctc cttcacctgc ctatcagcct ctacatgttc agctcccaa cccagtcctc 60



ttggggtttt	atggaagctt	caagacaccc	acattctttc	cccagagtat	agggcaagac	120
cttctctggg	gaggggttta	agaccacag	tcagaaaggt	ggggtgggt	caagattaga	180
gtcctgcctt	gacgggcarg	tgaaaggggt	agggggagta	ggtgagaaaa	attctgttta	240
ttttttcttt	ttttttttga	gacggagttt	cactcttggt	gccaggggtg	gagtgcattg	300
gcacaatctc	agctcactgc	aacctccgcc	tcccaggttt	aagcgattct	cctgcctcag	360
cctcccagat	agctgggatt	acaggcgtgt	gccacc			396

<210> 552

<211> 396

<212> DNA

<213> Homo sapiens

<400> 552

tcttcattcc	acaaagctca	gtgtcaaaac	atgggggttta	cactggaagc	tgaggtcaca	60
tcagtagccg	ggatcagggg	cgccctagct	gcccaatgca	gctcccaggc	ctcctgtaaa	120
accttgacct	ttgaggctcat	gacagccctc	tcttgctatg	ctcatagctg	accactgaac	180
tcttgagcac	tccctccsc	aagttcacag	agaatgtggg	cacatgcctt	acagtcttcc	240
cttgatccaa	actactgect	tcactctgag	tgacagcagc	atcttttga	tgtcttggcc	300
tgtctagctt	tatttttttg	tgttctgcca	tcaagttgct	acttctgttg	ccatcgtgcc	360
tgtcagcgca	gtgcaggctg	tggtgaaatc	ccacga			396

<210> 553

<211> 396

<212> DNA

<213> Homo sapiens

<400> 553

tatttttttg	tggtctgcca	tcaagttgct	acttctgttg	ccatcgtgcc	tgtcagcgca	60
gtgcaggctg	tggtgaaatc	ccacgaactc	aggcatcaca	ctgaccgggt	ctgagtcctg	120
tctcagttgt	cagctagttg	tgcaatgaag	ggaaaggagc	ctacactttc	caagcctcaa	180
ttcactcatc	tatggcatkg	tgacaataat	ggaggttgat	ttaaagtcct	ttgtaagaat	240
taagagttat	aatagacata	aagtgcctga	tctggtatac	ctagaaaaca	ttccataaaa	300
gtttagtaatt	gttggtcatg	taatgatgac	tctctaggct	aggatttcag	cttcattgca	360
tgcacatggt	gcactcacag	ggcgtgacct	ctctct			396

<210> 554

<211> 396

<212> DNA

<213> Homo sapiens

<400> 554

gggtataccta	gaaaacattc	cataaaaagtt	agtaattggt	ggatcatgtaa	tgatgactct	60
ctaggctagg	atttcagctt	cattgcatgc	acatggtgca	ctcacagggc	gtgacctctc	120
tctgtctcag	taacctcatc	tgaggaccgg	gataatcata	ccgcttcaaa	gggatgtcat	180
aaagattaaa	taatatgtrt	aaggctgctt	gcatttagct	gcattcaaca	aatattttctg	240
tatctttctc	ctcattttctc	cttactttct	tgcttattat	ctgctctagg	tatagatttc	300
agagaactaa	gcttggttaca	atccttcata	aaataaccag	gttggttagg	gcatttccaa	360
gagtcaatac	tgtttagtga	ctattctctg	tttaat			396

<210> 555

<211> 396

<212> DNA

<213> Homo sapiens

<400> 555

aaggctgctt	gcatttagct	gcattcaaca	aatattttctg	tatctttctc	ctcattttctc	60
cttactttct	tgcttattat	ctgctctagg	tatagatttc	agagaactaa	gcttggttaca	120
atccttcata	aaataaccag	gttggttagg	gcatttccaa	gagtcaatac	tgtttagtga	180
ctattctctg	tttaatctmt	tttgattgtc	cagggtcatc	ttttgctatg	tcatagggtg	240
ttggcttctt	ctagagaagt	gagacgatgg	acaagttcca	agtgagtga	gcgactgggc	300
aggatattcc	gctgaaaaac	tcattgtcagt	tctaattcgt	gattgtaatt	caatcacagc	360
ctgagaacag	taggactgta	gttcaaatgc	tctgtt			396

<210> 556  
 <211> 396  
 <212> DNA  
 <213> Homo sapiens

<400> 556  
 cctgggttca agcaattctc ctgcctcagc ctcccaagta gctgggacta caggcacatg 60  
 ccaccacgcc cagataaatt tctgattttt agtagagacg gggtttcccc ttgttgcca 120  
 ggggtggtctt gatctcttga cctcatgacg cgcacacctc ggctcccaa agtgctggga 180  
 ttacaggcgt gagccaccrc gcccggcctc tagaggataa tttttaaatg tgcttttgca 240  
 tttggaaaat gtgattggca tttttttcta attttcta atgatacgct gtcggatgct 300  
 atggattact taaacctctt ggctacctag aaagatcttt aagtggttct caacaagctt 360  
 catacgcaat gtaaattgta ttatctctca ggatgt 396

<210> 557  
 <211> 396  
 <212> DNA  
 <213> Homo sapiens

<400> 557  
 tgtgattggc atttttttct aatttttcta tatgatacgc tgcggatgc tatggattac 60  
 ttaaacctct tggctaccta gaaagatctt taagtgggtc tcaacaagct tcatacgc 120  
 tgtaaattgt attatctctc aggatgtgtg agaacatctg tttttcttct aatgcagtaa 180  
 acatataagg gtctcttgrg atatctttta aatagactta atacaacatt caggaatgat 240  
 aacaaaatat aatcacagtt gtaagggaat gtgagcattt catattaata acattggaac 300  
 cttatgttta atacagtgtt aaaagttgac aaacatgtag gagtcagaaa attcaattaa 360  
 aattatcaca gtaatatgaa tttagccaca tctgt 396

<210> 558  
 <211> 396  
 <212> DNA  
 <213> Homo sapiens

<400> 558  
 acttaaaccc tctggctacc tagaaagatc tttaagtgg tctcaacaag cttcatacgc 60  
 aatgtaaatt gtattatctc tcaggatgtg tgagaacatc tgtttttctt ctaatgcagt 120  
 aaacatataa gggctctctg ggatatcttt taaatagact taatacaaca ttcaggaatg 180  
 ataacaaaat ataatacarg ttgtaaggga atgtgagcat ttcataattaa taacattgga 240  
 accttatgtt taatacagtg ttaaaagttg acaaacatgt aggagtcaga aaattcaatt 300  
 aaaattatca cagtaatatg aatttagcca catcctgtgt tagttatgaa atccatttaa 360  
 caccacaaac agtaatatct ttagccagtt tattca 396

<210> 559  
 <211> 396  
 <212> DNA  
 <213> Homo sapiens

<400> 559  
 catttaacac cacaacacagt aatattttta gccagtttat tcaaaaggaa aacaggaact 60  
 aaaccacttt catgcaatat atactctgtt aatgtggtca ggctaatttt gctgggggaa 120  
 ggaacttaac ttttgaatat ttgaatgcc agtcatttaa tctgaatata ctatttcctt 180  
 gcatgttgca aaatttttkt caataaaagg cagaaaaaga aatctcttct ccattgctcat 240  
 ccctaagaga atgggttgct tgtaccctga gagcatttta tggaggggac aaccactttt 300  
 ctaatttttc ttcccacttc tctgtgggca caaatgctct ttgggttgaaa gagttgtaatt 360  
 tcagtcccaa gatgaggtgt gggtactgca tcccta 396

<210> 560  
 <211> 396  
 <212> DNA  
 <213> Homo sapiens

<400> 560  
 tcaatccatg ctccacactg cagccagagt gctctacaat gcaaatccat ttgtgagact 60

cctcctctta	aaatcctcaa	gtggcttctc	tttgccccc	ggatcatttt	gaaactcctt	120
aatggaagag	gcatggccct	ttgggatgtg	gttccccaac	ccctcccaca	tcattctttc	180
aatcagattt	cccactaart	ggaaattttt	tcaggtcctc	aactttatgg	tgactttctc	240
ttgctcagga	tctttgaaca	tactgtttct	tctttccttt	tgtatttgcc	aagacaacac	300
tctctctggg	aagattttcc	tgacatcctc	tataaaaaaa	gattgagata	gttgactacc	360
caaatgtgtt	cccattcatt	ccaagctcta	ttcaag			396

<210> 561  
 <211> 396  
 <212> DNA  
 <213> Homo sapiens

<400> 561						
aacacttctt	ctggtaagat	tttcttgaca	tcctctataa	aaaaagattg	agatagttga	60
ctacccaaaa	tggttcccat	tcattccaag	ctctattcaa	ggcagtaaag	tgcccggctg	120
acagattgca	ttcctcatct	tttctgaagc	tagcaatggc	catgcaacag	cattctggcc	180
aataagatag	aagtccaart	tgaagggttg	gattttccaa	aaagctcgtt	gaagacataa	240
ttctctggtt	cacttcttac	tctttctctt	tcctgcttcc	taaaatgcgg	tcagatggc	300
agacacttca	aagctgtctc	aggcaatcag	gtgatgttaa	ggcagaaacc	agctttatga	360
tgggtagaac	aggaagaaag	aaggcaccta	tgttct			396

<210> 562  
 <211> 396  
 <212> DNA  
 <213> Homo sapiens

<400> 562						
cctacaaatc	tcattgttgac	attttatccc	taatattgga	ggcagggcct	agtaggaggt	60
gttttggtca	tagtgataaa	tggttgggtg	ccgttctcac	agtaacgagt	gagtttttat	120
tctagtgggt	cctgcaagaa	ctgattgtta	aaagagcttg	gatccttcca	ccctctctc	180
actcttgctt	cctctctcwc	accttgtaat	ctctacaagc	tcttcacctc	cccttctcct	240
tttgccataa	gtggaagatt	tctgaggcct	caccagaagc	agatgttggt	tccatgcttc	300
ttgtacagcc	tgacagaacca	tgagccaaat	caacttcttt	tctttataat	tatccagtct	360
caggtattcc	tttatagcaa	cacaaatgga	ctaaga			396

<210> 563  
 <211> 396  
 <212> DNA  
 <213> Homo sapiens

<400> 563						
gttggtttcca	gctttgaact	attttgaatc	ctaaaagact	gccagttttg	aatgagaccc	60
cagaacaatg	aatgtaggct	ctgtatacaa	gttcaggctg	ctgggcaact	taggccttaa	120
gacacaactc	tgccacttag	gccttaagac	acaactgaca	tgatgggtgct	taaagtggct	180
gtgatggaaa	aggaggtctt	ttggagcctt	tggagtgcct	ttatagggtga	acccagcat	240
agcacctaata	gatttggagc	aaagctgtgt	cattcccca	agataactat	tcgccttttg	300
agaaacatct	tctagctact	atcaataata	aacacagaat	gcatacccat	gggccaccgt	360
gttggtctttt	gacctgagtt	tccattgtga	acaaga			396

<210> 564  
 <211> 396  
 <212> DNA  
 <213> Homo sapiens

<400> 564						
aactctgcc	cttaggcctt	aagacacaac	tgacatgatg	gtgcttaaag	tggctgtgat	60
ggaaaaggag	gctgtttgga	gcctttggag	tgccctttata	ggtgaacccc	agcatagcac	120
ctaattgattt	ggagcaaaagc	tgtgtcattc	cccaaagata	actattcgcc	ttttgagaaa	180
catcttctag	ctactatcra	taataaacac	agaatgcac	accatgggcc	accgtgttgt	240
cttttgacct	gagtttccat	tgtgaacaag	agtcatttga	tccaaggcag	aaagtgggt	300
gcacacagca	gtgttccatc	atcaaatgga	atatgagatt	gggcccaagt	aggctctgca	360
gacacaaata	agttgcaaga	gcaagtagta	caggcg			396

<210> 565  
 <211> 396  
 <212> DNA  
 <213> Homo sapiens

<400> 565  
 gaaaaggagg ctgtttggag ccttttgaggt gcctttatag gtgaacccca gcatagcacc 60  
 taatgatttg gagcaaagct gtgtcattcc ccaaagataa ctattcgcct tttagaagaa 120  
 atcttctagc tactatcaat aataaacaca gaatgcatca ccatgggcca ccgtgttgtc 180  
 ttttgacctg agtttccayt gtgaacaaga gtcatttgat ccaaggcaga aagttgggtg 240  
 cacacagcag tgttccatca tcaaattggaa tatgagattg ggcccaagta ggtcctgcag 300  
 acacaaataa gttgcaagag caagtagtac aggcgcttgg cctggccagt actgttgcca 360  
 agttgactgc ttccctcag tctgcatctg tggctt 396

<210> 566  
 <211> 396  
 <212> DNA  
 <213> Homo sapiens

<400> 566  
 ccccaaagat aactattcgc cttttgagaa acatcttcta gctactatca ataataaaca 60  
 cagaatgcat caccatgggc caccgtgttg tcttttgacc tgagtttcca ttgtgaacaa 120  
 gagtcatattg atccaaggca gaaagttggg tgcacacagc agtgttccat catcaaattg 180  
 aatatgagat tgggcccarg taggtcctgc agacacaaat aagttgcaag agcaagtagt 240  
 acaggcgctt ggccctggcca gtactgttgc caagttgact gcttcccctc agtctgcac 300  
 tgtggcttca tggggagttt cctatgacca cttgatggag gaaaaaaca attggagcat 360  
 agtttatagt gctggtacta cccaaagtgg ctactg 396

<210> 567  
 <211> 396  
 <212> DNA  
 <213> Homo sapiens

<400> 567  
 gtccgtgagt tacagatcta cacaaaatca cagagagtgg ttaatcgttt agtctgatgg 60  
 tcagggactt ccaagagaca tgattagaaa actggtgaca aggagtctg gggaagaggc 120  
 atatggatac ctctgaacac acacaaaaca tgagaataatg tatcccatat gaatgttaac 180  
 caaagagcag ccacaacasa agaggatttt aaaatcagct gaataagatg attcattctg 240  
 acagcatcag ctagtctctt tccccagcca ctgttgccca gtgggcttac atatatcatg 300  
 gccatggggg cagggctatg tatggacaca gcaacatgaa tttccactca tcaaggccaa 360  
 tttggctcca gccattgctg agtgctcagc ctgcca 396

<210> 568  
 <211> 396  
 <212> DNA  
 <213> Homo sapiens

<400> 568  
 acatgattag aaaactggtg acaaggagtc ctggggaaga ggcatatgga tacctctgaa 60  
 cacacacaaa acatgagaat atgtatccca tatgaatgtt aaccaagag cagccacaac 120  
 agaagaggat tttaaaatca gctgaataag atgattcatt ctgacagcat cagctagtct 180  
 ctttccccag ccactgttrc ccagtgggct tacatatatc atggccatgg gggcagggct 240  
 atgtatggac acagcaacat gaatttccac tcatcaaggc caatttggct ccagccattg 300  
 ctgagtgtc agcctgcca gatagaaatc tacgccaata tggcaccatt ccttgggcta 360  
 gaaaaccaac tgggtggaagg ttgattacat tggacc 396

<210> 569  
 <211> 396  
 <212> DNA  
 <213> Homo sapiens

<400> 569  
 gggaatacaa tgggtggtcc actaaactga cagctgagtt tgccatctcc tctgtccagt 60

gaatacacaa	gcaaggaagg	gggttccttt	ctcacctagg	gtgactgac	ctaattacca	120
aggagaaatt	ggactgccac	ttcacaatga	gggtgaggag	tatgtactct	atgtgtctgt	180
gattaatgtc	aatagaaart	gacaccaacc	tagtacacag	aggactgac	atgggccagg	240
cccttcagga	atgaagattt	gagtcaccag	gcaaggaact	tggactcact	gaggagggca	300
tattccaagg	agaatatttt	atctatgtcc	atctatgtcc	atctatattc	catctgtgtt	360
ccccttggaa	ttcctattca	tgaacatggg	gaattc			396

<210> 570

<211> 396

<212> DNA

<213> Homo sapiens

<400> 570

tatagaatga	gtagtggaag	gtagttataa	atgtaagtca	aaaaccacac	aaccaatttg	60
agaaatgagg	aaggtaatag	tgttgaatat	gtcttcttta	tcttgatata	aatgtatttg	120
tgcataatatt	aaccagttta	tttattttatt	attatTTTTT	gagatgagct	ctcgccatgt	180
tgcccagggt	ggtcttgamc	tcctgggctc	aactgattct	accatttagt	cctccgagta	240
gctgggacta	caggcatgca	ccaccatacc	cagctgacca	gttttttctt	attcctctac	300
ttaatTTTct	tactatacaa	cataatatgt	gttaatggta	gttaacttta	tatctcagta	360
ttaagtcaca	agatatcaaa	aagggaatgc	gactta			396

<210> 571

<211> 396

<212> DNA

<213> Homo sapiens

<400> 571

atgtcttctt	tatcttgata	taaatgtatt	tgtgcatata	ttaaccagtt	tattttattta	60
ttattatttt	ttgagatgag	ctctcgccat	gttgcccagg	ctggt.cttga	actcctgggc	120
tcaactgatt	ctaccattta	gtcctccgag	tagctgggac	tacaggcatg	caccaccata	180
cccagctgac	cagtttttyc	ctattcctct	acttaatttc	tctactatac	aacataatat	240
gtgttaatgg	tagttaactt	tatatctcag	tattaagtca	caagatatca	aaaaggggaat	300
gcgacttagt	tacaagcaga	atgaatatca	ctcaaagatg	aataaagaga	agaggggttag	360
tgcattttct	gttggatgag	agaaagtTtc	attgTt			396

<210> 572

<211> 396

<212> DNA

<213> Homo sapiens

<400> 572

gcagtggcgt	gateccagct	cactgcaatc	tctgcctcct	gggttcaagt	gattctcctg	60
cctcagcctc	ccgaggggct	gggattgtag	gcgtgcacca	ctatgcccat	ctaatttttg	120
tatttttagt	agagataggg	ttttgccatt	ttggccagac	tgtcttgaac	tcctgacctc	180
aggtgatctg	cctgcctcrg	cctcccacag	ttttgtgatt	ataggcatga	gccaccgtgc	240
ccggccttaa	cctttgtttt	cttacacaac	acactacgtg	atgttttcca	catgcatggg	300
tcatttgctt	catttacgta	caaatgcata	agcaatatac	tgtgtgggtg	gagtttgtga	360
tgggaaaagg	aagaagtttt	gcggatacta	cactgg			396

<210> 573

<211> 396

<212> DNA

<213> Homo sapiens

<400> 573

gccaggtctg	ttctccaact	cctggactca	agccatcctc	tagcctcggc	cttccaaagt	60
gctgggacta	taggcgtgag	ccacgggtgcc	aggcccttga	ccacattttt	aaccctctctg	120
aacctcagtt	tcactttctg	ggcaatggga	ggggggtaat	ttgtccctca	gaggggttgca	180
ctgaggggca	aatgtgagsc	tctgggtaca	atgccagta	cagactaggt	ccccacgaca	240
cagccgctca	gcggctccgg	attctgggct	gctctggact	gcggccaggc	ggtcttctgc	300
gggaatccgg	gcaggcaggg	cgggctgcgc	tccccctccc	ggctctcccg	gtgccccttg	360
tcttttttgt	ctgtctcagc	agctctctat	taagat			396

<210> 574  
 <211> 396  
 <212> DNA  
 <213> Homo sapiens

<400> 574  
 tttttgttct gtctcagcag ctctctatta agatgaatgg catttccaaa ggcttcacct 60  
 ctgataagtg ttctcttgca gctgcagcca gaatcttaat gtgcgcgctg taatttaagt 120  
 gccgtctcgg ctattaacac gctcttctcg ggtgaagtgg actccctcca tccccgggcc 180  
 tctgcacgtg ctctgcgcrc tggctggggg tgactccaag gagctcagag cgggggtgcc 240  
 ggcacctctc gccaggcgcc ttctgacctt ctaaagcgcg aatggctgga cttttctccc 300  
 atgtgtgggg cccagaagg tgtggggccc cagaagggtg ggggtccctg cgttccacgg 360  
 agcccggaag gtttccagtg atgggtgggg ctgacc 396

<210> 575  
 <211> 396  
 <212> DNA  
 <213> Homo sapiens

<400> 575  
 ggagcccgga aggtttccag tgatgggtggg ggctgaccac gttgggtcccc gtgggtgctg 60  
 ttttcatgtg ccggcagatt gggatgagtt taaaagacag aagcgtgtag gatagagaaa 120  
 cttctttaaa aactggaaat tttaatctgg ggattataac tattggacag tcaagtgcaa 180  
 gagtgaatac acttctcast cctcctccc aatttttat't tgcgggatta gtcagtcgcc 240  
 ctctgccaca tgataattgt gagaactacc aggggtcttca ttctcctgcc atctgggtga 300  
 cctctccaag aatggacacc cgggcagcct gggccaatga ggctgtccta agagtttaga 360  
 tgagagaagt cagtctttga caggtgatgg aagctg 396

<210> 576  
 <211> 396  
 <212> DNA  
 <213> Homo sapiens

<400> 576  
 cagtgatggg gggggctgac cacgttggtc cccgtgggtg ctgttttcat gtgccggcag 60  
 attgggatga gtttaaaaga cagaagcgtg taggatagag aaacttcttt aaaaactgga 120  
 aattttaatc tggggattat aactattgga cagtcaagtg caagagtga tacacttctc 180  
 actccctcct cccaatttyt atttgcgga ttagtcagtc cccctctgcc acatgataat 240  
 tgtgagaact accagggctt tcattctcct gccatctggt tgacctctcc aagaatggac 300  
 acccgggcag cctgggcca tgaggctgtc ctaagagttt agatgagaga agtcagtcct 360  
 tgacaggtga tggaagctgt aaaatgtaaa actcca 396

<210> 577  
 <211> 396  
 <212> DNA  
 <213> Homo sapiens

<400> 577  
 taagagaagc tgagagagag cgagaggaga gattggaaga aagacagaga cagaggtaga 60  
 gagaagggaa agagagagag aaagggacag aagagagaga aaaaagaggg ggccggggcg 120  
 ggtggctcac gcctgtaatc tcagcacttt gggaggccga ggcgggcaga tcacgaggtc 180  
 aggagatcga gaccatccyg gctaacacgg tgaaaccccc gtctctacta aaaaatataa 240  
 aaaaaattag ccaggcgtgg tgggtgggtgc ctgtagtccc agctactgag gaggtgaga 300  
 caggagaatg gcgtgaacc gggaggcaga gcttgcaagt agctgagatc gcgccactgc 360  
 actccagcct gggcaacaga gcaagactcc gtctca 396

<210> 578  
 <211> 396  
 <212> DNA  
 <213> Homo sapiens

<400> 578  
 tccaccagca gcttttctga gtctccagct tgcagatggc aaaccatgaa acttcatggg 60

gtccatgagc	atgtgaacca	atctctatta	taaatctgca	atatatatat	atgaggagac	120
ttattttatat	attggttcag	tttctctgga	gagccttggc	taatataaag	tctatactct	180
acaaagtgcc	ctaggtackc	agggagtacc	caagtgtgtc	atgaccagcc	cgacagccct	240
ggctgctggc	ttccccgcac	acaactctgc	acgctgcctt	catcagcctt	tctctctcag	300
ctgaaccgag	ggcattgaag	cgggcctctg	gcactgtacc	tatgaggggag	caatatcttc	360
ccctacactg	acctcttccg	tgccgagatg	cagccc			396

<210> 579  
 <211> 396  
 <212> DNA  
 <213> Homo sapiens

<400> 579						
gcctctggca	ctgtacctat	gagggagcaa	tatcttcccc	tacctgacc	tcttccgtgc	60
cgagatgcag	ccctccctgc	tgccactagt	tacagtgggc	catgttccct	ttcaaagtga	120
agttttgata	aaagcacctc	ttaaccaatg	ccaaatagct	aagtctggga	caaagattgc	180
aggtaattttg	cattttccwt	gtaacctcag	agggattgcc	attcacactg	atctgagctg	240
cagaatacaca	ggcagccacc	tcacccaccc	agcaggtcca	ctcttatact	ttctcagaaa	300
gcacagccac	tctactctta	ttcagttgaa	aagaatttcc	aggaagggtg	ttctgcgatt	360
gcctcagaaa	agtcagttcc	ctttgggaat	ttccct			396

<210> 580  
 <211> 396  
 <212> DNA  
 <213> Homo sapiens

<400> 580						
tactttttctc	tgaagaaatg	gagatatcag	ctgtccctcc	ccactgccat	ttattccttc	60
cttcattcaa	accttatgtg	gctgctactt	accgtgtgtt	aagtgttcac	tttttttctt	120
ggaattcaaa	aaaagaagga	cagtatttgg	ggcacagatc	ttttggtgtt	ctatacattt	180
ttttaaagt	tcattttaya	tttgtgtgtg	cgtgtgtgtg	tgtgtgtgag	acagtcttgc	240
tctgttgccc	aggctggagt	gcagtggcat	aatcattggc	tcactgtagc	ctcaaagtcc	300
tgggcccag	caatcttccc	acctcagcca	cccaaatg	tgggggttaca	ggtttatg	360
actctgtctg	acctgaaagt	tttgggttta	ctttcc			396

<210> 581  
 <211> 396  
 <212> DNA  
 <213> Homo sapiens

<400> 581						
gcataatcat	tggtcactg	tagcctcaaa	gtcctggggc	caagcaatct	tcccacctca	60
gccacccaaa	atgctggggt	tacaggttta	tgccactctg	tctgacctga	aagttttggg	120
tttactttcc	cttctttctc	tttgtgaag	tcagagatga	tggcagcttc	cagattctct	180
ggtgcctgtg	ctgggctcrt	gctggctcatg	gtcttgggtc	caggattcat	tctgggagact	240
ctcaggggaag	tttcccatga	caaggaaatg	taggagagtg	tgctggcttt	gcgtgctcct	300
ctgccaaagc	ctgcttctcc	tggtgggaca	cactgaacca	cagccagggc	attttgggtg	360
ttagttaaaa	aaaaaaaaaa	aaaaaaaaaa	aggaag			396

<210> 582  
 <211> 396  
 <212> DNA  
 <213> Homo sapiens

<400> 582						
cttcagaaat	tgtaatgatg	aaagagtgc	agctctcact	tcccccttcc	gtacagggca	60
ggttgtgcag	ctggaggcag	agcagtcctc	tctggggagc	ctgaagcaaa	catggatcaa	120
gaaactgtag	gcaatgttgt	cctgttggcc	atcgtaaccc	tcatacagct	ggtccagaat	180
ggtaaggaaa	gcccttcam	caggggaagaa	cagaagggga	gattttcttt	gatggttgtt	240
tggagtcag	gcttaaacaa	ttgtgtctgt	gtgtgcccgc	gcacaaacac	ttttacctta	300
tctttatatt	cttcttttta	tttgaatgta	taggggttgtg	tgtattttctg	tgtaaatttg	360
gggttttcc	cctcttagtc	tttcactttt	gtgggtg			396

<210> 583  
 <211> 396  
 <212> DNA  
 <213> Homo sapiens

<400> 583  
 ttttctaaca tctgcagtgc aattgaagtt accagtcata tgcagtctaa aaagaaagtg 60  
 attttgggag gtgcgtagaa aaaatcatct tattattttt cctctatatt acttttttct 120  
 ttttttctcc tgaagaaact tttttttttg gtgatacctt ctttttctct agcacgtata 180  
 attttgggaag catttttctt atgcagtgta tacttcagaa agagagagag agagaggaaa 240  
 attgtcctgt tcagcgtttg catttccatt attcctgcta ttagttaaaa acaacaacaa 300  
 caacaaaaaa caagcaggat acctagatct ggaaaaggga gaattgtgta gagctgtctt 360  
 cctaaagttc tgagtttagg ctgcctcaga ccactt 396

<210> 584  
 <211> 396  
 <212> DNA  
 <213> Homo sapiens

<400> 584  
 ttttgggaagc atttttcata tgcagtgtat acttcagaaa gagagagaga gagaggaaaa 60  
 ttgtcctgtt cagcgtttgc atttccatta ttctgtctat tagttaaaaa caacaacaac 120  
 aacaaaaaac aagcaggata cctagatctg gaaaaggag aattgtgtag agctgtcttc 180  
 ctaaagttct gagttaggrc tgccctcagac cactttcata actatctcca gtggctttgt 240  
 gttttatatt tattaagata gagaaaaaaa gagtaattac taagggcagc tgctgtagct 300  
 ttatggtgat tactgaacat tgacatgctg tcacgttttt ggaactttga gtatttaate 360  
 actttgggat attctatatt ccccatctt gactgt 396

<210> 585  
 <211> 396  
 <212> DNA  
 <213> Homo sapiens

<400> 585  
 ggaactttga gtatttaate actttgggat attctatatt ccccatctt gactgtggac 60  
 agatgctggt gatgtagcct tctgggcaca gagcaagcct cccctcagc ctctgcacca 120  
 gaaaggctca gcttcacaca ctccaagtat gttttctaca agaactacac tttgtggctt 180  
 tctgacc'caa acattttttrt actaaattac acacaacaaa gttgtagctc agagagggaa 240  
 caaatggctt atttaggcca ccattttctt gagccattat gatttcacac agggctccct 300  
 tggccctgta aattggcaag gattccatta ttcaaccgcg atacatgtac agagaccctg 360  
 ctctggccca gatagtattc tgggtacagg cggata 396

<210> 586  
 <211> 396  
 <212> DNA  
 <213> Homo sapiens

<400> 586  
 tgtggacaga tgctggtgat gtagccttct gggcacagag caagcctccc cctcagcctc 60  
 tgcaccagaa aggtcagct tcacacactc caagtatgtt ttctacaaga actacacttt 120  
 gtggctttct gacccaaaca tttttatact aaattacaca caacaaagt gttagctcaga 180  
 gaggaacaa atggcttayt taggccacca ttttcttgag ccattatgat ttcacacagg 240  
 gctcccttgg cctgtaaat tggcaaggat tccattatc aaccgcata catgtacaga 300  
 gaccctgctc tggccagat agtattctgg gtacaggcgg atagagcagg aaacaaaaca 360  
 gctacagtga tggacaggtc agcctgcagc aatgcc 396

<210> 587  
 <211> 396  
 <212> DNA  
 <213> Homo sapiens

<400> 587  
 tttttatact aaattacaca caacaaagt gttagctcaga gaggaacaa atggcttatt 60



taggccacca	ttttcttgag	ccattatgat	ttcacacagg	gctcccttgg	ccctgtaa	120
tggcaaggat	tccattattc	aacccgcata	catgtacaga	gaccctgctc	tggcccagat	180
agtattctgg	gtacaggcrg	atagagcagg	aaacaaaaca	gctacagtga	tggacagggtc	240
agcctgcagc	aatgcctgca	gtctctgcaa	aggtagctgt	atgggtgggc	aggtggctag	300
cacttattca	gctctggaag	gatctcccct	ctggcctctc	ccctgacacc	catcaataaa	360
actgaggagc	atcgggtggac	aggggacctt	gtgccc			396

<210> 588  
 <211> 396  
 <212> DNA  
 <213> Homo sapiens

<400> 588						
ttttcttgag	ccattatgat	ttcacacagg	gctcccttgg	ccctgtaa	tggcaaggat	60
tccattattc	aacccgcata	catgtacaga	gaccctgctc	tggcccagat	agtattctgg	120
gtacaggcgg	atagagcagg	aaacaaaaca	gctacagtga	tggacagggtc	agcctgcagc	180
aatgcctgca	gtctctgca	aggtagctgt	atgggtgggc	aggtggctag	cacttattca	240
gctctggaag	gatctcccct	ctggcctctc	ccctgacacc	catcaataaa	actgaggagc	300
atcgggtggac	aggggacctt	gtgccccctc	cctgcctgtg	cagttggggc	tgaaccagc	360
tacgaagttt	gagctcactc	tctccagctc	cctctc			396

<210> 589  
 <211> 396  
 <212> DNA  
 <213> Homo sapiens

<400> 589						
gacaggtcag	cctgcagcaa	tgcctgcagt	ctctgcaaag	gtagctgtat	gggtgggcag	60
gtggctagca	cttattcagc	tctggaagga	tctcccctct	ggcctctccc	ctgacaccca	120
tcaataaaaac	tgaggagcat	cggtggacag	gggaccttgt	gccccctccc	tgcctgtgca	180
gttggggctg	aacccagcya	cgaagtttga	gctcactctc	tccagctccc	tctcaattca	240
gagctgaact	gtgggaagct	tcagagctct	ctgtttcaag	gacaggttct	cctcacctct	300
cctaattggag	gtgcaccagg	gaactggccc	tgtcttgccc	agggctttct	cctggacttt	360
gccatcatgg	tctagcaaac	cctgttcaga	ttgagg			396

<210> 590  
 <211> 396  
 <212> DNA  
 <213> Homo sapiens

<400> 590						
cactctctcc	agctcccctct	caattcagag	ctgaactgtg	ggaagcttca	gagctctctg	60
tttcaaggac	aggttctcct	cacctctcct	aatggagggtg	caccagggaa	ctggccctgc	120
tctgcccagg	gctttctcct	ggactttgcc	atcatggtct	agcaaaccct	gttcagattg	180
aggtgagtg	tgagatttyg	aattcttttt	gacagatagg	attaagtctt	cttctgtggg	240
acaagtggga	ggtagaggta	agattaaaga	tggccaaatg	tctgagtcct	gacagccaca	300
atatggagat	ctagactttt	tacagaccac	agggcacagg	ggcctcacta	acagagttcc	360
cgggaagtgat	gagtgtgctg	ggggcttccct	ggttga			396

<210> 591  
 <211> 396  
 <212> DNA  
 <213> Homo sapiens

<400> 591						
taggattaag	tcttcttctg	tgggacaagt	gggaggtaga	ggtaagatta	aagatggcca	60
aatgtctgag	tccctgacagc	cacaatatgg	agatctagac	tttttacaga	ccacagggca	120
caggggcctc	actaacagag	ttcccgggaag	tgatgagtg	gctgggggct	tcctggttga	180
agagacacta	gaatggacsa	gctgggagct	aatttttttg	gctggagtg	gatggcctgc	240
acatcactgc	ctctgtccct	ccattgtcac	agctgcccct	taggagccag	ctgaggcaat	300
ttgtgggtcag	agtgaacttg	cacagttgtc	ctgcctgtgt	tcaggaaggg	agtttctgtg	360
gtccctttga	aaccacagaa	gagcccctcg	tatagc			396

<210> 592  
 <211> 396  
 <212> DNA  
 <213> Homo sapiens

<400> 592  
 agttgtcctg cctgtgttca ggaagggagt ttctgtggtc cctttgaaac cacagaagag 60  
 cccctcgtat agctctcaat ggagggggca aaacattcaa ataactcagg agataacaca 120  
 actatttgtt ttttaactgt agtttttagg caatcacaaa gatccagatg tatgtccaag 180  
 cctctctttg caattctawt taacctcaat gttgcaacca tagacctacc ttacagagtt 240  
 caaaaaaata tgcaaaaacc ctgcctttct tcttcctcat accccaaaat gccatttctga 300  
 acatttcctg ttagttaaaa aaagatttcc atgggtgttac caggcactgt acacagtctg 360  
 tgtccaaga caaggaggta cagttccaca tgcgcc 396

<210> 593  
 <211> 396  
 <212> DNA  
 <213> Homo sapiens

<400> 593  
 agggggcaaa acattcaaat aactcaggag ataacacaac tatttgtttt taactgtgag 60  
 tttttaggca atcacaaaga tccagatgta tgtccaagcc tctctttgca attctaatta 120  
 acctcaatgt tgcaaccata gacctacctt acagagttca aaaaaatatg caaaaaccct 180  
 gcctttcttc ttctcatwc cccaaaatgc cattctgaac atttctgtt agttaaaaaa 240  
 gattttccat ggtgttacca ggcactgtac acagtctgtg tccaagaca aggaggtaca 300  
 gttccacatg cgcccatgac tgggttgggc tctgcactct ctctatactt tgagagcctg 360  
 attttctgtg attgggcaga gctggcccac ctggtg 396

<210> 594  
 <211> 396  
 <212> DNA  
 <213> Homo sapiens

<400> 594  
 tctgcactct ctctatactt tgagagcctg attttctgtg attgggcaga gctggcccac 60  
 ctggtgcaat gtctctctct gcctttcaaa catgttttag tcatcaagat cttcaaattt 120  
 gtaacccttt ccagcttgat ccagcagaat gcagatttgg aaaaacagaa cgagtttaaa 180  
 atacatgatt ctaagaaayc tggaccagaa ctatcaaaac ttggtttccc agagaatata 240  
 gcaaattggc tcattggcca atactatgac attggctttt gagaaaagaa aggctttatt 300  
 gcaaggctgg ccagcaagga gacaggagtt gggctcaaat ctgtctcccc agtttggggc 360  
 ttagggcaag ttttaattac acagacgcac ttctta 396

<210> 595  
 <211> 396  
 <212> DNA  
 <213> Homo sapiens

<400> 595  
 aaccctttcc agcttgatcc agcagaatgc agatttggaa aaacagaacg agtttaaaat 60  
 acatgattct aagaaacctg gaccagaact atcaaaactt ggtttcccag agaatatagc 120  
 aaatgggctc attggccaat actatgacat tggcttttga gaaaagaaag gctttattgc 180  
 aaggctggcc agcaaggara caggagttgg gctcaaatct gtctccccag tttggggctt 240  
 agggcaagtt ttaattacac agacgcattt cttatgagta gcaggcagag agcctccaac 300  
 ttcttctgcc taggtaccag cagcttagac atgatgcaaa cctgggaagc acatactgta 360  
 tttggagaaa gtgattggga agaaatgtga gctgag 396

<210> 596  
 <211> 396  
 <212> DNA  
 <213> Homo sapiens

<400> 596  
 tacatgattc taagaaacct ggaccagaac tatcaaaact tggtttccca gagaatatag 60

caaatgggct	cattggccaa	tactatgaca	ttggctttttg	agaaaagaaa	ggctttattg	120
caaggctggc	cagcaaggag	acaggagttg	ggctcaaadc	tgtctcccca	gtttggggct	180
tagggcaagt	tttaattaya	cagacgcatt	tcttatgagt	agcaggcaga	gagcctccaa	240
cttcttctgc	ctaggtacca	gcagcttaga	catgatgcaa	acctgggaag	cacatactgt	300
atttgagaaa	agtgattggg	aagaaatgtg	agctgagggg	aggggctcag	tgcccctgag	360
ctacacttag	tgatggcaga	ggaaggatgt	cctccc			396

<210> 597

<211> 396

<212> DNA

<213> Homo sapiens

<400> 597

tggggcttag	ggcaagtttt	aattacacag	acgcattttct	tatgagtagc	aggcagagag	60
cctccaactt	cttctgccta	ggtaccagca	gcttagacat	gatgcaaacc	tggaagcac	120
atactgtatt	tgagaaaagt	gattgggaag	aaatgtgagc	tgaggggagg	ggctcagtgc	180
ccctgagcta	cacttagtra	tggcagagga	aggatgtcct	cccgaggag	gctgttccac	240
atctgctctg	gttgtagggg	gagctggcag	gcattagcag	cggcctcttt	cccccaagag	300
aggcagcctc	ctccaagt	tggcgacatt	atggccctgc	aatcataagg	gtttgtgagc	360
atagtgtctaa	ggaggggaaa	ggagctgctg	ttacta			396

<210> 598

<211> 396

<212> DNA

<213> Homo sapiens

<400> 598

cctcctgagt	agctaggact	acaagcatgt	gccaccacgc	ccagctaatt	tttgtatttt	60
tagtaaggac	agggtttcac	catgttggcc	aggttggcct	ccaactcctg	acctcaagtc	120
atcctcctgc	ctcgacctcc	caaagtgcctg	ggattacagg	catgaaacca	gcctagaaat	180
acatactatt	atctattcyt	gttttacaga	taagcaaagt	gagtcattga	gaatttggtt	240
gaaagtccca	aggtcaggag	tctgaagct	gggattaaaa	cctaatactc	tgactttaga	300
gagtagacac	ttgctccatg	catattgcct	ccaattcatt	cattcaagca	ctccctgctc	360
aagaagttct	ttcttatgtt	gagctgaaat	ctgcag			396

<210> 599

<211> 396

<212> DNA

<213> Homo sapiens

<400> 599

tcacttgaet	ttagagagta	gacacttgct	ccatgcatat	tgctccaat	tcattcattc	60
aagcactccc	tgctcaagaa	gttctttctt	atgttgagct	gaaatctgca	gccctatgcg	120
ttttaccag	cagtcctggg	gctgttccct	aaaatcactt	agactgtgcg	tgctctttct	180
gtgtttacag	tgtcagctrt	aatatcccc	tcttcggcct	aacgtttctg	aagtcctctg	240
ccactgggtc	tcctctcttc	ttcctgtgtt	ctttctaaga	acacctatgc	agataggtgt	300
cttctgtaca	gggaagctgt	tcttgagatc	cgggcacgca	ctctgttaga	ataatctacg	360
tatgagttat	ttttttgaga	actatgtgtc	attgct			396

<210> 600

<211> 396

<212> DNA

<213> Homo sapiens

<400> 600

atgttgagct	gaaatctgca	gccctatgcg	ttttaccag	cagtcctggg	gctgttccct	60
aaaatcactt	agactgtgcc	tgctctttct	gtgtttacag	tgtcagctgt	aatatcccc	120
tcttcggcct	aacgtttctg	aagtcctctg	ccactgggtc	tcctctcttc	ttcctgtgtt	180
ctttctaaga	acacctatrc	agataggtgt	cttctgtaca	gggaagctgt	tcttgagatc	240
cgggcacgca	ctctgttaga	ataatctacg	tatgagttat	ttttttgaga	actatgtgtc	300
attgctgact	catattaact	ctgtgggttaa	ctaaaatctc	aagatctctt	tatgtttgtt	360
gagaaactta	tttaacttct	ctggccctcc	gtttcc			396

<210> 601  
 <211> 396  
 <212> DNA  
 <213> Homo sapiens

<400> 601  
 gtcctggtgc tgttccctaa aatcacttag actgtgcctg ctctttctgt gtttacagt 60  
 tcagctgtaa tatccccctc ttccggcctaa cgtttctgaa gtcccttgcc actgggtctc 120  
 ctctctctct cctgtgttct ttctaagaac acctatgcag ataggtgtct tctgtacagg 180  
 gaagctgttc ctgagatcyg ggcacgcact ctgttagaat aatctacgta tgagttatct 240  
 ttttgagaac tatgtgtcat tgctgactca tattaactct gtggttaact aaaatctcaa 300  
 gatctcttta tgtttgttga gaaacttatt taacttctct ggcctccgt ttccttctact 360  
 gagcagtggg gtgattgata acctccacct gtggtt 396

<210> 602  
 <211> 396  
 <212> DNA  
 <213> Homo sapiens

<400> 602  
 cacctatgca gataggtgtc ttctgtacag ggaagctgtt cctgagatcc ggcacgcac 60  
 tctgttagaa taatctacgt atgagttatt tttttgagaa ctatgtgtca ttgctgactc 120  
 atattaactc tgtggttaac taaaatctca agatctcttt atgtttgttg agaaacttat 180  
 ttaacttctc tggccctcmg ttctcttcac tgagcagtgg agtgattgat aacctccacc 240  
 tgtggttgc gaaggtcttg cacaagatga tatagttaaa gtagctagca gtgcccacgt 300  
 acggcggatg cctcacaacg gtttgacagc atctctctat ctgtgtcttt gtctctctct 360  
 cacactgggt ttggcttact gttagcagct agccga 396

<210> 603  
 <211> 396  
 <212> DNA  
 <213> Homo sapiens

<400> 603  
 tctgtggtta actaaaatct caagatctct ttatgtttgt tgagaaactt atttaacttc 60  
 tctggccctc cgtttccttc actgagcagt ggagtgattg ataacctcca cctgtggttg 120  
 ctgaaggtct tgcacaagat gatatagtta aagtagctag cagtgccac gtagggcgga 180  
 tgcctcacia cggtttgcmg ccctctctct atctgtgtct ttgtctctct ctcacactgg 240  
 ttttggttta ctgttagcag ctagccgaga taagtgtgtt tatggtcttt gcatgtattg 300  
 tttctgtagc atactggagg attacaagag gttggggagt gagggggagg tgaggagtag 360  
 acaaaggcag ccaactcttc caagtttagc ttagaa 396

<210> 604  
 <211> 396  
 <212> DNA  
 <213> Homo sapiens

<400> 604  
 ttgataacct ccacctgtgg ttgctgaagg tcttgacaaa gatgatatag ttaaagtagc 60  
 tagcagtgcc cagctacggc ggatgcctca caacggtttg cagccatctc tctatctgtg 120  
 tctttgtctc tctctcacac tggttttggc ttactgttag cagctagccg agataagtgt 180  
 gtttatggtc tttgcatgta ttgtttctgt agcactactg aggattacaa gaggttgggg 240  
 agtgaggggg cggtgaggag tagacaaagg cagccaactc ttccaagttt agcttagaag 300  
 gaaggagcgg taaaccctag ttgaatgttg gactgaagca ggtttgtttt tgttttggtt 360  
 aaaggatagg gaagatctgt gcgtgtttcc aggata 396

<210> 605  
 <211> 396  
 <212> DNA  
 <213> Homo sapiens

<400> 605  
 acttgaagtc agtggcatgg acaggggtcaa gatcacagtt agaggatgca gccttagaga 60

```

aaaggaagg gctcggttct ctgagcaagg agggaaaagaa gagaggcaga tgcagagaag 120
tacggcacat cgtgctgctg gttgtagaaa taacctctga cttttaataa agtcatccct 180
cggatccct gggggatrrg ttctatgacc tccctcggat gccaaaattc gtggatgctc 240
aagtcctga tataaaatgg catagtattt gcattttaacc tacacacatc ctccatatcc 300
tttttttttt tttttttttt tttttttttt tttttgtgag atggagtctt gctctgtcgc 360
cctggctgga gtacagtggc tcgatcttgg ctccact 396

```

```

<210> 606
<211> 396
<212> DNA
<213> Homo sapiens

```

```

<400> 606
aatacctgat agaatgtaaa tgctatgtaa acagttgtta tactgtattg ttaaaagaca 60
gtaacaagaa aaaaaatctg tacatgttca gtcagacaa atggttttct gttttttttt 120
ttttttttta atatttttgg tcagtgggtg gttgactcca ggaatgcaga acccgcagat 180
atagaagggt gattatgert tcagaggcag ggaataccat cttgggttcc agaaagaaaa 240
tgatcagcat tttctgtcat actctggtaa aaacagatct tttgaatgga caggtgtatt 300
aaacctgtg gagctggctg ggcctggcgg ctccacgcctg taatcccagc actttgggag 360
gctgaggcag gtggatcacg aggtcaggag ttcgag 396

```

```

<210> 607
<211> 396
<212> DNA
<213> Homo sapiens

```

```

<400> 607
tgccccgcag agtttgaagt cccggctgca cctctcccca gcagcaggtt gactctggaa 60
agttgcagcg ttcttaccta cagagtggga acagtactac ccattgcaca gagtgggtgc 120
aaagctctgt gacggaatac atggcaagtg cccaccacat tgcctgggat gaggtgggac 180
cttcctttac gtaagagarc cctacagata cactcaaagt gggcacattc ctacagaagg 240
agtgttattt gtgtagaaaa gaaaaacatg aaaggctttt attcctatac acaataaagc 300
acccttttaa tgtctttttg aggaggataa tatgaaattg atgaaaagga accctgtggt 360
tggatccctg acaatcacat gtatcccttt ttccac 396

```

```

<210> 608
<211> 396
<212> DNA
<213> Homo sapiens

```

```

<220>
<221> misc_feature
<222> (227)..(326)
<223> n = A,T,C or G

```

```

<400> 608
tacagatata ctcaaagtgg gcacattcct acagaaggag tgttatttgt gtagaaaaga 60
aaaacatgaa aggcttttat tcctatacac aataaagcac ccctttaatg tctttttgag 120
gaggataata tgaaattgat gaaaaggaac cctgtggttg gatccctgac aatcacatgt 180
atcccttttt tcaactcttra aaaaggagta aaggaataaa atagaannnn nnnnnnnnnn 240
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 300
nnnnnnnnnn nnnnnnnnnn nnnnnnatgt ttcagtcact gtataataac tagccagatt 360
ttttgttgtt gttgttttgt tttgtttttt gttttt 396

```

```

<210> 609
<211> 396
<212> DNA
<213> Homo sapiens

```

```

<400> 609
acattctgaa ccacagacag ttctttaccc tgaacctttg catattttgt tctcttagct 60
tagagcggcc cctctccctc cgtctgcttg gctaatttct acttggtctt cagattttat 120
cttagatgtc attccctcaa ggaatccttc tgtgactcaa catggaatta agttgcctcc 180

```

tttgaccctg	aaagcacart	gtactcaatc	tcattcttggc	atgactcact	ttgctgtgtg	240
gaatgtctgc	tttccttgtt	tgtctattcc	tttagactgt	aagatcctag	aaagtggggg	300
ccgtgccttg	ctcatgactg	tgtttctaac	accaaacaca	gtgttcagta	gagagcagct	360
gctgagtacg	tttctgctaa	atgacagttg	atggag			396

<210> 610  
 <211> 396  
 <212> DNA  
 <213> Homo sapiens

<400> 610						
aatccttctg	tgactcaaca	tggaaattaag	ttgcctcctt	tgaccctgaa	agcaccatgt	60
actcaatctc	atcttggcat	gactcacttt	gctgtgtgga	atgtctgctt	tccttgtttg	120
tctattcctt	tagactgtaa	gatacctagaa	agtggggggc	gtgccttgct	catgactgtg	180
tttctaacac	caaacacart	gttcagtaga	gagcagctgc	tgagtacgtt	tctgctaaat	240
gacagttgat	ggaggacatt	tagggtttgc	tggaggtcaa	gtcaaggagg	catttaacat	300
tctagtaaaa	caaggaagta	acaggctcct	gaacatgccc	acaatgaacc	agatgcaaac	360
cttttccctt	ggcaggattc	tttgcccata	aagtgg			396

<210> 611  
 <211> 396  
 <212> DNA  
 <213> Homo sapiens

<400> 611						
aaagcaccat	gtactcaatc	tcattcttggc	atgactcact	ttgctgtgtg	gaatgtctgc	60
tttccttgtt	tgtctattcc	tttagactgt	aagatcctag	aaagtggggg	ccgtgccttg	120
ctcatgactg	tgtttctaac	accaaacaca	gtgttcagta	gagagcagct	gctgagtacg	180
tttctgctaa	atgacagtkg	atggaggaca	tttagggttg	cttggaggtc	aagtcaagga	240
ggcatttaac	attctagtaa	aacaaggaag	taacaggctc	ctgaacatgc	ccacaatgaa	300
ccagatgcaa	accttttccc	ttggcaggat	tctttgcccc	taaagtggag	cacgaaagca	360
ggacccagaa	tgggaggagc	ttccagagga	ccggaa			396

<210> 612  
 <211> 396  
 <212> DNA  
 <213> Homo sapiens

<400> 612						
ttctgctaaa	tgacagttga	tggaggacat	ttagggttgc	ttggagggtca	agtcaaggag	60
gcattttaaca	ttctagtaaa	acaaggaagt	aacaggctcc	tgaacatgcc	cacaatgaac	120
cagatgcaaa	ccttttccct	tggcaggatt	cctttgcccc	aaagtggagc	acgaaagcag	180
gacccagaat	gggaggagyt	tccagaggac	cggaaacactt	gcctttgagc	gggtctacac	240
tgccaagtga	gtcctaacc	tgatgttgct	aataagtggg	ggcatgggca	ggggggcctc	300
cttctaggag	tgatgaccac	ccttaatacc	acatgtctgt	ctgagccaag	tttctgagcg	360
ccagggaggt	gaggaaggtt	ggacttcacc	agagag			396

<210> 613  
 <211> 396  
 <212> DNA  
 <213> Homo sapiens

<400> 613						
ggcattttaac	attctagtaa	aacaaggaag	taacaggctc	ctgaacatgc	ccacaatgaa	60
ccagatgcaa	accttttccc	ttggcaggat	tctttgcccc	taaagtggag	cacgaaagca	120
ggacccagaa	tgggaggagc	ttccagagga	ccggaacact	tgcccttgag	cgggtctaca	180
ctgccaagtg	agtcctaamc	ctgatgttgc	taataagtgg	gggcatgggc	aggggggcct	240
ccttctagga	gtgatgacca	cccttaatac	cacatgtctg	tctgagccaa	gtttctgagc	300
gccagggagg	tgaggaaggt	tggacttcac	cagagaggct	ttgtggacac	cctttatcat	360
cttagtgagt	gctagtgtca	aaacaaaggg	agtggg			396

<210> 614  
 <211> 396

<212> DNA  
<213> Homo sapiens

<400> 614  
gctcctgaac atgcccacaa tgaaccagat gcaaacccttt tcccttggca ggattccttg 60  
cccataaagt ggagcacgaa agcaggaccc agaattggag gagcttccag aggaccggaa 120  
cacttgccct tgagcgggtc tacactgccca agtgagtcct aaccctgatg ttgctaataa 180  
gtgggggcat gggcaggggrg gcctccttct aggagtgatg accaccctta ataccacatg 240  
tctgtctgag ccaagtttct gagcgccagg gaggtgagga aggttggact tcaccagaga 300  
ggctttgttg acacccttta tcatcttagt gagtgcctagt gtcaaaacaa agggagtggg 360  
gatatggggc acattggttg agggaggtgt gatctc 396

<210> 615  
<211> 396  
<212> DNA  
<213> Homo sapiens

<400> 615  
ttgcccataa agtggagcac gaaagcagga cccagaatgg gaggagcttc cagaggaccg 60  
gaacacttgc ctttgagcgg gtctacactg ccaagtgagt cctaaccctg atgttgctaa 120  
taagtggggg catgggcagg ggggcctcct tctaggagtg atgaccaccc ttaataccac 180  
atgtctgtct gagccaagyt tctgagcgcc agggaggtga ggaagggttg acttcaccag 240  
agaggctttg tggacaccct ttatcatctt agtgagtgtc agtgtcaaaa caaaggaggt 300  
ggggatatgg ggcacattgg tggagggagg tgtgatctct gcagcttcag aaagatctga 360  
aagagtcatt tggtagaga agttgacctt tttcct 396

<210> 616  
<211> 396  
<212> DNA  
<213> Homo sapiens

<400> 616  
aaacaaaggg agtggggata tggggcacat tgggtggaggg aggtgtgatc tctgcagctt 60  
cagaaagatc tgaaagagtc atttggttag agaagttgac ctatttcctg tggggttaga 120  
ccagggttgc tactgtgaac accagccatg actcaccagt caccttcaga agccacaggc 180  
aggacatgct gacgacagyc ttcaactcac ccacccttg ctccctgcg ggtggaagtc 240  
tggaggtgac accactgcat tttctaacac gggggctcct tgagcaacta gaacaagaac 300  
agaaagaatg gggacattag caggtgcttt cccctctctc cattcttttc tttgaataaa 360  
aaggttggtt gaaaacacct gagcggctcc taaaga 396

<210> 617  
<211> 396  
<212> DNA  
<213> Homo sapiens

<400> 617  
ctcctctctt ctttatgcag agtgatttct aaggctcagc cagtggcagg catgctgggg 60  
actatggact acggactagg ggcctgtcac agaggaaggc ctcatgctag agagctaagg 120  
gaggagctgg ccttcagttc catcccagga gcaactttga tgttcccaga gatccttcca 180  
aagggggagt catggtcamc caagaaaaat gtattcagaa tgccaagaat ggtgcaaaact 240  
caggacaaaag attcacactg caggggttggg gtccctgggc ttgctgctgg caccatggga 300  
gggaggggtcc ccttcagggg taccgttggg ttctgtgtaa ttaaactggc ttcaagggat 360  
ctcgactgaa caggcctata tcacactcac tgatat 396

<210> 618  
<211> 396  
<212> DNA  
<213> Homo sapiens

<400> 618  
tctcctcatc taggtatttt taattgtttc agtgaggtgt aggcattgagg ggattggagg 60  
gggcatctcc tccattgcag tttttcattg gctgctttgc tccctcagct ccgaaatcgc 120  
tggggcactc tcgaacgcat tagtacggta gtcacaggtt gattgcctgg ccccttgccc 180

tctgtgggca	ttttccctyt	cagacagccc	ctgagtactc	acagtgctgc	tacagtgggc	240
cacctagatc	tcctcttttc	tccatgctcc	cacgtgctct	gggctccact	cccttctccc	300
aagcacttct	gtccagggct	attccagcag	tctgacctca	aggaaatcct	ttgctaaact	360
gattatagag	aggtttctat	tttaacattt	aggtct			396

<210> 619  
 <211> 396  
 <212> DNA  
 <213> Homo sapiens

<400> 619						
atctaggtat	ttttaattgt	ttcagtgagg	tgtaggcatg	aggggattgg	agggggcattc	60
tcctccattg	cagtttttca	ttggctgctt	tgctccctca	gctccgaaat	cgctgggcca	120
ctctcgaacg	cattagtacg	gtagtcacag	ggtgattgcc	tgcccccttg	ccctctgtgg	180
gcattttccc	tttcagacwg	cccctgagta	ctcacagtgc	tgctacagtg	ggccacctag	240
atctccctct	ttctccatgc	tcccacgtgc	tctgggctec	actcccttct	cccaagcact	300
tctgtccagg	gctattccag	cagtctgacc	tcaaggaaat	cctttgctaa	actgattata	360
gagaggtttc	tattttaaca	tttaggtctt	ccatgt			396

<210> 620  
 <211> 396  
 <212> DNA  
 <213> Homo sapiens

<400> 620						
aggtgttaggc	atgaggggat	tggagggggc	atctcctcca	ttgcagtttt	tcattggctg	60
ctttgtcccc	tcagctccga	aatcgctggg	ccactctcga	acgcattagt	acggtagtca	120
caggttgatt	gcctggcccc	ttgccctctg	tgggcatttt	ccctttcaga	cagccccctga	180
gtactcacag	tgctgctaya	gtggggccacc	tagatctccc	tctttctcca	tgctcccacg	240
tgctctgggc	tccactccct	tctcccaagc	acttctgtcc	agggtattc	cagcagtctg	300
acctcaagga	aatcccttgc	taaactgatt	atagagaggt	ttctatttta	acatttaggt	360
cttccatgta	ttaattctca	gaatcaattt	aagatg			396

<210> 621  
 <211> 396  
 <212> DNA  
 <213> Homo sapiens

<400> 621						
cctttcagac	agccccctgag	tactcacagt	gctgctacag	tgggccacct	agatctccct	60
ctttctccat	gctcccacgt	gctctgggct	ccactccctt	ctcccaagca	cttctgtcca	120
gggctatttc	agcagtctga	cctcaaggaa	atcctttgct	aaactgatta	tagagaggtt	180
tctattttta	catttaggyc	ttccatgtat	taattctcag	aatcaattta	agatgtttta	240
aggtgtgatt	taagacattt	taaaaccatt	tggaggagag	tacagaaatt	atgtcacttg	300
ctgtcagcct	ctttgcacca	tctgcagaga	aagatactag	agtcccgctt	tggacacatc	360
cacatgcaag	aggtgcaaa	aaggtgtctt	tgatga			396

<210> 622  
 <211> 396  
 <212> DNA  
 <213> Homo sapiens

<400> 622						
ttctcagaat	caattttaaga	tgtttaaagg	tgtgatttaa	gacattttta	aaccatttgg	60
aggagagtac	agaaattatg	tcacttgctg	tcagcctctt	tgcaccatct	gcagagaaag	120
atactagagt	ccgccttgg	acacatccac	atgcaagagg	tgcaaagaag	gtgtctttga	180
tgaggcaagg	tcaaaactyc	tccccagacg	aaatccaaag	aaagcattcc	tactatgcta	240
tatcagtttg	gaaagaaaaa	cttctgccag	gtgactgcat	tctcactggg	cacattgtgt	300
tcctatggac	tcctcagctc	aaccaatttg	gagaagttat	ggtgcaattt	caccatatct	360
ggttagaagt	taagtttcca	atttgctggc	aatgaa			396

<210> 623  
 <211> 396



<212> DNA  
<213> Homo sapiens

<400> 623

```
aagaaggtgt ctttgatgag gcaaggtcaa aacttctccc cagacgaaat ccaaagaaaag 60
cattcctact atgctatatc agtttggaag gaaaaacttc tgccaggtga ctgcattctc 120
actggtcaca ttgtgttcct atggactcct cagctcaacc aatttggaag agttatgggtg 180
caatttcacc atatctggyt agaagttaag tttccaattt gctggcaatg aagaagaaat 240
ggagcaggcc aggtctgtga gtttctgcca cgtgcccccg ggagtgaaca gctctgtttg 300
taagaagcca tgggtgcttag acctgggctc gctagttgcc agcctccaaa ttgcagaagt 360
gccctttggt tgggtggctat gctgtgtcac ttggga 396
```

<210> 624

<211> 396

<212> DNA

<213> Homo sapiens

<400> 624

```
gcaacatata tgtgtgcctg tctgggttgt aaaaagggtc aaagatcaat gcagcaggca 60
gctacatgct ggcaaaagcc agaggcagct ggtctgtttg cctgtgccag gaaaccactg 120
ggaatggggt tgtgtgttat tctaggagaa agtcgtccca gcagcagctt ctccaggggc 180
atccaagagc actgaaaarg gttgcaagat gacccatgag gctgcaggaa gaaaagaaca 240
tgcatttaat cttgctatct gaaaagtaag acatgaagct ttcttcattt ttaatataca 300
catggacagt agtatgtga tatagtttat atgcaaatat acttgttata aggttgcagt 360
ctcaaaattt ttggttcatg ggggtgtggga tcataa 396
```

<210> 625

<211> 396

<212> DNA

<213> Homo sapiens

<400> 625

```
cagctacatg ctggcaaaaag ccagaggcag ctgggtctgtt tgcctgtgcc aggaaaccac 60
tggaatggg gttgtgtgtt attctaggag aaagtcgtcc cagcagcagc ttctccaggg 120
gcatccaaga gcaactgaaa ggggtgcaag atgacccatg aggtctgcagg aagaaaagaa 180
catgcattta atcttgctrt ctgaaaagta agacatgaag ctttcctcat ttttaataca 240
cacatggaca gtagtatgtg tatatagttt atatgcaaat atacttgta taaggttgca 300
tgctcaaaat ttttggttca tgggggtgtg gatcataaat gtttagggac catggctatc 360
aaggaaaaac agcatgaagg ataaatgata ctgggtg 396
```

<210> 626

<211> 396

<212> DNA

<213> Homo sapiens

<400> 626

```
ctatctgaaa agtaagacat gaagctttcc tcatttttaa tatacacatg gacagtagta 60
tgtgtatata gtttatatgc aaatatactt gttataagggt tgcattgtca aaatttttgg 120
ttcatggggt gtgggatcat aaatgttttag ggaccatggc tatcaaggaa aaacagcatg 180
aaggataaat gatactggyg gattaaaaag acagatgcat gtatttttag cataaaacac 240
aactgctgac tgatacagat agctcaagat tctggggcag ctgctgaaca gatacactag 300
ccagtgtggc tcatcggtc agacttggcc ttaattaatg ggctgtccct ccacccatct 360
cccatgaggg cagagctgag ccagggtttg agagct 396
```

<210> 627

<211> 396

<212> DNA

<213> Homo sapiens

<400> 627

```
agtttatatg caaatatact tgttataagg ttgcatgctc aaaatttttg gttcatgggg 60
tgtgggatca taaatgttta gggaccatgg ctatcaaggaa aaaacagcat gaaggataaa 120
tgatactggg ggattaaaaa gacagatgca tgtattttta gcataaaaca caactgctga 180
```

ctgatacaga	tagctcaasa	ttctggggca	gctgctgaac	agatacacta	gccagtgtgg	240
ctcatcggct	cagacttggc	cttaattaat	gggctgtccc	tccacccatc	tcccatgagg	300
gcagagctga	gccagggttt	gagagctaaa	aggaattgga	cctggactct	gttcacgtgt	360
atattttaat	tctaattaat	tcattctttt	gaaaga			396

<210> 628  
 <211> 394  
 <212> DNA  
 <213> Homo sapiens

<400> 628						
gtatttttag	cataaaacac	aactgctgac	tgatacagat	agctcaagat	tctggggcag	60
ctgctgaaca	gatacactag	ccagtgtggc	tcacgcggctc	agacttggcc	ttaattaatg	120
ggctgtccct	ccacccatct	cccatgaggg	cagagctgag	ccagggtttg	agagctaaaa	180
ggaattggac	ctggactcdg	ttcacgtgta	tatttttaatt	ctaattaatt	cattcttttg	240
aaagacagag	tcacactctg	ttgcctaggg	tggagtgcag	tggcacgac	ttggctcact	300
gcaacctcgg	cctcccagg	tcaagttatt	ctcctgcttc	agcctcctga	gtagctggga	360
ttataggcac	atgcccccat	gcctgactaa	tttt			394

<210> 629  
 <211> 396  
 <212> DNA  
 <213> Homo sapiens

<400> 629						
gctaaaagga	attggacctg	gactctgttc	acgtgtatat	tttaattcta	attaattcat	60
tcttttgaaa	gacagagtea	cactctgttg	cctagggtgg	agtgcagtgg	cacgatcttg	120
gctcactgca	acctcgccct	cccagggttc	agttattctc	ctgcttcagc	ctcctgagta	180
gctgggatta	taggcacayg	cccccatgcc	tgactaattt	ttgtattttt	agtagagacg	240
gggtttcacc	atgtcaggct	ggctctgaac	tcctgacctc	aggttatcca	cccgccttgg	300
cccctcaaag	tggttgaatt	acagggtgtg	gccaccgtgc	ctggcctgtt	cacatgtata	360
aaacacagtt	taatgtccta	ttcccagcca	atgagc			396

<210> 630  
 <211> 396  
 <212> DNA  
 <213> Homo sapiens

<400> 630						
tcaggttatc	cacccgcctt	ggccccctcaa	agtgttggaa	ttacagggtgt	gagccaccgt	60
gcctggcctg	ttcacatgta	taaaacacag	tttaatgtcc	tattcccagc	caatgagcat	120
ggctagagca	gccttgggtc	aagtttgggt	tttggagaaa	aatccttggt	agctgacctc	180
agattcctct	ttgtgagtk	aagtaagcac	agggtgcaga	gaggagaagg	gtctctggag	240
agggtgtaatt	ttctaaatgg	attacaagtt	catggacttt	taacagggtgt	tacaggggat	300
aacaagttct	ttatagacag	acttttgagg	acgtttaagg	gtattctgat	tcttgggttt	360
ctaagagggg	aatgtattat	ttaactacag	acaccc			396

<210> 631  
 <211> 396  
 <212> DNA  
 <213> Homo sapiens

<400> 631						
aaaatccaga	ataataataa	tttgtcaata	ggaaagacat	ttccactggg	ggtaagaag	60
gaagacattg	gaacaatgat	agccaccact	tattgaatgc	ttactgtgag	ccagggtggca	120
cttcaccttg	tttcattctc	acaacagtct	agggaagtaa	ttactaatgt	ctccatccac	180
ctcttgtaga	tgagcaaayt	gagggtcatt	gaggctagga	aatgcaccca	cactcacata	240
gcccataaga	ggcagccatg	gcattggggc	cagaccatgt	gaacttcaa	gactacacga	300
gcagccactg	ggcagctgtc	atggctaaag	ccacttgaat	tcagcccagc	agcaaccccc	360
tctccaggag	gggcacataa	gcttgcagct	ttgggt			396

<210> 632  
 <211> 396

<212> DNA  
<213> Homo sapiens

<400> 632  
ataataataa tttgtcaata ggaaagacat ttccactggg ggtaagaag gaagacattg 60  
gaacaatgat agccaccact tattgaatgc ttactgtgag ccaggtggca cttcaccttg 120  
tttcattctc acaacagtct aggggaagtaa ttactaatgt ctccatccac ctcttgtaga 180  
tgagcaaaact gaggtcayt gaggctagga aatgcaccca cactcacata gcccataaga 240  
ggcagccatg gcattggggc cagaccatgt gaacttcaaa gactacacga gcagccactg 300  
ggcagctgtc atgggctaaag ccacttgaat tcagcccagc agcaaccccc tctccaggag 360  
gggcacataa gcttgcagct ttgggtagaa gctgca 396

<210> 633  
<211> 396  
<212> DNA  
<213> Homo sapiens

<400> 633  
gcacttgaag tcctggatgg cgagagggac tggcttgagc cagagccagg aacaaggctc 60  
tgagaatatt ctggaaatcc acaggaggaa cccattttct tacagctggg agaatttcat 120  
tcaactccag gctgaccatg ttttattagg aacgaagggtg acttgaacta atagtcagga 180  
atgggtgaat acggaccraa tgtcaaatca ctaggcagtt cacatttcta atgagcaaat 240  
cccttagaca attaagaatt tttttccttt tgcataaacc agacaaaatc gctacttaaa 300  
aacaaccaa agaccgaaa catgagaaag agaaggaagc aggggaaatc tttggtacta 360  
ataagttttt aaacaataag agcaccagat atttta 396

<210> 634  
<211> 396  
<212> DNA  
<213> Homo sapiens

<400> 634  
atgagcaaat cccttagaca attaagaatt tttttccttt tgcataaacc agacaaaatc 60  
gctacttaaa aacaaaccaa agaccgaaa catgagaaag agaaggaagc aggggaaatc 120  
tttggtacta ataagttttt aaacaataag agcaccagat attttacccc atcagacaca 180  
gaatgttatt cgaataacsa aaaaaggaat tttttctcta agtttcttga actggaaaat 240  
gaatcatatt ttctcagtc tgaggctgca attttgtgcc tctagtaaca tataagaata 300  
gatgtgatgc cagtgccag tagctgctgc aattgttact tggggacctg tttattcact 360  
aagcacttca cccagtgat aaattttagt gggcct 396

<210> 635  
<211> 396  
<212> DNA  
<213> Homo sapiens

<400> 635  
ccgtgtccat tagatcagtg gaaattcttg gattcagagc actttgcaag gtcagcaggg 60  
gtctgtctct tctgtctgt tcttggtttt tgggtgtgcc tggattccag ggtaggtttc 120  
tcatctgtta ccttcataga cttctccaga aaaggatctt ttgaccatca gaggaccag 180  
aagattccat tggtaggyg cagataacct gatctctctg ggttctctgc agggcacaga 240  
tgaagggctg gccattccca agttctcagt ggtaccactg aggcagaga ccctaattgt 300  
ttgcatgagc agtttgaaaa ttgcatcttt gtttttacct atataatcac atgaaacccg 360  
tggttctcaa acgtcagcag gcacagcat cacatg 396

<210> 636  
<211> 396  
<212> DNA  
<213> Homo sapiens

<400> 636  
tcagtggtag cactgaggca tgagacceta atggtttgca tgagcagttt gaaaattgca 60  
tctttgtttt tacctatata atcacatgaa acccggtggt ctcaaacgct agcaggcatc 120  
agcatcacat ggagggcttg ttaaaacaga tttctgggccc ccaacacaga gtttttaatt 180

ctgaaggcct	gaggtgggyg	tgaacatttg	cattttctaac	atgtttctcga	tgctgctgcc	240
gcctctggtc	ccgagagcat	gcctggagaa	ctgccacctt	cgaccatgga	ctgtgagaat	300
tcacatggac	ctcagaatta	taatcagtct	ctcagtttta	cagataagga	aactaaatcc	360
agagagattg	ttttgccaat	ggtgaacagc	tggtta			396

<210> 637  
 <211> 396  
 <212> DNA  
 <213> Homo sapiens

<400> 637						
atgggtttgca	tgagcagttt	gaaaattgca	tctttgtttt	tacctatata	atcacatgaa	60
accggtgggt	ctcaaacgtc	agcaggcatc	agcatcacat	ggagggcttg	ttaaaacaga	120
tttctggggc	ccaacacaga	gttttaaat	ctgaaggcct	gaggtgggtg	tgaacatttg	180
cattttctaac	atgtttctcra	tgctgctgcc	gcctctggtc	ccgagagcat	gcctggagaa	240
ctgccacctt	cgaccatgga	ctgtgagaat	tcacatggac	ctcagaatta	taatcagtct	300
ctcagtttta	cagataagga	aactaaatcc	agagagattg	ttttgccaat	ggtgaacagc	360
tggttaaagt	caggatggag	actttaatcc	tagtca			396

<210> 638  
 <211> 396  
 <212> DNA  
 <213> Homo sapiens

<400> 638						
gagcagtttg	aaaattgcat	ctttgttttt	acctatataa	tcacatgaaa	cccggtgggtc	60
tcaaacgcca	gcaggcatca	gcacacacatg	gagggcttgt	taaaacagat	ttctggggccc	120
caacacagag	ttttaaatcc	tgaaggcctg	agggtgggtgt	gaacatttgc	atttctaaca	180
tggtctcgat	gctgctgcyg	cctctgggtcc	cgagagcatg	cctggagaac	tgccaccttc	240
gaccatggac	tgtgagaatt	cacatggacc	tcagaattat	aatcagtcct	tcagttttac	300
agataaggaa	actaaatcca	gagagattgt	tttgccaatg	gtgaacagct	ggttaaagtc	360
aggatggaga	ctttaatcct	agtcaagtga	cctttc			396

<210> 639  
 <211> 396  
 <212> DNA  
 <213> Homo sapiens

<400> 639						
agtttgaaaa	ttgcatcttt	gtttttacct	atataatcac	atgaaaccgg	tggtttctcaa	60
acgtcagcag	gcacagcat	cacatggagg	gcttggttaa	acagatttct	gggccccaac	120
acagagtttt	aaattctgaa	ggcctgaggt	gggtgtgaac	atttgcat	ctaacatgtt	180
ctcgatgctg	ctgcccgcck	tggtcccggag	agcatgcctg	gagaactgcc	accttcgacc	240
atggactgtg	agaattcaca	tggacctcag	aattataatc	agtctctcag	ttttacagat	300
aaggaaacta	aatccagaga	gattgttttg	ccaatggtga	acagctgggt	aaagtcagga	360
tggagacttt	aatcctagtc	aagtgaacct	tcctct			396

<210> 640  
 <211> 396  
 <212> DNA  
 <213> Homo sapiens

<400> 640						
catctttgtt	tttacctata	taatcacatg	aaaccctggg	ttctcaaacg	tcagcaggca	60
tcagcatcac	atggagggct	tggttaaaaca	gattttctggg	ccccaacaca	gagtttttaa	120
ttctgaaggc	ctgaggtggg	tgtgaacatt	tgcatttcta	acatgttctc	gatgctgctg	180
ccgcctctgg	tcccagagac	atgcctggag	aactgccacc	ttcgaccatg	gactgtgaga	240
attcacatgg	acctcagaat	tataatcagt	ctctcagttt	tacagataag	gaaactaaat	300
ccagagagat	tgtttttgcca	atggtgaaca	gctggttaaa	gtcaggatgg	agactttaat	360
cctagtcagg	tgacctttcc	tctgtattta	tttccc			396

<210> 641  
 <211> 396

<212> DNA  
 <213> Homo sapiens

<400> 641  
 atttctgaca tcttgaacca tagtaaaagg gtgttttttg tttttttgag acagagtctt 60  
 gctctgttgc ctgggctgga gtgcagtggg gtgatcttgg ctgcgtgcaa cctccgcctc 120  
 ccaggttcaa gtgattctcc tgccctcagcc tcttgagtag ctgggattac aggtgcttgc 180  
 caccacacct ggctatcttkt tgtgttttta gtagagacag ggtttcacca tgttgggcag 240  
 gctgggtcttg aactcctgac cttgtgatct gcctgcctca gcctcccaa ttgctgggat 300  
 tacaaggcgt gttgttttaa gccactcagt ttgtggccac ttgttacagc agcaagagga 360  
 aactcataca gttatcatgt gaactcacag gaatat 396

<210> 642  
 <211> 396  
 <212> DNA  
 <213> Homo sapiens

<400> 642  
 gatctgcctg cctcagcctc ccaaattgct gggattacaa ggcgtgttgt ttttaagccac 60  
 tcagtttgtg gccacttggt acagcagcaa gaggaactc atacagttat catgtgaact 120  
 cacaggaata tgggtgagta aaaagagagg aagggtgcaa aacatccacg gtagagttag 180  
 aactctccag ggagttagra ctgtgcccag catacagtga tcacctctt agtaagctaa 240  
 gtttctgagc accagctttt ttgagttgac tttgttgtct ttaacatttg aagatcacc 300  
 ttctttgctc agcctggctt gcagacctgg gctgatttgt ggatctgata gaaaagtctc 360  
 cttagttggg ctcttctccc cgaccacccc catgcc 396

<210> 643  
 <211> 396  
 <212> DNA  
 <213> Homo sapiens

<400> 643  
 tgcctcagcc tcccaaattg ctgggattac aaggcgtgtt gttttaagcc actcagtttg 60  
 tggccacttg ttacagcagc aagaggaaac tcatacagtt atcatgtgaa ctcacaggaa 120  
 tatggtgagt taaaaagaga ggaagggtgc aaaacatcca cggtagagtg agaactctcc 180  
 agggagttag gactgtgcmc agcatacagt gatcacctc ttagtaagct aagtttctga 240  
 gcaccagctt ttttgagttg actttgttgt ctttaacatt tgaagatcac ccttctttgc 300  
 tcagcctggc ttgcagacct gggctgattt gtggatctga tagaaaagt tctttagttg 360  
 ggctcttctc ccgaccacc cccatgccag tgtggc 396

<210> 644  
 <211> 396  
 <212> DNA  
 <213> Homo sapiens

<400> 644  
 gctactttgc agccaaggta actcagactt ccctttgttc attctccttc tataaagtgc 60  
 atctcaagga ggttcaaagg gcaggctttt tgttgaaagg actttgcctg acctctggct 120  
 cccatctgtg aagccctgga gaggtgagag ccctcgggag gccgtgttct aggcattgctc 180  
 tgcacccgtg cagagcgct gtgataatgc attgctaag cttgtctcct ggtggctggc 240  
 tgagagctgc tgtgtgaca aggggtggtt aaggctaaat gtgactcaga atccttaagc 300  
 agtggttagt cagatacaag ggcattataa atgagagtgc ctgagggatc tattttggga 360  
 ccgctgtcac ttggctcttc tgctaataag cttcca 396

<210> 645  
 <211> 396  
 <212> DNA  
 <213> Homo sapiens

<400> 645  
 acagttatca gcagcccaca ggcttgactt gagcaagttg gaaagacaaa tcaacttcca 60  
 gagttgattt aacattgagt ggaaatcagt catacttttg gtccccttcc gggggcacgc 120  
 ctggcactgt gcctgggtggc agatcggcac gaactggcca gcttctgtgg ccctggaggg 180

cacaggcaga	aaggccacrc	tcagtcccat	gatgaactgt	ttaagactta	ttgtgtgtctc	240
cccgtctgt	aaagtagata	gagtggattt	tatgtccctt	attacctttc	aggatacttt	300
gactcagggg	gataaagtaa	cttgggtaca	gctactcagc	tggtgaagaa	cacaggcaga	360
atgagtgcct	gggtcttttg	acttaaaatt	ctggat			396

<210> 646  
 <211> 396  
 <212> DNA  
 <213> Homo sapiens

<400> 646						
ctgtgcctgg	tggcagatcg	gcataaactg	gccagcttct	gtggccctgg	agggcacagg	60
cagaaaggcc	acactcagtc	ccatgatgaa	ctgttttaaga	cttattgttg	tctcccgcct	120
ctgtaaagta	gatagagtgg	attttatgtc	ccttattacc	tttcaggata	ctttgactca	180
gggagataaa	gtaacttgsg	tacagctact	cagctgggtga	agaacacagg	cagaatgagt	240
gcctgggtct	tttgacttaa	aattctggat	ttttcacaaa	gatcctctta	ctttattcat	300
ttacataata	aatatatatt	gaagagctac	tctgtgccaa	gccctgtgcc	tagatataca	360
gtgataaata	aagagtagct	tctagaggtc	acctgg			396

<210> 647  
 <211> 396  
 <212> DNA  
 <213> Homo sapiens

<400> 647						
aagttcagtg	atagagagca	gaggtgaggc	ggcagcagaa	accacttaag	ggacaccacg	60
tggcactcct	tctgtgctga	gaaggctgtc	agtaagctca	ccatttattt	cctattttct	120
ctcctgagtt	aaataggaaa	catgtctcgc	attacttgaa	aaatcaagtc	aaactatgct	180
cttactagga	gttatggtyc	tttttatgtc	ttagatgatg	cttgatctag	atgaatgcgg	240
acttgctgta	gctagataaa	tacaatggga	gtttgaaggt	gtttcgtagc	cctggaaata	300
ggatatttct	gtcaaaaaca	gctttgtcat	tgccagcaga	caaaagcatc	agtaaccttg	360
gttgataatc	gtcatttctt	aggaataaag	tagact			396

<210> 648  
 <211> 396  
 <212> DNA  
 <213> Homo sapiens

<400> 648						
gtatttctctg	tcaaaacaag	ctttgtcatt	gccagcagac	aaaagcatca	gtaaccttgg	60
ttgataatcg	tcatttctta	ggaataaagt	agactgtaga	atttttttta	gcagaaagga	120
aacccaaga	taattctagt	geaaatccct	cactttatag	agcagaagct	caagtcccag	180
aggaacaagt	ggcttgaayg	aacatcagaa	tttttaggggc	tggatttgta	ccctcctggg	240
gccagcagcc	cacttccctg	caggaggcac	tcaccttctt	tgcacagggg	tatgagtgtg	300
gccattttcc	accataatc	tctgttagct	catgttcaat	tgggttccca	ttgaaagaaa	360
aatggaccag	taagttggag	cagaatcatt	cagatg			396

<210> 649  
 <211> 396  
 <212> DNA  
 <213> Homo sapiens

<400> 649						
agctttgtca	ttgccagcag	acaaaagcat	cagtaacctt	ggttgataat	cgtcatttct	60
taggaataaa	gtagactgta	gaattttttt	tagcagaaag	gaaacccaaa	gataatttcta	120
gtgcaaattcc	ctcactttat	agagcagaag	ctcaagtccc	agaggaacaa	gtggcttgaa	180
cgaacatcag	aatttttagkg	gctggatttg	taccttccctg	gtgccagcag	cccacttccc	240
tgcaggaggc	actcaccttc	cttgacacag	ggtatgagt	tggccatttt	ccaccataa	300
tctctgttag	ctcatgttca	attgggttcc	cattgaaaga	aaaatggacc	agtaagttgg	360
agcagaatca	ttcagatggg	ataacataag	gaaaaa			396

<210> 650  
 <211> 396

<212> DNA  
 <213> Homo sapiens

<400> 650  
 tgttttaaat gcttttatat ctgtagctct agataacact agttccagct tagttaactc 60  
 ccagctccaa gccttcagga cttcatagag ttattggggt gctgctcttg gcagtttccc 120  
 aaaaagctag aatgcagagg gaatctcctt cccaaaaagc tagaatgcag agggaatctc 180  
 cttcccaaaa ggctagaayg cagaggggaat ctcccttcca aaaagctaga atgcagaggg 240  
 aatctccttc ccaaaaggct agaacgcaga gggaaatctc ttcccaaaag gctagaacgc 300  
 agagggaatc tccttcccaa aaggctagaa tgcagagggg atgtccttct cttctaaatg 360  
 gtagctgtta gttcaagaaa ggttaaacat tgtgct 396

<210> 651  
 <211> 396  
 <212> DNA  
 <213> Homo sapiens

<400> 651  
 gctgcgtttg ctggactgat gtacttggtt gtgaggcaaa agtactttgt cggttaccta 60  
 ggagagagaa cgcagaggta ggtaactggg actactaaag aactgtggag cgattcctga 120  
 tttttgagca ggaagagtga caattcaaaa cagtatttga ctagattcac ggctccgtag 180  
 catccccttg ggtgggagsg ggaaggctga ctaggacctc tgattcttct ttccctgagc 240  
 tttgaaggct ctgaaaatac agctgggggg acttgcccag ttttcttatt aagcaattcc 300  
 tccgcatggg gctggctttc aaagggtgct tcagtgtgtt ttgctgcacg tgccttgacg 360  
 cccacacccc tgcactcccg ccctgcagag tctggc 396

<210> 652  
 <211> 396  
 <212> DNA  
 <213> Homo sapiens

<400> 652  
 gaggcaaaag tactttgtcg gttacctagg agagagaacg cagaggtagg taactgggac 60  
 tactaaagaa ctgtggagcg attcctgatt tttgagcagg aagagtgaca attcaaaaca 120  
 gtatttgact agattcacgg ctccgtagca tccccttggg tgggaggggg aaggctgact 180  
 aggacctctg attcttctyt cctcgagctt tgaaggctct gaaaatacag ctggggggac 240  
 ttgccagtt ttcttattaa gcaattcctc cgcattggtg tggctttcaa aggggtgctc 300  
 agtgctgttt gctgcacgtg ccttgcagcc ccacaccctg cactcccgcc ctgcagagtc 360  
 tggcgctgga atgacatttt aggtctgggt tcccag 396

<210> 653  
 <211> 396  
 <212> DNA  
 <213> Homo sapiens

<400> 653  
 tatcttttcag ggaccagaag aaagaatgtt gggaaaataa gatgcagtaa gatgcagaca 60  
 tgacagcagg gtgcagcggc tcacgcctat aatcccagca ctttgggagg ctgaggtggg 120  
 tggatcacct gaggtcagga gtttgagacc agcctggcca acatggtgaa accccgtctc 180  
 tactaaaaaa tatacaaaac attagccagg catggtggtg ggcgcctgta atcccagcta 240  
 ctccataggg tgaggctgga gaatcgcttg aaccaggag gcagaggttg cagtgcagccg 300  
 agattgcgcc actgcactcc agcctgggca acaaaaagcaa aactccatct caaaaaaaaa 360  
 aaaaaaaaaa aaaaaaaaaa tgcagacacg agactg 396

<210> 654  
 <211> 396  
 <212> DNA  
 <213> Homo sapiens

<400> 654  
 tgggcgcctg taatcccagc tactccatag gctgaggctg gagaatcgct tgaaccagc 60  
 aggcagaggt tgcagtgcgc cgagattgcg ccaactgcact ccagcctggg caacaaaagc 120  
 aaaactccat ctcaaaaaaa aaaaaaaaaa aaaaaaaaaa gatgcagaca cgagactgtg 180

aaactgacta	gcataccawt	tgcatgtgtt	atagatgttg	ccagacagaa	agccccaag	240
cagcacagta	ccttcctgac	atctggacta	ggaaatctag	attttagtaa	aatacatgct	300
aatacttaca	gaagaaatgt	cggcgtaga	gtatgccgtc	agttccttag	agattgcaat	360
tcctaattgca	ctagtatggt	ttcaggtgcc	aggaac			396

<210> 655  
 <211> 396  
 <212> DNA  
 <213> Homo sapiens

<400> 655						
actccatctc	aaaaaaaaaa	aaaaaaaaaa	aaaaaaagat	gcagacacga	gactgtgaaa	60
ctgactagca	tcaccattgc	attgtttata	gatgttgcca	gacagaaagc	cccaaagcag	120
cacagtaoct	tcctgacatc	tggtactagga	aatctagatt	ttagtataat	acatgctaata	180
acttacagaa	gaaatgtcrg	cgtttagagta	tgccgtcagt	tccttagaga	ttgcaattcc	240
taatgacta	gtatggtttc	aggtgccagg	aacacgttct	gtgaggctgc	tgccccaggt	300
gctgacccca	gccttcacac	ccattttcct	tccttgtgtt	cacagccgct	ctgtctttta	360
caatagcacc	cctctctagt	ggctaattgg	ctctat			396

<210> 656  
 <211> 396  
 <212> DNA  
 <213> Homo sapiens

<400> 656						
aaaaaaaaaa	aaaaaaaaaa	aagatgcaga	cacgagactg	tgaaactgac	tagcatcacc	60
attgcattgt	ttatagatgt	tgccagacag	aaagcccaa	agcagcacag	taccttcctg	120
acatctggac	taggaaatct	agattttagt	aaaatacatg	ctaataactta	cagaagaaat	180
gtcggcggtta	gagtatgcyg	tcagttcctt	agagattgca	attcctaata	cactagtatg	240
gtttcagggtg	ccaggaacac	gttctgtgag	gctgctgccc	caggtgctga	ccccagcctt	300
ccacaccatt	ttccttcctt	gtgttcacag	ccgctctgtc	ttttacaata	gcacccctct	360
ctagtggcta	atgggctcta	tgattagata	gcaccc			396

<210> 657  
 <211> 396  
 <212> DNA  
 <213> Homo sapiens

<400> 657						
tttcagggtgc	caggaacacg	ttctgtgagg	ctgctgcccc	aggtgctgac	cccagccttc	60
cacaccattt	tccttccttg	tggtcacacg	cgctctgtct	tttacaatag	caccctctc	120
tagtggctaa	tgggctctat	gattagatag	catccttcag	tagtgataaa	ggcagtgaca	180
tcctagggag	gtcagcggkt	gaaagcgcta	tatctggaaa	acctgagagc	ctgtgaagct	240
caaggacttg	acgggggttag	accgtgagcc	gggctgcagc	tggaataaga	atgactgttc	300
tttcagcaga	tccttccttg	tgccatctct	ttcttcattc	ctctctagtg	gcattcttat	360
ttatctctta	aaaccacaat	tccattatct	ctccta			396

<210> 658  
 <211> 396  
 <212> DNA  
 <213> Homo sapiens

<400> 658						
gagggtcttc	tcttttgctt	ggctccctat	gcagccctat	cttacccttc	gcaaagtccc	60
agggatgtgg	ctcagtcact	gctcctctct	tcattctgtca	ccacttgctt	gagatcctac	120
agctgcttta	attccgagac	catctgcaga	acatgacaaa	atttgtccac	ctaccacat	180
gtccttttta	ctttaaagrc	tttactaact	gattcctatt	agggaatgaa	cagaggtggc	240
aaaaataaac	aataggagat	tgattttaca	gaaatcttta	aaatagtaga	tttcttcgga	300
cctcattgaa	atataaatgg	cctgccttct	tgtgtccctc	cctgggtctcc	ctcttttaggt	360
gataagaaga	agatcctgcc	agccccataa	cccgcc			396

<210> 659  
 <211> 396



<212> DNA  
<213> Homo sapiens

<400> 659  
ttaaataagt agattttctt ggacctcatt gaaatataaa tggcctgcct tcttggtgctc 60  
ctccctgggc tccctcttta ggtgataaga agaagatcct gccagcccca taaccgcgca 120  
tctgcgcggg ttctagaccc ccttctcttc ccctctggcc gtggtaggca ttactgatga 180  
atcatggtgc tctttcttmc agagacccaaa cctggcctcg gaatccttct taacacagat 240  
actgcttaac acaaccactc tgagcagctg tcataagtag aagtaataga tactagaaga 300  
aatgtctaag cctaatactag accaaaatac ggcctgatat agatgcaagc cagaggggct 360  
ttatgggttaa atgcaaggag attttcaacc ctgccc 396

<210> 660  
<211> 396  
<212> DNA  
<213> Homo sapiens

<400> 660  
ctggtctccc tcttttaggtg ataagaagaa gatcctgccca gcccataaac ccgccatctg 60  
cgcggttctt agacccctt ctccctccct ctggcctggg taggcattac tgatgaatca 120  
tggtgctctt tcttccagag accaaacctg gcctcggaat ccttcttaac acagatactg 180  
cttaacacaa ccactctgrg cagctgtcat aagtagaagt aatagatact agaagaaatg 240  
tctaagccta atctagacca aaatacggcc tgatatagat gcaagccaga ggggctttat 300  
gggttaaatgc aaggagattt tcaaccctgc cgtctagaag ctacttgctg agatcttctt 360  
cagttggggc catctctctc ccaggcctct cttctg 396

<210> 661  
<211> 396  
<212> DNA  
<213> Homo sapiens

<400> 661  
ccataaccgc ccatctgcgc gggttctaga ccccttctc ctccctctct gccgtggtag 60  
gcattactga tgaatcatgg tgctctttct tccagagacc aaacctggcc tcggaatcct 120  
tcttaacaca gatactgctt aacacaacca ctctgagcag ctgtcataag tagaagtaat 180  
agatactaga agaaatgtmt aagcctaata tagaccacaaa tacggcctga tatagatgca 240  
agccagaggg gctttatggg taaatgcaag gagattttca accctgccgt ctagaagcta 300  
cttgctgaga tcttcttcag ttggggccat ctctcccca ggcctctctt ctgttctctg 360  
gctatgtcac acttggaact tgcagacacc taatgc 396

<210> 662  
<211> 396  
<212> DNA  
<213> Homo sapiens

<400> 662  
tggtaggcat tactgatgaa tcatgggtgct ctttcttcca gagaccaaac ctggcctcgg 60  
aatccttctt aacacagata ctgcttaaca caaccactct gagcagctgt cataagtaga 120  
agtaatagat actagaagaa atgtctaagc ctaatctaga ccaaaatacg gcctgatata 180  
gatgcaagcc agaggggckt tatgggttaa tgcaaggaga ttttcaacc tgccgtctag 240  
aagctacttg ctgagatctt ctacagttgg gccatctctc tccccaggcc tctcttctgt 300  
tcttgggcta tgtcacactt ggactctgca gacacctaat gctcttggga cctgctttag 360  
ttcttgacct caccaaccga ggaggaattg ctagat 396

<210> 663  
<211> 396  
<212> DNA  
<213> Homo sapiens

<400> 663  
cagagaccaa acctggcctc ggaatccttc ttaacacaga tactgcttaa cacaaccact 60  
ctgagcagct gtcataagta gaagtaatag atactagaag aaatgtctaa gcctaactta 120  
gacaaaata cggcctgata tagatgcaag ccagaggggc tttatgggta aatgcaagga 180

gattttcaac	cctgccgtyt	agaagctact	tgctgagatc	ttcttcagtt	gggcccattc	240
cctccccagg	cctctcttct	gttcctgggc	tatgtcacac	ttggactctg	cagacaccta	300
atgctcttgg	gacctgcttt	agttcttgac	ctcaccaacc	gaggaggaat	tgctagatga	360
gacccctccc	ccggaatttc	tctcttgaac	cccaga			396

<210> 664  
 <211> 396  
 <212> DNA  
 <213> Homo sapiens

<400> 664						
gggcttttatg	gttaaatgca	aggagatttt	caaccctgcc	gtctagaagc	tacttgctga	60
gatcttcttc	agttgggccc	atctcctccc	caggcctctc	ttctgttcct	gggctatgtc	120
acacttggac	tctgcagaca	cctaagtctc	ttgggacctg	ctttagtctt	tgacctcacc	180
aaccgaggag	gaattgctmg	atgagatcct	tccccggaa	tttctctctt	gaacccaga	240
tggtccggtg	cccctttcca	gaagttgctc	cagccctgtc	cgcttaggaa	gttcagtgtc	300
atccttgatc	cagtgggtag	ggaagacatt	ccataatgaa	tgccccagtc	tgagcttctt	360
ccttcaggct	tcaggctgcc	ctgcgaggat	tttgca			396

<210> 665  
 <211> 396  
 <212> DNA  
 <213> Homo sapiens

<400> 665						
gtagctgaga	ctacaggtgt	gcactaccac	accagctaa	ttttttgtat	ttttagtaga	60
gatagggttt	agctatgttg	gccaggctgg	tctcgaactg	ctgaactcaa	gcaatctgcc	120
atccccggcc	tcacaaagta	ctgggagtat	aggcataagc	cacccatgat	gcccagcctg	180
aatcttggtt	tcttccccrt	tcatttaagc	tattacctgg	gcctgaactc	aatggcacct	240
ggcaccaact	ggcaactgac	tcttggtctt	ttattacctc	ccttccctag	caggcactgg	300
gttgctccct	cttcttatcc	catggagtcc	tgctcctctg	tggggctcct	actgatcctc	360
ttggcaatat	gaagttctca	gctcaatggg	gggtgg			396

<210> 666  
 <211> 396  
 <212> DNA  
 <213> Homo sapiens

<400> 666						
cccggcctcc	caaagtactg	ggagtatagg	cataagccac	ccatgatgcc	cagcctgaat	60
cttggtttct	tccccattca	tttaagctat	tacctgggcc	tgaactcaat	ggcacctggc	120
accaactggc	aactgactct	tggtctttta	ttacctacct	tccctagcag	gcactgggtt	180
gctccctctt	cctatccert	ggagtccctg	cctctgttgg	ggctcctact	gacccctctg	240
gcaatatgaa	gttctcagct	caatgggtggg	tgggcaatga	ctgccaaactc	ttgaggccaa	300
tgaactcagg	ttaccccact	cctcctcctc	ctgagttgct	cactcactcc	tcattcactc	360
aacattgatt	cagtagatat	ttgctacctg	ctctgt			396

<210> 667  
 <211> 396  
 <212> DNA  
 <213> Homo sapiens

<400> 667						
ccggcctccc	aaagtactgg	gagtataggc	ataagccacc	catgatgccc	agcctgaatc	60
ttgggtttct	ccccattcat	tttaagctatt	acctgggcct	gaactcaatg	gcacctggca	120
ccaactggca	actgactctt	ggtcttttat	tacctacctt	ccctagcagg	cactgggttg	180
ctccctcttc	ctatcccayg	gagtcctgtc	ctctgttggg	gctcctactg	atcctcttgg	240
caatatgaag	ttctcagctc	aatgggtggg	gggcaatgac	tgccaactct	tgaggccaat	300
gaactcagg	tacccactc	ctcctcctcc	tgagttgctc	actcactcct	cattcactca	360
acattgattc	agtagatatt	tgctacctgc	tctgtg			396

<210> 668  
 <211> 396

<212> DNA  
<213> Homo sapiens

<400> 668

```
ggcataagcc acccatgatg cccagcctga atcttggttt cttccccatt catttaagct 60
attacctggg cctgaactca atggcacctg gcaccaactg gcaactgact cttgggtcttt 120
tattacctac cttccctagc aggcactggg ttgctccctc ttcctatccc atggagtcct 180
gtcctctgtt ggggctccya ctgatcctct tggcaatatg aagttctcag ctcaatgggtg 240
ggtgggcaat gactgccaac tcttgaggcc aatgaactca gggtacccca ctctctctcc 300
tcctgagttg ctcactcact cctcattcac tcaacattga ttcagtagat atttgctacc 360
tgctctgtgc caggtaccag gtcagttgct gaagga 396
```

<210> 669

<211> 396

<212> DNA

<213> Homo sapiens

<400> 669

```
cctggcacca actggcaact gactcttggt cttttattac ctaccttccc tagcaggcac 60
tgggttgctc cctcttctta tcccatggag tctgtctctc tgttggggct cctactgac 120
ctcttggaat tatgaagttc tcagctcaat ggtgggtggg caatgactgc caactcttga 180
ggccaatgaa ctcaggttgc cccactcctc ctctctctga gttgctcact cactcctcat 240
tcactcaaca ttgattcagt agatatttgc tacctgctct gtgccaggta ccaggtcagt 300
tgctgaagga gtaacagtga acatgacgga gtctttgtcc ccaaggagac ccaaggtgtc 360
tcctagagcc aggggcacat tgcaagacca aatata 396
```

<210> 670

<211> 396

<212> DNA

<213> Homo sapiens

<400> 670

```
ctggcaactg actcttggtc ttttattacc taccttccct agcaggcact ggggttgctcc 60
ctcttcttat cccatggagt cctgtcctct gttggggctc ctactgatcc tcttggcaat 120
atgaagttct cagctcaatg gtgggtgggc aatgactgcr aactcttgag gccaatgaac 180
tcaggttacc ccactcctyc tctctctgag ttgctcactc actcctcatt cactcaacat 240
tgattcagta gatatttgc acctgctctg tgccaggtag caggtcagtt gctgaaggag 300
taacagtga catgacggag tctttgtccc caaggagacc caaggtgtct cctagagcca 360
ggggcacatt gcaagaccaa atatattcaa cttacc 396
```

<210> 671

<211> 396

<212> DNA

<213> Homo sapiens

<400> 671

```
ccatggagtc ctgtcctctg ttggggctcc tactgatcct cttggcaata tgaagttctc 60
agctcaatgg tgggtgggca atgactgcca actcttgagg ccaatgaact caggttacc 120
cactcctcct cctcctgagt tgctcactca ctctcattc actcaacatt gattcagtag 180
atatttgcta cctgctctrt gccaggtagc aggtcagttg ctgaaggagt aacagtgaac 240
atgacggagt ctttgtcccc aaggagaccc aaggtgtctc ctgagagccag gggcacattg 300
caagacaaa tatattcaac ttacaaaat aatcatagac ctagtcttca aaaagcaaga 360
agactgattc ctggttgta tttctcctcc tcagca 396
```

<210> 672

<211> 396

<212> DNA

<213> Homo sapiens

<400> 672

```
ttagagtctg tgggcccctc caagtgtgga gtatggtgtt acttcaccag agtttgagga 60
gaaacattct tcttttgga ggccggggag catagatgga tatcaaggct gctgtttcta 120
aaagcgaaac ccaccaaaac acagtattag aatcatctgt ggtgcttatt aaagatacag 180
```

attcctgggc	cccatcccmg	acttatgaat	cagaatctct	gccagaggaa	gcctgagaat	240
ttgcattctc	agatgattct	gcattctcag	ataacacatt	ctttagggtga	ttcttacaca	300
cactggagtt	tgggaatcgc	tgaaggctgt	tcacttctct	tttctgagaa	atgattcatt	360
catttcagaa	atatttgcag	aggctccttat	ttattg			396

<210> 673  
 <211> 396  
 <212> DNA  
 <213> Homo sapiens

<400> 673						
tggcctcatt	cgtgtgataa	atctgagcca	ccacgatatt	tgacttttca	caatttaatt	60
tatctgaacc	ctctatttct	tggctaaaaa	atatccctta	cttggacttc	tttattttat	120
tttcaattcc	cttaccagca	ctagcagggg	actctgtact	catctgctgg	cgctgccata	180
acaaagcact	gcagcctgkg	gggctcaaac	cacagaattt	attctctcac	agtcctagag	240
gctagaagtc	caagatcaaa	gtgtgggcag	ggtcgggttc	tcctgcagcc	tctctccttg	300
gcttatagag	tgccaccttc	tacctgtgtc	ttcacatcat	cacctcactg	agcatgtctg	360
tgtccaaatc	tcccttctt	ataagacccc	agtcac			396

<210> 674  
 <211> 396  
 <212> DNA  
 <213> Homo sapiens

<400> 674						
tctccttggc	ttatagagtg	ccaccttcta	cctgtgtctt	cacatcatca	cctcactgag	60
catgtctgtg	tccaaatctc	cccttcttat	aagaccccag	tcatactgga	tgaggatcca	120
cccatatgag	ttcattttac	cttaattatc	tctttaaaca	ccctgtctcc	aaatacagtc	180
ccattctgag	gaactgagrg	taaagattca	acatatgaat	tttggagggg	acctaattca	240
gcccacaaca	ccctcttttg	ggatgtttat	tttccccctt	aaggagctag	ttaggatgtc	300
ttatctcatg	aacatgactg	tgaacaggaa	aacagggaga	gaatgaagct	ggccaaggaa	360
cagggtctgg	gtcagctagc	agtgtctttc	tgatgt			396

<210> 675  
 <211> 396  
 <212> DNA  
 <213> Homo sapiens

<400> 675						
cattttacct	taattatctc	tttaaaccac	ctgtctccaa	atacagtcce	attctgagga	60
actgagagta	aagattcaac	atatgaattt	tggaggggac	ctaattcagc	ccacaacacc	120
ctcttttggg	atgtttattt	tcccccttaa	ggagctagtt	aggatgtctt	atctcatgaa	180
catgactgtg	aacaggaara	caggagagaga	atgaagctgg	ccaaggaaca	gggctgggtg	240
cagctagcag	tgcttttctg	atgtgagtgg	gtcccacagg	gagcttggtt	aaatgcagat	300
tctgattcat	taggttccag	agggacctga	gatttcccat	ttctgacaag	tttccagtgt	360
gggggtgat	gctgctgggt	cacggaccat	actttg			396

<210> 676  
 <211> 396  
 <212> DNA  
 <213> Homo sapiens

<400> 676						
gggagagaat	gaagctggcc	aaggaaacagg	gctgggtgtca	gctagcagtg	cttttctgat	60
gtgagtgggt	cccacaggga	gcttggttaa	atgcagattc	tgattcatta	ggttccagag	120
ggacctgaga	tttcccattt	ctgacaagtt	tccagtgtgg	gggctgatgc	tgctgggtcca	180
cggaccatac	tttgagtakc	aaggagcttg	atacataatg	gctgagtgac	tttcagactc	240
ctgctgtaga	aaaattatga	gttggtctgg	cgtgggtggct	cagcctgta	atcccagcac	300
tttgggaggc	cgaggtgggc	agatcacctg	aggtcaggag	ttcgagacca	gcctggccaa	360
catggtgaaa	caccatctct	acaaaaata	caaaaa			396

<210> 677  
 <211> 396

<212> DNA  
<213> Homo sapiens

<400> 677

acttaagccc	agaagactga	ggttgcagtg	agccgagatt	gcaccactgc	actccagctt	60
gggctacaga	gtgagactct	atctcaaaaa	caaagaaaca	aacaacaaca	ataacaacaa	120
aaaccaagtc	tctccctcca	ctcaaaaatg	caagggcctg	tctcccattg	ctgggtgccc	180
aggtctcatg	aatgtagaya	tgaattattc	cagtcagcct	caggagaata	gaatgagccc	240
tcagatgccg	aagcaccttt	cagattccac	cggttttatc	ggctcattta	aacttcactt	300
ctaacacagt	cctgcattac	acacgtgtct	gtcgttatgg	gcagctgcag	agagggtctt	360
aatggctcta	atgctcagtg	aggatgcccc	atggtc			396

<210> 678  
<211> 396  
<212> DNA  
<213> Homo sapiens

<400> 678

ctcaaaaaa	aagaaacaaa	caacaacaat	aacaacaaaa	accAagtctc	tccctccact	60
caaaaatgca	agggcctgtc	tcccattgct	gggtgcccag	gtctcatgaa	tgtagatatg	120
aattattcca	gtcagcctca	ggagaataga	atgagccctc	agatgccgaa	gcacctttca	180
gattccaccg	gttttatcrg	ctcattttaa	cttcacttct	aacacagtcc	tgcattacac	240
acgtgtctgt	cgttatgggc	agctgcagag	agggctctta	tggtccta	gctcagtgag	300
gatgcccaat	ggccaacaga	acctgccatc	ttcaggccat	caaggagctc	tggagttaag	360
gaaatcatga	gagcacagag	gggcgggtac	agcaga			396

<210> 679  
<211> 396  
<212> DNA  
<213> Homo sapiens

<400> 679

tgtagatatg	aattattcca	gtcagcctca	ggagaataga	atgagccctc	agatgccgaa	60
gcacctttca	gattccaccg	gttttatcgg	ctcattttaa	cttcacttct	aacacagtcc	120
tgcattacac	acgtgtctgt	cgttatgggc	agctgcagag	agggctctta	tggtccta	180
gtcagtgag	gatgccart	ggccaacaga	acctgccatc	ttcaggccat	caaggagctc	240
tggagttaag	gaaatcatga	gagcacagag	gggcgggtac	agcagagccc	tcgtggta	300
gggttttgag	gtctaggtct	tcttcacttg	ggtttgaaat	aagttcaatg	actagtaata	360
gctgagacac	ttctaccctt	caaatgaagt	aatgg			396

<210> 680  
<211> 396  
<212> DNA  
<213> Homo sapiens

<400> 680

agcacctttc	agattccacc	ggttttatcg	gctcatttaa	acttcacttc	taacacagtc	60
ctgcattaca	cacgtgtctg	tcgttatggg	cagctgcaga	gagggcttta	atggctccta	120
tgctcagtga	ggatgcccga	tggtcaacag	aacctgccat	cttcaggcca	tcaaggagct	180
ctggagttaa	ggaaatcawg	agagcacaga	ggggcgggta	cagcagagcc	ctcgtggtaa	240
tgggttttga	ggtctaggct	ctcttcactt	gggtttgaaa	taagttcaat	gactagtaat	300
agctgagaca	cttctaccct	tcaaatgaag	taaatgggaa	aatggagcat	tgttgagtcc	360
aggagagctat	aatttaaacc	ccatatatct	aaaag			396

<210> 681  
<211> 396  
<212> DNA  
<213> Homo sapiens

<400> 681

cacacgtgtc	tgctggttatg	ggcagctgca	gagaggggtct	taatggctct	aatgctcagt	60
gaggatgccc	aatgggtcaac	agaacctgcc	atcttcaggc	catcaaggag	ctctggagtt	120
aaggaaatca	tgagagcaca	gagggggcggg	tacagcagag	ccctcgtggg	aatgggtttt	180

gagggtctagg	ctctcttctc	ttgggtttga	aataagttca	atgactagta	atagctgaga	240
cactttctacc	cttcaaata	agtaaattgg	aaaatggagc	attgttgagt	ccagggagct	300
ataattttaa	ccccatat	ctaaaagggg	taacattttt	gtgtgtgtga	aattgggtgc	360
attcgactg	catctacagt	tttctttttc	cttctc			396

<210> 682  
 <211> 396  
 <212> DNA  
 <213> Homo sapiens

<400> 682						
acatatttgg	gaaacgcac	atactcttcc	tgttcctcat	gtccgttgct	ggcatattca	60
actattacct	catcttcttt	ttcggaagt	actttgaaaa	ctacataaag	acgatctcca	120
ccaccatctc	ccctctactt	ctcatccct	aactctctgc	tgaatatggg	gttgggtgtc	180
tcattctaata	aatacctaya	agtcataata	attcagctct	tgagagcatt	ctgctcttct	240
ttagatggct	gtaaattctat	tggccatctg	ggcttcacag	cttgagttaa	ccttgctttt	300
ccgggaacaa	aatgatgtca	tgtcagctcc	gccccctgaa	catgaccgtg	gccccaaatt	360
tgctattccc	atgcattttg	tttgtttctt	cactta			396

<210> 683  
 <211> 396  
 <212> DNA  
 <213> Homo sapiens

<400> 683						
tggtgtttct	atctaataca	tacctacaag	tcatacataat	tcagctcttg	agagcattct	60
gctcttcttt	agatggctgt	aaatctattg	gccatctggg	cttcacagct	tgagttaacc	120
ttgctttttc	gggaacaaaa	tgatgtcatg	tcagctccgc	cccttgaaca	tgaccgtggc	180
cccaaatttg	ctattccctt	gcattttgtt	tgtttcttca	cttatectgt	tctctgaaga	240
tgttttgtga	ccaggtttgt	gttttcttaa	aataaaatgc	agagacatgt	tttaagctga	300
tagttgaggg	gtttttgttaa	tggcttttgg	gggatttatc	tctataccca	caaacgacta	360
gtttgttttc	ctcaaactaa	atgataatat	taaaaa			396

<210> 684  
 <211> 396  
 <212> DNA  
 <213> Homo sapiens

<400> 684						
ttatctctat	acccacaaac	gactagtttg	ttttcctcaa	actaaatgat	aatattaaaa	60
atacacatcc	tggccagggt	tggtggctca	tacctgtaat	cccagcactt	tgaggaggccg	120
aggcagggtg	atcacttgag	gtcaggaatt	aagaccagcc	tggccaatat	ggtgaaagcc	180
tgtctgtact	aaaaatacra	aaattagcca	ggatgtctgg	tggatgctta	taatcccagc	240
tacttgggag	gttgaggcag	gagaattgct	tgaacccggg	aggtagaggt	tgcatgtgagc	300
caagatcatg	ccactgcact	ccagcttggg	caacagagtg	agactccatc	tcaaattaaa	360
aaaaatacac	atctggcttc	tggaaaaaatt	acttga			396

<210> 685  
 <211> 396  
 <212> DNA  
 <213> Homo sapiens

<400> 685						
gatcatgcca	ctgcactcca	gcttgggcaa	cagagtgaga	ctccatctca	aattaaaaaa	60
aatacacatc	tggtttctgg	aaaaattact	tgaagatctt	ttatgacatc	catccctctt	120
cacacagcca	tgtgaattag	gttgggtatc	tcataacta	gcacgtgcc	cagcacttcc	180
atgttatata	gtttaaaakg	ttctgtaatt	ccctgtggga	acctaagata	atgcgaggac	240
cgtcatacgt	gcccccaaat	attggcaaac	caatgaataa	atgaatgaat	gagtttatga	300
atcgctaact	ggctgtatct	aatgaagtat	gtgtgttgag	ccatttccca	cagtgtggac	360
agatttgtcc	cacaatatgg	gcctcttccc	aaaggc			396

<210> 686  
 <211> 396

<212> DNA  
 <213> Homo sapiens

<400> 686  
 aattaaaaaa aatacacatc tggcttcttg aaaaattact tgaagatctt ttatgacatc 60  
 catccctctt cacacagcca tgtgaattag gttggtatct tcatatacta gcatcgtgcc 120  
 cagcacttcc atgttatata gtttaaaatg ttctgttaatt ccctgtggga acctaagata 180  
 atgcgaggac cgtcatacrt gcccccaa attggaac caatgaataa atgaatgaat 240  
 gagtttatga atcgctaact ggctgtatct aatgaagat gtgtgttgag ccatttccca 300  
 cagtgtggac agatttgtcc cacaatatgg gcctcttccc aaaggcccta ccacctaata 360  
 ccatcacact ggggatttga tttcaacatg tgaatt 396

<210> 687  
 <211> 396  
 <212> DNA  
 <213> Homo sapiens

<400> 687  
 agttcatagt gacagtgate cagccactgt catgacaggt gccacttggc agaaacagca 60  
 cagcttggaa gatggcgggg tgtagtcaag attccaggat cccaacaga gaagccagct 120  
 cttatagggg agccattcat caggattgaa ctctcaatcg agctggacag taataggtgg 180  
 gtctgtgtta ttccccagrt gagtatcatg acagtcacaa tcctaggaag gatgtgaagc 240  
 ctccccagc tctcctccag ttgcctgctt gggcagcaga gatgatggaa tgtggagtct 300  
 ggcgtggtct gaggcctgaa tccatgtgcc tcatgtatga tgctcaggca agaggatctc 360  
 tcaattcaag ggagagggcc tgaatgagcc ttgctt 396

<210> 688  
 <211> 396  
 <212> DNA  
 <213> Homo sapiens

<400> 688  
 cttggcagaa acagcacagc ttggaagatg gcggggtgta gtcaagattc caggatcccc 60  
 aacagagaag ccagctctta taggggagcc attcatcagg attgaactct caatcgagct 120  
 ggacagtaat aggtgggtct gtgttattcc ccagatgagt atcatgacag tcacaatcct 180  
 aggaaggatg tgaagcctyc ccagctctc ctccagttgc ctgcttgggc agcagagatg 240  
 atggaatgtg gactctggcg tggctctgagg cctgaatcca tgtgcctcat gtatgatgct 300  
 caggcaagag gatctctcaa ttcaagggag agggcctgaa tgagccttgc tttccaggcc 360  
 tgtctgatgg tccaggctga agccctcct ggcttg 396

<210> 689  
 <211> 396  
 <212> DNA  
 <213> Homo sapiens

<400> 689  
 ctggcgtggg ctgaggcctg aatccatgtg cctcatgtat gatgctcagg caagaggatc 60  
 tctcaattca agggagaggg cctgaatgag ccttgctttc caggcctgtc tgatggtcca 120  
 ggctgaagcc cctcctggct tgcactgcca gacctcatcc agcaggagct ccttggcatt 180  
 gactgcttca ggatagttsc ttctgctctg agtgcctctt aaagagcagt gctctaccat 240  
 ccaagctggg cttttctttt cttcttgctg atagggaagg catgggacat tgcaggatgg 300  
 aagtggcccc caggccttct catgcctggg cttggtttgg aagggtgtca ggtgatcaat 360  
 aatcctgatt ggcttggcat tgaggagttt tctctg 396

<210> 690  
 <211> 396  
 <212> DNA  
 <213> Homo sapiens

<400> 690  
 tgctctctaa agagcagtg cctaccatcc aagctgggct tttcttttct tcttgctgat 60  
 agggaaggca tgggacattg caggatggaa gtggcccca ggcttctca tgcctgggct 120  
 tggtttgaa ggtggtcagg tgatcaataa tcttgattgg cctggcattg aggagtttct 180

ctgggatgtg	gtcctttcrg	ttttttaaaa	attattttta	ttgatacaca	tatttgtagg	240
tatttgtagg	gtgcatgtga	tactttatta	tgtgtgtgga	ttgtgtaatg	atgaagtcag	300
ggcatttagg	gtcttcatca	ccttgattat	catttctatg	tggtgagaac	atttcaagtt	360
ctcagttcca	gctattttga	aatagacagt	ccattt			396

<210> 691  
 <211> 396  
 <212> DNA  
 <213> Homo sapiens

<400> 691						
gatactttat	tatgtgtgtg	gatttgtgtaa	tgatgaagtc	agggcattta	gggtcttcat	60
caccttgatt	atcattttcta	tggtttgaga	acattttcaag	ttctcagttc	cagctatttt	120
gaaatagaca	gtccattttg	ttagctacag	tcacccaacc	cggctgtcag	acattggaac	180
ttactcctat	tgaactgtrt	atttgtaccc	attcaccaaa	ctctctttgg	gctttcagtt	240
ttacaactgg	gatgatcctg	ggaaaactaa	agtaaatcag	acacccgacg	tgtgagctag	300
gttataatat	gcccagtgga	ccctggggac	atcttagctt	tcagaggtca	tgctgtccaa	360
gctgactgtg	gggcttccag	aaggtgggga	gaggaa			396

<210> 692  
 <211> 396  
 <212> DNA  
 <213> Homo sapiens

<400> 692						
tatgtgtgtg	gatttgtgtaa	tgatgaagtc	agggcattta	gggtcttcat	caccttgatt	60
atcattttcta	tgtgttgaga	acattttcaag	ttctcagttc	cagctatttt	gaaatagaca	120
gtccattttg	ttagctacag	tcacccaacc	cggctgtcag	acattggaac	ttactcctat	180
tgaactgtgt	atttgtacyc	attcaccaaa	ctctctttgg	gctttcagtt	ttacaactgg	240
gatgatcctg	ggaaaactaa	agtaaatcag	acacccgacg	tgtgagctag	gttataatat	300
gcccagtgga	ccctggggac	atcttagctt	tcagaggtca	tgctgtccaa	gctgactgtg	360
gggcttccag	aaggtgggga	gaggaaatga	tgcaat			396

<210> 693  
 <211> 396  
 <212> DNA  
 <213> Homo sapiens

<400> 693						
tgggaaaact	aaagtaaate	agacaccoga	cgtgtgagct	aggttataat	atgccagtg	60
gaccctgggg	acatcttagc	tttcagaggt	catgctgtcc	aagctgactg	tggggcttcc	120
agaaggtggg	gagaggaaat	gatgcaatgg	ccatcagag	gcactacttg	gggcctgggg	180
ccagagtgca	tgtctaagsc	attaagggga	ggggagagca	gccttcataa	ttatgaagag	240
gagtctcagg	tgcacagctt	ctgatgaggg	acagcttcta	attgaagaca	gcattgtgta	300
atgctcaaac	tcctgtctt	cagagtgcct	gctgtatccc	accatcagtt	ctgtgacttc	360
tcctaagcc	tcaattttgc	atgtgttaca	ttggga			396

<210> 694  
 <211> 396  
 <212> DNA  
 <213> Homo sapiens

<400> 694						
cctgcatagc	aaattcttgc	aaatgtaggg	actcaaaaaca	atataaattt	attatctgac	60
agtttttctg	ggtcagaggt	cttactaggc	tgtaatcaga	gggcaaccaa	agctgtgac	120
tcagctgaag	ctcaggattc	tcttccaagc	tactgggttg	ttggcagaat	tcagttcttt	180
ccagttggaa	gactaaagyc	tacagtcttc	agtctctaga	agccttttct	ctggcacagg	240
tttctctaca	acatggccat	ttatgtcttt	aaggccaata	ggagaacatg	attagcatat	300
tttttttaag	tgaactttag	accctttttt	aaaggcctat	ctgattaggc	caggcccaag	360
tgagctttta	gtcaactgat	tagagatctt	aattac			396

<210> 695  
 <211> 396



<212> DNA

<213> Homo sapiens

<400> 695

```
ctgaagctca ggattctctt ccaagctcac tggttgttgg cagaattcag ttctttccag 60
ttggaagact aaagcctaca gtcttcagtc tctagaagcc ttttctctgg cacagggttc 120
tctacaacat ggccatttat gtctttaagg ccaataggag aacatgatta gcatattttt 180
tttaagtga ctttagacyc ttttttaaag gcctatctga ttaggccagg cccaagtga 240
ctttaagtca actgattaga gatcttaatt acatctgcaa agtcccttca tgtttaccgt 300
ataacataac ttagtgaaag gagtgaaatt gcaaccaggt tctgcctgca ctccacggaa 360
ggggattctg cagaagtgtg ggtcacgggg ggggta 396
```

<210> 696

<211> 396

<212> DNA

<213> Homo sapiens

<400> 696

```
agaacatgat tagcatattt tttttaagtg aacttttagac ccttttttaa aggcctatct 60
gattaggcca ggcccaagtg agctttaagt caactgatta gagatcttaa ttacatctgc 120
aaagtccctt catgtttacc gtataacata acttagtgaa aggagtgaag ttgcaaccag 180
gttctgcctg cactccacrg aaggggattc tgcagaagtg tgggtcacgg ggggggttatt 240
ttgggattct gcctacgtca ctgagtcaaa agaagctgaa tggttgtgat gctgagggtt 300
ttgggcagca gcagtgtgtg tgtgtgagtg aattcatatc tatgaccacc tgggaagaaa 360
ggaggctgtg gtttctccca cctcctggca gacaga 396
```

<210> 697

<211> 396

<212> DNA

<213> Homo sapiens

<400> 697

```
gggattacag acacacactg ccacgcctgg ctaatttttg tatttttagt agagacgagg 60
ttttgccatg ttggccaggc tgggtcttgaa ctctgacct caagtgatcc gccacacctca 120
gcctcccaaa gtgctgggat tacagacgtg agccaccatt aaccattttt ctatctcctg 180
tgggaaaggg cacagtgara gaacagatga agctgagaca tacaagtga ctcctccctc 240
ctctccattt agactaaaat aggattatc atactgagat tctccctggg tgcaaagaga 300
taatctgtgc aactgggttt ttacaattat ccctacccta tgctttcttc atctgtcttc 360
ctcgtagtca gctcaggctg ctataacaaa acacca 396
```

<210> 698

<211> 396

<212> DNA

<213> Homo sapiens

<400> 698

```
ggcagattcg gtgtctaatt aggtcctgct ttccagttta tagacagtgc cttatcgcta 60
ccgccttaca cagtggaagg agaggacgag aagctccttg ggctttttt tgtttctttc 120
tttctctctc tctctctttt tttttttttt aataaggcca ctatcttagt ccattttgtg 180
ttgctaaaag gaacatctra ggttgagtaa tttattttat tttaaaaagt ggccaggcat 240
ggaggcttat cctgtaaccc taatccttta ggaggccaaa acagcaggat tgtttgaggc 300
caggagttca agaccagcct aggaagata gtgagacccc atctacccca tctctactaa 360
aattttaaaa aattagctgt gtgttgtaaa gtgtgc 396
```

<210> 699

<211> 396

<212> DNA

<213> Homo sapiens

<400> 699

```
aattttatatt attttaaaaa gtggccaggc atggaggctt atcctgtaac cctaatacctt 60
taggaggcca aaacagcagg attgtttgag gccaggagtt caagaccagc ctaggcaaga 120
tagtgagacc ccatctaccc catctctact aaaattttta aaaattagct gtgtgttgta 180
```

aagtgtgctt	gtagtcccr	ccacttgaga	ggctgaggtg	ggtggagttc	aaggctgcag	240
tgagttatga	ttgagccact	gcactccaac	ccgggtaacg	gggcaagacc	ttgtctctat	300
ttaaaaaaaa	aaaatcttta	tgtggctcac	tattctgggt	ggctggaaag	ttcaagattg	360
ggcatctgca	tctggtgaca	gcctcatgtc	gcttcc			396

<210> 700  
 <211> 396  
 <212> DNA  
 <213> Homo sapiens

<400> 700						
taaccctaatt	ccttttaggag	gccccaaacag	caggattgtt	tgaggccagg	agttcaagac	60
cagcctaggc	aagatagtga	gaccccatct	accccatctc	tactaaaatt	ttaaaaaatt	120
agctgtgtgt	tgtaaagtgt	gcttgtagtc	ccggccactt	gagaggctga	ggtgggtgga	180
gttcaaggct	gcagtgaagt	atgattgagc	caactgcactc	caacccgggt	aacggggcaa	240
gaccttgtct	ctatttataa	aaaaaaaaatc	tttatgtggc	tcactattct	gggtggctgg	300
aaagttcaag	attgggcac	tgcactctgt	gacagcctca	tgctgcttcc	agtcattggg	360
gaagacgaag	gagagctggc	acgtgcagat	atcacg			396

<210> 701  
 <211> 396  
 <212> DNA  
 <213> Homo sapiens

<400> 701						
atccttttagg	aggccaaaac	agcaggattg	tttgaggcca	ggagttcaag	accagcctag	60
gcaagatagt	gagaccccat	ctaccccatc	tctactaaaa	ttttaaaaaa	ttagctgtgt	120
gttgtaaagt	gtgctttag	tcccggccac	ttgagaggct	gaggtgggtg	gagttcaagg	180
ctgcagtga	ttatgattr	gccactgcac	tccaacccgg	gtaacggggc	aagaccctgt	240
ctctatttaa	aaaaaaaaaa	tctttatgtg	gctcactatt	ctgggtgggt	ggaaagtcca	300
agattgggca	tctgcactct	gtgacagcct	catgtcgttt	ccagtcattg	gggaagacga	360
aggagagctg	gcacgtgcag	atatcacgtg	ttgagg			396

<210> 702  
 <211> 396  
 <212> DNA  
 <213> Homo sapiens

<400> 702						
ttaaaaaatt	agctgtgtgt	tgtaaagtgt	gcttgtagtc	ccggccactt	gagaggctga	60
ggtgggtgga	gttcaaggct	gcagtgaagt	atgattgagc	caactgcactc	caacccgggt	120
aacggggcaa	gaccttgtct	ctatttataa	aaaaaaaaatc	tttatgtggc	tcactattct	180
gggtggctgg	aaagttcarg	attgggcac	tgcactctgt	gacagcctca	tgctgcttcc	240
agtcattggg	gaagacgaag	gagagctggc	acgtgcagat	atcacgtgtt	gagggcagaa	300
gcgagagaga	gaggggagag	atgccaggct	cttttataca	accagcactg	gggaaactaa	360
tagagtga	gctcactgac	tcctgagggg	ggacat			396

<210> 703  
 <211> 396  
 <212> DNA  
 <213> Homo sapiens

<400> 703						
atgggggaag	acgaaggaga	gctggcacgt	gcagatatca	cgtgttgagg	gcagaagcga	60
gagagagagg	ggagagatgc	caggctcttt	ttaacaacca	gcactgggga	aactaataga	120
gtgagagctc	actgactcct	gagggaggac	attaatctat	tgatgagcga	cctgcctcca	180
tgacccaaac	acctccaayg	atacccacc	tccaacactg	ccacactagg	gattaacttt	240
caacttgaga	tttagagggg	ggaaacttac	aaactatcgc	aggcactaat	accactcatg	300
agggctccac	cttcatgacc	taatcacttc	ctaaaggcct	tacctcttaa	tctcatcaca	360
ttgaggattc	gatttcaact	tgaattttgg	ggggac			396

<210> 704  
 <211> 396

<212> DNA  
<213> Homo sapiens

<400> 704  
ctcgcctgcc aatgaaatta gatcatttat ttaccccttt atttggtcag tttgccttgt 60  
ccgttagaat ataagcttcc aaagggcagg agctttgcct atattgtag gccgggcata 120  
caatgagcac tcaaaaaaat atttgatgag tgtatgaaag aacagactgg gttatgtaat 180  
tgtgcctact tacctatayg accgtgtggt ggggtttatg gtgggtgtgg tggatgatggc 240  
tatagggtta taagcaaatt tgggacaggg agtctaagaa atgttcttaa attttagtaa 300  
gcaaagcatc ctctacagaa cctgtcttaa aacatgaaag ttccttagtg ctacccccag 360  
aggtatgatt tggtaggtca aggatagggc ctggaa 396

<210> 705  
<211> 396  
<212> DNA  
<213> Homo sapiens

<400> 705  
tgccacctga aattagatca tttattttacc cctttatttg ttcagtttgc cttgtccgtt 60  
agaatataag cttccaaagg gcaggagctt tgcctatatt gttaggccgg gcatacaatg 120  
agcactcaaa aaaatatttg atgagtgtat gaaagaacag actgggttat gtaattgtgc 180  
ctacttacct atatgacct gtgggtgggg ttatgggtggg tgggtgtgg atggctatag 240  
ggctataagc aaatttggga caggagagtct aagaaatgtt cttaaatttt agtaagcaaa 300  
gcacccctca cagaacctgt cttaaaacat gaaagtctct tagtgctacc cccagaggta 360  
tgatttggtg ggtcaaggat agggccttga aattca 396

<210> 706  
<211> 396  
<212> DNA  
<213> Homo sapiens

<400> 706  
cctgtcttaa aacatgaaag ttccttagtg ctacccccag aggtatgatt tggtaggtca 60  
aggatagggc ctggaaattc acattcttgt taagatgttc ttcacccggg gtttgttgac 120  
caccttttca gaagattttt gctctgtagc tgtactaacc aatgcagtag ttcgtagtca 180  
gtgtggctcc tgagccctyg aagtgtagct cctctgaact gagacgtgct gtaaatgtaa 240  
attgcacacc ggagtttgaa gagttaatac aaagaaaaag gaatgcaaaa catctcatta 300  
ataatgcttt acactgatta catattgaaa tggtaatctt gtagatatag tgcgttaaat 360  
aaaatatact gttaggctta atttcacgtc tttata 396

<210> 707  
<211> 396  
<212> DNA  
<213> Homo sapiens

<400> 707  
tcagccaatc aacaagaggg caaaagaaca aacatttgat gtgtaattac ttaatttagt 60  
gcatatgcat ttgggtcttc aatgtcagca ctatggcaac cagaacatgg ccacaataac 120  
tgtctggaaa tgtctattct tacctggacc cagcaggcca tgccccactg attatataat 180  
ctccctctct ccttgttayg gtctgaatgc ttgcatccct caaaaattca tgtgttgaaa 240  
tcctaaccct caaggtgatg atattaggag gtcggccttt tgagaggtaa ttaggtcatg 300  
aagacagcat cctcatgaat gggatttagt tccttataaa ataggcccaa gggagctcat 360  
tcactttgtc caccatgtga gaacacagcg agaggg 396

<210> 708  
<211> 396  
<212> DNA  
<213> Homo sapiens

<400> 708  
ccttgttacg gtctgaatgc ttgcatccct caaaaattca tgtgttgaaa tcctaaccct 60  
caaggtgatg atattaggag gtcggccttt tgagaggtaa ttaggtcatg aagacagcat 120  
cctcatgaat gggatttagt tccttataaa ataggcccaa gggagctcat tcactttgtc 180

caccatgtga	gaacacagyg	agagggcacc	atztatgcac	caggaaatgg	gccttttcca	240
gacaatctgt	cgggtgcctgg	atcttggact	tcacagcctc	tagaactgtg	agaaattaat	300
ttgtttttta	taagccacca	aatctatgg	tttttttata	gaaaccgtaa	tggactaaaa	360
cactccctaa	ttatatattaa	acttatcagt	gcactg			396

<210> 709  
 <211> 396  
 <212> DNA  
 <213> Homo sapiens

<400> 709						
ctaaccacca	aggtgatgat	attaggaggt	cggccttttg	agaggtaatt	aggtcatgaa	60
gacagcatcc	tcataaatgg	gattagtgtc	cttataaaat	aggcccaagg	gagctcattc	120
actttgtcca	ccatgtgaga	acacagcgag	agggcaccat	ttatgcacca	ggaaatgggc	180
cttttccaga	caatctgtyg	gtgcctggat	cttggacttc	acagcctcta	gaactgtgag	240
aaattaattt	gttttttata	agccaccaaa	tctatggttt	tttttataga	aaccgtaatg	300
gactaaaaca	ctccctaatt	atatttaaac	ttatcagtgc	actgggcagt	gacatattaa	360
aagaatgctg	gccaacgtaa	ttgacaccat	aaggct			396

<210> 710  
 <211> 396  
 <212> DNA  
 <213> Homo sapiens

<400> 710						
tcattctcatt	ttaacctttt	gtttcaaagc	ctctcttttc	atgacttccc	cgcttccatt	60
tttcccatat	ggtgggggta	ttattaagac	attaaatgag	agtggacagg	taggcaaagg	120
aggtggggtg	caggggaggt	gaggggtgcc	tgtgtacttt	tctagactgt	tccacttcac	180
atcagtgaag	tattcccart	tgatactatc	atgaaacaaa	gcaaatgaaa	tgctgagcac	240
ggagcttcgt	cttgatgaaa	tgctgaaaga	aaagaaagga	aaaataaagt	agccattatt	300
tttgcccttc	ctcccacccc	catggtttact	actcttattt	ctcttttgta	ttgttgtgtt	360
ggaagcacag	catcagaaaa	actcccagtt	ttgaga			396

<210> 711  
 <211> 396  
 <212> DNA  
 <213> Homo sapiens

<400> 711						
acaggtaggc	aaaggaggtg	ggttgccaggg	gagttgaggg	ttgcctgtgt	acttttctag	60
actgttccac	ttcacatcag	tgaaatattc	ccaattgata	ctatcatgaa	acaaagcaaa	120
tgaaatgctg	agcacggagc	ttcgtcttga	tgaaatgctg	aaagaaaaga	aaggaaaaat	180
aaagtagcca	ttatttttrc	ccttccctccc	accccatgtt	ttactactct	tatttctctt	240
ttgtattgtt	gtgttggaag	cacagcatca	gaaaaactcc	cagttttgag	agataactca	300
gtgttttagt	cacttaaacc	tgagaaagga	gaagaggatg	ccaccgtgag	gtccaggacg	360
taaagaggaa	aaaaacagac	aaaaaaatcc	atatga			396

<210> 712  
 <211> 396  
 <212> DNA  
 <213> Homo sapiens

<400> 712						
caggtaggca	aaggaggtgg	gttgccagggg	agttgagggg	tgctgtgtga	cttttctaga	60
ctgttccact	tcacatcagt	gaaatattcc	caattgatac	tatcatgaaa	caaagcaaat	120
gaaatgctga	gcacggagct	tcgtcttgat	gaaatgctga	aagaaaagaa	aggaaaaata	180
aagtagccat	tatttttgmc	cttccctccc	cccccatgtt	tactactctt	atttctcttt	240
tgtattgttg	tggttggaagc	acagcatcag	aaaaactccc	agttttgaga	gataactcag	300
tgtttagttc	acttaaacct	gagaaaggag	aagaggatgc	caccgtgagg	tccaggacgt	360
aaagaggaaa	aaaacagaca	aaaaaatcca	tatgaa			396

<210> 713  
 <211> 396

<212> DNA  
<213> Homo sapiens

<400> 713  
ttcgtcttga tgaatgctg aaagaaaaga aaggaaaaat aaagtagcca ttatTTTTgc 60  
ccttcctccc acccccatgt ttactactct tatttctctt ttgtattgtt gtgttggaag 120  
cacagcatca gaaaaactcc cagttttgag agataactca gtgttttagt cacttaaacc 180  
tgagaaagga gaagaggayg ccaccgtgag gtccaggacg taaagaggaa aaaaacagac 240  
aaaaaaatcc atatgaaatg aaaatgtgaa agaggcgctt tcyagcagat gagtgttgta 300  
gattacagtg ttgagagctg tttgtgtcca gagctgcttg ctgcacctgg cgggataaac 360  
actggtctaa cagaggatcc ttgtttcaag gaggct 396

<210> 714  
<211> 396  
<212> DNA  
<213> Homo sapiens

<400> 714  
aagaaaagaa aggaaaaata aagtagccat tatttttggc cttcctccca ccccatgtt 60  
tactactctt atttctcttt tgtattgttg tgttggaagc acagcatcag aaaaactccc 120  
agttttgaga gataactcag tgttttagttc acttaaactt gagaaaggag aagaggatgc 180  
cacggtgagg tccaggacrt aaagaggaaa aaaacagaca aaaaaatcca tatgaaatga 240  
aaatgtgaaa gaggcgcttt cgagcagatg agtgtttagt attacagtgt tgagagctgt 300  
ttgtgtccag agctgcttgc tgcacctggc gggataaaca ctggtctaac agaggatcct 360  
tgtttcaagg aggtgcctt ttatttgggg ggacaa 396

<210> 715  
<211> 396  
<212> DNA  
<213> Homo sapiens

<400> 715  
attatTTTTg cccttcctcc ccccccatg tttactactc ttatttctct tttgtattgt 60  
tgtgttgga gacagcatc agaaaaactc ccagttttga gagataactc agtgtttagt 120  
tcacttaaacc ctgagaaagg agaagaggat gccaccgtga ggtccaggac gtaaagagga 180  
aaaaaacaga caaaaaaayc catatgaaat gaaaatgtga aagaggcgct ttcgagcaga 240  
tgagtgttgt agattacagt gttgagagct gtttgtgtcc agagctgctt gctgcacctg 300  
gcgggataaa cactggtcta acagaggatc cttgtttcaa ggaggctgcc ttttatttgg 360  
ggggacaaaa ttgttcttga aagctgctca gtgggt 396

<210> 716  
<211> 396  
<212> DNA  
<213> Homo sapiens

<400> 716  
tttgtattgt tgtgttgga gacagcatc agaaaaactc ccagttttga gagataactc 60  
agtgtttagt tcacttaaacc ctgagaaagg agaagaggat gccaccgtga ggtccaggac 120  
gtaaagagga aaaaaacaga caaaaaaatc catatgaaat gaaaatgtga aagaggcgct 180  
ttcgagcaga tgagtgttrt agattacagt gttgagagct gtttgtgtcc agagctgctt 240  
gctgcacctg gcgggataaa cactggtcta acagaggatc cttgtttcaa ggaggctgcc 300  
ttttatttgg ggggacaaaa ttgttcttga aagctgctca gtggttcaag ctacagcatg 360  
gtggactagc agaatggact ccagggcctc cgagga 396

<210> 717  
<211> 396  
<212> DNA  
<213> Homo sapiens

<400> 717  
ttttgagaga taactcagt tttagtctac ttaaacttga gaaaggagaa gaggatgcc 60  
ccgtgaggtc caggacgtaa agaggaaaaa aacagacaaa aaaatccata tgaaatgaaa 120  
atgtgaaaga ggcgctttcg agcagatgag tgtttagatg tacagtgttg agagctgttt 180

gtgtccagag	ctgcttgcyg	cacctggcgg	gataaacact	ggtctaacag	aggatccttg	240
tttcaaggag	gctgcctttt	atttgggggg	acaaaattgt	tcttgaaagc	tgctcagtgg	300
ttcaagctac	agcatggtgg	actagcagaa	tggactccag	ggcctccgag	gagacagtga	360
ctgctgccag	aaatagtcaa	ggatagaaag	gaagga			396

## **Application Data Sheet**

### **Application Information**

Application number::	Not Yet Assigned
Application Type::	Provisional
Subject Matter::	Utility
Suggested Group Art Unit::	N/A
CD-ROM or CD-R?::	None
Sequence submission?::	Yes
Computer Readable Form (CRF)?::	Yes
Title::	Combination Therapy Materials and Methods
Attorney Docket Number::	30847/40792
Request for Early Publication?::	No
Request for Non-Publication?::	No
Small Entity?::	No
Petition included?::	No
Secrecy Order in Parent Appl.?::	No

### **Applicant Information**

Applicant Authority Type::	Inventor
Primary Citizenship Country::	US
Status::	Full Capacity
Given Name::	Mark
Middle Name::	E.
Family Name::	Gurney
City of Residence::	Grand Rapids
State or Province of Residence::	MI
Country of Residence::	US
Street of mailing address::	910 Rosewood Avenue SE
City of mailing address::	Grand Rapids
Country of mailing address::	MI
Postal or Zip Code of mailing address::	49506

Applicant Authority Type:: Inventor  
Primary Citizenship Country:: US  
Status:: Full Capacity  
Given Name:: Jeffrey  
Middle Name:: R.  
Family Name:: Gulcher  
City of Residence:: Lake Barrington  
State or Province of Residence:: IL  
Country of Residence:: US  
Street of mailing address:: 25663 N. Countryside Drive  
City of mailing address:: Lake Barrington  
State or Province of mailing address:: IL  
Postal or Zip Code of mailing address:: 60010

Applicant Authority Type:: Inventor  
Primary Citizenship Country:: Iceland  
Status:: Full Capacity  
Given Name:: Hákon  
Family Name:: Hákonarson  
City of Residence:: Reykjavík  
Country of Residence:: Iceland  
Street of mailing address:: Grjotasel 3  
City of mailing address:: Reykjavík  
Country of mailing address:: Iceland  
Postal or Zip Code of mailing address:: 109



**Correspondence Information**

Correspondence Customer Number:: 04743

**Representative Information**

Representative Customer Number:: 04743

**Domestic Priority Information****Foreign Priority Information****Assignee Information**

Assignee name:: deCODE genetics ehf.  
Street of mailing address:: Sturlogötu 8  
City of mailing address:: Reykjavik  
Country of mailing address:: Iceland  
Postal or Zip Code of mailing address:: IS-101